{
  "metadata": [
    {
      "id": 0,
      "text": "Review Current concepts in coronary artery revascularisation Mario Gaudino, Felicita Andreotti, Takeshi Kimura Coronary artery revascularisation can be performed surgically or percutaneously。Surgery is associated with higher Lancet 2023; 401: 1611–28 procedural risk and longer recovery than percutaneous interventions, but with long-term reduction of recurrent Published Online cardiac events。For many patients with obstructive coronary artery disease in need of revascularisation, surgical or April 27, 2023 percutaneous intervention is indicated on the basis of clinical and anatomical reasons or personal preferences。https://doi。org/10。1016/ S0140-6736(23)00459-2 Medical therapy is a crucial accompaniment to coronary revascularisation, and data suggest that, in some subsets of Department of Cardiothoracic patients, medical therapy alone might achieve similar results to coronary revascularisation。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 1,
      "text": "iment to coronary revascularisation, and data suggest that, in some subsets of Department of Cardiothoracic patients, medical therapy alone might achieve similar results to coronary revascularisation。 Most revascularisation Surgery, Weill Cornell Medicine, data are based on prevalently White, non-elderly, male populations in high-income countries; robust data in women, New York, NY, USA older adults, and racial and other minorities, and from low-income and middle-income countries, are urgently (Prof M Gaudino MD); needed。Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Introduction complication of CABG, but data are mixed and without Gemelli IRCCS, Rome, Italy Coronary artery revascularisation is a common solid evidence。11,12 Some studies reported similar (F Andreotti MD); Department proce dure in current medical practice。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 2,
      "text": "without Gemelli IRCCS, Rome, Italy Coronary artery revascularisation is a common solid evidence。11,12 Some studies reported similar (F Andreotti MD); Department proce dure in current medical practice。 Every year almost neuropsychological dysfunction after either PCI or of Cardiology, Hirakata Kohsai Hospital, Osaka, Japan 800 000 patients in the USA,1 900 000 in China,2 CABG,13,14 suggesting that cognitive decline in CABG (Prof T Kimura MD) 250 000 in Japan,1,3 and over 12 million in Europe4 patients might relate to ageing and systemic Correspondence to: undergo revascularisation by either coronary artery atherosclerotic disease rather than to the surgery itself。Prof Mario Gaudino, Department bypass grafting (CABG) or percutaneous coronary Other important complications are postoperative renal of Cardiothoracic Surgery, Weill interventions(PCI)。In the past 20 years, PCI, CABG, and (occurring in 1–2% of cases)15 and respiratory failure Cornell Medicine, New York, NY 10065, USA medical therapy for coronary artery disease have (occurring in approximately 10% of cases);16 they are mfg9004@med。cornell。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 3,
      "text": "f cases)15 and respiratory failure Cornell Medicine, New York, NY 10065, USA medical therapy for coronary artery disease have (occurring in approximately 10% of cases);16 they are mfg9004@med。cornell。 edu undergone very important changes and their relative usually rapidly reversible in patients with preserved results have been tested in numerous randomised preoperative function。controlled trials (RCTs)。Postoperative atrial fibrillation is the most common In this Review, we evaluate the current evidence on complication of CABG, affecting 20–25% of patients。17 The coronary revascularisation with the aim of summarising arrhythmia is generally well tolerated, with most patients key concepts to help to inform clinical decision making。reverting to sinus rhythm within 1 or 2 days。17 However, We also highlight gaps in knowledge and future research postoperative atrial fibrillation significantly increases directions。length of in-hospital stay, costs, risk of subsequent heart failure and stroke, and even mortality, through Coronary artery bypass surgery mechanisms that are not entirely clear。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 4,
      "text": " increases directions。length of in-hospital stay, costs, risk of subsequent heart failure and stroke, and even mortality, through Coronary artery bypass surgery mechanisms that are not entirely clear。 17,18 Postoperative After almost three decades of attempts at indirect coronary atrial fibrillation also increases the risk of recurrent atrial surgery (through pericardial, sympathetic system, or fibrillation in the years after surgery。19 β blockers or thyroid gland interventions),5 CABG was introduced in amiodarone and left posterior pericardiotomy are effective the early 1970s and rapidly adopted (figure 1)。Currently, it measures to prevent postoperative atrial fibrillation,20,21 is the most common heart operation, representing over whereas the roles of rhythm versus rate control and of 50% of all adult cardiac surgeries worldwide。6,7 systemic anticoagulation are less clear。22,23 During CABG, segments of arteries or veins are Surgical wound complications occur in 5–10% of CABG connected to the coronary arteries distal to flow-limiting patients,24,25 particularly in individuals with multiple risk obstructions。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 5,
      "text": " or veins are Surgical wound complications occur in 5–10% of CABG connected to the coronary arteries distal to flow-limiting patients,24,25 particularly in individuals with multiple risk obstructions。 Most operations are performed through factors (eg, female sex, obesity, and diabetes), affecting median sternotomy, with a cardiopulmonary bypass postoperative quality of life。26 Sternal wound complications pump, grafting the left anterior descending coronary are associated with increased short-term and long-term artery with the internal thoracic artery and bypassing the remaining target coronary arteries with segments of the great saphenous vein。8 Operative mortality has Search strategy and selection criteria progressively declined despite referral of older and more We searched PubMed from the site’s inception to comorbid patients, currently ranging between 1% and 2% Dec 31, 2022 for references with the terms “coronary for elective cases, and with values in the low decimal revascularisation”, “percutaneous coronary intervention”, range for cases without preoperative organ dysfunction。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 6,
      "text": "rences with the terms “coronary for elective cases, and with values in the low decimal revascularisation”, “percutaneous coronary intervention”, range for cases without preoperative organ dysfunction。 7,8 “coronary bypass surgery”, “medical therapy”, or any Stroke is infrequent but is a serious complication of combination of these terms in the title or abstract, and no CABG, with a prevalence in modern series ranging language restrictions。We also identified relevant articles between 05% and 15%。8,9 Stroke can occur from the reference lists of selected articles。We prioritised intraoperatively, mainly through embolism from aortic RCTs and publications from the past 10 years, but we cited manipulation, or postoperatively from arrhythmias or other references when relevant。hypotension。10 Cognitive decline is a potential www。thelancet。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 7,
      "text": "and publications from the past 10 years, but we cited manipulation, or postoperatively from arrhythmias or other references when relevant。hypotension。10 Cognitive decline is a potential www。thelancet。 com Vol 401 May 13, 2023 1611 Review CABG 1967 1970 CABG introduced in clinical practice Introduction of cardioplegia 1971 1960 First CABG in a human Introduction of 1985 1958 radial artery Off-pump CABG 2009 First selective coronary 1977–1982 1986 SYNTAX trial (PCI vs CABG) 1 a 9 n 5 g 0 i – o 6 g 0 raphy V R C A A CT , B C s G A c w o S m S it , h p E a U ring B an e t n e e r fi io t r o d f e in sc t e e n rn d a in l t g h a o r r t a e c r i y c a a n rt a e s r t y o - m lef o t sis 2 EX 0 C 1 E 6 L and Indirect myocardial medical therapy 1994 NOBLE trials revascularisation alone Minimally invasive CABG (PCI vs CABG) 1935 1960 1970 1980 1990 2000 2010 2020 1977 1987 2002 2018 PTCA (POBA) BMS G1-DES Short 1980 1992 2006 DAPT First primary PCI for acute myocardial infarction Transradial approach Drug-coated balloon regimen 1981 1993 2008 2015 Steerable guidewire Rotational atherectomy G2-DES High bleeding 1995 risk concept Intravenous ultrasound-guided high-pressure inflation 2009 P2Y -inhibitor instead of anticoagulation Fractional flow 12 PCI reserve-guided PCI Figure 1: Timeline of key advancements in surgical and percutaneous coronary revascularisation BMS=bare-metal stent。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 8,
      "text": "P2Y -inhibitor instead of anticoagulation Fractional flow 12 PCI reserve-guided PCI Figure 1: Timeline of key advancements in surgical and percutaneous coronary revascularisation BMS=bare-metal stent。 CABG=coronary artery bypass surgery。CASS=Coronary Artery Surgery Study。DAPT=dual antiplatelet。G1-DES=first-generation drug-eluting stent。G2-DES=second-generation drug-eluting stent。PCI=percutaneous coronary intervention。PTCA=percutaneous transluminal coronary angioplasty。POBA=plain old balloon angioplasty。RCTs=randomised clinical trials。SYNTAX=Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery。VA=Veterans Administration。mortality25 and with higher risk of graft failure (probably and Japan, for example, most CABG procedures are owing to mediastinal inflammation and hypercoagula- performed off-pump)。8,35 bility)。27 Hospital readmission after CABG is frequent, The use of arterial rather than saphenous venous grafts with reported rates of 10–15% at 30 days and 20–25% at to revascularise non-left anterior descending coronary 90 days。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 9,
      "text": "n after CABG is frequent, The use of arterial rather than saphenous venous grafts with reported rates of 10–15% at 30 days and 20–25% at to revascularise non-left anterior descending coronary 90 days。 28 The most common reasons are pericardial artery targets has been hypothesised to improve long-term effusions, heart failure related to fluid overload, CABG outcomes on the basis of the higher failure rate of arrhythmias, and wound complications, whereas venous grafts compared with arterial conduits。36,37 myocardial ischaemia and graft failure are less common。28 Although observational series have generally reported Patients generally recover from surgery within better overall and event-free survival for patients operated 2–3 months, with large variations based on age, upon with multiple versus single arterial grafts, RCTs preoperative comorbidity, and severity of heart disease。have not shown significant differences between groups,38 Adoption of Enhanced Recovery After Surgery (ERAS) and treatment allocation and experience bias might be the protocols can reduce complications and accelerate return reason for the reported differences in observational to healthy life。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 10,
      "text": " Surgery (ERAS) and treatment allocation and experience bias might be the protocols can reduce complications and accelerate return reason for the reported differences in observational to healthy life。 29 Centre-based and home-based post- studies。The ongoing ROMA trial39 should provide more operative rehabilitation reduces hospital readmissions definitive information。and shortens recovery time。30 Depression and anxiety are Minimally invasive CABG through ministernotomy or common after surgery and behavioural, psychological, or small thoracotomies, often with the support of dedicated pharmacological interventions might improve quality of (port-access) or robotic technologies, has been proposed life and even clinical outcomes postoperatively。31 but not tested in adequately powered RCTs; it remains a niche for dedicated surgeons and highly selected Procedural aspects of CABG patients。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 11,
      "text": "roposed life and even clinical outcomes postoperatively。31 but not tested in adequately powered RCTs; it remains a niche for dedicated surgeons and highly selected Procedural aspects of CABG patients。 40 Hybrid revascularisation (minimally invasive Off-pump CABG is undertaken without the cardio- surgical grafting of the left anterior descending coronary pulmonary bypass pump, with the use of dedicated artery or of few selected targets, complemented by PCI of instruments to stabilise the target vessels and perform the remaining vessels) has not been widely embraced in anastomoses on the beating heart。32 Large RCTs have not clinical practice and the available evidence is scarce。41 reported significant benefits compared with traditional techniques,33,34 and there have been concerns over less Percutaneous coronary interventions complete revascularisation and higher risks of graft The first PCI was reported by Andreas Gruentzig in 1977 failure when CABG is performed off-pump。Off-pump to treat severe, discrete, non-calcified coronary artery CABG is currently adopted routinely only by dedicated stenoses。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 12,
      "text": "d by Andreas Gruentzig in 1977 failure when CABG is performed off-pump。Off-pump to treat severe, discrete, non-calcified coronary artery CABG is currently adopted routinely only by dedicated stenoses。 42 PCI was subsequently applied to patients with surgeons, although with important variations (in India acute myocardial infarction as early as 1980 (figure 1),43 1612 www。thelancet。com Vol 401 May 13, 2023 Review becoming the first-choice reperfusion therapy in this generation drug-eluting stents (everolimus or setting, given the survival and safety benefits of PCI over zotarolimus)。51 Thus, despite referral of increasingly intravenous thrombolytic therapy。44 PCI involves a guiding comorbid patients with complex lesions, short-term and catheter introduced under local anaesthesia from a long-term cardiovascular mortality following PCI has peripheral artery and directed to the coronary artery declined over the decades。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 13,
      "text": " short-term and catheter introduced under local anaesthesia from a long-term cardiovascular mortality following PCI has peripheral artery and directed to the coronary artery declined over the decades。 45,52 orifice, through which a dilation catheter with a distensible Early complications of PCI include periprocedural tip (balloon) is advanced across the stenotic or occluded myocardial infarction (with highly variable prevalence arterial site and inflated to compress and crack depending on definitions and ascertainment, from atherosclerotic or thrombotic material, thereby dilating 2% to 18%),53 stroke (01–1%),54 major bleeding (1–5%),55 the lumen。42 Clinical outcomes of patients treated by PCI and acute kidney injury (4–7%),56 all of which can adversely have progressively improved with technical and medical affect short-term and long-term survival。Midterm and advances (figure 2)。45 A first landmark was the introduction long-term stent-related adverse events include stent of coronary stents that greatly reduced the risk of abrupt thrombosis (01% per year) and restenosis requiring vessel closure。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 14,
      "text": " was the introduction long-term stent-related adverse events include stent of coronary stents that greatly reduced the risk of abrupt thrombosis (01% per year) and restenosis requiring vessel closure。 46 A major drawback, however, was stent revascularisation (05–1% per year),57 with little attenuation thrombosis within the first month, complicating 1–3% of up to 10 years after PCI, even with new-generation drug- elective procedures and 7–15% of emergency procedures, eluting stents。58 Stent thrombosis is classified on the basis despite the use of intravenous heparin and oral of timing after implantation as acute (0–24 h), subacute (24 anticoagulation。47 A second landmark was replacing oral h–30 days), late (30 days–1 year), or very late (>1 year)。59 anticoagulation with a platelet P2Y -receptor inhibitor Acute and subacute events are generally related to technical 12 (each on a background of aspirin), with dual antiplatelet issues (inadequate stent expansion, residual dissection, therapy (DAPT) substantially reducing stent thrombosis and tissue prolapse) or inadequate platelet inhibition, rates and contributing to widespread adoption of PCI。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 15,
      "text": "ent expansion, residual dissection, therapy (DAPT) substantially reducing stent thrombosis and tissue prolapse) or inadequate platelet inhibition, rates and contributing to widespread adoption of PCI。 48 A whereas late and very late events are generally persistent major drawback of the procedure—although related to discontinuation of antiplatelet therapy, with lower rates after stenting than with plain balloon neoatherosclerosis, and delayed vessel healing。60 Although angioplasty—was restenosis, necessitating repeated new-generation drug-eluting stents and more potent interventions。46,49 A third landmark was the introduction of platelet inhibitors have reduced the prevalence of stent drug-eluting stents that limited the prevalence of thrombosis, it still affects 1–25% of PCI patients。57,58 Stent- restenosis to single percent digits compared with bare- free PCI is a novel approach to avoid stent-related metal stenting。50 Older drug-eluting stents (sirolimus or complications。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 16,
      "text": "tients。57,58 Stent- restenosis to single percent digits compared with bare- free PCI is a novel approach to avoid stent-related metal stenting。50 Older drug-eluting stents (sirolimus or complications。 Drug-coated balloons are reported to be paclitaxel) have been largely superseded by second non-inferior to drug-eluting stents for small vessel lesions61 1986 Survival benefit of intravenous thrombolysis vs placebo in acute myocardial infarction 1988 1969 2014 35-day vascular death reduced by aspirin in Familial hypercholesterolaemia Cardiovascular death reduced by ARNI acute myocardial infarction linked to early coronary heart disease in heart failure with LVEF <41% 1994 1975 Survival benefit of long-term statin 2017 1950–60 Reversal of in coronary heart disease 50% non-adherence of patients Framingham epidemiology 1961 cardiovascular disease Coronary narrowing and events reduced with cardiovascular disease to study First CCU mortality in the USA by intensive risk factor control prescribed lifesaving medications 1950 1960 1970 1980 1990 2000 2010 2020 1960 1980 1992 2020 Coronary risk factor awareness Coronary thrombus MI prevention by Benefit of SGLT2 inhibition 1967 retrieved from most long-term aspirin in heart failure and diabetes Cardiovascular disease risk score concept patients with in chronic coronary 2007–09 early STEMI syndrome Benefit of new vs old P2Y inhibition post acute 1970 Survival benefit of ACEi coronary syndrome, but in 12 creased bleeding Experimental atherogenesis in acute myocardial slowed by diet and cholesterol lowering infarction with 2007 Benefit of cardiac resynchronisation therapy LVEF <41% 2004 1993 Benefit of intensive vs moderate lipid lowering Benefit of immediate angioplasty vs thrombolysis post acute coronary syndrome in acute myocardial infarction 2001 1996 Benefit of DAPT vs SAPT post acute coronary syndrome Survival benefit of β blocker in 2000 chronic heart failure and LVEF <36% Benefit of long-term ACEi in coronary heart disease and diabetes without heart failure Figure 2: Timeline of key advancements in medical therapy for coronary artery disease ACEi=angiotensin-converting enzyme inhibitor。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 17,
      "text": "rm ACEi in coronary heart disease and diabetes without heart failure Figure 2: Timeline of key advancements in medical therapy for coronary artery disease ACEi=angiotensin-converting enzyme inhibitor。 ARNI=angiotensin receptor–neprilysin inhibitor。CCU=coronary care unit。DAPT=dual antiplatelet therapy。LVEF=left ventricular ejection fraction。SAPT=single antiplatelet therapy。SGLT2=sodium-glucose cotransporter-2。STEMI=ST-segment elevation myocardial infarction。www。thelancet。com Vol 401 May 13, 2023 1613 Review and are used for in-stent restenosis,62 whereas bioresorbable major bleeding, vascular complications, major adverse stent scaffolds have so far not shown incremental benefits cardiovascular events, and mortality compared with the compared with drug-eluting stents。63 traditional femoral artery approach。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 18,
      "text": "ajor adverse stent scaffolds have so far not shown incremental benefits cardiovascular events, and mortality compared with the compared with drug-eluting stents。63 traditional femoral artery approach。 64,65 Fractional flow reserve assessed by adenosine Procedural aspects of PCI vasodilation or resting instantaneous wave-free ratio is Radial artery access has become standard PCI practice, as recommended by current guidelines to assess the trial findings and meta-analyses show lower rates of functional severity of intermediate epicardial artery Participants Patient Sex of Mean age of Modality of Follow-up Primary outcome (revascularisation vs (N [medical therapy; population participants (%) participants revascularisation (%) period medical therapy) revascularisation]) (years) AVERT (1999) 341 (164; 177) Patients with Female 159% 585 PCI 100% 15 years Composite of cardiac death, myocardial PMID: 10395630 coronary artery infarction, stroke, resuscitation after disease and cardiac arrest, repeat revascularisation, or negative stress test angina requiring hospitalisation: PCI 37%, medical therapy 13%; p=0048 MASS (1999) 214 (72; 142 [PCI 72, Patients with Female 18% 570 PCI 51%, CABG 49% 50 years Composite of cardiac death, acute PMID: 10567287 CABG 70]) coronary artery myocardial infarction, or refractory angina disease requiring revascularisation: CABG 86%, PCI 403%, medical therapy 239%; p=0001 TIME (2001) 305 (150; 155) Patients older than Female 429% 800 PCI 71%, CABG 29% 6 months Composite of death, myocardial infarction, PMID: 11583747 75 years and or hospitalisation for acute coronary chronic coronary syndrome: invasive 190%, medical therapy syndrome 490%; p<00001 RITA-2 (2003) 1018 (514; 504) Patients with Female 18% 580 PCI 100% 70 years Composite of death or myocardial PMID: 14522473 coronary artery infarction: PCI 145%, medical therapy disease and angina 123%; difference +22% (95% CI –20 to 64; p=021) COURAGE (2007) 2287 (1138; 1149) Patients with Female 15% 626 PCI 100% 46 years Composite of death or myocardial PMID: 17387127 coronary artery infarction: PCI 190%, medical therapy disease 185%; HR 105 (95% CI 087 to 127; p=062) COURAGE (2015) 1211 (598; 613) Patients with Female 85% 630 PCI 100% 119 years Death: PCI 25%, medical therapy 24%; PMID: 26559572 coronary artery HR 103 (95% CI 083 to 121; p=076) disease BARI 2D (2009) 2368 (1192; 1172 Patients with Female 296% 624 PCI 67%, CABG 33% 53 years Death: Revascularisation 117%, medical PMID: 19502645 [PCI 798, CABG 378]) diabetes and therapy 122%; p=097; PCI 108%, medical coronary artery therapy 102%; p=048; CABG 136%, disease medical therapy 164%; p=033 MASS II (2010) 611 (203; 405 [PCI 205, Patients with Female 31% 600 PCI 50%, CABG 50% 114 years Composite of death, Q-wave myocardial PMID: 20733102 CABG 203]) multivessel infarction, or angina requiring coronary artery revascularisation: CABG 330%, PCI 424%, disease medical therapy 591%; p<0001 STICH (2011) 1212 (602; 610) Patients with Female 122% 590 CABG 100% 46 years Death: CABG 36%, medical therapy 41%; PMID: 21463150 coronary artery HR 086 (95% CI 072 to 104; p=012) disease and left ventricular ejection fraction ≤35% STICHES (2016) 1212 (602; 610) Patients with Female 122% 590 CABG 100% 98 years Death: CABG 589%, medical therapy PMID: 27040723 coronary artery 661%; HR 084 (95% CI 073 to 097; disease and left p=002) ventricular ejection fraction ≤35% FAME-II (2018) 888 (441; 447) Patients with Female 212% 637 PCI 100% 5 years Composite of death, myocardial infarction, PMID: 29785878 functionally or urgent revascularisation: PCI 139%, significant lesions medical therapy 270%; HR 046 (95% CI (fractional flow 034 to 063; p<0001) reserve ≤080) ORBITA (2018) 200 (95; 105) Patients with Female 265% 660 PCI 100% 6 weeks Exercise time increment (s): PCI 284, PMID: 29103656 1-vessel coronary medical therapy 118; Difference 166 artery disease (95% CI –89 to 420; p=0200) (Table 1 continues on next page) 1614 www。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 19,
      "text": "6 weeks Exercise time increment (s): PCI 284, PMID: 29103656 1-vessel coronary medical therapy 118; Difference 166 artery disease (95% CI –89 to 420; p=0200) (Table 1 continues on next page) 1614 www。 thelancet。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 20,
      "text": "thelancet。 com Vol 401 May 13, 2023 Review Participants Patient Sex of Mean age of Modality of Follow-up Primary outcome (revascularisation vs (N [medical therapy; population participants (%) participants revascularisation (%) period medical therapy) revascularisation]) (years) (Continued from previous page) DECISION-CTO 834 (398; 417) Patients with Female 218% 626 PCI 100% 40 years Composite of death, myocardial infarction, (2019) chronic total stroke, or repeat revascularisation: PMID: 30813758 occlusion lesions PCI 224%, medical therapy 223%; HR 103 (95% CI 077 to 137; p=086) ISCHEMIA (2020) 5179 (2591; 2588 [PCI Patients with Female 226% 640 PCI 74%, CABG 26% 32 years Composite of cardiovascular death, PMID: 32227755 1915, CABG 673]) moderate-severe myocardial infarction, hospitalisation for ischaemia unstable angina, heart failure, or resuscitated cardiac arrest: invasive 164%, conservative 182%; difference –18% (95% CI –47 to 10) ISCHEMIA-CKD 777 (389; 388) Patients with Female 311% 627 PCI 85%, CABG 15% 22 years Composite of cardiovascular death or (2020) chronic kidney myocardial infarction: PMID: 32227756 disease and Invasive 364%, conservative 367%; moderate-severe HR 101 (95% CI 079 to 129; p=095) ischaemia REVIVED (2022) 700 (353; 347) Patients with Female 13% 693 PCI 100% 34 years Composite of death or hospitalisation for PMID: 36027563 extensive coronary heart failure: PCI 372%, medical therapy artery disease, left 380%; HR 099 (95% CI 078 to 127; ventricular ejection p=096) fraction ≤35%, and demonstrable myocardial viability CABG=coronary artery bypass grafting。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 21,
      "text": ": PCI 372%, medical therapy artery disease, left 380%; HR 099 (95% CI 078 to 127; ventricular ejection p=096) fraction ≤35%, and demonstrable myocardial viability CABG=coronary artery bypass grafting。 HR=hazard ratio。LVEF=left ventricular ejection fraction。PCI=percutaneous coronary intervention。Table 1: Main outcomes of randomised trials comparing revascularisation and medical therapy in patients with coronary artery disease stenoses。66,67 In the FAME trial, PCI guided by fractional risk related to comorbidities, complex coronary anatomy, flow reserve significantly reduced the composite or unstable haemodynamics。76 Many of these patients endpoint of death, myocardial infarction, and repeat have anatomical indications for CABG but a prohibitive revascularisation in patients with multivessel coronary surgical risk。artery disease compared with PCI guided by angiography only (132% vs 183%)。68 Two subsequent trials showed Medical therapy PCI guided by instantaneous wave-free ratio to be non- In the 1970s and 1980s, atherogenesis in animals was inferior to PCI guided by fractional flow reserve。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 22,
      "text": " subsequent trials showed Medical therapy PCI guided by instantaneous wave-free ratio to be non- In the 1970s and 1980s, atherogenesis in animals was inferior to PCI guided by fractional flow reserve。 69,70 PCI found to revert with changes in diet and serum guided by intravascular ultrasound has been associated cholesterol。77 Progression of coronary narrowing in with fewer ischaemic events than has PCI guided by humans was found to slow down with changes in diet, angiography only。71 More recently, PCI guided by optical smoking cessation, exercise, and control of blood coherence tomography was found to be non-inferior to pressure, bodyweight, and lipid profile。77,78 Since then, PCI guided by intravascular ultrasound。72 Despite the cardiovascular medical therapy has made great progress benefits suggested by the data, haemodynamic and (figure 2)。In the 1990s, statins,79 aspirin,80 and imaging guidance are seldom used in clinical practice。1 angiotensin-converting enzyme inhibitors81 were found With declining rates of ischaemic cardiovascular events to benefit patients with chronic coronary syndromes。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 23,
      "text": "re seldom used in clinical practice。1 angiotensin-converting enzyme inhibitors81 were found With declining rates of ischaemic cardiovascular events to benefit patients with chronic coronary syndromes。 after PCI, growing concerns have emerged over midterm Cardiovascular events were reduced by fibrinolysis in and long-term bleeding related to prolonged DAPT patients with ST-elevation myocardial infarction,82 and by therapy。Recent data show that short-term DAPT higher intensity statins,83 or by DAPT in patients with (1–3 months) followed by P2Y -inhibitor monotherapy acute coronary syndromes。84 In patients with chronic 12 reduces major bleeding events compared with standard heart failure, cardiovascular events were reduced by β 12-month DAPT, without significantly increasing blockade,85 angiotensin receptor–neprilsyn inhibitors,86 ischaemic events。73,74 and sodium-glucose cotransporter-2 inhibition PCI of chronic total occlusion is burdened by technical (figure 2)。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 24,
      "text": "easing blockade,85 angiotensin receptor–neprilsyn inhibitors,86 ischaemic events。73,74 and sodium-glucose cotransporter-2 inhibition PCI of chronic total occlusion is burdened by technical (figure 2)。 87 Yet a major limitation of medical therapy is challenges, low procedural success, and high complication the suboptimal long-term compliance rate of rates,75 but recent advances have improved patient approximately 50% reported in multiple studies, outcomes after chronic total occlusion-PCI undertaken by including revascularisation trials。88,89 experienced operators。75 Complex high-risk indicated PCI Numerous randomised trials have compared the is performed in patients with a clinical indication for efficacy and safety of revascularisation strategies against coronary revascularisation who are at high procedural medical therapy alone in non-acute patients with www。thelancet。com Vol 401 May 13, 2023 1615 Review obstructive coronary artery disease not involving the left 5179 patients with moderate or severe inducible ischaemia main stem (table 1)。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 25,
      "text": "tients with www。thelancet。com Vol 401 May 13, 2023 1615 Review obstructive coronary artery disease not involving the left 5179 patients with moderate or severe inducible ischaemia main stem (table 1)。 The COURAGE trial randomly and preserved ejection fraction to either an initial invasive assigned 2287 patients with coronary artery disease with strategy (74% by PCI, 26% by CABG) or to medical preserved left ventricular ejection fraction to initial PCI or therapy alone。At 32 years, the primary endpoint of medical therapy alone and found no difference between cardiovascular death, myocardial infarction, stroke, or groups at 46 years in the primary outcome of death and hospitalisation for unstable angina or resuscitated cardiac myocardial infarction (190% vs 185%)。90 The largest and arrest did not differ significantly between groups (164% most recent ISCHEMIA trial randomly assigned and 182%, respectively)。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 26,
      "text": "uscitated cardiac myocardial infarction (190% vs 185%)。90 The largest and arrest did not differ significantly between groups (164% most recent ISCHEMIA trial randomly assigned and 182%, respectively)。 91 Spontaneous myocardial ESC/EACTS 2018 guidelines ACC/AHA/SCAI 2021 guidelines JCS/JSCVS 2018 guidelines PMID: 30165437 PMID: 34882436 PMIDs: 35095031 and 30930428 Stable coronary artery disease One-vessel No proximal LAD stenosis: PCI* (COR: I; LOE: C); No proximal LAD stenosis: no revascularisation No proximal LAD stenosis: PCI* (COR: I; LOE: C); coronary artery proximal LAD stenosis: CABG or PCI (COR: I; LOE: A) (COR: III-no benefit; LOE: B-R); proximal LAD stenosis: proximal LAD stenosis: CABG* (COR: I; LOE: C) disease coronary revascularisation uncertain to improve survival (COR: IIb; LOE: B-R) Two-vessel No proximal LAD stenosis: PCI* (COR: I; LOE: C); No proximal LAD stenosis: no revascularisation (COR: SYNTAX score 0–22: CABG (COR: I; LOE: A) coronary artery proximal LAD stenosis: CABG (COR: I; LOE: B); PCI III-no benefit; LOE: B-R); proximal LAD stenosis: coronary PCI (COR: I; LOE: B); SYNTAX score 23–32: CABG* disease (COR: I; LOE: C) revascularisation uncertain to improve survival (COR: IIb; (COR: I; LOE: A); SYNTAX score ≥33: CABG (COR: I; LOE: B-R) LOE: A) Three- or SYNTAX score 0–22: CABG or PCI (COR: I; LOE: A); CABG and PCI (COR: IIb; LOE: B-R to improve survival SYNTAX score 0–22: CABG (COR: I; LOE: A) multivessel SYNTAX score >22: CABG* (COR: I; LOE: A) and COR: IIa; LOE B-R to reduce the risk of cardiovascular PCI (COR: I; LOE: B); SYNTAX score 23–32: CABG* coronary artery events); SYNTAX score >33: CABG to improve survival (COR: I; LOE: A); SYNTAX score ≥33: CABG (COR: I; disease (COR: IIa; LOE: B-R) LOE: A) Left main coronary SYNTAX score 0–22: CABG or PCI (COR: I; LOE: A); CABG (COR I; LOE: B-R); if PCI can provide equivalent Bifurcation lesions requiring <2 stents, and SYNTAX artery disease SYNTAX score 23–32: CABG* (COR: I; LOE: A); revascularisation: PCI acceptable (COR: IIa; LOE: B-NR) score 0–22: CABG (COR: I; LOE: A) SYNTAX score ≥33: CABG* (COR: I; LOE: A) PCI (COR: I; LOE: B); bifurcation lesions requiring <2 stents, and SYNTAX score 23–32: CABG* (COR: I; LOE: A); bifurcation lesions requiring 2 stents: CABG* (COR: I; LOE: A); SYNTAX score ≥33: CABG (COR: I; LOE: A) Diabetes Two-vessel NA NA SYNTAX score 0–22: CABG* (COR: I; LOE: A); coronary artery SYNTAX score 23–32: CABG* (COR: I; LOE: A); SYNTAX disease: score ≥33: CABG (COR: I; LOE: A) Three-vessel or CABG (COR: I; LOE: A) Involvement of LAD and appropriate surgical candidate: SYNTAX score 0–22: CABG* (COR: I; LOE: A); SYNTAX multivessel CABG (COR: I; LOE: A); poor surgical candidate: PCI score 23–32: CABG* (COR: I; LOE: A); SYNTAX coronary artery (COR: IIa; LOE: B-NR) score ≥33: CABG (COR: I; LOE: A) disease Left main stenosis NA Low-to-intermediate complexity in remaining coronary NA anatomy: PCI (COR: IIb; LOE: B-R) Low ejection fraction One-vessel or two- If complete revascularisation possible: consider NA CABG (COR: I; LOE: B) vessel coronary PCI (COR: IIa; LOE: C) artery disease Multivessel If acceptable surgical risk: CABG (COR: I; LOE: B) Ejection fraction <35%: CABG (COR: I; LOE: B-R); ejection CABG (COR: I; LOE: B) coronary artery fraction 35–50%: CABG (COR: IIa; LOE: B-NR) disease Acute coronary syndrome Non-ST-elevation Revascularisation according to same principles for Revascularisation by PCI or CABG (the mode of The revascularisation strategy should be stable coronary artery disease (COR: I; LOE: B) revascularisation should be based on the acuity of the discussed within the Heart Team as needed patient’s condition, the angiographic characteristics of (COR: I; LOE: C); failed PCI or technical difficulty, the culprit lesion, and the complexity of the patient’s persistent ischaemic attacks and haemodynamic anatomy and, when appropriate, include a Heart Team instability refractory to medical treatment, or frequent discussion; COR: I; LOE: A); failed PCI and ongoing ischemic attacks refractory to medical treatment ischaemia, haemodynamic compromise, or threatened and a large risk area (severe stenosis in left main stem or occlusion of an artery with substantial myocardium proximal LAD): CABG (COR: I; LOE: C) at risk: CABG (COR: IIa; LOE: B-NR) ACC=American College of Cardiology。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 27,
      "text": "ea (severe stenosis in left main stem or occlusion of an artery with substantial myocardium proximal LAD): CABG (COR: I; LOE: C) at risk: CABG (COR: IIa; LOE: B-NR) ACC=American College of Cardiology。 AHA=American Heart Association。BMS=bare-metal stents。B-NR=B-non-randomised。B-R=B-randomised。CABG=coronary artery bypass graft。COR=class of recommendation (I, IIa, IIb, or III)。DES=drug-eluting stents。ESC/EACTS=European Society of Cardiology and European Association for Cardio-Thoracic Surgery。JCS=Japanese Circulation Society。JSCVS=Japanese Society of Cardiovascular Surgeons。LAD=left anterior descending artery。LIMA=left internal mammary artery。LOE=level of evidence (A, B , or C)。PCI=percutaneous coronary intervention。SCAI=Society of Cardiovascular Angiography & Interventions。SYNTAX=Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery。*For categories with more than one revascularisation strategy recommended, we listed the one with the higher class of recommendation。Table 2: Summary of current practice guidelines’ recommendations for coronary revascularisation 1616 www。thelancet。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 28,
      "text": "tion strategy recommended, we listed the one with the higher class of recommendation。Table 2: Summary of current practice guidelines’ recommendations for coronary revascularisation 1616 www。thelancet。 com Vol 401 May 13, 2023 Review infarction, hospitalisation for unstable angina, and PCI CABG cardiac health deterioration were less frequent in the revascularisation group。91,92 Follow-up extension to 7 years showed no mortality difference between the groups (127% initial invasive strategy vs 134% initial medical therapy), but fewer cardiovascular deaths and more non- cardiovascular deaths in the invasive group。93 The BARI 2D trial94 in patients with coronary artery disease and diabetes with preserved ejection fraction also found no difference between initial revascularisation (PCI or Early period (<1 year) CABG) or medical therapy alone at 5 years follow-up。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 29,
      "text": "ery disease and diabetes with preserved ejection fraction also found no difference between initial revascularisation (PCI or Early period (<1 year) CABG) or medical therapy alone at 5 years follow-up。 By Sedation vs General anaesthesia contrast, in the FAME-II trial the composite of death, Radial or femoral puncture vs Median sternotomy or CPB myocardial infarction, or urgent revascularisation was Overnight in-hospital stay vs 4–7 day in-hospital stay significantly reduced in the fractional flow reserve-guided Lower risk of periprocedural vs Higher risk of periprocedural PCI group (139%) versus medical therapy alone complications complications (270%)。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 30,
      "text": "nificantly reduced in the fractional flow reserve-guided Lower risk of periprocedural vs Higher risk of periprocedural PCI group (139%) versus medical therapy alone complications complications (270%)。 95 5–7 days’ recovery vs 1–2 months’ recovery Comprehensive meta-analyses of trials comparing Late period (>1 year) Higher risk of adverse cardiac events* vs Lower risk of adverse cardiac events* revascularisation (CABG, PCI, or both) to medical therapy alone in patients with non-acute coronary artery disease Early advantages Late advantages and without left main disease or severely reduced left ventricular ejection fraction have found no significant difference in overall survival between strategies,96,97 but Key factors to be considered to guide the choice between PCI and CABG reductions in cardiac deaths97 and spontaneous myocardial Coronary Heart team Patient Surgical risk anatomy preference infarction, at the consequence of more frequent procedural myocardial infarctions with revascularisation。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 31,
      "text": "aths97 and spontaneous myocardial Coronary Heart team Patient Surgical risk anatomy preference infarction, at the consequence of more frequent procedural myocardial infarctions with revascularisation。 97 Two trials, STICH98,99 and REVIVED BCIS2,100 have compared revascularisation to medical therapy alone in patients with non-acute multivessel coronary artery disease and reduced left ventricular ejection fraction (≤35%)。The Clinical Comorbidities or Life expectancy Local expertise STITCH trial found no difference in all-cause deaths at presentation risk factor control 46 years, but fewer deaths with CABG after 98 years。98,99 In REVIVED BCIS2, the primary endpoint of all-cause death or hospitalisation for heart failure did not differ between PCI and medical therapy。100 An individual patient data analysis of 2523 patients with Figure 3: Comparison of key aspects of surgical and percutaneous coronary and without severely reduced ejection fraction derived revascularisation from four trials comparing CABG with medical therapy Parts of the figure were drawn with pictures from Flaticon。com (https://flaticon。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 32,
      "text": "hout severely reduced ejection fraction derived revascularisation from four trials comparing CABG with medical therapy Parts of the figure were drawn with pictures from Flaticon。com (https://flaticon。 alone found significantly lower 10-year mortality with com) and Servier Medical Art (https://smart。servier。com/)。Servier Medical Art by CABG (45% vs 52%), with the CABG survival benefit Servier is licensed under a CC BY 3。0 licence。CABG=coronary artery bypass grafting。CPB=cardiopulmonary bypass。PCI=percutaneous coronary becoming significant after the fourth postoperative year。101 intervention。*In particular, myocardial infarction and the need for repeat Chronic total occlusion-PCI compared with medical revascularisation。therapy alone has been found to improve angina and physical performance, but whether it reduces hard PCI versus CABG clinical outcomes remains unestablished。75 The available PCI and CABG are mechanistically and clinically very evidence on complex high-risk indicated-PCI compared different interventions (figure 3)。PCI treats only the flow- with medical therapy alone is limited to a few registry limiting stenosis and increases flow downstream; its studies。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 33,
      "text": "ndicated-PCI compared different interventions (figure 3)。PCI treats only the flow- with medical therapy alone is limited to a few registry limiting stenosis and increases flow downstream; its studies。 76 technical complexity depends on the lesion characteristics In summary, medical therapy should be used in all (location, calcification, and length)。102 Surgery, given its patients with coronary artery disease, with efforts focused more distal anastomoses, restores distal flow while on long-term compliance。Some patients might protecting against potential progression of proximal experience long-term reduction of cardiovascular events plaques that were not flow-limiting at the time of and anginal symptoms with revascularisation on top of intervention, and its technical complexity is independent medical therapy and lifestyle changes。For other patients, from lesion characteristics。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 34,
      "text": "f and anginal symptoms with revascularisation on top of intervention, and its technical complexity is independent medical therapy and lifestyle changes。For other patients, from lesion characteristics。 Periprocedural deaths are very revascularisation might not be necessary, or the low for both interventions, but non-fatal procedural periprocedural risks might outweigh the potential complications and rehospitalisation rates are higher, and long-term revascularisation benefits, and medical recovery periods longer, with surgery。In the years after the therapy alone could be the treatment of choice (table 2)。procedure, however, PCI requires more frequent www。thelancet。com Vol 401 May 13, 2023 1617 Review reinterventions than does surgery (mostly for disease trial, but not in the NOBLE trial。An individual patient-data progression in untreated areas),103 with a higher risk of analysis of four PCI versus CABG trials in patients with left acute coronary events。In clinical practice, most patients main coronary disease found 5-year deaths were similar for have clinical or anatomical characteristics (such as older PCI and CABG (112% vs 102%)。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 35,
      "text": "e coronary events。In clinical practice, most patients main coronary disease found 5-year deaths were similar for have clinical or anatomical characteristics (such as older PCI and CABG (112% vs 102%)。 113 Spontaneous age, diabetes, comorbidities, complex coronary anatomy, myocardial infarction was more common with PCI (62% or frailty) or strong preferences that make one or the other vs 26%), whereas there was no difference in the overall intervention more indicated。Published comparative trials risk of stroke (27% vs 31%), although in the first year after refer to patients where equipoise between PCI and CABG randomisation the risk of stroke was lower with PCI。113 existed for both the treating physicians and the patient。In Prespecified subanalyses of trials have reported overall the early 2000s, several RCTs compared the relative effects similar improvement in patients’ quality of life after PCI of PCI and CABG。These trials are not representative of and CABG, although the PCI group showed faster current practice and are mainly of historical interest。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 36,
      "text": "ent in patients’ quality of life after PCI of PCI and CABG。These trials are not representative of and CABG, although the PCI group showed faster current practice and are mainly of historical interest。 recovery and less physical limitations in the first months Table 3 shows the trials that inform current decision- and the surgery group showed better symptom relief at making。late follow-up。114,115 The SYNTAX trial in patients with multivessel disease or No RCT has directly compared PCI and CABG in left main disease104,105 found the composite outcome patients with reduced left ventricular ejection fraction。A including death, myocardial infarction, stroke, or repeat network meta-analysis of 23 studies involving revascularisation occurred significantly more frequently in 23 633 patients (including four small RCTs) found that the PCI group than the CABG group。No significant PCI and medical therapy were associated with more difference between groups was found in patients with low deaths than was CABG, but treatment allocation bias coronary artery disease complexity (expressed by a might have favoured surgery。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 37,
      "text": "d with more difference between groups was found in patients with low deaths than was CABG, but treatment allocation bias coronary artery disease complexity (expressed by a might have favoured surgery。 116 The ongoing STICH3C SYNTAX anatomical disease score <23), although the trial trial (NCT05427370) will provide new information。was underpowered for subgroup analysis on the basis of Overall, the evidence suggests a higher rate of SYNTAX score strata。At 10 years, deaths between the two periprocedural complications with CABG versus higher groups did not differ (28% for PCI vs 24% for CABG), but rates of myocardial infarction and re-revascularisation at 112 years, deaths were significantly higher with PCI。106 during follow-up with PCI。Current guidelines recommend The anatomical extent of coronary artery disease was a CABG for patients with complex coronary artery disease, significant treatment effect modifier, with patients with especially with diabetes or reduced ejection fraction, triple-vessel, but not those with left main, disease having whereas PCI is preferred for patients with less extensive or better survival with CABG。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 38,
      "text": "pecially with diabetes or reduced ejection fraction, triple-vessel, but not those with left main, disease having whereas PCI is preferred for patients with less extensive or better survival with CABG。 less complex coronary artery disease and for those at high The BEST trial107 compared new-generation everolimus- surgical risk (table 2)。66,67 All guidelines, however, specify eluting stents to CABG in patients with multivessel but that patient preference should be key in informing not left main coronary artery disease and found the treatment decisions。composite of death, myocardial infarction, and repeat revascularisation was significantly higher in the PCI Coronary revascularisation for acute coronary group at 46 years, but found no difference at 118 years syndromes of follow-up, although spontaneous myocardial infarction The aim of revascularisation in acute coronary syndromes and revascularisations were significantly more common is to salvage ischaemic myocardium and prevent adverse with PCI than with CABG。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 39,
      "text": "nfarction The aim of revascularisation in acute coronary syndromes and revascularisations were significantly more common is to salvage ischaemic myocardium and prevent adverse with PCI than with CABG。 108 events, including short-term death, while revascularisation In an individual patient data analysis of 11 PCI versus in chronic coronary syndromes has the scope of CABG trials including more than 11 000 patients, there improving symptoms and reducing the risk of long-term were fewer deaths with CABG (112% vs 92%), but eight cardiac events, particularly myocardial infarctions。trials used old PCI technology (bare-metal stenting and In patients hospitalised with ST-segment-elevation first-generation drug-eluting stents in four trials each)。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 40,
      "text": "articularly myocardial infarctions。trials used old PCI technology (bare-metal stenting and In patients hospitalised with ST-segment-elevation first-generation drug-eluting stents in four trials each)。 109 In myocardial infarction, early PCI of the culprit lesion the FAME-III trial,110 despite the use of fractional flow (primary PCI) reduces the rates of death, myocardial reserve guidance and current generations stents in the PCI infarction, stroke, and major bleeding compared with group, the incidence of the primary composite outcome fibrinolysis,44 and is a class I recommendation in the including death, myocardial infarction, stroke, or repeat current American, European, and Japanese guidelines revascularisation was significantly higher in the PCI group (fibrinolytic therapy is recommended when primary PCI than the CABG group (106% vs 69%)。The EXCEL111 and is not available)。66,67,117–119 In RCTs, complete revas- NOBLE112 trials found seemingly different results when cularisation, even as a staged procedure, reduced cardiac comparing PCI with CABG in patients with left main events compared with culprit lesion-only PCI。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 41,
      "text": "trials found seemingly different results when cularisation, even as a staged procedure, reduced cardiac comparing PCI with CABG in patients with left main events compared with culprit lesion-only PCI。 120–122 coronary disease, but this contradiction in results was due In patients with non-ST-segment-elevation acute to differences in the studies’ primary outcome definitions; coronary syndromes, early revascularisation is recom- myocardial infarction and re-revascularisation during mended in patients at high risk, and PCI is often the follow-up were more frequent in the PCI group in both chosen modality; however, in patients with complex trials, while mortality was lower with CABG in the EXCEL coronary anatomy, CABG should be considered。66,67,117,123 1618 www。thelancet。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 42,
      "text": " group in both chosen modality; however, in patients with complex trials, while mortality was lower with CABG in the EXCEL coronary anatomy, CABG should be considered。66,67,117,123 1618 www。thelancet。 com Vol 401 May 13, 2023 Review Participants Patient population Sex of participants Mean age of Follow-up Primary outcome (PCI vs CABG) (N [PCI; CABG]) (%) participants period (years) ARTS (2001) 1205 (600; 605) Patients with Female 235% 610 1 years Composite of death, myocardial infarction, repeat PMID: 11297702 multivessel disease revascularisation, stroke, or transient ischaemic attack: PCI 262%, CABG 122%; log-rank p<0001 AWESOME (2001) 454 (222; 232) Patients with Not reported 670 48 years Death: PCI 220%, CABG 270%; p>046 PMID: 11451264 medically refractory myocardial ischaemia ERACI-II (2001) 450 (225; 225) Patients with Female 206% 6195 30 days Composite of death, Q-wave myocardial infarction, PMID: 11153772 coronary artery stroke, or repeat revascularisation: PCI 18%, disease CABG 114%; p=00002 ERACI-II (2005) 450 (225; 225) Patients with Female 206% 6195 5 years Death: PCI 71%, CABG 115%; p=0182 PMID: 16098419 coronary artery disease Stent or Surgery (2002) 988 (488; 500) Patients with Female 219% 615 2 years Repeat revascularisation: PCI 21%, CABG 6%; PMID: 12383664 multivessel disease HR 385 (95% Cl 256 to 579; p<00001) OCTOstent (2005) 280 (138; 142 Patients with Female 315% 615 1 year Composite of death, myocardial infarction, stroke, PMID: 25696506 off-pump CABG) coronary artery or repeat revascularisation: PCI 145%, CABG 85%; disease difference –60% (95% CI –135 to 15) CARDia (2010) 510 (256; 254) Patients with Female 259% 640 1 year Composite of death, myocardial infarction, or stroke: PMID: 20117456 multivessel or PCI 13%, CABG 105%; HR 125 (95% CI 075 to 209; complex 1-vessel p=039) coronary artery disease and diabetes PRECOMBAT (2011) 600 (300; 300) Patients with left Female:235% 623 2 years Composite of death, myocardial infarction, stroke, PMID: 21463149 main disease or ischaemia-driven TVR: PCI 122%, CABG 81%; HR 150 (95% CI 090 to 252; p=012) PRECOMBAT (2020) 600 (300; 300) Patients with left Female 235% 623 113 years Composite of death, myocardial infarction, stroke, PMID: 32223567 main disease or ischaemia-driven TVR: PCI 298%, CABG 247%; HR 125 (95% CI 093 to 169) FREEDOM (2012) 1900 (953; 947) Patients with diabetes Female 287% 631 38 years Composite of death, myocardial infarction, or stroke: PMID: 23121323 and multivessel PCI 266%, CABG 187%; p=0005 disease FREEDOM (2019) 943 (478; 465) Patients with diabetes Female 310% 632 75 years Death: PCI 237%, CABG 187%; HR 132 PMID: 30428398 and multivessel (95% CI 097 to 178; p=0076) disease VA CARDS (2013) 198 (101/97) Patients with diabetes Female 11% 625 2 years Composite of death or myocardial infarction: PMID: 23428214 and multivessel or PCI 31%, CABG 53%; HR 089 (95% CI 047 to 171) isolated proximal LAD disease SYNTAX (2013) 1800 (903; 897) Patients with 3-vessel Female 224% 651 5 years Composite of death, myocardial infarction, stroke, or PMID: 23439102 or left main disease repeat revascularisation: PCI 321%, CABG 286%; HR 113 (95% CI 083 to 153; p=043) SYNTAXES (2019) 1689 (841; 848) Patients with 3-vessel Female 219% 651 112 years Death: PCI 270%, CABG 240%; HR 117 PMID: 31488373 or left main disease (95% CI 097 to 141; p=0092) BEST (2015) 880 (438; 442) Patients with Female 286% 646 46 years Composite of death, myocardial infarction, or TVR: PMID: 25774645 multivessel disease PCI 153%, CABG: 106%; HR 147 and Euroscore <8 (95% CI 101 to 213; p=004) BEST (2022) 880 (438; 442) Patients with Female 286% 646 118 years Composite of death, myocardial infarction, or TVR: PMID: 36121700 multivessel disease PCI 345%, CABG 303%; HR 118 and Euroscore <8 (95% CI 088 to 156; p=026) EXCEL (2019) 1905 (948; 957) Patients with left Female 231% 660 5 years Composite of death, myocardial infarction, or stroke: PMID: 31562798 main disease and PCI 220%, CABG 192%; event rate difference 28% SYNTAX score ≤32 (95% CI –09 to 65; p=013) NOBLE (2020) 1201 (598; 603) Patients with left Female 22% 662 49 years Composite of death, myocardial infarction, stroke, PMID: 31879028 main disease or repeat revascularisation: PCI 28%, CABG 19%; HR 158 (95% CI 124 to 201; p=00002) FAME-III (2022) 1500 (757; 743) Patients with Female 177% 652 1 year Composite of death, myocardial infarction, stroke, PMID: 34735046 3-vessel disease or repeat revascularisation: PCI 106%, CABG 69%; HR 15 (95% CI 11 to 22; p=035 for non-inferiority) CABG=coronary artery bypass grafting。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 43,
      "text": "myocardial infarction, stroke, PMID: 34735046 3-vessel disease or repeat revascularisation: PCI 106%, CABG 69%; HR 15 (95% CI 11 to 22; p=035 for non-inferiority) CABG=coronary artery bypass grafting。 HR=hazard ratio。LVEF=left ventricular ejection fraction。PCI=percutaneous coronary intervention。SYNTAX=Synergy between PCI with Taxus and Cardiac Surgery。TVR=target vessel revascularisation。Table 3: Main outcomes of randomised trials comparing PCI and CABG www。thelancet。com Vol 401 May 13, 2023 1619 Review Information on the relative effectiveness of PCI and revascularisation trials, women accounted for 20–30% of CABG in patients with acute coronary syndromes is the enrolled population (tables 1 and 3)。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 44,
      "text": "Information on the relative effectiveness of PCI and revascularisation trials, women accounted for 20–30% of CABG in patients with acute coronary syndromes is the enrolled population (tables 1 and 3)。 On the basis of scarce, but in the pooled analysis of left main disease available data, the benefits of several coronary artery trials, clinical presentation was a significant treatment disease therapies seem to be extendable to women, including effect modifier and patients with acute coronary fibrinolysis,82 antiplatelet regimens,80,125 renin-angiotensin- syndromes had lower mortality with PCI, whereas patients aldosterone inhibitors,81,125 statins,79,124,125 β blockers85 and with chronic coronary artery disease had better outcomes angiotensin receptor–neprilysin inhibitor,86 SGLT2- with surgery。113 inhibitors,87 radial arterial access,65 primary PCI,131 PCI in Antiplatelet therapy after PCI differs in patients with acute coronary syndromes,132 revascularisation for acute coronary syndromes or chronic coronary artery ischaemic cardio myopathy,98 drug-eluting stents,133 and disease: ticagrelor or prasugrel for 3–12 months are radial arteries for CABG。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 45,
      "text": "risation for acute coronary syndromes or chronic coronary artery ischaemic cardio myopathy,98 drug-eluting stents,133 and disease: ticagrelor or prasugrel for 3–12 months are radial arteries for CABG。 134,135 recommended in patients with acute coronary syndromes, In most revascularisation trials, patient age at baseline whereas clopidogrel for 1–6 months is recommended in was approximately 65 years (tables 1 and 3)。Most effects of patients with chronic coronary artery disease。Similarly, revascularisation and medical therapies also seem after CABG, aspirin alone is recommended long term for applicable to older adults, provided age adjustments are chronic coronary artery disease, whereas 12 months of made for drug doses, especially for prasugrel, fibrinolysis, DAPT is recommended for acute coronary syndromes。66,67,117 certain direct oral anticoagulants, and enoxaparin。129 History of stroke and a high-bleeding risk profile influence Coronary revascularisation in women and older the choice and duration of antiplatelet therapy。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 46,
      "text": "rect oral anticoagulants, and enoxaparin。129 History of stroke and a high-bleeding risk profile influence Coronary revascularisation in women and older the choice and duration of antiplatelet therapy。 129 Although adults procedural complications increase exponentially with age, Women with coronary artery disease are at higher risk so do the expected benefits of treatment。129 The SENIOR- than men given their smaller body size, average 4-year to RITA trial (NCT03052036) is comparing revascularisation 10-year older patient age, more frequent comorbidities (PCI or CABG) versus medical therapy alone in patients (diabetes, hyper tension, heart and renal failure), more aged 75 years or older with acute non-ST elevation atypical symptoms leading to delayed diagnoses,124–126 myocardial infarction。lower adherence to medications,127 and lower socioeconomic status128 than men。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 47,
      "text": "5 years or older with acute non-ST elevation atypical symptoms leading to delayed diagnoses,124–126 myocardial infarction。lower adherence to medications,127 and lower socioeconomic status128 than men。 124,125 Medical attention Coronary revascularisation in low-income and is on average delayed in women, recommended drugs middle-income countries and interventions underused, and revascularisation Approximately 84% (ie, 66 billion people) of the world’s more often incomplete with lesser use of arterial grafts current population live in low-income or middle-income when CABG is undertaken。124,125 Women have higher countries (LMICs)。136 Since 1990, age-standardised137 rates of adverse events, including bleeding, renal annual mortality from cardiovascular diseases has dysfunction, vascular or device complications, and early decreased by 43% (from 283 to 160 cases per and late mortality after coronary revascularisation, even 100 000 people) in high-income countries (HICs), largely after adjustment for baseline characteristics。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 48,
      "text": "ased by 43% (from 283 to 160 cases per and late mortality after coronary revascularisation, even 100 000 people) in high-income countries (HICs), largely after adjustment for baseline characteristics。 124,125 thanks to improved lifestyles, diets, medical therapy, and The prevalence of coronary artery disease constantly access to health care, but mortality has decreased by only increases with age, and up to 80% of older individuals are 13% (from 381 to 332 per 100 000 people) in LMICs。136,137 estimated to have asymptomatic coronary artery disease。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 49,
      "text": "ality has decreased by only increases with age, and up to 80% of older individuals are 13% (from 381 to 332 per 100 000 people) in LMICs。136,137 estimated to have asymptomatic coronary artery disease。 128 The PURE cohort study,138 evaluating 156 424 people from Advanced age is a risk-enhancer among patients with the general population of 17 countries between 2003 and coronary artery disease, given atypical disease 2009, found substantially higher rates of cardiovascular presentation and delayed diagnosis, more extensive disease and death in LMICs versus HICs, despite a lower coronary artery disease compared with younger patients, risk factor burden in LMICs,139 suggesting important more frequent frailty and comorbidity (particularly renal differences across countries in terms of access to failure), polypharmacy and poor compliance with medical recommended medical therapies and appropriate therapy with cognitive impairm ent, social dependency, revascularisation。and shorter life expect ancy driving second-line care Compared with HICs, patients with coronary artery strategies。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 50,
      "text": "appropriate therapy with cognitive impairm ent, social dependency, revascularisation。and shorter life expect ancy driving second-line care Compared with HICs, patients with coronary artery strategies。 129 The ISCHEMIA-CKD trial randomly disease in LMICs are generally younger and have fewer assigned patients with advanced chronic kidney disease risk factors (although the latter might be due to less and moderate or severe inducible myocardial ischaemia efficient screening and reporting),140 with significantly to an initial invasive strategy or to medical therapy higher fatality rates related to coronary artery disease。139,141,142 alone。130 After 22 years, the composite primary outcome Coronary artery disease is a more frequent cause of heart of death or myocardial infarction did not differ in the two failure143 and prevention, and revasculari sation procedures groups, but the risks of stroke and of death or dialysis are substantially underused in LMICs compared with were significantly increased with revascularisation。HICs。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 51,
      "text": " and revasculari sation procedures groups, but the risks of stroke and of death or dialysis are substantially underused in LMICs compared with were significantly increased with revascularisation。HICs。 141,142 The total number of PCI per million people is Treatment effects for women and older adults are positively correlated with gross national income per derived from underpowered subgroup analyses。In most capita (Kimura T, Kyoto University, Kyoto, Japan; 1620 www。thelancet。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 52,
      "text": "omen and older adults are positively correlated with gross national income per derived from underpowered subgroup analyses。In most capita (Kimura T, Kyoto University, Kyoto, Japan; 1620 www。thelancet。 com Vol 401 May 13, 2023 Review Sample (n) Leading institution Interventions Primary aim CABG vs PCI PROVERB 1040 Assistance Publique–Hpitaux de Paris, Intervention: CABG with total arterial Assess whether total arterial CABG vs PCI reduces (NCT05532631) France revascularisation; comparator: PCI MACCE at 3-year follow-up STICH3C 754 Sunnybrook Health Sciences Centre, Intervention: CABG; comparator: PCI Assess whether CABG vs PCI in patients with (NCT05427370) University of Toronto, Canada multivessel or left main coronary artery disease and reduced LVEF reduces MACCE at 5-year follow-up MILESTONE 1000 American Heart of Poland, Poland Intervention: CABG; comparator: PCI Assess whether CABG vs PCI in patients with (NCT01311323) multivessel or left main disease and NSTE-ACS reduces MACCE at 1-year follow-up Coronary Artery Bypass 1550 Danish Study Group, Denmark Intervention: CABG; comparator: PCI Assess whether CABG vs PCI in high-risk patients with Grafts or Percutaneous severe coronary artery disease reduces MACCE at 5-year Coronary Intervention follow-up for Revascularization in Moderate- to High- Risk Patients With Ischemic Heart Disease and Reduced Left Ventricular Ejection Fraction (NCT05534698) Minimally invasive surgery, hybrid revascularisation Hybrid 1048 Copenhagen University Hospital, Intervention: hybrid coronary revascularisation Assess whether hybrid coronary revascularisation vs Revascularization Denmark (MID-CAB using LIMA-LAD with PCI to ≥1 non- CABG reduces a composite outcome of MACCE or Versus Coronary Artery LAD lesion); comparator: CABG unplanned hospitalisation Bypass Grafting (NCT05504031) EDGE (NCT05121610) 2864 Beijing Anzhen Hospital, China Intervention: CABG; Comparator 1: PCI; Assess whether CABG vs PCI vs hybrid coronary comparator 2: hybrid coronary revascularisation revascularisation in multivessel coronary disease (SYNTAX score >22) reduces MACCE at 1-year follow-up HCR-EAST 200 Shanghai East Hospital, China Intervention: one-stop hybrid coronary Assess whether hybrid coronary revascularisation vs PCI (NCT04811586) revascularisation (off-pump MID-CAB using in multivessel or left main coronary artery disease LIMA-LAD with PCI to 1 or more non-LAD reduces MACCE at 2-year follow-up lesions); comparator: PCI Efficacy and Safety of 200 Peking University Third Hospital, China Intervention: MICS-CABG; comparator: Assess whether MICS-CABG vs off-pump CABG Minimal Invasive off-pump CABG improves physical quality of life and recovery (physical Coronary Surgery in component score of SF-36) at 30-day follow-up Patients With Complex Coronary Artery Lesions (NCT04795193) MIST (NCT03447938) 176 University of Ottawa Heart Institute, Intervention: MICS-CABG; comparator: CABG Assess whether MICS-CABG vs CABG improves physical Canada quality of life and recovery (physical component score of SF-36) at 30-day follow-up。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 53,
      "text": "art Institute, Intervention: MICS-CABG; comparator: CABG Assess whether MICS-CABG vs CABG improves physical Canada quality of life and recovery (physical component score of SF-36) at 30-day follow-up。 CABG—conduits ROMA 4300 Weill Cornell-New York Presbyterian, Intervention: CABG with multiple arterial grafts; Assess whether multiple arterial grafting reduces (NCT03217006) New York, USA comparator: CABG with single arterial graft postoperative MACCE in comparison with single arterial grafting ROMA: Women 1310 Weill Cornell-New York Presbyterian, Intervention: CABG with multiple arterial grafts; Assess whether multiple arterial grafting reduces (NCT04124120) New York, USA comparator: CABG with single arterial graft postoperative MACCE in comparison with single arterial grafting in women CABG—medical therapy TOP-CABG 2300 Fuwai Hospital, China Intervention: de-escalated DAPT (ticagrelor Assess whether de-escalated DAPT vs DAPT for (NCT05380063) 90 mg BID and 100 mg aspirin daily) for 12 months following elective CABG reduces SVG total 3 months, then aspirin 100 mg daily + placebo) occlusion (on cardiac CTA or coronary angiography) or for 9 months; comparator: DAPT (ticagrelor bleeding events at 1-year follow-up 90 mg BID and 100 mg aspirin daily) for 12 months BEEFBURGER 200 Royal University Hospital, University of Intervention: de-prescription of β blockers (half- Assess whether β blockers deprescription vs (NCT04788186) Saskatchewan, Canada dose for 3 days, then quarter-dose for 3 days, continuation reduces MACCE, heart failure then discontinuation); comparator: continued hospitalisations, cardiac arrhythmia, syncope or β blockers per usual clinical care permanent pacemaker, or recurrent myocardial ischemia at 3-year follow-up following uncomplicated CABG in patients with LVEF ≥45% and no atrial fibrillation or flutter (Table 4 continues on next page) www。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 54,
      "text": "nent pacemaker, or recurrent myocardial ischemia at 3-year follow-up following uncomplicated CABG in patients with LVEF ≥45% and no atrial fibrillation or flutter (Table 4 continues on next page) www。 thelancet。com Vol 401 May 13, 2023 1621 Review Sample (n) Leading institution Interventions Primary aim (Continued from previous page) PACES 3200 Icahn School of Medicine at Mount Intervention: SAPT (aspirin or P2Y inhibitor); Assess whether OAC plus SAPT vs SAPT reduces a 12 (NCT04045665) Sinai, USA comparator: OAC and SAPT (vitamin K composite of MACCE or systemic arterial or venous antagonist [INR 2–3] or DOAC and aspirin or thromboembolism at 180 days after randomisation。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 55,
      "text": "T04045665) Sinai, USA comparator: OAC and SAPT (vitamin K composite of MACCE or systemic arterial or venous antagonist [INR 2–3] or DOAC and aspirin or thromboembolism at 180 days after randomisation。 P2Y12 inhibitor) Assess whether OAC plus SAPT vs SAPT reduces BARC type 3 or 5 bleeding at 90 days after randomisation NEWTON-CABG 766 Unity Health Toronto, University of Intervention: evolocumab; comparator: placebo Assess whether evolocumab compared with placebo (NCT03900026) Toronto, Canada reduces SVG disease rate (proportion of vein grafts with significant stenosis [≥50%] or total occlusion on cardiac CTA or coronary angiography) at 2-year follow-up TACSI (NCT03560310) 2200 Vastra Gotaland Region, Uppsala Intervention: DAPT (ticagrelor 90 mg twice a day Assess whether DAPT vs SAPT reduces MACCE at 1-year University, Sweden and 75–100 mg aspirin daily); comparator: follow-up after CABG in patients with acute coronary aspirin 75–160 mg daily。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 56,
      "text": "ice a day Assess whether DAPT vs SAPT reduces MACCE at 1-year University, Sweden and 75–100 mg aspirin daily); comparator: follow-up after CABG in patients with acute coronary aspirin 75–160 mg daily。 syndrome PCI vs Sham ORBITA-2 400 Imperial College London, UK Intervention: PCI; comparator: sham procedure Assess whether PCI vs sham procedure in patients with (NCT03742050) symptoms of stable angina without background anti- anginal therapy reduces symptoms of angina at 3-month follow-up。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 57,
      "text": ": sham procedure Assess whether PCI vs sham procedure in patients with (NCT03742050) symptoms of stable angina without background anti- anginal therapy reduces symptoms of angina at 3-month follow-up。 DANANGINA 450 Herlev and Gentofte Hospital, Intervention: PCI; comparator: sham procedure Assess whether PCI vs sham procedure in patients with (NCT04496648) Denmark symptoms of stable angina reduces symptoms of angina or myocardial infarction at 3-month follow-up PCI—drug-coated balloon vs drug-eluting stents in native coronary artery disease Long-term efficacy of 400 Shanghai Songjiang Central Hospital, Intervention: PCI with drug-coated balloon; Assess whether PCI with drug-coated balloon compared drug-coated balloon China comparator: PCI with sirolimus-eluting sten with PCI with drug-eluting stent reduces target lesion versus drug-eluting failure stent in large de novo coronary lesions (NCT05101005) DEBATE 546 North Karelia Central Hospital, Finland Intervention: PCI with drug-coated balloon; Assess whether PCI with drug-coated balloon compared (NCT04814212) comparator: PCI with drug-eluting stent with PCI with drug-eluting stent reduces net clinical benefit (a composite of MACE and bleeding) TRANSFORM II 1325 Clinica Polispecialistica San Carlo, Italy Intervention: PCI with drug-coated balloon; Assess whether PCI with drug-coated balloon compared (NCT04893291) comparator: PCI with everolimus-eluting stent with PCI with everolimus-eluting stent reduces target lesion failure PCI—haemodynamic support strategies CHIP-BCIS3 250 Guy’s and St Thomas’ NHS Foundation Intervention: percutaneous temporary LVAD; Assess whether percutaneous temporary LVAD vs usual (NCT05003817) Trust, UK comparator: standard of care care in high-risk PCI reduces a composite outcome of MACCE, periprocedural myocardial infarction, or cardiovascular hospitalisation at 1-year to 4-year follow-up PIONEER Trial 306 Xijing Hospital, China Intervention: VA-ECMO with IABP; comparator: Assess whether haemodynamic support combining (NCT04045873) IABP VA-ECMO with IABP compared with IABP support alone in patients undergoing elective high-risk PCI reduces MACCE at 30-day follow-up PCI—antithrombotic, PCSK9 inhibition and gastroprotective strategies STOPDAPT-3 6000 Kyoto University, Graduate School of Intervention: reduced dose prasugrel SAPT; Assess whether reduced dose prasugrel SAPT compared (NCT04609111) Medicine, Japan comparator: DAPT (reduced dose prasugrel and with DAPT reduces bleeding events and is non-inferior aspirin) for cardiovascular events after PCI in acute coronary syndrome patients with high bleeding risk at 30-day follow-up NEOMINDSET 3400 Hospital Israelita Albert Einstein, Brazil Intervention: prasugrel or ticagrelor SAPT; Assess whether prasugrel or ticagrelor SAPT compared (NCT04360720) comparator: DAPT (prasugrel or ticagrelor and with DAPT reduces bleeding events and is non-inferior aspirin) for MACE after PCI in patients with acute coronary syndrome at 1-year follow-up SMART-CHOICE 3 5000 Samsung Medical Center, Korea Intervention: clopidogrel SAPT; Assess whether clopidogrel SAPT compared with (NCT04418479) comparator: aspirin SAPT aspirin SAPT beyond 12 months after PCI reduces MACCE at 1-year follow-up ETACS (NCT05457582) 1212 Nanjing First Hospital, Nanjing Medical Intervention: PCSK9 inhibitor with high intensity Assess whether PCSK9 inhibitor with high intensity University, China statin; statin compared with placebo with high intensity statin comparator: placebo with high intensity statin reduces MACCE at 1-year follow-up in patients with acute coronary syndrome and multiple lesions (Table 4 continues on next page) 1622 www。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 58,
      "text": "tensity statin comparator: placebo with high intensity statin reduces MACCE at 1-year follow-up in patients with acute coronary syndrome and multiple lesions (Table 4 continues on next page) 1622 www。 thelancet。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 59,
      "text": "thelancet。 com Vol 401 May 13, 2023 Review Sample (n) Leading institution Interventions Primary aim (Continued from previous page) PROTECT-HBR 3000 Asan Medical Center, Korea Intervention: potassium-competitive acid Assess whether potassium-competitive acid blocker (NCT04416581) blocker; comparator: proton-pump inhibitor compared with proton-pump inhibitor in patients with cardiovascular disease receiving antiplatelet or OAC therapy who are at high gastrointestinal bleeding risk reduces gastrointestinal bleeding at 6-month follow-up Intravascular ultrasound-guided left main PCI OPTMAL 800 John Radcliffe Hospital, Oxford Intervention: intravscular ultrasound-guided Assess whether intravscular ultrasound-guided (NCT04072003) University Hospitals, UK PCI; comparator: QCA-guided PCI PCI compared with qualitative angiography-guided PCI in patients with unprotected left main disease reduces MACCE at 2-year follow-up Follow-up after coronary revascularisation ARCACHON 2664 Piti-Salptrire, France Intervention: no stress testing strategy; Assess whether no stress testing strategy compared (NCT04566497) comparator: systematic stress testing strategy with systematic stress testing strategy is non-inferior for cardiovascular events in asymptomatic patients after coronary revascularisation Acute myocardial infarction BETAMI 10 000 Oslo University Hospital, Norway Intervention: β blockers; Assess whether β blockers in patients with acute (NCT03646357) comparator: no β blockers myocardial infarction without heart failure or left ventricular systolic dysfunction reduces MACE at ≥2-year follow-up DANBLOCK 3570 Bispebjerg Hospital, Denmark Intervention: β blockers; Assess whether β blockers in patients with acute (NCT03778554) comparator: no β blockers myocardial infarction without heart failure or left ventricular systolic dysfunction reduces MACCE at 2-year follow-up REDUCE-SWEDEHEART 7000 Karolinska Institutet, Sweden Intervention: β blockers; Assess whether β blockers in patients with acute (NCT03278509) comparator: no β blockers myocardial infarction without left ventricular systolic dysfunction reduces MACE at 1-year follow-up REBOOT 8468 Fundación Centro Nacional de Intervention: β blockers; Assess whether β blockers in patients with acute (NCT03596385) Investigaciones Cardiovasculares comparator: no β blockers myocardial infarction without heart failure or left Carlos III, Spain ventricular systolic dysfunction reduces MACCE at a median 275-year follow-up SMART- DECISION 2540 Samsung Medical Center, Korea Intervention: discontinuation of β blockers; Assess whether discontinuation of β blockers after at (NCT04769362) comparator: continuation of β blockers least 1 year of β blockers compared with continuation of β blockers in patients with acute myocardial infarction without heart failure or left ventricular systolic dysfunction is non-inferior to MACE at 2-year follow-up AβYSS 3700 Assistance Publique–Hpitaux de Paris, Intervention: discontinuation of β blockers; Assess whether discontinuation of β blockers after at (NCT03498066) France comparator: continuation of β blockers least 6 months of β blockers compared with continuation of β blockers in patients with acute myocardial infarction without left ventricular systolic dysfunction is non-inferior to MACE at 2-year follow-up SENIOR-RITA 2300 Newcastle-upon-Tyne Hospitals, UK Intervention: coronary angiography; Assess whether an initial invasive strategy of coronary (NCT03052036) comparator: optimal medical therapy angiography in older patients with NSTE-ACS compared with optimal medical therapy reduces death or myocardial infarction at 5-year follow-up BARC=Bleeding Academic Consortium。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 60,
      "text": " optimal medical therapy angiography in older patients with NSTE-ACS compared with optimal medical therapy reduces death or myocardial infarction at 5-year follow-up BARC=Bleeding Academic Consortium。 CABG=coronary artery bypass grafting。CTA=computed tomography angiography。DAPT=dual antiplatelet therapy。DOAC=direct oral anticoagulant。IABP=intra-aortic balloon counterpulsation。INR=international normalised ratio。LAD=left anterior descending artery。LIMA-LAD=left internal mammary artery to left anterior descending artery grafting。LVAD=left ventricular assist device。LVEF=left ventricular ejection fraction。MACCE=major adverse cardiovascular and cerebrovascular events。MACE=major adverse cardiac events。MICS-CABG=minimally invasive cardiac surgery coronary artery bypass grafting。MID-CABG=minimally invasive direct coronary artery bypass grafting。NSTE-ACS=non ST-elevation acute coronary syndrome。OAC, oral anticoagulation。PCI=percutaneous coronary intervention。PCSK9=proprotein convertase subtilisin–kexin type 9。QCA=qualitative coronary angiography。SAPT=single antiplatelet therapy。SF-36=short form 36-item physical and mental health questionnaire。SVG=saphenous vein graft。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 61,
      "text": "ein convertase subtilisin–kexin type 9。QCA=qualitative coronary angiography。SAPT=single antiplatelet therapy。SF-36=short form 36-item physical and mental health questionnaire。SVG=saphenous vein graft。 SYNTAX=Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery。VA-ECMO=veno-arterial extracorporeal membrane oxygenation。Table 4: Summary of ongoing randomised trials on coronary revascularisation personal communication)。When emergency reperfusion have shown important geographical differences in is recommended, patients with ST-segment elevation treatment effects between HICs and LMICs。144,145 Although myocardial infarction are mainly given fibrinolytic the available evidence suggests that in patients with therapy in LMICs, and primary PCI in HICs。139,140 coronary artery disease CABG is more cost-effective than Most published data on the effects of PCI, CABG, and PCI in the long-term,146 this finding is based on procedural medical therapy come from high income populations and outcomes and postoperative survival that might not be might not apply to LMICs。144 Many cardiovascular trials applicable to some LMICs。Differences in demographics, www。thelancet。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 62,
      "text": "ncome populations and outcomes and postoperative survival that might not be might not apply to LMICs。144 Many cardiovascular trials applicable to some LMICs。Differences in demographics, www。thelancet。 com Vol 401 May 13, 2023 1623 Review resources, insurance systems, and health policies between event only。This information will allow accurately LMICs and HICs make general considerations for informed treatment decisions based on clinical status and revascularisation choices in LMICs difficult。In general, personal expectations and goals to be made by individual the choice of coronary revascularisation method should be patients and their treating physicians。based on resource availability and local expertise。Given Finally, some of the classic concepts regarding coronary that the costs and technical challenges associated with revascularisation and its role compared with medical procedural complications can be very high (potentially therapy might have to be revisited。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 63,
      "text": " that the costs and technical challenges associated with revascularisation and its role compared with medical procedural complications can be very high (potentially therapy might have to be revisited。 Future indications for overwhelming fragile health systems147,148), the likelihood of the treatment of coronary artery disease could shift procedural success should drive the choice of towards less invasive treatments and towards prevention revascularisation method。rather than intervention, as generally happens with evolution in medicine。Future directions and gaps in knowledge Contributors More than five decades after the introduction of CABG All authors contributed equally to the conceptualisation, writing, editing, and four decades after the introduction of PCI into and review of this Review。clinical practice, the procedural and long-term outcomes Declaration of interests of the two revascularisation methods are now well The authors declare no competing interests。MG receives research grants from the Canadian Institutes of Health and Research and the characterised。Although technological improvements will National Institute of Health。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 64,
      "text": "lare no competing interests。MG receives research grants from the Canadian Institutes of Health and Research and the characterised。Although technological improvements will National Institute of Health。 FA reports personal fees from Amgen, continue to increase their safety and efficacy, the relative AstraZeneca, Bayer, Bristol Meyers Squibb/Pfizer, and Daiichi-Sankyo。advantages and disadvantages of the two interventions TK receives research grants from ABBOT and Boston Scientific。will probably remain substantially unchanged (for There has been no funding or payment directed towards this Review or the authors’ decision to submit for publication。a summary of key ongoing trials on coronary revascularisation see table 4)。Acknowledgments We thank Lamia Harik and Ko Yamamoto for their help in the A limitation of available data is that they are from preparation of this work。prevalently young, White, male, HIC populations。The References results of coronary revascularisation in women, non- 1 Inohara T, Kohsaka S, Spertus JA, et al。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 65,
      "text": "at they are from preparation of this work。prevalently young, White, male, HIC populations。The References results of coronary revascularisation in women, non- 1 Inohara T, Kohsaka S, Spertus JA, et al。 Comparative trends in White racial and ethnic groups, older adults, and LMICs percutaneous coronary intervention in Japan and the United States, require further and urgent investigation。124 2013 to 2017。J Am Coll Cardiol 2020; 76: 1328–40。2 Ma L-Y, Chen W-W, Gao R-L, et al。China cardiovascular diseases All trials comparing medical therapy, PCI, or CABG report 2018: an updated summary。J Geriatr Cardiol 2020; 17: 1–8。aimed at assessing superiority or non-inferiority of one or 3 Shimizu H, Okada M, Toh Y, et al。Thoracic and cardiovascular other strategy in relation to a short list of cardiovascular surgeries in Japan during 2018: annual report by the Japanese Association for Thoracic Surgery。Gen Thorac Cardiovasc Surg 2021; outcomes (typically death, myocardial infarction, stroke, 69: 179–212。and repeat revascularisation)。Advances in diagnostic 4 OECD。Health at a glance 2021: OECD indicators。2021。https:// techniques have enabled detection of minor non-fatal www。oecd-ilibrary。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 66,
      "text": ", 69: 179–212。and repeat revascularisation)。Advances in diagnostic 4 OECD。Health at a glance 2021: OECD indicators。2021。https:// techniques have enabled detection of minor non-fatal www。oecd-ilibrary。 org/deliver/ae3016b9-en。pdf (accessed Sept 10, 2022)。cardiovascular events, often neither associated with 5 Mueller RL, Rosengart TK, Isom OW。The history of surgery for symptoms nor affecting quality of life。There is ischemic heart disease。Ann Thorac Surg 1997; 63: 869–78。uncertainty on the definition of clinically relevant non- 6 Bowdish ME, D’Agostino RS, Thourani VH, et al。STS Adult fatal events (in particular myocardial infarction and Cardiac Surgery Database: 2021 update on outcomes, quality, and research。Ann Thorac Surg 2021; 111: 1770–80。stroke) and on how to account for the competing risk of 7 Ohri SK, Benedetto U, Luthra S, et al。Coronary artery bypass death,149 and this uncertainty has generated confusion surgery in the UK, trends in activity and outcomes from a 15-year and disagreement in the interpretation of the available complete national series。Eur J Cardiothorac Surg 2022; 61: 449–56。evidence。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 67,
      "text": "on surgery in the UK, trends in activity and outcomes from a 15-year and disagreement in the interpretation of the available complete national series。Eur J Cardiothorac Surg 2022; 61: 449–56。evidence。 Other events that are very important for 8 ElBardissi AW, Aranki SF, Sheng S, O’Brien SM, Greenberg CC, patients—such as renal, pulmonary, and neuro- Gammie JS。Trends in isolated coronary artery bypass grafting: psychological outcomes, as well as quality of life and the an analysis of the Society of Thoracic Surgeons adult cardiac surgery database。J Thorac Cardiovasc Surg 2012; 143: 273–81。ability to work and interact socially—have been largely 9 Chan J, Dimagli A, Dong T, Fudulu DP, Sinha S, Angelini GD。ignored or relegated to secondary analyses。Additionally, Trend and factors associated with multiple arterial revascularization trials have generally used a time-to-first-event analysis, in coronary artery bypass grafting in the UK。Eur J Cardiothorac Surg ignoring recurrent events and methods to adjust for 2022; 62: ezac284。10 Gaudino M, Rahouma M, Di Mauro M, et al。Early versus delayed multiplicity。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 68,
      "text": "ry bypass grafting in the UK。Eur J Cardiothorac Surg ignoring recurrent events and methods to adjust for 2022; 62: ezac284。10 Gaudino M, Rahouma M, Di Mauro M, et al。Early versus delayed multiplicity。 At this stage of knowledge, the use of a stroke after cardiac surgery: a systematic review and meta-analysis。superiority or non-inferiority approach seems outdated, J Am Heart Assoc 2019; 8: e012447。as the interventions used to treat coronary artery disease 11 Lappalainen L, Rajamaki B, Tolppanen A-M, Hartikainen S。Coronary artery revascularizations and cognitive decline— clearly have very different early and late risk profiles and a systematic review。Curr Probl Cardiol 2022; 47: 100960。are complementary rather than antagonistic。The new 12 Kuźma E, Airdrie J, Littlejohns TJ, et al。Coronary artery bypass generation of coronary revascularisation trials should graft surgery and dementia risk in the Cardiovascular Health Study。Alzheimer Dis Assoc Disord 2017; 31: 120–27。provide adequately powered estimates of the results of the 13 Whitlock EL, Diaz-Ramirez LG, Smith AK, et al。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 69,
      "text": "ementia risk in the Cardiovascular Health Study。Alzheimer Dis Assoc Disord 2017; 31: 120–27。provide adequately powered estimates of the results of the 13 Whitlock EL, Diaz-Ramirez LG, Smith AK, et al。 Association of two techniques in heterogenous groups of patients and coronary artery bypass grafting vs percutaneous coronary for a larger number of holistic outcomes, which should intervention with memory decline in older adults undergoing coronary revascularization。JAMA 2021; 325: 1955–64。not be limited to the cardiovascular system or to the first 1624 www。thelancet。com Vol 401 May 13, 2023 Review 14 Whrborg P, Booth JE, Clayton T, et al。Neuropsychological 37 Gaudino M, Antoniades C, Benedetto U, et al。Mechanisms, outcome after percutaneous coronary intervention or coronary consequences, and prevention of coronary graft failure。Circulation artery bypass grafting: results from the Stent or Surgery (SoS) Trial。2017; 136: 1749–64。Circulation 2004; 110: 3411–17。38 Taggart DP, D’Amico R, Altman DG。Effect of arterial 15 Rydn L, Sartipy U, Evans M, Holzmann MJ。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 70,
      "text": "ting: results from the Stent or Surgery (SoS) Trial。2017; 136: 1749–64。Circulation 2004; 110: 3411–17。38 Taggart DP, D’Amico R, Altman DG。Effect of arterial 15 Rydn L, Sartipy U, Evans M, Holzmann MJ。 Acute kidney injury revascularisation on survival: a systematic review of studies after coronary artery bypass grafting and long-term risk of end-stage comparing bilateral and single internal mammary arteries。Lancet renal disease。Circulation 2014; 130: 2005–11。2001; 358: 870–75。16 Gumus F, Polat A, Yektas A, et al。Prolonged mechanical ventilation 39 Gaudino M, Alexander JH, Bakaeen FG, et al。Randomized after CABG: risk factor analysis。J Cardiothorac Vasc Anesth 2015; comparison of the clinical outcome of single versus multiple 29: 52–58。arterial grafts: the ROMA trial-rationale and study protocol。17 Dobrev D, Aguilar M, Heijman J, Guichard J-B, Nattel S。Eur J Cardiothorac Surg 2017; 52: 1031–40。Postoperative atrial fibrillation: mechanisms, manifestations and 40 Guo MH, Wells GA, Glineur D, et al。Minimally Invasive coronary management。Nat Rev Cardiol 2019; 16: 417–36。surgery compared to STernotomy coronary artery bypass grafting: 18 Caldonazo T, Kirov H, Rahouma M, et al。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 71,
      "text": " GA, Glineur D, et al。Minimally Invasive coronary management。Nat Rev Cardiol 2019; 16: 417–36。surgery compared to STernotomy coronary artery bypass grafting: 18 Caldonazo T, Kirov H, Rahouma M, et al。 Atrial fibrillation after the MIST trial。Contemp Clin Trials 2019; 78: 140–45。cardiac surgery: a systematic review and meta-analysis。41 Dixon LK, Akberali U, Di Tommaso E, George SJ, Johnson TW, J Thorac Cardiovasc Surg 2023; 165: 94–103。Bruno VD。Hybrid coronary revascularization versus coronary artery 19 Park YM, Cha MS, Park C-H, et al。Newly developed post-operative bypass grafting for multivessel coronary artery disease: a systematic atrial fibrillation is associated with an increased risk of late review and meta-analysis。Int J Cardiol 2022; 359: 20–27。recurrence of atrial fibrillation in patients who underwent open 42 Grntzig A。Transluminal dilatation of coronary-artery stenosis。heart surgery: long-term follow up。Cardiol J 2017; 24: 633–41。Lancet 1978; 1: 263。20 Gaudino M, Sanna T, Ballman KV, et al。Posterior left 43 Hartzler GO, Rutherford BD, McConahay DR。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 72,
      "text": "y-artery stenosis。heart surgery: long-term follow up。Cardiol J 2017; 24: 633–41。Lancet 1978; 1: 263。20 Gaudino M, Sanna T, Ballman KV, et al。Posterior left 43 Hartzler GO, Rutherford BD, McConahay DR。 Percutaneous pericardiotomy for the prevention of atrial fibrillation after cardiac transluminal coronary angioplasty: application for acute myocardial surgery: an adaptive, single-centre, single-blind, randomised, infarction。Am J Cardiol 1984; 53: 117C–21C。controlled trial。Lancet 2021; 398: 2075–83。44 Keeley EC, Boura JA, Grines CL。Primary angioplasty versus 21 Gillinov AM, Bagiella E, Moskowitz AJ, et al。Rate control versus intravenous thrombolytic therapy for acute myocardial infarction: rhythm control for atrial fibrillation after cardiac surgery。a quantitative review of 23 randomised trials。Lancet 2003; N Engl J Med 2016; 374: 1911–21。361: 13–20。22 Yao RJR, Hawkins NM, Lavaie Y, Deyell MW, Andrade JG, Bashir J。45 Szummer K, Wallentin L, Lindhagen L, et al。Relations between Anticoagulation management of postoperative atrial fibrillation after implementation of new treatments and improved outcomes in cardiac surgery: a systematic review。J Card Surg 2021; 36: 2081–94。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 73,
      "text": "ween Anticoagulation management of postoperative atrial fibrillation after implementation of new treatments and improved outcomes in cardiac surgery: a systematic review。J Card Surg 2021; 36: 2081–94。 patients with non-ST-elevation myocardial infarction during the last 23 Arsenault KA, Yusuf AM, Crystal E, et al。Interventions for 20 years: experiences from SWEDEHEART registry 1995 to 2014。preventing post-operative atrial fibrillation in patients undergoing Eur Heart J 2018; 39: 3766–76。heart surgery。Cochrane Database Syst Rev 2013; 2013: CD003611。46 Fischman DL, Leon MB, Baim DS, et al。A randomized comparison 24 Huang T-Y, Huang T-S, Cheng Y-T, et al。Radial artery harvesting in of coronary-stent placement and balloon angioplasty in the treatment coronary artery bypass grafting surgery—endoscopic or open of coronary artery disease。N Engl J Med 1994; 331: 496–501。method。A meta-analysis。PLoS One 2020; 15: e0236499。47 Kimura T, Nosaka H, Yokoi H, Iwabuchi M, Nobuyoshi M。25 Perezgrovas-Olaria R, Audisio K, Cancelli G, et al。Deep sternal Serial angiographic follow-up after Palmaz-Schatz stent wound infection and mortality in cardiac surgery: a meta-analysis。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 74,
      "text": "obuyoshi M。25 Perezgrovas-Olaria R, Audisio K, Cancelli G, et al。Deep sternal Serial angiographic follow-up after Palmaz-Schatz stent wound infection and mortality in cardiac surgery: a meta-analysis。 implantation: comparison with conventional balloon angioplasty。Ann Thorac Surg 2023; 115: 272–80。J Am Coll Cardiol 1993; 21: 1557–63。26 Hokkanen M, Huhtala H, Laurikka J, Jrvinen O。The effect of 48 Schmig A, Neumann F-J, Kastrati A, et al。A randomized postoperative complications on health-related quality of life and comparison of antiplatelet and anticoagulant therapy after the survival 12 years after coronary artery bypass grafting—a prospective placement of coronary-artery stents。N Engl J Med 1996; cohort study。J Cardiothorac Surg 2021; 16: 173。334: 1084–89。27 Risnes I, Abdelnoor M, Almdahl SM, Svennevig JL。Mediastinitis 49 Serruys PW, de Jaegere P, Kiemeneij F, et al。A comparison of after coronary artery bypass grafting risk factors and long-term balloon-expandable-stent implantation with balloon angioplasty in survival。Ann Thorac Surg 2010; 89: 1502–09。patients with coronary artery disease。N Engl J Med 1994; 331: 489–95。28 Shawon MSR, Odutola M, Falster MO, Jorm LR。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 75,
      "text": " implantation with balloon angioplasty in survival。Ann Thorac Surg 2010; 89: 1502–09。patients with coronary artery disease。N Engl J Med 1994; 331: 489–95。28 Shawon MSR, Odutola M, Falster MO, Jorm LR。 Patient and 50 Morice M-C, Serruys PW, Sousa JE, et al。A randomized comparison hospital factors associated with 30-day readmissions after coronary of a sirolimus-eluting stent with a standard stent for coronary artery bypass graft (CABG) surgery: a systematic review and revascularization。N Engl J Med 2002; 346: 1773–80。meta-analysis。J Cardiothorac Surg 2021; 16: 172。51 Navarese EP, Tandjung K, Claessen B, et al。Safety and efficacy 29 Engelman DT, Ben Ali W, Williams JB, et al。Guidelines for outcomes of first and second generation durable polymer drug perioperative care in cardiac surgery: Enhanced Recovery After eluting stents and biodegradable polymer biolimus eluting stents in Surgery Society recommendations。JAMA Surg 2019; 154: 755–66。clinical practice: comprehensive network meta-analysis。BMJ 2013; 30 Anderson L, Sharp GA, Norton RJ, et al。Home-based versus 347: f6530。centre-based cardiac rehabilitation。Cochrane Database Syst Rev 2017; 52 Shiomi H, Morimoto T, Furukawa Y, et al。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 76,
      "text": "alysis。BMJ 2013; 30 Anderson L, Sharp GA, Norton RJ, et al。Home-based versus 347: f6530。centre-based cardiac rehabilitation。Cochrane Database Syst Rev 2017; 52 Shiomi H, Morimoto T, Furukawa Y, et al。 Coronary 6: CD007130。revascularization in the past two decades in Japan (from the 31 Rollman BL, Belnap BH, LeMenager MS, et al。Telephone-delivered CREDO-Kyoto PCI/CABG Registries Cohort -1, -2, and -3)。collaborative care for treating post-CABG depression: a randomized Am J Cardiol 2021; 153: 20–29。controlled trial。JAMA 2009; 302: 2095–103。53 Ueki Y, Otsuka T, Br S, et al。Frequency and outcomes of 32 Gaudino M, Angelini GD, Antoniades C, et al。Off-pump coronary periprocedural MI in patients with chronic coronary syndromes artery bypass grafting: 30 years of debate。J Am Heart Assoc 2018; undergoing PCI。J Am Coll Cardiol 2022; 79: 513–26。7: e009934。54 Kwok CS, Kontopantelis E, Myint PK, et al。Stroke following 33 Quin JA, Wagner TH, Hattler B, et al。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 77,
      "text": "ars of debate。J Am Heart Assoc 2018; undergoing PCI。J Am Coll Cardiol 2022; 79: 513–26。7: e009934。54 Kwok CS, Kontopantelis E, Myint PK, et al。Stroke following 33 Quin JA, Wagner TH, Hattler B, et al。 Ten-year outcomes of percutaneous coronary intervention: type-specific incidence, off-pump vs on-pump coronary artery bypass grafting in the outcomes and determinants seen by the British Cardiovascular Department of Veterans Affairs: a randomized clinical trial。Intervention Society 2007–12。Eur Heart J 2015; 36: 1618–28。JAMA Surg 2022; 157: 303–10。55 Subherwal S, Peterson ED, Dai D, et al。Temporal trends in and 34 Diegeler A, Brgermann J, Kappert U, et al。Five-year outcome after factors associated with bleeding complications among patients off-pump or on-pump coronary artery bypass grafting in elderly undergoing percutaneous coronary intervention: a report from the patients。Circulation 2019; 139: 1865–71。National Cardiovascular Data CathPCI Registry。J Am Coll Cardiol 2012; 59: 1861–69。35 Kuwahara G, Tashiro T。Current status of off-pump coronary artery bypass。Ann Thorac Cardiovasc Surg 2020; 26: 125–32。56 Tsai TT, Patel UD, Chang TI, et al。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 78,
      "text": "gistry。J Am Coll Cardiol 2012; 59: 1861–69。35 Kuwahara G, Tashiro T。Current status of off-pump coronary artery bypass。Ann Thorac Cardiovasc Surg 2020; 26: 125–32。56 Tsai TT, Patel UD, Chang TI, et al。 Contemporary incidence, predictors, and outcomes of acute kidney injury in patients 36 Gaudino M, Hameed I, Robinson NB, et al。Angiographic patency undergoing percutaneous coronary interventions: insights from of coronary artery bypass conduits: a network meta-analysis of the NCDR Cath-PCI registry。JACC Cardiovasc Interv 2014; 7: 1–9。randomized trials。J Am Heart Assoc 2021; 10: e019206。www。thelancet。com Vol 401 May 13, 2023 1625 Review 57 Giustino G, Colombo A, Camaj A, et al。Coronary in-stent restenosis: 79 Scandinavian Simvastatin Survival Study Group。Randomised trial JACC state-of-the-art review。J Am Coll Cardiol 2022; 80: 348–72。of cholesterol lowering in 4444 patients with coronary heart disease: 58 Brugaletta S, Gomez-Lara J, Ortega-Paz L, et al。10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)。Lancet 1994; patients with everolimus-eluting versus bare-metal stents after 344: 1383–89。ST-segment elevation myocardial infarction。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 79,
      "text": "year follow-up of the Scandinavian Simvastatin Survival Study (4S)。Lancet 1994; patients with everolimus-eluting versus bare-metal stents after 344: 1383–89。ST-segment elevation myocardial infarction。 J Am Coll Cardiol 2021; 80 Juul-Mller S, Edvardsson N, Jahnmatz B, Rosn A, Srensen S, 77: 1165–78。Omblus R。Double-blind trial of aspirin in primary prevention of 59 Garcia-Garcia HM, McFadden EP, Farb A, et al。Standardized end point myocardial infarction in patients with stable chronic angina definitions for coronary intervention trials: the Academic Research pectoris。Lancet 1992; 340: 1421–25。Consortium-2 consensus document。Circulation 2018; 137: 2635–50。81 Sleight P。The HOPE Study (Heart Outcomes Prevention 60 Claessen BE, Henriques JPS, Jaffer FA, Mehran R, Piek JJ, Evaluation)。J Renin Angiotensin Aldosterone Syst 2000; 1: 18–20。Dangas GD。Stent thrombosis: a clinical perspective。82 Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group。JACC Cardiovasc Interv 2014; 7: 1081–92。Indications for fibrinolytic therapy in suspected acute myocardial 61 Jeger RV, Farah A, Ohlow M-A, et al。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 80,
      "text": "inolytic Therapy Trialists’ (FTT) Collaborative Group。JACC Cardiovasc Interv 2014; 7: 1081–92。Indications for fibrinolytic therapy in suspected acute myocardial 61 Jeger RV, Farah A, Ohlow M-A, et al。 Drug-coated balloons for small infarction: collaborative overview of early mortality and major coronary artery disease (BASKET-SMALL 2): an open-label morbidity results from all randomised trials of more than randomised non-inferiority trial。Lancet 2018; 392: 849–56。1000 patients。Lancet 1994; 343: 311–22。62 Siontis GCM, Stefanini GG, Mavridis D, et al。Percutaneous 83 Cannon CP, Braunwald E, McCabe CH, et al。Intensive versus coronary interventional strategies for treatment of in-stent moderate lipid lowering with statins after acute coronary restenosis: a network meta-analysis。Lancet 2015; 386: 655–64。syndromes。N Engl J Med 2004; 350: 1495–504。63 Sorrentino S, Giustino G, Mehran R, et al。Everolimus-Eluting 84 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK。bioresorbable scaffolds versus everolimus-eluting metallic stents。Effects of clopidogrel in addition to aspirin in patients with acute J Am Coll Cardiol 2017; 69: 3055–66。coronary syndromes without ST-segment elevation。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 81,
      "text": "olds versus everolimus-eluting metallic stents。Effects of clopidogrel in addition to aspirin in patients with acute J Am Coll Cardiol 2017; 69: 3055–66。coronary syndromes without ST-segment elevation。 N Engl J Med 2001; 345: 494–502。64 Ferrante G, Rao SV, Jni P, et al。Radial versus femoral access for coronary interventions across the entire spectrum of patients with 85 Packer M, Bristow MR, Cohn JN, et al。The effect of carvedilol on coronary artery disease: a meta-analysis of randomized trials。morbidity and mortality in patients with chronic heart failure。JACC Cardiovasc Interv 2016; 9: 1419–34。N Engl J Med 1996; 334: 1349–55。65 Valgimigli M, Gagnor A, Calabr P, et al。Radial versus femoral 86 McMurray JJV, Packer M, Desai AS, et al。Angiotensin-neprilysin access in patients with acute coronary syndromes undergoing inhibition versus enalapril in heart failure。N Engl J Med 2014; invasive management: a randomised multicentre trial。Lancet 2015; 371: 993–1004。385: 2465–76。87 Vaduganathan M, Docherty KF, Claggett BL, et al。SGLT-2 66 Neumann F-J, Sousa-Uva M, Ahlsson A, et al。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 82,
      "text": "14; invasive management: a randomised multicentre trial。Lancet 2015; 371: 993–1004。385: 2465–76。87 Vaduganathan M, Docherty KF, Claggett BL, et al。SGLT-2 66 Neumann F-J, Sousa-Uva M, Ahlsson A, et al。 2018 ESC/EACTS inhibitors in patients with heart failure: a comprehensive meta- guidelines on myocardial revascularization。Eur Heart J 2019; analysis of five randomised controlled trials。Lancet 2022; 40: 87–165。400: 757–67。67 Lawton JS, Tamis-Holland JE, Bangalore S, et al。2021 ACC/AHA/ 88 Newby LK, LaPointe NM, Chen AY, et al。Long-term adherence to SCAI guideline for coronary artery revascularization: executive evidence-based secondary prevention therapies in coronary artery summary: a report of the American College of Cardiology/American disease。Circulation 2006; 113: 203–12。Heart Association Joint Committee on Clinical Practice Guidelines。89 Pinho-Gomes A-C, Azevedo L, Ahn J-M, et al。Compliance with Circulation 2022; 145: e4–17。guideline-directed medical therapy in contemporary coronary 68 Tonino PAL, De Bruyne B, Pijls NHJ, et al。Fractional flow reserve revascularization trials。J Am Coll Cardiol 2018; 71: 591–602。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 83,
      "text": "45: e4–17。guideline-directed medical therapy in contemporary coronary 68 Tonino PAL, De Bruyne B, Pijls NHJ, et al。Fractional flow reserve revascularization trials。J Am Coll Cardiol 2018; 71: 591–602。 versus angiography for guiding percutaneous coronary 90 Boden WE, O’Rourke RA, Teo KK, et al。Optimal medical therapy intervention。N Engl J Med 2009; 360: 213–24。with or without PCI for stable coronary disease。N Engl J Med 2007; 69 Gtberg M, Christiansen EH, Gudmundsdottir IJ, et al。356: 1503–16。Instantaneous wave-free ratio versus fractional flow reserve to guide 91 Maron DJ, Hochman JS, Reynolds HR, et al。Initial invasive or PCI。N Engl J Med 2017; 376: 1813–23。conservative strategy for stable coronary disease。N Engl J Med 2020; 70 Davies JE, Sen S, Dehbi H-M, et al。Use of the instantaneous wave-free 382: 1395–407。ratio or fractional flow reserve in PCI。N Engl J Med 2017; 376: 1824–34。92 Spertus JA, Jones PG, Maron DJ, et al。Health-status outcomes with 71 Zhang J, Gao X, Kan J, et al。Intravascular ultrasound versus invasive or conservative care in coronary disease。N Engl J Med angiography-guided drug-eluting stent implantation: the 2020; 382: 1408–19。ULTIMATE trial。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 84,
      "text": ", Kan J, et al。Intravascular ultrasound versus invasive or conservative care in coronary disease。N Engl J Med angiography-guided drug-eluting stent implantation: the 2020; 382: 1408–19。ULTIMATE trial。 J Am Coll Cardiol 2018; 72: 3126–37。93 Hochman JS, Anthopolos R, Reynolds HR, et al。Survival after 72 Kubo T, Shinke T, Okamura T, et al。Optical frequency domain invasive or conservative management of stable coronary disease。imaging vs。intravascular ultrasound in percutaneous coronary Circulation 2023; 147: 8–19。intervention (OPINION trial): one-year angiographic and clinical 94 Frye RL, August P, Brooks MM, et al。A randomized trial of results。Eur Heart J 2017; 38: 3139–47。therapies for type 2 diabetes and coronary artery disease。73 Costa F, Montalto C, Bhatt D, et al。Abbreviated dual antiplatelet N Engl J Med 2009; 360: 2503–15。therapy after PCI in patients at high bleeding risk: a collaborative 95 Xaplanteris P, Fournier S, Pijls NHJ, et al。Five-year outcomes with meta-analysis of randomized trials。Eur Heart J 2022; 43: ehac544。1402。PCI guided by fractional flow reserve。N Engl J Med 2018; 74 Benenati S, Galli M, De Marzo V, et al。Very short vs。long dual 379: 250–59。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 85,
      "text": "analysis of randomized trials。Eur Heart J 2022; 43: ehac544。1402。PCI guided by fractional flow reserve。N Engl J Med 2018; 74 Benenati S, Galli M, De Marzo V, et al。Very short vs。long dual 379: 250–59。 antiplatelet therapy after second generation drug-eluting stents in 96 Bangalore S, Maron DJ, Stone GW, Hochman JS。Routine 35 785 patients undergoing percutaneous coronary interventions: revascularization versus initial medical therapy for stable ischemic a meta-analysis of randomized controlled trials。heart disease: a systematic review and meta-analysis of randomized Eur Heart J Cardiovasc Pharmacother 2021; 7: 86–93。trials。Circulation 2020; 142: 841–57。75 Azzalini L, Karmpaliotis D, Santiago R, et al。Contemporary issues 97 Navarese EP, Lansky AJ, Kereiakes DJ, et al。Cardiac mortality in in chronic total occlusion percutaneous coronary intervention。patients randomised to elective coronary revascularisation plus JACC Cardiovasc Interv 2022; 15: 1–21。medical therapy or medical therapy alone: a systematic review and 76 Kirtane AJ, Doshi D, Leon MB, et al。Treatment of higher-risk meta-analysis。Eur Heart J 2021; 42: 4638–51。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 86,
      "text": "asc Interv 2022; 15: 1–21。medical therapy or medical therapy alone: a systematic review and 76 Kirtane AJ, Doshi D, Leon MB, et al。Treatment of higher-risk meta-analysis。Eur Heart J 2021; 42: 4638–51。 patients with an indication for revascularization: evolution within 98 Velazquez EJ, Lee KL, Deja MA, et al。Coronary-artery bypass the field of contemporary percutaneous coronary intervention。surgery in patients with left ventricular dysfunction。N Engl J Med Circulation 2016; 134: 422–31。2011; 364: 1607–16。77 Kannel WB, Sytkowski PA。Atherosclerosis risk factors。99 Velazquez EJ, Lee KL, Jones RH, et al。Coronary-artery bypass Pharmacol Ther 1987; 32: 207–35。surgery in patients with ischemic cardiomyopathy。N Engl J Med 78 Haskell WL, Alderman EL, Fair JM, et al。Effects of intensive 2016; 374: 1511–20。multiple risk factor reduction on coronary atherosclerosis and 100 Perera D, Clayton T, O’Kane PD, et al。Percutaneous clinical cardiac events in men and women with coronary artery revascularization for ischemic left ventricular dysfunction。disease。The Stanford Coronary Risk Intervention Project (SCRIP)。N Engl J Med 2022; 387: 1351–60。Circulation 1994; 89: 975–90。1626 www。thelancet。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 87,
      "text": "scularization for ischemic left ventricular dysfunction。disease。The Stanford Coronary Risk Intervention Project (SCRIP)。N Engl J Med 2022; 387: 1351–60。Circulation 1994; 89: 975–90。1626 www。thelancet。 com Vol 401 May 13, 2023 Review 101 Gaudino M, Audisio K, Hueb WA, et al。Coronary artery bypass 120 Mehta SR, Wang J, Wood DA, et al。Complete revascularization grafting versus medical therapy in patients with stable coronary vs culprit lesion-only percutaneous coronary intervention for artery disease: an individual patient data pooled meta-analysis of angina-related quality of life in patients with ST-segment elevation randomized trials。J Thorac Cardiovasc Surg 2022; published online myocardial infarction: results from the COMPLETE randomized June 9。https://doi。org/10。1016/j。jtcvs。2022。06。003。clinical trial。JAMA Cardiol 2022; 7: 1091–99。102 Doenst T, Bonow RO, Bhatt DL, Falk V, Gaudino M。Improving 121 Engstrm T, Kelbk H, Helqvist S, et al。Complete revascularisation terminology to describe coronary artery procedures: JACC Review versus treatment of the culprit lesion only in patients with Topic of the Week。J Am Coll Cardiol 2021; 78: 180–88。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 88,
      "text": "ete revascularisation terminology to describe coronary artery procedures: JACC Review versus treatment of the culprit lesion only in patients with Topic of the Week。J Am Coll Cardiol 2021; 78: 180–88。 ST-segment elevation myocardial infarction and multivessel disease 103 Taniwaki M, Stefanini GG, Silber S, et al。4-year clinical outcomes (DANAMI-3—PRIMULTI): an open-label, randomised controlled and predictors of repeat revascularization in patients treated with trial。Lancet 2015; 386: 665–71。new-generation drug-eluting stents: a report from the RESOLUTE 122 Wald DS, Morris JK, Wald NJ, et al。Randomized trial of preventive All-Comers trial (A Randomized Comparison of a Zotarolimus- angioplasty in myocardial infarction。N Engl J Med 2013; Eluting Stent With an Everolimus-Eluting Stent for Percutaneous 369: 1115–23。Coronary Intervention)。J Am Coll Cardiol 2014; 63: 1617–25。123 Fox KAA, Clayton TC, Damman P, et al。Long-term outcome 104 Farkouh ME, Domanski M, Sleeper LA, et al。Strategies for of a routine versus selective invasive strategy in patients with multivessel revascularization in patients with diabetes。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 89,
      "text": "Long-term outcome 104 Farkouh ME, Domanski M, Sleeper LA, et al。Strategies for of a routine versus selective invasive strategy in patients with multivessel revascularization in patients with diabetes。 N Engl J Med non-ST-segment elevation acute coronary syndrome a meta- 2012; 367: 2375–84。analysis of individual patient data。J Am Coll Cardiol 2010; 105 Mohr FW, Morice M-C, Kappetein AP, et al。Coronary artery bypass 55: 2435–45。graft surgery versus percutaneous coronary intervention in patients 124 Gaudino M, Di Franco A, Cao D, et al。Sex-related outcomes of with three-vessel disease and left main coronary disease: 5-year follow- medical, percutaneous, and surgical interventions for coronary up of the randomised, clinical SYNTAX trial。Lancet 2013; 381: 629–38。artery disease: JACC Focus Seminar 3/7。J Am Coll Cardiol 2022; 106 Thuijs DJFM, Kappetein AP, Serruys PW, et al。Percutaneous 79: 1407–25。coronary intervention versus coronary artery bypass grafting in 125 Andreotti F, Marchese N。Women and coronary disease。Heart 2008; patients with three-vessel or left main coronary artery disease: 94: 108–16。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 90,
      "text": "y intervention versus coronary artery bypass grafting in 125 Andreotti F, Marchese N。Women and coronary disease。Heart 2008; patients with three-vessel or left main coronary artery disease: 94: 108–16。 10-year follow-up of the multicentre randomised controlled 126 Andreotti F, Maggioni AP, Scambia G。Sex- and genderspecific SYNTAX trial。Lancet 2019; 394: 1325–34。precision medicine for chronic coronary syndromes: challenges and 107 Park S-J, Ahn J-M, Kim Y-H, et al。Trial of everolimus-eluting stents opportunities。Kardiol Pol 2021; 79: 373–75。or bypass surgery for coronary disease。N Engl J Med 2015; 127 Lee CMY, Mnatzaganian G, Woodward M, et al。Sex disparities in 372: 1204–12。the management of coronary heart disease in general practices in 108 Ahn J-M, Kang D-Y, Yun S-C, et al。Everolimus-eluting stents or Australia。Heart 2019; 105: 1898–904。bypass surgery for multivessel coronary artery disease: extended 128 Madhavan MV, Gersh BJ, Alexander KP, Granger CB, Stone GW。follow-up outcomes of multicenter randomized controlled Coronary artery disease in patients ≥80 years of age。BEST trial。Circulation 2022; 146: 1581–90。J Am Coll Cardiol 2018; 71: 2015–40。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 91,
      "text": "CB, Stone GW。follow-up outcomes of multicenter randomized controlled Coronary artery disease in patients ≥80 years of age。BEST trial。Circulation 2022; 146: 1581–90。J Am Coll Cardiol 2018; 71: 2015–40。 109 Head SJ, Milojevic M, Daemen J, et al。Mortality after coronary 129 Andreotti F, Geisler T, Collet JP, et al。Acute, periprocedural and artery bypass grafting versus percutaneous coronary intervention longterm antithrombotic therapy in older adults: 2022 update by with stenting for coronary artery disease: a pooled analysis of the ESC Working Group on Thrombosis。Eur Heart J 2023; individual patient data。Lancet 2018; 391: 939–48。44: 262–79。110 Fearon WF, Zimmermann FM, De Bruyne B, et al。Fractional flow 130 Bangalore S, Maron DJ, O’Brien SM, et al。Management of coronary reserve-guided PCI as compared with coronary bypass surgery。disease in patients with advanced kidney disease。N Engl J Med N Engl J Med 2022; 386: 128–37。2020; 382: 1608–18。111 Stone GW, Kappetein AP, Sabik JF, et al。Five-year outcomes after 131 Bueno H, Betriu A, Heras M, at el。Primary angioplasty vs PCI or CABG for left main coronary disease。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 92,
      "text": " 128–37。2020; 382: 1608–18。111 Stone GW, Kappetein AP, Sabik JF, et al。Five-year outcomes after 131 Bueno H, Betriu A, Heras M, at el。Primary angioplasty vs PCI or CABG for left main coronary disease。 N Engl J Med 2019; fibrinolysis in very old patients with acute myocardial infarction: 381: 1820–30。TRIANA (TRatamiento del Infarto Agudo de miocardio eN 112 Holm NR, Mkikallio T, Lindsay MM, et al。Percutaneous coronary Ancianos) randomized trial and pooled analysis with previous angioplasty versus coronary artery bypass grafting in the treatment studies。Eur Heart J 2011; 32: 51–60。of unprotected left main stenosis: updated 5-year outcomes from 132 O’Donoghue M, Boden WE, Braunwald E, et al。Early invasive vs the randomised, non-inferiority NOBLE trial。Lancet 2020; conservative treatment strategies in women and men with unstable 395: 191–99。angina and non-ST-segment elevation myocardial infarction: 113 Sabatine MS, Bergmark BA, Murphy SA, et al。Percutaneous a meta-analysis。JAMA 2008; 300: 71–80。coronary intervention with drug-eluting stents versus coronary 133 Stefanini GG, Baber U, Windecker S, et al。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 93,
      "text": "atine MS, Bergmark BA, Murphy SA, et al。Percutaneous a meta-analysis。JAMA 2008; 300: 71–80。coronary intervention with drug-eluting stents versus coronary 133 Stefanini GG, Baber U, Windecker S, et al。 Safety and efficacy of artery bypass grafting in left main coronary artery disease: drug-eluting stents in women: a patient-level pooled analysis of an individual patient data meta-analysis。Lancet 2021; 398: 2247–57。randomised trials。Lancet 2013; 382: 1879–88。114 Baron SJ, Chinnakondepalli K, Magnuson EA, et al。Quality-of-life 134 Schwann TA, Habib RH, Wallace A, et al。Operative outcomes of after everolimus-eluting stents or bypass surgery for left-main multiple-arterial versus single-arterial coronary bypass grafting。disease: results from the EXCEL trial。J Am Coll Cardiol 2017; Ann Thorac Surg 2018; 105: 1109–19。70: 3113–22。135 Gaudino M, Benedetto U, Fremes S, et al。Association of radial artery 115 Abdallah MS, Wang K, Magnuson EA, et al。Quality of life after graft vs saphenous vein graft with long-term cardiovascular outcomes surgery or DES in patients with 3-vessel or left main disease。among patients undergoing coronary artery bypass grafting: a J Am Coll Cardiol 2017; 69: 2039–50。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 94,
      "text": "t with long-term cardiovascular outcomes surgery or DES in patients with 3-vessel or left main disease。among patients undergoing coronary artery bypass grafting: a J Am Coll Cardiol 2017; 69: 2039–50。 systematic review and meta-analysis。JAMA 2020; 324: 179–87。116 Gaudino M, Hameed I, Khan FM, et al。Treatment strategies in 136 The World Bank。Population, total - Low & middle income。2021。ischaemic left ventricular dysfunction: a network meta-analysis。https://data。worldbank。org/indicator/SP。POP。TOTL。locations=XO Eur J Cardiothorac Surg 2020; 59: 293–301。(accessed Aug 27, 2022)。117 Nakamura M, Yaku H, Ako J, et al。JCS/JSCVS 2018 guideline on 137 Roth GA, Mensah GA, Johnson CO, et al。Global burden of revascularization of stable coronary artery disease。Circ J 2022; cardiovascular diseases and risk factors, 1990–2019: update from the 86: 477–588。GBD 2019 study。J Am Coll Cardiol 2020; 76: 2982–3021。118 Collet J-P, Thiele H, Barbato E, et al。2020 ESC Guidelines for the 138 Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 95,
      "text": "pdate from the 86: 477–588。GBD 2019 study。J Am Coll Cardiol 2020; 76: 2982–3021。118 Collet J-P, Thiele H, Barbato E, et al。2020 ESC Guidelines for the 138 Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S。 The Prospective management of acute coronary syndromes in patients presenting Urban Rural Epidemiology (PURE) study: examining the impact of without persistent ST-segment elevation。Eur Heart J 2021; societal influences on chronic noncommunicable diseases in 42: 1289–367。low-, middle-, and high-income countries。Am Heart J 2009; 119 Ibanez B, James S, Agewall S, et al。2017 ESC guidelines for the 158: 1–7。e1。management of acute myocardial infarction in patients presenting 139 Tern PJW, Ho AKH, Sultana R, et al。Comparative overview of with ST-segment elevation: the task force for the management of ST-elevation myocardial infarction epidemiology, demographics, acute myocardial infarction in patients presenting with ST-segment management, and outcomes in five Asia-Pacific countries: elevation of the European Society of Cardiology (ESC)。Eur Heart J a meta-analysis。Eur Heart J Qual Care Clin Outcomes 2021; 7: 6–17。2018; 39: 119–77。www。thelancet。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 96,
      "text": "omes in five Asia-Pacific countries: elevation of the European Society of Cardiology (ESC)。Eur Heart J a meta-analysis。Eur Heart J Qual Care Clin Outcomes 2021; 7: 6–17。2018; 39: 119–77。www。thelancet。 com Vol 401 May 13, 2023 1627 Review 140 Shimony A, Grandi SM, Pilote L, et al。Utilization of evidence-based 146 Magnuson EA, Chinnakondepalli K, Vilain K, et al。Cost- therapy for acute coronary syndrome in high-income and low/ effectiveness of percutaneous coronary intervention versus bypass middle-income countries。Am J Cardiol 2014; 113: 793–97。surgery for patients with left main disease: results from the EXCEL 141 Yusuf S, Rangarajan S, Teo K, et al。Cardiovascular risk and events trial。Circ Cardiovasc Interv 2022; 15: e011981。in 17 low-, middle-, and high-income countries。N Engl J Med 2014; 147 Jacobson KM, Hall Long K, McMurtry EK, Naessens JM, Rihal CS。371: 818–27。The economic burden of complications during percutaneous 142 Kmpfer J, Yagensky A, Zdrojewski T, et al。Long-term outcomes coronary intervention。Qual Saf Health Care 2007; 16: 154–59。after acute myocardial infarction in countries with different 148 Mehaffey JH, Hawkins RB, Byler M, et al。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 97,
      "text": "ewski T, et al。Long-term outcomes coronary intervention。Qual Saf Health Care 2007; 16: 154–59。after acute myocardial infarction in countries with different 148 Mehaffey JH, Hawkins RB, Byler M, et al。 Cost of individual socioeconomic environments: an international prospective cohort complications following coronary artery bypass grafting。study。BMJ Open 2017; 7: e012715。J Thorac Cardiovasc Surg 2018; 155: 875–82。e1。143 Tromp J, Ouwerkerk W, Cleland JGF, et al。Global differences in 149 McCarthy CP, Januzzi JL Jr。Periprocedural MI as an endpoint in burden and treatment of ischemic heart disease in acute heart clinical trials: a proposed path forward。J Am Coll Cardiol 2022; failure: REPORT-HF。JACC Heart Fail 2021; 9: 349–59。79: 527–29。144 Mentz RJ, Kaski J-C, Dan G-A, et al。Implications of geographical variation on clinical outcomes of cardiovascular trials。Am Heart J Copyright  2023 Elsevier Ltd。All rights reserved。2012; 164: 303–12。145 Yusuf S, Wittes J。Interpreting geographic variations in results of randomized, controlled trials。N Engl J Med 2016; 375: 2263–71。1628 www。thelancet。com Vol 401 May 13, 2023。",
      "source": "1-s2.0-S0140673623004592-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 98,
      "text": "JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL。78, NO。4, 2021 2021 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER JACC HISTORICAL BREAKTHROUGHS IN PERSPECTIVE Percutaneous Coronary Revascularization JACC Historical Breakthroughs in Perspective PatrickW。Serruys,MD,PHD,a,b,c,*MasafumiOno,MD,a,b,d,*ScotGarg,MD,PHD,eHironoriHara,MD,a,b,d HideyukiKawashima,MD,a,b,dGiulioPompilio,MD,PHD,f,gDanieleAndreini,MD,PHD,f,hDavidR。Holmes,JR,MD,i YoshinobuOnuma,MD,PHD,a,bSpencerB。KingIII,MDj ABSTRACT Overthelast4decades,percutaneouscoronaryinterventionhasevolveddramaticallyandisnowanacceptabletreat- mentoptionforpatientswithadvancedcoronaryarterydisease。However,trialistshavestruggledtoestablishthe respectiverolesforpercutaneouscoronaryinterventionandcoronaryarterybypassgraftsurgery,especiallyinpatients withmultivesseldiseaseandunprotectedleft-mainstemcoronaryarterydisease。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 99,
      "text": "ruggledtoestablishthe respectiverolesforpercutaneouscoronaryinterventionandcoronaryarterybypassgraftsurgery,especiallyinpatients withmultivesseldiseaseandunprotectedleft-mainstemcoronaryarterydisease。 Severalpivotaltrialsandmeta-analyses comparingthese2revascularizationstrategieshaveenabledtherelativemeritsofeachtechniquetobeestablishedwith regardtothetypeofischemicsyndrome,thecoronaryanatomy,andthepatient’soverallcomorbidity。Precisionmedicine withindividualizedprognosisisemergingasanimportantmethodofselectingtreatment。However,thenever-ending advancementoftechnology,inconjunctionwiththeemergenceofnovelpharmacologicalagents,willinthefuture continuetoforceustoreconsidertheevolvingquestion:“Whichtreatmentstrategyisbetterandforwhichpatient。” (JAmCollCardiol2021;78:384–407)2021bytheAmericanCollegeofCardiologyFoundation。W hen the first percutaneous transluminal “endoprosthesis,” bulkiness, stiffness, and the coronary angioplasty (PTCA) was per- thrombogenic nature of this alien body in the formed by Andreas Grntzig on coronarybloodstream(SupplementalTables2and3)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 100,
      "text": "prosthesis,” bulkiness, stiffness, and the coronary angioplasty (PTCA) was per- thrombogenic nature of this alien body in the formed by Andreas Grntzig on coronarybloodstream(SupplementalTables2and3)。 September16th,1977(SupplementalFigures1and2), The STRESS (Stent Restenosis Study) (3) and BENE- coronaryarterybypasssurgery(CABG)wasalreadya STENT trials (4) finally succeeded in validating this maturingsiblingthathadprogressivelyevolvedsince newtechnique,butdualantiplatelettherapybecamea the first human attempt by Robert H。Goetz in 1960 must(5,6)。(SupplementalTable1)(1,2)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 101,
      "text": "in validating this maturingsiblingthathadprogressivelyevolvedsince newtechnique,butdualantiplatelettherapybecamea the first human attempt by Robert H。Goetz in 1960 must(5,6)。(SupplementalTable1)(1,2)。 TheearlyresultsoftheRAVEL(RandomizedStudy Between 1986 and 1994, balloon-expandable and with the Sirolimus-Coated Bx Velocity Balloon- self-expanding stents struggled to address multiple Expandable Stent in the Treatment of Patients with technical and clinical problems, including poor de Novo Native Coronary Artery Lesions) trial (7) crimpingofthestentontheballoon,incompleteand comparing first-generation drug-eluting stents (DES) inaccurate deployment of the self-expanding with bare-metal stents (BMS) showed what could FromtheaDepartmentofCardiology,NationalUniversityofIreland,Galway(NUIG),Galway,Ireland;bCRAM-SFICentrefor ResearchinMedicalDevices,Galway,Ireland;cNHLI,ImperialCollegeLondon,London,UnitedKingdom;dDepartmentofCar- Listentothismanuscript’s diology,AcademicMedicalCenter,UniversityofAmsterdam,Amsterdam,theNetherlands;eDepartmentofCardiology,Royal audiosummaryby BlackburnHospital,Blackburn,UnitedKingdom;fCentroCardiologicoMonzino,IRCCS,Milan,Italy;gDepartmentofBiomedical, Editor-in-Chief SurgicalandDentalSciences,UniversityofMilan,Milan,Italy;hDepartmentofClinicalSciencesandCommunityHealth,Uni- Dr。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 102,
      "text": "m;fCentroCardiologicoMonzino,IRCCS,Milan,Italy;gDepartmentofBiomedical, Editor-in-Chief SurgicalandDentalSciences,UniversityofMilan,Milan,Italy;hDepartmentofClinicalSciencesandCommunityHealth,Uni- Dr。 ValentinFusteron versityofMilan,Milan,Italy;iDepartmentofCardiovascularDiseases,MayoClinic,Rochester,Minnesota,USA;andthejDivision JACC。org。ofCardiology,DepartmentofMedicine,EmoryUniversitySchoolofMedicine,Atlanta,Georgia,USA。*DrsSerruysandOno contributedequallytothiswork。Theauthorsattesttheyareincompliancewithhumanstudiescommitteesandanimalwelfareregulationsoftheauthors’ institutionsandFoodandDrugAdministrationguidelines,includingpatientconsentwhereappropriate。Formoreinformation, visittheAuthorCenter。ManuscriptreceivedMarch18,2021;revisedmanuscriptreceivedMay5,2021,acceptedMay11,2021。ISSN0735-1097/$36。00 https://doi。org/10。1016/j。jacc。2021。05。024 JACC VOL。78, NO。4, 2021 Serruysetal。385 JULY 27, 2021:384–407 TheHistoryandFutureofPCIVersusCABG smallvesselsarethecurrentandfuturetarget ABBREVIATIONS HIGHLIGHTS of this technology (18)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 103,
      "text": "。2021。05。024 JACC VOL。78, NO。4, 2021 Serruysetal。385 JULY 27, 2021:384–407 TheHistoryandFutureofPCIVersusCABG smallvesselsarethecurrentandfuturetarget ABBREVIATIONS HIGHLIGHTS of this technology (18)。 There are several AND ACRONYMS (cid:1) PCI techniques have evolved over 4 de- ongoing studies aiming to compare drug- 3VD=3-vesseldisease cades, as indications have expanded and coated balloon with DES including patients BMS=bare-metalstent(s) outcomes improved。with large de novo coronary arteries, and it would be an ironic paradox to see the stent CABG=coronaryarterybypass (cid:1) Numerous studies have addressed the graft beingagainrelegatedtoitshistoricalfunction role of PCI as an alternative to CABG in of“bail-out”device。CAD=coronaryarterydisease specific patient populations。DES=drug-elutingstent(s) (cid:1) Further studies are needed to clarify the 1。VULNERABLE PLAQUE, THE MI=myocardialinfarction optimum approach to selection of one UBIQUITOUS AND RESILIENT ENEMY: MVD=multivesseldisease revascularization strategy over another TO BE SEALED, BYPASSED, OR PCI=percutaneouscoronary for individual patients with coronary ar- DRUG PASSIVATED intervention tery disease。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 104,
      "text": " MVD=multivesseldisease revascularization strategy over another TO BE SEALED, BYPASSED, OR PCI=percutaneouscoronary for individual patients with coronary ar- DRUG PASSIVATED intervention tery disease。 ULM=unprotectedleftmain An important clinical challenge is managing acute potentially be achieved by using DES, with ideal re- coronary syndromes with nonflow-limiting, rupture- sultsandnountowardeventsinthisfirsttrial。How- prone plaques located proximal to stented segments ever, new problems were subsequently identified, (19) or in previously untreated vessels (Central including a new Damocles’ sword: late (1 to Illustration)。The surgical strategy of bypassing the 12 months) and very late ($1 year) stent thrombosis proximal origins of the 3 major epicardialvessels,in andlong-termdependenceondualantiplateletther- which life-threatening rupture-prone plaques are apy (8)。Long-lasting and careful watching became more prominent, seems to have a long-term car- the new rule, as very late stent thrombosis was dioprotective effect (19)。Preventing spontaneous perceivedasanunpredictabletimebomb。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 105,
      "text": "eful watching became more prominent, seems to have a long-term car- the new rule, as very late stent thrombosis was dioprotective effect (19)。Preventing spontaneous perceivedasanunpredictabletimebomb。 myocardial infarction (MI) may be more efficiently Today’s stents have ultrathin struts that are achieved by bypassing the vulnerable segments, made from alloys different to the initial bulky rather than focal stenting, which may leave the stainless steel, with sophisticated platform designs minefield located upstream to the stenosis unpro- and biocompatible, bioresorbable, or biostable tected。Only pharmacological agents inducing coatings that have dramatically helped mitigate the regression and passivation of those vulnerable pla- problems of restenosis and thrombosis。Conse- quesupstreamtothestentedlesioncouldeventually quently, historical strategies of dual antiplatelet bridge the existing therapeutic gap between percu- therapy (9) are now being challenged by mono- taneous coronary intervention (PCI) of a focal lesion therapy using just potent and selective P2Y in- versus surgery bypassing the treacherous pathway 12 hibitors (10-14)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 106,
      "text": "ow being challenged by mono- taneous coronary intervention (PCI) of a focal lesion therapy using just potent and selective P2Y in- versus surgery bypassing the treacherous pathway 12 hibitors (10-14)。 leading to the narrowed site and sustaining optimal The dream of “leaving nothing behind” with the flowbeyondthestenoticlesion。Itwashypothesized hype of bioresorbable scaffolds (BRS) was very thatBRS—bysealingvulnerableplaqueandrestoring seductive,butthetargetrateofmajoradversecardiac a safe endoluminal lining—would play a role in sta- events(MACE)achievedwithcurrentDESwasmissed bilizing these plaques。Notably, although BRS failed by a single digit (15-17)。That dream may one day be in the treatment of flow-limiting lesions, they did resurrectedwithmoreefficientandreliableiterations。not fail as a preventive treatment for rupture-prone Indeed, the old dream to eliminate flow-limiting plaques。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 107,
      "text": "ment of flow-limiting lesions, they did resurrectedwithmoreefficientandreliableiterations。not fail as a preventive treatment for rupture-prone Indeed, the old dream to eliminate flow-limiting plaques。 Serial imaging data have shown that after lesions by balloon dilatation and at the same time implantation, neointimal tissue was generated on inhibit constrictive remodeling and neointima top of the BRS, covering the underlying plaque with without “leaving anything behind” has been resur- a relatively thick cap (20)。The PROSPECT ABSORB rectedwithdrug-coatedballoons。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 108,
      "text": "eling and neointima top of the BRS, covering the underlying plaque with without “leaving anything behind” has been resur- a relatively thick cap (20)。The PROSPECT ABSORB rectedwithdrug-coatedballoons。 Passivevesselwall (ProvidingRegionalObservationstoStudyPredictors transmission of biophilic cytotoxic drugs such as of Events in the Coronary Tree II Combined with a paclitaxel has been replaced by active penetration Randomized, Controlled, Intervention) trial (21) has with electrostatic attachment and long-term resi- shown the feasibility and potential efficacy of dencyofmicrospheresorevennanospherescontain- implanting a BRS in nonflow-limiting (diameter inghydrophiliccytostaticsirolimus,sothatthevessel stenosis #40% or negative fractional flow reserve wall itself serves as a natural drug reservoir for a [FFR]orinstantaneouswave-freeratio[iFR])lesions duration almost comparable with that of the DES。with large plaque burden, and is an encouraging Beyondthetreatmentofrestenosis,nativelargeand (small) step forward。At 25-month follow-up, 386 Serruysetal。JACC VOL。78, NO。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 109,
      "text": "mparable with that of the DES。with large plaque burden, and is an encouraging Beyondthetreatmentofrestenosis,nativelargeand (small) step forward。At 25-month follow-up, 386 Serruysetal。JACC VOL。78, NO。 4, 2021 TheHistoryandFutureofPCIVersusCABG JULY 27, 2021:384–407 CENTRAL ILLUSTRATION State-of-the-ArtTreatmentFlowforPatientsWhoRequirePCIorCABG Serruys,P。W。etal。JAmCollCardiol。2021;78(4):384–407。Contemporarytreatmentflowwithrecentevidencesorongoingtrials。ACCAmericanCollegeofCardiology;ACEiangiotensin-converting enzymeinhibitor;AHAAmericanHeartAssociation;ARBangiotensinreceptorblocker;CABGcoronaryarterybypassgraft; CKDchronickidneydisease;GDMTguidelinedirectedmedicaltherapy;LMCADleftmaincoronaryarterydisease;MImyocardial infarction;MVDmultivesseldisease;PCIpercutaneouscoronaryintervention;QoLqualityoflife。JACC VOL。78, NO。4, 2021 Serruysetal。387 JULY 27, 2021:384–407 TheHistoryandFutureofPCIVersusCABG patients receiving BRS compared with guideline- established survival benefit (24)。The primary directed medical therapy (GDMT) alone had a endpoint was mechanistic and unusual: a change in significantly larger minimum lumen area (6。9 (cid:3) ejectionfraction(EF)。IntheCABGcohort,theEFwas 2。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 110,
      "text": "mary directed medical therapy (GDMT) alone had a endpoint was mechanistic and unusual: a change in significantly larger minimum lumen area (6。9 (cid:3) ejectionfraction(EF)。IntheCABGcohort,theEFwas 2。 6 mm2 vs 3。0 (cid:3) 1。0 mm2; P < 0。0001) on intra- unchangedbetweenbaselineand12-monthfollow-up vascular ultrasound, and had significantly lower (53。7 (cid:3) 6。7% vs 54。1 (cid:3) 8。9%; P  0。85), whereas it maximum lipid core burden index on near-infrared increasedsignificantlywithPCIfrom53。5(cid:3)10。7%to spectroscopy。However, it remains to be seen 58。0(cid:3)6。8%(P0。04);thebetween-groupdifference whether this approach would ever realistically at12monthswasalsosignificant(P0。01)(25)。At10 compete with either an effective strategy of bypass years,therewasatrendtowardahigherEFwithPCI surgery or aggressive pharmacological treatment。(54。9(cid:3)8。3%vs49。8(cid:3)10。3%;P0。07),albeitwithout any statistical significance because of incomplete 2。THE FIRST-GENERATION DES VERSUS follow-up(n46;43。9%)(23)。Amorerelevant,and CABG: WERE INTERVENTIONAL at the time,intriguingobservationin this very small CARDIOLOGISTS OVERCONFIDENT。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 111,
      "text": "se of incomplete 2。THE FIRST-GENERATION DES VERSUS follow-up(n46;43。9%)(23)。Amorerelevant,and CABG: WERE INTERVENTIONAL at the time,intriguingobservationin this very small CARDIOLOGISTS OVERCONFIDENT。 cohort was the absence of any significant between- groupdifferenceintherateofmajoradversecardiac In 2002, at least in Europe, the era of DES was and cerebrovascular events (MACCE) at 36 months triumphantly inaugurated by the presentation at the and10years(SupplementalFigure3)。EuropeanSocietyofCardiology(ESC)ofthelandmark The SYNTAX (Synergy Between PCI With Taxus RAVELtrial。With“early”restenosis,theworstenemy and Cardiac Surgery) trial (26) was, and still is, a of interventional cardiologists now defeated the remarkable trial with very long follow-up ($10years temptationtochallengethehegemonyofthesurgeon intheSYNTAXES[SYNTAXExtendedSurvival]study) wasrenascentonceagain。(27)。The surgical principal investigator, Frederick Cordis,aJohnson&Johnsoncompanyatthetime, Mohr,akeyopinionleaderinsurgery,puthisstamp and most importantly, the manufacturer of the new on the trial design by virtually eliminating any saviorofPCI—theCypherDES—hesitatedtoengagein exclusion criteria。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 112,
      "text": "eyopinionleaderinsurgery,puthisstamp and most importantly, the manufacturer of the new on the trial design by virtually eliminating any saviorofPCI—theCypherDES—hesitatedtoengagein exclusion criteria。 He did not want patients to be a new randomized trial, and only endorsed a single- cherry-picked for enrollment and thereby open the arm study: ARTS II (Arterial Revascularization Ther- trial to the same criticism that had been directed to apiesStudy II) (22)。ARTS-IIsubsequently reporteda previously conducted trials of PCI versus CABG, 5-year safety record (absence of death, MI, or cere- whichexcluded88%to98%ofthescreenedpopula- brovascular events) with the sirolimus-eluting tion (28,29)。Running parallel to the randomized Cypher stent that was significantly better than the group were 2 nested registries: a surgical one that same bare-metal VELOCITY stent platform (87。1% vs includedpatientswheretheextentandcomplexityof 81。9; P  0。008), and comparable to the historical coronaryarterydisease(CAD)wasjudgedbythePCI surgical cohort treated in the original ARTS trial operatortoprecludeapercutaneousapproach;anda (87。1% vs 86。0%; P 0。42)。Moreover, the 20。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 113,
      "text": "to the historical coronaryarterydisease(CAD)wasjudgedbythePCI surgical cohort treated in the original ARTS trial operatortoprecludeapercutaneousapproach;anda (87。1% vs 86。0%; P 0。42)。Moreover, the 20。 1% ab- percutaneousonethatincludedthosepatientswhere solute difference in MACE between surgery and PCI comorbiditiesprohibitedsurgery(29)。with BMS seen in ARTS I dropped substantially to a Inaddition,asemiquantitativetoolforassessment meresingle-digit6。4%absolutedifferenceinARTSII。oftheextentandcomplexityofCADwascreatedfrom However,acriticalobservationmadeatthetimewas anamalgamofexistingscores,andamongthem,the that the Kaplan-Meier curves for MACE following Leaman score that weighted the individual physio- surgery and PCI crossed over between the first and logicalimpactofanoccludedornarrowedvessel。The second year of follow-up and kept diverging there- SYNTAX score was born as just an angiographic tool after;thisobservationwouldbecontinuallyrepeated toforcethesurgeonsandinterventionalcardiologists overthenextdecade。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 114,
      "text": "llow-up and kept diverging there- SYNTAX score was born as just an angiographic tool after;thisobservationwouldbecontinuallyrepeated toforcethesurgeonsandinterventionalcardiologists overthenextdecade。 to meticulously examine the extent and complexity In 2008 the LE MANS (Left Main Coronary Artery of the patient’s coronary disease before their inclu- Stenting) study (23) was the first to randomize pa- sionintothetrial(30,31)。tients with an unprotected left main (ULM)—a PCI When the outcome of the trial was analyzed, the taboo at the time—between surgery and PCI with SYNTAXscoretransformedfromadiagnostictooltoa stents (35% first-generation DES)。From the outset, prognosticone。Indeed,outcomeswithPCIusingthe the trial of only 105 patients (53 CABG, 52 PCI) trig- first-generation TAXUS DES (Boston Scientific) were gered vehement waves of protests from surgeons, safe and comparable to CABG for patients with 3- who raised concerns about the quality of surgery vesseldisease(3VD)andascore#22(thefirsttercile performed,asonly72%ofsurgicalpatientsreceiveda ofthescore)andinthosepatientswithULMCADwho left internal mammary artery graft, despite its well- had a score <33。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 115,
      "text": "isease(3VD)andascore#22(thefirsttercile performed,asonly72%ofsurgicalpatientsreceiveda ofthescore)andinthosepatientswithULMCADwho left internal mammary artery graft, despite its well- had a score <33。 Around the same time, the Korean 388 Serruysetal。JACC VOL。78, NO。4, 2021 TheHistoryandFutureofPCIVersusCABG JULY 27, 2021:384–407 TABLE1 RandomizedTrialsComparingPCIWithDESvsCABG Patients,n EuroSCORE SYNTAXScore Published Disease Trial(Ref。#) Year Type PCI CABG PCI CABG PCI CABG Outcomes Follow-up LEMANS 2009 LMCAD 52 53 3。3(cid:3)23 3。5(cid:3)2。3 25。2(cid:3)8。7 24。7(cid:3)6。8 LVEF 1y (23,25) 2016 10y All-causedeath 1y 10y SYNTAX 2009 3VDorLMCAD 903 897 3。8(cid:3)2。6 3。8(cid:3)2。7 28。4(cid:3)11。5 29。1(cid:3)11。4 MACCE* 1y (26,27,125) 2013 5y 2019 All-causedeath 1y 5y 10y CARDia(126) 2010 DMwithMVDorcomplex 256 254 NA NA NA NA All-causedeath,MI, 1y 1VD(3VD:61。8%) orstroke All-causedeath 1y Boudriotetal。2011 LMCAD 100 101 2。4(1。5-3。7) 2。6(1。7-4。9) 24。0(19。0-29。0) 23。0(14。8-28。0) MACE† 1y (42) All-causedeath 1y PRECOMBAT 2011 LMCAD 300 300 2。6(cid:3)1。8 2。8(cid:3)1。9 24。3(cid:3)9。6 25。3(cid:3)10。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 116,
      "text": "etal。2011 LMCAD 100 101 2。4(1。5-3。7) 2。6(1。7-4。9) 24。0(19。0-29。0) 23。0(14。8-28。0) MACE† 1y (42) All-causedeath 1y PRECOMBAT 2011 LMCAD 300 300 2。6(cid:3)1。8 2。8(cid:3)1。9 24。3(cid:3)9。6 25。3(cid:3)10。 9 MACCE‡ 1y (32,127,128) 2015 2y 2020 5y 10y All-causedeath 1y 2y 5y 10y FREEDOM 2012 DMwithMVD(3VD:83。4%) 953 947 2。7(cid:3)2。4 2。8(cid:3)2。5 26。2(cid:3)8。4 26。1(cid:3)8。8 All-causedeath,MI, 5y (34,129) 2019 orstroke All-causedeath 5y 7。5y VACARDS 2013 DMwithMVDorisolated 104 103 NA NA 22。7(cid:3)10。6 21。5(cid:3)8。9 DeathornonfatalMI 2y (130) proximalLADdisease All-causedeath 2y BEST(37) 2015 MVD(3VD:77。2%) 438 442 2。9(cid:3)2。0 3。0(cid:3)2。1 24。2(cid:3)7。5 24。6(cid:3)8。1 Death,MI,orTVR 2y Median 4。6y All-causedeath Median 4。6y NOBLE 2015 LMCAD 598 603 2(2-4) 2(2-4) 22。5(cid:3)7。5 22。4(cid:3)8。0 MACCE 5y (36,131) 2020 All-causedeath 5y EXCEL(35,132) 2016 LMCADandSS#32 948 957 NA NA 26。9(cid:3)8。8 26。0(cid:3)9。8 Death,MI,orstroke 3y 2019 5y All-causedeath 3y 5y *Definedasacompositeofdeath,MI,stroke,andrepeatrevascularization。†Definedasacompositeofcardiacdeath,MI,andTVR。‡Definedasacompositeofdeath,MI,stroke,andischemia-drivenTVR。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 117,
      "text": " 2019 5y All-causedeath 3y 5y *Definedasacompositeofdeath,MI,stroke,andrepeatrevascularization。†Definedasacompositeofcardiacdeath,MI,andTVR。‡Definedasacompositeofdeath,MI,stroke,andischemia-drivenTVR。 Definedasacompositeofdeath,nonproceduralMI,repeatrevascularization,andstroke。1VD1-vesseldisease;2VD2-vesseldisease;3VD3-vesseldisease;BMSbare-metalstent;CABGcoronaryarterybypassgraft;CADcoronaryarterydisease;DESdrug-elutingstent; DMdiabetesmellitus;EESeverolimus-elutingstent;LADleftanteriordescendingartery;LIMAleftinternalmammaryartery;LVEFleftventricularejectionfraction;LMCADleftmaincoronary arterydisease;MACEmajoradversecardiacevents;MImyocardialinfarction;MVDmultivesseldisease;PCIpercutaneouscoronaryintervention;PESpaclitaxel-elutingstent;PMIprocedural myocardialinfarction;TVRtarget-vesselrevascularization。JACC VOL。78, NO。4, 2021 Serruysetal。389 JULY 27, 2021:384–407 TheHistoryandFutureofPCIVersusCABG Trial(Ref。#) TABLE1 Continued EventRates PCIvsCABG(%) Strengths Limitations 58。0%vs54。1% ThefirstprospectiverandomizedstudydedicatedtoLMCAD。Smallnumberofpatients。P0。01 TheuniqueprimaryendpointofimprovementinLVEF。BMSuse(30%)。54。9%vs49。8% Available10-yfollow-updata。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 118,
      "text": "Limitations 58。0%vs54。1% ThefirstprospectiverandomizedstudydedicatedtoLMCAD。Smallnumberofpatients。P0。01 TheuniqueprimaryendpointofimprovementinLVEF。BMSuse(30%)。54。9%vs49。8% Available10-yfollow-updata。 First-generationDESuse(70%)。P0。07 LimiteduseofLIMA(73%)。1。9%vs7。5% P0。37 21。6%vs30。2% P0。41 17。8%vs12。4% ThefirstlargerandomizedtrialcomparingPCIwithDESwith First-generationDESuse。P0。002 CABG。Relativelysmallsamplesizewhenfocusingondisease-specific 37。3%vs26。9% All-comerstrialwithminimumexclusioncriteriaandnested subgroups(eg,3VDorLMCAD)。P<0。0001 registries。10-yfollow-updatawasonlyforvitalstatus。Excludingless-severeCAD(ie1VDor2VDwithoutLMCAD)。4。4%vs3。5% High-riskpopulation/lesionssuggestedbythemeanEuroSCORE P0。37 andmeanSYNTAXscore。13。9%vs11。4% UniformuseofDES(TaxusPES)。P0。10 ProspectivevalidationoftheSYNTAXscore。28。4%vs24。5% Available10-yfollow-updata P0。066 Highfollow-uprateupto10y。13。0%vs10。5% Thefirstrandomizedtrialdedicatedtopatientswithdiabetesand Smallnumberofpatients。P0。393 MVD。BMSuse(31%)。3。2%vs3。2% First-generationDESuse(69%)。P0。97 Limited-termfollow-updata(upto1y)。Includingcomplex1VD。19。0%vs13。9% UniformuseofDES。Smallnumberofpatients。2。0%vs5。0% DedicatedtoLMCAD。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 119,
      "text": "0。393 MVD。BMSuse(31%)。3。2%vs3。2% First-generationDESuse(69%)。P0。97 Limited-termfollow-updata(upto1y)。Includingcomplex1VD。19。0%vs13。9% UniformuseofDES。Smallnumberofpatients。2。0%vs5。0% DedicatedtoLMCAD。 First-generationDESuse。Limited-termfollow-updata(upto1y)。Relativelylow-riskpopulationsuggestedbythemedianEuroSCORE。Relativelyless-severeCADsuggestedbythemedianSYNTAXscore。8。7%vs6。7% RandomizedtrialdedicatedtoLMCADwithrelativelylarger Relativelysmallnumberofpatients 12。2%vs8。1% numberofpatients。First-generationDESuse。P0。12 UniformuseofDES。Relativelywidenoninferioritymargin(absolutedifferenceof7 Available10-yfollow-updata。percentagepointsinMACCE)。17。5%vs14。3% Relativelylow-riskpopulationsuggestedbythemeanEuroSCORE。P0。26 Relativelyless-severeCADsuggestedbythemeanSYNTAXscore。29。8%vs24。7% Possibilityofunder-reportedeventscausedbylackofyearlyfollow-up 2。0%vs2。7% between5and10y。DedicatedtoEastAsianpopulation。2。4%vs3。4% P0。45 5。7%vs7。9% P0。32 14。5%vs13。8% 26。6%vs18。7% Thelargestrandomizedtrialdedicatedtodiabeticpatientswith Thetargetsamplesizewasamendedfrom2,400to1,900patients。P0。005 MVD。First-generationDESuse。16。3%vs10。9% UniformuseofDES。Relativelylow-riskpopulationsuggestedbythemeanEuroSCORE。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 120,
      "text": "atedtodiabeticpatientswith Thetargetsamplesizewasamendedfrom2,400to1,900patients。P0。005 MVD。First-generationDESuse。16。3%vs10。9% UniformuseofDES。Relativelylow-riskpopulationsuggestedbythemeanEuroSCORE。 P0。049 Available7。5-yfollow-updata。Limitednumberofpatientsforextendedfollow-upstudy(49。6%ofthe originalstudypopulation)。24。3%vs18。3% P0。01 25。3%vs18。4% DedicatedtodiabeticpatientswithsevereCAD(MVDincluding Earlyterminationcausedbyslowenrollment(25%oftheintended 21。0%vs5。0% LADorproximalLADdisease)。samplesize)。UniformuseofDES。Smallnumberofpatients。Limited-termfollow-updata(upto2y)。First-generationDESuse。Includingcomplex1VD(proximalLADdisease)。Relativelyless-severeCADsuggestedbythemeanSYNTAXscore。11。0%vs7。9% RandomizedtrialdedicatedtoMVDwithrelativelylargenumber Earlyterminationcausedbyslowenrollment(50%ofintendedsample 17。0%vs11。7% ofpatients。size)。P0。04 77。2%ofpatientshad3VD Relativelysmallnumberofpatients Uniformuseofnewer-generationDES(EES)。Relativelylow-riskpopulationsuggestedbythemeanEuroSCORE。6。6%vs5。0% Relativelyless-severeCADsuggestedbythemeanSYNTAXscore。P0。30 DedicatedtoEastAsianpopulation。28。4%vs19。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 121,
      "text": "rmuseofnewer-generationDES(EES)。Relativelylow-riskpopulationsuggestedbythemeanEuroSCORE。6。6%vs5。0% Relativelyless-severeCADsuggestedbythemeanSYNTAXscore。P0。30 DedicatedtoEastAsianpopulation。28。4%vs19。 0% RandomizedtrialdedicatedtoLMCADwithrelativelylarge PrimaryendpointsexcludingPMI。P0。0002 numberofpatients。Useoffirst-generationDES(approximately10%)。9。4%vs8。7% Useofnewer-generationDES(BiomatrixBES)aftertreatmentof Relativelylow-riskpopulationsuggestedbythemedianEuroSCORE。P0。68 73patientswithfirst-generationDES。Relativelyless-severeCADsuggestedbythemeanSYNTAXscore。Available5-yfollow-updata。15。4%vs14。7% ThelargestrandomizedtrialdedicatedtoLMCAD。SpecificdefinitionofPMI。P0。98 Uniformuseofnewer-generationDES(XienceEES)。25%ofincludedpatientsmetexclusioncriteriaofhighSYNTAXscore 22。0%vs19。2%P0。13 Available5-yfollow-updata。($33)accordingtocorelaboratoryassessments。8。2%vs5。9%P0。11 13。0%vs9。9% FIGURE1 Kaplan-MeierCurvesinSubgroupsoftheSYNTAXStudy All-Cause Death Up to 10 Years in Female )%( ytilatroM esuaC-llA A 50 Log-rank p = 0。601 40 33。0% 30 32。5% 20 10 0 0 1 2 3 4 5 6 7 8 9 10 Years Since Randomization B All-Cause Death Up to 10 Years in Diabetes )%( ytilatroM esuaC-llA 390 Serruysetal。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 122,
      "text": "atroM esuaC-llA A 50 Log-rank p = 0。601 40 33。0% 30 32。5% 20 10 0 0 1 2 3 4 5 6 7 8 9 10 Years Since Randomization B All-Cause Death Up to 10 Years in Diabetes )%( ytilatroM esuaC-llA 390 Serruysetal。 JACC VOL。78, NO。4, 2021 TheHistoryandFutureofPCIVersusCABG JULY 27, 2021:384–407 PCI CABG 50 Log-rank p = 0。551 40 36。4% 34。5% 30 20 10 0 0 1 2 3 4 5 6 7 8 9 10 Years Since Randomization PCI CABG Cumulativeincidenceofall-causemortalityupto10yearscomparingPCIversusCABGin(A)womenor(B)diabeticpatientsintheSYNTAXES study。(C)MACCEratesintheSYNTAXtrial(n1,652)。(C-1)PrevalenceofPMIaccordingtovariousdefinitions,(C-2)SYNTAXdefinition, (C-3)FourthUDMIdefinition,(C-4)ISCHEMIAdefinition,(C-5)SCAIorEXCELdefinition,and(C-6)MACCEratesexcludingPMIasintheNOBLE trial。ReprintedwithpermissionfromHaraetal。(33,38)。MACCEmajoradversecardiacorcerebrovascularevents;PMIperiprocedural myocardialinfarction;SCAISocietyforCardiovascularAngiographyandInterventions;UDMIUniversalDefinitionofMyocardial Infarction。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 123,
      "text": "l。(33,38)。MACCEmajoradversecardiacorcerebrovascularevents;PMIperiprocedural myocardialinfarction;SCAISocietyforCardiovascularAngiographyandInterventions;UDMIUniversalDefinitionofMyocardial Infarction。 Continuedonthenextpage FIGURE1 Continued C MACCE Rates Up to 5 Years According to Various Definitions of PMI (C-1) Prevalence of PMI According to Various Definitions Definitions Rates of Peri-Procedural MI Within 48 H PCI 2。7% SYNTAX p = 0。756 CABG 2。4% PCI 3。0% 4th Universal p = 0。281 Definition of MI CABG 2。1% PCI 6。0% p = 0。030 ISCHEMIA CABG 8。8% PCI 5。7% p < 0。001 SCAI / EXCEL CABG 16。5% 0 2 4 6 8 10 12 14 16 18 PMI Rate (%) (C-2) SYNTAX Definition 37。3% 17。4% 26。1% 11。8% teamledby S。J。Parkpublishedthe2- and5-year re- composite of death, stroke, MI, and ischemia-driven sults of PRECOMBAT (Bypass Surgery Versus Angio- target-vessel revascularization (TVR) (32)。At 1 year, plastyUsingSirolimus-ElutingStentinPatientsWith PCIwasnoninferiortoCABG(PCI8。7%vsCABG6。7%; Left Main Coronary Artery Disease), a trial with 600 P 0。01),whereasat5years,MACCErates noninferiority patients testing the first-generation Cypher DES in were comparable (PCI 17。5% vs CABG 14。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 124,
      "text": "G6。7%; Left Main Coronary Artery Disease), a trial with 600 P 0。01),whereasat5years,MACCErates noninferiority patients testing the first-generation Cypher DES in were comparable (PCI 17。5% vs CABG 14。 3%; ULMCAD with a primary endpoint of MACCE, a P  0。26)。The rates of death, MI, or stroke superiority )%( etaR ECCAM evitalumuC JACC VOL。78, NO。4, 2021 Serruysetal。391 JULY 27, 2021:384–407 TheHistoryandFutureofPCIVersusCABG 60 40 20 0 0 1 2 3 4 5 Years Since Randomization Patient Number at risk 857 703 653 611 563 518 795 679 637 609 584 548 PCI CABG Continuedonthenextpage FIGURE1 Continued (C-3) 4th UDMI Definition 37。5% 17。4% 25。8% 11。6% were 4。0% for CABG and 3。3% for PCI at 1 year, and assumethatoutcomecurvesthatdivergeinthefirst5 9。6%and8。4%,respectively,at5years。Recentlythe years will continue to do so over time, way beyond 10-year results were reported, with again no signifi- the first 5 years; contemporary data, however, have cantbetween-groupdifferencesinMACCE(29。8%vs questioned this。In the SYNTAX trial, the survival 24。7%;HR:1。25;95%CI:0。93-1。69)(32)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 125,
      "text": " again no signifi- the first 5 years; contemporary data, however, have cantbetween-groupdifferencesinMACCE(29。8%vs questioned this。In the SYNTAX trial, the survival 24。7%;HR:1。25;95%CI:0。93-1。69)(32)。 benefit of women was significantly lower withCABG TheSYNTAXandPRECOMBATtrialsopenedanew at5years,butthisadvantagecompletelysubsidedby avenueofrevascularizationoptionsforULMCADwith 10 years, with a similar mortality rate with PCI and favorable long-term results (Table 1)。It has to be CABG of around 33% (33)。In a similar fashion, the underscored that trialists, mainly surgeons, always diverging curves for all-cause mortality at 5 years in )%( etaR ECCAM evitalumuC (C-4) ISCHEMIA Definition 60 38。5% 40 19。8% 30。1% 20 17。0% 0 0 1 2 3 4 5 Years Since Randomization Patient number at risk 857 700 651 609 561 516 795 681 639 611 586 550 PCI CABG PCI CABG )%( etaR ECCAM evitalumuC 60 40 20 0 0 1 2 3 4 5 Years Since Randomization Patient number at risk 857 683 634 595 550 508 795 638 600 576 552 518 (C-5) SCAI or EXCEL Definition 38。4% 24。1% 36。6% 19。5% )%( etaR ECCAM evitalumuC (C-6) Excluding PMI 60 40 36。7% 16。7% 20 25。2% 10。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 126,
      "text": "tient number at risk 857 683 634 595 550 508 795 638 600 576 552 518 (C-5) SCAI or EXCEL Definition 38。4% 24。1% 36。6% 19。5% )%( etaR ECCAM evitalumuC (C-6) Excluding PMI 60 40 36。7% 16。7% 20 25。2% 10。 8% 0 0 1 2 3 4 5 Years Since Randomization Patient number at risk 857 685 635 596 551 509 795 583 545 524 500 469 PCI CABG PCI CABG )%( etaR ECCAM evitalumuC 392 Serruysetal。JACC VOL。78, NO。4, 2021 TheHistoryandFutureofPCIVersusCABG JULY 27, 2021:384–407 60 40 20 0 0 1 2 3 4 5 Years Since Randomization Patient number at risk 857 709 659 616 568 522 795 687 644 616 591 553 JACC VOL。78, NO。4, 2021 Serruysetal。393 JULY 27, 2021:384–407 TheHistoryandFutureofPCIVersusCABG diabeticpatientsconvergeat10years,withthecaveat spontaneousMIwasnot(PCI7。6%vsCABG2。7%;HR: thatinsulin-dependentpatientskeptbenefittingfrom 2。99;95%CI:1。66-5。39)。CABG(Figure1A)。TheEXCELtrial,whichrandomized1,900patients The FREEDOM trial was the last important trial withULMCADandaSYNTAXscore#32(35),aimedto with first-generation DES (Cypher 51%, Taxus 43%), demonstrate noninferiority of PCI at 3 years andspecificallytargeted1,900diabeticpatientswith compared with CABG (P  0。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 127,
      "text": "ndaSYNTAXscore#32(35),aimedto with first-generation DES (Cypher 51%, Taxus 43%), demonstrate noninferiority of PCI at 3 years andspecificallytargeted1,900diabeticpatientswith compared with CABG (P  0。 02 and noninferiority multivessel disease (MVD) (34)。The Kaplan-Meier P 0。98;HR:1。00;95%CI:0。79-1。26)forthe superiority curves here started to diverge at 2 years, and by 5 compositeprimaryendpointofdeath,MI,andstroke。yearstherateoftheprimaryendpoint(acompositeof In the last 2 years of follow-up, the Kaplan-Meier death,MI,andstroke)was26。6%withPCIand18。7% curves for the composite endpoint crossed-over and with CABG (P  0。005)。Notably, although mortality steadily diverged with a final HR at 5 years of 1。19 was significantly lower with CABG (PCI 16。3% vs (95%CI:0。95-1。50;P 0。13)。Therateofall- superiority CABG 10。9%; P  0。049), the rate of stroke was not cause mortality favored surgery (13。0% vs 9。9%; HR: (PCI2。4%vsCABG5。2%;P0。03)。1。38; 95% CI: 1。03-1。85), whereas the rate of cardio- vasculardeathdidnotdiffer。3。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 128,
      "text": "; P  0。049), the rate of stroke was not cause mortality favored surgery (13。0% vs 9。9%; HR: (PCI2。4%vsCABG5。2%;P0。03)。1。38; 95% CI: 1。03-1。85), whereas the rate of cardio- vasculardeathdidnotdiffer。3。 TACKLING THE LEFT MAIN STEM AND The difference in outcomes between the NOBLE 3-VESSEL DISEASE WITH THE and EXCEL trials is heavily dependent on the inclu- SECOND-GENERATION DES sionofPMIasanendpoint。Althoughcriticizedatthe time,thedecisionoftheNOBLEtrialiststoomitPMI ThepotentialroleofPCIinULMCAD,assuggestedby from their composite primary endpoint is now fully SYNTAX and PRECOMBAT, drove the hunger for the appreciated followingthe publisheddebateandcrit- EXCEL(EvaluationofXIENCEversusCoronaryArtery ical appraisal of PMIs and their definitions (38,39)。BypassSurgeryforEffectivenessofLeftMainRevas- Their clinical relevance and impact on time-event cularization) and NOBLE (Nordic-Baltic-British left curvesandcompositeendpointsisindeednowmore main revascularisation study) trials, which were transparent (38,39)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 129,
      "text": " relevance and impact on time-event cularization) and NOBLE (Nordic-Baltic-British left curvesandcompositeendpointsisindeednowmore main revascularisation study) trials, which were transparent (38,39)。 Contrast this with the EXCEL specificallydesignedtoexploretheoutcomesofthese trial, where the higher initial in-hospital primary patients randomized to CABG or PCI using second- endpoint with CABG was driven by the EXCEL defi- generation DES (35,36)。Meanwhile, in patients with nition of PMI, which required an isolated enzyme MVD, the BEST trial, which was terminated prema- release of CK-MB >10(cid:4) the upper limit of normal turely because of slow enrollment after recruiting without the necessity of other supporting evidence, only 880 of the planned1,776 patients (37), failed to whereasanelevationofCK-MB>5(cid:4)theupperlimitof show noninferiority for the composite primary normalhadtobeaccompaniedbyanewQ-wave。endpoint of death, MI, and TVR at 2 years with PCI IntheSYNTAXES,weretrospectivelyappliedthe5 using the Xience everolimus-eluting stents (Abbott definitions of PMI, together with reassessing the Vascular) compared with CABG (37)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 130,
      "text": "R at 2 years with PCI IntheSYNTAXES,weretrospectivelyappliedthe5 using the Xience everolimus-eluting stents (Abbott definitions of PMI, together with reassessing the Vascular) compared with CABG (37)。 Once again, the study’s 10-year composite endpoint following their superiorityofCABGoverPCIwasseenat5years,with removal (38)。These various analyses emphasize the significantly lower rates of the composite of death, impactofthedefinitionofPMIontime-to-eventcurves stroke,MI,andrepeatrevascularization(PCI19。9%vs and the primary composite endpoint, reiterating the CABG13。3%;HR:1。54;95%CI:1。11-2。14)。Notably,ata needforharmonyamongtrialists(Figure1B)。Whether median 4。6 years of follow-up, the absolute differ- PMIshouldbeconsideredatimedendpointinfuture ence in repeat revascularization was in the single trialsiscurrentlybeingseriouslydebated。digits:5。6%(PCI11。0%vsCABG5。4%)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 131,
      "text": "f follow-up, the absolute differ- PMIshouldbeconsideredatimedendpointinfuture ence in repeat revascularization was in the single trialsiscurrentlybeingseriouslydebated。digits:5。6%(PCI11。0%vsCABG5。4%)。 Moving forward, there will be 3 possible ways to In the design of NOBLE (36)—a trial randomizing proceedwiththeassessmentofPMIs:1)toeliminate 1,201 patients with ULMCAD to CABG or PCI (11% them from the composite endpoint when comparing first-generation DES, 89% biolimus-eluting stents)— surgeryandPCI;2)toapply,atleastforthetimebe- procedural myocardial infarction (PMI) was not ing, the 4 competing definitions; or 3) to compel included in the composite endpoint consisting of trialiststousewithoutquestiontheFourthUniversal death,non-PMI,stroke,andrepeat revascularization Definition, which only defines a PMI as occurring at5years。Inthistrial,theabsenceofanydifference whenanelevationofasensitivecardiacbiomarkeris in all-cause mortality at 5 years (PCI 9。4% vs CABG accompaniedbyotherevidenceofnewMIevidenced 8。7%; HR: 1。08; 95% CI: 0。74-1。59) was reassuring; by ECG or imaging, or complications leading to however, the higher incidence and HR of reducedcoronarybloodflow(38,39)。394 Serruysetal。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 132,
      "text": "ewMIevidenced 8。7%; HR: 1。08; 95% CI: 0。74-1。59) was reassuring; by ECG or imaging, or complications leading to however, the higher incidence and HR of reducedcoronarybloodflow(38,39)。394 Serruysetal。 JACC VOL。78, NO。4, 2021 TheHistoryandFutureofPCIVersusCABG JULY 27, 2021:384–407 FIGURE2 All-CauseMortalityBetweenPCIVersusCABGinRecentMeta-Analyses Study-Level Meta-Analysis Patient-Level Meta-Analysis Trial (Ref。#) Population Gaudino, et al (2020) Ahmad, et al。(2020) Head, et al。(2018) EXCEL (35,132) LMCAD NOBLE (36,131) LMCAD PRECOMBAT (32,128) LMCAD BEST (37) MVD SoS (133) MVD ARTS (134) MVD ERACI II (135) MVD LE MANS (23) LMCAD Boudriot et al (42) LMCAD MASS-II (136) MVD VA CARDS (130) DM with MVD CARDIA (126) DM with MVD or complex 1VD FREEDOM (34,129) DM with MVD SYNTAX (26,27,125) 3VD or LMCAD Cisowski et al (137) Proximal LAD Blazek et al (138) Proximal LAD Drenth et al (139) Proximal LAD Kim et al (140) Proximal LAD Myoprotect I (141) High risk features Octostent (142) Referred for PCI SIMA (143) Proximal LAD Hong et al (144) Proximal LAD Gaudino, et al。Stenting vs。CABG RR: 1。17 (1。05-1。29) Ahmad, et al。LMCAD RR: 1。03 (0。82-1。30) HR: 1。20 (1。06-1。37) Head, et al。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 133,
      "text": "2) Referred for PCI SIMA (143) Proximal LAD Hong et al (144) Proximal LAD Gaudino, et al。Stenting vs。CABG RR: 1。17 (1。05-1。29) Ahmad, et al。LMCAD RR: 1。03 (0。82-1。30) HR: 1。20 (1。06-1。37) Head, et al。 MVD or LMCAD 0。1 1 10 0。1 1 10 0。1 1 10 (Top)Threerecentmeta-analysesincludesdifferentpopulationwithstudy-orpatient-leveldata(40,43,44)。TheORswerederivedfromthefixed-effectsmodels。(Top)Thepatient-levelmeta-analysisbyHeadetal(40)enablesthesubgroupanalyses。ReprintedwithpermissionfromHeadetal(40),Ahmadetal(43),and Gaudinoetal(44)。CABGcoronaryarterybypassgraft;LADleftanteriordescendingartery;LMCADleft-maincoronaryarterydisease;LVEFleftventricular ejectionfraction;MImyocardialinfarction;MVDmultivesseldisease;PCIpercutaneouscoronaryintervention;PVDperipheralvasculardisease。Continuedonthenextpage 4。META-ANALYSES: (41)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 134,
      "text": "disease;LVEFleftventricular ejectionfraction;MImyocardialinfarction;MVDmultivesseldisease;PCIpercutaneouscoronaryintervention;PVDperipheralvasculardisease。Continuedonthenextpage 4。META-ANALYSES: (41)。 A more recent meta-analysis by Ahmad (43) BIGGER IS NOT ALWAYS BETTER focusingmorespecificallyonthelast5trialsenrolling large cohorts with ULMCAD (a trialby Boudriot et al A patient-level meta-analysis by Head et al (40), (42), SYNTAX, PRECOMBAT, EXCEL, and NOBLE) including 11,518 patients randomized to PCI concluded that there was no difference in all-cause (n5,753)andCABG(n5,765)from11randomized mortality between surgery and PCI with an HR of controlled trials, conducted between 2011 and 2017, 1。03 (95% CI: 0。81-1。32; P0。779) (Figure 2A) (43)。A seems to almost be the current “final word” on the meta-analysis on the itemized endpoints of these 4 topic (Figure 2)。At 5 years, PCI for MVD (3VD (cid:3) studies is currently being conducted by the TIMI LMCAD) had a higher mortality (HR: 1。44; 95% CI: (ThrombolysisInMyocardialInfarction)group,under 1。20-1。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 135,
      "text": "Figure 2)。At 5 years, PCI for MVD (3VD (cid:3) studies is currently being conducted by the TIMI LMCAD) had a higher mortality (HR: 1。44; 95% CI: (ThrombolysisInMyocardialInfarction)group,under 1。20-1。 74), particularly in those with diabetes and the leadership of Eugene Braunwald and Marc Saba- higher coronary complexity; in nondiabeticpatients, tine, without involvement of the respective trial in- mortality was almost identical (PCI 8。7% vs CABG vestigators。The latest published meta-analysis by 8。4%)。In patients with ULMCAD, there was no mor- Gaudinoetal(44)wasperformedbyaconsortiumof talitybenefitforCABGoverPCI。Thesedifferencesin surgeons and cardiologists, and we cannot resist prognosis were perfectly reflected in the 2018 ESC/ quoting their conclusions (Figure 2A): “This meta- EACTS Guidelines on Myocardial Revascularization analysisfoundthatPCIisassociatedwithhigher all- FIGURE2 Continued Diabetes )%( ytilatroM evitalumuC 20 HR: 1。44, 95% CI: 1。20-1。74; 15。7% 15 P = 0。0001 10 10。7% 5 0 0 1 2 3 4 5 Follow-Up (Years) Number at risk CABG 2,171 1,958 1,786 1,325 1,044 629 PCI 2,215 2,041 1,856 1,376 1,086 681 Non-Diabetes )%( ytilatroM evitalumuC 20 HR: 1。02, 95% CI: 0。86-1。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 136,
      "text": "0 10。7% 5 0 0 1 2 3 4 5 Follow-Up (Years) Number at risk CABG 2,171 1,958 1,786 1,325 1,044 629 PCI 2,215 2,041 1,856 1,376 1,086 681 Non-Diabetes )%( ytilatroM evitalumuC 20 HR: 1。02, 95% CI: 0。86-1。 21; 15 P = 0。81 10 8。7% 8。4% 5 0 0 1 2 3 4 5 Follow-Up (Years) Number at risk CABG 3,594 3,402 3,208 2,436 2,255 1,633 PCI 3,538 3,417 3,245 2,477 2,296 1,724 LMCAD )%( ytilatroM evitalumuC MVD 20 HR: 1。07, 95% CI: 0。87-1。33; P = 0。52 15 10。7% 10 10。5% 5 0 0 1 2 3 4 5 Follow-Up (Years) Number at risk CABG 2,245 2,086 1,903 932 804 406 PCI 2,233 2,120 1,946 978 849 478 )%( ytilatroM evitalumuC JACC VOL。78, NO。4, 2021 Serruysetal。395 JULY 27, 2021:384–407 TheHistoryandFutureofPCIVersusCABG Subgroup Analyses in the Patient-Level Meta-Analysis by Head, et al PCI vs。CABG P Value P HR (95% CI) Plots Interaction Sex 0。82 Male 0。0181 Female 0。0854 Age at baseline 0。98 <65 y。o。0。0534 ≥65 y。o。0。0284 Body mass index 0。43 <30 kg/m2 0。0156 ≥30 kg/m2 0。0179 Hypertension 0。25 Yes 0。0527 No 0。0144 Dyslipidemia 0。76 Yes 0。0272 No 0。0527 Diabetes 0。0077 Yes 0。0001 No 0。81 PVD 0。66 Yes 0。0869 No 0。0084 Previous MI 0。97 Yes 0。0852 No 0。0180 LVEF 0。65 ≥50% 0。0974 30-49% 0。0122 <30% 0。52 SYNTAX score 0。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 137,
      "text": "lipidemia 0。76 Yes 0。0272 No 0。0527 Diabetes 0。0077 Yes 0。0001 No 0。81 PVD 0。66 Yes 0。0869 No 0。0084 Previous MI 0。97 Yes 0。0852 No 0。0180 LVEF 0。65 ≥50% 0。0974 30-49% 0。0122 <30% 0。52 SYNTAX score 0。 21 0-22 0。91 23-32 0。14 ≥33 0。0029 0。5 1 2 20 HR: 1。28, 95% CI: 1。09-1。49; P = 0。0019 15 11。5% 10 8。9% 5 0 0 1 2 3 4 5 Follow-Up (Years) Number at risk CABG 3,520 3,274 3,091 2,829 2,495 1,856 PCI 3,520 3,338 3,155 2,875 2,533 1,928 396 Serruysetal。JACC VOL。78, NO。4, 2021 TheHistoryandFutureofPCIVersusCABG JULY 27, 2021:384–407 FIGURE3 Cardiac-RelatedMedicationsAfterRevascularizationintheContemporaryLargeRCTs Medication at Discharge (%) Trials Treatment P2Y12 Beta ACE (Ref。#) Arm Aspirin P P Statins P P P ARB P Inhibitor Blockers Inhibitor (%) Value Value (%) Value Value Value (%) Value (%) (%) (%) SYNTAX PCI 96。3 96。8 86。7 81。3 55。1 13。3 (125) < 0。001 < 0。001 < 0。001 0。17 < 0。001 < 0。001 CABG 88。5 19。5 74。5 78。6 44。6 7。0 PRECOMBAT PCI 99。0 98。3 72。1 61。1 15。1 24。5 (145) 0。69 0。001 0。72 < 0。001 0。028 0。055 CABG 98。6 92。5 73。5 41。2 9。2 18。0 FREEDOM*1 PCI 99。1 98。4 88。4 83。7 74。3 22。1 (129) < 0。05 < 0。05 > 0。05 > 0。05 < 0。05 < 0。05 CABG 88。4 24。6 88。6 83。2 67。9 15。9 BEST PCI 97。0 96。6 83。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 138,
      "text": "。001 0。028 0。055 CABG 98。6 92。5 73。5 41。2 9。2 18。0 FREEDOM*1 PCI 99。1 98。4 88。4 83。7 74。3 22。1 (129) < 0。05 < 0。05 > 0。05 > 0。05 < 0。05 < 0。05 CABG 88。4 24。6 88。6 83。2 67。9 15。9 BEST PCI 97。0 96。6 83。 1 68。5 44。5 (37) 0。72 < 0。001 0。88 < 0。001 < 0。001 CABG 96。6 89。4 83。5 42。8 25。3 NOBLE*2 PCI 92。9 97。4 (131) NA NA NA CABG NA NA EXCEL PCI 98。5 97。6 96。7 83。4 56。8 (132) 0。43 < 0。001 < 0。001 < 0。001 < 0。001 CABG 98。0 32。3 92。4 92。5 42。2 *1Atthetimeofdischargeor30dayspost-procedure。*2Thetimingisunknown。AbbreviationsasinFigure2。cause, cardiac, and noncardiac mortality compared needlesstosay,thefinaldecisionshouldbemadeon withCABG。Thesignificantlyhighernoncardiacmor- an individual basis in the context of precision med- talityassociatedwithPCIsuggeststhatevennoncar- icine, taking into account all of the patient’s risk diac deaths after PCI may in fact be related to the factors。As an editorial note, we have to emphasize procedure and/or subsequent management, and our theverysimilarHRsbetweenthepatientlevelmeta- datastronglysupporttheuseofall-causemortalityas analysis by Head et al (40) (HR: 1。20; 95% CI: 1。06- the most comprehensive and unbiased endpoint for 1。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 139,
      "text": "ur theverysimilarHRsbetweenthepatientlevelmeta- datastronglysupporttheuseofall-causemortalityas analysis by Head et al (40) (HR: 1。20; 95% CI: 1。06- the most comprehensive and unbiased endpoint for 1。 37) and the study level meta-analysis of Gaudino myocardial revascularization trials” (44)。Provoca- et al (44) (HR: 1。17; 95% CI: 1。05-1。29), and highlight tively,thediscussionsoftheirpublication(44)might that both upper 95% CIs were within 1。4, which trigger a second “ESC firestorm”; lest we forget the is commonly used as the margin of noninferiority first in 2006, when statisticians and epidemiologists (as a side note, the margin is 1。65 in the FAME 3 from Basel claimed in the main arena, and subse- [Fractional Flow Reserve versus Angiography for quentlypublishedintheEuropeanHeartJournal(45), MultivesselEvaluation3]trial),withtheconnotation that DES with cytostatic agents could trigger cancer that below this threshold, differences are “not “duetoarapidimpairmentoftheimmunesystem。”It clinically meaningful。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 140,
      "text": "ation3]trial),withtheconnotation that DES with cytostatic agents could trigger cancer that below this threshold, differences are “not “duetoarapidimpairmentoftheimmunesystem。”It clinically meaningful。 ” Although a study-level should be noted that, per definition, any death that meta-analysis can be pooled more easily than a cannotbeclearlyattributedtoanoncardiaccause(of patient-level meta-analysis, complex statistical ap- course, including any remote possible procedural proaches with or without statistical adjustment to mortality) is adjudicated as cardiac (46)。However, find the most beneficial/harmful treatment in a contemporary improvements in periproceduralman- subgroup analysis are not permitted in a study-level agement, such as increased adoption of the radial analysis。Consequently, it would be hard to apply approach and more tailored antiplatelet strategies, the results of a study-level meta-analysis to an in- may mitigate the so-called noncardiac mortality (eg, dividual, and hence, they should be used more critical bleedings) observed in previous randomized cautiouslythanpatient-levelstudiesduringpractical studies(10,11,47)。decision making。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 141,
      "text": "ac mortality (eg, dividual, and hence, they should be used more critical bleedings) observed in previous randomized cautiouslythanpatient-levelstudiesduringpractical studies(10,11,47)。decision making。 Therefore, the patient-level meta- These contemporary meta-analyses convey an analysis of Head et al (40) provides more granular, importantclinicalmessageforinterventionalistsand specific, and balanced information with respect to surgeons: there may be a substantial proportion of precision medicine (LM vs MVD, diabetic vs nondi- patients with severe CAD who derive a survival abetic patients, complex MVD vs simple MVD) benefit from surgery compared with PCI。However, (Figure 2B)。JACC VOL。78, NO。4, 2021 Serruysetal。397 JULY 27, 2021:384–407 TheHistoryandFutureofPCIVersusCABG 5。GUIDELINE-DIRECTED MEDICAL THERAPY TABLE2 GeographicRegionsandOutcomesintheFREEDOMandtheEXCELTrials AFTER PCI OR CABG EventRates PCIvs PValuefor Optimizing medications is of paramount importance Trial,(Ref。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 142,
      "text": "INE-DIRECTED MEDICAL THERAPY TABLE2 GeographicRegionsandOutcomesintheFREEDOMandtheEXCELTrials AFTER PCI OR CABG EventRates PCIvs PValuefor Optimizing medications is of paramount importance Trial,(Ref。 #) Region n Outcomes Follow-up CABG(%) Interaction in complex CAD, and following the established ben- FREEDOM,(34,129) efits seen in numerous studies, current guidelines NorthAmerica 770 All-causedeath, 5y 28vs16 0。05 clearly state that any revascularization must be Other 1,130 MI,orstroke 25vs21 accompanied by optimal GDMT (41,48-52)。Despite NorthAmerica 770 All-causedeath 8y 26。0vs13。8 0。02 Other 1,130 23。0vs21。5 this, the prescription of cardiac-related medications EXCEL,(35,132) post-procedure varies considerably, even in large NorthAmerica 752 Death,MI, 3y 15。5vs12。4 0。14 randomizedtrials(Figure3)。Notably,inpatientswith Europe 1,075 orstroke 15。5vs15。6 3VDand/orLMCADintheSYNTAXstudy,theeffectof Other 78 9。5vs22。2 adherence to GDMT (36% relative reduction in mor- NorthAmerica 752 5y 24。2vs17。3 NA tality over 5 years) was greater than the treatment Europe 1,075 21。1vs19。6 effect of revascularization strategy (26% relative Other 78 9。6vs29。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 143,
      "text": "ive reduction in mor- NorthAmerica 752 5y 24。2vs17。3 NA tality over 5 years) was greater than the treatment Europe 1,075 21。1vs19。6 effect of revascularization strategy (26% relative Other 78 9。6vs29。 6 reductioninmortalitywithCABGvsPCIover5years) AbbreviationsasinTable1。(53)。The latest medical strategies, includingaspirin- free P2Y inhibitor monotherapy post-PCI, anti-in- 12 flammatorytherapywithcanakinumaborcolchicine, annual ULMCAD cases) has to be better emphasized andintensivelipid-loweringtherapywithproprotein (65,66)。convertase subtilisin/kexin type 9 (PCSK-9) in- Geography may also be a factorinfluencingrevas- hibitors, ezetimibe, bempedoic acid, or icosapent cularization strategy and subsequent clinical out- ethyl, on top of statins, all have the potential to comes。Subgroup analyses of the FREEDOM and further improve outcomes in high-risk patients EXCEL trials suggested that the favorable effects of (10,11,54-59)。CABGoverPCIforcomplexCADseenmorefrequently in North America than Europe or other regions 6。EXPERIENCE WITH (Table 2)。However, these findings are obviously REVASCULARIZATION PROCEDURE insufficient to determine the full impact of regional differences。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 144,
      "text": "th America than Europe or other regions 6。EXPERIENCE WITH (Table 2)。However, these findings are obviously REVASCULARIZATION PROCEDURE insufficient to determine the full impact of regional differences。 Giventhediversityinraceandethnicity, The local standard-of-care and experience/expertise aswellasmedicalservicesandreimbursementprac- of PCI or CABG operators plays an essential part in ticesworldwide,thosestudiesdedicatedtoparticular deciding the optimal modality of revascularization regions,suchasPRECOMBATandBEST,maybebet- mode。A meta-analysis by Post et al (60) suggested tersuitedtoinvestigatethis(67)。that in-hospital mortality was significantly lower for PCI (OR: 0。87; 95% CI: 0。83-0。91) and CABG (OR: 7。WILL PHYSIOLOGY-GUIDED PCI OR CABG 0。85; 95% CI: 0。79-0。92) when performed in hospi- IMPROVE OUTCOMES FOR 3VD。tals with high-volume compared with low-volume activity, although the cutoff points to define high- The FAME trial (N 1,005) showed that FFR-guided volume varied from 33 to 600 cases annually (60)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 145,
      "text": "VD。tals with high-volume compared with low-volume activity, although the cutoff points to define high- The FAME trial (N 1,005) showed that FFR-guided volume varied from 33 to 600 cases annually (60)。 PCI is associated with lower rates of MACE (a com- The 2018 ESC/EACTS Guidelines on Myocardial posite of death, nonfatal MI, and repeat revasculari- Revascularization recommended that procedures zation) and resource utilization compared with were performed in institutions with sufficient angiography-guided PCI in patients with a stenosis annual volumes (CABG $200, PCI: acute coronary >50% in at least 2 major epicardial vessels (68,69)。syndrome [ACS] $400, or chronic coronary syn- Themeannumberofstentswassignificantlylowerin drome [CCS] $200) and sufficient operator experi- the FFR vs angiography-only arm (1。9 vs 2。7; P < ence (41)。For CABG, the experience/expertise of the 0。001), whereas rates of angina were comparable。operator directly affects the planned strategy, such Resultsat5yearsshowedcomparableratesofMACE as use of off-pump coronary artery bypass and/or (FFR28%vsangiography-only31%;relativerisk0。91; bilateral internal mammary artery grafting, more 95% CI: 0。75-1。10; P  0。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 146,
      "text": "arsshowedcomparableratesofMACE as use of off-pump coronary artery bypass and/or (FFR28%vsangiography-only31%;relativerisk0。91; bilateral internal mammary artery grafting, more 95% CI: 0。75-1。10; P  0。 31), and its components, than for PCI, potentially resulting in better/worse suggesting that an FFR-guided strategy is safe, effi- clinical outcomes (61-64)。For PCI, especially in case cacious, and cost-effective (69)。Of note, the ESC of high-risk CAD, such as ULMCAD or chronic guidelines for management of CCS recommend the total occlusions, experience/expertise (eg, $25 use of FFR or iFR in patients with MVD, even in the FIGURE4 HistoricalImprovementinPercutaneousorSurgicalOutcomes Three-Year Events in SYNTAX II PCI vs SYNTAX PCI or CABG in 3VD )%( noitaziralucsaveR/IM/ekortS/htaeD 30% SYNTAX II PCI vs。SYNTAX PCI 26。7% HR: 0。60, 95% CI: 0。44-0。82 25% P = 0。001 SYNTAX PCI 19。3% 20% 15% 17。2% SYNTAX CABG 10% SYNTAX II PCI 5% SYNTAX II PCI vs。SYNTAX CABG HR: 0。87, 95% CI: 0。62-1。22 P = 0。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 147,
      "text": "TAX II PCI vs。SYNTAX PCI 26。7% HR: 0。60, 95% CI: 0。44-0。82 25% P = 0。001 SYNTAX PCI 19。3% 20% 15% 17。2% SYNTAX CABG 10% SYNTAX II PCI 5% SYNTAX II PCI vs。SYNTAX CABG HR: 0。87, 95% CI: 0。62-1。22 P = 0。 43 0% 0 90 180 270 365 730 1,095 Days from Randomization Number at risk 315 275 256 242 225 334 289 277 263 247 454 423 400 387 327 Three-Year Events in EXCEL CABG vs SYNTAX CABG in LMCAD nevirD-aimehcsI/IM/ekortS/htaeD )%( noitaziralucsaveR 398 Serruysetal。JACC VOL。78, NO。4, 2021 TheHistoryandFutureofPCIVersusCABG JULY 27, 2021:384–407 A B 25 HR: 1。54 [95% CI: 1。12-2。14] p-value = 0。008 SYNTAX CABG 20。9% 20 15 EXCEL CABG 14。0% 10 5 0 0 6 12 18 24 30 36 Time (Months) Number at risk: SYNTAX 329 294 282 272 261 252 248 EXCEL 580 530 519 506 492 476 461 TheSYNTAXII(A)andEXCEL(B)trialshighlightthehistoricalimprovementsbothinPCIandCABGcomparedwiththeSYNTAXtrial(90,92)。ReprintedwithpermissionfromModoloetal。(92)。3VD3-vesseldisease;CABGcoronaryarterybypassgraft;LMCADleft-main coronaryarterydisease;PCIpercutaneouscoronaryintervention。JACC VOL。78, NO。4, 2021 Serruysetal。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 148,
      "text": "eprintedwithpermissionfromModoloetal。(92)。3VD3-vesseldisease;CABGcoronaryarterybypassgraft;LMCADleft-main coronaryarterydisease;PCIpercutaneouscoronaryintervention。JACC VOL。78, NO。4, 2021 Serruysetal。 399 JULY 27, 2021:384–407 TheHistoryandFutureofPCIVersusCABG presence of documented ischemia, to localize target as FFR-REACT may clarify the feasibility of this lesions。Recently,DiGioiaetal(70)suggestedthatit approach(81)。would be interesting to assess whether FFR-guided In addition to physiological optimization, PCI would affect hard endpoints (eg, mortality and contemporary data have now established the prog- MI) in diabetic patients following PCI as observed in nostic benefit of complete revascularization in pa- theFREEDOMtrial。tientswithACSorCCSandMVD,especiallywithPCI In contrast to PCI, the efficacy of physiological (82-85)。The 2018 ESC/EACTS Guidelines on Myocar- guidance for CABG is still debated, as although dialRevascularizationgaveprioritizingcompleteness observational data (71) are supportive, results from ofrevascularizationwhenselectingrevascularization randomizedstudiesareinconsistent。modeaClassIIarecommendation(41)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 149,
      "text": "iongaveprioritizingcompleteness observational data (71) are supportive, results from ofrevascularizationwhenselectingrevascularization randomizedstudiesareinconsistent。modeaClassIIarecommendation(41)。 Inthisrespect, The randomized FARGO (Fractional Flow Reserve the residual SYNTAX score has a role in predicting Versus Angiography Randomization for Graft Opti- recurrent events, with a value >8 associated with a mization) (n  100) and GRAFFITI (Graft Patency significantly higher risk of mortality (82)。The com- After FFR-guided Versus Angio-guided CABG) bination with functional assessment, particularly (n  172) trials both showed that compared with angiography-derived FFR, may help establish “func- angiography-guided CABG, FFR-guided CABG tional completeness” after PCI to further improve (lesions with FFR >0。80 were not grafted) had no prognosis(78,79,86-89)。impact on graft failure at 6 months (16% vs 12%; P  0。97) and 12 months (19% vs 20%; P  NS) 8。THE SYNTAX II TRIAL, SO FAR “THE BEST (72,73)。Of note, in FARGO, FFR values were PRACTICE”: TO BE CONFIRMED BY FAME III。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 150,
      "text": "t failure at 6 months (16% vs 12%; P  0。97) and 12 months (19% vs 20%; P  NS) 8。THE SYNTAX II TRIAL, SO FAR “THE BEST (72,73)。Of note, in FARGO, FFR values were PRACTICE”: TO BE CONFIRMED BY FAME III。 significantly lower in deferred lesions after 6 months, suggesting disease progression after The single-arm SYNTAX II trial aimed to introduce CABG。Compare these data to the IMPAG (Impact of and then assess the benefits of contemporary im- Preoperative FFR on Arterial Bypass Graft Func- provements in PCI (90)。To justify a single arm, the tionality) trial, where a pre-procedural vessel SYNTAXscoreIIwasusedasaselectioncriteriaanda FFR #0。78 was associated with functional anasto- form of propensity score to compare outcomes be- moses and high patency rates at 6 months after tween patients receiving contemporary PCI with CABG (74)。Although the IMPAG trial demonstrated those receiving PCI and CABG performed in the the utility of preprocedural FFR as a risk prediction SYNTAX trial。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 151,
      "text": "tients receiving contemporary PCI with CABG (74)。Although the IMPAG trial demonstrated those receiving PCI and CABG performed in the the utility of preprocedural FFR as a risk prediction SYNTAX trial。 Patients could only be included if the tool for graft failure, further trials (eg, the RFR- predictedmortalityat4yearsforthePCIpatientwas CABG [Resting Full-cycle Flow Ratio (RFR) Versus comparable to the predicted mortality of the same Angiography to Guide Revascularization Strategy in propensity-matchedpatient undergoing CABG(equi- Patients Undergoing Coronary Artery By-pass poise)。BestcontemporaryPCIpracticecompromised Grafting (CABG)] trial; NCT04375306) are needed of: 1) only PCI of those lesions that were physiologi- to define the role of physiological assessment as a cally assessed and identified as flow-limiting; 2) decision-making tool for planning CABG。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 152,
      "text": "ed of: 1) only PCI of those lesions that were physiologi- to define the role of physiological assessment as a cally assessed and identified as flow-limiting; 2) decision-making tool for planning CABG。 intracoronary imaging, such as intravascular ultra- The next prospective step will be to assess the sound,forstentoptimization;3)inclusioninthePCI functional optimization of PCI by physiological team of an accredited expert in chronic total occlu- assessment and try to optimize the hemodynamics siontreatment;4)usageofthin-strut,biodegradable- and ideally normalize the value of FFR/iFR/quanti- polymer, newer-generation DES; and 5) mandatory tative flow ratio (QFR) beyond the recommended useofGDMT,toincludeacombinationofantiplatelet thresholds (75-77)。In patients with MVD, frequent drug, statin, b-blocker, and angiotensin-converting post-stenting physiological assessments will be enzyme inhibitor/angiotensin receptor blocker dur- needed, so angiography-derived FFR, which enables ingfollow-up。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 153,
      "text": "b-blocker, and angiotensin-converting post-stenting physiological assessments will be enzyme inhibitor/angiotensin receptor blocker dur- needed, so angiography-derived FFR, which enables ingfollow-up。 Intheireditorial“The2010-2014-2018 functional assessment by 2 angiographic projections Trilogy of ESC-EACTS Guidelines on Myocardial withoutwireinsertionorhyperemia,maybecomean Revascularization” (91), David Glineur and William ideal tool (78,79)。Retrospective analyses have Wijns stated: “We cannot jump 3 steps this way and already documented the benefit of this strategy, in thenreturntowherewebegan。”The3-yearresultsof which the residualfunctionalstenosisbasedon QFR this trial were quite amazing and reflect what the post-PCI was associated with an increased risk of communitydescribesas“bestpractice。” adverse events (76,77)。Although the TARGET-FFR ThelackofacontrolarmintheSYNTAXIIstudyis trial highlighted the difficulties in achieving physio- a major methodological limitation, and although the logicaloptimizationafterPCI,evenwiththeintensive resultsareprovocative,theyneedtobechallengedby treatmentfollowingstenting(80),ongoingtrialssuch a randomized trial (90)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 154,
      "text": "l limitation, and although the logicaloptimizationafterPCI,evenwiththeintensive resultsareprovocative,theyneedtobechallengedby treatmentfollowingstenting(80),ongoingtrialssuch a randomized trial (90)。 Notably, no crossover was 400 Serruysetal。JACC VOL。78, NO。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 155,
      "text": "Notably, no crossover was 400 Serruysetal。JACC VOL。78, NO。 4, 2021 TheHistoryandFutureofPCIVersusCABG JULY 27, 2021:384–407 FIGURE5 TheFASTTRACKCABGTrial(120) A Conventional Heart Team Screening of patients who have been already referred to CABG treatment by (cid:129) Interventional cardiologist \"Conventional Heart Team\" using ICA (cid:129) Cardiac surgeon (documentation of type and location of bypass grafts) coronary CTA Planning and Patient informed consent Operating Heart Team (cid:129) Cardiac surgeon (cid:129) Radiologist (experienced coronary CTA reader) Confirm inclusion and exclusion criteria GE Revolution™ coronary CTA (if not yet) with HeartFlow FFR CT Transfer coronary CTA to Academic Core Lab If surgical planning is not feasible Academic Core Lab results back to site (eg, images of insufficient quality or the operator is uncomfortable to perform CABG), the ICA will be revealed and surgeon “unblind” \"coronary CTA Planning and Operating Heart Team\": (FEASIBILITY ASSESSMENT) Planning of bypass procedure solely based on coronary CTA with FFR CT CABG procedure 30-day follow-up visit plus GE Revolution™ coronary CTA Safety assessment acquisition (patency assessment) TheFASTTRACKCABGtrialisinvestigatingthefeasibilityandsafetyofsurgicaldecisionmaking,planning,andtheexecutionofbypasssurgery,solelybasedonMSCT。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 156,
      "text": "ry CTA Safety assessment acquisition (patency assessment) TheFASTTRACKCABGtrialisinvestigatingthefeasibilityandsafetyofsurgicaldecisionmaking,planning,andtheexecutionofbypasssurgery,solelybasedonMSCT。 (A)Flowchart。(B1)Pre-proceduralMPRimage。(B2)Pre-proceduralFFRct。(B3)Post-CABGMPRimage。(B4)Post-CABGFFRct。CABGcoronaryarterybypassgraft; CTAcomputedtomographyangiography;D1firstdiagonalbranch;FFRfractionalflowreserve;LIMAleftinternalmammaryartery;MPRmultiplanar reformationorreconstruction;MSCTmultisliceCTscans;RIMArightinternalmammaryartery。Continuedonthenextpage evident when the Kaplan-Meier curves for FAMEIIIstudy,whichwillrandomize1,500patients outcomes from PCI in SYNTAX II were compared with 3VD to FFR-guided PCI (n  750) with new- with the matched surgical cohort of SYNTAX I (90) generation DES if the FFR #0。80 or angiography- (Figure 4A); however, over almost 2 decades, there based CABG (n  750), cannot be over emphasized has understandably been tremendous evolution in (93)。The trial aims to demonstrate noninferiority of CABG, as exemplified by the comparison of the FFR-guidedPCItoCABGwithanoninferioritymargin surgical outcomes of SYNTAX I and EXCEL (92) of1。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 157,
      "text": "ion in (93)。The trial aims to demonstrate noninferiority of CABG, as exemplified by the comparison of the FFR-guidedPCItoCABGwithanoninferioritymargin surgical outcomes of SYNTAX I and EXCEL (92) of1。 65intheHR(changedfrom1。45[94])intermsof (Figure4B)。theprimaryendpointforMACCE(acompositeofall- Whether FFR-guided PCI with second-generation causedeath,MIincludingPMIaccordingtothethird DES is noninferior to CABG in patients with MVD, universal definition, stroke, and any repeat revascu- andifso,forhowlong—3,5,or10years—isofgenuine larization) at 1 year (93), with clinical follow-up interest(70)。Hence,theparamountimportanceofthe continuingfor5years。JACC VOL。78, NO。4, 2021 Serruysetal。401 JULY 27, 2021:384–407 TheHistoryandFutureofPCIVersusCABG FIGURE5 Continued Along similar lines, whether FFR/iFR can be inSTEMIpatientswithMVD(HR:0。74;95%CI:0。60- substitutedbyQFRderivedfrom3-dimensionalcoro- 0。91) (97)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 158,
      "text": "07 TheHistoryandFutureofPCIVersusCABG FIGURE5 Continued Along similar lines, whether FFR/iFR can be inSTEMIpatientswithMVD(HR:0。74;95%CI:0。60- substitutedbyQFRderivedfrom3-dimensionalcoro- 0。91) (97)。 Importantly, in the COMPLETE trial, non- naryangiographyorevenfromasingleangiographic culprit lesion PCI was performed with angiography view(95)isofutmostimportance,especiallyinpatients guidance, and the efficacy of physiological guidance with MVD who require multiple cumbersome func- inthiscontextremainstobeestablished。Incontrast tional assessments necessitating guidewire insertion to the angiography-guided complete revasculariza- in every vessel。The FAVOR III trial (NCT03656848), tion studies (COMPLETE, PRAMI [Preventive Angio- comparingQFR with visualguidance,andthe Multi- plasty in Acute Myocardial Infarction], and CvLPRIT vessel TALENT trial (NCT04390672), incorporating [Complete versus Lesion-only Primary PCI Trial] prospectiveQFRassessmentasapartof“bestpractice trials), the Compare-Acute trial and the DANAMI- PCI”inpatientswith3VD,arecurrentlyexploringthe 3-PRIMULTI (Primary PCI in Patients With possibilityofreplacingiFR/FFRwithQFR(96)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 159,
      "text": "sapartof“bestpractice trials), the Compare-Acute trial and the DANAMI- PCI”inpatientswith3VD,arecurrentlyexploringthe 3-PRIMULTI (Primary PCI in Patients With possibilityofreplacingiFR/FFRwithQFR(96)。 ST-Elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Com- 9。ACS WITH MULTIVESSEL DISEASE plete Revascularization) trial showed that the favor- ableeffectsofFFR-guidedcompleterevascularization Recent studies have emphasized the importance of over culprit-lesion–only treatment were mainly complete revascularization in cases of ST-segment driven by the significant reduction in repeat revas- elevation myocardial infarction (STEMI) and MVD。cularization,withoutanyreductioninhardendpoints The large randomized COMPLETE (Complete versus (98-101)。This may be attributable to the underesti- Culprit-Only Revascularization Strategies to Treat mation of FFR in this specific condition (102-104) Multivessel Disease after Early PCI for STEMI) trial and/or a preventive overtreatment of nonflow- (N4,041)demonstratedthatcompleterevasculari- limiting vulnerable lesions by angiography-guided zation resulted in a significant reduction in the hard PCI (21,105,106)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 160,
      "text": "entive overtreatment of nonflow- (N4,041)demonstratedthatcompleterevasculari- limiting vulnerable lesions by angiography-guided zation resulted in a significant reduction in the hard PCI (21,105,106)。 The ongoing FLOWER-MI (FLOW endpoint of cardiovascular death or new MI Evaluation to Guide Revascularization in Multi- compared with culprit-lesion–only revascularization vessel ST-elevation Myocardial Infarction) trial 402 Serruysetal。JACC VOL。78, NO。4, 2021 TheHistoryandFutureofPCIVersusCABG JULY 27, 2021:384–407 (NCT02943954)isexpectedtoclarifythetruebenefit FREEDOM,BEST,PRECOMBAT,andEXCELtrialshas of FFR-guided versus angiography-guided PCI in confirmed its impressive predictive performance to STEMI patients with MVD (107)。Of note, the COM- stratifypatientswhowillbenefitfromeitherCABGor PLETEtrialalsodemonstratedthatnonculpritlesion PCI (Supplemental Figure 4) (115)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 161,
      "text": "edictive performance to STEMI patients with MVD (107)。Of note, the COM- stratifypatientswhowillbenefitfromeitherCABGor PLETEtrialalsodemonstratedthatnonculpritlesion PCI (Supplemental Figure 4) (115)。 The score is PCI performed during index hospitalization or after derivedusingdatafromtheSYNTAXtrial,whichused discharge confers similar benefit on major cardio- the first-generation paclitaxel-eluting stent, and vascular events (cardiovascular death or MI) (during althoughthisisamajorlimitation,thesearetheonly initial hospitalization: HR: 0。77; 95% CI: 0。59-1。00; 10-yearoutcomedataavailabletodate。Recently the after initial hospitalization: HR: 0。69; 95% CI: 0。49- score was validated in the CREDO-Kyoto PCI/CABG 0。97; P  0。62) (108), potentially suggesting registry cohort 3 (116,117), in which 90。3% of PCIs interaction that CABG is feasible after stabilizing patients with were performed using newer-generation DES, sup- very complex CAD (eg, SYNTAX score $33)。The porting the utility of decision making using the ongoing MULTISTARS AMI (MULTivessel Immediate SYNTAX score II 2020 in contemporary practice。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 162,
      "text": "tion DES, sup- very complex CAD (eg, SYNTAX score $33)。The porting the utility of decision making using the ongoing MULTISTARS AMI (MULTivessel Immediate SYNTAX score II 2020 in contemporary practice。 Versus STAged RevaScularization in Acute Myocar- Its availability on smartphones and other devices dial Infarction-The MULTISTARS AMI Trial) renders its use more accessible and applicable (NCT03135275) or BIOVASC (Direct Complete Versus thanever。Staged Complete Revascularization in Patients Pre- Second, the fact that similar decision making can senting With Acute Coronary Syndromes and Multi- now be derived from multislice CT scans (MSCT), vessel Disease) trial (NCT03621501) aim to further instead of conventional cine angiography, may clarify the best timing for nonculprit vesselrevascu- become a game-changer and have an impact on the larizationinSTEMIwithMVD(109,110)。traditional gatekeeper relationship between the The SMILE (Impact of One Stage Compared With invasivecardiologistandsurgeon,andpromoteanew Multistaged PCI Complete Revascularization on interactionbetweenradiologistandsurgeon(118,119)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 163,
      "text": "p between the The SMILE (Impact of One Stage Compared With invasivecardiologistandsurgeon,andpromoteanew Multistaged PCI Complete Revascularization on interactionbetweenradiologistandsurgeon(118,119)。 Clinical Outcome in Multivessel NSTEMI Patients) Indeed, the invasive cardiologist may be replaced as trialistheonlyrandomizedtrialtodateassessingthe theproviderofsurgicalcasesbytheradiologistorby efficacy of single vs staged complete revasculariza- thecardiologist/radiologistinadirectdialogbetween tion in patients with non–ST-segment elevation ACS the surgeon and/or the noninvasive “cardio-radiolo- (111)。The trial demonstrated the efficacy of single- gist”—the hybrid expert of the future。A pilot study, stage complete revascularization with a significant the FASTTRACK CABG trial (Safety and Feasibility reduction in MACCE (cardiac death, death, reinfarc- Evaluation of Planning and Execution of Surgical tion, rehospitalization for unstable angina, repeat RevascularizationSolelyBasedonCoronaryCTAand revascularization,orstroke)at1yearcomparedwitha FFRCT in Patients With Complex Coronary Artery multistaged strategy (HR: 0。549; 95% CI: 0。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 164,
      "text": "e angina, repeat RevascularizationSolelyBasedonCoronaryCTAand revascularization,orstroke)at1yearcomparedwitha FFRCT in Patients With Complex Coronary Artery multistaged strategy (HR: 0。549; 95% CI: 0。 363- Disease) (NCT04142021), is currently testing the 0。828), mainly driven by the significant reduction in feasibility and safety of surgical decision making, repeat revascularization (HR: 0。522; 95% CI: 0。310- planning, and execution of bypass surgery, solely 0。878) (111)。However, because of limited robust basedonMSCT(Figure5)(120)。clinicaldata,currentguidelinesrecommendselecting Third, the decade of 2020-2030 will probably wit- themodalityofrevascularization(PCIorCABG)orthe ness the emergence and combination of metabolic strategyfortreatingMVDasthoughpatientshadCCS and anti-inflammatory (54,58,59) (CANTOS [Canaki- or STEMI (41,52)。In fact, several studies have sug- numab Antiinflammatory Thrombosis Outcome gestedthefeasibilityandefficacyofCABGoverPCIin Study], COLCOT [Colchicine Cardiovascular Out- thissetting(112,113)。comes Trial], LoDoCo2 [Low-dose Colchicine 2], and so on) interventions that will curb the need 10。IN THE NEAR FUTURE for percutaneous and surgical revascularization。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 165,
      "text": "ascular Out- thissetting(112,113)。comes Trial], LoDoCo2 [Low-dose Colchicine 2], and so on) interventions that will curb the need 10。IN THE NEAR FUTURE for percutaneous and surgical revascularization。 Because the potential for plaque regression now WHATCANWEEXPECTINTHENEARFUTURE。First, exists with novel pharmacological interventions precision medicine for decision making between such as PCSK9inhibition by micro-RNA and neutral- surgeryandPCIwillbecomefullyindividualizedand ization by monoclonal antibodies administered accurate,andwillhavetobesharedwiththepatient’s quarterly or biannually (121), patients with diffuse families and relatives (Central Illustration) (114)。In nonobstructive CAD (122) without flow limiting thisregard,theredevelopmentandvalidationofthe stenosis—thereby not candidates for any type of SYNTAX score II 2020 for prediction of 10-year mor- mechanicalrevascularization—willbecomethetarget talityafterPCIorCABGisamajorstepforward(115)。of choice for these pharmacological interventions External validation in the pooled population of the (SupplementalFigure5)(31)。JACC VOL。78, NO。4, 2021 Serruysetal。403 JULY 27, 2021:384–407 TheHistoryandFutureofPCIVersusCABG 11。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 166,
      "text": "logical interventions External validation in the pooled population of the (SupplementalFigure5)(31)。JACC VOL。78, NO。4, 2021 Serruysetal。403 JULY 27, 2021:384–407 TheHistoryandFutureofPCIVersusCABG 11。 FURTHER PERSPECTIVES guidance of MSCT and FFRct。Logically, the inter- ventional cardiologist should no longer have any At a certain point of time, the illusion that the “de- reluctance in treating patients based on noninva- vice”couldreplace“thesurgeon,”existed;however, sive imaging provided advanced knowledge of the therealdebatewas,andstillis,ofatotallydifferent coronary anatomy and that both the functionality nature。In the future, maybe both treatments, and tissue composition of stenotic lesions are percutaneous and surgical, might be replaced by known, even before entering the “catheterization intelligent primordial primary prevention dictated laboratory” now upgraded to “an interventional andguidedbytheprecognitivedetectionofominous suite。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 167,
      "text": "y known, even before entering the “catheterization intelligent primordial primary prevention dictated laboratory” now upgraded to “an interventional andguidedbytheprecognitivedetectionofominous suite。 ” Over the next decade, the progressive but “omics” with combined noninvasive imaging and inevitable replacement of invasive angiography by detection of the diseased phenotype: the era of the noninvasive MSCT for excluding CAD, diagnosing “imagomics。”Timewilltell。ischemic and nonobstructive CAD patients, nonin- Intheupcomingdecade,noninvasiveimagingwill vasive follow-up after prescribing aggressive phar- be the game changer: conventional invasive cine macological interventions, planning percutaneous fluoroscopy will be replaced progressively, but ines- treatment of 1 and 2 functional vessel disease, capably,byMSCT(50)。Thesensitivityandspecificity deciding between surgery and PCI, and planning of the technique to rule out CAD is high and is CABG without conventional cine fluoroscopy will recognizedbyexpertsinthefield(123)。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 168,
      "text": "itivityandspecificity deciding between surgery and PCI, and planning of the technique to rule out CAD is high and is CABG without conventional cine fluoroscopy will recognizedbyexpertsinthefield(123)。 Patientswith have major implications on the relationships among nonobstructive CAD defined by the presence of the noninvasive cardiologist, the invasive cardiolo- (multiple) lumen encroachments without flow limi- gist, the interventional cardiologist, the surgeon, tation (Leaman score >5, with FFRct >0。8 [122,124]) and the cardiac imager。It is hoped that these arenotcandidatesforeitherpercutaneousorsurgical technological advances will enable the patient and revascularization, and their long-term outcomes can physician to make better informed decisions。onlybeimprovedbylifestylemodificationsupported by intensive and aggressive pharmacological in- CONCLUSIONS terventions (122)。When single or double “functional vessel disease” (with FFRct <0。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 169,
      "text": "decisions。onlybeimprovedbylifestylemodificationsupported by intensive and aggressive pharmacological in- CONCLUSIONS terventions (122)。When single or double “functional vessel disease” (with FFRct <0。 80) is diagnosed by RecentstudieshaveenabledtherelativemeritsofPCI noninvasive MSCT, the 3-dimensional angiographic andCABGtobeestablishedwithregardtothetypeof view will be sufficient as a reliable diagnostic tool, ischemic syndrome, coronary anatomy, and the pa- which can then be converted into a 2-dimensional tient’s overall comorbidity, with updated precision angiographic view, so that on the day of the inter- medicine。However, the never-ending advancement vention planning of the optimal gantry geometry in oftechnology,inconjunctionwiththeemergenceof the fluoroscopic interventional suite can be antici- novel pharmacological agents, will force us to pated and the treatment strategy planned and elab- continually re-evaluate the best revascularization oratedinadvance。strategy。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 170,
      "text": "onal suite can be antici- novel pharmacological agents, will force us to pated and the treatment strategy planned and elab- continually re-evaluate the best revascularization oratedinadvance。strategy。 When 3VD with or without LMCAD is observed on MSCT, the decision between CABG and PCI can FUNDINGSUPPORTANDAUTHORDISCLOSURES be made immediately, following on from the SYN- TAX III trial, which demonstrated the concordance DrSerruyshasreceivedpersonalfeesfromBiosensors,MicelTech- of decision making (Cohen’s kappa value of 0。82, nologies,SinomedicalSciencesTechnology,Philips/Volcano,Xeltis, andHeartFlowoutsideofthesubmittedwork。DrHarahasreceiveda almost perfect in the statistical jargon of the kappa grantforstudyingoverseasfromtheJapaneseCirculationSociety,a statistics) in favor of either PCI or CABG, based grant-in-AidforJSPSFellows,andagrantfromtheFukudaFounda- either on conventional invasive fluoroscopic angi- tion for Medical Technology。All other authors have reported that ography or solely on MSCT and FFRct (118)。As theyhavenorelationshipsrelevanttothecontentsofthispaperto mentioned in section entitled “In the Near Future,” disclose。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 171,
      "text": "ll other authors have reported that ography or solely on MSCT and FFRct (118)。As theyhavenorelationshipsrelevanttothecontentsofthispaperto mentioned in section entitled “In the Near Future,” disclose。 if the FASTTRACK trial confirms the feasibility and safety of this noninvasive imaging strategy for ADDRESS FOR CORRESPONDENCE: Dr Patrick W。CABG (without knowledge of the conventional cine Serruys, National University of Ireland, Galway fluoroscopy), then in the future the surgeon may, (NUIG), University Road, Galway H91 TK33, Ireland。can, and will operate safely on the most complex E-mail: patrick。serruys@nuigalway。ie。Twitter: patients of the CAD pyramid using the sole @nuigalway。404 Serruysetal。JACC VOL。78, NO。4, 2021 TheHistoryandFutureofPCIVersusCABG JULY 27, 2021:384–407 REFERENCES 1。Gruntzig A。Transluminal dilatation of 14。Kim BK, Hong SJ, Cho YH, et al。Effect of withthree-vesseldiseaseandleftmaincoronary coronary-artery stenosis。Lancet 1978;1(8058): ticagrelormonotherapyvsticagrelorwithaspirin disease: 5-year follow-up of the randomised, 263。on major bleeding and cardiovascular events in clinical SYNTAX trial。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 172,
      "text": "artery stenosis。Lancet 1978;1(8058): ticagrelormonotherapyvsticagrelorwithaspirin disease: 5-year follow-up of the randomised, 263。on major bleeding and cardiovascular events in clinical SYNTAX trial。 Lancet 2013;381(9867): patientswithacutecoronarysyndrome:theTICO 629–38。2。KonstantinovIE。RobertH。Goetz:thesurgeon whoperformedthefirstsuccessfulclinicalcoro- randomized clinical trial。JAMA 2020;323(23): 27。Thuijs D, Kappetein AP, Serruys PW, et al。2407–16。nary artery bypass operation。Ann Thorac Surg Percutaneous coronary intervention versus 2000;69(6):1966–72。15。StoneGW,KimuraT,GaoR,etal。Time-varying coronaryarterybypassgraftinginpatientswith 3。Fischman DL, Leon MB, Baim DS, et al。outcomeswiththeabsorbbioresorbablevascular three-vesselorleftmaincoronaryarterydisease: A randomized comparison of coronary-stent scaffold during 5-year follow-up: a systematic 10-yearfollow-upofthemulticentrerandomised placementandballoonangioplastyinthetreat- meta-analysisandindividualpatientdatapooled controlled SYNTAX trial。Lancet 2019; mentofcoronaryarterydisease。StentRestenosis study。JAMACardiol2019;4(12):1261–9。394(10206):1325–34。StudyInvestigators。NEnglJMed 1994;331(8): 16。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 173,
      "text": "alpatientdatapooled controlled SYNTAX trial。Lancet 2019; mentofcoronaryarterydisease。StentRestenosis study。JAMACardiol2019;4(12):1261–9。394(10206):1325–34。StudyInvestigators。NEnglJMed 1994;331(8): 16。 WykrzykowskaJJ,KraakRP,HofmaSH,etal。28。Hoffman SN, TenBrook JA, Wolf MP, 496–501。Bioresorbablescaffoldsversusmetallicstentsin PaukerSG,SalemDN,WongJB。Ameta-analysisof 4。SerruysPW,deJaegereP,KiemeneijF,etal。, routinePCI。NEnglJMed2017;376(24):2319–28。randomizedcontrolledtrialscomparingcoronary BenestentStudyGroup。Acomparisonofballoon- 17。Sorrentino S, Giustino G, Mehran R, et al。artery bypass graft with percutaneous trans- expandable-stent implantation with balloon an- Everolimus-elutingbioresorbablescaffoldsversus luminalcoronaryangioplasty:one-toeight-year gioplastyinpatientswithcoronaryarterydisease。everolimus-eluting metallic stents。J Am Coll outcomes。J Am Coll Cardiol 2003;41(8): NEnglJMed1994;331(8):489–95。Cardiol2017;69(25):3055–66。1293–304。5。MehtaSR,YusufS,PetersRJ,etal。Effectsof 18。JegerRV,EccleshallS,WanAhmadWA,etal。29。SerruysPW,FarooqV。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 174,
      "text": "omes。J Am Coll Cardiol 2003;41(8): NEnglJMed1994;331(8):489–95。Cardiol2017;69(25):3055–66。1293–304。5。MehtaSR,YusufS,PetersRJ,etal。Effectsof 18。JegerRV,EccleshallS,WanAhmadWA,etal。29。SerruysPW,FarooqV。 Cherry-pickinghistori- pretreatment with clopidogrel and aspirin fol- Drug-coatedballoonsforcoronaryarterydisease: cal data to legitimize contemporary practice: lowedbylong-termtherapyinpatientsundergo- thirdreportoftheInternationalDCBConsensus shoulddiabeticstatusinfluencedecision-making ing percutaneous coronary intervention: the Group。J Am Coll Cardiol Intv 2020;13(12): incomplexCAD。JAmCollCardiol2017;69(4): PCI-CUREstudy。Lancet2001;358(9281):527–33。1391–402。404–8。6。SteinhublSR,BergerPB,MannJT3rd。,etal。19。DoenstT,HaverichA,SerruysP,etal。PCIand 30。SerruysPW,OnumaY,GargS,etal。Assess- Earlyandsustaineddualoralantiplatelettherapy CABGfortreatingstablecoronaryarterydisease: mentoftheSYNTAXscoreintheSyntaxstudy。following percutaneous coronaryintervention: a JACCreviewtopicoftheweek。JAmCollCardiol EuroIntervention2009;5(1):50–6。randomizedcontrolledtrial。JAMA2002;288(19): 2019;73(8):964–76。31。SerruysPW,ChichareonP,ModoloR,etal。The 2411–20。20。BourantasCV,SerruysPW,NakataniS,etal。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 175,
      "text": "k。JAmCollCardiol EuroIntervention2009;5(1):50–6。randomizedcontrolledtrial。JAMA2002;288(19): 2019;73(8):964–76。31。SerruysPW,ChichareonP,ModoloR,etal。The 2411–20。20。BourantasCV,SerruysPW,NakataniS,etal。 SYNTAXscoreonitswayoutortowardsartificial 7。Morice MC, Serruys PW, Sousa JE, et al。Bioresorbablevascularscaffoldtreatmentinduces intelligence:partI。EuroIntervention2020;16(1): Arandomizedcomparisonofasirolimus-eluting the formation of neointimal cap that seals the 44–59。stentwithastandardstentfor coronaryrevas- underlying plaque without compromising the 32。Park DW, Ahn JM, Park H, et al。Ten-year cularization。N Engl J Med 2002;346(23): luminal dimensions: a concept based on serial outcomes after drug-eluting stents versus cor- 1773–80。optical coherence tomography data。Euro- onary artery bypass grafting for left main cor- Intervention2015;11(7):746–56。8。McFaddenEP,StabileE,RegarE,etal。Late onary disease: extended follow-up of the thrombosisindrug-elutingcoronarystentsafter 21。StoneGW,MaeharaA,AliZA,etal。Percuta- PRECOMBAT Trial。Circulation 2020;141(18): discontinuation of antiplatelet therapy。Lancet neouscoronaryinterventionforvulnerablecoro- 1437–46。2004;364(9444):1519–21。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 176,
      "text": "toneGW,MaeharaA,AliZA,etal。Percuta- PRECOMBAT Trial。Circulation 2020;141(18): discontinuation of antiplatelet therapy。Lancet neouscoronaryinterventionforvulnerablecoro- 1437–46。2004;364(9444):1519–21。 nary atherosclerotic plaque。J Am Coll Cardiol 2020;76(20):2289–301。33。HaraH,TakahashiK,vanKlaverenD,etal。Sex 9。MauriL,KereiakesDJ,YehRW,etal。Twelveor differences in all-cause mortality in the decade 30monthsofdualantiplatelettherapyafterdrug- 22。SerruysPW,OnumaY,GargS,etal。5-year following complex coronary revascularization。eluting stents。N Engl J Med 2014;371(32): clinicaloutcomesoftheARTSII(ArterialRevas- JAmCollCardiol2020;76(8):889–99。2155–66。cularizationTherapiesStudyII)ofthesirolimus- eluting stent in the treatment of patients with 34。FarkouhME,DomanskiM,DangasGD,etal。10。VranckxP,ValgimigliM,JniP,etal。Tica- Long-term survival following multivessel revas- multivesseldenovocoronaryarterylesions。JAm grelorplusaspirinfor1month,followedbytica- CollCardiol2010;55(11):1093–101。cularization in patients with diabetes: the grelormonotherapyfor23monthsvsaspirinplus FREEDOM Follow-On Study。J Am Coll Cardiol clopidogrelorticagrelorfor12months,followed 23。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 177,
      "text": "diol2010;55(11):1093–101。cularization in patients with diabetes: the grelormonotherapyfor23monthsvsaspirinplus FREEDOM Follow-On Study。J Am Coll Cardiol clopidogrelorticagrelorfor12months,followed 23。 Buszman PE, Buszman PP, Banasiewicz- 2019;73(6):629–38。byaspirinmonotherapyfor12monthsafterim- SzkrbkaI,etal。Leftmainstentingincomparison plantationofadrug-elutingstent:amulticentre, withsurgicalrevascularization:10-yearoutcomes 35。StoneGW,KappeteinAP,SabikJF,etal。,for open-label, randomised superiority trial。Lancet of the (Left Main Coronary Artery Stenting) LE theEXCELTrialInvestigators。Five-yearoutcomes 2018;392(10151):940–9。MANS Trial。J Am Coll Cardiol Intv 2016;9(4): afterPCIorCABGforleftmaincoronarydisease。318–27。NEnglJMed2019;381(19):1820–30。11。MehranR,BaberU,SharmaSK,etal。Ticagrelor withorwithoutaspirininhigh-riskpatientsafter 24。Meliga E, Valgimigli M, Buszman P, 36。Holm NR, Mkikallio T, Lindsay MM, et al。PCI。NEnglJMed2019;381(21):2032–42。Serruys PW。Percutaneouscoronaryintervention Percutaneous coronary angioplasty versus coro- orcoronaryarterybypassgraftforunprotected naryartery bypassgraftinginthe treatmentof 12。WatanabeH,DomeiT,MorimotoT,etal。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 178,
      "text": "Percutaneouscoronaryintervention Percutaneous coronary angioplasty versus coro- orcoronaryarterybypassgraftforunprotected naryartery bypassgraftinginthe treatmentof 12。WatanabeH,DomeiT,MorimotoT,etal。 Ef- left main coronary artery disease: the endless unprotected left main stenosis: updated 5-year fectof1-monthdualantiplatelettherapyfollowed debate。J Am Coll Cardiol 2008;52(7):582–4。outcomes from the randomised, non-inferiority by clopidogrel vs 12-month dual antiplatelet authorreply584-586。NOBLEtrial。Lancet2020;395(10219):191–9。therapyoncardiovascularandbleedingeventsin patientsreceivingPCI:theSTOPDAPT-2Random- 25。BuszmanPE,BuszmanPP,KieszRS,etal。Early 37。ParkSJ,AhnJM,KimYH,etal。,fortheBEST izedClinicalTrial。JAMA2019;321(24):2414–27。and long-term results of unprotected left main Trial Investigators。Trial of everolimus-eluting coronaryarterystenting:theLEMANS(LeftMain stents or bypass surgery for coronary disease。13。HahnJY,SongYB,OhJH,etal。EffectofP2Y12 Coronary Artery Stenting) registry。J Am Coll NEnglJMed2015;372(13):1204–12。inhibitormonotherapyvsdualantiplatelettherapy Cardiol2009;54(16):1500–11。oncardiovasculareventsinpatientsundergoing 38。HaraH,SerruysPW,TakahashiK,etal。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 179,
      "text": "registry。J Am Coll NEnglJMed2015;372(13):1204–12。inhibitormonotherapyvsdualantiplatelettherapy Cardiol2009;54(16):1500–11。oncardiovasculareventsinpatientsundergoing 38。HaraH,SerruysPW,TakahashiK,etal。 Impact percutaneouscoronaryintervention:theSMART- 26。Mohr FW, Morice MC, Kappetein AP, et al。ofperi-proceduralmyocardialinfarctiononout- CHOICE Randomized Clinical Trial。JAMA 2019; Coronary artery bypass graft surgery versus comesafterrevascularization。JAmCollCardiol 321(24):2428–37。percutaneous coronary intervention in patients 2020;76(14):1622–39。JACC VOL。78, NO。4, 2021 Serruysetal。405 JULY 27, 2021:384–407 TheHistoryandFutureofPCIVersusCABG 39。GregsonJ,StoneGW,Ben-YehudaO,etal。Cardiovascular Nurses Association, Society for coronaryintervention。JAmCollCardiolIntv2016; Implications of alternative definitions of peri- Cardiovascular Angiography and Interventions, 9(20):2086–93。procedural myocardial infarction after coronary andSocietyofThoracicSurgeons。JAmCollCar- 66。Kinnaird T, Johnson T, Anderson R, et al。revascularization。JAmCollCardiol2020;76(14): diol2014;64(18):1929–49。Intravascularimagingand12-monthmortalityaf- 1609–21。52。ColletJP,ThieleH,BarbatoE,etal。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 180,
      "text": " 66。Kinnaird T, Johnson T, Anderson R, et al。revascularization。JAmCollCardiol2020;76(14): diol2014;64(18):1929–49。Intravascularimagingand12-monthmortalityaf- 1609–21。52。ColletJP,ThieleH,BarbatoE,etal。 ,forthe terunprotectedleftmainstemPCI:ananalysis 40。HeadSJ,MilojevicM,DaemenJ,etal。Mor- ESCScientificDocumentGroup。2020ESCguide- fromtheBritishCardiovascularInterventionSoci- talityaftercoronaryarterybypassgraftingversus linesforthemanagementofacutecoronarysyn- etyDatabase。JAmCollCardiolIntv2020;13(3): percutaneouscoronaryinterventionwithstenting dromesinpatientspresentingwithoutpersistent 346–57。forcoronaryarterydisease:apooledanalysisof ST-segment elevation。Eur Heart J 2021;42(14): individualpatientdata。Lancet2018;391(10124): 1289–367。67。Sotomi Y, Onuma Y, Cavalcante R, et al。939–48。Geographicaldifferenceoftheinteractionofsex 53。IqbalJ,ZhangYJ,HolmesDR,etal。Optimal with treatment strategy in patients with multi- 41。NeumannFJ,Sousa-UvaM,AhlssonA,etal。, medical therapy improves clinical outcomes in vessel disease and left main disease: a meta- fortheESCScientificDocumentGroup。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 181,
      "text": "t strategy in patients with multi- 41。NeumannFJ,Sousa-UvaM,AhlssonA,etal。, medical therapy improves clinical outcomes in vessel disease and left main disease: a meta- fortheESCScientificDocumentGroup。 2018ESC/ patientsundergoingrevascularizationwithpercu- analysis from SYNTAX (Synergy Between PCI EACTSguidelinesonmyocardialrevascularization。taneouscoronaryinterventionorcoronaryartery With Taxus and Cardiac Surgery), PRECOMBAT EurHeartJ2019;40(2):87–165。bypass grafting: insights from the Synergy Be- (Bypass Surgery Versus Angioplasty Using 42。BoudriotE,ThieleH,WaltherT,etal。Ran- tween Percutaneous Coronary Intervention with Sirolimus-ElutingStentinPatientsWithLeftMain domized comparison of percutaneous coronary TAXUSandCardiacSurgery(SYNTAX)trialatthe CoronaryArteryDisease),andBEST(BypassSur- interventionwithsirolimus-elutingstentsversus 5-year follow-up。Circulation 2015;131(14): geryandEverolimus-ElutingStentImplantationin coronaryarterybypassgraftinginunprotectedleft 1269–77。theTreatmentofPatientsWithMultivesselCoro- main stem stenosis。J Am Coll Cardiol 2011;57: 54。RidkerPM,EverettBM,ThurenT,etal。,for naryArteryDisease)randomizedcontrolledtrials。538–45。theCANTOSTrialGroup。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 182,
      "text": "heTreatmentofPatientsWithMultivesselCoro- main stem stenosis。J Am Coll Cardiol 2011;57: 54。RidkerPM,EverettBM,ThurenT,etal。,for naryArteryDisease)randomizedcontrolledtrials。538–45。theCANTOSTrialGroup。 Antiinflammatoryther- CircCardiovascInterv2017;10(5):e005027。43。AhmadY,HowardJP,ArnoldAD,etal。Mor- apywithcanakinumabforatheroscleroticdisease。68。ToninoPA,DeBruyneB,PijlsNH,etal。,for talityafterdrug-elutingstentsvscoronaryartery NEnglJMed2017;377(12):1119–31。the FAME Study Investigators。Fractional flow bypassgraftingforleftmaincoronaryarterydis- 55。RayKK,BaysHE,CatapanoAL,etal。Safety reserveversusangiographyforguidingpercuta- ease: a meta-analysis of randomized controlled and efficacy of bempedoic acid to reduce LDL neouscoronaryintervention。NEnglJMed2009; trials。EurHeartJ2020;41(34):3228–35。cholesterol。NEnglJMed2019;380(11):1022–32。360(3):213–24。44。Gaudino M, Hameed I, Farkouh ME, et al。56。BudoffMJ,BhattDL,KinningerA,etal。Effect 69。vanNunenLX,ZimmermannFM,ToninoPA, Overallandcause-specificmortalityinrandomized of icosapent ethyl on progression of coronary etal。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 183,
      "text": "d I, Farkouh ME, et al。56。BudoffMJ,BhattDL,KinningerA,etal。Effect 69。vanNunenLX,ZimmermannFM,ToninoPA, Overallandcause-specificmortalityinrandomized of icosapent ethyl on progression of coronary etal。 Fractionalflowreserveversusangiography clinical trials comparing percutaneous in- atherosclerosis in patients with elevated tri- forguidanceofPCIinpatientswithmultivessel terventionswithcoronarybypasssurgery:ameta- glyceridesonstatintherapy:finalresultsofthe coronaryarterydisease(FAME):5-yearfollow-up analysis。JAMA Intern Med 2020;180(12): EVAPORATE trial。Eur Heart J 2020;41(40): of a randomised controlled trial。Lancet 2015; 1638–46。3925–32。386(10006):1853–60。45。NordmannAJ,BrielM,BucherHC。Mortalityin 57。CannonCP,BlazingMA,GiuglianoRP,etal。70。Di Gioia G, Soto Flores N, Franco D, et al。randomized controlled trials comparing drug- Ezetimibe added to statin therapy after acute Coronaryarterybypassgraftingorfractionalflow eluting vs bare metal stents in coronary artery coronarysyndromes。NEnglJMed2015;372(25): reserve-guided percutaneous coronary interven- disease:ameta-analysis。EurHeartJ2006;27(23): 2387–97。tionindiabeticpatientswithmultivesseldisease。2784–814。58。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 184,
      "text": "y coronarysyndromes。NEnglJMed2015;372(25): reserve-guided percutaneous coronary interven- disease:ameta-analysis。EurHeartJ2006;27(23): 2387–97。tionindiabeticpatientswithmultivesseldisease。2784–814。58。 TardifJC,KouzS,WatersDD,etal。Efficacy CircCardiovascInterv2020;13(10):e009157。46。Garcia-GarciaHM,McFaddenEP,FarbA,etal。andsafetyoflow-dosecolchicineaftermyocardial 71。FournierS,TothGG,DeBruyneB,etal。Six- Standardized end point definitions for coronary infarction。NEnglJMed2019;381(26):2497–505。yearfollow-upoffractionalflowreserve-guided intervention trials: the Academic Research 59。Nidorf SM, Fiolet ATL, Mosterd A, et al。versus angiography-guided coronary artery Consortium-2ConsensusDocument。EurHeartJ Colchicineinpatientswithchroniccoronarydis- bypassgraftsurgery。CircCardiovascInterv2018; 2018;39(23):2192–207。ease。NEnglJMed2020;383(19):1838–47。11(6):e006368。47。ValgimigliM,GagnorA,CalabrP,etal。Radial 60。PostPN,KuijpersM,EbelsT,ZijlstraF。The 72。ThuesenAL,RiberLP,VeienKT,etal。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 185,
      "text": "Interv2018; 2018;39(23):2192–207。ease。NEnglJMed2020;383(19):1838–47。11(6):e006368。47。ValgimigliM,GagnorA,CalabrP,etal。Radial 60。PostPN,KuijpersM,EbelsT,ZijlstraF。The 72。ThuesenAL,RiberLP,VeienKT,etal。 Frac- versusfemoralaccessinpatientswithacutecor- relationbetweenvolumeandoutcomeofcoronary tionalflowreserveversusangiographically-guided onary syndromes undergoing invasive manage- interventions: a systematic review and meta- coronaryarterybypassgrafting。JAmCollCardiol m 38 e 5 n ( t 9 : 9 a 8 r 6 an ): d 2 o 4 m 65 is – e 7 d 6 m。ulticentretrial。Lancet2015; analysis。EurHeartJ2010;31(16):1985–92。2018;72(22):2732–43。48。Boden WE, O’Rourke RA, Teo KK, et al。61。BenedettoU,LauC,CaputoM,etal。Com- 73。Toth GG, De Bruyne B, Kala P, et al。Graft parisonofoutcomesforoff-pumpversuson-pump patency after FFR-guided versus angiography- OptimalmedicaltherapywithorwithoutPCIfor coronaryarterybypassgraftinginlow-volumeand guided coronary artery bypass grafting: the stable coronary disease。N Engl J Med 2007; 356(15):1503–16。high-volumecentersandbylow-volumeandhigh- GRAFFITI trial。EuroIntervention 2019;15(11): volumesurgeons。AmJCardiol2018;121(5):552–7。e999–1005。49。Al-LameeR,ThompsonD,DehbiHM,etal。62。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 186,
      "text": "007; 356(15):1503–16。high-volumecentersandbylow-volumeandhigh- GRAFFITI trial。EuroIntervention 2019;15(11): volumesurgeons。AmJCardiol2018;121(5):552–7。e999–1005。49。Al-LameeR,ThompsonD,DehbiHM,etal。62。 BenedettoU,PuskasJ,KappeteinAP,etal。74。Spadaccio C, Glineur D, Barbato E, et al。Percutaneous coronary intervention in stable Off-pumpversuson-pumpbypasssurgeryforleft Fractional flow reserve-based coronary artery angina (ORBITA): a double-blind, randomised controlledtrial。Lancet2018;391(10115):31–40。maincoronaryarterydisease。JAmCollCardiol bypasssurgery:currentevidenceandfuturedi- 2019;74(6):729–40。rections。J Am Coll Cardiol Intv 2020;13(9): 50。MaronDJ,HochmanJS,ReynoldsHR,etal。1086–96。63。Taggart DP, Benedetto U, Gerry S, et al。Initialinvasiveorconservativestrategyforstable coronary disease。N Engl J Med 2020;382(15): Bilateral versus single internal-thoracic-artery 75。JeremiasA,DaviesJE,MaeharaA,etal。Blin- 1395–407。grafts at 10 years。N Engl J Med 2019;380(5): dedphysiologicalassessmentofresidualischemia 437–46。aftersuccessfulangiographicpercutaneouscoro- 51。FihnSD,BlankenshipJC,AlexanderKP,etal。64。GaudinoM,DiFrancoA,FlatherM,etal。As- naryintervention:theDEFINEPCIStudy。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 187,
      "text": "calassessmentofresidualischemia 437–46。aftersuccessfulangiographicpercutaneouscoro- 51。FihnSD,BlankenshipJC,AlexanderKP,etal。64。GaudinoM,DiFrancoA,FlatherM,etal。As- naryintervention:theDEFINEPCIStudy。 JAmColl 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused sociation of age with 10-year outcomes after CardiolIntv2019;12(20):1991–2001。update of the guideline for the diagnosis and management of patients with stable ischemic coronarysurgeryinthearterialrevascularization 76。KogameN,TakahashiK,TomaniakM,etal。heartdisease:areportoftheAmericanCollegeof trial。JAmCollCardiol2021;77(1):18–26。Clinicalimplicationofquantitativeflowratioafter Cardiology/AmericanHeartAssociationTaskForce 65。Xu B, Redfors B, Yang Y, et al。Impact of percutaneous coronary intervention for 3-vessel onPracticeGuidelines,andtheAmericanAssoci- operatorexperienceandvolumeonoutcomesaf- disease。J Am Coll Cardiol Intv 2019;12(20): ation for Thoracic Surgery, Preventive ter left main coronary artery percutaneous 2064–75。406 Serruysetal。JACC VOL。78, NO。4, 2021 TheHistoryandFutureofPCIVersusCABG JULY 27, 2021:384–407 77。Biscaglia S, Tebaldi M, Brugaletta S, et al。90。Serruys PW, Kogame N, Katagiri Y, et al。101。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 188,
      "text": " 2064–75。406 Serruysetal。JACC VOL。78, NO。4, 2021 TheHistoryandFutureofPCIVersusCABG JULY 27, 2021:384–407 77。Biscaglia S, Tebaldi M, Brugaletta S, et al。90。Serruys PW, Kogame N, Katagiri Y, et al。101。 Smits PC, Laforgia PL, Abdel-Wahab M, Prognostic value of QFR measured immediately Clinical outcomes of state-of-the-art percuta- etal。Fractionalflowreserve-guidedmultivessel aftersuccessfulstentimplantation:theinterna- neouscoronaryrevascularisationinpatientswith angioplasty in myocardial infarction: three-year tional multicenter prospective HAWKEYE Study。three-vessel disease: two-year follow-up of the follow-up with cost benefit analysis of the JAmCollCardiolIntv2019;12(20):2079–88。SYNTAX II study。EuroIntervention 2019;15(3): Compare-Acute trial。EuroIntervention 2020; e244–52。16(3):225–32。78。XuB,TuS,QiaoS,etal。Diagnosticaccuracyof angiography-based quantitative flow ratio mea- 91。Glineur D, Wijns W。The 2010-2014- 102。ThimT,GtbergM,FrbertO,etal。Non- surementsforonlineassessmentofcoronaryste- 2018 trilogy of ESC-EACTS guidelines on culprit stenosis evaluation using instantaneous nosis。JAmCollCardiol2017;70(25):3077–87。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 189,
      "text": "mT,GtbergM,FrbertO,etal。Non- surementsforonlineassessmentofcoronaryste- 2018 trilogy of ESC-EACTS guidelines on culprit stenosis evaluation using instantaneous nosis。JAmCollCardiol2017;70(25):3077–87。 myocardial revascularisation: we cannot jump wave-free ratio in patients with ST-segment three steps this way and then return to elevationmyocardialinfarction。JAmCollCardiol 79。FearonWF,AchenbachS,EngstromT,etal。, where we began。EuroIntervention 2019; Intv2017;10(24):2528–35。fortheFAST-FFRStudyInvestigators。Accuracyof fractional flow reserve derived from coronary 14(14):1429–33。103。van der Hoeven NW, Janssens GN, de angiography。Circulation2019;139(4):477–84。92。Modolo R, Chichareon P, Kogame N, et al。WaardGA,etal。Temporalchangesincoronary Contemporaryoutcomesfollowingcoronaryartery hyperemic and resting hemodynamic indices in 80。Collison D。TARGET-FFR Physiology-guided bypassgraftsurgeryforleftmaindisease。JAm nonculprit vessels of patients with ST-segment optimizationofPCI:arandomizedcontrolledtrial。CollCardiol2019;73(15):1877–86。elevation myocardial infarction。JAMA Cardiol Paperpresentedat:TCTCONNECT;October16, 2019;4(8):736–44。2020。93。ZimmermannFM,DeBruyneB,PijlsNH,etal。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 190,
      "text": "ndomizedcontrolledtrial。CollCardiol2019;73(15):1877–86。elevation myocardial infarction。JAMA Cardiol Paperpresentedat:TCTCONNECT;October16, 2019;4(8):736–44。2020。93。ZimmermannFM,DeBruyneB,PijlsNH,etal。 Rationale and design of the Fractional Flow 104。BeijninkCWH,ThimT,vanderHeijdenDJ, 81。van Zandvoort LJC, Masdjedi K, Tovar ReserveversusAngiographyforMultivesselEval- etal。Instantaneouswave-freeratioguidedmul- ForeroMN,etal。Fractionalflowreserveguided uation(FAME)3trial:acomparisonoffractional tivessel revascularisation during percutaneous percutaneouscoronaryinterventionoptimization flow reserve-guided percutaneous coronary coronary intervention for acute myocardial directed by high-definition intravascular ultra- intervention and coronary artery bypass graft infarction: study protocol of the randomised sound versus standard of care: Rationale and surgeryinpatientswithmultivesselcoronaryar- controllediMODERNtrial。BMJOpen2021;11(1): studydesignoftheprospectiverandomizedFFR- terydisease。AmHeartJ2015;170(4):619–26。e2。e044035。REACTtrial。AmHeartJ2019;213:66–72。94。ZimmermannFM,DeBruyneB,PijlsNHJ,etal。105。Stone GW, Maehara A, Lansky AJ, et al。82。Farooq V, Serruys PW, Bourantas CV, et al。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 191,
      "text": "。AmHeartJ2015;170(4):619–26。e2。e044035。REACTtrial。AmHeartJ2019;213:66–72。94。ZimmermannFM,DeBruyneB,PijlsNHJ,etal。105。Stone GW, Maehara A, Lansky AJ, et al。82。Farooq V, Serruys PW, Bourantas CV, et al。 AprotocolupdateoftheFractionalFlowReserve A prospective natural-history study of coronary Quantificationofincompleterevascularizationand versus Angiography for Multivessel Evaluation atherosclerosis。NEnglJMed2011;364(3):226–35。its association with five-year mortality in the (FAME) 3 trial: a comparison of fractional flow 106。Kedhi E。Combined Optical Coherence To- synergy between percutaneous coronary inter- reserve-guided percutaneous coronary interven- mography and Fractional Flow Reserve Assess- ventionwithtaxusandcardiacsurgery(SYNTAX) tionandcoronaryarterybypassgraftsurgeryin menttoBetterPredictAdverseEventOutcomesin trialvalidationoftheresidualSYNTAXscore。Cir- culation2013;128(2):141–51。patientswithmultivesselcoronaryarterydisease。DM Patients: COMBINE (OCT–FFR) Trial。Paper AmHeartJ2019;214:156–7。presentedat:TCTCONNECT;October14,2020。83。BangaloreS,GuoY,SamadashviliZ,BleckerS, 95。TuS,DingD,ChangY,LiC,WijnsW,XuB。107。Puymirat E, Simon T, de Bruyne B, et al。Xu J, Hannan EL。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 192,
      "text": " AmHeartJ2019;214:156–7。presentedat:TCTCONNECT;October14,2020。83。BangaloreS,GuoY,SamadashviliZ,BleckerS, 95。TuS,DingD,ChangY,LiC,WijnsW,XuB。107。Puymirat E, Simon T, de Bruyne B, et al。Xu J, Hannan EL。 Everolimus-eluting stents or Diagnosticaccuracyofquantitativeflowratiofor RationaleanddesignoftheFlowEvaluationto bypasssurgeryformultivesselcoronarydisease。assessmentofcoronarystenosissignificancefrom Guide Revascularization in Multivessel ST- NEnglJMed2015;372(13):1213–322。asingleangiographicview:Anovelmethodbased Elevation Myocardial Infarction (FLOWER-MI) 84。KawashimaH,TakahashiK,OnoM,etal。,for onbifurcationfractallaw。CircCardiovascInterv trial。AmHeartJ2020;222:1–7。the SYNTAX Extended Survival Investigators。2021;97Suppl2:1040–7。108。WoodDA,CairnsJA,WangJ,etal。Timingof Mortality10yearsafterpercutaneousorsurgical 96。HaraH,GaoC,KogameN,etal。Arandomised stagednonculpritarteryrevascularizationinpa- revascularizationinpatientswithtotal coronary controlled trial of the sirolimus-eluting biode- tients with ST-segment elevation myocardial arteryocclusions。JAm CollCardiol 2021;77(5): gradablepolymerultra-thinSupraflexstentversus infarction: COMPLETE Trial。J Am Coll Cardiol 529–40。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 193,
      "text": "uting biode- tients with ST-segment elevation myocardial arteryocclusions。JAm CollCardiol 2021;77(5): gradablepolymerultra-thinSupraflexstentversus infarction: COMPLETE Trial。J Am Coll Cardiol 529–40。 the everolimus-eluting biodegradable polymer 2019;74(22):2713–23。85。AhnJM,ParkDW,LeeCW,etal。Comparison SYNERGYstentfor three-vesselcoronaryartery 109。Sthli BE, Varbella F, Schwarz B, et al。ofstentingversusbypasssurgeryaccordingtothe disease:rationaleanddesignoftheMultivessel Rationale and design of the MULTISTARS AMI completenessofrevascularizationinseverecoro- TALENT trial。EuroIntervention 2020;16: Trial: A randomized comparison of immediate naryarterydisease:patient-levelpooledanalysis e997–1004。versus staged complete revascularization in pa- of the SYNTAX, PRECOMBAT, and BEST Trials。97。MehtaSR,WoodDA,StoreyRF,etal。Com- tients with ST-segment elevation myocardial JAmCollCardiolIntv2017;10(14):1415–24。plete revascularization with multivessel PCI for infarction and multivessel disease。Am Heart J 86。KobayashiY,NamCW,ToninoPA,etal。,for myocardialinfarction。NEnglJMed2019;381(15): 2020;228:98–108。the FAME Study Investigators。The prognostic 1411–21。110。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 194,
      "text": "nfarction and multivessel disease。Am Heart J 86。KobayashiY,NamCW,ToninoPA,etal。,for myocardialinfarction。NEnglJMed2019;381(15): 2020;228:98–108。the FAME Study Investigators。The prognostic 1411–21。110。 denDekkerWK,VanMieghemNM,BennettJ, value of residual coronary stenoses after func- 98。Wald DS, Morris JK, Wald NJ, et al。Ran- et al。Percutaneous complete revascularization tionally complete revascularization。J Am Coll domized trial of preventive angioplasty in strategies using sirolimus-eluting biodegradable Cardiol2016;67(14):1701–11。myocardial infarction。N Engl J Med 2013; polymer-coatedstentsinpatientspresentingwith 87。ChoiKH,LeeJM,KooBK,etal。Prognostic 369(12):1115–23。acutecoronarysyndromeandmultivesseldisease: implicationoffunctionalincompleterevasculari- Rationale and design of the BIOVASC trial。Am zation and residual functional SYNTAX score in 99。Gershlick AH, Banning AS, Parker E, et al。HeartJ2020;227:111–7。Long-termfollow-upofcompleteversuslesion- patientswithcoronaryarterydisease。JAmColl only revascularization in STEMI and multivessel 111。SardellaG,LucisanoL,GarboR,etal。Single- CardiolIntv2018;11(3):237–45。disease:theCvLPRITTrial。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 195,
      "text": "ersuslesion- patientswithcoronaryarterydisease。JAmColl only revascularization in STEMI and multivessel 111。SardellaG,LucisanoL,GarboR,etal。Single- CardiolIntv2018;11(3):237–45。disease:theCvLPRITTrial。 JAmCollCardiol2019; stagedcomparedwithmulti-stagedPCIinmulti- 88。Lee JM, Hwang D, Choi KH, et al。74(25):3083–94。vesselNSTEMIpatients:theSMILETrial。JAmColl Prognostic impact of residual anatomic disease Cardiol2016;67(3):264–72。100。Calvio-Santos R, Estvez-Loureiro R, burden after functionally complete revasculari- 112。ChangM,LeeCW,AhnJM,etal。Comparison Peteiro-VzquezJ,etal。Angiographicallyguided zation。Circ Cardiovasc Interv 2020;13(9): of outcome of coronary artery bypass grafting completerevascularizationversusselectivestress e009232。versus drug-eluting stent implantation for non- echocardiography-guidedrevascularizationinpa- ST-elevation acute coronary syndrome。Am J 89。Kobayashi Y, Lnborg J, Jong A, et al。tients with st-segment-elevation myocardial Cardiol2017;120(3):380–6。Prognostic value of the residual SYNTAX score infarctionandmultivesseldisease:theCROSS-AMI after functionally complete revascularization in RandomizedClinicalTrial。CircCardiovascInterv 113。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 196,
      "text": "0(3):380–6。Prognostic value of the residual SYNTAX score infarctionandmultivesseldisease:theCROSS-AMI after functionally complete revascularization in RandomizedClinicalTrial。CircCardiovascInterv 113。 RamanathanK,AbelJG,ParkJE,etal。Sur- ACS。JAmCollCardiol2018;72(12):1321–9。2019;12(10):e007924。gical versus percutaneous coronary JACC VOL。78, NO。4, 2021 Serruysetal。407 JULY 27, 2021:384–407 TheHistoryandFutureofPCIVersusCABG revascularization in patients with diabetes and coronaryatheroscleroticburden:validationofthe multivessel coronary artery disease。Circulation acutecoronarysyndromes。JAmCollCardiol2017; computed tomography-Leaman score。Circ Car- 2010;122:949–57。70(24):2995–3006。diovascImaging2015;8(2):e002332。137。Cisowski M, Drzewiecki J, Drzewiecka- 114。Yeh RW, Kramer DB。Decision tools to GerberA,etal。PrimarystentingversusMIDCAB: 125。SerruysPW,MoriceMC,KappeteinAP,etal。improvepersonalizedcareincardiovasculardis- preliminaryreport-comparisonoftwomethodsof Percutaneouscoronaryinterventionversuscoro- ease:movingtheartofmedicinetowardscience。revascularizationinsingleleftanteriordescending nary-artery bypass grafting for severe coronary Circulation2017;135(12):1097–100。arterydisease。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 197,
      "text": "tionversuscoro- ease:movingtheartofmedicinetowardscience。revascularizationinsingleleftanteriordescending nary-artery bypass grafting for severe coronary Circulation2017;135(12):1097–100。arterydisease。 NEnglJMed2009;360:961–72。coronaryarterystenosis。AnnThoracSurg2002; 74:S1334–9。115。Takahashi K, Serruys PW, Fuster V, et al。126。KapurA,HallRJ,MalikIS,etal。Randomized Redevelopment and validation of the SYNTAX 138。BlazekS,HolzheyD,JungertC,etal。Com- comparisonofpercutaneouscoronaryintervention scoreIItoindividualisedecisionmakingbetween parison of bare-metal stenting with minimally withcoronaryarterybypassgraftingindiabetic percutaneous and surgical revascularisation in invasive bypass surgery for stenosis of the left patients。1-yearresultsoftheCARDia(Coronary patients with complex coronary artery disease: anterior descending coronary artery: 10-year ArteryRevascularizationinDiabetes)trial。JAm secondaryanalysisofthemulticentrerandomised follow-upofarandomizedtrial。JAmCollCardiol controlled SYNTAXES trial with external cohort CollCardiol2010;55:432–40。Intv2013;6:20–6。validation。Lancet2020;396(10260):1399–412。127。ParkSJ,KimYH,ParkDW,etal。Randomized 139。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 198,
      "text": "izedtrial。JAmCollCardiol controlled SYNTAXES trial with external cohort CollCardiol2010;55:432–40。Intv2013;6:20–6。validation。Lancet2020;396(10260):1399–412。127。ParkSJ,KimYH,ParkDW,etal。Randomized 139。 DrenthDJ,VeegerNJ,MiddelB,ZijlstraF, trialofstentsversusbypasssurgeryforleftmain 116。YamamotoK,ShiomiH,MorimotoT,etal。Boonstra PW。Comparison of late (four years) coronaryarterydisease。NEnglJMed2011;364: Percutaneouscoronaryinterventionversuscoro- functional health status between percutaneous 1718–27。naryarterybypassgraftingamongpatientswith transluminal angioplasty intervention and off- unprotectedleftmaincoronaryarterydiseasein 128。AhnJM,RohJH,KimYH,etal。Randomized pumpleftinternalmammaryarterybypassgraft- thenew-generationdrug-elutingstentsera(from TrialofStentsVersusBypassSurgeryforLeftMain ing for isolated high-grade narrowing of the the CREDO-Kyoto PCI/CABG Registry Cohort-3)。CoronaryArteryDisease:5-YearOutcomesofthe proximalleftanteriordescendingcoronaryartery。AmJCardiol2021;145:37–46。PRECOMBAT Study。J Am Coll Cardiol 2015;65: AmJCardiol2004;94:1414–7。117。Matsumura-NakanoY,ShiomiH,MorimotoT, 2198–206。140。KimJW,LimDS,SunK,ShimWJ,RhoYM。etal。Comparisonofoutcomesofpercutaneous 129。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 199,
      "text": "–46。PRECOMBAT Study。J Am Coll Cardiol 2015;65: AmJCardiol2004;94:1414–7。117。Matsumura-NakanoY,ShiomiH,MorimotoT, 2198–206。140。KimJW,LimDS,SunK,ShimWJ,RhoYM。etal。Comparisonofoutcomesofpercutaneous 129。 FarkouhME,DomanskiM,SleeperLA,etal。Stenting or MIDCAB using ministernotomy for coronary intervention versus coronary artery Strategiesformultivesselrevascularizationinpa- revascularization of proximal left anterior bypassgraftingamongpatientswiththree-vessel tients with diabetes。N Engl J Med 2012;367: descendingartery。IntJCardiol2005;99:437–41。coronary artery disease in the new-generation 2375–84。141。Pohl T, Giehrl W, Reichart B, et al。Retro- drug-elutingstentsera(fromCREDO-KyotoPCI/ infusion-supportedstentinginhigh-riskpatients CABGRegistryCohort-3)。AmJCardiol2021;145: 130。Kamalesh M, Sharp TG, Tang XC, et al。forpercutaneousinterventionandbypasssurgery: 25–36。Percutaneouscoronaryinterventionversuscoro- resultsoftheprospectiverandomizedmyoprotect narybypasssurgeryinUnitedStatesveteranswith 118。ColletC,OnumaY,AndreiniD,etal。Coronary diabetes。JAmCollCardiol2013;61:808–16。I study。Catheter Cardiovasc Interv 2004;62: computed tomography angiography for heart 323–30。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 200,
      "text": "nUnitedStatesveteranswith 118。ColletC,OnumaY,AndreiniD,etal。Coronary diabetes。JAmCollCardiol2013;61:808–16。I study。Catheter Cardiovasc Interv 2004;62: computed tomography angiography for heart 323–30。 teamdecision-makinginmultivesselcoronaryar- 131。Mkikallio T, Holm NR, Lindsay M, et al。142。Eefting F, Nathoe H, van Dijk D, et al。terydisease。EurHeartJ2018;39(41):3689–98。Percutaneous coronary angioplasty versus coro- Randomized comparison between stenting and naryarterybypassgraftingintreatmentofun- 119。ModoloR,ColletC,OnumaY,SerruysPW。off-pumpbypasssurgeryinpatientsreferredfor protected left main stenosis (NOBLE): a SYNTAXIIandSYNTAXIIItrials:whatisthetake angioplasty。Circulation2003;108:2870–6。prospective, randomised, open-label, non-inferi- home message for surgeons。Ann Cardiothorac oritytrial。Lancet2016;388:2743–52。143。Goy JJ, Kaufmann U, Hurni M, et al。10- Surg2018;7(4):470–82。yearfollow-upofaprospectiverandomizedtrial 132。StoneGW,SabikJF,SerruysPW,etal。Ever- 120。KawashimaH,PompilioG,AndreiniD,etal。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 201,
      "text": "388:2743–52。143。Goy JJ, Kaufmann U, Hurni M, et al。10- Surg2018;7(4):470–82。yearfollow-upofaprospectiverandomizedtrial 132。StoneGW,SabikJF,SerruysPW,etal。Ever- 120。KawashimaH,PompilioG,AndreiniD,etal。 comparing bare-metal stenting with internal olimus-ElutingStentsorBypassSurgeryforLeft Safetyandfeasibilityevaluationofplanningand mammary artery grafting for proximal, isolated MainCoronaryArteryDisease。NEnglJMed2016; execution of surgical revascularization solely de novo left anterior coronary artery stenosis 375:2223–35。basedoncoronaryCTAandFFRCTinpatientswith the SIMA (Stenting versus Internal Mammary complexcoronaryarterydisease:studyprotocolof 133。Coronary artery bypass surgery versus Artery grafting) trial。J Am Coll Cardiol 2008; the FASTTRACK CABG Study。BMJ Open 2020; percutaneous coronary intervention with stent 52:815–7。10(12):e038152。implantationinpatientswithmultivesselcoronary 144。HongSJ,LimDS,SeoHS,etal。Percutaneous 121。SabatineMS,GiuglianoRP,KeechAC,etal。artery disease (the Stent or Surgery trial): a coronaryinterventionwithdrug-elutingstentim- Evolocumabandclinicaloutcomesinpatientswith randomised controlled trial。Lancet 2002;360: plantationvs。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 202,
      "text": ",etal。artery disease (the Stent or Surgery trial): a coronaryinterventionwithdrug-elutingstentim- Evolocumabandclinicaloutcomesinpatientswith randomised controlled trial。Lancet 2002;360: plantationvs。 minimallyinvasivedirectcoronary cardiovascular disease。N Engl J Med 2017; 965–70。artery bypass (MIDCAB) in patients with left 376(18):1713–22。134。SerruysPW,OngAT,vanHerwerdenLA,etal。anterior descending coronary artery stenosis。122。Andreini D, Pontone G, Mushtaq S, et al。Five-yearoutcomesaftercoronarystentingversus CatheterCardiovascInterv2005;64:75–81。Long-term prognostic impact of CT-Leaman bypasssurgeryforthetreatmentofmultivessel 145。ParkSJ,KimYH,ParkDW,etal。Randomized score in patients with non-obstructive CAD: disease:thefinalanalysisoftheArterialRevas- trialofstentsversusbypasssurgeryforleftmain Results from the COronary CT Angiography cularization Therapies Study (ARTS) randomized coronaryarterydisease。NEnglJMed2011;364: EvaluatioN For Clinical Outcomes InteRnational trial。JAmCollCardiol2005;46:575–81。1718–27。Multicenter(CONFIRM)study。IntJCardiol2017; 135。RodriguezAE,BaldiJ,FernndezPereiraC, 231:18–25。etal。Five-yearfollow-upoftheArgentineran- 123。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 203,
      "text": "es InteRnational trial。JAmCollCardiol2005;46:575–81。1718–27。Multicenter(CONFIRM)study。IntJCardiol2017; 135。RodriguezAE,BaldiJ,FernndezPereiraC, 231:18–25。etal。Five-yearfollow-upoftheArgentineran- 123。 KnuutiJ,BalloH,Juarez-OrozcoLE,etal。The domizedtrialofcoronaryangioplastywithstent- KEYWORDS coronaryarterybypassgraft, performanceofnon-invasiveteststorule-inand ing versus coronary bypass surgery in patients coronaryarterydisease,drug-elutingstent, rule-out significant coronary artery stenosis in withmultiplevesseldisease(ERACIII)。JAmColl percutaneouscoronaryintervention patients with stable angina: a meta-analysis Cardiol2005;46:582–8。focused on post-test disease probability。Eur 136。HuebW,LopesN,GershBJ,etal。Ten-year HeartJ2018;39(35):3322–30。follow-upsurvivaloftheMedicine,Angioplasty,or APPENDIX Forsupplementalfiguresand 124。MushtaqS,DeAraujoGonalvesP,Garcia- SurgeryStudy(MASSII):arandomizedcontrolled tables,pleaseseetheonlineversionofthis GarciaHM,etal。Long-termprognosticeffectof clinical trial of 3 therapeutic strategies for paper。",
      "source": "1-s2.0-S0735109721051731-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 204,
      "text": "JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL。80, NO。22, 2022 2022 PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION THE PRESENT AND FUTURE JACC STATE-OF-THE-ART REVIEW A Practical Approach to Left Main Coronary Artery Disease JACC State-of-the-Art Review LauraJ。Davidson,MD,a,*JosephC。Cleveland,MD,b,yFrederickG。Welt,MD,c,*SaifAnwaruddin,MD,d,* RobertO。Bonow,MD,aMichaelS。Firstenberg,MD,e,yMarioF。Gaudino,MD,f,yBernardJ。Gersh,MBCHB,DPHIL,g KendraJ。Grubb,MD,MHA,h,yAjayJ。Kirtane,MD,SM,i,*JacquelineE。Tamis-Holland,MD,j AlexanderG。Truesdell,MD,k,*StephanWindecker,MD,lRozaA。Taha,MBCHB,aS。ChrisMalaisrie,MD,a,y OnbehalfoftheACC’sInterventionalandCardiacSurgeryLeadershipCouncils ABSTRACT Thetreatmentofleftmain(LM)coronaryarterydisease(CAD)requirescomplexdecision-making。Recentclinicalpractice guidelinesprovideclinicianswithguidance;however,decisionsregardingtreatmentforindividualpatientscanstillbe difficult。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 205,
      "text": "LM)coronaryarterydisease(CAD)requirescomplexdecision-making。Recentclinicalpractice guidelinesprovideclinicianswithguidance;however,decisionsregardingtreatmentforindividualpatientscanstillbe difficult。 TheAmericanCollegeofCardiology’sCardiacSurgeryTeamandInterventionalCounciljoinedtogetherto developapracticalapproachtothetreatmentofLMCAD,takingintoaccountrandomizedclinicaltrial,meta-analyses, andclinicalpracticeguidelines。ThevariouspresentationsofLMCADbasedonanatomyandphysiologyarepresented。RecognizingthecomplexityofLMCAD,whichrarelypresentsisolatedandisoftenincombinationwithmultivessel disease,atreatmentalgorithmwithmedicaltherapyaloneorinconjunctionwithpercutaneouscoronaryinterventionor coronaryarterybypassgraftingisproposed。Aheartteamapproachisrecommendedthataccountsforclinical,proce- dural,operator,andinstitutionalfactors,andfeaturesshareddecision-makingthatmeetstheneedsandpreferencesof eachpatientandtheirspecificclinicalsituation。(JAmCollCardiol2022;80:2119–2134)2022PublishedbyElsevieron behalfoftheAmericanCollegeofCardiologyFoundation。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 206,
      "text": "cision-makingthatmeetstheneedsandpreferencesof eachpatientandtheirspecificclinicalsituation。(JAmCollCardiol2022;80:2119–2134)2022PublishedbyElsevieron behalfoftheAmericanCollegeofCardiologyFoundation。 T he natural history of medically treated left disease and significant LM disease to prevent fatal main (LM) disease has been associated with acute myocardial infarction (MI)。1 Randomized clin- 73% mortality at 15 years, and historically, icaltrialsonthesurvivalbenefitofCABGovermedi- coronaryarterybypassgrafting(CABG)hasbeenrec- cal therapy in that era showed a substantial ommended in allpatients withstable ischemic heart treatmenteffectofCABGinthesubsetofLMstenosis, From the aDivisions of Cardiology and Cardiac Surgery, Northwestern University, Chicago, Illinois, USA; bDepartment of CardiothoracicSurgery,UniversityofColorado,Aurora,Colorado,USA;cDepartmentofCardiovascularMedicine,Universityof Utah,SaltLakeCity,Utah,USA;dDepartmentofCardiology&InterventionalCardiology,St。VincentHospital,Worcester,Mas- sachusetts,USA;eDepartmentofCardiothoracicSurgery,St。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 207,
      "text": "fCardiovascularMedicine,Universityof Utah,SaltLakeCity,Utah,USA;dDepartmentofCardiology&InterventionalCardiology,St。VincentHospital,Worcester,Mas- sachusetts,USA;eDepartmentofCardiothoracicSurgery,St。 ElizabethMedicalCenter,Appleton,Wisconsin,USA;fDepartmentof CardiothoracicSurgery,WeillCornellMedicine,NewYork,NewYork,USA;gDepartmentofCardiovascularMedicine,MayoClinic CollegeofMedicineandScience,Rochester,Minnesota,USA;hDepartmentofSurgery,DivisionofCardiothoracicSurgery,Emory University,Atlanta,Georgia,USA;iDivisionofCardiologyandtheCardiovascularResearchFoundation,ColumbiaUniversity Listentothismanuscript’s IrvingMedicalCenter/NewYork-PresbyterianHospital,NewYork,NewYork,USA;jDepartmentofCardiology,MountSinai,New audiosummaryby York,NewYork,USA;kDepartmentofInterventionalCardiology,VirginiaHeartandtheInovaHeartandVascularInstitute,Falls Editor-in-Chief Church,Virginia,USA;andthelDepartmentofCardiology,BernUniversityHospital,Inselspital,Bern,Switzerland。*American DrValentinFusteron CollegeofCardiologyInterventionalCouncil。yAmericanCollegeofCardiologyCardiacSurgeryTeamCouncil。www。jacc。org/journal/jacc。HabibSamady,MD,servedasGuestAssociateEditorforthispaper。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 208,
      "text": "can DrValentinFusteron CollegeofCardiologyInterventionalCouncil。yAmericanCollegeofCardiologyCardiacSurgeryTeamCouncil。www。jacc。org/journal/jacc。HabibSamady,MD,servedasGuestAssociateEditorforthispaper。 JavedButler,MD,MPH,MBA,servedasGuestEditor-in-Chief forthispaper。Theauthorsattesttheyareincompliancewithhumanstudiescommitteesandanimalwelfareregulationsoftheauthors’ institutionsandFoodandDrugAdministrationguidelines,includingpatientconsentwhereappropriate。Formoreinformation, visittheAuthorCenter。ManuscriptreceivedAugust10,2022;acceptedSeptember7,2022。ISSN0735-1097/$36。00 https://doi。org/10。1016/j。jacc。2022。09。034 2120 Davidsonetal JACC VOL。80, NO。22, 2022 LeftMainCoronaryArteryDisease NOVEMBER 29, 2022:2119–2134 ABBREVIATIONS precluding any further studies involving HIGHLIGHTS AND ACRONYMS medical treatment alone for patients with LMdisease。2-4Unliketheotherepicardialar- (cid:2) LMCADcanbecategorizedasostial/shaft ACC=AmericanCollegeof teriesinwhichsignificantstenosisisdefined and distal lesions, and may be compli- Cardiology as diameter reduction >70%, the threshold cated by multivessel disease。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 209,
      "text": "asostial/shaft ACC=AmericanCollegeof teriesinwhichsignificantstenosisisdefined and distal lesions, and may be compli- Cardiology as diameter reduction >70%, the threshold cated by multivessel disease。 AHA=AmericanHeart Association for intervention in LM disease is set at 50% (cid:2) Clinical, procedural, and institutional CABG=coronaryarterybypass because of early observations that patients factors should be considered along with grafting with 50% to 70% LM stenosis derive a sur- clinical practice guidelines in selecting CAD=coronaryarterydisease vival benefit after CABG。1,3,4 Revasculariza- the mode of revascularization for pa- CTA=computedtomography tion, whether CABG or percutaneous tients with LM CAD。angiography coronary intervention (PCI), may be appro- EACTS=EuropeanAssociation priate on an urgent basis for some patients (cid:2) Engagement of a multidisciplinary heart forCardio-ThoracicSurgery withLMstenosisinwhomhospitaladmission team and shared decision making are key ESC=EuropeanSocietyof and subsequent revascularization may be components of management for patients Cardiology preferred after diagnosis of LM disease。5 LM with LM CAD。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 210,
      "text": " shared decision making are key ESC=EuropeanSocietyof and subsequent revascularization may be components of management for patients Cardiology preferred after diagnosis of LM disease。5 LM with LM CAD。 FFR=fractionalflowreserve disease is treated on a nonelective (urgent IVUS=intravascular oremergent)basisin17%to59%ofpatients。6 cardiologiststoprovideamultidisciplinaryreviewon ultrasound The left main (LM) coronary artery arises the management of LM CAD。The goal is to decrease LAD=leftanteriordescending from the aorta and branches into the left ambiguity and shed light on the spirited debate sur- LCx=leftcircumflexcoronary anterior descending (LAD) and left circum- rounding this complex topic。Optimal outcomes rely artery flex(LCx)coronaryarteries。TheLMcoronary on the engagement with a heart team, composed at LIMA=leftinternalmammary artery artery supplies circulation to a large portion least of general cardiologists, interventional cardiol- LM=leftmain (75% to 100%) of the left ventricular (LV) ogists, cardiac surgeons, anesthesiologists, and the myocardium; as a result, significant LM ste- patient/family with shared decision-making。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 211,
      "text": "ol- LM=leftmain (75% to 100%) of the left ventricular (LV) ogists, cardiac surgeons, anesthesiologists, and the myocardium; as a result, significant LM ste- patient/family with shared decision-making。 It is LMB=leftmainbifurcation nosisplacestheleftventricleatconsiderable important to recognize that LM disease is heteroge- LMCA=leftmaincoronary artery risk。MIafterLMplaqueruptureinvolvesthe neous,andasingleapproachwillnotbeapplicableto LOE=LevelofEvidence entire left ventricle and the inferior wall of each individual patient’s circumstances。Specific pa- the right ventricle in patients with left tient characteristics will be addressed in this LV=leftventricular dominantanatomy。LMstenosiscanoccurin document。MI=myocardialinfarction the ostial (23%), mid-shaft (15%), and distal MVD=multivesseldisease (61%) segments, and depending on the loca- CLINICAL FACTORS FOR DECISION-MAKING PCI=percutaneouscoronary tion and severity of the disease, treatment intervention strategies may differ。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 212,
      "text": "tivesseldisease (61%) segments, and depending on the loca- CLINICAL FACTORS FOR DECISION-MAKING PCI=percutaneouscoronary tion and severity of the disease, treatment intervention strategies may differ。 7 Patients with LM cor- WhenweighingtherisksandbenefitsofPCIvsCABG RIMA=rightinternal onary artery disease (CAD) commonly have forLMdisease,itisimportanttotakeintoaccountthe mammaryartery multivessel disease (MVD), and isolated LM factors that are important to the patient first and SCAI=Societyfor CardiovascularAngiography stenosisoccursinonly4%to6%ofpatients。8 foremost, while also considering clinical factors that andInterventions The historical gold standard for diagnosis of may affect optimal outcomes。From a patient LM disease is coronary angiography,withsignificant perspective,factorsthatmaybetakenintoconsider- stenosis defined as luminal diameter reduction of ation in the decision for revascularization method >50%9; within the category of severe disease, the may include symptom relief, longevity, recovery stenosis severity can be further subclassified as in- time, and freedom from complications post- termediate (50% to 69%), severe (70% to 90%), and procedure。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 213,
      "text": "nclude symptom relief, longevity, recovery stenosis severity can be further subclassified as in- time, and freedom from complications post- termediate (50% to 69%), severe (70% to 90%), and procedure。 When reviewing these potential benefits critical(>90%)(Figure1)。with a patient, clinical factors must be thoroughly In clinical practice, decisions regarding the choice considered and discussed。Multiple methods have ofmedicaltherapyalone,PCI,orCABGforLMdisease been validated to objectively determine patient out- require a tailored multidisciplinary team-based and comeswithcoronaryrevascularization,includingthe patient-centered approach that integrates clinical clinical risk scores of the STS (Society of Thoracic factors,10,11 procedural considerations,12-14 operator Surgeons), the EuroSCORE II (European System for and institution issues,15,16 and clinical practice Cardiac Operative Risk Evaluation), and the NCDR guideline recommendations (Figure 2)。The revascu- (National Cardiovascular Data Registry) CathPCI larizationguidelinesprovideanexcellentframework Registry。19-21 Integrated anatomical and clinical for addressing these complex issues。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 214,
      "text": "e 2)。The revascu- (National Cardiovascular Data Registry) CathPCI larizationguidelinesprovideanexcellentframework Registry。19-21 Integrated anatomical and clinical for addressing these complex issues。 17,18 This paper scores such as the SYNTAX (Synergy Between PCI represents a collaborative effort among cardiac sur- withTaxus and Cardiac Surgery) score andthe more geons, general cardiologists, and interventional recent SYNTAX II 2020 update provide additional JACC VOL。80, NO。22, 2022 Davidsonetal 2121 NOVEMBER 29, 2022:2119–2134 LeftMainCoronaryArteryDisease FIGURE1 DistalLeftMainCoronaryArteryStenosisSeverity Angiographydemonstratingvariousdegreesofsignificantdistalleftmaincoronaryarterystenosisbyquantitativecategories。Theseverityofleftmainstenosismay influenceclinicaldecisionsregardingurgencyofrevascularization。valueinassessingthesuitabilityforPCIvsCABG。22-25 clinicaltrials,andfrailtyisinadequatelymeasuredin Overall, the purpose of a comprehensive preproce- currentriskpredictionmodels。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 215,
      "text": "ncyofrevascularization。valueinassessingthesuitabilityforPCIvsCABG。22-25 clinicaltrials,andfrailtyisinadequatelymeasuredin Overall, the purpose of a comprehensive preproce- currentriskpredictionmodels。 35-39Age,comorbidity duralassessmentistodelineateclinical,anatomical, burden, and clinical frailty often travel together, andproceduralfactorsmostfavorableorunfavorable affectbothsurgicalandpercutaneousoutcomes,and for short-, medium-, and long-term outcomes for shouldbeconsideredinconjunctionwithtraditional CABG, PCI, and medical therapy, identify where risk factors in the decision-making process when equipoise may exist, and assign comparative per- counseling patients regarding periprocedural risks centagestoriskandsuccessestimates,fromwhichto associated with PCI or CABG。40-43 Although CABG is best align physician and patient objectives。Unfortu- feasibleandmayoffersuperiorlonger-termoutcomes nately, most of these tools are limited in how they vs PCI in the elderly, postoperative stays, intensive incorporatespecificcomorbidities。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 216,
      "text": "ives。Unfortu- feasibleandmayoffersuperiorlonger-termoutcomes nately, most of these tools are limited in how they vs PCI in the elderly, postoperative stays, intensive incorporatespecificcomorbidities。 Furthermore,with care unit readmission, and hospital stays are all the rapid pace of medical therapies, the impact of significantly higher compared with younger surgical revascularization in a patient receiving guideline- patients and may influence patient-centered shared directed medical therapy on short-term and long- decision-making。44Octogenariansandnonagenarians termoutcomescontinuestobeamovingtarget。are also more often focused on near-term risks and Factors that may favor CABG include diabetes outcomes,inparticularrecoverytimeandshort-term mellitus (especially with concurrent significant relativerisksofstroke,atrialfibrillation,acutekidney MVD),26,27 a contraindication to dual antiplatelet injury,andphysicaldebility,andmaythusfavorless therapy, history of recurrent in-stent restenosis, or invasive therapeutic options。45 For similar reasons, concomitant ascending aortic or valvular pathology the long-term benefits of revascularization for an withanindependentindicationforsurgery。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 217,
      "text": "is, or invasive therapeutic options。45 For similar reasons, concomitant ascending aortic or valvular pathology the long-term benefits of revascularization for an withanindependentindicationforsurgery。 28,29 asymptomatic patient with LM disease may be less Clinicalfactorsthatmay favorPCIincludeclinical relevantintheelderly,andtherefore,thebenefitsof frailty or severe comorbidities that may affect a pa- revascularization over medical therapy alone for LM tient’s ability to rehabilitate after CABG。Some of diseaseshouldalsobeconsideredbeforeentertaining these comorbidities are severe chronic obstructive revascularization for the sole purpose of improving pulmonary disease, severe chest deformity, prior survival。sternotomyand/orlackofconduits,sequelaeofprior Special consideration should be given to patients chest radiation,29 advanced chronic kidney dis- with LV systolic dysfunction and decompensated ease,30,31 immunosuppression, reduced life expec- heart failure as these conditions increase the short- tancy,orsuboptimalpsychosocialsupport。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 218,
      "text": "idney dis- with LV systolic dysfunction and decompensated ease,30,31 immunosuppression, reduced life expec- heart failure as these conditions increase the short- tancy,orsuboptimalpsychosocialsupport。 32 term risks of both surgical and percutaneous ap- Despite the established benefits of revasculariza- proaches; however, in observational studies, CABG tion for LM disease, medical therapy alone may be appears superior to PCI for patients with LM disease preferred if the weight of comorbidities is high, life andsevereLVsystolicdysfunction。46,47Theabsence expectancyorthelikelihoodofbenefitislow,4,33,34or of myocardial viability on noninvasive testing in pa- a fully informed patient desires this approach。18,26,27 tients with ischemic cardiomyopathy is not neces- Increasing age is a predictor of adverse events, yet sarily a contraindication to revascularization。48 older adults are underrepresented in randomized Finally, when mechanical support is necessary to 2122 Davidsonetal JACC VOL。80, NO。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 219,
      "text": "dverse events, yet sarily a contraindication to revascularization。48 older adults are underrepresented in randomized Finally, when mechanical support is necessary to 2122 Davidsonetal JACC VOL。80, NO。 22, 2022 LeftMainCoronaryArteryDisease NOVEMBER 29, 2022:2119–2134 FIGURE2 HeartTeamConsiderationsforLeftMainCoronaryArteryDisease Procedural Operator and Clinical Practice Clinical Factors Considerations Institution Issues Guidelines • Disease acuity • Coronary anatomy • Operator and institution • Evidence-based • Cardiac and noncardiac • Ability to achieve expertise and outcomes medicine to guide comorbidities reasonably complete for surgical and/or clinical decision- • Health preferences revascularization percutaneous making • Consideration of revascularization percutaneous mechanical circulatory support use • Factors that may favor CABG: Diabetes mellitus, complex multivessel disease, significant left ventricular systolic dysfunction, concomitant ascending aortic or valvular pathology, recurrent prior stent failure, anatomy unlikely to achieve complete revascularization with PCI, contraindications to dual antiplatelet therapy • Factors that may favor PCI: Significant obstructive or restrictive lung disease, advanced age, clinical frailty, severe chest deformation, porcelain aorta, sequelae of prior chest radiation, poor surgical conduits or bypass targets, barriers to post-operative rehabilitation, ST-segment elevation MI or cardiogenic shock • Factors that may favor Medical Therapy: High burden of severe comorbidities, severe frailty, limited life expectancy, informed patient preference Theheartteammustconsiderclinicalfactors,proceduralconsiderations,operatorandinstitutionissues,andclinicalpracticeguidelinestoinformdecisionmakingon theoptimaltreatmentofleftmaincoronaryarterydiseaseforeachindividualpatient。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 220,
      "text": "rclinicalfactors,proceduralconsiderations,operatorandinstitutionissues,andclinicalpracticeguidelinestoinformdecisionmakingon theoptimaltreatmentofleftmaincoronaryarterydiseaseforeachindividualpatient。 Ifclinicallyfeasible,amultidisciplinaryheartteamapproachtoeachpatientis imperativewhenmakingdecisionsregardingtreatmentstrategiesforleftmaindisease。CABGcoronaryarterybypassgrafting;MImyocardialinfarction; PCIpercutaneouscoronaryintervention。perform PCI, the elevated risks of vascular compli- as the anticipated risks and benefits of each cations and major bleeding with current percuta- approach。Consideration must also be given to pa- neous mechanical support devices in this patient tients who cannot, or will not, be adherent to rec- populationshouldbefactoredintotheassessmentof ommended postprocedure therapies (ie, sternal therelativeriskofCABGvsPCI。49,50Decision-making precautions after CABG or the need for dual anti- regarding the options for pursuing non- platelet therapies after PCI)。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 221,
      "text": "rocedure therapies (ie, sternal therelativeriskofCABGvsPCI。49,50Decision-making precautions after CABG or the need for dual anti- regarding the options for pursuing non- platelet therapies after PCI)。 Patient preferences are revascularization therapies, such as long-term ven- important, but patients must understand when such tricular assist devices or transplants, should be preferences are not aligned with current guidelines considered in such high-risk patients, and although or the recommendations of the heart team。17 Pres- such protocols and options are beyond the scope of ently, a detailed, but understandable, highly visual, this paper, early engagement with a heart team and standardized decision aid, aimed to provide the should be encouraged for patients with advanced patient with a detailed understanding of all options, cardiomyopathiesthatarenotanticipatedtoimprove whichcanbeusedbyallmembersoftheheart team withstandardrecommendedtherapies。to consistently convey individualized and weighted Integrating a multidisciplinary heart team into risks and benefits to all patients is strongly institutionalpracticeprovidesaformalizedapproach needed。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 222,
      "text": " consistently convey individualized and weighted Integrating a multidisciplinary heart team into risks and benefits to all patients is strongly institutionalpracticeprovidesaformalizedapproach needed。 53,54 to evaluate complex LM disease and to best ensure standardized and equitable care delivery。51,52 Con- PROCEDURAL CONSIDERATIONS FOR versations with the patient and designated family PCI AND CABG IN LM DISEASE membersshouldbeconductedinthepatient’snative language to both maximize understanding of the is- When evaluating revascularization strategies for un- sues and minimize health care disparities。The pa- protectedLMdisease,itisimportanttoconsiderthat tient should be informed of the clinical relevance of isolatedLMdiseaseisanuncommonissue。Concom- LM disease, the possible treatment options, as well itant severe MVD should weigh in as a technical JACC VOL。80, NO。22, 2022 Davidsonetal 2123 NOVEMBER 29, 2022:2119–2134 LeftMainCoronaryArteryDisease FIGURE3 LeftMainPCITechnicalConsiderations Leftmainpercutaneouscoronaryintervention(PCI)requirescarefulconsiderationoflesioncharacteristics,includinglesionlength,bifurcationangle,plaqueburden, andmorphology。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 223,
      "text": " LeftMainPCITechnicalConsiderations Leftmainpercutaneouscoronaryintervention(PCI)requirescarefulconsiderationoflesioncharacteristics,includinglesionlength,bifurcationangle,plaqueburden, andmorphology。 Forleftmainshaftandsimplebifurcationlesions,aprovisionalsingle-stentstrategymaybepreferred,andformorecomplexbifurcationlesions,a2- stentstrategymayberequired。Intravascularultrasound(IVUS)shouldbeusedforpreinterventionlesionandvesselassessment,periproceduralguidanceoflesion preparationandstentdeployment,andpostinterventionassessmentofoptimalendpointsandexclusionofcomplications。considerationinthedecisiontopursuepercutaneous has important implications for performing PCI vs surgical treatment with the goal of complete compared with patients with ostial and mid-vessel revascularization。Technicalconsiderationsshouldbe stenosis。55 The use of intravascular imaging remains factoredintothedecision-makingprocessasoptimal an important and necessary adjunct for assessing resultswillbeinfluencednotonlybyoperatorexpe- lesion severity, technical PCI approach, proper stent rience,butalsobytechnicalfeasibility。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 224,
      "text": "cessasoptimal an important and necessary adjunct for assessing resultswillbeinfluencednotonlybyoperatorexpe- lesion severity, technical PCI approach, proper stent rience,butalsobytechnicalfeasibility。 Consideration sizing, and stent apposition in both non-LMB and should also be given to hybrid or staged therapies LMBanatomy,whereasfunctionaltestingcanhelpto when neither CABG nor PCI is ideal—especially, as assesshemodynamicsignificanceofLMstenosisand discussed in the preceding text, when patients pre- to evaluate side branch compromise if a provisional sentwithacutesymptoms。stenting strategy is being considered。For angio- TECHNICALCONSIDERATIONSFORPCIINLMDISEASE。graphically intermediate lesions, intravascular ultra- AnatomyofLMdiseasecanaddtechnicalchallenges sound (IVUS) is commonly used to determine toPCIandshouldweighonthedecisiontopursuePCI significance of a stenosis, and revascularization is vs CABG (Figure 3)。The majority of LM stenoses generallyacceptedtobesafetodeferifIVUSrevealsa involve the LM bifurcation (LMB), and this location minimumlumenareaof6mm2orgreater。56InAsian 2124 Davidsonetal JACC VOL。80, NO。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 225,
      "text": " majority of LM stenoses generallyacceptedtobesafetodeferifIVUSrevealsa involve the LM bifurcation (LMB), and this location minimumlumenareaof6mm2orgreater。56InAsian 2124 Davidsonetal JACC VOL。80, NO。 22, 2022 LeftMainCoronaryArteryDisease NOVEMBER 29, 2022:2119–2134 populations,asmallerminimumlumenareacutoffof complex PCI, the use of circulatory devices can pro- 4。5mm2maybeacceptable。57Onetypeoffunctional vide essential hemodynamic support。Ensuring testing, fractional flow reserve (FFR), has also been adequate arterial access (either femoral, axillary, or useful in deciding whether revascularization is indi- transcaval) to facilitate support should be an impor- cated, with FFR values of >0。8, representing an tantconsideration。acceptablenumbertodeferPCI。TECHNICAL CONSIDERATIONS FOR CABG IN LM In LMB PCI, several technical considerations DISEASE。The nature of isolated LM lesions is an should be considered when deciding on stenting irrelevant issue for CABG, because distal epicardial strategies。The first is a provisional single-stent vesselsalmostalwaysprovetobeappropriatebypass strategy vs an upfront dedicated 2-stent strategy。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 226,
      "text": "irrelevant issue for CABG, because distal epicardial strategies。The first is a provisional single-stent vesselsalmostalwaysprovetobeappropriatebypass strategy vs an upfront dedicated 2-stent strategy。 targets unless there is concomitant severe diffuse Although the vast majority of LMB PCIs can be per- distal disease。For patients with LM CAD and formed using a provisional single-stent strategy, concomitant MVD, complete revascularization is sometimes an anatomically complex lesion will achievable with adequate (minimum 1。5 mm) distal require the use of a dedicated 2-stent strategy。58,59 targetvessels。Epicardialvesselswithsmallercaliber Second, with regard to bifurcation techniques for a targets, calcified walls,or intramyocardial course in- dedicated2-stentstrategy,doublekisscrushstenting crease CABG complexity,but are challenges encoun- appearssuperiortoculottestentingwithlowerrates teredmoreofteninMVDwithoutLMcoronaryartery oftargetvesselrevascularization。60 (LMCA)involvement。Lesion complexity in LMB PCI is an important Several technical considerations are unique to consideration in deciding on anatomical feasibility CABGforLMdisease(Figure4)。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 227,
      "text": "rization。60 (LMCA)involvement。Lesion complexity in LMB PCI is an important Several technical considerations are unique to consideration in deciding on anatomical feasibility CABGforLMdisease(Figure4)。 Cardioplegicarrestof and the decision to pursue a provisional vs a dedi- theheartduringon-pumpCABGmaybehinderedby cated 2-stent strategy。The utility of the SYNTAX severeLMstenosis。IncasesofcriticalLMCAdisease, score, as a predictor of adverse outcomes, typically patients may become unstable during induction of usedtoassesslesioncomplexity,hasnotbeenborne anesthesia,so carefulattentionshouldbe paidupon out in the 2 most recent trials of LM stenting。61,62 inductionwithlesscardiodepressiveagents;insome However, the DEFINITION (Definitions and impact cases,preinductionuseofhemodynamicsupport(eg, of complEx biFurcation lesIons on clinical outcomes withanintra-aorticballoonpump)maymitigatethis after percutaNeous coronary intervenTION using issue。Inadequatemyocardialprotectionusingsolely drug-eluting steNts) trial investigators proposed antegradecardioplegiamayresultinapoordistribu- criteria for simple vs complex bifurcations based on tion of cardioplegia and failure to arrest the heart。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 228,
      "text": "g-eluting steNts) trial investigators proposed antegradecardioplegiamayresultinapoordistribu- criteria for simple vs complex bifurcations based on tion of cardioplegia and failure to arrest the heart。 anatomical criteria and demonstrated that 30% of The addition of retrograde cardioplegia to facilitate patientshadcomplexbifurcations。Notonlydidthese adequate distribution during CABG is a simple solu- patients have higher rates of adverse events than tion for myocardial protection。64 Porcelain aorta or those with simple LMB lesions, but they also had aorta with atheroma can be addressed via off-pump betteroutcomeswitha2-stentstrategy。12Themulti- CABG and avoidance of aortic cannulation, aortic centerrandomizedDEFINITIONIItrialdemonstrated cross-clamping,andgraftanastomosistotheaortato that a 2-stent strategy compared with a provisional avoid embolic stroke。65,66 However, surgeon experi- approach was associated with improved outcomes, encewithoff-pumpCABGisnecessarytoachievethe and the EBC MAIN (European Bifurcation Club Left best results。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 229,
      "text": "embolic stroke。65,66 However, surgeon experi- approach was associated with improved outcomes, encewithoff-pumpCABGisnecessarytoachievethe and the EBC MAIN (European Bifurcation Club Left best results。 Minimally invasive and hybrid revascu- MainCoronaryStent)trialdemonstratedfurtherma- larization strategies, to avoid a sternotomy, have jor cardiac events with a provisional approach vs a been described and are an area of active 2-stent strategy, but did not reach statistical signifi- investigation。67,68 cance。59,63 Therefore, studies have been contradic- Complete surgical revascularization with durable tory with regard to 2-stent vs provisional strategies bypass grafts is the objective of CABG。Utilization of for LM PCI, and lack of standardization between the left internal mammary artery (LIMA) is the gold studies prevents definitive conclusions regarding standard in modern CABG and provides both graft superiority。durability and superior patient survival。69,70 Use of The use of adjunctive mechanical circulatory sup- multiarterial grafting has been associated with portdevices,suchasImpella(Abiomed)ortheintra- improvedoutcomesinsomeseries。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 230,
      "text": "ient survival。69,70 Use of The use of adjunctive mechanical circulatory sup- multiarterial grafting has been associated with portdevices,suchasImpella(Abiomed)ortheintra- improvedoutcomesinsomeseries。 69,71,72Choicesfor aortic balloon pump, can be of value in carefully the second arterial graft include the right internal selected patients。In patients with LM disease, mammary artery (RIMA) and the radial artery。The particularly those with LMB disease and unstable RIMAcanbetakeninsitufromthesubclavianartery, hemodynamics or depressed ejection fraction who routed either anterior or posterior to the aorta, and might not be able to tolerate the ischemic insult of graftedtoasecondleft-sidedepicardialvessel。Insitu JACC VOL。80, NO。22, 2022 Davidsonetal 2125 NOVEMBER 29, 2022:2119–2134 LeftMainCoronaryArteryDisease RIMA grafts necessarily cross midline, and the pros- FIGURE4 CABGTechnicalConsiderationsinLMDisease pect of reoperative surgery must be factored into decision-making。Both the RIMA and radial artery grafts can be grafted to the aorta or from another Coronary Artery Bypass Grafting bypass graft in a Y or T configuration。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 231,
      "text": "surgery must be factored into decision-making。Both the RIMA and radial artery grafts can be grafted to the aorta or from another Coronary Artery Bypass Grafting bypass graft in a Y or T configuration。 Sequencing arterialgraftstomultiplebypasstargetsincreasesthe flowthroughtheconduitandmayimprovelong-term Bypass Bypass graft graft patency。Finally, devascularization of vascular beds Bypass graft are concerns during both RIMA and radial artery harvest。However, the risk of deep-sternal wound infection secondary to sternal devascularization can Flow-limiting lesion be mitigated by harvesting the RIMA from the chest Not-flow-limiting wallasaskeletonizedgraftasopposedtoapedicled lesion graft but may come at the cost of reduced graft CABG provides collateral patency。73,74 Similarly, hand devascularization after flow that bypasses LM radial artery harvest can be minimized by selecting lesions and protects against concomitant the nondominant hand and evaluating for sufficient multivessel disease ulnar blood flow into the palmar arch; hand neurop- athy is an infrequent and generally transitory complication。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 232,
      "text": "inst concomitant the nondominant hand and evaluating for sufficient multivessel disease ulnar blood flow into the palmar arch; hand neurop- athy is an infrequent and generally transitory complication。 75 Coronaryarterybypassgrafting(CABG)providescollateralflow An unanswered question regarding CABG for LM thataddressesleftmain(LM)lesionsregardlessofcomplexity disease is the revascularization strategy when the andprotectsagainstmultivesseldiseasebybypassingboth currentandfutureupstream-limitinglesions。lesion does not involve the LM bifurcation。The traditional teaching is to bypass both the LAD and LCx distribution, selecting the largest obtuse mar- and NOBLE (Nordic-Baltic-British Left Main Revas- ginal branch as the distal target on the lateral wall。cularization Study) trials recommended an IVUS- However, concern arises for competitive flow be- guided PCI strategy。Although IVUS has not been tweenthelargerveingrafttothecircumflexandthe formallystudiedinthesetrials,subsetanalyseshave LIMA graft to the LAD。On the other hand, a single- indicatedthatuseofIVUSisassociatedwithreduced vessel bypass, LIMA to LAD, can be considered for targetlesionrevascularization。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 233,
      "text": "als,subsetanalyseshave LIMA graft to the LAD。On the other hand, a single- indicatedthatuseofIVUSisassociatedwithreduced vessel bypass, LIMA to LAD, can be considered for targetlesionrevascularization。 78 patients with small nondominant circumflex distri- PublishedoutcomesofLMdiseasehavegenerated butions。There remain concerns that the flow in the controversy。79-82 However, several meta-analyses LIMA may be inadequate to supply the entire left have been conducted analyzing the 4 major LM PCI ventricle and does not address the potential evolu- vs CABG trials; the most recent of which is a collab- tion of proximal LM disease into the bifurcation。orative,individualpatient-levelanalysisthatseeksto Multiarterial grafting with bilateral internal mam- critically evaluatethe available data(Table2)。These mary artery grafts might be considered the ideal meta-analysesconsistentlyhavedemonstratedalack compromise, avoiding competitive flow from a high- ofsignificantmortalitydifferencebetweenCABGand flow vein graft while providing blood flow to both PCI。83-86 In, Bayesian analysis, there was an 85。7% LADandLCxterritories。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 234,
      "text": "ompetitive flow from a high- ofsignificantmortalitydifferencebetweenCABGand flow vein graft while providing blood flow to both PCI。83-86 In, Bayesian analysis, there was an 85。7% LADandLCxterritories。 probabilitythatdeathat5yearswasgreaterwithPCI COMPARATIVE TRIALS OF CABG VS PCI than with CABG; however, this difference was more likelythannot<0。2%peryear。86Inanotheranalysis, Several randomized clinical trials have studied the itwasshownthattheestimatedposteriorprobability comparative effectiveness of CABG and PCI for LM (ie,ofany)excessmortalitywithPCIoverCABGwas CAD (Table 1)。24,62,76,77 In these 4 major studies, LM 85%witha47% probabilityofexceeding1eventper stenosis was defined visually as >50%, but EXCEL 100 treated。87 Although differences in the rates of (Evaluation of XIENCE Everolimus Eluting Stent procedural MI depended upon the ascertainment of Versus Coronary Artery Bypass Surgery for Effec- biomarkers (and definition of MI) used within the tiveness of Left Main Revascularization) included specific trials, the incidence of spontaneous MI was patientswithlesions#70%onlyifhemodynamically lowerwithCABGcomparedwithPCI。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 235,
      "text": "of MI) used within the tiveness of Left Main Revascularization) included specific trials, the incidence of spontaneous MI was patientswithlesions#70%onlyifhemodynamically lowerwithCABGcomparedwithPCI。 Withrespectto significantasdeterminedbyadditionalhemodynamic other outcomes, stroke was found to be similar be- testing。Another notable difference between the tweenPCIandCABGandrepeatrevascularizationwas earliertrialsandmorerecenttrialsisthattheEXCEL consistentlylessafterCABG。2126 Davidsonetal JACC VOL。80, NO。22, 2022 LeftMainCoronaryArteryDisease NOVEMBER 29, 2022:2119–2134 TABLE1 LMCADRandomizedClinicalTrialsComparedbyPrimaryCompositeEndpoint SYNTAX24 PRECOMBAT77 EXCEL62 NOBLE61,76 Serruys2009 Park2011 Stone2016 Holm2020 Sponsor BostonScientific CardiovascularResearchFoundation AbbottVascular AarhusUniversityHospital Trialdesign RCT,subsetanalysis,1-year RCT,noninferiority,1-year RCT,noninferiority,3-year RCT,noninferiority,5-year N 705 600 1,905 1,201 Anatomy >50%stenosis >50%stenosis >70%stenosisor50%-70% >50%stenosisorFFR#0。80 hemodynamicallysignificant Primarycomposite 1。death 1。death 1。death 1。death endpoint 2。stroke 2。stroke 2。stroke 2。stroke 3。MI 3。MI 3。MI—SCAI 3。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 236,
      "text": "50%stenosis >70%stenosisor50%-70% >50%stenosisorFFR#0。80 hemodynamicallysignificant Primarycomposite 1。death 1。death 1。death 1。death endpoint 2。stroke 2。stroke 2。stroke 2。stroke 3。MI 3。MI 3。MI—SCAI 3。 MI—nonprocedural 4。repeatrevascularization 4。repeatrevascularization 4。repeatrevascularization Results 15。8%PCIvs13。7%CABG 8。7%PCIvs6。7%CABG 15。4%PCIvs14。7%CABG 28%PCIvs19%CABG Conclusions Hypothesisgenerating Hypothesisgenerating PCInoninferiortoCABG PCIinferiortoCABG CABGcoronaryarterybypassgrafting;EXCELEvaluationofXIENCEEverolimusElutingStentVersusCoronaryArteryBypassSurgeryforEffectivenessofLeftMainRevascularization;FFRfractional flowreserve;MImyocardialinfarction;NOBLENordic-Baltic-BritishLeftMainRevascularizationStudy;PCIpercutaneouscoronaryintervention;PRECOMBATBypassSurgeryVersusAngioplasty UsingSirolimus-ElutingStentinPatientsWithLeftMainCoronaryArteryDisease;RCTrandomizedclinicaltrial;SCAISocietyforCardiovascularAngiographyandInterventions;SYNTAXSynergy BetweenPCIWithTAXUSandCardiacSurgery。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 237,
      "text": "Sirolimus-ElutingStentinPatientsWithLeftMainCoronaryArteryDisease;RCTrandomizedclinicaltrial;SCAISocietyforCardiovascularAngiographyandInterventions;SYNTAXSynergy BetweenPCIWithTAXUSandCardiacSurgery。 The comparative studies of CABG and PCI on LM Shareddecision-making isoneof the most impor- CADdifferbytrialdesign,inclusioncriteria,primary tant take-home points of the 2021 ACC/AHA/SCAI composite endpoints, length of follow-up, and even guidelines for coronary artery revascularization。As types of stents and adjunctive techniques (eg, IVUS) mentioned earlier, and as is critical in all cases of used。Table 3 contains data on the longest available coronary revascularization, a patient’s own beliefs follow-upfromthesetrials。and preferences must be considered when deciding whethertoproceedwithrevascularizationandwhen CURRENT GUIDELINE RECOMMENDATIONS contemplating the mode of revascularization。The FOR MANAGINGPATIENTSWITHLMDISEASE discussion should be fully transparent, highlighting the institutional volume and expertise with each Recent guidelines committees have considered the method of revascularization。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 238,
      "text": "ATIENTSWITHLMDISEASE discussion should be fully transparent, highlighting the institutional volume and expertise with each Recent guidelines committees have considered the method of revascularization。 Educational tools evidence base for LMCA revascularization and includingillustrationsorvideosarestronglyencour- formulatedrecommendationsbroadly。Whenconsid- aged。88,89 The goal is to provide the patient with ering patients with LM disease, the 2021 American sufficient information and appropriate time to make CollegeofCardiology(ACC)/AmericanHeartAssocia- aneducateddecision。tion (AHA)/Society for Cardiovascular Angiography Both guidelines emphasize the importance of the and Interventions (SCAI) guidelines for coronary ar- heart team in cases where there is uncertainty tery revascularization focus on several key issues: regarding the optimal approach to revascularization。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 239,
      "text": "Interventions (SCAI) guidelines for coronary ar- heart team in cases where there is uncertainty tery revascularization focus on several key issues: regarding the optimal approach to revascularization。 1) the importance of shared decision-making incor- This is imperative because by design, randomized poratingthe patient’spreferences andbeliefs; 2) the trials include patients that meet very stringent roleoftheheartteaminfacilitatingthesedecisions;3) enrollment criteria, and in clinical practice, many the indications for revascularization to improve sur- patients will fall outside of the exact patient popu- vival;4)situationsinwhichonetherapyispreferred lation that is studied in an individual trial。In addi- overanother;and5)theuseofintravascularimaging tion to general cardiologists, cardiac surgeons, to assess patients with intermediate disease and, interventionalcardiologists,andanesthesiologists,in whenPCIisplanned,theuseofimagingtoguidePCI many situations, the heart team may include in- (Table 4)。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 240,
      "text": "assess patients with intermediate disease and, interventionalcardiologists,andanesthesiologists,in whenPCIisplanned,theuseofimagingtoguidePCI many situations, the heart team may include in- (Table 4)。 17The 2018 EuropeanSociety of Cardiology ternists, geriatricians, vascular specialists, neurolo- (ESC)/European Association for Cardio-Thoracic Sur- gists,nephrologists,oncologists,pulmonologists,and gery (EACTS) guidelines on myocardial revasculari- nursing and/or social workers。They should consider zationemphasize:1)theuseofestablishedriskscores the indications for revascularization, disease to estimate operative risk (STS Class I, Level of Evi- complexity, mode of revascularization, anticipated dence[LOE]:B;EuroSCOREIIClassII,LOE:B);2)the risks/benefitsofrevascularizationstrategies,andthe calculation of the SYNTAX score (Class I, LOE: B) to patient’s preferences。Risk assessment should not determine anatomical complexity; 3) the importance solelyfocusoncomplexityofdisease,STSriskscore, toachievecompleterevascularization(ClassIIa,LOE: orotherscoringsystems,butshouldalsoincorporate B);and4)theheartteam(ClassI,LOE:C)。18 other relevant clinical factors that are not JACC VOL。80, NO。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 241,
      "text": "ore, toachievecompleterevascularization(ClassIIa,LOE: orotherscoringsystems,butshouldalsoincorporate B);and4)theheartteam(ClassI,LOE:C)。18 other relevant clinical factors that are not JACC VOL。80, NO。 22, 2022 Davidsonetal 2127 NOVEMBER 29, 2022:2119–2134 LeftMainCoronaryArteryDisease TABLE2 Meta-AnalysesComparisonofPrimaryEndpoints Ahmad202083RR(95%CI) Gallo202084OR(95%CI) Kuno202085HR(95%CI) Sabatine202186HR(95%CI) Journal EuropeanHeartJournal JournalofThoracicand AmericanHeartJournal Lancet CardiovascularSurgery Death 1。03(0。82-1。30) 1。13(0。57-1。38) 1。11(0。91-1。35) 1。10(0。91-1。32) Stroke 0。74(0。36-1。50) 0。88(0。61-1。28) 0。81(0。42-1。53) 0。84(0。59-1。21) MI 1。22(0。96-1。56) 1。43(1。13-1。79)P[0。003 1。48(0。88-2。48) 1。34(1。08-1。67)P[0。0087 Revascularization 1。73(1。49-2。02)P<0。001 1。89(1。58-2。26)P<0。0001 1。80(1。52-2。13)P<0。01 1。78(1。51-2。10)P<0。0001 Statisticallysignificantvaluesareinbold。MImyocardialinfarction。always included in risk scores。Similarly, the 2018 ThemajorityofstudiescomparingPCItoCABGin ESC/EACTS guidelines on myocardial revasculariza- patients with LM disease excluded patients with tionhighlighttheimportanceofthemultidisciplinary complex disease, such as SYNTAX score $33。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 242,
      "text": "CItoCABGin ESC/EACTS guidelines on myocardial revasculariza- patients with LM disease excluded patients with tionhighlighttheimportanceofthemultidisciplinary complex disease, such as SYNTAX score $33。 76,92,93 heart team to guide a balanced, multidisciplinary Pooled data from these and other randomized trials decision-making process and establish institutional did not demonstrate a clear survival advantage of protocols to implement the appropriate revasculari- CABG over PCI in patients with low-to-intermediate zationstrategyinaccordancewithcurrentguidelines complexity of LM stenosis。83,84,86 With this in (ClassI,LOE:C)。18 mind, the guidelines do not provide comparative The 2021 ACC/AHA/SCAI guidelines provide spe- recommendations to favor one mode of revasculari- cific recommendations for proceeding with revascu- zationoveranotherwhentreatingpatientswithlow- larization in stable patients to improve survival。In to-intermediatecomplexityLMdisease。Ontheother stable patients, revascularization of significant LM hand,inpatientswithcomplexdisease,theSYNTAX disease with CABG has been shown to improve sur- trial showed clear superiority of CABG over PCI。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 243,
      "text": "other stable patients, revascularization of significant LM hand,inpatientswithcomplexdisease,theSYNTAX disease with CABG has been shown to improve sur- trial showed clear superiority of CABG over PCI。 94-96 vivalcomparedwithmedicaltherapy,andtherefore, For this reason, in patients with complex LM dis- revascularization with CABG to treat LM disease is ease, CABG is recommended over PCI as a Class I recommended。3,17,90 There is a Class I, LOE: B recommendation with a goal toward improving sur- recommendation for revascularization with vival for high-complexity CAD。17 The 2018 ESC/ CABG。3,34,90 The guidelines also recommend revas- EACTSguidelinesmentionthesignificantinteraction cularizationwithPCItoimprovemortalitycompared withtimethatisnotableinrandomizedclinicaltrials with medical therapy as a reasonable strategy if suggesting early benefit for PCI in terms of peri- revascularizationwithPCIcanprovidesimilarresults procedural stroke and MI, which is subsequently to that seen with CABG。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 244,
      "text": " as a reasonable strategy if suggesting early benefit for PCI in terms of peri- revascularizationwithPCIcanprovidesimilarresults procedural stroke and MI, which is subsequently to that seen with CABG。 This is based on a network offset by a higher risk of spontaneous MI and the meta-analysis demonstrating that the survival consistent observation of more frequent revascular- advantage with PCI compared with medical therapy izationwithPCIthanCABG,pointingtotheneedfor was similar to that achieved with CABG。3,34,90,91 It is individual decision-making taking a patient- importanttonotethattherandomizedtrialsshowing centered approach。The recommendations to asurvivaladvantagewithCABGwereperformedata choosebetweenPCIandCABGinthespecificsetting time before the use of antiplatelet therapies and of LM stenosis have been guided by underlying statins。Although medical therapy has evolved disease complexity as estimated by the SYNTAX dramatically since that time, newer surgical tech- score。Whereas CABG assumes a Class I, LOE: A niques including the use of arterial grafting have indication irrespective of disease complexity in pa- also improved the safety and success of CABG。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 245,
      "text": "tech- score。Whereas CABG assumes a Class I, LOE: A niques including the use of arterial grafting have indication irrespective of disease complexity in pa- also improved the safety and success of CABG。 The tients at low predicted surgical risk, PCI is contra- 2018 ESC/EACTS guidelines on myocardial revascu- indicated in patients with LM disease and high larization distinguishbetween prognostic andsymp- complexity (SYNTAX score $33, Class III, LOE: B) tomatic indications for revascularization in patients owing to the low number of patients included in with stable angina or silent ischemia, and allocate a randomized clinical trials, as well as the improved Class Ia indication for revascularization in patients long-term outcomes in patients with high- with LM stenosis >50% in the presence of docu- complexity MVD undergoing CABG。Conversely, PCI mented ischemia or hemodynamically relevant ste- has been considered an alternative to CABG among noses defined by a positive instantaneous wave-free patients with LM disease and low (SYNTAX ratio or FFR or lesions with angiographic stenosis score #22; Class Ia) or intermediate (SYNTAX score >90%。23-32;ClassIIa,LOE:A)diseasecomplexity。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 246,
      "text": "us wave-free patients with LM disease and low (SYNTAX ratio or FFR or lesions with angiographic stenosis score #22; Class Ia) or intermediate (SYNTAX score >90%。23-32;ClassIIa,LOE:A)diseasecomplexity。 Ofnote, 2128 Davidsonetal JACC VOL。80, NO。22, 2022 LeftMainCoronaryArteryDisease NOVEMBER 29, 2022:2119–2134 TABLE3 LMRandomizedClinicalTrialsComparedbyIndividualEndpointsandLongestReportedFollow-Up EXCEL93 NOBLE76 SYNTAX94,96 PRECOMBAT92 Follow-up 5y 5y 10ya 10y Published 2019 2019 2014/2019 2020 N 1,905 1,186 1,800 600 Death 13%PCIvs9。9%CABG; 9%PCIvs9%CABG; 27%PCIvs28%CABG; 14。5%PCIvs13。8%CABG; OR:1。38(1。03-1。85) HR:1。08(0。74-1。59);P0。68 HR:0。92(0。69-1。22) HR:1。13(0。75-1。70) Stroke 2。9%PCIvs3。7%CABG; 4%PCIvs2%CABG; 2。4%PCIvs3。7%CABG; 1。9%PCIvs2。2%CABG; OR:0。78(0。46-1。31) HR:1。75(0。86-3。55);P0。11 P0。09 HR:0。71(0。22-2。23) MI 10。6%PCIvs9。1%CABG; 8%PCIvs3%CABG; 9。7%PCIvs3。8%CABG; 3。2%PCIvs2。8%CABG; OR:1。14(0。84-1。55)b HR:2。99(1。66-5。39);P[0。0002 P<0。001 HR:0。76(0。32-1。82) Revascularization 17。2%PCIvs10。5%CABG; 17%PCIvs10%CABG; 25。9%PCIvs13。7%CABG; 16。1%PCIvs8。0%CABG; OR:1。79(1。36-2。36) HR:1。73(1。25-2。40);P[0。0009 P<0。0001 HR:1。98(1。21-3。21) Valuesinparenthesisare95%CI。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 247,
      "text": "Revascularization 17。2%PCIvs10。5%CABG; 17%PCIvs10%CABG; 25。9%PCIvs13。7%CABG; 16。1%PCIvs8。0%CABG; OR:1。79(1。36-2。36) HR:1。73(1。25-2。40);P[0。0009 P<0。0001 HR:1。98(1。21-3。21) Valuesinparenthesisare95%CI。 a10yearsformortalityonly,5yearsforotherendpoints。bUsingtheUniversalDefinitionofMyocardialInfarction,9。6%PCIvs4。7%CABG(95%CI:2。6%-7。2%)。105 Boldindicatesstatisticallysignificantresults。AbbreviationsasinTables1and2。the latter recommendation is currently not sup- testingwererandomizedtoaninvasivevsconserva- ported by EACTS and is being reviewed。18 tive strategy, screening computed tomography angi- IntravascularimagingisusefulinpatientswithLM ography (CTA) was performed before randomization disease。For this reason, the 2021 ACC/AHA/SCAI in patients with uncompromised renal function。guidelines recommend IVUS as a reasonable option Among this cohort, significant LM disease was iden- for evaluating patients with intermediate LM dis- tified in 8% of patients。100 With the mortality ease。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 248,
      "text": "elines recommend IVUS as a reasonable option Among this cohort, significant LM disease was iden- for evaluating patients with intermediate LM dis- tified in 8% of patients。100 With the mortality ease。 17 In patients with LM disease in whom PCI is advantageaffordedbyrevascularization,missingthe planned, IVUS or optical coherence tomography can diagnosis of a significant LM disease may be lethal, provide useful information related to degree of cal- especially given the association of LM lesions with cium, volume and extent of plaque, and vessel size。significant MVD。On the other hand, a shift toward Poststent imaging can also be useful to identify calciumscoringand/orCTAforriskstratificationmay geographicmiss,orperistentdissectionor thrombus enrich the population of patients diagnosed with and to assess for adequate stent expansion。The UL- either calcified or noncalcified LM plaques, necessi- TIMATE (Intravascular Ultrasound Guided Drug tatingacarefulassessmentoftheclinicalindications ElutingStentsImplantationin\"All-Comers\"Coronary for further workup and testing (eg, cardiac Lesions) trial demonstrated that IVUS-guided PCI catheterization)。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 249,
      "text": "carefulassessmentoftheclinicalindications ElutingStentsImplantationin\"All-Comers\"Coronary for further workup and testing (eg, cardiac Lesions) trial demonstrated that IVUS-guided PCI catheterization)。 resultedinalowerrateoftargetvesselfailureat1and Beyond the upstream consideration of the pres- 3 years, and a lower rate of stent thrombosis at 3 ence (or absence) of LM disease in the outpatient years。97,98 Additionally, meta-analyses of studies setting, within the cardiac catheterization labora- evaluating IVUS-guided PCI, including the Ultimate tory,theangiographicassessmentofLMstenosiscan trial, have shown a lower cardiac mortality with be challenging。Coronary angiography has been IVUS-guided PCI。99 Both sets of guidelines recom- demonstrated to both underestimate and over- mendtheuseofIVUSasausefultoolforprocedural estimate the significance of LM stenoses when guidanceforLMPCI(ClassIIa,LOEB)。17,18 compared with either invasive imaging (eg, IVUS) or physiological assessment (eg, FFR)。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 250,
      "text": "USasausefultoolforprocedural estimate the significance of LM stenoses when guidanceforLMPCI(ClassIIa,LOEB)。17,18 compared with either invasive imaging (eg, IVUS) or physiological assessment (eg, FFR)。 Thus, especially PRACTICAL APPROACH TO LM DISEASE for intermediate LM stenoses, a complete assess- ment using intravascular imaging or physiology is LMdiseaseistheCADsubsetwiththestrongestevi- reasonable。dencethatrevascularizationprovidessurvivalbenefit Withrespecttoin-labdecision-making,inpatients overmedicaltreatmentaloneinstablepatients。91As with stable disease and symptoms, ad hoc interven- such, for practicing clinicians, it is important to tion is strongly discouraged。In more urgent situa- ascertain an individual patient’s likelihood of LM tions, rapid collaborative multidisciplinary team diseaseaspartofriskstratification。IntheISCHEMIA consultation may be preferred if immediately avail- (International Study of Comparative Health Effec- able on-site or via virtual consultation。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 251,
      "text": "ary team diseaseaspartofriskstratification。IntheISCHEMIA consultation may be preferred if immediately avail- (International Study of Comparative Health Effec- able on-site or via virtual consultation。 101 In tivenessWithMedicalandInvasiveApproaches)trial, contemporary practice, owing to persistently high inwhichmildlysymptomaticandstablepatientswith operative risks,few patientswithST-segment eleva- moderate-severe ischemia on noninvasive stress tion MI or cardiogenic shock are presently managed JACC VOL。80, NO。22, 2022 Davidsonetal 2129 NOVEMBER 29, 2022:2119–2134 LeftMainCoronaryArteryDisease TABLE4 RecommendationsFromthe2021ACC-AHA-SCAIand2018ESC-EACTSRelevanttoPatientsWithLeftMainDisease FocusArea ACC-AHA-SCAIRecommendation COR,LOE ESC-EACTSRecommendation COR,LOE Shareddecision-making Inpatientsundergoingrevascularization,decisions I,C—LD shouldbepatientcentered—thatis,considerateof I,C—LD thepatient’spreferencesandgoals,culturalbeliefs, healthliteracy,andsocialdeterminantsofhealth— andmadeincollaborationwiththepatient’ssupport system。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 252,
      "text": "shouldbepatientcentered—thatis,considerateof I,C—LD thepatient’spreferencesandgoals,culturalbeliefs, healthliteracy,andsocialdeterminantsofhealth— andmadeincollaborationwiththepatient’ssupport system。 Inpatientsundergoingcoronaryangiographyor revascularization,adequateinformationabout benefits,risks,therapeuticconsequences,and potentialalternativesintheperformanceof percutaneousandsurgicalmyocardial revascularizationshouldbegiven,whenfeasible, withsufficienttimeforinformeddecision-makingto improveclinicaloutcomes。Theheartteam Inpatientsforwhomtheoptimaltreatmentstrategyis I,B—NR Itisrecommendedthatinstitutionalprotocolsare I,C unclear,aheartteamapproachthatincludes developedbytheheartteamtoimplementthe representativesfrominterventionalcardiology, appropriaterevascularizationstrategyin cardiacsurgery,andclinicalcardiologyis accordancewithcurrentguidelines。recommendedtoimprovepatientoutcomes。Assessinglesionseverityin InpatientswithintermediatestenosisoftheLMartery, IIa,B—NR IVUSshouldbeconsideredtoassesstheseverityof IIa,B intermediateleftmain intravascularultrasoundisreasonabletohelpdefine unprotectedLMlesions。disease lesionseverity。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 253,
      "text": "diatestenosisoftheLMartery, IIa,B—NR IVUSshouldbeconsideredtoassesstheseverityof IIa,B intermediateleftmain intravascularultrasoundisreasonabletohelpdefine unprotectedLMlesions。disease lesionseverity。 Indicationsfor InpatientswithSIHDandsignificantLMstenosis,CABG I,B Inpatientswithstableanginaorsilentischemiaand I,A revascularizationto isrecommendedtoimprovesurvival。IIa,B—NR LMdiseasewithstenosis>50%inthepresence improvesurvival InselectedpatientswithSIHDandsignificantLM ofdocumentedischemiaorhemodynamically comparedwithmedical stenosisforwhomPCIcanprovideequivalent significantcoronarystenosis(FFR#0。80or therapy revascularizationtothatpossiblewithCABG,PCIis iwFR#0。89or>90%stenosis),treatmentwith reasonabletoimprovesurvival。revascularizationisrecommended。SituationsinwhichPCIor Inpatientswhorequirerevascularizationforsignificant I,B—R InLMdiseasewithintermediateSYNTAXscore(0- I,AvsI,A CABGwouldbe LMCADwithhigh-complexityCADitis 22),CABGandPCIareequallyrecommendeda I,AvsIIa,A preferred recommendedtochooseCABGoverPCItoimprove InLMdiseasewithintermediateSYNTAXscore(23- I,AvsIII,B survival。32),CABGisrecommendedoverPCI。InLMdiseasewithhigh($33)SYNTAXscore,CABG isrecommendedbutnotPCI。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 254,
      "text": "red recommendedtochooseCABGoverPCItoimprove InLMdiseasewithintermediateSYNTAXscore(23- I,AvsIII,B survival。32),CABGisrecommendedoverPCI。InLMdiseasewithhigh($33)SYNTAXscore,CABG isrecommendedbutnotPCI。 Useofintravascular Inpatientsundergoingcoronarystentimplantation, IIa,B—R IVUSshouldbeconsideredtoassesstheseverityof IIa,B imagingtoguidePCI IVUScanbeusefulforproceduralguidance, unprotectedLMstenoses。particularlyincasesofLMorcomplexPCI,toreduce ischemicevents。Operator/institutional ItshouldbeconsideredthatCABGbeperformedat IIa,C volumeinmyocardial institutionswithannualinstitutionalvolumes IIa,C revascularization of$200CABGcases。ItshouldbeconsideredthatPCIforLMbe performedbytrainedoperatorswithanannual volumeof$25LMPCIcasesperyear。aTheEuropeanAssociationforCardio-ThoracicSurgery(EACTS)haswithdrawnsupportoftheguidelineduetothisrecommendation。81,82 ACCAmericanCollegeofCardiology;AHAAmericanHeartAssociation;CORclassofrecommendation;ESCEuropeanSocietyofCardiology;IVUSintravascularultrasound;iwFRinstantaneous wave-freeratio;LDlimiteddata;LMleftmain;LOElevelofevidence;NRnonrandomizeddata;Rrandomizeddata;SIHDstableischemicheartdisease;otherabbreviationsasinTable1。acutelywithCABG。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 255,
      "text": "ultrasound;iwFRinstantaneous wave-freeratio;LDlimiteddata;LMleftmain;LOElevelofevidence;NRnonrandomizeddata;Rrandomizeddata;SIHDstableischemicheartdisease;otherabbreviationsasinTable1。acutelywithCABG。 102,103BecausebothCABGandPCI prohibitive risk, a referral to centers specializing in have important roles in the treatment of LM CAD, a thetreatmentofcomplexCADpatients(bothsurgical thoughtful heart team–based approach is preferred, and interventional) may allow patients who are especially if the patient is stable。Most patients with deemed inoperable at a local center to be evaluated critical and/or severe LM stenosis should undergo andtreatedsuccessfully。expedited surgical evaluations, typically before It is important to explicitly state that the optimal discharge, but for selected and truly stable patients, revascularization strategy for a given patient can anexpeditedoutpatientevaluationwithclosefollow- vary, based upon the expertise, experience, and upmaybereasonable。Anotherkeyprinciplerelating outcomes of the specific surgical and interventional tothemultidisciplinarymanagementofLMdiseaseis teams at a given institution。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 256,
      "text": "xpertise, experience, and upmaybereasonable。Anotherkeyprinciplerelating outcomes of the specific surgical and interventional tothemultidisciplinarymanagementofLMdiseaseis teams at a given institution。 The complexity of per- that for patients who are too high risk for CABG, a forming CABG for a distal LM lesion with associated review of the feasibility of PCI should be performed MVD,for example,istypicallylessfor the“average” by an experienced interventional team rather than surgeonperformingCABGthanthecomplexityofPCI simplyrelegatingthepatienttoastrategyofmedical in the same patient for the “average” interventional therapy alone。Finally, if a patient is deemed cardiologist performing PCI in the United States。2130 Davidsonetal JACC VOL。80, NO。22, 2022 LeftMainCoronaryArteryDisease NOVEMBER 29, 2022:2119–2134 CENTRAL ILLUSTRATION LeftMainCoronaryArteryDiseaseClinicalDecision-MakingAlgorithm DavidsonLJ,etal。JAmCollCardiol。2022;80(22):2119–2134。Thisalgorithmoutlinesaclinicalapproachthatmaybeutilizedbyclinicianstoassistwithdecision-makingforpatientswhopresentwithleftmaincoronaryartery disease。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 257,
      "text": "idsonLJ,etal。JAmCollCardiol。2022;80(22):2119–2134。Thisalgorithmoutlinesaclinicalapproachthatmaybeutilizedbyclinicianstoassistwithdecision-makingforpatientswhopresentwithleftmaincoronaryartery disease。 Medicaltherapy,percutaneouscoronaryintervention(PCI),orcoronaryarterybypassgrafting(CABG)maybereasonablestrategiesdependingoneach patient’sclinicalhistory,anatomy,andpreferences。When invoking the results of head-to-head clinical institutional experience with the offered procedure trials of CABG vs PCI in order to guide clinical (eg, does an interventional cardiologist have suffi- decision-making, the optimized strategies for coro- cient volume andexperience to treat LMdisease us- naryrevascularizationusedinthesetrialsneedtobe ing the best possible PCI technique such as routine takenintoaccount。Further,someinstitutionsarenot intravascular imaging, comfort with plaque modifi- facile withperformingLMinterventions; asurvey of cationstrategies,familiaritywithbifurcationstenting the NCDR demonstrated that the average hospital in techniques, and safe and especially judicious use of the United States performed <5 LM PCIs per year。mechanical circulatory support。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 258,
      "text": "urcationstenting the NCDR demonstrated that the average hospital in techniques, and safe and especially judicious use of the United States performed <5 LM PCIs per year。mechanical circulatory support。 ; and 4) the clinical Irrespective of operator experience, if the institu- evidencebaseforaspecificrevascularizationstrategy tional support is inadequate, outcomes will likely (eg,datafavoringCABGinreductionofespeciallylate suffer。MIandrepeatrevascularizationoffsetbytheupfront The best revascularization strategy chosen for an greater invasiveness of the operation) (Central individualpatientshouldthereforereflectinputfrom Illustration)。several domains including: 1) patient characteristics A careful assessment of both the short- and including patient preference for one strategy vs longer-term goals for the patient is necessary when another;2)proceduralconsiderations;3)operatorand determining the best treatment options for the JACC VOL。80, NO。22, 2022 Davidsonetal 2131 NOVEMBER 29, 2022:2119–2134 LeftMainCoronaryArteryDisease patient。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 259,
      "text": "er;2)proceduralconsiderations;3)operatorand determining the best treatment options for the JACC VOL。80, NO。22, 2022 Davidsonetal 2131 NOVEMBER 29, 2022:2119–2134 LeftMainCoronaryArteryDisease patient。 A vibrant and independent octogenarian isacomplexclinicalprocessthatcanbetreatedwith may not wish to undergo the up-front morbidity medical therapy alone, PCI, or CABG。The clinical andrecovery followingaCABGoperation andwould circumstancesaccompanyingLMdiseasearedifficult accept thetradeoffofahigh-qualityLMPCI,despite toquantify。Theseclinicaldifferencesinpresentation a greater risk for repeat revascularization and/or andanatomyarecrucialindecision-making。Thus,it late MI。On the other hand, a 50-year-old diabetic is for that reason that ultimately, a heart team patient with an ejection fraction of 45% would approach, which includes specific, individualized likely live long enough to realize these late benefits attention to each patient’s clinical circumstances, and would be done a disservice if a PCI was per- preferences, and goals, is imperative when choosing formed, especially by a less experienced operator treatment strategies for LM CAD。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 260,
      "text": "l circumstances, and would be done a disservice if a PCI was per- preferences, and goals, is imperative when choosing formed, especially by a less experienced operator treatment strategies for LM CAD。 In institutions not using imaging guidance or using a poorly indi- wheretheheartteamapproachisembraced,itisour cated hemodynamic support device due to discom- experience and hope that the divisions manifest in fort performing a higher-risk procedure。In making the recent literature will be rare。Our paradigm, as these decisions collectively at an institutional level, outlined,canhopefullyserveasatemplateforsucha it is important to be objective and circumspect, and program。Movingforward,thereisaneedforprofes- to place the patient’s best interests at the forefront sional societies to come together and agree upon of clinical decision-making。mutually acceptable clinical endpoints in order to Finally, it is important to consider the long-term allow meaningful research to continue on this follow-up of patients who undergo LM revasculari- importanttopic。zation and the prompt initiation of proper medical therapy following both revascularization strategies。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 261,
      "text": "ul research to continue on this follow-up of patients who undergo LM revasculari- importanttopic。zation and the prompt initiation of proper medical therapy following both revascularization strategies。 FUNDINGSUPPORTANDAUTHORDISCLOSURES In the case of patients who undergo LM PCI, dual antiplatelet therapy must be initiated, and patients Dr Davidson is a co-investigator for Edwards Lifesciences and mustunderstandtheimportanceofcompliancewith Abbott clinical trials。Dr Cleveland has received research grants fromMedtronicandAbbott;hasservedonresearchcommitteesfor dualantiplatelettherapytoavoidsuchcomplications Abbott; has been a consultant for and received honoraria from asin-stentthrombosis。ForthosethatundergoCABG, ConneX Biomedical and Medtronic; and has received honoraria sternotomy precautions must be discussed thor- fromEdwardsLifesciences。DrWelthasbeenaconsultantforand oughly with patients and their families。All patients receivedhonorariafromMedtronic;andholdsstockinXenter,Inc。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 262,
      "text": "recautions must be discussed thor- fromEdwardsLifesciences。DrWelthasbeenaconsultantforand oughly with patients and their families。All patients receivedhonorariafromMedtronic;andholdsstockinXenter,Inc。 Dr Anwaruddin has been a consultant and proctor for Edwards withLMdiseasewillalsorequireaggressive,disease- LifesciencesandMedtronic;hasservedonasteeringcommitteefor modifying guideline-directed medical therapy Boston Scientific; and holdsequityin EastEndMedical。Dr Grubb including high-intensity statins, lifestyle modifica- hasbeenaspeakerforEdwardsLifesciences,BostonScientific,and tion(eg,smokingcessationandexercise),andcontrol Medtronic; has been a proctor for Edwards Lifesciences and Med- tronic; has served on advisory boards for Medtronic and Abbott; of hypertension (including beta-blockers and has been a principal investigator for trials sponsored by Edwards angiotensin-converting enzyme inhibitor/angio- LifesciencesandMedtronic;andhasbeenaconsultantforGore。Dr tensin receptor blockers), diabetes mellitus, and Kirtane has been a consultant for IMDS; has received travel ex- othercardiovascularriskfactors。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 263,
      "text": "fesciencesandMedtronic;andhasbeenaconsultantforGore。Dr tensin receptor blockers), diabetes mellitus, and Kirtane has been a consultant for IMDS; has received travel ex- othercardiovascularriskfactors。 104ForthosewithLV penses/meals from Medtronic, Boston Scientific, Abbott Vascular, CSI, Siemens, Philips, ReCor Medical, Chiesi, OpSens, Zoll, and dysfunction, maximizing guideline-directed medical Regeneron; and hasreceived research grants from, been a consul- therapy is alsoimperative。It isalsostandardfor pa- tant for, an/or received speaker fees from Medtronic, Boston Sci- tients to be referred to a cardiac rehabilitation pro- entific, Abbott Vascular, Amgen, CSI, Philips, ReCor Medical, gram where efforts at lifestyle management can be Neurotronic, Biotronik, Chiesi, Bolt Medical, Magenta Medical, Canon, and SoniVie, paid to his institution。Dr Truesdell has implemented。Patients must understand that adher- receivedconsultantandspeakerfees,paidtohisinstitution,from ence to medical therapy following revascularization AbiomedInc。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 264,
      "text": "institution。Dr Truesdell has implemented。Patients must understand that adher- receivedconsultantandspeakerfees,paidtohisinstitution,from ence to medical therapy following revascularization AbiomedInc。 DrWindeckerhasreceivedresearchandeducational with regular follow-up is imperative to their long- grants paid to employer from Abbott, Abiomed, Amgen, AstraZe- neca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, termsuccess。Bristol Myers Squibb, Cardinal Health, CardioValve, Corflow Ther- apeutics, CSL Behring, Daiichi-Sankyo, Edwards Lifesciences, CONCLUSIONS Guerbet, InfraRedx, Janssen-Cilag, Johnson & Johnson, Medicure, Medtronic, MerckSharp & Dohm, Miracor Medical, Novartis, Novo TheissueofLMarteryrevascularizationhasemerged Nordisk,Organon,OrPhaSuisse,Pfizer,Polares,Regeneron,Sanofi, Servier, Sinomed, Terumo, Vifor, V-Wave; has served as advisory as a topic of considerable debate within our profes- board member and/or member of the steering/executive group of sional societies。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 265,
      "text": "fi, Servier, Sinomed, Terumo, Vifor, V-Wave; has served as advisory as a topic of considerable debate within our profes- board member and/or member of the steering/executive group of sional societies。 Although the clinical trial data and trials funded by Abbott, Abiomed, Amgen, AstraZeneca, Bayer, recent guidelines are crucial to understand and to Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Life- sciences, Janssen, MedAlliance, Medtronic, Novartis, Polares, inform clinical decisions, the patients included in Recardio,Sinomed,Terumo,V-Wave,andXeltiswithpaymentsto theseclinicaltrialsreflectonlyasmallportionofthe employerbutnopersonalpayments;andhasbeenamemberofthe patientsencounteredin clinicalpractice。LM disease steering/executivecommitteegroupofseveralinvestigator-initiated 2132 Davidsonetal JACC VOL。80, NO。22, 2022 LeftMainCoronaryArteryDisease NOVEMBER 29, 2022:2119–2134 trials that receive funding by industry without impact on his per- sonal remuneration。Dr Malaisrie has been a consultant for and ADDRESS FOR CORRESPONDENCE: Dr S。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 266,
      "text": "ryDisease NOVEMBER 29, 2022:2119–2134 trials that receive funding by industry without impact on his per- sonal remuneration。Dr Malaisrie has been a consultant for and ADDRESS FOR CORRESPONDENCE: Dr S。 Chris received research funding from Edwards Lifesciences, Medtronic, Malaisrie,DepartmentofCardiacSurgery,Northwestern Terumo Aortic, and Artivion。All other authors have reported that University, 676 North St。Clair,Suite 730, Chicago, Illi- theyhavenorelationshipsrelevanttothecontentsofthispaperto disclose。nois60611,USA。E-mail:chris。malaisrie@nm。org。REFERENCES 1。CampeauL,CorbaraF,CrochetD,PetitclercR。11。HuismanJ,vanderHeijdenLC,KokMM,etal。models: part 2-statistical methods and results。Leftmaincoronaryarterystenosis:theinfluence Impact of severe lesion calcification on clinical AnnThoracSurg。2018;105:1419–1428。ofaortocoronarybypasssurgeryonsurvival。Cir- outcomeofpatientswithstableangina,treated 22。Escaned J, Collet C, Ryan N, et al。Clinical culation。1978;57:1111–1115。withnewergenerationpermanentpolymer-coated outcomesofstate-of-the-artpercutaneouscoro- drug-elutingstents:apatient-levelpooledanal- 2。EuropeanCoronarySurgeryStudyGroup。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 267,
      "text": "ical culation。1978;57:1111–1115。withnewergenerationpermanentpolymer-coated outcomesofstate-of-the-artpercutaneouscoro- drug-elutingstents:apatient-levelpooledanal- 2。EuropeanCoronarySurgeryStudyGroup。 Long- nary revascularization in patients with de novo ysisfromTWENTEandDUTCHPEERS(TWENTEII)。t c e o r r m ona re ry su a lt r s te o ry fp b r y o p s a p s e s ct s iv u e rg r e a r n y d i o n m s is t e ab d le stu a d ng y in o a f AmHeartJ。2016;175:121–129。t II h s re tu e d v y e。s E s u e r ld H i e se a a rt se J :。1 2 - 0 ye 17 a ; r 3 r 8 e : s 3 u 1 l 2 t 4 s – o 3 f 13 th 4 e。SYNTAX pectoris。Lancet。1982;2:1173–1180。12。ChenSL,SheibanI,XuB,etal。Impactofthe 23。Farooq V, van Klaveren D, Steyerberg EW, 3。CaraccioloEA,DavisKB,SopkoG,etal。Com- c d o ru m g p - l e e l x u i t t i y ng o s f te b n i t f s u : rc t a h t e io D n EF le IN si I o T n IO s N tr s e t a u t d e y d (D w e i fi th - e g t uid a e l。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 268,
      "text": "loEA,DavisKB,SopkoG,etal。Com- c d o ru m g p - l e e l x u i t t i y ng o s f te b n i t f s u : rc t a h t e io D n EF le IN si I o T n IO s N tr s e t a u t d e y d (D w e i fi th - e g t uid a e l。 d A e n c a is to io m n ic m al ak a i n n d g c b l e in tw ic e al en ch c a o r r a o c n te a r r i y sti a c r s te t r o y parisonofsurgicalandmedicalgroupsurvivalin nitionsandimpactofcomplExbiFurcationlesIons bypasssurgeryandpercutaneouscoronaryinter- patients withleft main coronaryartery disease。onclinicaloutcomesafterpercutaNeouscoronary ventionforindividualpatients:developmentand Long-termCASSexperience。Circulation。1995;91: 2325–2334。I C n a t r e d r i v o e l n In T t IO v。n 2 u 0 s 1 in 4 g ;7 d :1 r 2 u 6 g 6 -e – l 1 u 2 t 7 in 6 g。steNts)。JAmColl 6 va 3 l 9 id – a 6 t 5 io 0 n。ofSYNTAXscoreII。Lancet。2013;381: 4。TakaroT,PeduzziP,DetreKM,etal。Survivalin 13。Gossl M, Faxon DP, Bell MR, Holmes DR, 24。SerruysPW,MoriceMC,KappeteinAP,etal。subgroupsofpatientswithleftmaincoronaryar- Gersh BJ。Complete versus incomplete revascu- Percutaneous coronary intervention versus terydisease。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 269,
      "text": "ell MR, Holmes DR, 24。SerruysPW,MoriceMC,KappeteinAP,etal。subgroupsofpatientswithleftmaincoronaryar- Gersh BJ。Complete versus incomplete revascu- Percutaneous coronary intervention versus terydisease。 VeteransAdministrationCooperative larization with coronary artery bypass graft or coronary-arterybypassgraftingforseverecoro- StudyofSurgeryforCoronaryArterialOcclusive percutaneousinterventioninstablecoronaryar- naryarterydisease。NEnglJMed。2009;360:961– Disease。Circulation。1982;66:14–22。tery disease。Circ CardiovascInterv。2012;5:597– 972。604。5。RamadanR,BodenWE,KinlayS。Management 25。Takahashi K, Serruys PW, Fuster V, et al。ofleftmaincoronaryarterydisease。JAmHeart 14。MalkinCJ,GeorgeV,GhobrialMS,etal。Re- Redevelopment and validation of the SYNTAX Assoc。2018;7(7):e008151。https://doi。org/10。sidual SYNTAX score after PCI for triple vessel scoreIItoindividualisedecisionmakingbetween 1161/JAHA。117。008151 coronaryarterydisease:quantifyingtheadverse percutaneous and surgical revascularisation in 6 in。te P r a v r e k nt D io W n , of P l a e r f k tm S a J。in P d e is r e c a u s t e a : ne p o re u - s an co d ro p n o a s r t y - e In f t f e e r c v t en o ti f on。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 270,
      "text": "cal revascularisation in 6 in。te P r a v r e k nt D io W n , of P l a e r f k tm S a J。in P d e is r e c a u s t e a : ne p o re u - s an co d ro p n o a s r t y - e In f t f e e r c v t en o ti f on。 in 2 c 0 o 1 m 3; p 8 le :1 t 2 e 86 r – e 1 v 2 a 9 s 5 c。ularisation。Euro- p se a c t o ie n n d t a s ry w a it n h aly c s o i m s p o l f e t x he co m ro u n lt a ic ry ent a r r e te r r a y nd d o is m e i a s s e e d : EXCEL(EvaluationofXIENCEEverolimusEluting 15。BenedettoU, Lau C,Caputo M,et al。Com- controlled SYNTAXES trial with external cohort StentVersusCoronaryArteryBypassSurgeryfor parisonofoutcomesforoff-pumpversuson-pump validation。Lancet。2020;396:1399–1412。EffectivenessofLeftMainRevascularization)and coronaryarterybypassgraftinginlow-volumeand 26。TheBARIInvestigators。Influenceofdiabetes NOBLE(Nordic-Baltic-BritishLeftMainRevascu- high-volumecentersandbylow-volumeandhigh- on5-yearmortalityandmorbidityinarandomized larization Study) era。Circ Cardiovasc Interv。volumesurgeons。AmJCardiol。2018;121:552–557。trialcomparingCABGandPTCAinpatientswith 2017;10(6):e004792。https://doi。org/10。1161/ 16。GaudinoM,BakaeenF,BenedettoU,etal。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 271,
      "text": "n Study) era。Circ Cardiovasc Interv。volumesurgeons。AmJCardiol。2018;121:552–557。trialcomparingCABGandPTCAinpatientswith 2017;10(6):e004792。https://doi。org/10。1161/ 16。GaudinoM,BakaeenF,BenedettoU,etal。 Use multivessel disease: the Bypass Angioplasty CIRCINTERVENTIONS。117。004792 rateandoutcomeinbilateralinternalthoracicar- RevascularizationInvestigation(BARI)。Circulation。7。Morice MC, SerruysPW,Kappetein AP,et al。tery grafting:insightsfrom asystematicreview 1997;96:1761–1769。andmeta-analysis。JAmHeartAssoc。2018;77(11): Outcomesinpatientswithdenovoleftmaindis- 27。LeeK,AhnJM,YoonYH,etal。Long-term(10- e009361。https://doi。org/10。1161/JAHA。118。ease treated with either percutaneous coronary year)outcomesofstentingorbypasssurgeryfor 009361 intervention using paclitaxel-eluting stents or leftmaincoronaryarterydiseaseinpatientswith coronary artery bypass graft treatment in the 17。Lawton JS, Tamis-Holland JE, Bangalore S, andwithoutdiabetesmellitus。JAmHeartAssoc。Synergy Between Percutaneous Coronary Inter- etal。2021ACC/AHA/SCAIguidelineforcoronary 2020;9:e015372。vention with TAXUS and Cardiac Surgery (SYN- arteryrevascularization:areportoftheAmerican 28。GabaP,GershBJ,AliZA,MosesJW,StoneGW。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 272,
      "text": "ronary Inter- etal。2021ACC/AHA/SCAIguidelineforcoronary 2020;9:e015372。vention with TAXUS and Cardiac Surgery (SYN- arteryrevascularization:areportoftheAmerican 28。GabaP,GershBJ,AliZA,MosesJW,StoneGW。 TAX)trial。Circulation。2010;121:2645–2653。CollegeofCardiology/AmericanHeartAssociation Completeversusincompletecoronaryrevascular- 8。RagostaM。Leftmaincoronaryarterydisease: Joint Committee on Clinical Practice Guidelines。ization:definitions,assessmentandoutcomes。Nat importance,diagnosis,assessment,andmanage- JAmCollCardiol。2022;79:e21–e129。RevCardiol。2021;18:155–168。ment。CurrProblCardiol。2015;40:93–126。18。NeumannFJ,Sousa-UvaM,AhlssonA,etal。29。LeonardiS,CapodannoD,Sousa-UvaM,etal。2018ESC/EACTSguidelinesonmyocardialrevas- 9。LevineGN,BatesER,BlankenshipJC,etal。2011 cularization。EurHeartJ。2019;40:87–165。Composition, structure, and function of heart ACCF/AHA/SCAIguidelineforpercutaneouscoro- teams:ajointpositionpaperoftheACVC,EAPCI, naryintervention:areportoftheAmericanCol- 19。BrennanJM,CurtisJP,DaiD,etal。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 273,
      "text": "sition, structure, and function of heart ACCF/AHA/SCAIguidelineforpercutaneouscoro- teams:ajointpositionpaperoftheACVC,EAPCI, naryintervention:areportoftheAmericanCol- 19。BrennanJM,CurtisJP,DaiD,etal。 Enhanced EACTS,andEACTAfocusedonthemanagementof lege of Cardiology Foundation/American Heart mortalityriskpredictionwithafocusonhigh-risk patients with complex coronary artery disease AssociationTaskForceonPracticeGuidelinesand percutaneouscoronaryintervention:resultsfrom requiringmyocardialrevascularization。EurJCar- the Society for Cardiovascular Angiography and 1,208,137proceduresintheNCDR(NationalCar- diothoracSurg。2021;59:522–531。Interventions。JAmCollCardiol。2011;58(24):e44– diovascularDataRegistry)。JAmCollCardiolIntv。30。AliZA,KarimiGalougahiK,NazifT,etal。Im- e122。https://doi。org/10。1016/j。jacc。2011。08。007 2013;6:790–799。aging-andphysiology-guidedpercutaneouscor- 20。Nashef SA, Roques F, Sharples LD, et al。onaryinterventionwithoutcontrastadministration 10。BourantasCV,ZhangYJ,GargS,etal。Prog- nosticimplicationsofseverecoronarycalcification EuroSCOREII。EurJCardiothoracSurg。2012;41: inadvancedrenalfailure:afeasibility,safety,and 734–744。discussion744-745。outcomestudy。EurHeartJ。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 274,
      "text": "gS,etal。Prog- nosticimplicationsofseverecoronarycalcification EuroSCOREII。EurJCardiothoracSurg。2012;41: inadvancedrenalfailure:afeasibility,safety,and 734–744。discussion744-745。outcomestudy。EurHeartJ。 2016;37:3090–3095。in patients undergoing coronary artery bypass surgery:ananalysisoftheSYNTAXstudy。Catheter 21。O’BrienSM,FengL,HeX,etal。TheSocietyof 31。GiustinoG,MehranR,SerruysPW,etal。Left CardiovascInterv。2015;85:199–206。ThoracicSurgeons2018adultcardiacsurgeryrisk main revascularization with PCI or CABG in JACC VOL。80, NO。22, 2022 Davidsonetal 2133 NOVEMBER 29, 2022:2119–2134 LeftMainCoronaryArteryDisease patientswithchronickidneydisease:EXCELtrial。46。CuiK,ZhangD,LyuS,etal。Meta-analysis 58。ChenX,LiX,ZhangJJ,etal。3-Yearoutcomes JAmCollCardiol。2018;72:754–765。comparing percutaneous coronary revasculariza- oftheDKCRUSH-VtrialcomparingDKcrushwith tionusingdrug-elutingstentversuscoronaryar- provisionalstentingforleftmainbifurcationle- 32。DoenstT,HaverichA,SerruysP,etal。PCIand tery bypass grafting in patients with left sions。JAmCollCardiolIntv。2019;12:1927–1937。CABGfortreatingstablecoronaryarterydisease: ventricular systolic dysfunction。Am J Cardiol。JACCreviewtopicoftheweek。JAmCollCardiol。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 275,
      "text": "ting in patients with left sions。JAmCollCardiolIntv。2019;12:1927–1937。CABGfortreatingstablecoronaryarterydisease: ventricular systolic dysfunction。Am J Cardiol。JACCreviewtopicoftheweek。JAmCollCardiol。 59。ZhangJJ,YeF,XuK,etal。Multicentre,ran- 2019;73:964–976。2018;122:1670–1676。domizedcomparisonoftwo-stentandprovisional 33。BodenWE,O’RourkeRA,TeoKK,etal。Optimal 47。SunLY,GaudinoM,ChenRJ,BaderEddeenA, stenting techniques in patients with complex medical therapy with or without PCI for stable Ruel M。Long-term outcomes in patients with coronary bifurcation lesions: the DEFINITION II coronarydisease。NEnglJMed。2007;356:1503– severelyreducedleftventricularejectionfraction trial。EurHeartJ。2020;41:2523–2536。1516。undergoingpercutaneouscoronaryinterventionvs 60。ChenSL,XuB,HanYL,etal。Comparisonof 3 co 4 r。o Y n u a s r u y f a S rt , e Z r u y c b k y e p r a D s , s P g e r d af u t zz s i u P rg , e e r t y a o l n。E s f u f r e v c i t va o l f : c 2 o 0 r 2 o 0 n ; a 5 r : y 63 a 1 r – t 6 e 4 ry 1。bypass grafting。JAMA Cardiol。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 276,
      "text": " Z r u y c b k y e p r a D s , s P g e r d af u t zz s i u P rg , e e r t y a o l n。E s f u f r e v c i t va o l f : c 2 o 0 r 2 o 0 n ; a 5 r : y 63 a 1 r – t 6 e 4 ry 1。bypass grafting。JAMA Cardiol。 d un o p ub ro le tec k t is e s d ing dis c t r a u l sh lef v t er m su a s in C b u i l f o u t r t c e at s i t o e n nt l i e n s g io f n o s r : overviewof10-yearresultsfromrandomisedtrials 48。Panza JA, Ellis AM, Al-Khalidi HR, et al。resultsfromamulticenter,randomized,prospec- by the Coronary Artery Bypass Graft Surgery MyocardialViabilityandLong-TermOutcomesin tive DKCRUSH-III study。J Am Coll Cardiol。TrialistsCollaboration。Lancet。1994;344:563–570。Ischemic Cardiomyopathy。N Engl J Med。2013;61:1482–1488。35。AfilaloJ,AlexanderKP,MackMJ,etal。Frailty 2019;381:739–748。61。Makikallio T, Holm NR, Lindsay M, et al。assessment in the cardiovascular care of older 49。AtkinsonTM,OhmanEM,O’NeillWW,RabT, Percutaneous coronary angioplasty versus coro- adults。JAmCollCardiol。2014;63:747–762。CigarroaJE。InterventionalScientificCouncilofthe naryarterybypassgraftingintreatmentofun- American College of Cardiology。A practical protected left main stenosis (NOBLE): a 36。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 277,
      "text": "lCardiol。2014;63:747–762。CigarroaJE。InterventionalScientificCouncilofthe naryarterybypassgraftingintreatmentofun- American College of Cardiology。A practical protected left main stenosis (NOBLE): a 36。 Lemaire A, Soto C, Salgueiro L, Ikegami H, approach to mechanical circulatory support in prospective, randomised, open-label, non-inferi- RussoMJ,LeeLY。Theimpactofageonoutcomes patients undergoing percutaneous coronary oritytrial。Lancet。2016;388:2743–2752。ofcoronaryarterybypassgrafting。JCardiothorac Surg。2020;15:158。intervention:aninterventionalperspective。JAm 62。StoneGW,SabikJF,SerruysPW,etal。Ever- CollCardiolIntv。2016;9:871–883。olimus-eluting stentsor bypasssurgery for left 37。Madhavan MV, Gersh BJ, Alexander KP, GrangerCB,StoneGW。Coronaryarterydiseasein 50。Patel N, Sharma A, Dalia T, et al。Vascular main coronary artery disease。N Engl J Med。patients>/80yearsofage。JAmCollCardiol。complications associated with percutaneous left 2016;375:2223–2235。2018;71:2015–2040。ventricularassistdeviceplacement:a10-yearUS 63。Hildick-SmithD,EgredM,BanningA,etal。perspective。CatheterCardiovascInterv。2020;95: TheEuropeanBifurcationClubLeftMainCoronary 38。McNultyEJ,NgW,SpertusJA,etal。Surgical 309–316。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 278,
      "text": "ceplacement:a10-yearUS 63。Hildick-SmithD,EgredM,BanningA,etal。perspective。CatheterCardiovascInterv。2020;95: TheEuropeanBifurcationClubLeftMainCoronary 38。McNultyEJ,NgW,SpertusJA,etal。Surgical 309–316。 Stentstudy:arandomizedcomparisonofstepwise candidacy and selection biases in nonemergent leftmainstenting:implicationsforobservational 51。HolmesDRJr,RichJB,ZoghbiWA,MackMJ。provisionalvs。systematicdualstentingstrategies studies。JAmCollCardiolIntv。2011;4:1020–1027。Theheartteamofcardiovascularcare。JAmColl (EBCMAIN)。EurHeartJ。2021;42:3829–3839。39。Waldo SW, Secemsky EA, O’Brien C, et al。Cardiol。2013;61:903–907。64。Buckberg GD。Antegrade/retrograde blood Surgicalineligibilityandmortalityamongpatients 52。Luckraz H, Norell M, Buch M, James R, cardioplegia to ensure cardioplegic distribution: withunprotectedleftmainormultivesselcoro- CooperG。Structureandfunctioningofamulti- operativetechniquesandobjectives。JCardSurg。naryarterydiseaseundergoingpercutaneouscor- disciplinary’HeartTeam’forpatientswithcoro- 1989;4(37):216–238。https://doi。org/10。1093/ onary intervention。Circulation。2014;130:2295– nary artery disease: rationale and eurheartj/ehab283 2301。recommendations from a joint BCS/BCIS/SCTS 65。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 279,
      "text": "coro- 1989;4(37):216–238。https://doi。org/10。1093/ onary intervention。Circulation。2014;130:2295– nary artery disease: rationale and eurheartj/ehab283 2301。recommendations from a joint BCS/BCIS/SCTS 65。 Dietl CA, Madigan NP, Laubach CA, et al。40。Kumar S, McDaniel M, Samady H, workinggroup。EurJCardiothoracSurg。2015;48: Myocardialrevascularizationusingthe\"no-touch\" Forouzandeh F。Contemporary revascularization 524–529。technique, with mild systemic hypothermia, in dilemmas in older adults。J Am Heart Assoc。53。Chhatriwalla AK, Decker C, Gialde E, et al。patients with a calcified ascending aorta。2020;9:e014477。Developingandtestingapersonalized,evidence- JCardiovascSurg(Torino)。1995;36:39–44。41。MamasMA,Fath-OrdoubadiF,DanziGB,etal。based, shared decision-making tool for stent 66。Lev-Ran O, Ben-Gal Y, Matsa M, et al。’No Prevalenceandimpactofco-morbidityburdenas selection in percutaneous coronary intervention touch’techniquesforporcelainascendingaorta: definedbytheCharlsonco-morbidityindexon30- usingapre-poststudydesign。CircCardiovascQual comparisonbetweencardiopulmonarybypasswith dayand1-and5-yearoutcomesaftercoronary Outcomes。2019;12:e005139。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 280,
      "text": "rta: definedbytheCharlsonco-morbidityindexon30- usingapre-poststudydesign。CircCardiovascQual comparisonbetweencardiopulmonarybypasswith dayand1-and5-yearoutcomesaftercoronary Outcomes。2019;12:e005139。 femoral artery cannulation and off-pump stentimplantation(fromtheNobori-2study)。Am 54。DollJA,JonesWS,LokhnyginaY,etal。PRE- myocardial revascularization。J Card Surg。JCardiol。2015;116:364–371。PAREDStudy:AStudyofSharedDecision-Making 2002;17:370–376。42。PottsJ,NagarajaV,AlSuwaidiJ,etal。The forCoronaryArteryDisease。CircCardiovascQual 67。Halkos ME, Rab ST, Vassiliades TA, et al。influence of Elixhauser comorbidity index on Outcomes。2019;12:e005244。Hybridcoronaryrevascularizationversusoff-pump percutaneous coronary intervention outcomes。55。Rab T, Sheiban I, Louvard Y, Sawaya FJ, coronaryarterybypassforthetreatmentofleft CatheterCardiovascInterv。2019;94:195–203。ZhangJJ,ChenSL。CurrentInterventionsforthe maincoronarystenosis。AnnThoracSurg。2011;92: 2155–2160。43。ReichartD,RosatoS,NammasW,etal。Clinical Left Main Bifurcation。J Am Coll Cardiol Intv。frailty scale and outcome after coronary artery 2017;10:849–865。68。Harskamp RE, Bonatti JO, Zhao DX, et al。bypassgrafting。EurJCardiothoracSurg。2018;54: 56。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 281,
      "text": "Left Main Bifurcation。J Am Coll Cardiol Intv。frailty scale and outcome after coronary artery 2017;10:849–865。68。Harskamp RE, Bonatti JO, Zhao DX, et al。bypassgrafting。EurJCardiothoracSurg。2018;54: 56。 de la Torre Hernandez JM, Hernandez Standardizing definitions for hybrid coronary 1102–1109。HernandezF,AlfonsoF,etal。Prospectiveappli- revascularization。J Thorac Cardiovasc Surg。44。WangW,BagshawSM,NorrisCM,etal。As- cation of pre-defined intravascular ultrasound 2014;147:556–560。sociationbetweenolderageandoutcomeafter criteriaforassessmentofintermediateleftmain 69。Cameron A, Davis KB, Green G, Schaff HV。cardiacsurgery:apopulation-basedcohortstudy。coronary artery lesions results from the multi- Coronary bypass surgery with internal-thoracic- JCardiothoracSurg。2014;9:177。centerLITROstudy。JAmCollCardiol。2011;58: artery grafts–effects on survival over a 15-year 351–358。period。NEnglJMed。1996;334:216–219。45。Kok MM, von Birgelen C。Involving the pa- tient’s perspective and preferences concerning 57。ParkSJ,AhnJM,KangSJ,etal。Intravascular 70。LoopFD,LytleBW,CosgroveDM,etal。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 282,
      "text": "eriod。NEnglJMed。1996;334:216–219。45。Kok MM, von Birgelen C。Involving the pa- tient’s perspective and preferences concerning 57。ParkSJ,AhnJM,KangSJ,etal。Intravascular 70。LoopFD,LytleBW,CosgroveDM,etal。 In- coronaryangiographyandpercutaneouscoronary ultrasound-derivedminimallumenareacriteriafor fluenceoftheinternal-mammary-arterygrafton intervention。EuroIntervention。2020;15:1228– functionallysignificantleftmaincoronaryartery 10-yearsurvivalandothercardiacevents。NEnglJ 1231。stenosis。JAmCollCardiolIntv。2014;7:868–874。Med。1986;314:1–6。2134 Davidsonetal JACC VOL。80, NO。22, 2022 LeftMainCoronaryArteryDisease NOVEMBER 29, 2022:2119–2134 71。He GW。Arterial grafts for coronary artery 84。GalloM,BlitzerD,LaforgiaPL,etal。Percu- interventionorcoronaryarterybypassgraftingin bypass grafting: biological characteristics, func- taneous coronary intervention versus coronary the Synergy Between Percutaneous Coronary tionalclassification,andclinicalchoice。AnnThorac arterybypassgraftforleftmaincoronaryartery InterventionWithTaxusandCardiacSurgerytrial。Surg。1999;67:277–284。disease: a meta-analysis。J。Thorac Cardiovasc Circulation。2014;129:2388–2394。Surg。2022;163:94–105。e15。72。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 283,
      "text": "graftforleftmaincoronaryartery InterventionWithTaxusandCardiacSurgerytrial。Surg。1999;67:277–284。disease: a meta-analysis。J。Thorac Cardiovasc Circulation。2014;129:2388–2394。Surg。2022;163:94–105。e15。72。 Schwann TA, Yammine MB, El-Hage- 96。Thuijs D, Kappetein AP, Serruys PW, et al。SleimanAM,EngorenMC,BonnellMR,HabibRH。85。KunoT, UeyamaH, RaoSV, etal。Percuta- Percutaneouscoronaryinterventionversuscoro- The effect of completeness of revascularization neous coronary intervention or coronary artery naryarterybypassgraftinginpatientswiththree- duringCABGwithsingleversusmultiplearterial bypassgraftsurgeryforleftmaincoronaryartery vesselorleftmaincoronaryarterydisease:10- grafts。JCardSurg。2018;33:620–628。disease:ameta-analysisofrandomizedtrials。Am year follow-up of the multicentre randomised HeartJ。2020;227:9–10。controlledSYNTAXtrial。Lancet。2019;394:1325– 73。Gaudino M, Audisio K, Rahouma M, et al。1334。Comparison of long-term clinical outcomes of 86。SabatineMS,BergmarkBA,MurphySA,etal。skeletonizedvspedicledinternalthoracicartery Percutaneous coronary intervention with drug- 97。GaoXF,GeZ,KongXQ,etal。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 284,
      "text": "Comparison of long-term clinical outcomes of 86。SabatineMS,BergmarkBA,MurphySA,etal。skeletonizedvspedicledinternalthoracicartery Percutaneous coronary intervention with drug- 97。GaoXF,GeZ,KongXQ,etal。 3-Yearoutcomes harvestingtechniquesinthearterialrevasculari- eluting stents versus coronary artery bypass of the ULTIMATE trial comparing intravascular zationtrial。JAMACardiol。2021;6:1380–1386。graftinginleftmaincoronaryarterydisease:an ultrasound versus angiography-guided drug- individual patient data meta-analysis。Lancet。elutingstentimplantation。JAmCollCardiolIntv。74。LamyA,BrowneA,ShethT,etal。Skeletonized 2021;398:2247–2257。2021;14:247–257。vs pedicled internal mammary artery graft har- vestingincoronaryarterybypasssurgery:apost 87。Brophy JM。Bayesian interpretation of the 98。ZhangJ,GaoX,KanJ,etal。Intravascularul- hocanalysisfromtheCOMPASStrial。JAMACar- EXCELtrialandotherrandomizedclinicaltrialsof trasoundversusangiography-guideddrug-eluting diol。2021;6(9):1042–1049。https://doi。org/10。leftmaincoronaryarteryrevascularization。JAMA stentimplantation:theULTIMATEtrial。JAmColl 1001/jamacardio。2021。1686 InternMed。2020;180:986–992。Cardiol。2018;72:3126–3137。88。CoronaryArteryDisease。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 285,
      "text": "。org/10。leftmaincoronaryarteryrevascularization。JAMA stentimplantation:theULTIMATEtrial。JAmColl 1001/jamacardio。2021。1686 InternMed。2020;180:986–992。Cardiol。2018;72:3126–3137。88。CoronaryArteryDisease。 ThePatientGuideto 99。DarmochF,AlraiesMC,Al-KhadraY,Moussa 75。HolmanWL,DaviesJE,LinJY,etal。Conse- Heart,Lung,andEsophagealSurgery。TheSociety PachaH,PintoDS,OsbornEA。Intravascularul- quencesofradialarteryharvest:resultsofapro- of Thoracic Surgeons。Accessed July 15, 2022。trasound imaging-guided versus coronary spective, randomized, multicenter trial。JAMA Surg。2013;148:1020–1023。https://ctsurgerypatients。org/adult-heart-disease/ angiography-guidedpercutaneouscoronaryinter- coronary-artery-disease vention:a systematicreviewandmeta-analysis。76。Holm NR, Makikallio T, Lindsay MM, et al。JAmHeartAssoc。2020;9:e013678。89。CoronaryArteryDisease:CardioSmart。Amer- Percutaneous coronary angioplasty versus coro- ican College of Cardiology。Accessed July 15, 100。Hochman JS, Reynolds HR, Bangalore S, naryarterybypassgrafting inthe treatmentof 2022。https://www。cardiosmart。org/topics/ etal。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 286,
      "text": "ngioplasty versus coro- ican College of Cardiology。Accessed July 15, 100。Hochman JS, Reynolds HR, Bangalore S, naryarterybypassgrafting inthe treatmentof 2022。https://www。cardiosmart。org/topics/ etal。 Baselinecharacteristicsandriskprofilesof unprotected left main stenosis: updated 5-year coronary-artery-disease participantsintheISCHEMIArandomizedclinical outcomes from the randomised, non-inferiority trial。JAMACardiol。2019;4:273–286。NOBLEtrial。Lancet。2020;395:191–199。90。TakaroT,HultgrenHN,LiptonMJ,DetreKM。TheVAcooperativerandomizedstudyofsurgery 101。Blankenship JC, Gigliotti OS, Feldman DN, 77。ParkSJ,KimYH,ParkDW,etal。Randomized forcoronaryarterialocclusivediseaseII。Subgroup etal。Adhocpercutaneouscoronaryintervention: trialofstentsversusbypasssurgeryforleftmain with significant left main lesions。Circulation。aconsensusstatementfromtheSocietyforCar- coronaryarterydisease。NEnglJMed。2011;364: 1976;54:III107–III117。diovascularAngiographyandInterventions。Cath- 1718–1727。eterCardiovascInterv。2013;81:748–758。91。Bittl JA, He Y, Jacobs AK, Yancy CW, 78。LadwiniecA,WalshSJ,HolmNR,etal。Intra- Normand SL。American College of Cardiology 102。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 287,
      "text": "phyandInterventions。Cath- 1718–1727。eterCardiovascInterv。2013;81:748–758。91。Bittl JA, He Y, Jacobs AK, Yancy CW, 78。LadwiniecA,WalshSJ,HolmNR,etal。Intra- Normand SL。American College of Cardiology 102。 Gu YL, van der Horst IC, Douglas YL, vascular ultrasound to guide left main stem Foundation/American Heart Association Task SvilaasT,MarianiMA,ZijlstraF。Roleofcoronary intervention: a NOBLE trial substudy。Euro- Force on Practice Guidelines。Bayesian methods arterybypassgraftingduringtheacuteandsub- Intervention。2020;16:201–209。affirm the use of percutaneous coronary inter- acutephaseofST-elevationmyocardialinfarction。ventiontoimprovesurvivalinpatientswithun- NethHeartJ。2010;18:348–354。79。GaudinoM,Brophy JM。The controversyon thetreatmentofleftmaincoronaryarterydisease。protected left main coronary artery disease。103。MehtaRH,GrabJD,O’BrienSM,etal。Clinical JThoracCardiovascSurg。2022;163(5):1864–1869。Circulation。2013;127:2177–2185。characteristics and in-hospital outcomes of pa- https://doi。org/10。1016/j。jtcvs。2020。08。122 92。Park DW, Ahn JM, Park H, et al。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 288,
      "text": "ThoracCardiovascSurg。2022;163(5):1864–1869。Circulation。2013;127:2177–2185。characteristics and in-hospital outcomes of pa- https://doi。org/10。1016/j。jtcvs。2020。08。122 92。Park DW, Ahn JM, Park H, et al。 Ten-year tientswithcardiogenicshockundergoingcoronary outcomesafterdrug-elutingstentsversuscoro- arterybypasssurgery:insightsfromtheSocietyof 80。StoneGW,SerruysPW,SabikJF。PCIorCABG naryarterybypassgraftingforleftmaincoronary Thoracic Surgeons National Cardiac Database。forleftmaincoronaryarterydisease。reply。NEngl disease:extendedfollow-upofthePRECOMBAT Circulation。2008;117:876–885。JMed。2020;383:292–294。trial。Circulation。2020;141:1437–1446。104。Kawashima H, Serruys PW, Ono M, et al。81。CohenD,BrownE。Surgeonswithdrawsupport 93。StoneGW,KappeteinAP,SabikJF,etal。Five- Impact of optimal medical therapy on 10-year for heart disease advice。BBC Newsnight。BBC year outcomes after PCI or CABG for left main mortality after coronary revascularization。J Am News:BBC;2019。AccessedJuly15,2022。https:// coronarydisease。NEnglJMed。2019;381:1820– CollCardiol。2021;78:27–38。www。bbc。com/news/health-50715156 1830。105。LozanoI,RondanJ,VegasJM。PCIorCABG 82。PaganoD。ChangingEvidence,ChangingPrac- 94。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 289,
      "text": "22。https:// coronarydisease。NEnglJMed。2019;381:1820– CollCardiol。2021;78:27–38。www。bbc。com/news/health-50715156 1830。105。LozanoI,RondanJ,VegasJM。PCIorCABG 82。PaganoD。ChangingEvidence,ChangingPrac- 94。 Mohr FW, Morice MC, Kappetein AP, et al。for left main coronary artery disease。N Engl J tice。EACTS:EACTS。2019。AccessedJuly15,2022。Coronary artery bypass graft surgery versus Med。2020;383:290–291。https://www。eacts。org/changing-evidence- percutaneous coronary intervention in patients changing-practice/ withthree-vesseldiseaseandleftmaincoronary 83。AhmadY,HowardJP,ArnoldAD,etal。Mor- disease: 5-year follow-up of the randomised, KEYWORDS coronaryarterybypass talityafterdrug-elutingstentsvs。coronaryartery clinicalSYNTAXtrial。Lancet。2013;381:629–638。grafting,coronaryarterydisease,leftmain bypassgraftingforleftmaincoronaryarterydis- 95。MoriceMC,SerruysPW,KappeteinAP,etal。coronaryarterydisease,myocardial ease: a meta-analysis of randomized controlled Five-year outcomes in patients with left main revascularization,percutaneouscoronary trials。EurHeartJ。2020;41:3228–3235。diseasetreatedwitheitherpercutaneouscoronary intervention。",
      "source": "1-s2.0-S0735109722070267-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 290,
      "text": "JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL。81, NO。5, 2023 2023 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER JACC REVIEW TOPIC OF THE WEEK Evolving Management Paradigm for Stable Ischemic Heart Disease Patients JACC Review Topic of the Week WilliamE。Boden,MD,a,bMarioMarzilli,MD,cFilippoCrea,MD,dG。B。JohnMancini,MD,eWilliamS。Weintraub,MD,f VivianyR。Taqueti,MD,MPH,gCarlJ。Pepine,MD,hJavierEscaned,MD,PHD,iRashaAl-Lamee,MBBS,MA,j LuisHenriqueW。Gowdak,MD,kColinBerry,MD,PHD,lJuanCarlosKaski,DSC,MD,m onbehalfoftheChronicMyocardialIschemicSyndromesTaskForce ABSTRACT Managementofstablecoronaryarterydisease(CAD)hasbeenbasedontheassumptionthatflow-limitingatherosclerotic obstructionsaretheproximatecauseofanginaandmyocardialischemiainmostpatientsandrepresentanimportant targetforrevascularization。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 291,
      "text": "rydisease(CAD)hasbeenbasedontheassumptionthatflow-limitingatherosclerotic obstructionsaretheproximatecauseofanginaandmyocardialischemiainmostpatientsandrepresentanimportant targetforrevascularization。 However,theroleofrevascularizationinreducinglong-termcardiaceventsinthesepatients hasbeenlimitedmainlytothosewithleftmaindisease,3-vesseldiseasewithdiabetes,ordecreasedejectionfraction。Mountingevidenceindicatesthatnonepicardialcoronarycausesofanginaandischemia,includingcoronarymicrovascular dysfunction,vasospasticdisorders,andderangementsofmyocardialmetabolism,aremoreprevalentthanflow-limiting stenoses,raisingconcernsthatmanyimportantcausesotherthanepicardialCADareneitherconsiderednorprobed diagnostically。Thereisaneedforamoreinclusivemanagementparadigmthatuncouplesthesingularassociation betweenepicardialCADandrevascularizationandbetteralignsdiagnosticapproachesthattailortreatmenttothe underlyingmechanismsandprecipitantsofanginaandischemiaincontemporaryclinicalpractice。(JAmCollCardiol2023;81:505–514)2023bytheAmericanCollegeofCardiologyFoundation。S incethe advent of coronary angiography more and myocardial ischemia in most cases。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 292,
      "text": "schemiaincontemporaryclinicalpractice。(JAmCollCardiol2023;81:505–514)2023bytheAmericanCollegeofCardiologyFoundation。S incethe advent of coronary angiography more and myocardial ischemia in most cases。 This belief, than 60 years ago, stable coronary artery dis- supported by anatomic and physiologic evidence ease (CAD) management has been based on that obstructive coronary stenoses can result in the plausible assumption that “significant” flow- regional ischemia and may, in the acute setting, limiting atherosclerotic obstructions of epicardial cause acute myocardial infarction (MI), has pro- coronary arteries are the proximate cause of angina foundly influenced our approach to CAD From the aVA Boston Healthcare System, Boston, Massachusetts, USA; bBoston University School of Medicine, Boston, Massachusetts,USA;cCardiologyDepartment,UniversityofPisa,Pisa,Italy;dDepartmentofCardiology,CatholicUniversity, Rome,Italy;eDepartmentofMedicine,VancouverGeneralHospital,UniversityofBritishColumbia,Vancouver,BritishColumbia, Canada;fMedStarHealthResearchInstitute,GeorgetownUniversity,Washington,DC,USA;gDivisionofCardiovascularMedicine Listentothismanuscript’s and Imaging, Departments of Medicine and Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, audiosummaryby Massachusetts,USA;hDivisionofCardiovascularMedicine,UniversityofFloridaSchoolofMedicine,Gainesville,Florida,USA; Editor-in-Chief iHospitalClinicoSanCarlosIDISSC,ComplutenseUniversity,Madrid,Spain;jImperialCollegeLondon,London,UnitedKingdom; DrValentinFusteron kHeartInstitute,UniversityofSoPauloMedicalSchool,SoPaulo,Brazil;lUniversityofGlasgow,Glasgow,Scotland,United www。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 293,
      "text": "niversity,Madrid,Spain;jImperialCollegeLondon,London,UnitedKingdom; DrValentinFusteron kHeartInstitute,UniversityofSoPauloMedicalSchool,SoPaulo,Brazil;lUniversityofGlasgow,Glasgow,Scotland,United www。 jacc。org/journal/jacc。Kingdom; and the mMolecular and Clinical Sciences Research Institute, St George’s University of London, London, United Kingdom。Theauthorsattesttheyareincompliancewithhumanstudiescommitteesandanimalwelfareregulationsoftheauthors’ institutionsandFoodandDrugAdministrationguidelines,includingpatientconsentwhereappropriate。Formoreinformation, visittheAuthorCenter。ManuscriptreceivedMarch25,2022;revisedmanuscriptreceivedAugust2,2022,acceptedAugust15,2022。ISSN0735-1097/$36。00 https://doi。org/10。1016/j。jacc。2022。08。814 506 Bodenetal JACC VOL。81, NO。5, 2023 ParadigmShiftinStableAnginaManagement FEBRUARY 7, 2023:505–514 ABBREVIATIONS management。In acute MI patients, either HIGHLIGHTS AND ACRONYMS percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) (cid:1) Several mechanisms other than obstruc- CABG=coronaryarterybypass can restore coronary flow and improve tive coronary artery disease may cause grafting event-free survival。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 294,
      "text": "pass grafting (CABG) (cid:1) Several mechanisms other than obstruc- CABG=coronaryarterybypass can restore coronary flow and improve tive coronary artery disease may cause grafting event-free survival。 1,2 There is also a preva- myocardial ischemia。CAD=coronaryarterydisease lent belief that epicardial coronary stenosis CCTA=coronarycomputed (cid:1) A conservative approach to management, remains the dominant cause or sine qua tomographyangiography including noninvasive testing, lifestyle non of stable angina and ischemia。While, CMD=coronarymicrovascular interventions, and goal-directed multi- dysfunction indeed, revascularization may reduce inci- faceted medical therapy, is evidence GDMT=guideline-directed dent cardiac events in high-risk subsets basedandofteneffectiveinpatientswith medicaltherapy with stable CAD (eg, left main disease, stable angina。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 295,
      "text": "medical therapy, is evidence GDMT=guideline-directed dent cardiac events in high-risk subsets basedandofteneffectiveinpatientswith medicaltherapy with stable CAD (eg, left main disease, stable angina。 INOCA=ischemiaandno 3-vessel CAD with diabetes, and decreased obstructivecoronaryarteries ejection fraction), evidence from multiple (cid:1) Pharmacologic and procedural ap- MI=myocardialinfarction randomized controlled trials (RCTs) has proaches to stable ischemic heart disease PCI=percutaneouscoronary shown that revascularization of epicardial are complementary, and integrating intervention coronary obstructions, particularly with these can optimize outcomes。RCT=randomizedcontrolled the use of PCI, does not reduce mortality trial or morbidity compared with guideline- directed medical therapy (GDMT) in the great ma- jority of stable CAD patients。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 296,
      "text": " outcomes。RCT=randomizedcontrolled the use of PCI, does not reduce mortality trial or morbidity compared with guideline- directed medical therapy (GDMT) in the great ma- jority of stable CAD patients。 3,4 LESSONS LEARNED FROM RECENT Whilerevascularizationofepicardialstenosespro- COMPARATIVE EFFECTIVENESS TRIALS videsbetter symptom reliefandimprovedquality of lifecomparedwithGDMT,recurrenceofanginaranges Earlier RCTs3,4 showed no incremental benefit of between20%and30%withinayearaftersuccessful revascularization in reducing mortality, MI, and PCI5andupto40%within3years,6frequentlyleading repeated revascularization when added to GDMT, tosubsequentcoronaryangiographyandrepeatedPCI。which included multifaceted pharmacologic second- However,becauserepeatangiographyoftenrevealsno ary prevention and lifestyle intervention。Those evidence of in-stent restenosis or residual coronary studies, however, had limitations, eg, inclusion of obstruction,it isessentialtoconsider nonobstructive low-risk subjects,those withmild to moderate base- causes of angina。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 297,
      "text": "enosis or residual coronary studies, however, had limitations, eg, inclusion of obstruction,it isessentialtoconsider nonobstructive low-risk subjects,those withmild to moderate base- causes of angina。 Thus, an often-unforeseen conse- line ischemia, use of bare-metal or first-generation quence of focusing disproportionately on epicardial drug-eluting stents, and lack of blinding before coronary obstruction is that other pathogenetically diagnostic coronary angiography, that may have importantcausesofanginaandischemiamaynotbe resulted in exclusion of subjects with severe angio- considered。Thesecausesincludeepicardialormicro- graphic obstructive disease。The ISCHEMIA (Interna- vascularcoronaryvasospasm,coronarymicrovascular tional Study of Comparative Health Effectiveness dysfunction(CMD),andderangementsofmyocardial with Medical and Invasive Approaches) randomized energyormetabolism。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 298,
      "text": "ronaryvasospasm,coronarymicrovascular tional Study of Comparative Health Effectiveness dysfunction(CMD),andderangementsofmyocardial with Medical and Invasive Approaches) randomized energyormetabolism。 7 patientswithmoderate-to-severeinducible ischemia Accordingly, there is a need for a new, more to an initial invasive strategy with revascularization broadlyinclusive,managementparadigmforpatients (third-generation drug-eluting stents or CABG) plus with stable angina that uncouples the often-singular GDMT vs an initial conservative strategy of GDMT association between obstructive CAD and revascu- alone。8Itfoundnobenefitofaninvasiveapproachon larization。Because there are many other potential the primary endpoint (cardiovascular death, MI, pathogeneticmechanismsresponsibleforanginaand resuscitatedsuddencardiacdeath,orhospitalization ischemia, it is essential to identify diagnostic and for unstable angina or heart failure) or secondary therapeutic approaches to better tailor appropriate endpoint (cardiovascular death or MI)。The invasive treatment of both obstructive and nonobstructive strategydidresultinastatisticallysignificantquality causes of myocardial ischemia。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 299,
      "text": "ailor appropriate endpoint (cardiovascular death or MI)。The invasive treatment of both obstructive and nonobstructive strategydidresultinastatisticallysignificantquality causes of myocardial ischemia。 In so doing, a more of life improvement, although the overall effect was pathogeneticallydirectedapproachtodiagnosingand modestandconcentratedmainlyinthew20%ofpa- treatinganginaandischemiawouldmorelikelyalign tientswithweeklytodailyangina。9 pharmacologicandproceduralinterventionsascom- In addition, a meta-analysis of GDMT with or plementary and synergistic for a broader population without PCI in patients with stable CAD (10 RCTs ofstableCADpatients。comprising 12,125 patients, including ISCHEMIA)10 JACC VOL。81, NO。5, 2023 Bodenetal 507 FEBRUARY 7, 2023:505–514 ParadigmShiftinStableAnginaManagement confirmedthatPCIdidnotreducemortalityorMIvs horizon(3-6months)isoftenrequiredforanempiric GDMT alone, though the invasive strategy was asso- courseofGDMTtobeadequatelyevaluatedandeffi- ciated with fewer follow-up revascularizations and cacy assessed。20,21 Finally, difficulty in achieving improvedanginalsymptoms。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 300,
      "text": "invasive strategy was asso- courseofGDMTtobeadequatelyevaluatedandeffi- ciated with fewer follow-up revascularizations and cacy assessed。20,21 Finally, difficulty in achieving improvedanginalsymptoms。 optimal GDMT should not necessarily represent To evaluate potential bias in unblinded trials, the justification to refer patients for revascularization, efficacy of PCIforthetreatmentofanginawasstud- particularly if a sufficient empiric trial has not been ied in a placebo-controlled trial, which showed no implemented19-22 or if symptoms are infrequent and incrementalimprovement intreadmillwalkingtime, mild。Instead,effectiveGDMTcanbeachievedbyan anginarelief,orqualityoflifewithPCIGDMTvsa iterative process that entails collaboration with pa- placebo procedure  GDMT。11 While limited by the tients,alongwitheducationandcounseling,towarda small sample size and short follow-up, this study goaloflargelypatient-directedself-care。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 301,
      "text": "ration with pa- placebo procedure  GDMT。11 While limited by the tients,alongwitheducationandcounseling,towarda small sample size and short follow-up, this study goaloflargelypatient-directedself-care。 23-25 raises the issue of whether the observed salutary ef- Nevertheless, ensuring that patients are treated fect on angina relief attributed to PCI in earlier un- optimally with both lifestyle intervention and blinded trials was due, at least in part, to a placebo multifaceted pharmacologic secondary prevention is effect。12 time and labor intensive, and many cardiologists to Finally, we should recognize that managing pa- whom patients are referred for specific diagnostic tientswithstableanginamust includeinformedand testing, including invasive angiography and revas- well considered decision making involving the pa- cularization, may lack resources to oversee the tient, family, and physician。Both invasive and con- intensification of medical therapy personally。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 302,
      "text": "as- well considered decision making involving the pa- cularization, may lack resources to oversee the tient, family, and physician。Both invasive and con- intensification of medical therapy personally。 servativeapproachesmaybeappropriateandshould Therefore, more inclusive and coordinated team- not be viewed as competing treatment approaches management strategies incorporating physician ex- butratherascomplementaryandpotentiallyadditive tenders (nurse practitioners, physician assistants, strategies to enhance optimal patient-centered pharmacists) are needed to facilitate optimization of outcomes。13,14 GDMT and improve patient care。23 Using standard- ized care pathways and management algorithms WHY REVASCULARIZATION MAY NOT BE A may further enhance the use of these proven ap- THERAPEUTIC SOLUTION IN MANY STABLE proaches。24,25 Finally, implementation of GDMT ANGINA PATIENTS likewise remains suboptimal in patients undergoing revascularization,26-28 and such therapies must be In contrast to type 1 MI, for which prompt revascu- similarly prioritized to reduce incident events larization is indicated,1,2 revascularization has not following revascularization。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 303,
      "text": "therapies must be In contrast to type 1 MI, for which prompt revascu- similarly prioritized to reduce incident events larization is indicated,1,2 revascularization has not following revascularization。 been shown to reduce cardiac events in most stable CAD patients。3,4,8,15 Because atherosclerosis is IMPORTANCE OF DIAGNOSING ANGINA AND fundamentallyasystemicvascularandinflammatory ISCHEMIA ACCORDING TO THE UNDERLYING condition affecting epicardial arteries and coronary PATHOGENETIC CAUSE(S) microcirculation as well as other vascular beds, appropriate GDMT management of ischemia and Essential insights on the need for a more encom- atherosclerosis must include lifestyle modification passing view of the many causes and precipitants of (diet,exercise,tobaccocessation),intensiveriskfac- angina and ischemia derive from the SCOT-HEART tor control, and multifaceted pharmacologic second- (ScottishComputedTomographyoftheHeart)trial。29 aryprevention(targetinghypertension,dyslipidemia, There,mostpatientswithknownorsuspectedstable diabetes, and perhaps inflammation), and, when CAD did not have flow-limiting stenoses, indicating anginaispresent,effectivesymptomcontrol。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 304,
      "text": "n,dyslipidemia, There,mostpatientswithknownorsuspectedstable diabetes, and perhaps inflammation), and, when CAD did not have flow-limiting stenoses, indicating anginaispresent,effectivesymptomcontrol。 16,17 that the vast majority (approximately 4 in 5 in- Important observational data from recent large dividuals) had underlying causes of angina and registries indicate that self-reported angina may ischemia not attributed to epicardial stenoses improveorresolveovertimewithmedicaltherapyin (Figure 1)。For this reason, a purely anatomic diag- most stable CAD patients,18 and subsequent revas- nosticapproachusinginvasivecoronaryangiography cularizationmaybeneededinonlyaminorityofpa- or coronary computed tomography angiography tients (w5%) during 5-year follow-up。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 305,
      "text": "ts,18 and subsequent revas- nosticapproachusinginvasivecoronaryangiography cularizationmaybeneededinonlyaminorityofpa- or coronary computed tomography angiography tients (w5%) during 5-year follow-up。 19 Because (CCTA) may fail to diagnose microvascular and/or angina may relapse or remit over time and coronary vasospastic angina as treatable causes of angina, plaques may become quiescent, an appropriate leaving many patients in whom no obstructive coro- assessment of angina requires careful follow-up and nary lesions are identified and thence falsely reas- systematic ascertainment of patient-reported symp- sured that ischemia is not present。Often such toms and quality of life。Thus, a sufficient time patients are discharged from cardiology, at which 508 Bodenetal JACC VOL。81, NO。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 306,
      "text": "f patient-reported symp- sured that ischemia is not present。Often such toms and quality of life。Thus, a sufficient time patients are discharged from cardiology, at which 508 Bodenetal JACC VOL。81, NO。 5, 2023 ParadigmShiftinStableAnginaManagement FEBRUARY 7, 2023:505–514 FIGURE1 ClinicalAssessmentofMyocardialIschemiaandCAD Anatomic Assessment of Stable Angina Diagnostic test, eg, CCTA Occluded or stenotic No obstructive coronary arteries coronary lesions ≥2 in 5 patients; OMT with/without 1 in 5 Small-vessel disease stents or bypass patients INOCA mostly women surgery mostly men Obstructive CMD, no CAD vasospasm INOCA Nonobstructive Microvascular CAD, or epicardial No CMD vasospasm • Specific tests often not used • Diagnosis: possible false negative No epicardial • Specific treatments: suboptimal CAD, No CMD • ≥30% readmit to hospital • 2-fold risk of CV events InSCOT-HEART,33mostpatientswithsuspectedstablecoronaryarterydisease(CAD)didnothaveepicardialcoronaryobstructions,withthevastmajority(w4in5) havinganginaand/orischemianotduetoepicardialstenoses。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 307,
      "text": "events InSCOT-HEART,33mostpatientswithsuspectedstablecoronaryarterydisease(CAD)didnothaveepicardialcoronaryobstructions,withthevastmajority(w4in5) havinganginaand/orischemianotduetoepicardialstenoses。 CCTAcoronarycomputedtomographyangiography;CMDcoronarymicrovasculardysfunction; CVcardiovascular;INOCAischemiawithnoobstructivecoronaryarteries;MImyocardialinfarction;OMToptimalmedicaltherapy。pointmyriadpotential(andcostly)noncardiaccauses obstructive CAD,33 indicating a need to embrace a are probed rather than pursuing a more diligent more inclusive management approach that includes evaluation of nonepicardial coronary causes of manyotherpathophysiologicmechanisms,including angina。CMD and coronary vasospasm (epicardial and/or This is particularly important for women, because microvascular)。34-36Similarly,the2019EuropeanSo- most patients with ischemia and no obstructive ciety of Cardiology guidelines on chronic coronary coronary arteries (INOCA) are female。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 308,
      "text": " women, because microvascular)。34-36Similarly,the2019EuropeanSo- most patients with ischemia and no obstructive ciety of Cardiology guidelines on chronic coronary coronary arteries (INOCA) are female。 30 Heart dis- syndromesshowedthat,amongpatientswithtypical ease in women is underrecognized and under- angina in the most common age range for detecting treated, particularly INOCA, where failure to stable CAD (50-59 years), 68% of men and 87% of account for microvascular and vasospastic angina womendidnothaveobstructivecoronarystenoses,37 within the primarily noninvasive anatomic imaging and the CorMicA (Coronary Microvascular Angina) strategy may result in misdiagnosis。31 Certain trial36andothers34revealedthatapproximately45% stakeholder organizations have recognized that us- ofpatientspresentingwithanginaorischemiadidnot ing CCTA as the primary diagnostic testing strategy have CAD at angiography。Yet nearly 90% of these in angina patients may help only in diagnosing patientsdemonstratedobjectiveevidenceofcoronary obstructive epicardial CAD, which is not the most vasomotor dysfunction,38 including 81% with CMD。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 309,
      "text": " these in angina patients may help only in diagnosing patientsdemonstratedobjectiveevidenceofcoronary obstructive epicardial CAD, which is not the most vasomotor dysfunction,38 including 81% with CMD。 common cause of angina and is even less common Thus,inasizableproportionofsuspectedstableCAD in women than men。32 patients, CMD or epicardial vasoconstriction can Indeed, a large observational study of almost contributetoangina,andbecausefunctionalmecha- 400,000 angina patients undergoing elective coro- nisms may coexist with obstructive CAD, these nary angiography found that, among those with a ischemia precipitants are not necessarily mutually positive noninvasive stress test, only 41% had exclusiveandmayoftenoccurinthesamepatient。39 JACC VOL。81, NO。5, 2023 Bodenetal 509 FEBRUARY 7, 2023:505–514 ParadigmShiftinStableAnginaManagement Accordingly, a complete medical evaluation of pixel-encoded maps of myocardial blood flow (mL/ stableanginapatientsshouldcharacterizethenatural minpergtissue)duringvasodilatorstressandatrest。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 310,
      "text": "nagement Accordingly, a complete medical evaluation of pixel-encoded maps of myocardial blood flow (mL/ stableanginapatientsshouldcharacterizethenatural minpergtissue)duringvasodilatorstressandatrest。 history, cardiovascular risk factors, physical exami- Postprocessing software gives accurate measure- nation, and pharmacotherapy (including treatment mentsforbothregionalandglobalstressandresting response, medication intolerance, and adherence)。myocardial blood flow and myocardial perfusion Treadmill exercise testing remains useful to assess reserve (the ratio of stress to rest myocardial blood functionalcapacity,responsetothephysiologicstress flow)。A myocardial perfusion reserve <2。0, in the of exercise, and limiting symptoms and features of absenceofobstructiveCAD,iswidelyacceptedasthe inducible ischemia (notably symptoms and electro- CMDthresholdassociatedwithadverseoutcomes。41 cardiographic changes)。The response to treatment An algorithm for practical assessment of the mul- can be diagnostically informative, and the initial tiplecausesofanginaandischemiaisproposedinthe management plan should include antianginal drug Central Illustration。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 311,
      "text": " practical assessment of the mul- can be diagnostically informative, and the initial tiplecausesofanginaandischemiaisproposedinthe management plan should include antianginal drug Central Illustration。 It outlines a pragmatic approach therapy, such as short-acting nitrates and either a stemming from current international guideline rec- beta-blockeroracalcium-channelblocker。Thisinitial ommendations and results of landmark studies。3,8,29 approach complements referral for CCTA because It supports an initial evidence-based approach, heartratecontrol(target60beats/min)isrequiredfor including lifestyle interventions and pharmacologic optimalimaging。secondary prevention with GDMT, to achieve and maintain multiple cardiovascular treatment targets HOW TO DIAGNOSE AND MANAGE forbloodpressure,lipids,andglycemiclevelsasper VASOSPASM, MICROVASCULAR the current U。S。40 and European guidelines。37 This DYSFUNCTION, AND OTHER CAUSES OF algorithm endorses selective functional or anatomic MYOCARDIAL ISCHEMIA imaging to identify high-risk subsets of stable CAD patients for whom revascularization is more appro- Both the 2021 AHA/ACC chest pain guideline40 and priatethanmedicaltherapyalone。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 312,
      "text": "OCARDIAL ISCHEMIA imaging to identify high-risk subsets of stable CAD patients for whom revascularization is more appro- Both the 2021 AHA/ACC chest pain guideline40 and priatethanmedicaltherapyalone。 the 2019 European Society of Cardiology chronic If noninvasive studies identify a very low angina coronary syndromes guideline37 delineate the 3 thresholdand/oralargeareaofischemicmyocardium different mechanisms of stable angina (obstructive at risk during noninvasive stress testing, CCTA or CAD, coronary vasospasm, and CMD)。However, a invasive coronary angiography is appropriate to fundamental limitation is the lack of a standard excludeleftmainand/orhigh-grademultivesselCAD。diagnostic evaluation for all patients with suspected In all other chronic stable angina patients, an initial angina。Although anginal chest discomfort is “the trialofempiricantianginaltreatmentisanimportant alarm system of the heart” and often the cardinal initialstepandup-titratingdosagesoraddingagents symptomofmyocardialischemia,itdoesnotprovide for symptom control, as needed, is advocated。21,22 specificity on its cause。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 313,
      "text": " heart” and often the cardinal initialstepandup-titratingdosagesoraddingagents symptomofmyocardialischemia,itdoesnotprovide for symptom control, as needed, is advocated。21,22 specificity on its cause。 Therefore, it is critical not Stable CAD patients with angina should receive at onlytoruleinorruleoutobstructiveCADbutalsoto least2antianginaldrugclassesandadjustedover3to establish the cause of myocardial ischemia and to 6 months before referral for revascularization, prove or disprove the ischemic origin of symptoms。particularly if anginal symptoms are mild or infre- Such a diagnostic evaluation that comprehensively quent(Figure2)。assesses anatomic and functional coronary alter- In those with persistent or recurrent ischemic ationswouldhelptoconfirmorexcludethediagnosis symptomsdespiteintensivesymptomatictreatment, of myocardial ischemia and determine the precipi- coronaryangiographyisindicatedtoidentifypatients tatingcausewheneverpossible。with flow-limiting stenoses who might benefit from Myocardial perfusion imaging using positron myocardial revascularization。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 314,
      "text": "oronaryangiographyisindicatedtoidentifypatients tatingcausewheneverpossible。with flow-limiting stenoses who might benefit from Myocardial perfusion imaging using positron myocardial revascularization。 In patients without emission tomography or cardiovascular magnetic obstructive stenosis, the functional assessment of resonance imaging is useful for diagnosing CMD。41 coronary circulation, including acetylcholine testing These noninvasive imaging techniques provide for spasm, coronary flow reserve, and microvascular quantitativeandqualitativeinformationoninducible resistance,shouldbeconsideredtoguidesubsequent myocardial ischemia。Dynamic first-pass vasodilator pharmacologic treatment。This algorithm allows stress/restpositronemissiontomographyusesradio- tailoring of the diagnostic workup to the clinical tracers (eg, 82Rb, 13N-ammonia, 15O-H O) and quan- situation (Central Illustration) and places less 2 tifies absolute myocardial blood flow。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 315,
      "text": "esradio- tailoring of the diagnostic workup to the clinical tracers (eg, 82Rb, 13N-ammonia, 15O-H O) and quan- situation (Central Illustration) and places less 2 tifies absolute myocardial blood flow。 42 Advances emphasis on CCTA, which, as currently used, is un- with stress cardiovascular magnetic imaging include able to detect functional coronary alterations (endo- fully automatic pixelwise quantitative mapping of thelial dysfunction or vasospasm) responsible for myocardial perfusion。43,44 This method generates ischemia。In SCOT-HEART,29 nonfatal MI at 5 years 510 Bodenetal JACC VOL。81, NO。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 316,
      "text": "antitative mapping of thelial dysfunction or vasospasm) responsible for myocardial perfusion。43,44 This method generates ischemia。In SCOT-HEART,29 nonfatal MI at 5 years 510 Bodenetal JACC VOL。81, NO。 5, 2023 ParadigmShiftinStableAnginaManagement FEBRUARY 7, 2023:505–514 CENTRAL ILLUSTRATION ManagementAlgorithmforObstructiveandNonobstructiveCoronaryCausesofAngina Suspected Stable Angina Lifestyle Start therapy for angina interventions & optimize CV /angina equivalent risk factor control Functional imaging LMD suspected or LMD excluded or CCTA (FFR) documented or not likely confirms CAD Functional testing- guided antianginal Optimize GDMT for CV Uptitrate antianginal treatment event reduction therapy, if needed Symptoms Coronary angiography unresponsive No/diffuse LMD or high-grade Focal stenoses atherosclerosis multivessel CAD Functional FFR >0。80 ≤0。80 Revascularization, assessment FFR / iFR ACh/CFR/IMR iFR >0。89 ≤0。90 if indicated BodenWE,etal。JAmCollCardiol。2023;81(5):505–514。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 317,
      "text": "cal stenoses atherosclerosis multivessel CAD Functional FFR >0。80 ≤0。80 Revascularization, assessment FFR / iFR ACh/CFR/IMR iFR >0。89 ≤0。90 if indicated BodenWE,etal。JAmCollCardiol。2023;81(5):505–514。 Amoreinclusivemanagementparadigmforstablecoronaryarterydisease(CAD)patientsthataddressesthemanypathogeneticmechanismsresponsibleforangina andischemiaisnecessarytoidentifydiagnosticandtherapeuticapproachesthatwouldbettertailortheappropriatetreatmentofobstructiveandnonobstructive causesofmyocardialischemiatotheunderlyingischemiaprecipitants。Suchanapproachseekstopromotebothevidence-basedpharmacologicsecondaryprevention andproceduralinterventionsascomplementaryandpotentiallyadditivetreatmentstooptimizethemanagementofstableanginapatients。AChacetylcholine; CCTAcoronarycomputedtomographyangiography;CFRcoronaryflowreserve;CVcardiovascular;FFRfractionalflowreserve(ahyperemicpressureratio); GDMTguideline-directedmedicaltherapy;iFRinstantaneousfreewaveratio;IMRindexofmicrovascularresistance;LMDleftmaindisease。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 318,
      "text": "flowreserve;CVcardiovascular;FFRfractionalflowreserve(ahyperemicpressureratio); GDMTguideline-directedmedicaltherapy;iFRinstantaneousfreewaveratio;IMRindexofmicrovascularresistance;LMDleftmaindisease。 was lower in the CCTA-guided group than in the do not improve (or if they worsen) despite appro- standard care group, but there was no effect on priate antianginal therapy of at least 2 drug mortality。Secondary prevention therapy, including classes。21 aspirin and statins, was higher in the CCTA-guided WHY WE NEEDA PARADIGM SHIFT IN OUR group, further implying that disclosure of athero- APPROACH TOANGINA AND ISCHEMIA sclerosisresultedinlinkedtherapy。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 319,
      "text": "spirin and statins, was higher in the CCTA-guided WHY WE NEEDA PARADIGM SHIFT IN OUR group, further implying that disclosure of athero- APPROACH TOANGINA AND ISCHEMIA sclerosisresultedinlinkedtherapy。 Ideally, the above-proposed diagnostic evaluation should be performed in all stable angina patients in Cardiologists should reappraise their thinking of whom obstructive CAD has been excluded, but, anginaandprioritizethefollowing:1)anginamaybe from a practical standpoint, many centers will not due to obstructive CAD and/or INOCA; 2) most pa- have access to such sophisticated testing modalities tients presenting with chronic angina do not have or may lack the skill or expertise to undertake epicardial coronary obstructions; 3) if CCTA is the such evaluations, and there are potential cost- initial diagnostic test and obstructive coronary ste- effectiveness concerns that need to be considered noses are excluded, subsequent testing should as well。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 320,
      "text": "valuations, and there are potential cost- initial diagnostic test and obstructive coronary ste- effectiveness concerns that need to be considered noses are excluded, subsequent testing should as well。 Therefore, we advocate additional diag- include stress perfusion imaging, positron emission nostic testing, described above, only after obstruc- tomography, and/or invasive functional coronary tive CAD has been excluded and only if symptoms angiography with pharmacologic testing to detect JACC VOL。81, NO。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 321,
      "text": ", described above, only after obstruc- tomography, and/or invasive functional coronary tive CAD has been excluded and only if symptoms angiography with pharmacologic testing to detect JACC VOL。81, NO。 5, 2023 Bodenetal 511 FEBRUARY 7, 2023:505–514 ParadigmShiftinStableAnginaManagement FIGURE2 AntianginalTreatmentDirectedtotheMechanismResponsibleforIschemia CCB (either DHP CCB or non-DHP CCB), nicorandil, LAN Occlusive CAD Effort-induced angina HR >80 beats/min BB, non-DHP CCB, ivabradine, ranolazine, trimetazidine HR <50 beats/min DHP CCB, LAN, ranolazine, trimetazidine, nicorandil Coronary Low BP spasm Ranolazine, ivabradine, trimetazidine, low-dose BB, or low-dose non-DHP CCB Coronary microcirculation Coronary microvascular dysfunction Microvascular spasm Abnormal vasodilatation Arteriole CCB, ranolazine, Capillaries BB + non-DHP CCB, trimetazidine, nicorandil, LAN CCB (either DHP CCB or non-DHP CCB), nicorandil, LAN Microvessel unable to dilate Forexertionalangina,antianginaldrugsthatreducemyocardialoxygenconsumption(ie,beta-blockers[BBs],nondihydropyridinecalcium-channelblockers[CCBs], orivabradine)aremostefficacious,whereasforvariablethresholdanginaorcoronarymicrovasculardysfunction,agentsthatimprovemyocardialoxygenutilization (ie,ranolazineortrimetazidine)aresuitabletreatmentoptions。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 322,
      "text": "vabradine)aremostefficacious,whereasforvariablethresholdanginaorcoronarymicrovasculardysfunction,agentsthatimprovemyocardialoxygenutilization (ie,ranolazineortrimetazidine)aresuitabletreatmentoptions。 CCBsarethepreferredoptionforepicardialormicrovascularspasm,butnitratesandnicorandilmayalso beappropriate。BPbloodpressure;CADcoronaryarterydisease;DHPdihydropyridine;HRheartrate;LANlong-actingnitrate。coronary microvascular or vasospastic mechanisms PHARMACOLOGIC MANAGEMENT thatmayrequiremoretargetedtherapy;and4)most TARGETING THE PRECIPITANTS OF INOCApatientsarewomen,andadiagnosticstrategy ANGINA AND ISCHEMIA withasingularfocusondefiningepicardialcoronary obstructionsmaybeinadequate。Areductionofcoronary/myocardialflowreservemay Of interest, a comprehensive noninvasive diag- reflect ischemia due to epicardial stenoses,impaired nostic approach that contemplates both anatomic microvascularfunction,orboth,eveninthesamepa- and functional issues may be provided by multi- tient,asnotedabove。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 323,
      "text": "ia due to epicardial stenoses,impaired nostic approach that contemplates both anatomic microvascularfunction,orboth,eveninthesamepa- and functional issues may be provided by multi- tient,asnotedabove。 Inthissetting,drugsthatreduce modality imaging such as PET/CCTA or “dynamic” myocardial oxygen consumption (beta-blockers, CCTA and could be viewed as a noninvasive “one- nondihydropyridine calcium-channel blockers, or stop shop” model to diagnose angina and suspected ivabradine)oroptimizemyocardialoxygenutilization CAD,bothobstructiveandnonobstructive。45Ongoing (ranolazineortrimetazidine)arelikelythebestoption。RCTs will determine whether dynamic CCTA fulfills Their combination can also be considered (Figure 2)。thispromise。Alternatively, ischemia can also be caused by 512 Bodenetal JACC VOL。81, NO。5, 2023 ParadigmShiftinStableAnginaManagement FEBRUARY 7, 2023:505–514 epicardialormicrovascularspasm。Inthissetting,va- outcomesinstableCADpatientswhohadundergone sodilators(calcium-channelblockers,nitrates,ornic- CABG or PCI。In this way, perhaps we can rebalance orandil)aremostappropriate,andtheircombination patient management in a way that does not view canalsobeconsidered。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 324,
      "text": "ium-channelblockers,nitrates,ornic- CABG or PCI。In this way, perhaps we can rebalance orandil)aremostappropriate,andtheircombination patient management in a way that does not view canalsobeconsidered。 Thus,totheextentpossible,it procedural and pharmacologic interventions as ishighlydesirabletotailorpharmacologictherapiesto competing treatments but rather as complementary theunderlyingcausesandprecipitantsofischemia。and additive therapeutic approaches best suited to achievingoptimalclinicaloutcomesandsymptomre- CONCLUSIONS: liefforourpatients。WHERE DOWE GO FROM HERE。FUNDINGSUPPORTANDAUTHORDISCLOSURES The time hascome for a paradigm shift in managing stable CAD patients。First, we need to expand our ThispublicationwassupportedbyaneducationalgrantfromServier, currentscientificthinkingaboutthemanycausesand SuresnesCedex,France。Supportinthedevelopmentofthemanu- scriptwasalsoprovidedbyLiberumIME,London,UnitedKingdom。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 325,
      "text": "ssupportedbyaneducationalgrantfromServier, currentscientificthinkingaboutthemanycausesand SuresnesCedex,France。Supportinthedevelopmentofthemanu- scriptwasalsoprovidedbyLiberumIME,London,UnitedKingdom。 mechanismsofbothanginaandmyocardialischemia Dr Boden receives research grant support from AbbVie, Amarin anduncouplethenarrowassociationofischemiawith Pharmaceuticals,Amgen,AstraZeneca,Sanofi,MassachusettsVeter- obstructive epicardial disease46 as the guiding ansEpidemiologyResearchandInformationCenter,VANewEngland HealthcareSystem’sClinicalTrialsNetwork,andtheNationalHeart, approach to management。Both angina and ischemia Lung,andBloodInstitute(NHLBI),whereheservedasnationalco- havemanycauses,butobstructiveepicardialdisease principalinvestigatorfortheISCHEMIAtrial;isontheBoardofDi- may or may not be the underlying pathogenetic rectorsfortheBostonVAResearchInstitute;receivesconsultingfees mechanism (Central Illustration, Figure 2)。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 326,
      "text": "nvestigatorfortheISCHEMIAtrial;isontheBoardofDi- may or may not be the underlying pathogenetic rectorsfortheBostonVAResearchInstitute;receivesconsultingfees mechanism (Central Illustration, Figure 2)。 Therefore, from Amarin Pharmaceuticals, Amgen, Janssen Pharmaceuticals, our nomenclature shouldreflect the actualcausesof Metuchen Pharmaceuticals, and Servier; is on the VA Cooperative Studies Program data monitoring committee; and has received ischemiaandanginabeyondthecurrentlyusedterms speakinghonorariafromAmarin,Amgen,JanssenPharmaceuticals, “coronary” and “disease,” both of which connote Pfizer,andServier。DrMarzillilecturesforServier,Menarini,Degussa epicardial coronary obstruction and are perhaps too Pharma Group, Baldacci, Abbott, and AstraZeneca。Dr Crea has received personal speaker fees from Amgen, AstraZeneca, Servier, narrowlyrestrictive。Amoreinclusiveanddescriptive andBMS;andisamemberoftheadvisoryboardforGlyCardialDi- nomenclature might be considered, such as “acute agnostics。DrMancinihasreceivedgrants,advisoryboardappoint- andchronicmyocardialischemicsyndromes。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 327,
      "text": "andBMS;andisamemberoftheadvisoryboardforGlyCardialDi- nomenclature might be considered, such as “acute agnostics。DrMancinihasreceivedgrants,advisoryboardappoint- andchronicmyocardialischemicsyndromes。 ”47 ments,andhonorariaforeducationallecturesfromAmgen,Sanofi, Second, we must embrace a more enlightened NovoNordisk,Lilly/BoehringerIngelheim,andHLITherapeutics;is ontheadvisoryboardforEsperion;andreceivesreportsongrants managementapproach。Assessmentsofischemiathat fromtheNationalInstitutesofHealth(NIH)fortheCOURAGEand do not delineate abnormal coronary angiographic ISCHEMIAtrials。DrWeintraubhasreceivedresearchsupportfrom findings should not necessarily shift diagnostic and AmarinCorporation,NIH,andCentersforDiseaseControlandPre- vention; and has served as a consultant for Amarin Corporation, therapeutic considerations to noncardiac causes of AstraZeneca,Pfizer,Janssen,SCPharma,Lexicon,Faraday,andThe anginabutrathertoexploringnonepicardialcoronary Medicines Company。Dr Taqueti is supported by NIH grant causes(eg,CMDandvasospasticdisorders)。Wemust K23HL135438。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 328,
      "text": "Janssen,SCPharma,Lexicon,Faraday,andThe anginabutrathertoexploringnonepicardialcoronary Medicines Company。Dr Taqueti is supported by NIH grant causes(eg,CMDandvasospasticdisorders)。Wemust K23HL135438。 DrPepinereceivesresearchgrantsupportfromNIH/ remainmindfulthattheevaluationandtreatmentof NHLBI(R21AG063143,K08HL130945,K01HL138172,R01HL146158, AG065141, R01 HL152162, R21 HL152264, R01 HL132448, UM1 angina and ischemia need to be tailored to the indi- HL087366, UM1 HL087318), NIH/National Center for Advancing vidual patient and that adoption of available diag- TranslationalSciences(UL1TR001427),U。S。DepartmentofDefense nostic tools required for personalized approaches in (W81XWH-17-2-0030, WARRIOR), Biocardia,Brighamand Women’s clinicalpracticeremainschallenging。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 329,
      "text": "lationalSciences(UL1TR001427),U。S。DepartmentofDefense nostic tools required for personalized approaches in (W81XWH-17-2-0030, WARRIOR), Biocardia,Brighamand Women’s clinicalpracticeremainschallenging。 Hospital, CSL Behring, Cytori Therapeutics, DCRI, GE Healthcare, Mesoblast,andPfizer;receivesconsultantfees/honorariafromCala- Third, we must invest in developing newer man- drius Biosciences, Slack, and Xylocor; and receives grant support agement strategies and health care delivery models from the Gatorade Foundation through the University of Florida thatmaybetteralignwithtreatmentsproventobenefit DepartmentofMedicineandfromtheMcJunkinFamilyFoundation, patients and society。48-52 Proven secondary preven- Plantation, Florida。Dr Escaned has received speaker and advisory boardhonorariafromAbbottLaboratoriesandPhilips。DrAl-Lamee tion strategies and lifestyle interventions in has received speaker honoraria from Philips Volcano, Abbott contemporary GDMT continue to be underutilized, Vascular, and Menarini Pharmaceuticals。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 330,
      "text": "Lamee tion strategies and lifestyle interventions in has received speaker honoraria from Philips Volcano, Abbott contemporary GDMT continue to be underutilized, Vascular, and Menarini Pharmaceuticals。 Dr Gowdak has received particularlyintheUnitedStates,whereasfewas40% congress-related travel expenses from Servier; has participated in to50%ofeligibleCADsubjectsaretreatedaccordingto clinicaltrialssponsoredbyServierandAngionBiomedica;hasbeena speakerforServier,Boehringer-Lilly,andAbbott;isanadvisoryboard established clinical practice guidelines, including memberforServier;andhaspreparedwrittenscientificmaterialfor those who have been revascularized。26,49,51 A recent ServierandAbbott。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 331,
      "text": "isanadvisoryboard established clinical practice guidelines, including memberforServier;andhaspreparedwrittenscientificmaterialfor those who have been revascularized。26,49,51 A recent ServierandAbbott。 DrBerryisemployedbytheUniversityofGlas- Viewpoint52 addressing the new coronary artery gow,whichholdsconsultancyandresearchagreementsforhiswork revascularizationrecommendations53underscoresthe with Abbott Vascular, AstraZeneca, Auxilius Pharma, Boehringer Ingelheim, Causeway Therapeutics, Coroventis, Genentech, GSK, critical importance of concomitant preventive thera- HeartFlow,Menarini,Neovasc,SiemensHealthcare,andValoHealth; pies in enhancing event-free survival and improving and receives research funding from the British Heart Foundation JACC VOL。81, NO。5, 2023 Bodenetal 513 FEBRUARY 7, 2023:505–514 ParadigmShiftinStableAnginaManagement (grantRE/18/6134217),ChiefScientistOffice,EngineeringandPhys- ical SciencesResearch Council(EP/R511705/1, EP/S030875/1), Euro- ADDRESS FOR CORRESPONDENCE: Dr William E。pean Union (754946-2), Medical Research Council (MR/S018905/1), Boden, VA Boston Healthcare System, Boston Uni- andUKRI(MC/PC/20014)。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 332,
      "text": "5/1, EP/S030875/1), Euro- ADDRESS FOR CORRESPONDENCE: Dr William E。pean Union (754946-2), Medical Research Council (MR/S018905/1), Boden, VA Boston Healthcare System, Boston Uni- andUKRI(MC/PC/20014)。 DrKaskihasreceivedspeakerhonoraria versity School of Medicine, 150 S。Huntington Ave, fromA。MenariniFarmaceuticalnternazionale,Servier,andBayerUK。DrEscanedhasreportedthathehasnorelationshipsrelevanttothe Boston, Massachusetts 02130, USA。E-mail: william。contentsofthispapertodisclose。boden@va。gov。Twitter:@webmd11。REFERENCES 1。GrinesC,PatelA,ZijlstraF,etal。Primarycor- 13。Ferrari R, Camici PG, Crea F, et al。Expert coronarysyndromes。CritPathwCardiol。2019;18: onary angioplasty compared with intravenous consensus document: a “diamond” approach to 167–175。thrombolytictherapyforacutemyocardialinfarc- personalizedtreatmentofangina。NatRevCardiol。tion:six-monthfollowupandanalysisofindivid- 2018;15:120–132。25。Brummel A, Carlson AM。Comprehensive medication management and medication adher- ualpatientdatafromrandomizedtrials。AmHeart J。2003;145:47–57。14。YanagawaB,PuskasJD,BhattDL,VermaS。encefor chronicconditions。JManagCareSpec The coronary heart team。Curr Opin Cardiol。Pharm。2016;22:56–62。2。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 333,
      "text": "lpatientdatafromrandomizedtrials。AmHeart J。2003;145:47–57。14。YanagawaB,PuskasJD,BhattDL,VermaS。encefor chronicconditions。JManagCareSpec The coronary heart team。Curr Opin Cardiol。Pharm。2016;22:56–62。2。 Kirov H, Caldonazo T, Rahouma M, et al。2017;32:627–632。Asystematicreviewandmeta-analysisofpercu- 26。XieJX,GunzburgerEC,KaunL,etal。Medical taneouscoronaryinterventioncomparedtocoro- 15。de Bruyne B, Fearon WF, Pijls NHJ, et al。therapy utilization and long-term outcomes nary artery bypass grafting in non–ST-elevation Fractionalflowreserve-guidedPCIforstablecor- following percutaneous coronary intervention: acutecoronarysyndrome。SciRep。2022;12:5138。onary artery disease。N Engl J Med。2014;371: five-yearresultsfromtheveteransaffairsclinical 1208–1217。assessment,reporting,andtrackingsystempro- 3。BodenWE,O’RourkeRA,TeoKK,etal。Optimal 16。RidkerPM。FromCANTOStoCIRTtoCOLCOT gram。Circ Cardiovasc Qual Outcomes。2019;12: medical therapy with or without PCI for stable coronarydisease。NEnglJMed。2007;356:1503– toclinic:willallatherosclerosispatientssoonbe e005455。treated with combination lipid-lowering and 1516。27。Iqbal J, Zhang Y-J, Holmes DR, et al。inflammation-inhibiting agents。Circulation。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 334,
      "text": "007;356:1503– toclinic:willallatherosclerosispatientssoonbe e005455。treated with combination lipid-lowering and 1516。27。Iqbal J, Zhang Y-J, Holmes DR, et al。inflammation-inhibiting agents。Circulation。 Optimal medical therapy improves clinical out- 4。BARI 2D Study Group, Frye RL, August P, 2020;141:787–789。comes in patients undergoing revascularization BrooksMM,etal。Arandomizedtrialoftherapies fortype2diabetesandcoronaryarterydisease。17。Weintraub WS, Daniels SR, Burke LE, et al。withpercutaneouscoronaryinterventionorcor- NEnglJMed。2009;360:2503–2515。Value of primordial and primary prevention for onary artery bypass grafting: insights from the cardiovascular disease: a policy statement from Synergy Between Percutaneous Coronary Inter- 5。Ben-Yehuda O, Kazi DS, Bonafede M, et al。the American Heart Association。Circulation。vention WithTAXUSandCardiacSurgery (SYN- Anginaandassociatedhealthcarecostsfollowing 2011;124:967–990。TAX) trial at the 5-year follow-up。Circulation。percutaneouscoronaryintervention:areal-world 2015;131:1269–1277。analysis from a multi-payer database。Catheter 18。Orsini E, Marzilli M, Zito GB, et al。Clinical CardiovascInterv。2016;88:1017–1024。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 335,
      "text": "ation。percutaneouscoronaryintervention:areal-world 2015;131:1269–1277。analysis from a multi-payer database。Catheter 18。Orsini E, Marzilli M, Zito GB, et al。Clinical CardiovascInterv。2016;88:1017–1024。 outcomesofnewlydiagnosed,stableanginapa- 28。KhattabAA,KnechtM,MeierB,etal。Persis- tientsmanagedaccordingto currentguidelines。tenceofuncontrolledcardiovascularriskfactorsin 6。Crea F, Bairey Merz CN, Beltrame JF, et al。TheARCA(ArcaRegistryforChronicAngina)reg- patientstreatedwithpercutaneousinterventions Mechanismsanddiagnosticevaluationofpersis- istry: a prospective, observational, nationwide for stable coronary artery disease not receiving tentorrecurrentanginafollowingpercutaneous study。IntJCardiol。2022;352:9–18。cardiacrehabilitation。EurJPrevCardiol。2013;20: coronaryrevascularization。EurHeartJ。2019;40: 743–749。2455–2462。19。MesnierJ,DucrocqG,DanchinN,etal。Inter- nationalobservationalanalysisof evolutionand 29。SCOT-HEART Investigators。CT coronary 7。KaskiJ-C,CreaF,GershBJ,CamiciPG。Reap- outcomesofchronicstableangina:themultina- angiographyinpatientswithsuspectedanginadue praisal of ischemic heart disease。Circulation。2018;138:1463–1480。tional CLARIFY study。Circulation。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 336,
      "text": ",CamiciPG。Reap- outcomesofchronicstableangina:themultina- angiographyinpatientswithsuspectedanginadue praisal of ischemic heart disease。Circulation。2018;138:1463–1480。tional CLARIFY study。Circulation。 2021;144:512– to coronary heart disease (SCOT-HEART): an 523。open-label,parallel-group,multicentretrial。Lan- 8。Maron DJ, Hochman JS, Reynolds HR, et al。cet。2015;385:2383–2391。20。DouradoLOC,PoppiNT,AdamEL,etal。The Initialinvasiveorconservativestrategyforstable coronarydisease。NEnglJMed。2020;382:1395– effectiveness of intensive medical treatment in 30。TaquetiVR,diCarliMF。Coronarymicrovas- patientsinitiallydiagnosedwithrefractoryangina。culardiseasepathogenicmechanismsandthera- 1407。IntJCardiol。2015;186:29–31。peuticoptions:JACCstate-of-the-artreview。JAm 9。SpertusJA,JonesPG,MaronDJ,etal。Health- CollCardiol。2018;72:2625–2641。statusoutcomeswithinvasiveorconservativecare 21。Boden WE, Kaski JC, Al-Lamee R, in coronary disease。N Engl J Med。2020;382: Weintraub WS。What constitutes an appropriate 31。Shah NR, Hulten EA, Tandon S, Murthy VL, 1408–1419。empiricaltrialofantianginaltherapyinpatients Dorbala S, Thompson RC。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 337,
      "text": "y disease。N Engl J Med。2020;382: Weintraub WS。What constitutes an appropriate 31。Shah NR, Hulten EA, Tandon S, Murthy VL, 1408–1419。empiricaltrialofantianginaltherapyinpatients Dorbala S, Thompson RC。 Recent clinical trials withstableanginabeforereferralforrevascular- supportcontinuedemphasisonpatient-firstover 10。ShahR,NayyarM,LeFK,etal。Ameta-analysis isation。Lancet。2022;399:691–694。modality-firstapproachestoinitialtestselection of optimal medical therapy with or without in patients with stable ischemic heart disease。percutaneous coronary intervention in patients 22。BodenWE,StonePH。Tostentornottostent。JNuclCardiol。PublishedonlineFebruary11,2022。withstablecoronaryarterydisease。CoronArtery TreatinganginaafterISCHEMIA—whyaconserva- https://www。doi。org/10。1007/s12350-022-02908-7 Dis。2022;33:91–97。tiveapproachwithoptimalmedicaltherapyisthe preferredinitialmanagementstrategyforchronic 32。Hobson P, Bakker J。How the heart attack 11。Al-LameeR,ThompsonD,DehbiH-M,etal。coronarysyndromes:insightsfromtheISCHEMIA gender gapis costing women’s lives。Br J Card Percutaneous coronary intervention in stable trial。EurHeartJ。2021;42:1394–1400。Nurs。2019;14:1–3。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 338,
      "text": "nD,DehbiH-M,etal。coronarysyndromes:insightsfromtheISCHEMIA gender gapis costing women’s lives。Br J Card Percutaneous coronary intervention in stable trial。EurHeartJ。2021;42:1394–1400。Nurs。2019;14:1–3。 angina (ORBITA): a double-blind, randomised controlledtrial。Lancet。2018;391:31–40。23。MasonCM。Preventingcoronaryheartdisease 33。Patel MR, Peterson ED, Dai D, et al。Low andstrokewithaggressivestatintherapyinolder diagnosticyieldofelectivecoronaryangiography。12。RajkumarCA,NijjerSS,ColeGD,Al-LameeR, FrancisDP。Faithhealing”and“subtractionanxi- adults using a team management model。J Am NEnglJMed。2010;362:886–895。ety” in unblinded trials of procedures: lessons AcadNursePract。2009;21:47–53。34。SudaA,TakahashiJ,HaoK,etal。Coronary from DEFER and FAME-2 for end points in the 24。BrenerMI,TungJ,StantJ,etal。Anupdated functional abnormalitiesin patients with angina ISCHEMIA Trial。Circ Cardiovasc Qual Outcomes。healthcare system–wide clinical pathway for andnonobstructivecoronaryarterydisease。JAm 2018;11:e004665。managing patients with chest pain and acute CollCardiol。2019;74:2350–2360。514 Bodenetal JACC VOL。81, NO。5, 2023 ParadigmShiftinStableAnginaManagement FEBRUARY 7, 2023:505–514 35。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 339,
      "text": "e。JAm 2018;11:e004665。managing patients with chest pain and acute CollCardiol。2019;74:2350–2360。514 Bodenetal JACC VOL。81, NO。5, 2023 ParadigmShiftinStableAnginaManagement FEBRUARY 7, 2023:505–514 35。 TaquetiVR,HachamovitchR,MurthyVL,etal。42。GuptaA,TaquetiVR,vandeHoefTP,etal。patients。CircCardiovascQualOutcomes。2008;1: Global coronary flow reserve is associated with Integrated noninvasive physiological assessment 12–20。adverse cardiovascular events independently of of coronary circulatory function and impact on 49。WeintraubWS,BodenWE。Makingcardiovas- luminal angiographic severity and modifies the cardiovascular mortality in patients with stable cularcaremoreresponsivetosocietalneeds。AmJ effect of early revascularization。Circulation。coronary artery disease。Circulation。2017;136: Med。2017;130:1259–1261。2015;131:19–27。2325–2336。50。DiamondGA,KaulS。Evidence-basedfinancial 36。FordTJ,StanleyB,SidikN,etal。1-Yearout- 43。Jacobs M, Benovoy M, Chang L-C, et al。incentives for healthcare reform: putting it comesofanginamanagementguidedbyinvasive Automatedsegmentalanalysisoffullyquantita- together。CircCardiovascQualOutcomes。2009;2: coronary function testing (CorMicA)。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 340,
      "text": "es for healthcare reform: putting it comesofanginamanagementguidedbyinvasive Automatedsegmentalanalysisoffullyquantita- together。CircCardiovascQualOutcomes。2009;2: coronary function testing (CorMicA)。 J Am Coll tive myocardial blood flow maps by first-pass 134–140。CardiolIntv。2020;13:33–45。perfusion cardiovascular magnetic resonance。IEEEAccess。2021;9:52796–52811。51。BucholzEM,RoddayAM,KolorK,KhouryMJ, 37。KnuutiJ,WijnsW,SarasteA,etal。2019ESC de Ferranti SD。Prevalence and predictors of guidelinesforthediagnosisandmanagementof 44。Kotecha T, Martinez-Naharro A, Boldrini M, cholesterol screening, awareness, and statin chroniccoronarysyndromes。EurHeartJ。2020;41: etal。Automatedpixel-wisequantitativemyocar- treatmentamongUSadultswithfamilialhyper- 407–477。dial perfusion mapping by CMR to detect cholesterolemiaorotherformsofseveredyslipi- 38。OngP,CamiciPG,BeltrameJF,etal。Inter- obstructivecoronaryarterydiseaseandcoronary demia (1999-2014)。Circulation。2018;137:2218– microvascular dysfunction: validation against nationalstandardizationofdiagnosticcriteriafor 2230。microvascularangina。IntJCardiol。2018;250:16– invasive coronary physiology。J Am Coll Cardiol Img。2019;12:1958–1969。52。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 341,
      "text": "ysfunction: validation against nationalstandardizationofdiagnosticcriteriafor 2230。microvascularangina。IntJCardiol。2018;250:16– invasive coronary physiology。J Am Coll Cardiol Img。2019;12:1958–1969。52。 Cardoso R, Abovich A, Boden WE, Arbab- 20。ZadehA,BlanksteinR,BlumenthalRS。The2021 45。SerruysPW,HaraH,GargS,etal。Coronary 39。Sechtem U, Brown D, Godo S, Lanza GA, AHA/ACC/SCAI coronary artery revascularization Shimokawa H, Sidik N。Coronary microvascular computedtomographicangiographyforcomplete recommendations。JACCAdv。2022;1:1–5。assessmentofcoronaryarterydisease:JACCstate- dysfunction in stable ischaemic heart disease of-the-artreview。JAmCollCardiol。2021;78:713– 53。Writing Committee Members, Lawton JS, (nonobstructive coronary artery disease and 736。Tamis-HollandJE,BangaloreS,etal。2021ACC/ obstructive coronary artery disease)。Cardiovasc AHA/SCAIguidelineforcoronaryarteryrevascu- Res。2020;116:771–786。46。Marzilli M, Merz CNB, Boden WE, et al。larization: a report of the American College of Obstructivecoronaryatherosclerosisandischemic 40。Writing Committee Members, Gulati M, Cardiology/American Heart Association Joint heartdisease:anelusivelink。JAmCollCardiol。LevyPD,MukherjeeD,etal。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 342,
      "text": "e of Obstructivecoronaryatherosclerosisandischemic 40。Writing Committee Members, Gulati M, Cardiology/American Heart Association Joint heartdisease:anelusivelink。JAmCollCardiol。LevyPD,MukherjeeD,etal。 2021AHA/ACC/ASE/ CommitteeonClinicalPracticeGuidelines。JAm CHEST/SAEM/SCCT/SCMRguidelinefortheeval- 2012;60:951–956。CollCardiol。2022;79:e21–e129。uationanddiagnosisofchestpain:areportofthe 47。deCaterinaR,BodenWE。Thenomenclature American College of Cardiology/American Heart vagaries for the clinical manifestations of AssociationJointCommitteeonClinicalPractice myocardialischemicsyndromes—acalltoaction。KEYWORDS coronarymicrovascular Guidelines。JAmCollCardiol。2021;78:e187–285。IntJCardiol。2020;304:5–7。dysfunction,epicardialcoronaryartery 41。Bradley C, Berry C。Definition and epidemi- 48。Weintraub WS, Boden WE, Zhang Z, et al。disease,myocardialischemia,percutaneous ologyofcoronarymicrovascular disease。JNucl Cost-effectiveness of percutaneous coronary coronaryintervention,revascularization, Cardiol。2022;29:1763–1775。interventioninoptimallytreatedstablecoronary stableangina。",
      "source": "1-s2.0-S0735109722075362-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 343,
      "text": "JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 2021 THE AUTHORS。PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION。THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE (http://creativecommons。org/licenses/by-nc-nd/4。0/)。STATE-OF-THE-ART REVIEW Principles of Intravascular Lithotripsy for Calcific Plaque Modification DeanJ。Kereiakes,MD,aRenuVirmani,MD,bJasonY。Hokama,PHD,cUdayIllindala,PHD,c CarlosMena-Hurtado,MD,dAndrewHolden,MD,eJonathanM。Hill,MD,fSeanP。Lyden,MD,gZiadA。Ali,MD,DPHIL h ABSTRACT Asignificantproportionoflesionstreatedwithtranscatheterinterventionsinthecoronaryandperipheralvascularbeds exhibitmoderatetoseverecalcificplaquesknowntoportendlowerproceduralsuccessrates,increasedperi-procedural adverseevents,andunfavorableclinicaloutcomescomparedwithnoncalcificplaques。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 344,
      "text": "ipheralvascularbeds exhibitmoderatetoseverecalcificplaquesknowntoportendlowerproceduralsuccessrates,increasedperi-procedural adverseevents,andunfavorableclinicaloutcomescomparedwithnoncalcificplaques。 Adaptedfromlithotripsytech- nologyusedfortreatmentofureterorenalcalculi,intravascularlithotripsy(IVL)isanoveltechniqueforthetreatmentof severelycalcificplaquelesionsthatusesacousticshockwavesinaballoon-baseddeliverysystem。Shockwavesinduce calciumfractures,whichfacilitatestentexpansionandluminalgain。Inthisreview,theauthorssummarizethephysics, preclinicalandclinicaldataonIVLuseinthecoronaryandperipheralvasculature,andfuturedirectionsofIVLin transcathetercardiovasculartherapies。(J Am Coll Cardiol Intv 2021;14:1275–92)  2021 The Authors。Published by ElsevieronbehalfoftheAmericanCollegeofCardiologyFoundation。ThisisanopenaccessarticleundertheCCBY- NC-ND license (http://creativecommons。org/licenses/by-nc-nd/4。0/)。V ascularcalcificationreducesarterialcompli- lesion revascularization (10)。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 345,
      "text": "ardiologyFoundation。ThisisanopenaccessarticleundertheCCBY- NC-ND license (http://creativecommons。org/licenses/by-nc-nd/4。0/)。V ascularcalcificationreducesarterialcompli- lesion revascularization (10)。 Techniques for modi- ance and complicates both short- and fying coronary artery calcification, including non- long-termclinicaloutcomesfollowingrevas- compliant, cutting, and scoring balloons as well as cularization (1–3)。Coronary and peripheral artery atheroablative technologies (atherectomy), have calcification are reported in 18% to 31% and 30% to inherentlimitations。High-pressureballoondilatation 50% of percutaneous procedures, respectively (4–6)。with noncompliant or specialty balloons may have Commonriskfactorsforvascularcalcificationinclude insufficient force to fracture calcium and achieve advanced age, diabetes mellitus, and chronic kidney vesselexpansionandcanleadtobarotrauma-related disease(1,7,8)。dissection or perforation。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 346,
      "text": "oninclude insufficient force to fracture calcium and achieve advanced age, diabetes mellitus, and chronic kidney vesselexpansionandcanleadtobarotrauma-related disease(1,7,8)。dissection or perforation。 Laser atherectomy re- Coronary artery calcification negatively affects mains unpredictable, and rotational or orbital athe- outcomesofcoronaryinterventionsbyimpedingde- rectomy exhibits wire bias in its effect, which may vice crossing and stent apposition and expansion result in eccentric “rut or trough” formation with (4,5), causing delamination of drug-eluting polymer little impact on the circumference of calcium (11)。(6), and altering drug delivery and elution kinetics Peri-procedural complications, including slow flow, (9)。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 347,
      "text": "ng delamination of drug-eluting polymer little impact on the circumference of calcium (11)。(6), and altering drug delivery and elution kinetics Peri-procedural complications, including slow flow, (9)。 Stent underexpansion is associated with subse- myocardialinfarction,flow-limitingdissection,distal quent stent thrombosis and/or the need for target embolization, and perforation, are more frequent FromaTheChristHospitalandLindnerResearchCenter,Cincinnati,Ohio,USA;bCardiovascularPathologyInstitute,Gaithersburg, Maryland,USA;cShockwaveMedical,SantaClara,California,USA;dYale-NewHavenHospital,YaleUniversitySchoolofMedicine, NewHaven,Connecticut,USA;eAucklandCityHospital,Auckland,NewZealand;fRoyalBromptonHospital,London,United Kingdom;gClevelandClinic,Cleveland,Ohio,USA;andthehColumbiaUniversityMedicalCenter,NewYork,NewYork,USA。Theauthorsattesttheyareincompliancewithhumanstudiescommitteesandanimalwelfareregulationsoftheauthors’ institutionsandFoodandDrugAdministrationguidelines,includingpatientconsentwhereappropriate。Formoreinformation, visittheAuthorCenter。ManuscriptreceivedDecember3,2020;revisedmanuscriptreceivedFebruary23,2021,acceptedMarch16,2021。ISSN1936-8798 https://doi。org/10。1016/j。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 348,
      "text": "consentwhereappropriate。Formoreinformation, visittheAuthorCenter。ManuscriptreceivedDecember3,2020;revisedmanuscriptreceivedFebruary23,2021,acceptedMarch16,2021。ISSN1936-8798 https://doi。org/10。1016/j。 jcin。2021。03。036 1276 Kereiakesetal。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 PrinciplesofIntravascularLithotripsy JUNE 28, 2021:1275–92 ABBREVIATIONS with the adjunctive use of atheroablative HIGHLIGHTS AND ACRONYMS technologies compared with balloon alone (7,12,13)。(cid:4) IVL has emerged as a novel therapy for CT=computedtomography Similarly, peripheral artery calcification treatment of vascular calcification。EHL=electrohydraulic restricts vessel expansion, resulting in a lithotripsy (cid:4) IVL safely and effectively modifies calci- higher residual stenosis that reduces proce- ESWL=extracorporealshock- fied lesions via lithotripsy-driven duraleffectivenessandmayimpairtheanti- wavelithotripsy fracture。proliferative effect of drug-coated balloons ISWL=intracorporealshock- wavelithotripsy (14,15)。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 349,
      "text": "ock- fied lesions via lithotripsy-driven duraleffectivenessandmayimpairtheanti- wavelithotripsy fracture。proliferative effect of drug-coated balloons ISWL=intracorporealshock- wavelithotripsy (14,15)。 Endovascular treatment with percu- (cid:4) Understand longer-term outcomes IVL=intravascularlithotripsy taneoustransluminalangioplastyorstenting following IVL modification of vascular OCT=opticalcoherence is associated with increased rates of dissec- calcification。tomographic tion,perforation,anddistalembolizationand RVD=referencevessel reduced long-term patency (16–18) in the treatment, high-energy shockwaves are focused diameter presence of peripheral artery calcification。throughaprocessofparabolicreflection(focusing)to VF=ventricularfibrillation Although atherectomy has been shown to concentrate their fragmenting impact on the stone improve luminal diameter and reduce the need for withintherenalsystem。Energydischargedfromthe bailout stenting, vascular complications including spark gap results in the formation of a plasmavapor distal atheroembolization remain a significant chal- bubble,whichimmediately followstheinitial acous- lenge(19–21)。tic shockwave。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 350,
      "text": "ications including spark gap results in the formation of a plasmavapor distal atheroembolization remain a significant chal- bubble,whichimmediately followstheinitial acous- lenge(19–21)。tic shockwave。 The rapid expansion and collapse of Intravascular lithotripsy (IVL) has emerged as a thevaporbubble,alsoknownasacavitationbubble, noveltherapyforthetreatmentofvascularcalcifica- creates secondary shockwaves (34)。A standard EHL tion。IVL is based on the established therapeutic shockwave pressure pulse lasts about 5 to 10 ms and strategy of using acoustic pressure waves to treat consists of a near instantaneous peak positive renal calculi, with specific modifications in delivery component that generates compressive stress, fol- to address vascular calcium。These adaptations lowedbyalongerdurationnegativepressuretrough include the incorporation of lithotripsy emitters that generates tensile stress。The application of EHL (source of acoustic pressure waves) ontheshaft ofa in ESWL treatment is summarized in Supplemental balloon angioplasty catheter that deliver localized Figure1。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 351,
      "text": "es tensile stress。The application of EHL (source of acoustic pressure waves) ontheshaft ofa in ESWL treatment is summarized in Supplemental balloon angioplasty catheter that deliver localized Figure1。 pulsatileacousticpressurewavescircumferentiallyto Shockwaves travel through soft tissue with mini- modify vascular calcium (22,23)。The safety and mal effect because of similar acoustic impedance effectiveness of IVL have been reported across mul- characteristics of water and soft tissue (i。e。, water, tiple clinical studies involving severely calcified 1。5 (cid:1) 106 kg/[m2 $ s]; kidney, 1。6 (cid:1) 106 kg/[m2 $ s]; coronary and peripheral artery disease (24–30) muscle, 1。7 (cid:1) 106 kg/[m2 $ s])。Fracturing effects are (Supplemental Tables 1 and 2)。In this context, it is observed when shockwaves encounter tissue with appropriatetoreviewthefundamentalprinciplesand differingacousticimpedances,suchasthetransition proposed mechanism(s) of action of IVL on vascular from soft tissue to calcified tissue (acoustic imped- calcification on the basis of available in vitro and ance of bone, 7。8 (cid:1) 106 kg/[m2 $ s]) (23,35)。The invivodata。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 352,
      "text": " action of IVL on vascular from soft tissue to calcified tissue (acoustic imped- calcification on the basis of available in vitro and ance of bone, 7。8 (cid:1) 106 kg/[m2 $ s]) (23,35)。The invivodata。 mechanism by which shockwaves fracture kidney stones is attributed to stresses created by the peak USEOFELECTROHYDRAULICEXTRACORPOREAL positiveandnegativepressuresgeneratedduringthe ANDINTRACORPOREALLITHOTRIPSY procedure by multiple mechanisms, including compressive, spalling, superfocusing, shearing, and Since its introduction in the 1980s, extracorporeal squeezing stresses (Supplemental Figure 2) (23,36)。shockwavelithotripsy(ESWL)hasbeenusedasafirst Compressive stress is directly related to the positive line treatment for urolithiasis (22,31–33) and peakpressureamplitude。WithESWLtreatmentusing commonly uses electrohydraulic lithotripsy (EHL) to EHL technology, positive peak pressures range from generate high-energy acoustic shockwaves for stone 30to110MPa(w300to1,100atm)。Spallstress,which fragmentation (i。e。, stone comminution)。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 353,
      "text": "psy (EHL) to EHL technology, positive peak pressures range from generate high-energy acoustic shockwaves for stone 30to110MPa(w300to1,100atm)。Spallstress,which fragmentation (i。e。, stone comminution)。 In EHL, a is tensile stress imparting a “pulling” force on the sparkgapdischargebetweentwoelectrodesresultsin targetedstone,isdirectlyrelatedtothenegativepeak theformationofanacousticpressurewavewithinthe pressure amplitude。During ESWL treatment, nega- transmitting fluid medium that expands spherically tivepeakpressuresrangefrom(cid:3)8to(cid:3)15MPa(w80to outwards from the emitter。Because the spark gap 150 atm) (23,37,38)。Cavitation bubble formation and discharge is initiated outside the body during ESWL collapse on the surface of kidney stones also JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 Kereiakesetal。1277 JUNE 28, 2021:1275–92 PrinciplesofIntravascularLithotripsy FIGURE1 IVLShockwaveGeneration (A)Theintravascularlithotripsy(IVL)ballooncatheterispositionedacrossthetargetlesionandinflatedto4atm。(B)Emittersparkgap dischargeproducescompressiveshockwavesthatemanatesphericallyoutward;vaporbubbleformationiscontainedwiththeintegrated balloon。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 354,
      "text": "heterispositionedacrossthetargetlesionandinflatedto4atm。(B)Emittersparkgap dischargeproducescompressiveshockwavesthatemanatesphericallyoutward;vaporbubbleformationiscontainedwiththeintegrated balloon。 (C)IVLshockwavesaffectsuperficialanddeepcalcium。(D)AfterIVLtherapyisdelivered,theballoonisinflatedto6atmpriorto deflation。(E)SuperimposedIVL(blue)andextracorporealshockwavelithotripsy(red)waveforms。Notethecontrastinpositiveandnegative peakpressuresbetweenthetwoelectrohydrauliclithotripsytechnologies。RepresentativeIVLwaveformdemonstratingpositivepeak pressureofabout5MPawithminimalnegativepeakpressuregeneration(inset)。contributes to fragmentation。Cavitation is induced catheter, which is passed through an endoscope bythetrailingpeaknegativepressurewavegenerated inserted into the urethra and positioned in close during ESWL treatment and results in microjet for- proximitytothestone,therebydecreasingtheenergy mation(high-velocityfluidspikes)thatcontributeto required for stone fragmentation and allowing stone fragmentation through shearing as well。unfocused delivery of shockwave pressure pulses。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 355,
      "text": "ngtheenergy mation(high-velocityfluidspikes)thatcontributeto required for stone fragmentation and allowing stone fragmentation through shearing as well。unfocused delivery of shockwave pressure pulses。 Microjets and heat generation created through cavi- SmallerISWLprobeshaveallowedimprovedaccessto tation may be associated with soft tissue damage, anatomically challenging stone locations。The effect including abdominal wall dissection, perforation of of ISWL acoustic shockwaves remain consistent: thecolon,hepatichematoma,andmajordisruptionof stone fracture with safe propagation through soft renalvasculature(23,39,40)。tissue。However, the margin of safety for ISWL is EHL technology has also been adapted for endo- narrow because of direct exposure of the activated scopic treatment of bladder, ureteral, and kidney emitter and cavitation bubbles to the surrounding stones in situations in which ESWL is less effective tissue, which may increase the risk for tissue injury (i。e。, patients with morbid obesity, lower pole stone with consequent perforation, hemorrhage, and location)。During intracorporeal shockwave litho- mucosal denudation (39,41,42)。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 356,
      "text": "isk for tissue injury (i。e。, patients with morbid obesity, lower pole stone with consequent perforation, hemorrhage, and location)。During intracorporeal shockwave litho- mucosal denudation (39,41,42)。 Although risks for tripsy (ISWL), the emitter is located at the tip of a thermal injury or tissue damage from cavitation are 1278 Kereiakesetal。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 PrinciplesofIntravascularLithotripsy JUNE 28, 2021:1275–92 peaknegativepressurepulses,whichallowsufficient TABLE1 ElectrohydraulicLithotripsyCharacteristicsinESWL,ISWL,andIVL compressive force to modify vascular calcium while ESWL ISWL IVL mitigating soft tissue injury due to excessive cavita- Emitterlocation Extracorporeal Intracorporeal Intravascular tion or tensile stress; 2) pressure wave emitters are Focusedorunfocused Focused Unfocused Unfocused enclosed within an inflated, fluid-filled balloon to lithotripsy mitigate thermalinjury; and3) multiple emitters are Peakpositiveacoustic 30–110 3–6 w5 arranged in series along the shaft of the catheter for pressure(MPa)* Peaknegativeacoustic (cid:3)8to(cid:3)15 (cid:3)1to(cid:3)4 (cid:3)0。3 longitudinaltreatmentofthecalcifiedvessel。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 357,
      "text": "ic 30–110 3–6 w5 arranged in series along the shaft of the catheter for pressure(MPa)* Peaknegativeacoustic (cid:3)8to(cid:3)15 (cid:3)1to(cid:3)4 (cid:3)0。3 longitudinaltreatmentofthecalcifiedvessel。 pressure(MPa)* IVL ACOUSTIC PRESSURE WAVEFORM MODIFICATION。Energyfluxdensity 0。1to3。0 — w0。0086 (mJ/mm2) IVLemittersproduceelectricsparksthatcreatevapor Penetrationdepthof w150 w10 3–7 bubbles in the surrounding fluid medium within the acousticpressure integratedballoon。IVLproduceslowlevelsofelectric wave(mm) energy, which leads to the formation and rapid Primarymechanismsof Compressionandtensilestress, Compressionand Compression calciumfracture cavitation,spall,squeezing, tensilestress, stress expansionofvaporbubbles,whichresultinacoustic superfocusing cavitation pressure waves that radiate circumferentially and transmurally in an unfocused manner (Figure 1A, *1MPa9。8atm。ESWL  extracorporeal shockwave lithotripsy; ISWL  intracorporeal shockwave lithotripsy; Video1)。Bymodifyingthepulsewidthappliedtothe IVLintravascularlithotripsy。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 358,
      "text": "focused manner (Figure 1A, *1MPa9。8atm。ESWL  extracorporeal shockwave lithotripsy; ISWL  intracorporeal shockwave lithotripsy; Video1)。Bymodifyingthepulsewidthappliedtothe IVLintravascularlithotripsy。 emitters, the IVL acoustic pressure wave achieves a relatively low positive peak pressure of approxi- mately 5 MPa (w50 atm) with a negligible peak mitigated by features that shield healthy soft tissue negative pressure (about (cid:3)0。3 MPa or (cid:3)3 atm) from direct contact with the vapor bubble and cavi- compared with ESWL (Figure 1B)。Similar to ESWL, tation, carefulattention to probe placement remains IVL shockwaves propagate through soft tissue with criticalforpreventingtissueinjurywithISWL(42)。minimal effect。The leading edge of the shockwave imparts compressive stress once calcium is encoun- PRINCIPLES OF SHOCKWAVE IVL teredandisthe primarymechanism of calcium frac- turewithIVL。UnlikeESWL,IVLshockwavesproduce IVL SYSTEM AND PROCEDURE。The Shockwave IVL negligiblepeaknegativepressures,andtheresulting catheter(ShockwaveMedical,SantaClara,California) tensile stress (about (cid:3)0。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 359,
      "text": "ikeESWL,IVLshockwavesproduce IVL SYSTEM AND PROCEDURE。The Shockwave IVL negligiblepeaknegativepressures,andtheresulting catheter(ShockwaveMedical,SantaClara,California) tensile stress (about (cid:3)0。 3 MPa or (cid:3)3 atm) remains is a single-use, sterile, disposable catheter that con- well below the threshold associated with tissue tains multiple spark gap–based lithotripsy emitters damage (44), thus mitigating cavitation-induced tis- along the shaft of an integrated balloon sueinjury。The unfocusednatureofIVLshockwaves (Supplemental Figure 3)。The IVL catheter is intro- results in several orders of magnitude lower energy ducedintothetargetvesselovera0。014-inchguide- flux density (the amount of acoustic energy per unit wire and is positioned across the target lesion using area) compared with ESWL。As the goal is calcium balloonmarkerbandsasvisualguides。Thecatheteris fracture(asopposedtopulverizationwithESWL),and connected using a connector cable to the generator IVLshockwavesareinitiatedincloseproximitytothe that is programmed to deliver a pre-defined number targetvascularcalcium,muchlessenergyisrequired ofpulses(accordingtoIVLcathetertype)atarateof1 forIVL(comparedwithESWL)。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 360,
      "text": "nitiatedincloseproximitytothe that is programmed to deliver a pre-defined number targetvascularcalcium,muchlessenergyisrequired ofpulses(accordingtoIVLcathetertype)atarateof1 forIVL(comparedwithESWL)。 Thus,IVLenergyflux pulse/s。The integrated balloon, filled with a 50:50 density is adequate for vascular calcium fracture saline/contrast mixture (ions are required for spark while limiting the potential for soft tissue injury generation), is inflated to subnominal pressure (4 associatedwithhigherenergylevels。EHLdevicepa- atm) to provide apposition with the vessel wall, rametersaresummarizedinTable1。whichcreatesaneffective fluid-tissue interface with INTEGRATED IVL BALLOON。Integration of a semi- similar acoustic impedances to facilitate efficient compliant balloon with emitters on the shaft offers transmissionofshockwaveenergytovasculartissue。several advantages during IVL treatment。First, the ADAPTATIONOFEHLTECHNOLOGYFORINTRAVASCULAR balloon provides a mixture of contrast and saline to USE。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 361,
      "text": "ers transmissionofshockwaveenergytovasculartissue。several advantages during IVL treatment。First, the ADAPTATIONOFEHLTECHNOLOGYFORINTRAVASCULAR balloon provides a mixture of contrast and saline to USE。 Although EHL spark gap technology was lever- dissipate heat generatedduring the formationof va- agedforuseinIVL(43),theuniquechallengesposed por bubbles (SupplementalFigure 4) andshields the byvascularcalciumnecessitatedadaptationsforsafe emittersfromdirectcontactwiththevesselwall。In- and effective intravascular treatment。Three key tegrated periodic deflation of the balloon between modificationswereincorporatedforIVL:1)IVLpres- pulsedeliverycyclesalsoservestodissipateheatand sure waves deliver tissue-safe positive and minimal removeresidualgasbubblesthroughfluidevacuation JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 Kereiakesetal。1279 JUNE 28, 2021:1275–92 PrinciplesofIntravascularLithotripsy while allowing tissue reperfusion to mitigate TABLE2 IntravascularLithotripsyCatheterSpecifications ischemia。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 362,
      "text": " NO。12, 2021 Kereiakesetal。1279 JUNE 28, 2021:1275–92 PrinciplesofIntravascularLithotripsy while allowing tissue reperfusion to mitigate TABLE2 IntravascularLithotripsyCatheterSpecifications ischemia。 Second, the integrated balloon provides mechanical support and stabilization that serves to ShockwaveM5 ShockwaveS4 ShockwaveC2 minimize any tissue deformation during IVL treat- Use Peripheral Peripheral Coronary ment。Third, the integrated balloon is thin and Diameter(mm) 3。5–7。0 2。5–4。0 2。5–4。0 acoustically transparent to provide efficient fluid-to- Sheathcompatibility 6F(3。5–6。0mm),7F 5F 6F* (6。5–7。0mm) tissue transmission and effective coupling of IVL Guidewirecompatibility 0。014inch 0。014inch 0。014inch pressure pulse propagation from emitter to vascular Length(mm) 60 40 12 wall。The importance of such coupling was demon- Workinglength(cm) 110 135 138 stratedinaseriesofexperimentsinwhichUltracal30 Crossingprofile(inches) 0。054–0。073 0。048–0。050 0。044–0。047 gypsum rings were subjected to IVL shockwaves un- Pulsefrequency(pulses/s) 1 1 1 der varying balloon-wall apposition conditions。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 363,
      "text": "hUltracal30 Crossingprofile(inches) 0。054–0。073 0。048–0。050 0。044–0。047 gypsum rings were subjected to IVL shockwaves un- Pulsefrequency(pulses/s) 1 1 1 der varying balloon-wall apposition conditions。 Maximumnumberofpulsesper 300 160 80 Ultracal 30 gypsum does not account for micromor- catheter phological conditions encountered in vivo (i。e。, Numberofchannels 3 2 1 lipid and fibrous tissue) but does mimic the acoustic properties of calcium encountered in vivo *Guidecatheter。and provides a reproducible model of calcium fracture in lithotripsy research (45,46)。Greater ring fracturing was observed when the IVL balloon was distributionprofileforeachIVLcathetermodelhelps appropriatelysizedtoensureballoon-wallapposition theoperatoralignthegreatestacousticpressurewith (Supplemental Figure 5)。Adequate balloon–vessel theareaofmaximumcalciumburden。wall apposition is achieved at the subnominal pres- IVL CATHETER SIZING AND EMITTER ALIGNMENT。sureof4atm,thusminimizingbarotraumanormally The importance of IVL balloon sizing and emitter associated with high-pressure balloon angio- alignmentwasobservedinaposthocanalysisofthe plasty(47–49)。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 364,
      "text": "ENT。sureof4atm,thusminimizingbarotraumanormally The importance of IVL balloon sizing and emitter associated with high-pressure balloon angio- alignmentwasobservedinaposthocanalysisofthe plasty(47–49)。 DisruptPADII(ShockwaveLithoplastyDISRUPTTrial EMITTER ALIGNMENT AND ENERGY DISTRIBUTION。forPAD)study,highlightingtheimpactofoptimalIVL IVL uses multiple emitters outside the guidewire techniqueon12-monthprimarypatencywhenusedas lumen, arranged in series along the length of the stand-alonetherapyinsuperficialfemoralandpopli- balloon segment。IVL emitters are positioned as dia- tealarterialsegments(29)。Theoptimaltechniquewas metricallyopposingpairs(180(cid:5) fromeachother)and emit spherical energy profiles that are nearly sym- metricalmirrorimagesalongtheballoonedge。These FIGURE2 AcousticPeakPressureAlignsWithEmitterLocation emittersarearrangedintochannels,witheachchan- nel pulsing at 1 Hz。Three IVL catheter models are currently available, allowing variation in vessel diameterandlengthoftreatablesegmentsassociated withcoronaryandperipheralvessels(Table2)。Signaturepatternsofpeakacousticpressuresalong thelengthoftheIVLcatheteralignwiththelocation of the emitters。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 365,
      "text": "sel diameterandlengthoftreatablesegmentsassociated withcoronaryandperipheralvessels(Table2)。Signaturepatternsofpeakacousticpressuresalong thelengthoftheIVLcatheteralignwiththelocation of the emitters。 The distribution of acoustic energy for each catheter type is shown in Figure 2。When channelsareactivated,theIVLpairedemitterscreate acoustic pressure waves that radiate in a circumfer- ential and transmural fashion to disrupt vascular calcium。As IVL delivers unfocused lithotripsy, the effective radiating pressure effect decreases with distance from the emitter。For the Shockwave M5 catheter, note that the center channel has a single emitter; consequently, the activation energy for the center channel is not shared across 2 emitters, Shadedareasrepresentacousticpressureprofilesforthe(A)ShockwaveM5,(B) resulting in a greater peak acoustic pressure relative ShockwaveS4,and(C)ShockwaveC2intravascularlithotripsycatheters。Notethatpeak to the proximal and distal channels where energy is acousticpressuresarealignedwithemitterlocation(*)。sharedacrosstwoemitters。Understandingtheenergy 1280 Kereiakesetal。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 366,
      "text": "l and distal channels where energy is acousticpressuresarealignedwithemitterlocation(*)。sharedacrosstwoemitters。Understandingtheenergy 1280 Kereiakesetal。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。 12, 2021 PrinciplesofIntravascularLithotripsy JUNE 28, 2021:1275–92 FIGURE3 RepresentativeMicro–ComputedTomographicImagesBeforeandAfterIVLTreatment Abluminalviewoftheleftdistalfemoralarterydemonstratingpredominantlymedialcalcification。(A)Beforeintravascularlithotripsy(IVL) treatmentand(B)afterIVLtreatment。Circumferential,transverse,andlongitudinalcalciumfractureswereobservedfollowingIVLtreatment (arrows)。defined as correct balloon sizing and avoidance of COMPARISON OF IVL SHOCKWAVE AND ULTRASOUND therapeutic miss (Supplemental Figures 6A to 6C)。PROPERTIES。In contrast to IVL shockwaves, diag- Balloon sizing was calculated as the ratio of the IVL nostic(i。e。,imaging)andtherapeutic(i。e。,deeptissue balloon to reference vessel diameter (RVD), with a heating or tissue ablation) ultrasound waves propa- ratio$1definedasappropriateballoonsizing。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 367,
      "text": " IVL nostic(i。e。,imaging)andtherapeutic(i。e。,deeptissue balloon to reference vessel diameter (RVD), with a heating or tissue ablation) ultrasound waves propa- ratio$1definedasappropriateballoonsizing。 Thera- gatethroughtissuewithhighfrequency(1to12MHz) peuticmisswasdefinedasfailuretoprovidefulllith- and with equal positive and negative pressure am- otripsy treatment at an overlap segment or at the plitudes (Supplemental Table 3)。Ultrasound waves proximalordistallesionlocation。UseofoptimalIVL are absorbed or reflected by tissues of differing technique was associated with significant improve- acoustic impedance。Energy from absorbed ultra- mentin12-monthprimarypatencyandareductionin sound waves results in heat generation, with higher clinically driven target lesion revascularization energy ultrasound leading to tissue ablation (50,51)。(SupplementalFigure6D)。Importantly,noincreasein Ultrasoundisalsoassociatedwithcavitationbubble– adverse events was observed when IVL balloon size inducedinjuryresultingfromtheoscillatingnegative exceeded RVD。On the basis of these findings, the pressure cycle inherent to ultrasound waveforms ShockwaveM5andS4IVLinstructionsforuserecom- (50,51)。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 368,
      "text": "e inducedinjuryresultingfromtheoscillatingnegative exceeded RVD。On the basis of these findings, the pressure cycle inherent to ultrasound waveforms ShockwaveM5andS4IVLinstructionsforuserecom- (50,51)。 As IVL shockwaves have neither similar fre- mend IVL catheter sizing of 1。1:1 with target vessel quencies nor sinusoidal oscillations compared with RVD, in addition to sufficient balloon overlap when ultrasound, the potential for thermal injury is less。treating long lesions to ensure optimal results。The Thus, both negligible negative pressures and fluid- instructionsforusefortheShockwaveC2IVLcatheter filled balloon integration combine to reduce the risk (currentlyapprovedforuseoutsidetheUnitedStates) for cavitation bubble–induced injury during IVL recommend IVL balloon sizing of 1:1 with target treatment。Waveform characteristics for IVL and ul- vesselRVD。trasoundareshowninSupplementalTable3。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 Kereiakesetal。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 369,
      "text": "alloon sizing of 1:1 with target treatment。Waveform characteristics for IVL and ul- vesselRVD。trasoundareshowninSupplementalTable3。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 Kereiakesetal。 1281 JUNE 28, 2021:1275–92 PrinciplesofIntravascularLithotripsy FIGURE4 HistologicalandMicro–ComputedTomographicImagingAfterIntravascularLithotripsyTreatment Cross-sectionalhistologicalExaktgroundsection(A)matchedwiththemicro–computedtomographiccross-sectionalimage(C)。Bothsections showcross-shapedcrackshighlightedbyredboxedareas,whichareshownathigh-powermagnification(B,D)。IVL CALCIUM MODIFICATION IMPROVES sizeanddeploymentwerebasedonmeasurementsof VASCULAR COMPLIANCE the vessel cross-sectional area using baseline micro- CT。At the time these experiments were performed MICRO–COMPUTEDTOMOGRAPHICANDHISTOPATHOLOGIC (2018), the 60-mm IVL catheter’s maximum output VISUALIZATION OF IVL-MEDIATED CALCIUM FRACTURE。was 180 pulses。Therefore, IVL treatment using 180 An independent cadaveric study using micro– pulses was delivered at 4-atm balloon pressure in computed tomography (CT) and histopathology was eacharteryperthedeviceinstructionsforuse。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 370,
      "text": "atment using 180 An independent cadaveric study using micro– pulses was delivered at 4-atm balloon pressure in computed tomography (CT) and histopathology was eacharteryperthedeviceinstructionsforuse。 Pulses performed on heavily calcified, excised human su- were delivered at 1 pulse per second, with30pulses perficial femoral arteries to evaluate the mecha- percyclefollowedbyballoondeflationfor10seconds nism(s) by which IVL affects superficial and deep between cycles。Six cycles were delivered for a total calcium (CVPath Institute, Gaithersburg, Maryland)。of 180 pulses。Micro-CT was performed before and The test model consisted of fresh-frozen human afterIVLtreatment。Longitudinalandcross-sectional cadavericfemoralarteries(n6)withdemonstrated images were generated to evaluate the effect of IVL presenceofintimalandmedialcalcium。Incontrastto on calcium。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 371,
      "text": "rIVLtreatment。Longitudinalandcross-sectional cadavericfemoralarteries(n6)withdemonstrated images were generated to evaluate the effect of IVL presenceofintimalandmedialcalcium。Incontrastto on calcium。 For histopathology, nondecalcified ar- formalin-preserved cadaveric arteries, fresh-frozen teries were embedded in Spurr’s resin, sawed, and cadaveric arteries retain much of the tissue proper- ground using the Exakt method to create sections ties necessary for clinically relevant vascular in- varying in thickness from 50 to 90 mm and stained terventions。Arteries were cannulated and placed in withhematoxylinandeosin。thelumenofaclosedchamberwithatubularelastic Micro-CT demonstrated circumferential, trans- balloon cuff to simulate perivascular pressure。The verse, and longitudinal calcium fractures with Shockwave IVL 60-mm catheter was used with involvementofbothsuperficialanddeeplayersofthe balloonsizesrangingfrom5。5to7。0mm。Theballoon vessels following IVL treatment (Figure 3)。1282 Kereiakesetal。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 372,
      "text": "involvementofbothsuperficialanddeeplayersofthe balloonsizesrangingfrom5。5to7。0mm。Theballoon vessels following IVL treatment (Figure 3)。1282 Kereiakesetal。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。 12, 2021 PrinciplesofIntravascularLithotripsy JUNE 28, 2021:1275–92 FIGURE5 HistologicalExaminationofaHumanCadavericSuperficialFemoralArteryFollowingIntravascularLithotripsyTreatment Hematoxylinandeosin–stainedsectionsdemonstrate(A)multiplefracturesofsuperficialanddeepcalcification。(B)BlueboxedareainAis shownathighermagnification。(C)Furthermagnificationdemonstratesmicrofractures(arrow)notreadilyvisibleatlowermagnification。(D) HistologicalExaktsectiondemonstratesanareaoffractureatthetipoftheintimalcalciumextendingintotheadventitia。(E)Redboxedarea inDisshownathighermagnification,demonstratingfracture(arrow)。Coregistration of micro-CT and histopathology iden- findings from cadaveric studies。Consistent obser- tified multiple full-thickness and deep calcium frac- vations across these OCT substudies included the tures that did not traverse to the luminal surface。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 373,
      "text": "ings from cadaveric studies。Consistent obser- tified multiple full-thickness and deep calcium frac- vations across these OCT substudies included the tures that did not traverse to the luminal surface。 following: 1) the mechanism of luminal gain Magnified histopathologic images revealed micro- following IVL treatment is calcium fracture, without fracturesinvolvingboththesuperficial(Figure4)and the need for high-pressure balloon dilatation; 2) IVL deeplayers(Figure5)ofaheavilycalcifiedlesion。results in circumferential and longitudinal calcium fracture; and 3) IVL treatment improves vessel OPTICAL COHERENCE TOMOGRAPHIC VISUALIZATION compliance and facilitates stent expansion in calci- OF IVL-INDUCED CALCIUM FRACTURE。The Disrupt fied coronary arteries。In this clinical setting, an in- CAD I (Shockwave Coronary Rx Lithoplasty(cid:2)Study), crease in arterial luminal area is evident following Disrupt CAD II (Shockwave Coronary Lithoplasty(cid:2) IVL, when the balloon is inflated to the same pres- Study),andDisruptCADIII(DisruptCADIIIWiththe sure。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 374,
      "text": " arterial luminal area is evident following Disrupt CAD II (Shockwave Coronary Lithoplasty(cid:2) IVL, when the balloon is inflated to the same pres- Study),andDisruptCADIII(DisruptCADIIIWiththe sure。 Although differentiation between intimal and Shockwave Coronary IVL System) optical coherence medial calcification can be observed in peripheral tomographic(OCT)substudies(25,30,52)andDisrupt vessels, the medial layer becomes attenuated in PAD II OCT subanalyses (53) demonstrated calcium advanced coronary artery disease (54), and the fracture following IVL treatment similar to the distinction between intima and media on OCT im- micro–computed tomographic and histopathologic aging is challenging。Medial calcification, which is JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 Kereiakesetal。1283 JUNE 28, 2021:1275–92 PrinciplesofIntravascularLithotripsy FIGURE6 OCTImaginginPeripheralandCoronaryArteriesAfterIVLTreatment (A)Cross-sectionalopticalcoherencetomographic(OCT)imageacquiredbeforeintravascularlithotripsy(IVL)demonstrates274(cid:5)calciumarc andluminalareaof9。8mm2inthedistalsuperficialfemoralartery。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 375,
      "text": "LTreatment (A)Cross-sectionalopticalcoherencetomographic(OCT)imageacquiredbeforeintravascularlithotripsy(IVL)demonstrates274(cid:5)calciumarc andluminalareaof9。8mm2inthedistalsuperficialfemoralartery。 (B)Post-IVLOCTimagedemonstratescalciumfractures(arrows)and largeluminalareagainto12。6mm2。(C)Cross-sectionalimageacquiredbeforeIVLdemonstrates360(cid:5)calciumarcandluminalareaof3。2mm2 inthemid-rightcoronaryartery。(D)Post-IVLOCTimagedemonstratescalciumfractures(arrows)andlargeluminalareagainto6。9mm2。commoninperipheralarterydisease,isnotobserved Performance Study of the Shockwave Lithoplasty in coronary arteries。Therefore, the designations System), Disrupt PAD II, Disrupt PAD III (Shockwave “superficial” and “deep” as they relate to calcium Medical Peripheral Lithoplasty System Study for location may be more appropriately applied to cor- PAD), Disrupt BTK (Safety and Feasibility of the onary calcification。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 376,
      "text": "deep” as they relate to calcium Medical Peripheral Lithoplasty System Study for location may be more appropriately applied to cor- PAD), Disrupt BTK (Safety and Feasibility of the onary calcification。 Regardless of anatomic differ- Shockwave Lithoplasty(cid:2) System for the Treatment ences,thesafetyandeffectivenessofIVLincalcified of Peripheral Vascular Stenosis), and Disrupt CFA peripheral and coronary vessels have been consis- peripheralarterystudiesdemonstratednodifference tently demonstrated across peripheral and coronary in final diameter stenosis between eccentric and vascular beds (25,30,55,56)。Data are limited concentric lesions。Similarly, in coronary arteries, regarding the effect of IVL treatment on eccentric patient-level pooled angiographic data from Disrupt and nodular calcium。Likewise, OCT imaging of IVL CAD I and Disrupt CAD II (57) demonstrated similar treatment in peripheral arteries is limited, as intra- angiographic outcomes and complications between vascular ultrasound is more commonly used in pa- eccentric and concentric lesions。Furthermore, a tients with peripheral artery disease。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 377,
      "text": "mited, as intra- angiographic outcomes and complications between vascular ultrasound is more commonly used in pa- eccentric and concentric lesions。Furthermore, a tients with peripheral artery disease。 However, tertile analysis stratified by calcium burden in the angiographic data from a 336 patient-level pooled Disrupt CAD I OCT substudy demonstrated similar analysis from the Disrupt PAD I (Safety and stent expansion (>100%) at the site of maximum 1284 Kereiakesetal。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 PrinciplesofIntravascularLithotripsy JUNE 28, 2021:1275–92 FIGURE7 OCTImagingDemonstratesLongitudinalandDeepCalciumFracturesAfterCoronaryIVLTreatment (A)Longitudinalimageacquiredpost-stentingdemonstrateslongitudinalfracturedisplacement(arrows)。(B)Post-IVLOCTimagedemon- stratesdeepcalciumfracture(1。09mm)uptotheadventitia。(C)Post-stentimagingdemonstrateswideningofthedeepfracture(1。10mm)。AbbreviationsasinFigures1and6。calcium thickness, regardless of calcium angle (52)。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 378,
      "text": "stratesdeepcalciumfracture(1。09mm)uptotheadventitia。(C)Post-stentimagingdemonstrateswideningofthedeepfracture(1。10mm)。AbbreviationsasinFigures1and6。calcium thickness, regardless of calcium angle (52)。 been observed following IVL treatment (Figure 7), Finally, a more robust analysis is forthcoming using which underscore the ability of IVL to modify deep patient-level pooled data from the Disrupt CAD I, vascular calcium, no vessel perforations were Disrupt CAD II, Disrupt CAD III, and Disrupt CAD IV observedfollowingIVLtreatmentaloneintheDisrupt (Disrupt CAD IV With the Shockwave Coronary IVL CAD and Disrupt PAD studies (28–30,52,58)。The risk System) OCT substudies (n  250) to examine the forvesselperforationislikelymitigatedbytheability effect of IVL treatment in eccentric and nodular of IVL acoustic shockwaves to traverse soft tissue calcium。Representative OCT images following IVL with minimal effect and by the presence of adventi- treatment in peripheral and coronary vessels are tial fibrosis, which has been demonstrated in shown in Figure 6。advanced coronary and peripheral artery disease A consistent increase in vessel minimal luminal (59–62)。Calcium fracture was observed in 67。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 379,
      "text": " fibrosis, which has been demonstrated in shown in Figure 6。advanced coronary and peripheral artery disease A consistent increase in vessel minimal luminal (59–62)。Calcium fracture was observed in 67。 7% of area was observed after low-pressure IVL balloon lesionsafterIVLinDisruptCADIII。Interestingly,no treatment in both peripheral and coronary vessels, differences were observed in minimal stent area, suggesting improved vessel compliance following minimalluminalarea,andstentexpansionatthesite IVL-mediated calcium modification (30,52,53)。Both of maximum calcification when comparing target le- circumferentialandlongitudinalcalciumfracturesin sions withorwithout demonstrablecalciumfracture multiple planes were observed on OCT imaging by OCT imaging (30)。The apparent dissociation be- following IVL treatment (Figures 6 and 7), and frac- tweenthepresenceofcalciumfracturedemonstrated ture width increased following stent expansion (30)。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 380,
      "text": "y OCT imaging (30)。The apparent dissociation be- following IVL treatment (Figures 6 and 7), and frac- tweenthepresenceofcalciumfracturedemonstrated ture width increased following stent expansion (30)。 by OCT imaging and optimized indexes of stent im- These observations suggest that calcium fracture is plantation might be ascribed to fractures that were the likely mechanism by which IVL enhances vessel “out of plane” and not visualized or microfractures compliance and facilitates optimal stent expansion。beyond the resolution of current OCT technology Althoughdeepcalciumfractures(toadventitia)have (63,64)。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 Kereiakesetal。1285 JUNE 28, 2021:1275–92 PrinciplesofIntravascularLithotripsy CENTRAL ILLUSTRATION IntravascularLithotripsy Kereiakes,D。J。etal。JAmCollCardiolIntv。2021;14(12):1275–92。Intravascularlithotripsy(IVL)whichusesacousticpressurewavestofracturevascularcalciumhasemergedasanoveltreatmentforpatientswithheavily calcifiedperipheralandcoronaryvessels。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 381,
      "text": "iolIntv。2021;14(12):1275–92。Intravascularlithotripsy(IVL)whichusesacousticpressurewavestofracturevascularcalciumhasemergedasanoveltreatmentforpatientswithheavily calcifiedperipheralandcoronaryvessels。 Multipleopticalcoherencetomographic(OCT)imagingsub-studieshavedemonstratedcircumferentialand longitudinalIVL-inducedcalciumfractures(denotedbyarrowsinrepresentativeOCTimages),whichfacilitatestentexpansioninseverelycalcifiedcor- onaryvessels。IVLdeviceease-of-usewasdemonstratedinDisruptCADIII,assafetyandeffectivenessoutcomesweresimilarbetweentheinitialIVL procedure(roll-in)ateachparticipatingsiteandsubsequentIVLprocedures(pivotal)。WhileIVL-inducedventricularcapturehasbeenobserved (denotedbygreendotsinECGtracing),primarilyinbradycardicpatients,thesetemporaleventsareusuallybenignwithoutadversesequelae。Clinicaland angiographiccomplicationsremainlowfollowingIVLtreatmentofbothperipheralandcoronarycalcifiedarteries。*Allangiographicoutcomeswere adjudicatedbyanindependentangiographiccorelaboratory。**Pooledpatient-levelanalysis。OCTopticalcoherencetomography。1286 Kereiakesetal。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 382,
      "text": "iographicoutcomeswere adjudicatedbyanindependentangiographiccorelaboratory。**Pooledpatient-levelanalysis。OCTopticalcoherencetomography。1286 Kereiakesetal。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。 12, 2021 PrinciplesofIntravascularLithotripsy JUNE 28, 2021:1275–92 FIGURE8 SafetyandEffectivenessAcrosstheDisruptCADStudies Freedomfrom30-daymajoradversecardiovascularevents(MACE)isdefinedasfreedomfromthecompositeoccurrenceofcardiacdeath, myocardialinfarction,ortargetvesselrevascularizationat30days。Proceduralsuccessisdefinedassuccessfulstentdeliverywitharesidual stenosis<50%bycorelaboratoryassessment。CADIShockwaveCoronaryRxLithoplastyStudy;CADIIShockwaveCoronaryLithoplasty Study;CADIIIDisruptCADIIIWiththeShockwaveCoronaryIVLSystem;CADIVDisruptCADIVWiththeShockwaveCoronaryIVLSystem。EFFECT OF IVL ON SOFT TISSUE LOW VASCULAR COMPLICATION RATES WITH IVL。IVL therapy is balloon based, and therefore the risk HISTOPATHOLOGIC ANALYSIS。A histopathologic for atheromatous embolization may be lower than analysis examining the effect of IVL therapy (180 observedfollowingdebulkingatheroablativedevices。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 383,
      "text": "e the risk HISTOPATHOLOGIC ANALYSIS。A histopathologic for atheromatous embolization may be lower than analysis examining the effect of IVL therapy (180 observedfollowingdebulkingatheroablativedevices。 pulses over 6cycles)delivery at 4-atm ballooninfla- Atherectomydevicesoftengeneratemicroparticulate tionpressureonvascularinjuryandinflammationin debris that may embolize, causing distal microcircu- porcine iliac and femoral arteries compared with latory occlusion with resultant slow or no reflow, treatment with balloon angioplasty alone was per- tissue ischemia, and/or infarction。Fractured, larger formed by an independent laboratory。Twenty-eight calciumfragmentsgeneratedbyIVLappeartoremain days after treatment, histomorphometric analysis in situ。Indeed, an interim analysis of the “real- was performed on arterial sections for the following world” Disrupt PAD III observational study reported parameters: tissue injury,inflammation,fibrin depo- no distal embolization, no-reflow, or abrupt closure sition, endothelialization, and neointimal smooth events(66)eitherwithorwithouttheuseofembolic muscle content。Each parameter was graded on a filters。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 384,
      "text": " distal embolization, no-reflow, or abrupt closure sition, endothelialization, and neointimal smooth events(66)eitherwithorwithouttheuseofembolic muscle content。Each parameter was graded on a filters。 Similarly, a pooled patient-level analysis scale of 0 to 3 according to previously published (n 336 patients) of peripheral IVL studies reported methodology (65)。No differences were observed be- verylowratesofperforation,distalembolization,no tweenthe2treatmentgroupsforanyofthemeasured reflow,orabruptclosure(55)。Furthermore,complex parameters, which supports the premise that IVL or flow-limiting dissections (types D to F) were rare, treatment has little effect on soft tissue likelyreflectingthelackofbarotraumafollowingthe (SupplementalFigure 7)。Furthermore,noabnormal- low-pressure balloon inflations used during stand- itieswerefoundinsurroundingmuscletissue,which aloneIVL。suggeststhattheimpactofIVLtreatmentislimitedto Similarly, the Disrupt CAD I and Disrupt CAD II thevesselwall。trials demonstrated very low rates of coronary JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 Kereiakesetal。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 385,
      "text": "Ltreatmentislimitedto Similarly, the Disrupt CAD I and Disrupt CAD II thevesselwall。trials demonstrated very low rates of coronary JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 Kereiakesetal。 1287 JUNE 28, 2021:1275–92 PrinciplesofIntravascularLithotripsy TABLE3 AngiographicComplicationsWithPeripheralCalciumModificationTechnologies IVL DirectionalAtherectomy RotationalAtherectomy OrbitalAtherectomy Study Patient-levelpooledanalysis: DEFINITIVECa(19) XL-PADregistry CONFIRMregistries(76) DisruptPADI, (21,75) DisruptPADII,DisruptPADIII, DisruptBTK,DisruptCFA(55) n 336 133 141,26 3,135 ModeratetosevereCa,% 95。6 94。1% 14。4–100 81。1 Angiographycorelaboratory Yes Yes Yes No Distalembolization,% 0。0 2。3* 8。0† 2。2 Dissection(typesD–F),% 0。9 0。8 NR‡ NR Perforation,% 0。3 2。3 NR 0。7 Abruptclosure,% 0。0 NR NR 1。5 Slowflow,% 0。0 NR NR 4。4 Valuesare%,unlessotherwiseindicated。*97。2%embolicfilterusewith88。4%offilterswithcaptureddebris。†Withoutembolicfilteruse。‡27。3%reportedforalldissections (75)。11。3%reportedforalldissections。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 386,
      "text": "0 NR NR 4。4 Valuesare%,unlessotherwiseindicated。*97。2%embolicfilterusewith88。4%offilterswithcaptureddebris。†Withoutembolicfilteruse。‡27。3%reportedforalldissections (75)。11。3%reportedforalldissections。 DEFINITIVECaStudyoftheSilverHawk/TurboHawkPlaqueExcisionSystemsUsedWithSpiderFXtoTreatCalcifiedPeripheralArterialDisease;DisruptBTKSafetyand FeasibilityoftheShockwaveLithoplastySystemfortheTreatmentofPeripheralVascularStenosis;DisruptPADISafetyandPerformanceStudyoftheShockwaveLithoplasty System;DisruptPADIIShockwaveLithoplastyDISRUPTTrialforPAD;DisruptPADIIIShockwaveMedicalPeripheralLithoplastySystemStudyforPAD;NRnotreported; XL-PADMulti-CenterRegistryforPeripheralArterialDiseaseInterventionsandOutcomes。peri-procedural complications (rates of in-hospital intervals vary to be >1 s。The resulting IVL-induced myocardial infarction were 5。0% in Disrupt CAD I capture is at a rate of 60 beats/min for the dura- and 5。8% in Disrupt CAD II), with no unresolved tion of IVL treatment (10 s)。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 387,
      "text": " resulting IVL-induced myocardial infarction were 5。0% in Disrupt CAD I capture is at a rate of 60 beats/min for the dura- and 5。8% in Disrupt CAD II), with no unresolved tion of IVL treatment (10 s)。 Capture may be limited complex dissections (types D to F), perforations, tosingleatrialcapture,singleventricularcapture,or abrupt closures, and slow- or no-reflow events ventricular capture sustained for more than 1 beat, (25,56)。The pivotal Disrupt CAD III trial demon- butrarelymorethanforthe10-sdurationoftheIVL stratednoperforations,abruptclosures,orno-reflow application。eventsfollowingIVLalonedespitetreatmentofmore The probability of ventricular tachycardia or ven- complexlesionsthanweretreatedintheDisruptCAD tricular fibrillation (VF) induction by IVL is remote IandDisruptCADIIstudies(30)。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 388,
      "text": "espitetreatmentofmore The probability of ventricular tachycardia or ven- complexlesionsthanweretreatedintheDisruptCAD tricular fibrillation (VF) induction by IVL is remote IandDisruptCADIIstudies(30)。 Thus,incontrastto consideringthatthe8mJ(distributedoverthesurface relatively high vascular complication rates observed oftheC2IVLballoon)ofmechanicalenergyappliedis after ESWL treatment, animal and core laboratory– several orders of magnitude lower than that used adjudicated human clinical studies in both coronary in standard implantable cardioverter-defibrillator and peripheral vessels suggest that IVL-related testing。In contrast, the electric energy required for vascular complications are infrequent (Central ventriculartachycardiaorVFinductionduringtesting Illustration)。of a newly implanted implantable cardioverter- IVL-INDUCED CAPTURE。IVL acoustic pressure defibrillator is 0。6 to 2。0 J。Nevertheless, an isolated waves have a pulse duration of 0。6 to 1。2 ms and are case report suggests the potentialassociationof cor- deliveredatarateof1Hz(1pulse/s),withnoelectric onaryIVLwithVFinductionbutisconfoundedbythe component introduced to surrounding tissue。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 389,
      "text": "2 ms and are case report suggests the potentialassociationof cor- deliveredatarateof1Hz(1pulse/s),withnoelectric onaryIVLwithVFinductionbutisconfoundedbythe component introduced to surrounding tissue。 These concurrent effects of balloon inflation–induced acoustic pressure waves produce extremely low myocardial ischemia, spontaneous (not IVL related) amountsofenergy(8to10mJ),whichdecayrapidly。ventricular ectopic effect on electric “vulnerability,” During coronary IVL treatment, ventricular andtheuseofIVLforanoff-labelindication(67)。VFis ectopic activity or transient IVL-induced capture aknownriskincoronarydiagnosticandinterventional may occur and is dependent largely on resting heart procedures, especially in the presence of underlying rate。IVL-induced capture results from mechano- myocardial ischemia (68)。Clearly, electrocardio- electriccouplingofacousticpressurewaveswiththe graphic monitoring is required during all coronary cardiac conduction system that is mediated by car- interventionalprocedures。diac stretch–activatedchannels usedfor conduction。Wilson et al。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 390,
      "text": "eswiththe graphic monitoring is required during all coronary cardiac conduction system that is mediated by car- interventionalprocedures。diac stretch–activatedchannels usedfor conduction。Wilson et al。 (69) reported a high incidence of Sustained ventricular capture is possible only when coronary IVL-induced pacing that was dependent the acoustic pressure waves depolarize the cardiac largely on resting heart rate。Patients with heart tissue via the stretch-activated response and the rates <65 beats/min prior to IVL were 16-fold native heart rate is lower than 60 beats/min, or R-R more likely (odds ratio: 16。3; 95% confidence 1288 Kereiakesetal。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 PrinciplesofIntravascularLithotripsy JUNE 28, 2021:1275–92 TABLE4 AngiographicComplicationsWithCoronaryCalciumModificationTechnologies IVL RotationalAtherectomy OrbitalAtherectomy LaserAtherectomy Study DisruptCADI,DisruptCADII,DisruptCADIII, PREPARE-CALC(77) ORBITII(78) Bilodeauetal。(79) DisruptCADIV(25,30,56,73) n 60,120,384,64 100 443 95 ModeratetosevereCa,% 94。2–100 100 100* 80%† Angiographycorelaboratory Yes Yes Yes Yes In-hospitalMI,% 5。0–6。8‡ 2。0 9。3‡ 2。1 Dissection(typesD–F),% 0。0–0。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 391,
      "text": "tCADIV(25,30,56,73) n 60,120,384,64 100 443 95 ModeratetosevereCa,% 94。2–100 100 100* 80%† Angiographycorelaboratory Yes Yes Yes Yes In-hospitalMI,% 5。0–6。8‡ 2。0 9。3‡ 2。1 Dissection(typesD–F),% 0。0–0。 3 3。0|| 0。9 5。3 Perforation,% 0。0–0。3 4。0 0。9 0。0 Abruptclosure,% 0。3 NR 0。2 0。0 Slowflow,% 0。0 2。0# 0。5 0。0 Noreflow,% 0。0 — 0。0 — Valuesare%,unlessotherwiseindicated。*Sitereported。†Presenceofcalciumnoted,butseveritynotspecified。‡CK-MB>3timestheupperlimitofnormal。CK-MB>3times theURLortroponin>3timestheURL。||Largedissection(>5mm)。IncludesdissectiontypesCtoF。#Includesnoreflowandslowflow。CK-MBcreatinekinasemyocardialband;DisruptCADIShockwaveCoronaryRxLithoplastyStudy;DisruptCADIIShockwaveCoronaryLithoplastyStudy;DisruptCAD IIIDisruptCADIIIWiththeShockwaveCoronaryIVLSystem;DisruptCADIVDisruptCADIVWiththeShockwaveCoronaryIVLSystem;IVLintravascularlithotripsy; MI  myocardial infarction; NR  not reported; ORBIT II  Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions; PREPARE- CALCComparisonofStrategiestoPrepareSeverelyCalcifiedCoronaryLesionsTrial;URLupperreferencelimit。interval: 2。4 to 110。8; p  0。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 392,
      "text": " Efficacy of OAS in Treating Severely Calcified Coronary Lesions; PREPARE- CALCComparisonofStrategiestoPrepareSeverelyCalcifiedCoronaryLesionsTrial;URLupperreferencelimit。interval: 2。4 to 110。8; p  0。 004) to experience differences were observed when comparing the 47 IVL-induced capture compared with patients with roll-inprocedures(thefirstcaseateachinternational heart rates $65 beats/min。No patient experienced site)withthesubsequent384intention-to-treatpro- sustained arrhythmias or clinically significant hypo- cedures with respect to procedural success, device tension as a result of coronary IVL-induced capture, crossing success, and 30-day freedom from major and all patients had successful percutaneous coro- adverse cardiovascular events despite the marked nary intervention procedures without clinical complexityoflesionstreated(30),whichunderscores sequelae。therelativeeaseofIVLuse。To further evaluate this phenomenon, heart IVL IN CLINICAL PRACTICE。The Shockwave M5 and rhythm assessment was systematically performed in S4 IVL catheters are approved for use in Europe, the Disrupt CAD III (30)。IVL-induced capture was United States, and additional countries globally for observed in 41。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 393,
      "text": "t was systematically performed in S4 IVL catheters are approved for use in Europe, the Disrupt CAD III (30)。IVL-induced capture was United States, and additional countries globally for observed in 41。 1% of cases but did not result in sus- treatment of peripheral vascular disease。Safety and tainedventriculararrhythmiasduringorimmediately effectiveness have been demonstrated in multiple after the IVL procedure and was not associated with clinical studies in various peripheral vascular beds adverse events。Multivariate Cox regression analysis (SupplementalTable1)。Arecentpatient-levelpooled identified heart rate #60 beats/min, male sex, and analysis of 336 patients with moderate to severely totalnumberofIVLpulsesdeliveredasindependent calcifiedperipherallesionsundergoingIVLtreatment predictors of IVL-induced capture。Although IVL- demonstrated consistent reductions in residual induced capture was relatively frequent, its occur- luminal diameter stenosis after IVL treatment rence was benign and without clinical consequence regardless of vessel bed, calcium severity, calcium (30)(CentralIllustration)。distribution (eccentric or concentric), or patient risk subgroup (55)。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 394,
      "text": "t rence was benign and without clinical consequence regardless of vessel bed, calcium severity, calcium (30)(CentralIllustration)。distribution (eccentric or concentric), or patient risk subgroup (55)。 Increasing clinical experience is CLINICAL USE OF IVL availableregardingtheuseofIVLfacilitationoflarge- bore catheter placement using transfemoral artery LEARNING CURVE ASSESSMENT。IVL technology le- access for transcatheter aortic valve replacement, verages the familiarity of angioplasty balloon cathe- endovascular abdominal or thoracic aortic stent tersusedforcoronaryandperipheralinterventionto grafts, and mechanical cardiac support devices (e。g。, provide a safe, effective, and intuitively under- Impella)(70–72)。Thisexperiencesuggeststhatalarge standable (operator-friendly) procedure when treat- portion of patients deemed unacceptable for trans- ing complex calcified lesions。In Disrupt CAD III, femoral access can be successfully and safely “con- whichrepresentedtheinitialcoronaryIVLexperience verted,” obviating the need for alternative for U。S。interventional cardiologists, no significant (frequently surgical) access with the attendant JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 395,
      "text": "perience verted,” obviating the need for alternative for U。S。interventional cardiologists, no significant (frequently surgical) access with the attendant JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。 12, 2021 Kereiakesetal。1289 JUNE 28, 2021:1275–92 PrinciplesofIntravascularLithotripsy morbidities of general anesthesia and prolonged injury and vascular complications。Wire bias in their hospitalization in addition to greater procedure effectresultsineccentricrutsortroughswiththerisk related resource consumption。Furthermore, compli- for incomplete calcium modification。Furthermore, cations including perforation, complex dissection, atheroablativetechnologiesarelimitedintheirability and the need for unplanned “bail-out” stent place- tomodifydeepcalciumintheabsenceofmarkedwire ment following IVL to facilitate transfemoral access bias and/or larger device sizes, both of which may proceduresarerare。negativelyaffectproceduresafety。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 396,
      "text": "- tomodifydeepcalciumintheabsenceofmarkedwire ment following IVL to facilitate transfemoral access bias and/or larger device sizes, both of which may proceduresarerare。negativelyaffectproceduresafety。 Alternatively,IVL TheShockwaveC2IVLcatheterhasbeencommer- fractures both superficial and deep calcium in situ cially available in Europe since 2018, following the andminimizes the risk for vascular complications or completionofDisruptCADI(56),andisnowavailable thermal injury。Rates of vascular complications for commerciallyinmorethan49countries。DisruptCAD peripheral and coronary calcium-modifying technol- III(U。S。investigationaldeviceexemptionpre-market ogiesusedinheavilycalcifiedtargetlesionsarelisted study) and Disrupt CAD IV (Japanese pre-market inTables3and4。study) completed enrollment in 2020 (30,73)。In all DisruptCADtrials,patientswithstableischemicheart FUTURE DIRECTIONS disease and severely calcified target lesions were treated (Supplemental Table 2)。Rates of safety and Shockwave IVL builds upon the principles of EHL effectivenesswereconsistentlyhighacrossallDisrupt usedinkidneystonefragmentationwithadaptations CAD studies, as shown in Figure 8。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 397,
      "text": ")。Rates of safety and Shockwave IVL builds upon the principles of EHL effectivenesswereconsistentlyhighacrossallDisrupt usedinkidneystonefragmentationwithadaptations CAD studies, as shown in Figure 8。 All Disrupt CAD made for safety, effectiveness, and ease of use to studies included independent core laboratory– treat vascular calcium。The IVL acoustic waveform adjudicated OCT substudies that demonstrated cal- adapted for intravascular use has been shown to cium fractures in multiple planes and confirmed obviatemanyofthevascularcomplicationsobserved calciumfractureasthedominantmechanismofaction with lithotripsy used to treat urolithiasis。The com- for increased vessel compliance after IVL treatment bined evidence from preclinical (Ultracal 30 and (25,52)。Clinical experience with coronary IVL con- cadaveric micro-CT) and clinical (Disrupt PAD and tinuestoexpandwiththeuseofIVLacrossarangeof Disrupt CAD) studies consistently supports the target lesion calcium phenotypes in varied anatomic concept that IVL modifies both superficial and deep and procedural scenarios (Supplemental Table 4)。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 398,
      "text": " Disrupt CAD) studies consistently supports the target lesion calcium phenotypes in varied anatomic concept that IVL modifies both superficial and deep and procedural scenarios (Supplemental Table 4)。 calcium by producing multiplane, circumferential, Although the optimal percutaneous coronary inter- and longitudinal calcium fractures with consequent vention strategy for calcified lesions is evolving, the enhancement of transmural vessel compliance and recently developed Society for Cardiovascular Angi- stent expansion。IVL’s unique mechanism of action ographyandInterventionsalgorithmincorporatesthe for calcium modification has consistently been asso- useofcalcium-modifyingtechnologiesincludingIVL ciated with low rates of clinical and vascular- with intravascular imaging in guiding treatment of angiographiccomplications。thesecomplexcoronarylesions(74)。There are several areas of potential iteration and improvement to the IVL catheter system that may COMPARISON WITH OTHER CALCIUM- enhancetheclinicalutilityofthistechnology。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 399,
      "text": "ecomplexcoronarylesions(74)。There are several areas of potential iteration and improvement to the IVL catheter system that may COMPARISON WITH OTHER CALCIUM- enhancetheclinicalutilityofthistechnology。 First,a MODIFYING TECHNOLOGIES reductionindevicecrossingprofileandincreasedIVL catheter flexibility could improve deliverability Inthetreatmentofseverelycalcifiedlesions,IVLof- across heavily stenotic or tortuous lesions。The cur- fersseveraladvantagescomparedwithballoon-based rent crossing profile is larger than standard angio- technologies (i。e。, high-pressure noncompliant and plastyballooncathetersbecauseoftheintegrationof cutting/scoring balloons) and atheroablative tech- EHL emitters into the shaft of the IVL catheter。nologies (rotational or orbital atherectomy)。First, Crossing profile and flexibility affect delivery。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 400,
      "text": "cutting/scoring balloons) and atheroablative tech- EHL emitters into the shaft of the IVL catheter。nologies (rotational or orbital atherectomy)。First, Crossing profile and flexibility affect delivery。 Sec- whereas balloon-based technologies are dependent ond, a longer IVL catheter shaft length could allow on high static pressure for plaque modification, IVL thetreatmentofmoredistallesions,whilelargerIVL uses acoustic shockwaves delivered through a semi- balloonsizescouldfacilitateoptimalsizingrelativeto compliant balloon inflated to only 4 atm, thus larger coronary (i。e。, left main) and peripheral (i。e。, avoidinghigh-pressureinflationwiththeconsequent commoniliac)vessels。Thus,expansionofthecurrent potentialforbarotraumaobservedwithconventional maximum balloon matrix for the Shockwave C2 IVL noncompliant balloons。Second, atheroablative tech- catheter for coronary arteries (4。0 mm) and the S4 nologies rely on localized debulking of superficial (4。0 mm) and M5 (7。0 mm) IVL catheters used for calcium, which subjects target vessels to thermal peripheral arteries would allow more optimal IVL 1290 Kereiakesetal。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 401,
      "text": " M5 (7。0 mm) IVL catheters used for calcium, which subjects target vessels to thermal peripheral arteries would allow more optimal IVL 1290 Kereiakesetal。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。 12, 2021 PrinciplesofIntravascularLithotripsy JUNE 28, 2021:1275–92 balloon-to-artery sizing with improved acoustic en- DisruptCADIII,andDisruptCADIVOCTsubstudiesis ergytransfer。Last,anincreaseinthetotalnumberof currently being performed to address these ques- pulses delivered per catheter might allow more pa- tions。Randomized clinical trials of IVL with tients to be treated with a single IVL catheter and other calcium-modifying therapies (i。e。, high- could potentially reduce the time and cost of the pressure balloon, atheroablative technologies, procedure。laseratherectomy)arerequiredtoprovidedirectev- AlthoughacuteoutcomesfollowingIVLinseverely idenceregardingtherelativesafetyandeffectiveness calcified coronary lesions have been very promising of these therapies and guide algorithms for to date, longer term follow-up is required to under- treatment of heavily calcified lesions in the stand how these acute outcomes, particularly opti- coronary and peripheral vasculature。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 402,
      "text": "lgorithms for to date, longer term follow-up is required to under- treatment of heavily calcified lesions in the stand how these acute outcomes, particularly opti- coronary and peripheral vasculature。 Similarly, the mized stent expansion and minimal stent area, will potential applications of IVL to severely calcified affectlateclinicalresults。DisruptCADIIIhasplanned aortic valves, rheumatic mitral stenosis, and mitral 2-yearfollow-upandwillprovidelongertermclinical annular calcification are areas of potential outcome data with which to assess the impact of investigation。optimized stent implantation after the intracoronary use of IVL。Additional areas of interest and investi- FUNDINGSUPPORTANDAUTHORDISCLOSURES gationwithrespecttomodificationofvascularcalci- fication include patients with unstable coronary Dr。KereiakesisaconsultantforSINOMedicalSciencesTechnologies, Boston Scientific, Elixir Medical, Svelte Medical Systems, Caliber syndromes, ostial or bifurcation coronary lesions, Therapeutics/Orchestra Biomed, and Shockwave Medical; and is a treatment of in-stent restenosis or underexpanded stockholder in Ablative Solutions。Dr。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 403,
      "text": "yndromes, ostial or bifurcation coronary lesions, Therapeutics/Orchestra Biomed, and Shockwave Medical; and is a treatment of in-stent restenosis or underexpanded stockholder in Ablative Solutions。Dr。 Virmani has received grant, coronary stents(69–73),severe calcification inupper research, and clinical trial support from the National Institutes of extremity vessels (i。e。, carotid, subclavian/axillary, Health,theLeducqFoundation,480Biomedical,4CMedical,4Tech, Abbott, Accumedical, Amgen, Biosensors, Boston Scientific, Canon innominate)andveingrafts,aswellastheinfrarenal USA,CardiacImplants,Celonova,ClaretMedical,ConceptMedical, aorta, radial, and brachial arteries。An investigator- Cook, CSI, DuNing, Edwards Lifesciences, Emboline, Endotronix, sponsored “all-comers” registry is currently Envision Scientific, Lutonix/Bard, Gateway, Lifetech, Limflo, Med- enrolling in Spain (REPLICA [Registry of Coronary Alliance, Medtronic, Mercator, Merrill, Microport Medical, Micro- Lithotripsy in Spain; NCT04298307], N  400) and, vention, Mitralign, MitrAssist, NAMSA, Nanova, Neovasc, NIPRO, Novogate, Occulotech, OrbusNeich Medical, Phenox, Profusa, Pro- following U。S。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 404,
      "text": "l, Micro- Lithotripsy in Spain; NCT04298307], N  400) and, vention, Mitralign, MitrAssist, NAMSA, Nanova, Neovasc, NIPRO, Novogate, Occulotech, OrbusNeich Medical, Phenox, Profusa, Pro- following U。S。 Food and Drug Administration tembis, Qool, ReCor Medical, Senseonics, Shockwave, Sinomed, approval of the Shockwave Coronary IVL System, a Spectranetics, Surmodies, Terumo, Vesper, W。L。Gore, and Xeltis; post-marketapprovalstudyisbeingdevelopedtouse andisaconsultantforAbbottVascular,BostonScientific,Celenova, Cook Medical, CSI, Edwards Lifesciences, Bard BD, Medtronic, the American College of Cardiology National Cardio- OrbusNeich Medical, ReCor Medical, SinoMedical Technology, Sur- vascular Data Registry CathPCI Registry to provide modics,Terumo,W。L。Gore,andXeltis。Dr。Hokamaisanemployeeof insights into device safety and effectiveness in an Shockwave Medical。Dr。Illindala is an employee of Shockwave expanded “real-world” patient population。Addi- Medical。Dr。Mena-Hurtado is a consultant for Abbott, Boston Sci- entific, Cook, Medtronic, Cardinal Health, and Optum Labs。Dr。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 405,
      "text": "is an employee of Shockwave expanded “real-world” patient population。Addi- Medical。Dr。Mena-Hurtado is a consultant for Abbott, Boston Sci- entific, Cook, Medtronic, Cardinal Health, and Optum Labs。Dr。 tional investigator-initiated randomized controlled Holdenisaclinicalinvestigatorandmedicaladvisoryboardmember pilot studies involving comparisons of IVL with cut- forShockwaveMedical。Dr。Hillreportsfeesandgrantsupportfrom tingorscoringballoons(BALI[BalloonLithoplastyfor AbbottVascular,BostonScientific,Abiomed,andShockwaveMedi- Preparation of Severely Calcified Coronary Lesions; cal; and is a stockholder in Shockwave Medical。Dr。Lyden is a consultant to Boston Scientific, Abbott, Medtronic, Shockwave NCT04253171], N  200; CCS [Coronary Calcification Medical,PQBypass,Intact,andPenumbra。Dr。Alihasreceivedgrants Study; NCT04428177], N 40) or rotational atherec- from the National Institutes of Health/National Heart, Lung, and tomy and laser atherectomy (ROLLERCOASTER Blood Institute, Abbott Vascular, and Cardiovascular Systems; has receivedpersonalfeesfromAmgen,AstraZeneca,andBostonScien- [RotationalAtherectomy,LithotripsyorLaserforthe tific;andholdsequityinShockwaveMedical。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 406,
      "text": "tute, Abbott Vascular, and Cardiovascular Systems; has receivedpersonalfeesfromAmgen,AstraZeneca,andBostonScien- [RotationalAtherectomy,LithotripsyorLaserforthe tific;andholdsequityinShockwaveMedical。 Allotherauthorshave Treatment of Calcified Stenosis; NCT04181268], reportedthattheyhavenorelationshipsrelevanttothecontentsof N  150) are planned to evaluate the safety and thispapertodisclose。effectiveness of IVL compared with other calcium- modifying technologies in severely calcified coro- ADDRESS FOR CORRESPONDENCE: Dr。Dean J。Ker- nary lesions prior to stent implantation。Evidence eiakes, The Carl and Edyth Lindner Center for on the effectiveness of IVL treatment in eccentric Research and Education at The Christ Hospital, 2123 and/or nodular calcification is limited as well, and a Auburn Avenue, Suite 424, Cincinnati, Ohio 45219, pooledanalysisoftheDisruptCADI,DisruptCADII, USA。E-mail:dean。kereiakes@thechristhospital。com。JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 Kereiakesetal。1291 JUNE 28, 2021:1275–92 PrinciplesofIntravascularLithotripsy REFERENCES 1。Rocha-SinghKJ, Zeller T, Jaff MR。Peripheral 13。Matsuo H, Watanabe S, Watanabe T, et al。stenoses:theDisruptCADIIstudy。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 407,
      "text": "setal。1291 JUNE 28, 2021:1275–92 PrinciplesofIntravascularLithotripsy REFERENCES 1。Rocha-SinghKJ, Zeller T, Jaff MR。Peripheral 13。Matsuo H, Watanabe S, Watanabe T, et al。stenoses:theDisruptCADIIstudy。 CircCardiovasc arterial calcification: prevalence, mechanism, Prevention of no-reflow/slow-flow phenomenon Interv2019;12:e008434。detection,andclinicalimplications。CatheterCar- during rotational atherectomy—a prospective 26。BrodmannM,HoldenA,ZellerT。Safetyand diovascInterv2014;83:E212–20。randomized study comparing intracoronary feasibility of intravascular lithotripsy for treat- continuousinfusionofverapamilandnicorandil。2。MattesiniA,DiMarioC。Calcium:apredictorof ment of below-the-knee arterial stenoses。interventionaltreatmentfailureacrossallfieldsof AmHeartJ2007;154:994。e1–6。JEndovascTher2018;25:499–503。cardiovascular medicine。Int J Cardiol 2017;231: 14。FanelliF,CannavaleA,GazzettiM,etal。Cal- 27。Brodmann M, Schwindt A, Argyriou A, 97–8。cium burden assessment and impact on drug- GammonR。Safetyandfeasibilityofintravascular eluting balloons in peripheral arterial disease。3。LeeMS,ShahN。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 408,
      "text": "l。Cal- 27。Brodmann M, Schwindt A, Argyriou A, 97–8。cium burden assessment and impact on drug- GammonR。Safetyandfeasibilityofintravascular eluting balloons in peripheral arterial disease。3。LeeMS,ShahN。 Theimpactandpathophysio- lithotripsyfortreatmentofcommonfemoralar- logic consequences of coronary artery calcium CardiovascIntervRadiol2014;37:898–907。terystenoses。JEndovascTher2019;26:283–7。deposition in percutaneous coronary in- 15。TepeG,BeschornerU,RuetherC,etal。Drug- 28。Brodmann M, Werner M, Brinton TJ, et al。terventions。JInvasiveCardiol2016;28:160–7。eluting balloon therapy for femoropopliteal Safetyandperformanceoflithoplastyfortreat- 4。Mori S, Yasuda S, Kataoka Y, Morii I, occlusivedisease: predictorsof outcomewitha mentofcalcifiedperipheralarterylesions。JAm KawamuraA,MiyazakiS。Significantassociationof special emphasis on calcium。J Endovasc Ther CollCardiol2017;70:908–10。2015;22:727–33。coronaryarterycalcificationinstentdeliveryroute 29。BrodmannM,WernerM,HoldenA,etal。Pri- withrestenosisafter sirolimus-elutingstentim- 16。Kawaguchi R, Tsurugaya H, Hoshizaki H, mary outcomes and mechanism of action of plantation。CircJ2009;73:1856–63。ToyamaT,OshimaS,TaniguchiK。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 409,
      "text": "A,etal。Pri- withrestenosisafter sirolimus-elutingstentim- 16。Kawaguchi R, Tsurugaya H, Hoshizaki H, mary outcomes and mechanism of action of plantation。CircJ2009;73:1856–63。ToyamaT,OshimaS,TaniguchiK。 Impactoflesion intravascular lithotripsy in calcified, femo- calcificationonclinicalandangiographicoutcome 5。KiniAS,VengrenyukY,PenaJ,etal。Optical ropopliteal lesions: results of Disrupt PAD II。coherencetomographyassessmentofthemech- aftersirolimus-elutingstentimplantationinreal- CatheterCardiovascInterv2019;93:335–42。worldpatients。CardiovascRevascMed2008;9: anisticeffectsofrotationalandorbitalatherec- 2–8。30。Hill JM, Kereiakes DJ, Shlofmitz RA, et al。tomy in severely calcified coronary lesions。Intravascularlithotripsyfortreatmentofseverely CatheterCardiovascInterv2015;86:1024–32。17。Lee MS, Canan T, Rha SW, Mustapha J, calcifiedcoronaryarterydisease。JAmCollCardiol 6。Wiemer M, Butz T, Schmidt W, Schmitz KP, AdamsGL。PooledanalysisoftheCONFIRMreg- 2020;76:2635–46。istries: impact of gender on procedure and HorstkotteD,LangerC。Scanningelectronmicro- angiographic outcomes in patients undergoing 31。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 410,
      "text": "chmitz KP, AdamsGL。PooledanalysisoftheCONFIRMreg- 2020;76:2635–46。istries: impact of gender on procedure and HorstkotteD,LangerC。Scanningelectronmicro- angiographic outcomes in patients undergoing 31。 Carlsson P, Kinn AC, Tiselius HG, Ohlsen H, scopic analysis of different drug eluting stents orbitalatherectomyforperipheralarterydisease。RahmqvistM。Costeffectivenessofextracorporeal afterfailedimplantation:fromnearlyundamaged JEndovascTher2015;22:57–62。shock wave lithotripsy and percutaneous neph- tomajordamagedpolymers。CatheterCardiovasc rolithotomy for medium-sized kidney stones。A Interv2010;75:905–11。18。Babaev A, Zavlunova S, Attubato MJ, randomised clinical trial。Scand J Urol Nephrol 7。Madhavan MV, Tarigopula M, Mintz GS, M re a c r t t o i m ns y en p B la J q , u M e in m tz od G ifi S, ca M ti a o e n ha a r s a se A s。sm Or e b n it t al o a f th th e e - 1992;26:257–63。MaeharaA,StoneGW,GenereuxP。Coronaryar- femoropopliteal artery via intravascular ultra- 32。PeschelR,JanetschekG,BartschG。Extracor- tery calcification: pathogenesis and prognostic sound (TRUTH Study)。Vasc Endovascular Surg porealshockwavelithotripsyversusureteroscopy implications。JAmCollCardiol2014;63:1703–14。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 411,
      "text": "G,BartschG。Extracor- tery calcification: pathogenesis and prognostic sound (TRUTH Study)。Vasc Endovascular Surg porealshockwavelithotripsyversusureteroscopy implications。JAmCollCardiol2014;63:1703–14。 2015;49:188–94。fordistalureteralcalculi:aprospectiverandom- 8。Newman AB, Naydeck BL, Sutton-Tyrrell K, izedstudy。JUrol1999;162:1909–12。19。RobertsD,NiaziK,MillerW,etal。Effective FeldmanA,EdmundowiczD,KullerLH。Coronary endovascular treatment of calcified femo- 33。LamJS,GreeneTD,GuptaM。Treatmentof artery calcification in older adults to age 99: ropoplitealdiseasewithdirectionalatherectomy proximalureteralcalculi:holmium:YAGlaserure- prevalenceandriskfactors。Circulation2001;104: anddistalembolicprotection:finalresultsofthe terolithotripsyversusextracorporealshockwave 2679–84。DEFINITIVECatrial。CatheterCardiovascInterv lithotripsy。JUrol2002;167:1972–6。9。TzafririAR,Garcia-PoliteF,ZaniB,etal。Calci- 2014;84:236–44。34。DelacretazG,RinkK,PittomvilsG,LafautJP, fiedplaquemodificationalterslocaldrugdelivery 20。McKinsey JF, Zeller T, Rocha-Singh KJ, Vandeursen H, Boving R。Importance of the in the treatment of peripheral atherosclerosis。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 412,
      "text": "K,PittomvilsG,LafautJP, fiedplaquemodificationalterslocaldrugdelivery 20。McKinsey JF, Zeller T, Rocha-Singh KJ, Vandeursen H, Boving R。Importance of the in the treatment of peripheral atherosclerosis。 Jaff MR, Garcia LA, for the DEFINITIVE LE In- implosion of ESWL-induced cavitation bubbles。JControlRelease2017;264:203–10。vestigators。Lower extremity revascularization UltrasoundMedBiol1995;21:97–103。10。GenereuxP,MadhavanMV,MintzGS,etal。using directional atherectomy: 12-month pro- 35。WessOJ。Physicsandtechniqueofshockwave Ischemicoutcomesaftercoronaryinterventionof spectiveresultsoftheDEFINITIVELEstudy。JAm lithotripsy (SWL)。In: Talai J, Tieselius HG, calcified vessels in acute coronary syndromes。CollCardiolIntv2014;7:923–33。AlbalaDM,YeZ,editors。Urolithiasis:BasicScience Pooled analysis from the HORIZONS-AMI 21。Banerjee A, Sarode K, Mohammad A, et al。and Clinical Practice。London: Springer Verlag, (Harmonizing Outcomes With Revascularization Safety and effectiveness of the Nav-6 filter in 2012:301–11。and Stents in Acute Myocardial Infarction) and preventing distal embolization during Jetstream 36。RassweilerJJ,KnollT,KohrmannKU,etal。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 413,
      "text": "ation Safety and effectiveness of the Nav-6 filter in 2012:301–11。and Stents in Acute Myocardial Infarction) and preventing distal embolization during Jetstream 36。RassweilerJJ,KnollT,KohrmannKU,etal。 ACUITY(AcuteCatheterizationandUrgentInter- atherectomyofinfrainguinalperipheralarteryle- Shockwave technologyandapplication:an up- ventionTriageStrategy)TRIALS。JAmCollCardiol sions。JInvasiveCardiol2016;28:330–3。date。EurUrol2011;59:784–96。2014;63:1845–54。22。PowersCJ,Tinterow MM,BurpeeJF。Extra- 37。LingemanJE,McAteerJA,GnessinE,EvanAP。11。YamamotoMH,MaeharaA,KarimiGalougahiK, corporealshockwavelithotripsy:astudyofrenal Shock wave lithotripsy: advances in technology et al。Mechanisms of orbital versus rotational stonedifferences。KansMed1989;90:19–22。andtechnique。NatRevUrol2009;6:660–70。atherectomy plaque modification in severely calcified lesions assessed by optical coherence 23。ClevelandRO,McAteerJA。Physicsofshock- 38。McAteer JA, Evan AP。The acute and long- tomography。J Am Coll Cardiol Intv 2017;10: wavelithotripsy。In:Smith’sTextbookofEndour- term adverse effects of shock wave lithotripsy。2584–6。ology。Hoboken, NJ: Wiley-Blackwell, 2012: SeminNephrol2008;28:200–13。527–58。39。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 414,
      "text": " Cardiol Intv 2017;10: wavelithotripsy。In:Smith’sTextbookofEndour- term adverse effects of shock wave lithotripsy。2584–6。ology。Hoboken, NJ: Wiley-Blackwell, 2012: SeminNephrol2008;28:200–13。527–58。39。 VorreutherR,CorleisR,KlotzT,BernardsP, 12。Abdel-Wahab M, Richardt G, Joachim 24。Ali ZA, McEntegart M, Hill JM, Spratt JC。EngelmannU。Impactofshockwavepatternand ButtnerH,etal。High-speedrotationalatherec- Intravascular lithotripsy for treatment of stent cavitation bubble size on tissue damage during tomybeforepaclitaxel-elutingstentimplantation in complex calcified coronary lesions: the ran- underexpansion secondary to severe coronary ureteroscopicelectrohydrauliclithotripsy。JUrol calcification。EurHeartJ2020;41:485–6。1995;153:849–53。domizedROTAXUS(RotationalAtherectomyPrior to Taxus Stent Treatment for Complex Native 25。Ali ZA, Nef H, Escaned J, et al。Safety and 40。MatlagaBR,McAteerJA,ConnorsBA,etal。CoronaryArteryDisease)trial。JAmCollCardiol effectivenessofcoronaryintravascularlithotripsy Potentialforcavitation-mediatedtissuedamagein Intv2013;6:10–9。for treatment of severely calcified coronary shockwavelithotripsy。JEndourol2008;22:121–6。1292 Kereiakesetal。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 415,
      "text": "onaryintravascularlithotripsy Potentialforcavitation-mediatedtissuedamagein Intv2013;6:10–9。for treatment of severely calcified coronary shockwavelithotripsy。JEndourol2008;22:121–6。1292 Kereiakesetal。 JACC: CARDIOVASCULAR INTERVENTIONS VOL。14, NO。12, 2021 PrinciplesofIntravascularLithotripsy JUNE 28, 2021:1275–92 41。ScotlandKB,KroczakT,PaceKT,ChewBH。peripheralarterialdisease:anindividualpatient- 69。WilsonSJ,SprattJC,HillJ,etal。Incidenceof Stone technology: intracorporeal lithotripters。level pooled data analysis。Catheter Cardiovasc “shocktopics”andasynchronouscardiacpacingin WorldJUrol2017;35:1347–51。Interv2020;95:959–68。patientsundergoingcoronaryintravascularlitho- tripsy。EuroIntervention2020;15:1429–35。42。ZhengW,DenstedtJD。Intracorporeallitho- 56。BrintonTJ,AliZA,HillJM,etal。Feasibilityof tripsy。Updateontechnology。UrolClinNorthAm Shockwavecoronaryintravascularlithotripsyfor 70。Di Mario C, Goodwin M, Ristalli F, et al。2000;27:301–13。thetreatmentofcalcifiedcoronarystenoses:first Aprospectiveregistryofintravascularlithotripsy- description。Circulation2019;139:834–6。enabled vascular access for transfemoral trans- 43。Karimi Galougahi K, Patel S, Shlofmitz RA, et al。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 416,
      "text": "tenoses:first Aprospectiveregistryofintravascularlithotripsy- description。Circulation2019;139:834–6。enabled vascular access for transfemoral trans- 43。Karimi Galougahi K, Patel S, Shlofmitz RA, et al。 Calcific plaque modification by acoustic 57。BlachutzikF,HontonB,EscanedJ,etal。Safety catheter aortic valve replacement。J Am Coll CardiolIntv2019;12:502–4。shockwaves:intravascularlithotripsyincoronary andeffectivenessofcoronaryintravascularlitho- interventions。Circ Cardiovasc Interv 2021;14: tripsy in eccentric calcified coronary lesions: a 71。Rosseel L, De Backer O, Sondergaard L, e009354。patient-level pooled analysis from the Disrupt BieliauskasG。Intravasculariliacarterylithotripsy 44。Li D, Pellegrino A, Hallack A, Petrinic N, CADIandCADIIstudies。ClinResCardiol2021; to enable transfemoral thoracic endovascular Jerusalem A, Cleveland RO。Response of single 110:228–36。aorticrepair。CatheterCardiovascInterv2020;95: E96–9。cellstoshockwavesandnumericallyoptimized 58。GrayW。Intravascularlithotripsyforperipheral waveforms for cancer therapy。Biophys J 2018; arterycalcification:theDisruptPADIIIrandomized 72。RileyRF,CorlJD,KereiakesDJ。Intravascular 114:1433–9。controlled trial 30-day outcomes。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 417,
      "text": "tripsyforperipheral waveforms for cancer therapy。Biophys J 2018; arterycalcification:theDisruptPADIIIrandomized 72。RileyRF,CorlJD,KereiakesDJ。Intravascular 114:1433–9。controlled trial 30-day outcomes。 Available at: lithotripsy-assisted Impella insertion: a case 45。McAteer JA, Williams JC Jr, Cleveland RO, https://www。vivaphysicians。org/viva-programming report。Catheter Cardiovasc Interv 2019;93: et al。Ultracal-30 gypsum artificial stones for 2020。AccessedMarch23,2021。1317–9。researchonthemechanismsofstonebreakagein 59。CaiWJ,KoltaiS,KocsisE,etal。Remodelingof 73。SaitoS,YamazakiS,TakahashiA,etal。Intra- shockwavelithotripsy。UrolRes2005;33:429–34。theadventitiaduringcoronaryarteriogenesis。Am vascular lithotripsy for vessel preparation in 46。PishchalnikovYA,McAteerJA,WilliamsJCJr, JPhysiolHeartCircPhysiol2003;284:H31–40。severelycalcifiedcoronaryarteriespriortostent placement:primaryoutcomesfromtheJapanese Pishchalnikova IV, Vonderhaar RJ。Why stones 60。PasterkampG,GalisZS,deKleijnDP。Expan- DisruptCADIVstudy。CircJ2021;85(6):826–33。breakbetteratslowshockwaveratesthanatfast sivearterialremodeling:location,location,loca- rates: in vitro study with a research electrohy- tion。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 418,
      "text": "KleijnDP。Expan- DisruptCADIVstudy。CircJ2021;85(6):826–33。breakbetteratslowshockwaveratesthanatfast sivearterialremodeling:location,location,loca- rates: in vitro study with a research electrohy- tion。 Arterioscler Thromb Vasc Biol 2004;24: 74。RileyRF, Henry TD,MahmudE, et al。SCAI drauliclithotripter。JEndourol2006;20:537–41。650–7。positionstatementonoptimalpercutaneouscor- onaryinterventionaltherapyforcomplexcoronary 47。Dashwood MR, Noertersheuser P, 61。MichelJB,ThaunatO,HouardX,MeilhacO, arterydisease。CatheterCardiovascInterv2020; Kirchengast M, Munter K。Altered endothelin-1 CaligiuriG,NicolettiA。Topologicaldeterminants 96:346–62。bindingfollowingballoonangioplastyofpigcor- and consequences of adventitial responses to onaryarteries:effectoftheETAreceptorantag- arterialwallinjury。ArteriosclerThrombVascBiol 75。Maehara A, Mintz GS, Shimshak TM, et al。onist,LU135252。CardiovascRes1999;43:445–56。2007;27:1259–68。IntravascularultrasoundevaluationofJETSTREAM atherectomyremovalofsuperficialcalciuminpe- 4 fis 8 s。u G ri a n s g se a r nd T d C i , ss H ec o t l i z o a n p d fe u l rin G g A b。a M llo o o d n el a in n g gio p p la la q s u t e y 6 ad 2 v。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 419,
      "text": " atherectomyremovalofsuperficialcalciuminpe- 4 fis 8 s。u G ri a n s g se a r nd T d C i , ss H ec o t l i z o a n p d fe u l rin G g A b。a M llo o o d n el a in n g gio p p la la q s u t e y 6 ad 2 v。 e X n u tit F i , al Ji fi J b , r L o i bl L a , st C s he c n on R t , ri H bu u te W s。t A o cti t v h a e tio e n ar o ly f ripheralarteries。EuroIntervention2015;11:96–103。intervention。AnnBiomedEng2007;35:711–23。developmentofatherosclerosis:anovelhypoth- 76。DasT,MustaphaJ,IndesJ,etal。Technique 49。Maglione J, Bergersen L, Lock JE, esis that complements the “response-to-injury optimization of orbital atherectomy in calcified McElhinney DB。Ultra-high-pressure balloon an- hypothesis” and the “inflammation hypothesis”。peripheral lesions of the lower extremities: the gioplasty for treatment of resistant stenoses MedHypotheses2007;69:908–12。CONFIRMseries,aprospectivemulticenterregis- try。CatheterCardiovascInterv2014;83:115–22。within or adjacent to previously implanted pul- 63。WangX,MatsumuraM,MintzGS,etal。Invivo monary arterial stents。Circ Cardiovasc Interv calciumdetectionbycomparingopticalcoherence 77。Abdel-Wahab M, Toelg R, Byrne RA, et al。2009;2:52–8。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 420,
      "text": "implanted pul- 63。WangX,MatsumuraM,MintzGS,etal。Invivo monary arterial stents。Circ Cardiovasc Interv calciumdetectionbycomparingopticalcoherence 77。Abdel-Wahab M, Toelg R, Byrne RA, et al。2009;2:52–8。 tomography,intravascularultrasound,andangi- High-speedrotationalatherectomyversusmodi- 50。MillerDL,SmithNB,BaileyMR,etal。Over- ography。JAmCollCardiolImg2017;10:869–79。fiedballoonspriortodrug-elutingstentimplan- tationinseverelycalcifiedcoronarylesions。Circ view of therapeutic ultrasound applications and 64。Mori H, Torii S, Kutyna M, Sakamoto A, CardiovascInterv2018;11:e007415。safetyconsiderations。JUltrasoundMed2012;31: FinnAV,VirmaniR。Coronaryarterycalcification 623–34。and its progression: what does it really mean。78。Chambers JW, Feldman RL, Himmelstein SI, 51。O’BrienWDJr。Ultrasound-biophysicsmecha- JAmCollCardiolImg2018;11:127–42。etal。Pivotaltrialtoevaluatethesafetyandeffi- nisms。ProgBiophysMolBiol2007;93:212–55。65。Schwartz RS, Huber KC, Murphy JG, et al。c d a e cy n o o f v t o h , eo s r e b v i e ta re l l a y the c r a e lc c i t fi o e m d ys c y o s r t o e n m ar i y ntr l e e a si t o in n g s 52。Ali ZA, Brinton TJ, Hill JM, et al。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 421,
      "text": "y JG, et al。c d a e cy n o o f v t o h , eo s r e b v i e ta re l l a y the c r a e lc c i t fi o e m d ys c y o s r t o e n m ar i y ntr l e e a si t o in n g s 52。Ali ZA, Brinton TJ, Hill JM, et al。 Optical Restenosis and the proportional neointimal (ORBITII)。JAmCollCardiolIntv2014;7:510–8。coherencetomographycharacterizationofcoro- response to coronary artery injury: results in a narylithoplastyfortreatmentofcalcifiedlesions: porcinemodel。JAmCollCardiol1992;19:267–74。79。BilodeauL,FretzEB,TaeymansY,KoolenJ, fi 8 r 9 s 7 t – d 9 e 0 s 6 c。ription。JAmCollCardiolImg2017;10: 6 In 6 tr。a A v d a a sc m u s la G r , lit S h h o a t m ri m ps a y s f N or , t M re a a n t g m a e lm nt ur o t f i c S a , l e ci t fie al d。T e co x a c r y o i l m o n r a e r r K y , l a a H r s t e i e l r t r o y c n a le t D h si e J o。t n e N s r。o C f v o a e r t l h c u e a t s l e c e r ifi o C e f a d r a d a i h o n i v d g a h s c - c o e m I n n e p t r e l g e rv y x 53。Holden A。Safety and performance of the lowerextremityarterialstenosis:initialanalysisof 2004;62:155–61。ShockwaveLithoplastySystemintreatingcalcified theDisruptPADIIIstudy。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 422,
      "text": " n e p t r e l g e rv y x 53。Holden A。Safety and performance of the lowerextremityarterialstenosis:initialanalysisof 2004;62:155–61。ShockwaveLithoplastySystemintreatingcalcified theDisruptPADIIIstudy。 JEndovascTher2020; peripheral vascular lesions: intravascular OCT 27:473–80。analysis。Leipzig,Germany:LINC;2018。67。McGarveyM,KumarS,ViolarisA,etal。Ven- KEYWORDS calcification,coronaryartery 54。IsnerJM,DonaldsonRF,FortinAH,TischlerA, tricularfibrillationinducedbyalithotripsy-pulse disease,intravascularlithotripsy,peripheral ClarkeRH。Attenuationofthemediaofcoronary on T during coronary intravascular shockwave arterydisease arteriesinadvancedatherosclerosis。AmJCardiol lithotripsy。EurHeartJCaseRep2020;4:1–3。1986;58:937–9。68。ShaikFA,SlotwinerDJ,GustafsonGM,DaiX。55。Madhavan MV, Shahim B, Mena-Hurtado C, Intra-proceduralarrhythmiaduringcardiaccathe- APPENDIX Forsupplementalfigures,a GarciaL,CrowleyA,ParikhSA。Efficacyandsafety terization:asystematicreviewofliterature。World video,andtables,pleaseseetheonlineversion of intravascularlithotripsy for the treatment of JCardiol2020;12:269–84。ofthispaper。",
      "source": "1-s2.0-S193687982100501X-main.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 423,
      "text": "中国胸心血管外科临床杂志 2024年12月第31卷第12期 • 1713 • 指南与规范 中国经导管主动脉瓣置换术临床路径 专家共识（2024版） 中国医师协会心血管内科医师分会结构性心脏病学组，亚太结构性心脏病俱乐部 【摘要】 本文采用德尔菲法更新了《中国经导管主动脉瓣置换术临床路径专家共识（2021版）》，通过检索 近4年PubMed、中国知网及万方数据库经导管主动脉瓣置换术（transcatheter aortic valve replacement，TAVR）临 床路径相关的证据，在TAVR团队的构成与临床评估、围术期影像学评估、手术过程、患者围术期及远期管理 4个方向提出了35个核心观点。具体更新点包括：细化TAVR团队的职责与构成，明确临床评估的步骤与内 容；强调CT在围术期影像学评估中的核心地位，并介绍了人工智能、数值仿真及3D打印等新技术的应用；优 化TAVR手术流程，包括麻醉选择、入路建立、瓣膜选择及释放等关键环节；提出针对特殊类型患者（如急诊 TAVR、简化TAVR、单纯主动脉瓣反流、合并冠状动脉粥样硬化性心脏病及心房颤动等）的管理策略。此外，共 识还强调了术后随访和康复的重要性，并提供了详细的抗血栓及康复指导。本共识的更新将进一步推动我国 TAVR技术的规范发展，提升临床治疗效果。【关键词】 经导管主动脉瓣置换术；临床评估；影像学评估；规范化手术流程；围术期管理；专家共识 2024 expert consensus on clinical pathway for transcatheter aortic valve replacement in China Structural Cardiology Committee of Cardiovascular Physicians Branch, Chinese Medical Doctor Association, Asia Pacific Structural Heart Disease Club Corresponding authors: SONG Guangyuan, Email: songgy_anzhen@vip。163。com; PAN Wenzhi, Email: peden@sina。com; ZHOU Daxin, Email: zhou。daxin@zs-hospital。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 424,
      "text": "ation, Asia Pacific Structural Heart Disease Club Corresponding authors: SONG Guangyuan, Email: songgy_anzhen@vip。163。com; PAN Wenzhi, Email: peden@sina。com; ZHOU Daxin, Email: zhou。daxin@zs-hospital。 sh。cn; WU Yongjian, Email: yongjianwu_nccd@163。com 【Abstract】 We update the \"2021 expert consensus on clinical pathway for transcatheter aortic valve replacement in China\" using the Delphi method。By searching for evidence related to the clinical pathways of transcatheter aortic valve replacement (TAVR) in PubMed, CIKI, and Wanfang Database over the past four years, 35 core viewpoints were proposed in four directions: TAVR team composition and clinical evaluation, perioperative imaging assessment, surgical process, and perioperative and postoperative long-term management of patients。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 425,
      "text": "re proposed in four directions: TAVR team composition and clinical evaluation, perioperative imaging assessment, surgical process, and perioperative and postoperative long-term management of patients。 The specific updates include: refining the responsibilities and composition of the TAVR team, clarifying the steps and content of clinical evaluation; emphasizing the core position of CT in perioperative imaging assessment, and introducing the application of new technologies such as artificial intelligence, numerical simulation, and 3D printing; optimizing the TAVR surgical process, including anesthesia selection, access establishment, valve selection and release, and others; and proposing management strategies for special types of patients (such as emergency TAVR, simplified TAVR, pure aortic regurgitation, combined coronary heart disease and atrial fibrillation)。In addition, the consensus also emphasizes the importance of postoperative follow-up and rehabilitation, and provides detailed antithrombotic and rehabilitation guidance。The update of this consensus will further promote the standardized development of TAVR technology in China and improve clinical treatment effects。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 426,
      "text": "s detailed antithrombotic and rehabilitation guidance。The update of this consensus will further promote the standardized development of TAVR technology in China and improve clinical treatment effects。 【Key words】 Transcatheter aortic valve replacement; clinical evaluation; imaging assessment; standardized procedures; perioperative management; expert consensus Foundation items: National Key Research and Development Program of China (2020YFC2008100); Capital C linical Characteristic Application Research and Production Promotion (Z221100007422117) DOI：10。7507/1007-4848。202410009 基金项目：国家重点研发计划（2020YFC2008100）；首都临床特色诊疗技术研究及转化应用项目（Z221100007422117） 通信作者：宋光远，Email：songgy_anzhen@vip。163。com；潘文志，Email：peden@sina。com；周达新，Email：zhou。daxin@zs- hospital。sh。cn；吴永健，Email：yongjianwu_nccd@163。com 本文同时发表在《中国循环杂志》第39卷第11期，《中国介入心脏病学杂志》第32卷第11期 http://www。tcsurg。org • 1714 • Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, Dec。2024, Vol。31, No。12 近3年来，经导管主动脉瓣置换术（trans- 1。3。1 TAVR的绝对适应证 主动脉根部及入路解 catheter aortic valve replacement，TAVR）领域在循 剖结构符合TAVR（特别是经股动脉TAVR）要求 证证据、应用经验、指南更新、器械研发、术式改良 且预期寿命>1年。等方面陆续取得重要进展。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 427,
      "text": "ar Surgery, Dec。2024, Vol。31, No。12 近3年来，经导管主动脉瓣置换术（trans- 1。3。1 TAVR的绝对适应证 主动脉根部及入路解 catheter aortic valve replacement，TAVR）领域在循 剖结构符合TAVR（特别是经股动脉TAVR）要求 证证据、应用经验、指南更新、器械研发、术式改良 且预期寿命>1年。等方面陆续取得重要进展。 为进一步契合最新证 （1）年龄≥70岁，有下列情况之一： 据经验，推进我国TAVR治疗技术规范、安全、稳 ① 重度主动脉瓣狭窄（aortic stenosis，AS）患 步发展，我们检索最新文献，依据德尔菲方法，更 者有AS导致的如下临床症状：运动性呼吸困难、 新了2018和2021版TAVR临床路径专家共识[1-2]。心力衰竭、心绞痛、晕厥、既往或运动试验时晕厥 方法参考2021版共识[2]。先兆。② 运动试验可以诱发症状或血压下降的无症 1 TAVR团队的构成与临床评估 状重度AS患者。1。1 TAVR团队的构成 ③ 无症状的重度AS，左心室射血分数（left 核心观点1：TAVR团队是一个由多学科组成 ventricular ejection fraction，LVEF）<55%（无其他诱 的综合管理团队，负责术前评估、手术策略制 因导致的左心室收缩功能不全）。定、手术实施及术后全病程管理。④ 无症状的重度AS，LVEF>55%，运动试验结 一个完整的TAVR团队包括心血管内科医师、 果正常，干预风险低且具备以下条件之一：极重 影像评估医师、心脏瓣膜病介入医师、心血管外科 度AS［平均压差 ≥60 mm Hg（1 mm Hg=0。133 kPa） 手术医师、重症监护室医师、麻醉科医师、导管室 或最大峰值流速>5 m/s］；重度瓣膜钙化（经CT评 技术人员、护理及康复管理人员等[3-4]。TAVR团队 估）且最大峰值流速进展≥0。3 m/（sa）；经重复检 需要完成患者术前评估、制定手术策略并评估其可 测确认无其他诱因的B型利钠肽显著升高（大于经 行性、实施TAVR并进行围术期管理以及术后全病 性别、年龄校正的正常值的3倍）。程管理。（2）年龄<70岁的重度AS患者，存在外科手术 1。2 临床评估 禁忌或高危，或存在其他危险因素，如胸部放射治 核心观点2：临床评估是以患者主动脉瓣疾病 疗后、肝功能衰竭、主动脉弥漫性严重钙化、极度 干预指征为核心的临床综合评估，其重点包括 虚弱等[2]。TAVR的适应证、手术方式选择及禁忌证三大步 （3）外科主动脉生物瓣膜毁损。骤。内容包括主动脉瓣疾病症状及严重程度评 1。3。2 TAVR的相对适应证 （1）年龄60～69岁的 估、临床基线数据的采集、心血管相关合并症的 患者，满足1。3。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 428,
      "text": "，如胸部放射治 核心观点2：临床评估是以患者主动脉瓣疾病 疗后、肝功能衰竭、主动脉弥漫性严重钙化、极度 干预指征为核心的临床综合评估，其重点包括 虚弱等[2]。TAVR的适应证、手术方式选择及禁忌证三大步 （3）外科主动脉生物瓣膜毁损。骤。内容包括主动脉瓣疾病症状及严重程度评 1。3。2 TAVR的相对适应证 （1）年龄60～69岁的 估、临床基线数据的采集、心血管相关合并症的 患者，满足1。3。 1 TAVR的绝对适应证（1）中的条件 评估、非心血管相关合并症的评估、老年综合评 之一，经过临床团队综合评估认为更适合行TAVR 估、神经系统功能评估和无效性评估。手术。瓣膜置换的适应证和预期获益主要通过评估 （2）二叶式重度AS患者满足上述条件之一， 患者超声心动图及临床症状，确定主动脉瓣疾病的 可在有经验的中心（年手术量≥50例）或术者（年手 严重程度及风险分期，从而确认干预时机及获 术量≥25例）中开展。益[2,5]。在手术方式选择方面，外科风险评分不再是 （3）有症状的重度单纯主动脉瓣反流（pure 衡量主动脉瓣疾病治疗方式的独立指标，而是综合 aortic regurgitation，PAR）患者，外科手术禁忌或高 考虑患者临床情况、解剖特点、手术意愿以及预期 危，预期治疗后能够临床获益，解剖特点经过充分 寿命等因素，由心脏综合管理团队决策。禁忌证评 评估适合TAVR，可在有经验的中心（年手术量 估方面则需要根据患者临床资料的全面采集了解 ≥50例）或术者（年手术量 ≥25例）中开展[10]。有无急性心肌梗死、流出道梗阻、左心血栓形成或 （4）无症状的重度PAR患者，外科手术禁忌或 解剖不适合TAVR的情况，同时还需进行无效性评 高危，预期治疗后能临床获益，解剖特点经过充分 估，考量术后预期寿命及生活质量改善的可能[2,6-9]。评估适合TAVR，需满足下述条件之一：左心室舒 1。3 TAVR的适应证和禁忌证 张末期内径>70 mm；左心室收缩末期内径>50 mm； 核心观点3：近年来TAVR指南更新的重点是 左心室收缩末期内径指数>25 mm/m2；LVEF≤55%， 适应证的拓展和干预方式的转变，强调干预方式 可在有经验的中心（年手术量≥50例）或术者（年手 选择依赖于临床评估团队和根据患者个体化的临 术量≥25例）中开展。床和解剖特点共同决策[2]。1。3。3 TAVR的禁忌证 TAVR的禁忌证参考 http://www。tcsurg。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 429,
      "text": "径>50 mm； 核心观点3：近年来TAVR指南更新的重点是 左心室收缩末期内径指数>25 mm/m2；LVEF≤55%， 适应证的拓展和干预方式的转变，强调干预方式 可在有经验的中心（年手术量≥50例）或术者（年手 选择依赖于临床评估团队和根据患者个体化的临 术量≥25例）中开展。床和解剖特点共同决策[2]。1。3。3 TAVR的禁忌证 TAVR的禁忌证参考 http://www。tcsurg。 org 中国胸心血管外科临床杂志 2024年12月第31卷第12期 • 1715 • 表 1 TAVR术前影像学评估方法的推荐 项目 首选 次选 备选 心脏瓣膜 瓣环大小和形状 CT TEE、CMR 3D TTE 瓣叶数量 CT TEE、TTE CMR 钙化程度 CT TEE、TTE 冠状动脉 开口到瓣环距离 CT − TEE、CMR、造影 合并冠心病 造影 CT、SPECT、PET − 入路 同轴性 CT − − 升主动脉 CT CMR TEE 主动脉斑块 CT − TEE、CMR、造影 髂动脉及股动脉 CT − 造影、CMR TAVR：经导管主动脉瓣置换术；TTE：经胸超声心动图；TEE：经食管超声心动图；CMR：心脏磁共振成像；SPECT：单光子发射计 算机断层成像；PET：正电子发射断层成像；3D：三维 2021版共识[2]。图像质量或完整度不足以满足TAVR术前规划 的相关评估要求，则需要进行二次检查或补充 2 TAVR围术期影像学评估 扫描[11]。核心观点4：TAVR围术期影像学评估中术前 术前测量评估：需要有经验的影像核心实验 评估最为关键。CT是评估主动脉根部及入路解剖 室对CT图像通过专业软件进行分析，主要观察主 结构和钙化的最重要手段，特定情况下超声心动 动脉根部和入路的形态学特征，其中主要包括瓣叶 图、心脏磁共振成像（cardiac magnetic 分型、钙化情况、主动脉瓣环上下相关解剖径线、 resonance，CMR）、造影等检查方式可以达到协 冠状动脉开口、左心室、入路血管管壁钙化程度、 同或替代评估作用。人工智能分析、数值仿真及 管腔狭窄程度及走行迂曲程度、合并严重的主动脉 三维（three dimension，3D）打印等新技术未来可 病变（动脉瘤、夹层及闭塞等）等指标[12-13]。能成为TAVR围术期评估的重要补充（表1）。核心观点6：术者需要熟练掌握CT影像评估 2。1 CT评估 方法并对结果进行充分解读及个体化分析，可根 核心观点5：CT在TAVR术前评估、术中指 据图像结果识别解剖难度、评估风险并制定正确 导以及术后随访中处于核心地位，是术前人工瓣 的手术策略[2]。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 430,
      "text": "ee dimension，3D）打印等新技术未来可 病变（动脉瘤、夹层及闭塞等）等指标[12-13]。能成为TAVR围术期评估的重要补充（表1）。核心观点6：术者需要熟练掌握CT影像评估 2。1 CT评估 方法并对结果进行充分解读及个体化分析，可根 核心观点5：CT在TAVR术前评估、术中指 据图像结果识别解剖难度、评估风险并制定正确 导以及术后随访中处于核心地位，是术前人工瓣 的手术策略[2]。 膜及入路选择的影像“金标准”[2]，推荐心电门控 术中、术后CT评估：通过CT可对导丝跨瓣 全时相CT血管造影（CT angiography，CTA）扫 及最佳释放角度进行预测，以减少术中X线的辐射 描作为主动脉根部解剖评估的重要手段。剂量及对比剂的使用并精确指导释放深度及位置， TAVR术前CT检查图像采集需评估患者心脏 对于解剖结构复杂及单纯反流患者选择合理的投 肾脏功能以及相关用药，尽量采用64排及以上 照角度尤为重要[2]。术后通过主动脉根部CT可判 CT扫描设备。检查应包括3个方面内容：（1）心 断TAVR瓣膜置换位置及深度、瓣架膨胀程度及圆 电门控非增强CT扫描；（2）心电门控全时相 度，对功能区严重膨胀不良或椭圆率较高的患者可 CTA扫描；（3）大范围非心电门控螺旋CTA扫 考虑再次进行经导管球囊扩张成形术治疗。同时 描，扫描范围及重建参数需特别关注（表2）。对比 术后CT可观察联合部错位程度及冠状动脉开口是 剂注射流率及总量的确定需综合考虑选用的对比 否受到人工瓣膜缝制区或外裙边遮挡，评估冠状动 剂浓度、管电压、设备扫描速度、患者静脉血管条 脉通路通畅性及再介入可行性[14]。通过舒张期及四 件、患者体重、心肾功能状态等因素。TAVR术前 维（four dimension，4D）CT动态观察瓣叶，可了解 CTA检查需立刻评价图像质量及扫描完整度，如 有无异常瓣叶增厚或血栓形成来评价器械远期效 http://www。tcsurg。org • 1716 • Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, Dec。2024, Vol。31, No。12 表 2 TAVR术前CT推荐扫描范围、扫描模式及重建参数 CT检查 推荐扫描范围 推荐扫描方式 推荐重建参数 心电门控非增强 覆盖主动脉根部区域和全部心脏 舒张期前瞻性心电门控扫描 （1）舒张期重建； CT扫描 （2）小视野重建； （3）层厚亚毫米级（计算冠状动脉钙化积 分、主动脉瓣钙化时可用2。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 431,
      "text": "nd Cardiovascular Surgery, Dec。2024, Vol。31, No。12 表 2 TAVR术前CT推荐扫描范围、扫描模式及重建参数 CT检查 推荐扫描范围 推荐扫描方式 推荐重建参数 心电门控非增强 覆盖主动脉根部区域和全部心脏 舒张期前瞻性心电门控扫描 （1）舒张期重建； CT扫描 （2）小视野重建； （3）层厚亚毫米级（计算冠状动脉钙化积 分、主动脉瓣钙化时可用2。 5 mm重建） 心电门控全时相 上界：气管隆突处（包括升主动脉中段）； 建议全心动周期回顾性心电门 （1）以10% R-R间期为间隔重建多期图像； CTA扫描 下界：心脏下缘（全部心脏） 控扫描 （2）小视野重建； （3）层厚亚毫米级 大范围非心电门控 上界：下颌角水平（包括部分颈总动脉）； （1）非心电门控螺旋扫描； （1）大视野重建； 螺旋CTA扫描 下界：股骨小转子水平（包括左右股动脉 （2）双源CT建议行大螺距扫描 （2）层厚亚毫米 近段） TAVR：经导管主动脉瓣置换术；CTA：CT血管造影 果或制订抗凝抗栓策略。目前高分辨率4D CT是 表 3 生物瓣膜退化的阶段分级 诊断TAVR瓣膜血栓形成的金标准，主要影像学特 项目 内容 征是不同程度的低衰减瓣叶增厚征和瓣叶运动 阶段1 形态学瓣膜退化：结构性瓣膜退化，非结构性瓣膜功能 减弱[2]。障碍（除瓣周漏或瓣膜-患者不匹配之外），血栓形成或 核心观点7：建议TAVR术后半年内常规行全 心内膜炎的证据，但没有显著的血流动力学影响 时相CT扫描，评价瓣膜置换效果、位置、冠状动 阶段2 中度血流动力学瓣膜退化：与术后1～3个月进行的超 声心动图评估相比，平均跨瓣压差增加≥10 mm Hg，导 脉再介入可行性及血栓情况，制定合理抗栓方案。致平均压差≥20 mm Hg，并伴有效瓣口面积减少≥0。3 cm2 2。2 超声心动图评估 或≥25%，和/或多普勒速度指数减少≥0。1或≥20%；或 核心观点8：超声心动图主要评价主动脉瓣病 者新发或增加≥1级的假体内AR，导致中度及以上AR 变的严重程度、其他瓣膜和心脏功能及围术期并 阶段3 重度血流动力学瓣膜退化：与术后1～3个月进行的超 声心动图评估相比，平均跨瓣压差增加≥20 mm Hg，导 发症，是围术期影像评价的重要手段。致平均压差≥30 mm Hg，并伴有效瓣口面积减少≥0。6 cm2 术前评估、术中监测及术后随访的方法及要点 或≥50%，和/或多普勒速度指数减少≥0。2或≥40%；或 参考2021版共识[2]。者新发或增加≥2级的假体内AR，导致重度AR 基于目前TAVR适应证向外科低危患者拓展， AR：主动脉瓣反流 人工生物瓣膜耐久性成为术后评价的重要指标。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 432,
      "text": " mm Hg，导 发症，是围术期影像评价的重要手段。致平均压差≥30 mm Hg，并伴有效瓣口面积减少≥0。6 cm2 术前评估、术中监测及术后随访的方法及要点 或≥50%，和/或多普勒速度指数减少≥0。2或≥40%；或 参考2021版共识[2]。者新发或增加≥2级的假体内AR，导致重度AR 基于目前TAVR适应证向外科低危患者拓展， AR：主动脉瓣反流 人工生物瓣膜耐久性成为术后评价的重要指标。 瓣膜学术联盟-3标准[15]所提出的生物瓣膜功能障 望进一步降低手术并发症风险，成为TAVR术前 碍分为结构性瓣膜退化、非结构性瓣膜功能障碍、 评估的重要手段[16]。临床瓣膜血栓形成或心内膜炎。其中结构性瓣膜 基于人工智能的TAVR术前评估：通过导入 退化被定义为人工瓣膜发生的内在性永久性变化， 高质量CTA影像至分析系统，自动完成主动脉根 包括磨损、瓣叶破损、瓣叶连枷、瓣叶纤维化和/或 部多目标精细分割与3D重建，自动识别瓣叶分 钙化、支架断裂或变形；非结构性瓣膜功能障碍被 型、窦底及冠状动脉开口，精确定位关键解剖结构 定义为人工瓣膜本身以外的任何因素导致的瓣膜 并测量，同时动态评估钙化斑块，辅助术者精准规 功能障碍。划手术方案，提升手术成功率。核心观点9：生物瓣膜功能障碍严重程度的主 基于人工智能TAVR术后评估：通过对瓣膜 要衡量指标为跨瓣压差绝对值升高、跨瓣压差较 支架的高精度分割、去伪影操作和逐层的全自动形 前进展、有效瓣口面积减少以及多普勒速度指数 态学指标定量评估，能够精准评价支架膨胀程度和 减少等（表3），作为术后超声心动图随访评价瓣 效果，为复盘手术过程、优化手术策略、改进器械 膜耐久性的重要指标，需特别关注。设计提供重要参考依据。2。3 人工智能分析、数值仿真及3D打印技术 TAVR手术数值模拟仿真及3D打印技术：TAVR 核心观点10：人工智能及3D打印等影像学新 数值模拟仿真可以根据患者解剖特点，通过计算机 技术应用于TAVR患者影像学分析，可辅助提升 数值模拟不同尺寸和类型支架的置入效果，选择最 评估的精准性和效率、缩短术者的学习曲线，有 优瓣膜型号和释放位置，分析并发症风险（图1）。http://www。tcsurg。org 中国胸心血管外科临床杂志 2024年12月第31卷第12期 • 1717 • 图 1 人工智能分析主动脉根部及经导管主动脉瓣置换术数值模拟仿真效果 Ascending Aorta：升主动脉；STJ：窦管交界；SOV：瓦氏窦；LVOT：左心室流出道；PD：周长衍生直径；AD：面积衍生直径； Aortic Annulus：主动脉瓣环；L：左冠窦；R：右冠窦；N：无冠窦 3D打印技术通过CT构建3D模型进行仿真与体外 要，应根据患者状况采用不同的麻醉方式。模拟，优化手术策略与效果[17-18]。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 433,
      "text": "分析主动脉根部及经导管主动脉瓣置换术数值模拟仿真效果 Ascending Aorta：升主动脉；STJ：窦管交界；SOV：瓦氏窦；LVOT：左心室流出道；PD：周长衍生直径；AD：面积衍生直径； Aortic Annulus：主动脉瓣环；L：左冠窦；R：右冠窦；N：无冠窦 3D打印技术通过CT构建3D模型进行仿真与体外 要，应根据患者状况采用不同的麻醉方式。模拟，优化手术策略与效果[17-18]。 利用3D打印具有 麻醉方式包括：局部麻醉、镇静或监护麻醉、 内部传感器的主动脉根部模型模拟TAVR，可以映 全身麻醉。患者本身、术者和麻醉医师、TAVR入 射出施加在主动脉根部关键区域的压力，判断介入 路是决定TAVR麻醉方式选择的主要因素，其中入 瓣膜锚定的稳定性、传导阻滞风险等问题[19]。同 路是最主要的因素[24-27]。经股动脉入路TAVR建议 时，3D打印模型还可通过4D MR技术识别并量化 优选镇静或监护麻醉方式，对于特殊入路、危重患 TAVR术后瓣周漏，助力瓣周漏检测与量化[20]。而 者及各中心早期开展阶段可选择全身麻醉。水凝胶瓣膜与熔融电铸技术制造的高度可调且空 3。3 入路选择和建立 间异质性的纤维管状支架是目前3D生物打印的前 核心观点14：股动脉入路是TAVR最主要的 沿方向[21-22]。入路，90%以上患者可以选择股动脉入路。对于 2。4 CMR评估 股动脉，如无钙化，一般置入鞘管外面积可以超 核心观点11：在TAVR术前评估中，CMR可 过血管面积20%～30%。在我国，颈动脉、锁骨下 在特定条件下作为CT的合理替代方案。动脉（腋动脉）途径已成为仅次于股动脉途径的 CMR可精确测量主动脉根部的尺寸和形态， 常用外周血管入路。帮助确定解剖适应证并制定手术策略及器械选择， 经股动脉入路的方法参考2021版共识[2]。其 同时无创地评估从主动脉根部到外周血管的解剖 他入路建议需有血管外科或心脏外科支持，并且在 结构，帮助选择最佳导管路径，减少术中并发症。经验较为丰富且具备完善心脏团队的TAVR中心 其避免对比剂和辐射、对心功能和心肌纤维化疤痕 来完成，具体入路也需要依据器械特点、患者解剖 组织评估能力强等特点具有一定优势和临床应用 情况，由心脏团队讨论后决定[28-29]。近期，国内开始 价值[23]。尝试All in one技术，应用单支血管入路完成经股 动脉TAVR治疗[30-32]。3 TAVR的手术过程 3。4 瓣膜选择 3。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 434,
      "text": "术中并发症。经验较为丰富且具备完善心脏团队的TAVR中心 其避免对比剂和辐射、对心功能和心肌纤维化疤痕 来完成，具体入路也需要依据器械特点、患者解剖 组织评估能力强等特点具有一定优势和临床应用 情况，由心脏团队讨论后决定[28-29]。近期，国内开始 价值[23]。尝试All in one技术，应用单支血管入路完成经股 动脉TAVR治疗[30-32]。3 TAVR的手术过程 3。4 瓣膜选择 3。 1 场地及器械准备 核心观点15：进行瓣膜选择时应结合术前 核心观点12：完整的多学科团队和完善的杂 CT综合评估结果，如瓣膜分型、瓣膜钙化分布、 交手术室是TAVR手术的最好保障，但随着技术 冠状动脉堵塞风险、永久起搏器植入可能性、瓣 的发展和熟练程度的增加，各中心根据医院条 环破裂风险、生物瓣膜不匹配等，并根据患者血 件、团队配备情况在保障手术安全顺利的情况 管入路情况和人工瓣膜特性，做到个体化选择， 下，因地制宜地在导管室采用简化TAVR是可以 必要时结合术中球囊扩张的结果[2]。推荐的。需根据术前评估方案及患者个体化需求 目前中国大陆共有8款经股动脉入路的TAVR 充分准备好手术器械。瓣膜、1款经心尖入路的TAVR瓣膜上市，包括球 3。2 麻醉准备与选择 囊扩张式瓣膜、自膨胀式瓣膜两大类，其中已有 核心观点13：充分的麻醉术前准备非常必 4款升级为可回收系统。数款针对PAR的经股动 http://www。tcsurg。org • 1718 • Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, Dec。2024, Vol。31, No。12 脉途径瓣膜已经完成临床试验，即将应用于临床。球囊型号，同时应考虑是否有球囊扩张时观察球囊 3。5 脑保护装置的使用 腰部及根部造影反流量、评估冠状动脉闭塞风险的 核心观点16：TAVR术前完善脑血管和神经 需要进行型号调整。对于瓣叶重度钙化、瓣叶交界 系统功能评估，对于高危栓塞风险患者，与神经 粘连、二叶式主动脉瓣的AS患者，建议球囊预扩 内外科及血管外科专家共同制定治疗策略，并推 张，但尽量避免多次球囊预扩张。球囊扩张前充分 荐使用脑保护装置。考虑可能发生的风险，准备好应对措施。TAVR术后高危栓塞风险包括既往脑卒中史、 3。7 瓣膜的输送、定位及释放 高龄、新发心房颤动、冠状动脉粥样硬化性心脏病 核心观点18：瓣膜输送时，应特别关注跨越 （冠心病）史、外周血管病史、术中反复球囊扩张、 主动脉弓和主动脉瓣这两个位置的过程。不同瓣 心脏瓣膜移位、高流速高压差等因素[15]。现有研究 叶结构类型和瓣膜型号对起始定位的高度要求有 表明TAVR期间应用脑保护装置安全性高，但其临 所不同，应从术前CT分析中确定TAVR瓣膜的锚 床结果仍需更多研究证实。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 435,
      "text": "放 高龄、新发心房颤动、冠状动脉粥样硬化性心脏病 核心观点18：瓣膜输送时，应特别关注跨越 （冠心病）史、外周血管病史、术中反复球囊扩张、 主动脉弓和主动脉瓣这两个位置的过程。不同瓣 心脏瓣膜移位、高流速高压差等因素[15]。现有研究 叶结构类型和瓣膜型号对起始定位的高度要求有 表明TAVR期间应用脑保护装置安全性高，但其临 所不同，应从术前CT分析中确定TAVR瓣膜的锚 床结果仍需更多研究证实。 定区和封堵区[2]，决定起始位置及优选释放位置。3。6 瓣膜置换前的准备 瓣膜输送的操作要点见2021版共识[2]。二叶 核心观点17：瓣膜置换前应基于临床和影像 式主动脉瓣大多数需要高位释放，其瓣膜的锚定区 评估结果合理制定手术方案。包括临时起搏电极 多数是瓣上结构；而对于三叶式主动脉瓣，多数的 植入、跨瓣角度的选择以及跨瓣导丝的操作、瓣 锚定区在瓣环到流出道之间，一般选择标准位释 膜释放角度的判定、球囊预扩张方案、瓣膜类型及 放。瓣膜释放过程中可能需要应用快速起搏，根据 型号选择和可能出现的并发症以及处理预案。瓣膜类型以及释放策略不同，起搏频率常规120～ 临时起搏电极植入：TAVR术中的临时快速起 220次/min[2]。搏用于球囊扩张或瓣膜释放过程中减弱心脏搏动 3。8 瓣膜置换后的评估 幅度以减少球囊或瓣膜移位[2]。左心室导丝起搏技 核心观点19：术后应观察血流动力学情况， 术的应用逐渐增加[33]，但对于高风险患者仍建议传 通过超声心动图和主动脉根部造影评估瓣膜的位 统起搏方式，必要时TAVR术后留置临时起搏电 置及反流情况，同时观察二尖瓣、左心室功能以 极24～48 h[34]。经颈静脉或锁骨下静脉置入心室主 及术中并发症[2]。动电极，不仅可以满足术中起搏需要，必要时还可 TAVR术后瓣膜反流的评估：TAVR术后的瓣 以桥接到过渡性永久起搏器技术以延长观察时间、 膜反流根据其位置分为中心型反流以及瓣周漏。有利于患者早期活动[35]。瓣周漏与严重钙化、瓣环偏心、瓣膜尺寸过小、瓣 跨瓣角度的选择以及跨瓣导丝的操作：术前 膜置入过深等原因相关。通过CT可帮助选择最合适的跨瓣角度及优先透视 瓣周漏的评估应该建立综合评估体系： 角度。跨瓣的核心步骤是逐步有序地调整导管轴 （1）造影评估：根据左心室内对比剂相对密度 向及高度，操作导丝头端跨过瓣口，及时更换不同 评估反流程度，初筛反流，粗估反流总量，但不能 指引导管进行尝试[2]。对于跨瓣困难的患者，也可 评估反流数目、位置、方向。根据Selles分级标准， 采用经房间隔和经心尖穿刺后顺行跨瓣后抓捕导 分为4个等级：Ⅰ级：无反流；Ⅱ级：轻度反 丝建立轨道。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 436,
      "text": "立综合评估体系： 角度。跨瓣的核心步骤是逐步有序地调整导管轴 （1）造影评估：根据左心室内对比剂相对密度 向及高度，操作导丝头端跨过瓣口，及时更换不同 评估反流程度，初筛反流，粗估反流总量，但不能 指引导管进行尝试[2]。对于跨瓣困难的患者，也可 评估反流数目、位置、方向。根据Selles分级标准， 采用经房间隔和经心尖穿刺后顺行跨瓣后抓捕导 分为4个等级：Ⅰ级：无反流；Ⅱ级：轻度反 丝建立轨道。 流：造影剂进入左心室流出道及中部，经过1次心 瓣膜释放角度的选择：术前通过多排CT对器 搏即可排除；Ⅲ级：中度反流：造影剂进入整个 械释放角度进行预测，结合术中主动脉根部造影， 左心室，1次心搏不能完全清除，经过数次心搏后 确定瓣膜最佳释放角度，常用方法包括右窦中心 显影变淡；Ⅳ级：重度反流：整个左心室及主动 位、左右窦重叠位（Cusp-overlap）及双S曲线技术[2]。脉均匀显影，1次心搏后仍保持。若存在特殊结构关注点或风险，例如存在冠状动脉 （2）Sinning和Hasan主动脉瓣反流指数（aortic 堵塞风险时可选择冠状动脉切线位造影观察。对 regurgitation index，ARI）作为评估指标：ARI=（主 于二叶式主动脉瓣患者，最理想角度通常为平行于 动脉舒张压−左心室舒张末期压力）/主动脉收缩压 交界区连线的方向（双窦展开位），无论采取何种 100，或ARI=（主动脉舒张压−左心室舒张末期压 方法，均需要打齐瓣环平面。力）/心率80。ARI与反流程度呈负相关，ARI<25 球囊预扩张：术前应根据CT评估瓣环及瓣上 患者术后1年病死率是ARI>25患者的2。9倍，故 结构径线和患者心功能及临床状态来选择合适的 ARI阈值定为25，作为判断瓣周漏是否需要采取进 http://www。tcsurg。org 中国胸心血管外科临床杂志 2024年12月第31卷第12期 • 1719 • 一步治疗的评估依据。表 4 脑卒中的预防措施 （3）超声心动图多普勒评估：TAVR术后超声 措施 作用 心动图评估时需要尽可能将患者血流动力学控制 术前 在较稳定的范围内，新发快速心律失常可影响瓣周 头颅CT/颈部动脉超声 高危患者筛查 漏判断，必要时可使用药物干预。计算彩色多普勒 TAVR CT评估最佳跨瓣角度 减少跨瓣操作，并缩短时间 反流束的内径与左心室流出道的比值、胸骨旁短轴 TAVR CT评估主动脉根部结构 合理预扩张 切面测量的弧状反流长度与瓣环长度的比值（无： TAVR CT评估升主动脉及弓部 选择合适器械降低过弓风险 无彩色反流；轻度：10%以下；中度：10%～30%， 结构 重度：>30%）、主动脉舒张期反向血流频谱。术中 3。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 437,
      "text": "使用药物干预。计算彩色多普勒 TAVR CT评估最佳跨瓣角度 减少跨瓣操作，并缩短时间 反流束的内径与左心室流出道的比值、胸骨旁短轴 TAVR CT评估主动脉根部结构 合理预扩张 切面测量的弧状反流长度与瓣环长度的比值（无： TAVR CT评估升主动脉及弓部 选择合适器械降低过弓风险 无彩色反流；轻度：10%以下；中度：10%～30%， 结构 重度：>30%）、主动脉舒张期反向血流频谱。术中 3。 9 TAVR术中常见并发症的处理 优化释放方式 避免反复释放及回收 核心观点20：常见并发症包括循环崩溃、瓣 超声和影像评估 合理后扩张 周漏、瓣膜移位、冠状动脉闭塞、心肌梗死、脑 缩短高速起搏时间 避免低灌注 卒中、血管并发症、传导阻滞，需特别关注。麻醉 TAVR术中常见并发症包括[15]： （1）循环崩溃：循环崩溃常见原因包括术中新 局部麻醉加镇静麻醉方式 更好监测患者神经系统功能 发急性主动脉瓣反流、术前心功能低下、冠状动脉 TAVR：经导管主动脉瓣置换术 阻塞、难以耐受高频起搏、瓣环破裂、心脏压塞、自 杀左心室、血管并发症、急性二尖瓣反流等。术前 评估需要甄别循环崩溃的高危患者，采取相应预防 和处理措施。1 2 3 4 （2）瓣周漏：新一代瓣膜的瓣周漏显著减少。对于中度以上瓣周漏，需要立即进行纠正，瓣周漏 的处理应基于对其病因的正确判断，如膨胀不良， 5 6 7 8 则应该考虑球囊后扩张；如果瓣膜释放位置不佳， 则应该考虑瓣中瓣；如果由于严重钙化导致瓣膜 9 10 11 12 不能完全贴壁，则应该考虑瓣周漏封堵。（3）瓣膜移位：瓣膜移位可能导致紧急开胸或 图 2 过渡性永久起搏器技术 再次置入瓣膜。术前影像学评估瓣环及环上结构 1：穿刺锁骨下静脉或腋静脉；2：保留穿刺导丝；3：置入 非常重要，对已发生移位的瓣膜，可尝试使用抓捕器 7F或8F可撕开鞘管；4：植入心室主动电极至右心室间隔 调整位置。某些病例瓣膜置换后突发临床症状加 部；5：撕开鞘管；6：用缝线将电极固定在皮肤表面；7～ 8：无菌敷料覆盖电极；9：电极尾端连接起搏器脉冲发生器； 重或血流动力学恶化需考虑迟发瓣膜移位的发生。10：用缝线将起搏器脉冲发生器固定在皮肤表面；11：无菌 （4）冠状动脉闭塞及心肌梗死：在术前评估时 敷料覆盖脉冲发生器；12：通过程控仪调整起搏器参数 应特别注意冠状动脉开口高度、窦部容积、瓣叶增 厚及钙化情况以及人工瓣膜与冠状动脉开口的关 者，应积极准备应急处理措施，包括外周血管球 系，术中球囊预扩张同时行主动脉根部造影有助于 囊、覆膜支架等，必要时及时外科切开处理。观察冠状动脉灌注情况。预判冠状动脉闭塞高风 （7）传导阻滞：TAVR术后传导阻滞主要与瓣 险则建议预先冠状动脉保护，可预埋延长导管、球 膜架体或导管与传导系统之间的直接机械相互作 囊或支架保护冠状动脉。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 438,
      "text": "高度、窦部容积、瓣叶增 厚及钙化情况以及人工瓣膜与冠状动脉开口的关 者，应积极准备应急处理措施，包括外周血管球 系，术中球囊预扩张同时行主动脉根部造影有助于 囊、覆膜支架等，必要时及时外科切开处理。观察冠状动脉灌注情况。预判冠状动脉闭塞高风 （7）传导阻滞：TAVR术后传导阻滞主要与瓣 险则建议预先冠状动脉保护，可预埋延长导管、球 膜架体或导管与传导系统之间的直接机械相互作 囊或支架保护冠状动脉。 BASILICA技术可通过撕 用导致的局部炎症、水肿或缺血相关。术后发生传 裂瓣叶来预防冠状动脉开口阻塞[2]。导阻滞后植入永久起搏器时机存在较大差异。起 （5）脑卒中：脑卒中的预防措施包括充分的术 搏方式的选择建议尽量生理起搏。左心室功能降 前评估、减少术中操作次数和采用脑保护装置 低的患者中，预期右心室起搏要求高（>40%）可考 （表4）。脑保护装置已被证实安全，其临床疗效需 虑心脏再同步化治疗。过渡性永久起搏器技术可 更多循证医学证据支持。以降低TAVR术后永久起搏器植入率，降低成本， （6）血管并发症：血管入路并发症发生率较 早期康复，改善患者生活质量（图2）[35]。高，有时甚至可致命。对可能出现血管并发症的患 核心观点21：其他并发症包括：（1）心包积 http://www。tcsurg。org • 1720 • Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, Dec。2024, Vol。31, No。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 439,
      "text": "并发症：血管入路并发症发生率较 早期康复，改善患者生活质量（图2）[35]。高，有时甚至可致命。对可能出现血管并发症的患 核心观点21：其他并发症包括：（1）心包积 http://www。tcsurg。org • 1720 • Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, Dec。2024, Vol。31, No。 12 症状性主动脉瓣重度狭窄患者 急危重症状态 否 是 择期 TAVR 病情恶化至急危 心脏团队会诊决 患者及家属 重症状态 定急诊手术 同意手术 麻醉优选全身麻醉评估器 主动脉根部及冠状 入路评估 械循环辅助，必要时尽早 动脉评估 应用 否 是 有术前增强 CT 无术前增强 CT 否 是 有术前增强 CT 无术前增强 CT 根据术前 CT 评估 TEE 测量主动脉瓣瓣环内径、主动脉窦部直径、 根据术前 CT 评估结果选择 超声、CT 平扫、造影联合应用 结果选择合适入路 冠状动脉开口高度等 合适瓣膜 术中血管造影选择血管条件更好 术中主动脉根部造影选择合适球囊进行扩张 的一侧进行手术 并估测瓣环直径大小，选择合适瓣膜 注意冠状动脉开口及瓣膜反流情况：术中同时行 冠状动脉造影，必要时行冠状动脉支架置入术 图 3 急诊TAVR流程 TAVR：经导管主动脉瓣置换术；TEE：经食管超声心动图 液及心脏压塞；（2）左心室左心房漏；（3）主 表 5 传统TAVR和简化TAVR的对比 动脉瓣环撕裂；（4）主动脉夹层、撕裂；（5）二 项目 传统TAVR 简化TAVR 尖瓣功能损伤；（6）感染性心内膜炎；（7）瓣 麻醉 气管插管全身麻醉 局部麻醉+镇静/局部麻醉 膜血栓；（8）急性肾功能损伤；（9）出血[2]。入路 动脉切开/经皮穿刺 经皮穿刺/All in one 3。10 急诊TAVR 起搏 植入临时起搏电极 左心室导丝起搏 核心观点22：对药物治疗反应性差的难治性 超声 TEE TTE 症状性重度AS患者，伴或不伴有血流动力学不稳 导尿 Foley尿管 不导尿 定，需要最短时间内完成的紧急经导管主动脉瓣 静脉置管 颈内静脉 颈内静脉/肘正中 球囊扩张或TAVR，定义为急诊主动脉瓣球囊扩张 术/TAVR。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 440,
      "text": "动脉切开/经皮穿刺 经皮穿刺/All in one 3。10 急诊TAVR 起搏 植入临时起搏电极 左心室导丝起搏 核心观点22：对药物治疗反应性差的难治性 超声 TEE TTE 症状性重度AS患者，伴或不伴有血流动力学不稳 导尿 Foley尿管 不导尿 定，需要最短时间内完成的紧急经导管主动脉瓣 静脉置管 颈内静脉 颈内静脉/肘正中 球囊扩张或TAVR，定义为急诊主动脉瓣球囊扩张 术/TAVR。 循环监测 Swan-Ganz导管 动脉压力 核心观点23：急诊主动脉瓣球囊扩张术/ 手术地点 杂交手术室 导管室 TAVR适应证包括：（1）心源性休克；（2）合并 TAVR：经导管主动脉瓣置换术；TEE：经食管超声心动图； TTE：经胸超声心动图；All in one：单支血管入路 有持续性室性心动过速或发生心室颤动；（3）药 物难以改善需要器械循环辅助装置的不稳定性心 根据目前国内外经验做出以下建议：（1）首选 绞痛或慢性心力衰竭；（4）在TAVR 评估及手术 全身麻醉，根据血管超声及术中造影结果，优选经 阶段出现血流动力学崩溃接受心肺复苏的患者[2]。股动脉入路；（2）应用TEE评估主动脉根部结构； 核心观点24：如果决定使用机械循环辅助装 （3）根据CT和超声心动图评估结果选择预扩张球 置，建议在TAVR术前预防性植入，优选体外膜 囊型号，术中预扩张时应特别关注冠状动脉灌注以 氧合装置，如不具备条件，可选择主动脉内球囊 及反流量情况，必要时可选择小球囊序贯扩张，避 反搏装置。免大量反流所致循环不稳定；（4）根据术中根部造 核心观点25：因病情严重无法完善增强 影和球囊扩张造影选择人工瓣膜型号；（5）术后建 CT时，平扫CT、术中3D经食管超声心动图 议患者在监护病房进行过渡治疗[36-38]（图3）。（transesophageal echocardiography，TEE）及血管 3。11 简化TAVR 造影的联合应用对于入路及根部评价有一定作用。核心观点26：简化TAVR的安全性和有效性 http://www。tcsurg。org 中国胸心血管外科临床杂志 2024年12月第31卷第12期 • 1721 • 1 型 2 型 3 型 4 型 瓣环 + + + − 左心室流出道 + − + − 升主动脉 + + − − TAVR 可行性 是 是 是 否 图 4 CT双锚定多平面测量方案和解剖分型 TAVR：经导管主动脉瓣置换术；+：能锚定；−：不能锚定 不逊于传统TAVR，能够促进患者早期恢复，缩短 时推荐使用可回收的自膨胀式瓣膜，建议术前采 住院时间，降低医疗费用。各中心可因地制宜， 用CTA评估患者的解剖，根据CTA分析结果判断 制定适合本中心的简化手术方案（表5）。患者是否适合手术，并选择合适的瓣膜型号[10]。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 441,
      "text": "R 可行性 是 是 是 否 图 4 CT双锚定多平面测量方案和解剖分型 TAVR：经导管主动脉瓣置换术；+：能锚定；−：不能锚定 不逊于传统TAVR，能够促进患者早期恢复，缩短 时推荐使用可回收的自膨胀式瓣膜，建议术前采 住院时间，降低医疗费用。各中心可因地制宜， 用CTA评估患者的解剖，根据CTA分析结果判断 制定适合本中心的简化手术方案（表5）。患者是否适合手术，并选择合适的瓣膜型号[10]。 必须对能够从简化手术中获益的患者进行严 CT双锚定多平面测量方案和解剖分型对TAVR有 格筛选，以确保其安全性。简化TAVR倾向于选择 指导意义：1型：瓣环、左心室流出道、升主动脉 血管解剖条件合适的低危患者，应遵从个体化原 均能锚定；2型：左心室流出道不能锚定，瓣环、 则，筛选标准包括：（1）具备合适的血管入路； 升主动脉可锚定；3型：瓣环、左心室流出道可锚 （2）冠状动脉阻塞风险较低；（3）无慢性疼痛； 定，升主动脉不能锚定；4型：瓣环、左心室流出 （4）TTE声窗条件好；（5）可紧急插管；（6）可以 道、升主动脉均不能锚定（图4）。术中应以高速心 平卧。不适宜行简化TAVR的标准包括：（1）入路 室起搏辅助，快速释放瓣膜到可回收位置，然后根 血管条件较差；（2）冠状动脉阻塞风险较高； 据情况选择回收或完全释放[10,43]。（3）瓣环破裂风险较高；（4）患者焦虑、术中不能 3。13 TAVR合并冠心病的血运重建策略 配合；（5）瓣膜大小不确定；（6）患者无法平卧； 核心观点29：重度AS合并冠心病发病率为 （7）TTE声窗差。目前，国内大多数中心采用的简 30%～50%，但是目前关于冠心病是否影响TAVR 化TAVR方法包括在导管室进行局部麻醉、穿刺股 患者预后的临床研究结果并不完全一致，而且这 动脉为主入路、桡动脉作为副入路或All in one技 些冠心病患者是否均需要血运重建仍存在争议。术、左心室导丝起搏、直接瓣膜置入术、减少有创 核心观点30：一站式TAVR+经皮冠状动脉介 监测和通路、术中采用TTE、鼓励早期活动、早期 入治疗（percutaneous coronary intervention，PCI） 出院等[39-42]。应在有经验的中心开展，早期应选择简单组合进 3。12 PAR的TAVR 行处理，建议进行预先跨瓣置入猪尾导管。对于 核心观点27：我国目前尚无确切主动脉瓣反 合并左主干病变、多个靶病变、需要旋磨以及二 流患病率的流行病学数据，但现有证据显示其流 叶式主动脉瓣的复杂TAVR+PCI一站式治疗的患 行病学规律不同于西方，我国的主动脉瓣反流可 者，应特别注意基础心功能及肾功能，避免多个 能更常见[10]。难点进行组合导致手术难度过大、时间过长、对 核心观点28：CT双锚定多平面测量方案和解 比剂用量过多从而增加风险（表6）。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 442,
      "text": "27：我国目前尚无确切主动脉瓣反 合并左主干病变、多个靶病变、需要旋磨以及二 流患病率的流行病学数据，但现有证据显示其流 叶式主动脉瓣的复杂TAVR+PCI一站式治疗的患 行病学规律不同于西方，我国的主动脉瓣反流可 者，应特别注意基础心功能及肾功能，避免多个 能更常见[10]。难点进行组合导致手术难度过大、时间过长、对 核心观点28：CT双锚定多平面测量方案和解 比剂用量过多从而增加风险（表6）。 手术过程中 剖分型对PAR的TAVR有指导意义。建议人工瓣 对于冠状动脉病变复杂及基础心功能状态不佳患 膜在锚定平面的直径（周长）超尺寸比率应在 者，应充分评估其麻醉方式及是否需要左心辅助 10%以上。装置[2,44-48]。目前我国仅有经心尖入路的J-Valve人工主动 TAVR术前均应进行冠状动脉影像学评估。国 脉瓣膜被批准用于主动脉瓣反流的TAVR治疗，但 外指南建议冠状动脉造影仍是大多数TAVR患者 是多款经股动脉瓣膜已经完成临床试验，即将上 进行冠心病评估的主要手段；但冠状动脉CTA作 市。对PAR患者行经股动脉TAVR，超适应证应用 为TAVR术前冠状动脉评估的主要初筛手段是可 http://www。tcsurg。org • 1722 • Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, Dec。2024, Vol。31, No。12 表 6 TAVR与PCI时机及优缺点 项目 TAVR前分站式PCI TAVR后分站式 PCI TAVR术中一站式 PCI 优点 （1）缩短TAVR手术操作时间； （1）缩短双联抗血小板治疗时间； （1）减少花费、缩短两次手术的时间间隔； （2）减少单次手术的射线曝光量； （2）降低TAVR术后出血风险； （2）避免两次手术，减少血管及出血并发症； （3）更加优化造影剂用量； （3）更好地鉴别患者临床症状是否由冠心 （3）避免TAVR期间心肌缺血的影响和冠心病 （4）保证TAVR术中血流动力学稳定 病引起 相关血流动力学后果 缺点 （1）对临界病变的FFR/iFR评估受限； （1）由于受TAVR人工瓣膜支架的影响， （1）延长手术时间； （2）多次动脉穿刺； 指引导管与造影导管到达冠脉开口可能出 （2）增加射线曝光量； （3）PCI术中出现循环崩溃，补救 现困难； （3）增加造影剂用量 TAVR困难； （2）PCI操作过程中可能会导致 TAVR瓣 （4）花费更大 膜移位 TAVR：经导管主动脉瓣置换术；PCI：经皮冠状动脉介入治疗；FFR：血流储备分数；iFR：瞬时无波形比率 行的，若冠状动脉CTA提示病变严重，则进一步行 生，或再发心源性脑卒中，除外瓣膜血栓因素后， 冠状动脉造影检查。严重AS患者的冠状动脉生理 可考虑再次行LAAC治疗。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 443,
      "text": "，补救 现困难； （3）增加造影剂用量 TAVR困难； （2）PCI操作过程中可能会导致 TAVR瓣 （4）花费更大 膜移位 TAVR：经导管主动脉瓣置换术；PCI：经皮冠状动脉介入治疗；FFR：血流储备分数；iFR：瞬时无波形比率 行的，若冠状动脉CTA提示病变严重，则进一步行 生，或再发心源性脑卒中，除外瓣膜血栓因素后， 冠状动脉造影检查。严重AS患者的冠状动脉生理 可考虑再次行LAAC治疗。 术后抗栓方案尚存在 学评估的临床价值需要更多数据支持。指南建议 部分争议，可根据患者脑卒中和出血风险进行个体 TAVR患者合并冠状动脉近端狭窄>70%时可采用 化策略制定。PCI方式进行干预。PCI相对于TAVR的时间安排 3。15 主动脉瓣生物瓣损毁的瓣中瓣技术 应基于患者临床表现、解剖特征和冠状动脉病变的 核心观点33：生物瓣损毁是我们即将面对的 复杂性。目前TAVR后进行PCI因冠状动脉入路 重要问题，包括在外科毁损瓣中行TAVR治疗 难度增加不作为常规推荐。（TAVR-in-SAVR）及在TAVR毁损瓣中行 3。14 AS伴心房颤动的TAVR与左心耳封堵治疗 TAVR治疗（TAVR-in-TAVR）的瓣中瓣技术是解 （left atrial appendage closure，LAAC） 决生物瓣毁损的重要方式。核心观点31：LAAC是TAVR合并心房颤动 在首次瓣膜置换时即应考虑全生命周期中再 患者重要的脑卒中二级预防手段，对于出血高危 次瓣膜置换面临的问题，冠状动脉风险和冠状动脉 患者或术后无法坚持长期抗凝患者可考虑行同期 通路风险以及瓣膜-患者不匹配是要考虑的最重要 手术。问题。TAVR-in-SAVR的关键步骤参考2021版共 核心观点32：盘式封堵器患者可口服氯吡格 识[2]。冠状动脉闭塞高风险是TAVR-in-SAVR待解 雷75 mg 1次/d+阿司匹林100 mg 1次/d，半年后 决的问题，瓣叶切割技术对原外科瓣膜的瓣叶进行 改为口服阿司匹林100 mg 1次/d；塞式封堵器患 切割，减少冠状动脉闭塞风险发生。者可口服抗凝+阿司匹林100 mg 1次/d，45 d，45 d 行TAVR-in-TAVR（Redo-TAVR）时需要特别 后阿司匹林100 mg 1次/d+氯吡格雷75 mg 1次/d 关注的内容包括：（1）根据首次置入瓣膜类型与型 至术后6个月，6个月后阿司匹林100 mg 1次/d 号，评估冠状动脉风险并选择第二枚置入瓣膜的类 持续服用。若患者不能耐受高强度抗栓治疗，抗 型和尺寸、确定置入瓣膜的位置；（2）充分的 栓方案可根据患者耐受程度降级。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 444,
      "text": "45 d 行TAVR-in-TAVR（Redo-TAVR）时需要特别 后阿司匹林100 mg 1次/d+氯吡格雷75 mg 1次/d 关注的内容包括：（1）根据首次置入瓣膜类型与型 至术后6个月，6个月后阿司匹林100 mg 1次/d 号，评估冠状动脉风险并选择第二枚置入瓣膜的类 持续服用。若患者不能耐受高强度抗栓治疗，抗 型和尺寸、确定置入瓣膜的位置；（2）充分的 栓方案可根据患者耐受程度降级。 术后第45天、 CT分析，包括首次置入前后CT影像；（3）Redo- 6个月时通过TEE或CTA观察封堵器是否完全封 TAVR时，窦隔离是重要的冠状动脉闭塞风险因 闭左心耳、有无器械表面血栓[49-52]。素，瓣叶切割技术、Chimney支架技术在Redo- TAVR+LAAC的最适人群为心房颤动伴脑卒 TAVR中效果并不确切且操作困难[53-55]。瓣膜的几 中高危患者，不能耐受长期抗凝治疗或在规范抗凝 何形状、瓣架的长度、释放位置均可以影响新裙边 治疗中仍反复发生心源性脑卒中患者。LAAC在 的高度，应根据患者的个体情况制定相应的手术策 TAVR术后进行，推荐TEE/心腔内超声心动图 略（图5）。（intracardiac echocardiography，ICE）指引下完成 4 TAVR 患者围术期及远期管理 LAAC，确保手术安全性和封堵的有效性。患者具 备TAVR+LAAC指征，但由于各种原因并未接受 4。1 TAVR患者围术期管理及随访康复策略 LAAC治疗（包括经济原因、个人意愿、患者身体状 核心观点34：TAVR患者病情复杂、并发症 况等），TAVR术后因服用抗凝药导致出血事件发 病情变化快，围术期管理尤为重要。http://www。tcsurg。org 中国胸心血管外科临床杂志 2024年12月第31卷第12期 • 1723 • 图 5 Redo-TAVR的手术策略规划 a：短瓣架置入短瓣架；b：短瓣架置入长瓣架；c：长瓣架置入短瓣架；d：长瓣架置入长瓣架；Redo-TAVR：再次经导管主动脉瓣置 换术 核心观点35：术后随访和康复对TAVR患者 二叶式主动脉瓣患者：应着重主动脉内径（尤其是 术后远期预后和生活质量具有重要作用。升主动脉内径）CT评估，监测二叶式主动脉瓣患者 在术后应根据麻醉方式及入路情况，酌情于重 升主动脉内径的扩张程度及速度，必要时行CMR 症监护室进行过渡或于普通病房进行治疗，需进行 进一步评估管壁应力及涡流位置等，警惕严重大血 精细的循环容量管理，疼痛管理，呼吸系统、神经 管并发症。对于升主动脉内径较大（>4。5 cm）、 系统及消化系统的综合管理[2]。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 445,
      "text": "其是 术后远期预后和生活质量具有重要作用。升主动脉内径）CT评估，监测二叶式主动脉瓣患者 在术后应根据麻醉方式及入路情况，酌情于重 升主动脉内径的扩张程度及速度，必要时行CMR 症监护室进行过渡或于普通病房进行治疗，需进行 进一步评估管壁应力及涡流位置等，警惕严重大血 精细的循环容量管理，疼痛管理，呼吸系统、神经 管并发症。对于升主动脉内径较大（>4。5 cm）、 系统及消化系统的综合管理[2]。 容量管理建议根据 增长速度较快或具有家族遗传史患者、瓷化主动脉 患者性别、年龄、体重、疾病特点、术前全身状况和 或主动脉严重动脉粥样硬化患者以及TAVR同期 血循环容量状态等指标，采取个体化补液方案[56]。行冠状动脉支架置入患者的随访策略见2021版 TAVR围术期脑卒中的发病机制复杂多样，涉及瓣 共识[2]。膜置入过程中的机械损伤、血流动力学改变、血栓 5 结语 形成等多个环节，需要遵循标准化流程评估和管 理。其他监测重点包括心律变化（起搏器评估）、 随着TAVR适应证的拓宽、手术器械的多样 呼吸道感染、穿刺点出血、急性肾损伤、谵妄、心脏 化、操作流程的优化，TAVR在我国必将有更广泛 结构并发症及瓣周反流等[2]（详见本文“3 TAVR的 的应用。通过十余年的不懈探索，在TAVR领域， 手术过程”）。中国数据和方案已经开始在国际舞台绽放并具有 术后抗栓方面：对于有抗凝适应证者（如心房 越来越大的影响力。希望本临床路径的更新可以 颤动、血栓栓塞等），建议长期应用口服抗凝药物， 更好地助力我国TAVR技术发展，继续开拓中国 对于合并急性冠状动脉综合征和近期PCI患者可 TAVR特色创新之路，造福更多瓣膜性心脏病患者。酌情加用单种抗血小板药物；对于无抗凝适应证 者，建议直接单种抗血小板药物长期治疗，如患者 利益冲突：无。为高栓塞风险、急性冠状动脉综合征或近期PCI的 院士专家顾问组（按姓氏汉语拼音排序）：高润霖 予以适当时长的双联抗血小板治疗[5,57-58]；对于明确 （中国医学科学院阜外医院），葛均波（复旦大学附属中 出现临床瓣膜血栓证据患者，应调整为维生素K拮 山医院），韩雅玲（中国人民解放军北部战区总医院）， 抗剂口服。目前基于术后抗栓方案的国内相关研 王建安（浙江大学医学院附属第二医院） 究TAORTA研究[59]、CREATE研究（ChiCTR24000 核心专家组成员（按姓氏汉语拼音排序）：安贵鹏 87454）、SCOPE研究（ChiCTR2400087453）等均在 （山东大学齐鲁医院），白明（兰州大学第一医院），白元 进行，旨在进一步探索抗栓优化方案。（海军军医大学第一附属医院），卜军（上海交通大学医 TAVR后康复包括围术期康复、门诊康复和居 学院附属仁济医院），陈晖（首都医科大学附属北京友谊 家康复[60]。术后康复策略参考2021版共识[2]。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 446,
      "text": "组成员（按姓氏汉语拼音排序）：安贵鹏 87454）、SCOPE研究（ChiCTR2400087453）等均在 （山东大学齐鲁医院），白明（兰州大学第一医院），白元 进行，旨在进一步探索抗栓优化方案。（海军军医大学第一附属医院），卜军（上海交通大学医 TAVR后康复包括围术期康复、门诊康复和居 学院附属仁济医院），陈晖（首都医科大学附属北京友谊 家康复[60]。术后康复策略参考2021版共识[2]。 若出 医院），陈静（武汉大学人民医院），陈良龙（福建医科 现心血管系统疾病或其他系统疾病的症状，应随时 大学附属协和医院），陈茂（四川大学华西医院），陈绍良 增加随访内容和频率。（南京市第一医院），陈生龙（北京大学人民医院）， 4。2 特殊类型患者随访要点 陈韵岱（中国人民解放军总医院），程翔（华中科技大学 特殊类型的TAVR术后患者需要增加个体化 同济医学院附属协和医院），董念国（华中科技大学同济 的随访项目，明确各种特殊患者的随访重点。对于 医学院附属协和医院），范瑞新（广东省人民医院），方军 http://www。tcsurg。org • 1724 • Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, Dec。2024, Vol。31, No。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 447,
      "text": "要增加个体化 同济医学院附属协和医院），董念国（华中科技大学同济 的随访项目，明确各种特殊患者的随访重点。对于 医学院附属协和医院），范瑞新（广东省人民医院），方军 http://www。tcsurg。org • 1724 • Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, Dec。2024, Vol。31, No。 12 （福建医科大学附属协和医院），方臻飞（中南大学湘雅 安贞医院），王焱（厦门大学附属心血管病医院），王宇彬 二医院），冯沅（四川大学华西医院），傅国胜 （首都医科大学宣武医院），吴延庆（南昌大学第二附属 （浙江大学医学院附属邵逸夫医院），龚韧（南昌大学第 医院），吴永健（中国医学科学院阜外医院），修建成 二附属医院），谷兴华（山东大学齐鲁医院），郭亮（中 （南方医科大学南方医院），徐凯（中国人民解放军北部 国医科大学附属第一医院），郭然（大连医科大学附属第 战区总医院），徐磊（首都医科大学附属北京安贞医院）， 一医院），郭晓刚（浙江大学医学院附属第一医院），郭延松 徐吉喆（兰州大学第一医院），薛亚军（清华大学附属北 （福建省立医院），郭应强（四川大学华西医院），韩克 京清华长庚医院），杨剑（空军军医大学第一附属医 （西安交通大学第一附属医院），何奔（上海交通大学医 院），杨杰孚（北京医院），杨毅宁（新疆医科大学第一 学院附属胸科医院），何泉（重庆医科大学附属第一医院）， 附属医院），杨跃进（中国医学科学院阜外医院），殷伟贤 何怡华（首都医科大学附属北京安贞医院），洪浪（江西 （中国台北振兴医院），于波（哈尔滨医科大学附属第二 省心血管病医院），黄晖（宁夏医科大学总医院），霍晓川 医院），俞飞成（浙江大学医学院附属邵逸夫医院）， （首都医科大学附属北京安贞医院），季福绥（北京医 袁义强（河南省胸科医院），袁祖贻（西安交通大学第一 院），贾绍斌（宁夏医科大学总医院），江磊（青岛大学 附属医院），曾和松（华中科技大学同济医学院附属同济 附属医院），姜楠（天津市胸科医院），姜小飞（珠海市 医院），张纯（首都医科大学附属北京安贞医院），张春鹏 人民医院），姜正明（首都医科大学附属北京安贞医 （吉林大学第二医院），张东会（哈尔滨医科大学附属第 院），晋军（陆军军医大学第二附属医院），孔祥清（江 二医院），张海波（首都医科大学附属北京安贞医院）， 苏省人民医院），来永强（首都医科大学附属北京安贞医 张慧平（北京医院），张俊杰（南京市第一医院），张龙岩 院），李传宝（山东大学齐鲁医院），李飞（空军军医大 （武汉亚心总医院），张力（上海交通大学医学院附属新 学第一附属医院），李捷（广东省人民医院），李伟栋 华医院），张瑞岩（上海交通大学医学院附属瑞金医 （浙江大学医学院附属第一医院），李怡（中山大学附属 院），张申伟（郑州市第七人民医院），张晓春（复旦大 第一医院），李妍（空军军医大学第二附属医院），李永在 学附属中山医院），张志辉（陆军军医大学第一附属医 （中国台北振兴医院），林逸贤（香港嘉诺撒医院亚洲心 院），钟禹成（华中科技大学同济医学院附属协和医 脏中心），刘斌（吉林大学第二医院），刘长福（中国人 院），钟炜（梅州市人民医院），周浩（温州医科大学附 民解放军总医院），刘健（北京大学人民医院），刘杰 属第一医院），周达新（复旦大学附属中山医院），周胜华 （南宁市第一人民医院），刘巍（北京积水潭医院），刘先宝 （中南大学湘雅二医院），周玉杰（首都医科大学附属北 （浙江大学医学院附属第二医院），刘新民（首都医科大 京安贞医院），朱政斌（上海交通大学医学院附属瑞金医 学附属北京安贞医院），刘洋（空军军医大学第一附属医 院），庄晓东（中山大学附属第一医院） 院），陆方林（海军军医大学第一附属医院），罗建方 审核组成员（按姓氏汉语拼音排序）：白元（海军军 （广东省人民医院 ），吕滨（中国医学科学院阜外医 医大学第一附属医院），方军（福建医科大学附属协和医 院），马根山（东南大学附属中大医院），马为（北京大 院），韩克（西安交通大学第一附属医院），李飞（空军 学第一医院），马翔（新疆医科大学第一附属医院），马玉良 军医大学第一附属医院），李捷（广东省人民医院），李妍 （北京大学人民医院），聂如琼（中山大学孙逸仙纪念医 （空军军医大学第二附属医院），刘长福（中国人民解放 院），牛冠男（中国医学科学院阜外医院），潘文志（复 军总医院），马为（北京大学第一医院），彭小平（南昌 旦大学附属中山医院），潘欣（上海交通大学医学院附属 大学第一附属医院），尚小珂（华中科技大学同济医学院 胸科医院），裴汉军（内蒙古科技大学包头医学院第一附 附属协和医院），王斌（厦门大学附属心血管病医院）， 属医院），彭小平（南昌大学第一附属医院），彭勇（四 王建德 （中国医学科学院阜外医院），徐凯（中国人民解 川大学华西医院），乔帆（海军军医大学第一附属医 放军北部战区总医院），张海波（首都医科大学附属北京 院），曲鹏（大连医科大学附属第二医院），尚小珂（华 安贞医院） 中科技大学同济医学院附属协和医院），宋光远（首都医 主要执笔专家（按姓氏汉语拼音排序）：刘新民（首 科大学附属北京安贞医院），宋思贤（中国台北荣民总医 都医科大学附属北京安贞医院），王墨扬（中国医学科学 院），苏晞（武汉亚心总医院），孙英贤（中国医科大学 院阜外医院） 附属第一医院），谭冠昶（中国澳门镜湖医院），唐熠达 写作组成员（按姓氏汉语拼音排序）：陈阳（北京大 （北京大学第三医院），陶凌（空军军医大学第一附属医 学人民医院），杜润（上海交通大学医学院附属瑞金医 院），王斌（厦门大学附属心血管病医院），王墨扬（中 院），胡祥铭（中国医学科学院阜外医院），姜正明（首 国医学科学院阜外医院），王晟（首都医科大学附属北京 都医科大学附属北京安贞医院），科雨彤（首都医科大学 http://www。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 448,
      "text": "镜湖医院），唐熠达 写作组成员（按姓氏汉语拼音排序）：陈阳（北京大 （北京大学第三医院），陶凌（空军军医大学第一附属医 学人民医院），杜润（上海交通大学医学院附属瑞金医 院），王斌（厦门大学附属心血管病医院），王墨扬（中 院），胡祥铭（中国医学科学院阜外医院），姜正明（首 国医学科学院阜外医院），王晟（首都医科大学附属北京 都医科大学附属北京安贞医院），科雨彤（首都医科大学 http://www。 tcsurg。org 中国胸心血管外科临床杂志 2024年12月第31卷第12期 • 1725 • 附属北京安贞医院），李兰兰（空军军医大学第一附属医 Clinical Practice Guidelines。Circulation, 2021, 143(5): e35-e71。6 Gertz ZM, Pibaro TP, Douglas PS, et al。Implications of left 院），林多茂（首都医科大学附属北京安贞医院），刘然 ventricular geometry in low-flow aortic stenosis: A partner 2 trial （首都医科大学附属北京安贞医院），刘先宝（浙江大学 subanalysis。JACC Cardiovasc Imaging, 2019, 12(2): 367-368。医学院附属第二医院），刘新民（首都医科大学附属北京 7 Sharma N, Sachedina AK, Kumar S。Low-flow, low-gradient severe 安贞医院），牛冠男（中国医学科学院阜外医院），潘文志 aortic stenosis: A review。Heart Int, 2023, 17(1): 8-12。8 于子凯, 许海燕, 齐喜玲, 等。老年综合评估在经导管主动脉瓣 （复旦大学附属中山医院），宋光远（首都医科大学附属 置换术患者心脏康复中的应用价值。中华老年心脑血管病杂志, 北京安贞医院），王力涵（浙江大学医学院附属第二医 2019, 21(7): 691-694。院），王墨扬（中国医学科学院阜外医院），王瑞（首都 Yu ZK, Xu HY, Qi XL, et al。Application of multidimensional geriatric assessment in cardiac rehabilitation of patients receiving 医科大学附属北京安贞医院），王宇彬（首都医科大学宣 transcatheter aortic valve replacement。Chin J Geriatr Heart Brain 武医院），席子惟（首都医科大学附属北京安贞医院）， Vessel Dis, 2019, 21(7): 691-694。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 449,
      "text": " in cardiac rehabilitation of patients receiving 医科大学附属北京安贞医院），王宇彬（首都医科大学宣 transcatheter aortic valve replacement。Chin J Geriatr Heart Brain 武医院），席子惟（首都医科大学附属北京安贞医院）， Vessel Dis, 2019, 21(7): 691-694。 修建成（南方医科大学南方医院），姚晶（首都医科大学 9 Vahanian A, Beyersdorf F, Praz F, et al。ESC/EACTS Scientific 附属北京安贞医院），叶蕴青（中国医学科学院阜外医 Document Group。2021 ESC/EACTS guidelines for the management of valvular heart disease。Eur Heart J, 2022, 43(7): 院），苑飞（首都医科大学附属北京安贞医院），张倩 561-632。（中国医学科学院阜外医院），赵晟（中国医学科学院阜 10 中国医师协会心血管内科医师分会结构性心脏病学组, 周达新, 外医院），周政（中国医学科学院阜外医院），朱政斌 吴永健。单纯主动脉瓣反流经股动脉主动脉瓣置换中国专家共 （上海交通大学医学院附属瑞金医院） 识2023。中国介入心脏病学杂志, 2023, 31(11): 801-809。Structural Heart Disease Branch, Chinese Society of Cardiology, Structural Cardiology Committee of Cardiovascular Physicians 参考文献 Branch, Zhou DX, Wu YJ。Chinese expert consensus on trans- 1 中华医学会心血管病学分会结构性心脏病学组, 中国医师协会 femoral transcatheter aortic valve replacement for pure aortic 心血管内科医师分会结构性心脏病专业委员会。中国经导管主 regurgitation 2023。Chin J Interv Cardiol, 2023, 31(11): 801-809。动脉瓣置换术临床路径专家共识。中国循环杂志, 2018, 33(12): 11 中国医师协会放射医师分会心血管学组, 国家心血管病专业质 1162-1169。控中心心血管影像质控专家工作组, 中国研究型医院学会心血 Structural Heart Disease Branch, Chinese Society of Cardiology, 管影像专业委员会。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 450,
      "text": "3, 31(11): 801-809。动脉瓣置换术临床路径专家共识。中国循环杂志, 2018, 33(12): 11 中国医师协会放射医师分会心血管学组, 国家心血管病专业质 1162-1169。控中心心血管影像质控专家工作组, 中国研究型医院学会心血 Structural Heart Disease Branch, Chinese Society of Cardiology, 管影像专业委员会。 经导管主动脉瓣置换术CT检查技术中国 Structural Cardiology Committee of Cardiovascular Physicians 专家共识。中华放射学杂志, 2024, 58(4): 365-374。Branch, Chinese Medical Doctor Association。Expert consensus on Cardiovascular Group of Chinese Association of Radiologists, clinical pathway for transcatheter aortic valve replacement in Expert Group on Quality Control of Cardiovascular Imaging of China。Chin Circ J, 2018, 33(12): 1162-1169。National Center for Cardiovascular Quality Improvement, 2 中国医师协会心血管内科医师分会结构性心脏病专业委员会。Cardiovascular Imaging Committee of Chinese Research Hospital 中国经导管主动脉瓣置换术临床路径专家共识(2021版)。中国 Association。Chinese expert consensus on the CT examination for 循环杂志, 2022, 37(1): 12-23。transcatheter aortic valve replacement。Chin J Radiol, 2024, 58(4): Structural Cardiology Committee of Cardiovascular Physicians 365-374。Branch, Chinese Medical Doctor Association。2021 expert 12 Blanke P, Weir-McCall JR, Achenbach S, et al。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 451,
      "text": "Chin J Radiol, 2024, 58(4): Structural Cardiology Committee of Cardiovascular Physicians 365-374。Branch, Chinese Medical Doctor Association。2021 expert 12 Blanke P, Weir-McCall JR, Achenbach S, et al。 Computed consensus on clinical pathway for transcatheter aortic valve tomography imaging in the context of transcatheter aortic valve replacement in China。Chin Circ J, 2022, 37(1): 12-23。implantation (TAVI)/transcatheter aortic valve replacement 3 Bavaria JE, Tommaso CL, Brindis RG, et al。2018 (TAVR): An expert consensus document of the society of AATS/ACC/SCAI/STS expert consensus systems of care cardiovascular computed tomography。JACC Cardiovasc Imaging, document: Operator and institutional recommendations and 2019, 12(1): 1-24。requirements for transcatheter aortic valve replacement: A joint 13 中国医师协会放射医师分会心血管学组, 国家心血管病专业质 report of the American Association for Thoracic Surgery, 控中心心血管影像质控专家工作组, 中国研究型医院学会心血 American College of Cardiology, Society for Cardiovascular 管影像专业委员会。经导管主动脉瓣置换术CT规范化评估中 Angiography and Interventions, and Society of Thoracic Surgeons。国专家共识。中华放射学杂志, 2024, 58(6): 576-586。J Am Coll Cardiol, 2019, 73(3): 340-374。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 452,
      "text": "ogy, Society for Cardiovascular 管影像专业委员会。经导管主动脉瓣置换术CT规范化评估中 Angiography and Interventions, and Society of Thoracic Surgeons。国专家共识。中华放射学杂志, 2024, 58(6): 576-586。J Am Coll Cardiol, 2019, 73(3): 340-374。 Cardiovascular Group of Chinese Association of Radiologists, 4 中国医师协会心血管内科医师分会结构性心脏病专业委员会。Expert Group on Quality Control of Cardiovascular Imaging of 经导管主动脉瓣置换术中国专家共识(2020更新版)。中国介入 National Center for Cardiovascular Quality Improvement, 心脏病学杂志, 2020, 28(6): 301-309。Cardiovascular Imaging Committee of Chinese Research Hospital Structural Cardiology Committee of Cardiovascular Physicians Association。Chinese expert consensus on standardized evaluation Branch, Chinese Medical Doctor Association。2020 expert of CT for transcatheter aortic valve replacement。Chin J Radiol, consensus on transcatheter aortic valve replacement in China。Chin 2024, 58(6): 576-586。J Interv Cardiol, 2020, 28(6): 301-309。14 Tarantini G, Tang G, Nai Fovino L, et al。Management of coronary 5 Otto CM, Nishimura RA, Bonow RO, et al。2020 ACC/AHA artery disease in patients undergoing transcatheter aortic valve guideline for the management of patients with valvular heart implantation。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 453,
      "text": "ronary 5 Otto CM, Nishimura RA, Bonow RO, et al。2020 ACC/AHA artery disease in patients undergoing transcatheter aortic valve guideline for the management of patients with valvular heart implantation。 A clinical consensus statement from the European disease: Executive summary: A report of the American College of Association of Percutaneous Cardiovascular Interventions in Cardiology/American Heart Association Joint Committee on collaboration with the ESC Working Group on cardiovascular http://www。tcsurg。org • 1726 • Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, Dec。2024, Vol。31, No。12 Surgery。EuroIntervention, 2023, 19(1): 37-52。Liu XM, Yao J, Dong Z, et al。Three cases of transcatheter aortic 15 Gnreux P, Piazza N, Alu MC, et al。Valve academic research valve replacement using single arterial access technique。Chin Circ consortium 3: Updated endpoint definitions FOR aortic valve J, 2022, 37(4): 421-424。clinical research。J Am Coll Cardiol, 2021, 77(21): 2717-2746。31 刘新民, 姚晶, 董哲, 等。使用单血管入路技术行经导管主动脉 16 Wang M, Niu G, Chen Y, et al。Development and validation of a 瓣置换术1例。中华心血管病杂志, 2023, 51(1): 73-75。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 454,
      "text": "424。clinical research。J Am Coll Cardiol, 2021, 77(21): 2717-2746。31 刘新民, 姚晶, 董哲, 等。使用单血管入路技术行经导管主动脉 16 Wang M, Niu G, Chen Y, et al。Development and validation of a 瓣置换术1例。中华心血管病杂志, 2023, 51(1): 73-75。 deep learning-based fully automated algorithm for pre-TAVR CT Liu XM, Yao J, Dong Z, et al。Transcatheter aortic valve assessment of the aortic valvular complex and detection of replacement via single-vessel approach technique: A case report。anatomical risk factors: A retrospective, multicentre study。Chin J Cardiol, 2023, 51(1): 73-75。EBioMedicine, 2023, 96(104794): 1-15。32 姚晶, 刘新民, 苑飞, 等。使用“All in One”单动脉/血管技术行 17 Faza NN, Harb SC, Wang DD, et al。Physical and computational 经导管主动脉瓣置换术。中华心血管病杂志, 2023, 51(9): 990- modeling for transcatheter structural heart interventions。JACC 994。Cardiovasc Imaging, 2024, 17(4): 428-440。Yao J, Liu XM, Yuan F, et al。Safety and efficacy of transcatheter 18 Haghiashtiani G, Qiu K, Zhingre Sanchez JD, et al。3D printed aortic valve replacement using the \"All in One\" single artery/vessel patient-specific aortic root models with internal sensors for technique。Chin J Cardiol, 2023, 51(9): 990-994。minimally invasive applications。Sci Adv, 2020, 6(35): eabb4641-12。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 455,
      "text": "ne\" single artery/vessel patient-specific aortic root models with internal sensors for technique。Chin J Cardiol, 2023, 51(9): 990-994。minimally invasive applications。Sci Adv, 2020, 6(35): eabb4641-12。 33 宋光远, 刘新民, 滕思勇, 等。使用左心室导丝起搏技术行经导 19 Aigner P, Sella Bart E, Panfili S, et al。Quantification of 管主动脉瓣置换术。中华心血管病杂志, 2021, 49(5): 461-466。paravalvular leaks associated with TAVI implants using 4D MRI in Song GY, Liu XM, Teng SY, et al。Left ventricular guidewire pacing an aortic root phantom made possible by the use of 3D printing。during transcatheter aortic valve replacement。Chin J Cardiol, Front Cardiovasc Med, 2023, 10(1083300): 11-12。2021, 49(5): 461-466。20 Saidy NT, Fernandez-Colino A, Heidari BS, et al。Spatially 34 Lilly SM, Deshmukh AJ, Epstein AE, et al。2020 ACC expert heterogeneous tubular scaffolds for in situ heart valve tissue consensus decision pathway on management of conduction engineering using melt electrowriting。Adv Funct Mater, 2022, disturbances in patients undergoing transcatheter aortic valve 32(2110716): 1-9。replacement: A report of the American College of Cardiology 21 Rioux Y, Fradette J, Maciel Y, et al。Biofabrication of sodium Solution Set Oversight Committee。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 456,
      "text": "anscatheter aortic valve 32(2110716): 1-9。replacement: A report of the American College of Cardiology 21 Rioux Y, Fradette J, Maciel Y, et al。Biofabrication of sodium Solution Set Oversight Committee。 J Am Coll Cardiol, 2020, alginate hydrogel scaffolds for heart valve tissue engineering。Int J 76(20): 2391-2411。Mol Sci, 2022, 23(15): 1-15。35 Chang S, Jiang Z, Liu X, et al。Permanent pacemaker reduction 22 Yang H, Ji M, Yang M, et al。Fabricating hydrogels to mimic using temporary-permanent pacemaker as a 1-month bridge after biological tissues of complex shapes and high fatigue resistance。transcatheter aortic valve replacement: A prospective, multicentre, Matter, 2021, 4(6): 1-15。single-arm, observational study。EClinicalMedicine, 2024, 72: 23 Reindl M, Lechner I, Holzknecht M, et al。Cardiac magnetic 102603。resonance imaging versus computed tomography to guide 36 Besis G, Dimitrakakis G, Chetty G, et al。Aortic stenosis presenting transcatheter aortic valve replacement: A randomized, open-label, with cardiogenic shock。Is there a role for intra-aortic balloon noninferiority trial。Circulation, 2023, 148(16): 1220-1230。pump use。Hellenic J Cardiol, 2020, 61(6): 447-449。24 Sato K, Jones PM。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 457,
      "text": "label, with cardiogenic shock。Is there a role for intra-aortic balloon noninferiority trial。Circulation, 2023, 148(16): 1220-1230。pump use。Hellenic J Cardiol, 2020, 61(6): 447-449。24 Sato K, Jones PM。 Sedation versus general anesthesia for 37 Husser O, Holzamer A, Philipp A, et al。Emergency and transcatheter aortic valve replacement。J Thorac Dis, 2018, prophylactic use of miniaturized veno-arterial extracorporeal 10(Suppl 30): S3588-S3594。membrane oxygenation in transcatheter aortic valve implantation。25 Hyman MC, Vemulapalli S, Szeto WY, et al。Conscious sedation Catheter Cardiovasc Interv, 2013, 82(4): E542-E551。versus general anesthesia for transcatheter aortic valve 38 周政, 张龙岩, 杨剑, 等。急诊经导管主动脉瓣置换术的疗效初 replacement: Insights from the National Cardiovascular Data 探: 一项多中心研究。中华心血管病杂志, 2022, 50(7): 698-704。Registry Society of Thoracic Surgeons/American College of Zhou Z, Zhang LY, Yang J, et al。Preliminary evaluation on the Cardiology Transcatheter Valve Therapy Registry。Circulation, efficacy of emergency transcatheter aortic valve replacement: A 2017, 136(22): 2132-2140。multicenter study。Chin J Cardiol, 2022, 50(7): 698-704。26 Goins AE, Smeltz A, Ramm C, et al。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 458,
      "text": "istry。Circulation, efficacy of emergency transcatheter aortic valve replacement: A 2017, 136(22): 2132-2140。multicenter study。Chin J Cardiol, 2022, 50(7): 698-704。26 Goins AE, Smeltz A, Ramm C, et al。 General anesthesia for 39 Mack MJ, Leon MB, Thourani VH, et al。Transcatheter aortic-valve transcatheter aortic valve replacement: Total intravenous replacement in low-risk patients at five years。N Engl J Med, 2023, anesthesia is associated with less delirium as compared to volatile 389(21): 1949-1960。agent technique。J Cardiothorac Vasc Anesth, 2018, 32(4): 1570-1577。40 宋光远, 赵跃武, 杜国勇, 等。股动脉路径经导管主动脉瓣置换 27 Ahmad M, Patel JN, Vipparthy SC, et al。Conscious sedation versus 术式简化的单中心经验。中华心血管病杂志, 2022, 50(6): 563- general anesthesia in transcatheter aortic valve replacement: A cost 569。and outcome analysis。Cureus, 2019, 11(6): e4812。Song GY, Zhao YW, Du GY, et al。Single center experience of 28 Toggweiler S, Gurvitch R, Leipsic J, et al。Percutaneous aortic valve transcatheter aortic valve replacement with a simplified operative replacement: Vascular outcomes with a fully percutaneous protocol。Chin J Cardiol, 2022, 50(6): 563-569。procedure。J Am Coll Cardiol, 2012, 59(2): 113-118。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 459,
      "text": " valve replacement with a simplified operative replacement: Vascular outcomes with a fully percutaneous protocol。Chin J Cardiol, 2022, 50(6): 563-569。procedure。J Am Coll Cardiol, 2012, 59(2): 113-118。 41 赵振燕, 张洪亮, 张喆, 等。在单纯局部麻醉下行经导管主动脉 29 Schymik G, Wrth A, Bramlage P, et al。Long-term results of 瓣置换术可行性和安全性的初步研究。中国循环杂志, 2022, transapical versus transfemoral TAVI in a real world population of 37(4): 341-347。1000 patients with severe symptomatic aortic stenosis。Circ Zhao ZY, Zhang HL, Zhang Z, et al。Feasibility and safety of Cardiovasc Interv, 2015, 8(1): e000761。transfemoral transcatheter aortic valve replacement under pure 30 刘新民, 姚晶, 董哲, 等。使用单动脉入路技术行经导管主动脉 local anesthesia。Chin Circ J, 2022, 37(4): 341-347。瓣置换术三例。中国循环杂志, 2022, 37(4): 421-424。42 陈阳, 王墨扬, 牛冠男, 等。中国首例完全局部麻醉且无镇静下 http://www。tcsurg。org 中国胸心血管外科临床杂志 2024年12月第31卷第12期 • 1727 • 极简式经导管主动脉瓣置换术。中国循环杂志, 2021, 36(10): transcatheter laao with the first-generation watchman and next- 1027-1030。generation watchman FLX devices。JACC Cardiovasc Interv, 2022, Chen Y, Wang MY, Niu GN, et al。China's first fully local 15(21): 2115-2123。anesthesia and non-sedation minimally invasive transcatheter 53 De Backer O, Landes U, Fuchs A, et al。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 460,
      "text": "rdiovasc Interv, 2022, Chen Y, Wang MY, Niu GN, et al。China's first fully local 15(21): 2115-2123。anesthesia and non-sedation minimally invasive transcatheter 53 De Backer O, Landes U, Fuchs A, et al。 Coronary access after aortic valve replacement。Chin Circ J, 2021, 36(10): 1027-1030。TAVR-in-TAVR as evaluated by multidetector computed 43 Yao J, Lu ZN, Modine T, et al。Evaluation of the safety and efficacy tomography。JACC Cardiovasc Interv, 2020, 13(21): 2528-2538。of a novel anatomical classification and dual anchoring theory to 54 Akodad M, Sellers S, Landes U, et al。Balloon-expandable valve for optimize the TAVR strategy for pure severe aortic regurgitation treatment of evolut valve failure: Implications on neoskirt height (aurora): A prospective cohort study。BMC Cardiovasc Disord, and leaflet overhang。JACC Cardiovasc Interv, 2022, 15(4): 368- 2022, 22(445): 1-10。377。44 Popma JJ, Deeb GM, Yakubov SJ, et al。Transcatheter aortic-valve 55 Khan JM, Bruce CG, Babaliaros VC, et al。TAVR roulette: Caution replacement with a self-expanding valve in low-risk patients。N regarding basilica laceration for TAVR-in-TAVR。JACC Engl J Med, 2019, 380(18): 1706-1715。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 461,
      "text": "CG, Babaliaros VC, et al。TAVR roulette: Caution replacement with a self-expanding valve in low-risk patients。N regarding basilica laceration for TAVR-in-TAVR。JACC Engl J Med, 2019, 380(18): 1706-1715。 Cardiovasc Interv, 2020, 13(6): 787-789。56 赵玉沛, 杨尹默, 楼文晖, 等。外科病人围手术期液体治疗专家 45 Sankaramangalam K, Banerjee K, Kandregula K, et al。Impact of coronary artery disease on 30-day and 1-year mortality in patients 共识(2015)。中国实用外科杂志, 2015, 35(9): 960-966。Zhao YP, Yang YM, Lou WH, et al。Expert consensus on undergoing transcatheter aortic valve replacement: A meta- perioperative fluid therapy for surgical patients (2015)。Chin J analysis。J Am Heart Assoc, 2017, 6(10): 1-19。Pract Surg, 2015, 35(9): 960-966。46 D'ascenzo F, Verardi R, Visconti M, et al。Independent impact of 57 Ten Berg J, Sibbing D, Rocca B, et al。Management of extent of coronary artery disease and percutaneous antithrombotic therapy in patients undergoing transcatheter aortic revascularisation on 30-day and one-year mortality after TAVI: A valve implantation: A consensus document of the ESC Working meta-analysis of adjusted observational results。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 462,
      "text": "going transcatheter aortic revascularisation on 30-day and one-year mortality after TAVI: A valve implantation: A consensus document of the ESC Working meta-analysis of adjusted observational results。 EuroIntervention, Group on Thrombosis and the European Association of 2018, 14(11): e1169-e1177。Percutaneous Cardiovascular Interventions (EAPCI), in 47 Minten L, Wissels P, Mccutcheon K, et al。The effect of coronary collaboration with the ESC Council on Valvular Heart Disease。Eur lesion complexity and preprocedural revascularization on 5-year Heart J, 2021, 42(23): 2265-2269。outcomes after TAVR。JACC Cardiovasc Interv, 2022, 15(16): 58 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会。1611-1620。经导管主动脉瓣植入术后抗血栓治疗中国专家共识。中华心血 48 Faroux L, Guimaraes L, Wintzer-Wehekind J, et al。Coronary 管病杂志, 2022, 50(2): 117-131。artery disease and transcatheter aortic valve replacement: JACC Chinese Society of Cardiology, Chinese Medical Association, state-of-the-art review。J Am Coll Cardiol, 2019, 74(3): 362-372。Editorial Board of Chinese Journal of Cardiology。Chinese expert 49 王宇彬, 宋光远, 张海彤, 等。经导管主动脉瓣置换术后心房颤 consensus on antithrombotic therapy after transcatheter aortic 动行左心耳封堵术二例。中国循环杂志, 2019, 34(2): 196-197。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 463,
      "text": "itorial Board of Chinese Journal of Cardiology。Chinese expert 49 王宇彬, 宋光远, 张海彤, 等。经导管主动脉瓣置换术后心房颤 consensus on antithrombotic therapy after transcatheter aortic 动行左心耳封堵术二例。中国循环杂志, 2019, 34(2): 196-197。 valve implantation。Chin J Cardiol, 2022, 50(2): 117-131。Wang YB, Song GY, Zhang HT, et al。Left atrial appendage 59 Hu X, Xu H, Wang C, et al。Early 6 months usage of single occlusion after transcatheter aortic valve replacement in patients anTiplAtelet OR anTicoAgulant followed by single antiplatelet with atrial fibrillation: Two cases report。Chin Circ J, 2019, 34(2): after transcatheter aortic valve replacement: Protocol for a 196-197。multicentre, open-label, randomised controlled clinical trial。BMJ 50 王宇彬, 吴永健, 宋光远, 等。接受其他心脏介入手术治疗的心 Open, 2023, 13(11): 1-8。房纤颤患者左心耳封堵术应用观察。山东医药, 2018, 58(35): 28- 60 中国医师协会心血管内科医师分会结构性心脏病专业委员会。32。经导管主动脉瓣置换术后运动康复专家共识。中国介入心脏病 Wang YB, Wu YJ, Song GY, et al。Feasibility and safety of left atrial 学杂志, 2020, 28(7): 361-368。appendage closure in atrial fibrillation patients undergoing other Structural Cardiology Committee of Cardiovascular Physicians intervention therapy。Shandong Med J, 2018, 58(35): 28-32。Branch, Chinese Medical Doctor Association。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 464,
      "text": "fibrillation patients undergoing other Structural Cardiology Committee of Cardiovascular Physicians intervention therapy。Shandong Med J, 2018, 58(35): 28-32。Branch, Chinese Medical Doctor Association。 Expert consensus on 51 Kapadia SR, Krishnaswamy A, Whisenant B, et al。Concomitant exercise rehabilitation after transcatheter aortic valve replacement。left atrial appendage occlusion and transcatheter aortic valve Chin J Interv Cardiol, 2020, 28(7): 361-368。replacement among patients with atrial fibrillation。Circulation, 2024, 149(10): 734-743。收稿日期：2024-10-08 修回日期：2024-10-28 52 Price MJ, Friedman DJ, Du C, et al。Comparative safety of 本文编辑：雷芳，刘雪梅 http://www。tcsurg。org。",
      "source": "1.中国经导管主动脉瓣置换术临...路径专家共识（2024版）_中国医师协会心血管内科医师分会结构性心脏病学组_.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 465,
      "text": "中国康复 年 月 第 卷第 期 ２０２３ ６  ３８ ６ ３６９ 综述 左心室辅助装置植入患者运动训练的理论与实践进展 罗泽汝心 ，王渝强 ，张秀 ，郭应强 ，喻鹏铭 ａ ｂ ａ ｂ ａ 【关键词】 左心室辅助装置 运动训练 心脏康复 ； ； 【中图分类号】 ＤＯＩ Ｒ４９ 【 】 １０．３８７０／ｚｇｋｆ．２０２３．０６．０１１ 左心室辅助装置 （Ｌｅｆｔ ｈｅａｒｔ ａｓｓｉｓｔ ｄｅｖｉｃｅ， ＬＶＡＤ） １ 患者运动过程中生理反应 是一种为准备接受心脏移植或那些无法进行移植手术 ＬＶＡＤ 患者的一种替代治疗方式 我国在该领域的研究开展 的基本原理是通过抽吸左心室的血液输送。ＬＶＡＤ 相对较早 万峰教授团队于 年完成了国内首例 到主动脉来帮助心力衰竭患者减轻负荷的机械辅助装 ， １９９１ 植入手术［１］ 近年来 国内在该领域取得了突 置 目前旋转式血泵已经发展到第三代全磁悬浮离心 ＬＶＡＤ。，。破性进展 其有效性和安全性已经得到了广泛的验 式连续血流装置［１５］ 新一代的装置普遍采取连续血 ，。证［２］ 随着 技术的成熟 植入后患者的生存期 流固定流速模式 提供 的流量以保证器官。ＬＶＡＤ ， ， ３ ～１０Ｌ／ｍｉｎ 不断延长［３］ 这对该类患者的生活质量提出了更高的 灌注水平［１６］ 然而 运动是一个需要人体多个系统参 ，。， 要求 然而 患者的运动耐量和生活质量恢复并 与的生理过程 除心血管系统以外 呼吸系统和骨骼肌。ＬＶＡＤ ， ， 不如人意［４］ 有研究报道 该类患者术后远期的最大 也扮演着同样重要的角色 任何一个系统的限制都影。， ， 摄氧量仍然停留在低水平 ［５－６］ 响患者的运动耐量 （１０ ～１７ｍｌ／ｋｇ／ｍｉｎ）。基于心脏康复在改善心力衰竭患者功能能力和预后的 影响 患者运动耐量的心血管因素 １．１ ＬＶＡＤ ＬＶＡＤ 共识［７－８］ 人们期望把这些经验运用于 患者中 植入术后患者运动时心血管系统发生了明显的变化 ， ＬＶＡＤ。",
      "source": "1_2023+左心室辅助装置植入患者运动训练的理论与实践进展.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 466,
      "text": "有研究报道 该类患者术后远期的最大 也扮演着同样重要的角色 任何一个系统的限制都影。， ， 摄氧量仍然停留在低水平 ［５－６］ 响患者的运动耐量 （１０ ～１７ｍｌ／ｋｇ／ｍｉｎ）。基于心脏康复在改善心力衰竭患者功能能力和预后的 影响 患者运动耐量的心血管因素 １．１ ＬＶＡＤ ＬＶＡＤ 共识［７－８］ 人们期望把这些经验运用于 患者中 植入术后患者运动时心血管系统发生了明显的变化 ， ＬＶＡＤ。 越来越多的研究表明以运动训练 一般情况下 心输出量会随着运动负荷的增加而呈线 （Ｅｘｅｒｃｉｓｅ ｔｒａｉｎｉｎｇ， ， 为基础的心脏康复计划能够让 患者获益 性变化 这种变化主要来自于心率和心脏收缩舒张水 ＥＴ） ＬＶＡＤ ， ， 这主要体现在运动耐量和生活质量方面［９］ 对于该 平的增加 这使得极量运动时的心输出量会增加。， ４ ～６ 领域 目前在国内除了一些个案报道的观察性研究 目 倍［１７］ 患者的心输出量主要由 机械泵的做功 ， ，。ＬＶＡＤ 前还没有心脏康复计划对 患者围手术期的安全 产生 一般被称为泵流量即单位时间内流经血泵的血 ＬＶＡＤ ， 性和效果的随机对照试验［１０－１２］。同时 ， 在全球范围内 流量［１７］。泵流量主要由转速和跨泵压力差两方面的 ＬＶＡＤ 患者的心脏康复参与率仍然低下［１３］。一项来 因素决定［１８］。跨泵压力差常用 “ΔＰ” 表示 ， 其定义是 自北美的调查发现该类患者的心脏康复参与率仅有 泵出口和入口的压力差 中 的大小主要取。ＬＶＡＤ ΔＰ ３０％ ［１４］ ， 其主要障碍包括 ： 物理治疗师对该类患者有 决于患者左心室残存的收缩能力和血管外周阻力。在 限的认知 临床专家重视不够以及目前缺乏指南和标 运动过程中 患者残余的心脏收缩能力使得左心 、 ＬＶＡＤ 准化的临床指导 本文针对目前国内外研究现状在 室充盈压力提高改变了跨泵压力差 从而增加泵流。， 术后运动生理学理论的基础上 总结了该类患 量［１５］ 然而这种增加通常是有限的 这使得 患。， ＬＡＶＤ ＬＶＡＤ ， 者虽然能够执行低到中等强度的日常生活活动 但无 者进行 方案的进展 为从事该领域心脏康复的同 ， ＥＴ ， 行提供参考 法满足更高强度的运动需求［１７］ 除此之外 右心功。，。能 肺动脉高压以及外周血管阻力等也是影响泵流量 、 的主要因素 运动时心脏对心输出量的贡献取决于右。基金项目 国家重点研发计划资助项目 ： （２０１８ＹＦＣ２００２３０４） 心室和左心室收缩储备的相互作用 因此 右心功能 收稿日期。",
      "source": "1_2023+左心室辅助装置植入患者运动训练的理论与实践进展.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 467,
      "text": "够执行低到中等强度的日常生活活动 但无 者进行 方案的进展 为从事该领域心脏康复的同 ， ＥＴ ， 行提供参考 法满足更高强度的运动需求［１７］ 除此之外 右心功。，。能 肺动脉高压以及外周血管阻力等也是影响泵流量 、 的主要因素 运动时心脏对心输出量的贡献取决于右。基金项目 国家重点研发计划资助项目 ： （２０１８ＹＦＣ２００２３０４） 心室和左心室收缩储备的相互作用 因此 右心功能 收稿日期。 ， 作者单位 ：２ 四 ０２ 川 ２⁃ 大 ０６ 学 ⁃２ 华 ９ 西医院 康复医学中心 心脏大血管外科 成都 障碍会导致左心室前负荷不足从而限制患者运动时的 ： ａ． ，ｂ． ， ６ 作 １０ 者 ０４ 简 １ 介 罗泽汝心 男 技师 主要从事心脏外科围手术期物 心输出量进而影响患者的运动耐量［１９］。右心功能衰 ： （１９９１⁃） ， ， ， 理治疗方面的研究 竭在晚期心力衰竭患者中很常见 而且被认为是 通讯作者 喻鹏铭。， ： ，１３４３８２０１４５１＠１２６．ｃｏｍ 患者重要的预后因素［２０］ ＬＶＡＤ。３７０ ＣｈｉｎｅｓｅＪｏｕｒｎａｌｏｆＲｅｈａｂｉｌｉｔａｔｉｏｎ，Ｊｕｎ２０２３，Ｖｏｌ． ３８ Ｎｏ．６ 影响 患者运动耐量的呼吸因素 受心衰 血等恶性事件的风险更高［３１］ 因此强调每次的训练 １．２ ＬＶＡＤ。终末期继发性肺动脉高压和长期的卧床等因素的影 过程中需要整个多学科团队尤其是 执行者对患者 ＥＴ 响 患者常常合并严重的呼吸功能障碍［２１］ 有 进行谨慎评估和在整个训练计划初期对患者进行严密 ，ＬＶＡＤ。证据显示虽然接受了 植入后患者的肺淤血和死 的监测 ＬＶＡＤ。腔通气得以改善 但肺功能似乎并没有得到提高［２２］ 有效性 以 为基础的心脏康复计划主要目 ，。２．２ ＥＴ 等［２３］对比该类患者 个月的肺功能测试结 的是提高 患者的功能能力和生活质量 等 Ｄｉｏｐｏｕｌｏｓ ６ ＬＶＡＤ。Ｌｉｚａ 果发现大部分患者的呼吸肌力和最大自主通气等指标 总结了近 年发表的对 患者以 为主要干预 ３０ ＬＶＡＤ ＥＴ 仅为预计值的一半 在一项纳入 名 患者的 方式的临床研究［９］ 其结果显示 组患者的功能能。４４ ＬＶＡＤ ， ＥＴ 队列研究中发现相比术前 患者术后的 力显著改善 其结果主要反映在峰值摄氧量和六分钟 ， Ｔｉｆｆｅｎｅａｕ⁃ ， 指数和一秒率 步行测试距离上 等［３２］在 年发表的系统 Ｐｉｎｅｌｌｉ （Ｆｏｒｃｅｄ ｅｘｐｉｒａｔｏｒｙ ｖｏｌｕｍｅ ｉｎ ｏｎｅ。Ｔｏｕｆｉｋ ２０１７ 等肺功能指标并没有明显的提高［２４］ 综述和荟萃分析中定量分析了纳入的 项有关研究 ｓｅｃｏｎｄ，ＦＥＶ１）。３。",
      "source": "1_2023+左心室辅助装置植入患者运动训练的理论与实践进展.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 468,
      "text": " ＥＴ 队列研究中发现相比术前 患者术后的 力显著改善 其结果主要反映在峰值摄氧量和六分钟 ， Ｔｉｆｆｅｎｅａｕ⁃ ， 指数和一秒率 步行测试距离上 等［３２］在 年发表的系统 Ｐｉｎｅｌｌｉ （Ｆｏｒｃｅｄ ｅｘｐｉｒａｔｏｒｙ ｖｏｌｕｍｅ ｉｎ ｏｎｅ。Ｔｏｕｆｉｋ ２０１７ 等肺功能指标并没有明显的提高［２４］ 综述和荟萃分析中定量分析了纳入的 项有关研究 ｓｅｃｏｎｄ，ＦＥＶ１）。３。 这些结果提示 植入可能并不能完全改善此类患 其结果表明 组增加了 个单位的公斤摄氧量 ＬＶＡＤ ＥＴ ３ 者的呼吸功能障碍 而且呼吸功能障碍也可能成为影 Ｐ 同时 步行距 ， （９５％ ＣＩ， ０．６４ －５．３５， ＝０．００１）， ６ｍｉｎ 响患者运动耐量的重要因素 离平均增加了 Ｐ。６０ｍ（９５％ ＣＩ， ２２． ６１ －９７． ５０， ＝０． 影响 患者运动耐量的外周骨骼肌肉因素 对于 植入术后患者生活质量的研究目 １．３ ＬＶＡＤ ００２）。ＬＶＡＤ 终末期心力衰竭患者可因活动受限和代谢失衡等原 前主要采用的评估方法包括明尼苏达心衰问卷 堪萨 、 因造成全身肌肉退化和体重减轻 甚至发生恶病质 斯城心肌病问卷调查和 健康量表 种方式进行 ，。ＳＦ⁃３６ ３ 这些外周骨骼肌肉的改变与 患者的运动能力 量化［４］ 不同评估方式均显示 能够显著提高该类 ＬＶＡＤ 、。ＥＴ 生活质量和死亡率密切相关［２５］ 及其同事报 患者的生活质量［３３］。Ｋｅｒｒｉｇａｎ。道了 患者肌力和耐力与运动能力和生活质量的 开展时机 对于 术后开始 的时机 目 ＬＶＡＤ ２．３ ＬＶＡＤ ＥＴ ， 关系［２５］ 其结果显示 股四头肌肌力与堪萨斯城心肌 前尚未有明确的指南建议 回顾之前的研究 干预。，。，ＥＴ 病问卷得分有相关性 ｒ Ｐ 方案主要集中在 植入后的 周至 个月期间执 （ ＝ ０． ５８， ＝ ０． ００６）。Ｙｏｓｔ ＬＶＡＤ １ ３ 等［２６］的研究结果也显示了 术前患者肌力握力 行［３４］ 在临床实践中 患者的 是围手术期康 ＬＶＡＤ。ＬＶＡＤ ＥＴ 与住院时间密切相关 这些证据都提示外周骨骼肌肉 复的一部分 即从监护室和术后早期就应该为 的。， ＥＴ 的限制可能是影响 患者运动耐量的重要因素之 开展做准备 术后早期康复治疗主要干预目标是帮助 ＬＶＡＤ。一［２７］ 当然 除心血管系统 呼吸系统以及外周骨骼 患者早期活动和减少术后并发症的发生［３５］ 其次。， 、。，ＥＴ 系统之外 还应注意其它影响因素 比如 长期贫血也 计划需要根据患者病情变化作动态调整 干预开始的 ，。， ， 是 患者再入院的重要预测因素［２８］ 实际上 在 决策应该由多学科团队中心脏外科或重症医学专家开 ＬＶＡＤ。， 机械辅助装置下患者的运动生理过程是极其复杂的 授 ，。",
      "source": "1_2023+左心室辅助装置植入患者运动训练的理论与实践进展.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 469,
      "text": "Ｄ。一［２７］ 当然 除心血管系统 呼吸系统以及外周骨骼 患者早期活动和减少术后并发症的发生［３５］ 其次。， 、。，ＥＴ 系统之外 还应注意其它影响因素 比如 长期贫血也 计划需要根据患者病情变化作动态调整 干预开始的 ，。， ， 是 患者再入院的重要预测因素［２８］ 实际上 在 决策应该由多学科团队中心脏外科或重症医学专家开 ＬＶＡＤ。， 机械辅助装置下患者的运动生理过程是极其复杂的 授 ，。 至今还有很多未知的领域值得探索 前评估 大部分 患者都处于心力衰竭。２．４ ＥＴ ＬＶＡＤ 终末期 心脏手术的打击使得更加虚弱 因此在 计 ２ 患者 的现有证据 ， ， ＥＴ ＬＶＡＤ ＥＴ 划初期需要对患者的病情和运动风险进行严格的评 安全性 安全性是开展临床新干预方法的前提 估 该类患者术后在监护室或早期的评估原则与其他 ２．１ ，。等［２９］首次报道了 患者进行 的安全 心脏外科患者没有本质的区别 推荐参照重症康复物 Ｍｏｒｒｏｎｅ ＬＶＡＤ ＥＴ ， 事件发生情况 该研究中 名参与者一共进行了 理治疗的指南进行评估［３６］ 内容包括病史 以及疾病。３４。， 个疗程 小时 的 其中出现了 起轻微 前的运动能力水平 基本生命体征 伤口情况 心理和 １８７８ （１３９０ ） ＥＴ， ４ 、 、 、 安全事件 但没有任何严重的不良事件发生 这四项 认知水平 活动能力 平衡 肌力耐力和功能能力等内 ，。、 、 、 不良事件主要与训练中发生的泵流量下降相关 这提 容 同时 推荐此类患者每一次 之前需要重点关 ，。， ＥＴ 示在该类患者 中需要特别注意设备的参数变化 注的临床评估结果包括最近的影像学检查和实验室检 ＥＴ。最近 等［３０］的综述中总结了关于 患者 验结果以及药物的使用情况 主要包括与心血管系统 ，Ａｌｓａｒａ ＬＶＡＤ ＥＴ。安全事件的结果 纳入的 项研究中仅有一项有不良 相关的检查如心电图 心脏彩超或胸部 等 近期 ， ４ 、 ＣＴ。事件的报道 但并未出现死亡等严重不良事件 基于 重要的实验室检验如心肌酶谱指标 凝血功能指标 血 ，。、 、 目前有限的证据可以初步得出在医疗监督下进行规范 细胞指标 电解质水平和血气分析 同时还要求每次 、。的 对这类患者是安全的 相对于其他心血管疾 之前干预人员检查设备的工作情况如泵流量 血泵 ＥＴ。ＥＴ 、 病 这类患者发生恶性心律失常 心肌梗死 中风 和出 转数 波形 运行电流 电压和设备设备报警情况以及 ， 、 、 、 、 、 ／ 中国康复 年 月 第 卷第 期 ２０２３ ６  ３８ ６ ３７１ 近期发生的重要临床事件等信息 能的提高需要不断调整时间比例 门诊康复阶段推荐。",
      "source": "1_2023+左心室辅助装置植入患者运动训练的理论与实践进展.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 470,
      "text": "同时还要求每次 、。的 对这类患者是安全的 相对于其他心血管疾 之前干预人员检查设备的工作情况如泵流量 血泵 ＥＴ。ＥＴ 、 病 这类患者发生恶性心律失常 心肌梗死 中风 和出 转数 波形 运行电流 电压和设备设备报警情况以及 ， 、 、 、 、 、 ／ 中国康复 年 月 第 卷第 期 ２０２３ ６  ３８ ６ ３７１ 近期发生的重要临床事件等信息 能的提高需要不断调整时间比例 门诊康复阶段推荐。 特殊注意事项 患者在进行 时应 强度为峰值摄氧量的 或自感劳累分级 ２．５ ＥＴ ＬＶＡＤ ＥＴ ４０％ ～ ６０％ 该避免 动作 同时因为大部分患者存在心脏 的训练强度 Ｖａｌｓａｌｖａ ， １３ ～１５。变时功能障碍推荐该类患者在运动处方中设置足够的 抗阻训练 患者在日常生活中需要负重 ２．８ ＬＶＡＤ 热身和放松时间 另外 为了保证设备的正常运行在 至少 的电池设备 因此术后早期对患者进行肌肉。， ２ｋｇ ， 运动时要避免突然的姿势变化和弯腰运动 运动强度 力量和耐力训练十分必要 下肢的抗阻训练在监护室。和时间设置强调循序渐进 为避免训练造成的过度疲 即可开始 围手术期推荐抗阻训练主要以下肢闭链运 ，。劳和体液流失 应该教授患者液体补充原则 对这类 动方式为主 出院后稳定期在康复门诊或社区康复中 ，。患者还应该强调训练前后对设备进行严格消毒 并且 心推荐弹力带或者运动器械 推荐进行每周 次 ，。３ ～５ 建议在每次门诊训练后留观 抗阻训练 每次训练时间 训练强度控制在 １５ｍｉｎ。， １５ ～２０ｍｉｎ， 禁忌或停止标准 基于 患者的特殊 自感劳累分级 关于此类患者上肢的抗阻训 ２．６ ＥＴ ＬＶＡＤ １３ ～１５。性 推荐干预者掌握 患者 的禁忌症和停止 练介入时机 在没有更多证据推荐的情况下目前仍遵 ， ＬＶＡＤ ＥＴ ， 标准［３４，３７］ 期间需要密切观察运动不耐受相关的 循美国运动医学院发表的指南［３４，３７］ 在 周后才开。ＥＴ ， １２ 症状和体征 头昏 严重的呼吸困难 胸痛或不适 心 始轻度到中等强度的抗阻训练 （ 、 、 、。动过速和异常的血压反应 一般不推荐安静时心率 ）。３ 结语与展望 超过 次 吸氧状态下氧饱和度仍低于 的 １００ ／ｍｉｎ， ９０％ 患者参与 计划 不明原因的发热 新出现的出血 在未来 植入后基于 的心脏康复必将扮 ＥＴ。， ，ＬＶＡＤ ＥＴ 或血栓症状 体征 怀疑发生复杂而频繁的室性心律失 演越来越重要的角色 因为仅仅延长生存时间已经不 ／ ， ， 常和近期体重的突然增加 内体重增加 能满足该类患者的需求 而 在提高该类患者的运 （１ ～３ｄ ＞１．。ＥＴ 的 患者也是 的禁忌症 过程中需 动能力和生活质量方面已经得到了初步证实 当然目 ８ｋｇ） ＬＶＡＤ ＥＴ。ＥＴ。",
      "source": "1_2023+左心室辅助装置植入患者运动训练的理论与实践进展.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 471,
      "text": "在未来 植入后基于 的心脏康复必将扮 ＥＴ。， ，ＬＶＡＤ ＥＴ 或血栓症状 体征 怀疑发生复杂而频繁的室性心律失 演越来越重要的角色 因为仅仅延长生存时间已经不 ／ ， ， 常和近期体重的突然增加 内体重增加 能满足该类患者的需求 而 在提高该类患者的运 （１ ～３ｄ ＞１．。ＥＴ 的 患者也是 的禁忌症 过程中需 动能力和生活质量方面已经得到了初步证实 当然目 ８ｋｇ） ＬＶＡＤ ＥＴ。ＥＴ。 要严密关注 设备运行情况 出现设备报警或参 前该领域的研究还存在一定的局限性 对 植 ＬＶＡＤ ，。① ＬＶＡＤ 数异常 如泵流量小于 应该停止训练 入候选者进行术前预康复的研究目前处于未知领域 （ ３Ｌ）。实施方案 根据目前的证据 术后患 大部分 植入候选者都是处于心衰末期 这些患 ２．７ ＥＴ ，ＬＶＡＤ ＬＶＡＤ ， 者的 方案主要包括有氧训练和抗阻训练［３４，３７］ 根 者术前的生理和心理状态普遍不佳 基于在心脏外科 ＥＴ ，。据运动处方的原则推荐 患者 运动类型 干 的经验 术前以 为基础的预康复能够提高患者抵 ＬＶＡＤ ＥＴ ， ， ＥＴ 预的强度 频率和时间 御手术打击的能力 减少患者术后并发症的风险和住 ，。， 有氧训练方式的选择 考虑到安全性推荐 院时间［３９］ 遗憾的是目前还没有相关的研究报道 ２．７．１。患者早期院内有氧运动方案中选择踏车的方式 植入候选者进行预康复的价值 目前仍缺乏 ＬＶＡＤ ＬＶＡＤ。② 以便于观察设备参数 在出院后门诊和居家心脏康复 术后长期居家心脏康复的研究和远期观察结果 目前。方案则推荐患者以步行或慢跑为主的运动方式 同 大部分的研究都集中基于术后短期 术后 周 个。（ １ ～３ 时 基于安全的考虑不建议患者参与游泳或其他类型 月 大于 周或者基于居家 的研究仍缺乏［１８］ 同 ， ）， １２ ＥＴ ， 的水上运动 时 对于该类患者远期的生存率和再入院率的结果。ＥＴ 有氧训练时长和频率 患者在有氧训 目前仍然没有报道 在新冠流行的大背景下随着数字 ２．７．２ ＬＶＡＤ。练在时长和频率方面相对其他病种并没有特殊的要 医疗和远程康复在心衰患者中的安全性和有效性被逐 求 目前的专家共识推荐进行每周 次 ［３４，３７］ 步验证［４０］ 希望有研究聚焦该主题 对于 患。３ ～５ ＥＴ。，。③ ＬＶＡＤ 患者在运动前后需要足够的热身和放松时间 者目前基于证据的物理治疗方法单一 目前的研究仅 ＬＶＡＤ ，。特别是存在心脏变时功能障碍的患者［３４，３７］ 限于有氧训练和抗阻训练 一些针对性的功能训练如。",
      "source": "1_2023+左心室辅助装置植入患者运动训练的理论与实践进展.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 472,
      "text": "病种并没有特殊的要 医疗和远程康复在心衰患者中的安全性和有效性被逐 求 目前的专家共识推荐进行每周 次 ［３４，３７］ 步验证［４０］ 希望有研究聚焦该主题 对于 患。３ ～５ ＥＴ。，。③ ＬＶＡＤ 患者在运动前后需要足够的热身和放松时间 者目前基于证据的物理治疗方法单一 目前的研究仅 ＬＶＡＤ ，。特别是存在心脏变时功能障碍的患者［３４，３７］ 限于有氧训练和抗阻训练 一些针对性的功能训练如。 ， 有氧训练强度和进阶 患者 的强度 吸气肌训练的安全性和有效性在该类患者中并没有得 ２．７．３ ＬＶＡＤ ＥＴ 需要根据个体情况和术后的不同阶段进行个性化地设 到足够的验证 这使得面对该类患者基于证据医学的 ， 计 术后早期的 计划中不应强调训练的强 康复手段手段单一 因此我们呼吁未来有更多的物理。ＥＴ。度［３４，３７］ 而是应该从低强度患者能够承受的范围内 治疗手段的安全性和有效性在 患者中验证 ， ， ＬＶＡＤ。逐渐增加训练时长 如果患者因为过度虚弱而不能承 综上 本综述在总结 运动生理学理论的基。， ＬＶＡＤ 受最低强度的连续有氧训练模式 可以考虑间歇的方 础上 结合目前临床证据和实践经验总结了该类患者 ， ， 式进行代替［３８］ 推荐目标负荷训练 然后让 的 评估和干预的主要内容及注意事项为临床实践。２０ ～３０ｓ ＥＴ 患者休息 的间歇性训练［３４，３７］ 随着患者体适 提供参考 植入术后患者作为心脏康复的新领 ４０ ～６０ｓ ，。ＬＶＡＤ ３７２ ＣｈｉｎｅｓｅＪｏｕｒｎａｌｏｆＲｅｈａｂｉｌｉｔａｔｉｏｎ，Ｊｕｎ２０２３，Ｖｏｌ． ３８ Ｎｏ．６ 域值得更多的探索。",
      "source": "1_2023+左心室辅助装置植入患者运动训练的理论与实践进展.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 473,
      "text": "实践经验总结了该类患者 ， ， 式进行代替［３８］ 推荐目标负荷训练 然后让 的 评估和干预的主要内容及注意事项为临床实践。２０ ～３０ｓ ＥＴ 患者休息 的间歇性训练［３４，３７］ 随着患者体适 提供参考 植入术后患者作为心脏康复的新领 ４０ ～６０ｓ ，。ＬＶＡＤ ３７２ ＣｈｉｎｅｓｅＪｏｕｒｎａｌｏｆＲｅｈａｂｉｌｉｔａｔｉｏｎ，Ｊｕｎ２０２３，Ｖｏｌ． ３８ Ｎｏ．６ 域值得更多的探索。 ａｎｄａｃｕｔｅａｎｄｅｘｅｒｃｉｓｅｔｒａｉｎｉｎｇｒｅｓｐｏｎｓｅｓ［Ｊ］． Ｐｒｏｇｒｅｓｓｉｎｃａｒｄｉｏｖａｓ⁃ ｃｕｌａｒｄｉｓｅａｓｅｓ，２０２２，７０：３３⁃３９． 【参考文献】 ［１９］ ＲｅｉｓｓＮ，ＳｃｈｍｉｄｔＴ，ＷｏｒｋｏｗｓｋｉＡ，ｅｔａｌ． ＰｈｙｓｉｃａｌｃａｐａｃｉｔｙｉｎＬＶＡＤ 万峰 张喆 机械循环辅助的现状与展望 新进展 新设备 ｐａｔｉｅｎｔｓ：ｈｅｍｏｄｙｎａｍｉｃ ｐｒｉｎｃｉｐｌｅｓ， ｄｉａｇｎｏｓｔｉｃ ｔｏｏｌｓ ａｎｄ ｔｒａｉｎｉｎｇ ｃｏｎ⁃ ［１］ ， ． ———“ ， ， 新思路 中国心血管病研究 ｔｒｏｌ［Ｊ］． Ｔｈｅ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｊｏｕｒｎａｌ ｏｆ Ａｒｔｉｆｉｃｉａｌ Ｏｒｇａｎｓ， ２０１６， ３９ ” ［Ｊ］． ，２０１２，１０（４）：２５０⁃２５５． 贺涛 易定华 左心室辅助装置的临床应用现状及展望 心 （９）：４５１⁃４５９． ［２］ ， ． ［Ｊ］． 肺血管病杂志 ［２０］ ＬｅｅＳ，ＫａｍｄａｒＦ，Ｍａｄｌｏｎ⁃ＫａｙＲ，ｅｔａｌ． ＥｆｆｅｃｔｓｏｆｔｈｅＨｅａｒｔＭａｔｅＩＩ ，２００６，２５（３）：１８３⁃１８５． ｃｏｎｔｉｎｕｏｕｓ⁃ｆｌｏｗｌｅｆｔｖｅｎｔｒｉｃｕｌａｒａｓｓｉｓｔｄｅｖｉｃｅｏｎｒｉｇｈｔｖｅｎｔｒｉｃｕｌａｒｆｕｎｃ⁃ ［３］ ＭｅｈｒａＭＲ，ＧｏｌｄｓｔｅｉｎＤＪ，ＵｒｉｅｌＮ，ｅｔａｌ． Ｔｗｏ⁃ｙｅａｒｏｕｔｃｏｍｅｓｗｉｔｈ ａ ｔｉｏｎ ［Ｊ］． Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ ｈｅａｒｔ ａｎｄ ｌｕｎｇ ｔｒａｎｓｐｌａｎｔａｔｉｏｎ， ２０１０， ２９ ｍａｇｎｅｔｉｃａｌｌｙｌｅｖｉｔａｔｅｄｃａｒｄｉａｃｐｕｍｐ ｉｎ ｈｅａｒｔ ｆａｉｌｕｒｅ ［Ｊ］． Ｎｅｗ Ｅｎｇ⁃ （２）：２０９⁃２１５． ｌａｎｄＪｏｕｒｎａｌｏｆＭｅｄｉｃｉｎｅ，２０１８，３７８（１５）：１３８６⁃１３９５． ［２１］ Ｄａｌｌ’ＡｇｏＰ，ＣｈｉａｐｐａＧＲ，ＧｕｔｈｓＨ，ｅｔａｌ． Ｉｎｓｐｉｒａｔｏｒｙｍｕｓｃｌｅｔｒａｉｎ⁃ ［４］ ＡｄａｍｓＥＥ， Ｗｒｉｇｈｔｓｏｎ ＭＬ． Ｑｕａｌｉｔｙ ｏｆ ｌｉｆｅ ｗｉｔｈ ａｎ ＬＶＡＤ： ａ ｍｉｓｕｎ⁃ ｉｎｇｉｎｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅａｒｔ ｆａｉｌｕｒｅ ａｎｄ ｉｎｓｐｉｒａｔｏｒｙ ｍｕｓｃｌｅ ｗｅａｋｎｅｓｓ： ａ ｄｅｒｓｔｏｏｄｃｏｎｃｅｐｔ［Ｊ］． Ｈｅａｒｔ＆Ｌｕｎｇ，２０１８，４７（３）：１７７⁃１８３． ‐ ｒａｎｄｏｍｉｚｅｄｔｒｉａｌ［Ｊ］． ＪｏｕｒｎａｌｏｆｔｈｅＡｍｅｒｉｃａｎＣｏｌｌｅｇｅｏｆＣａｒｄｉｏｌｏｇｙ， ［５］ ＳｃｈｍｉｄｔＴ，Ｂｊａｒｎａｓｏｎ ＷｅｈｒｅｎｓＢ，Ｂａｒｔｓｃｈ Ｐ，ｅｔａｌ． Ｅｘｅｒｃｉｓｅｃａ⁃ ２００６，４７（４）：７５７⁃７６３． ｐａｃｉｔｙａｎｄ ｆｕｎｃｔｉｏｎａｌ ｐｅｒｆｏｒｍａｎｃｅ ｉｎ ｈｅａｒｔ ｆａｉｌｕｒｅ ｐａｔｉｅｎｔｓ ｓｕｐｐｏｒｔｅｄ ［２２］ Ｊｕｎｇ ＭＨ， Ｈａｎｓｅｎ ＰＢ， Ｓａｎｄｅｒ Ｋ， ｅｔ ａｌ． Ｅｆｆｅｃｔ ｏｆ ｉｎｃｒｅａｓｉｎｇ ｐｕｍｐ ｂｙａｌｅｆｔｖｅｎｔｒｉｃｕｌａｒａｓｓｉｓｔｄｅｖｉｃｅａｔｄｉｓｃｈａｒｇｅｆｒｏｍｉｎｐａｔｉｅｎｔｒｅｈａｂｉｌｉｔａ⁃ ｓｐｅｅｄｄｕｒｉｎｇｅｘｅｒｃｉｓｅｏｎｐｅａｋｏｘｙｇｅｎ ｕｐｔａｋｅ ｉｎ ｈｅａｒｔ ｆａｉｌｕｒｅ ｐａｔｉｅｎｔｓ ｔｉｏｎ［Ｊ］． ＡｒｔｉｆｉｃｉａｌＯｒｇａｎｓ，２０１８，４２（１）：２２⁃３０． ‐ ｓｕｐｐｏｒｔｅｄｗｉｔｈ ａ ｃｏｎｔｉｎｕｏｕｓ ｆｌｏｗ ｌｅｆｔ ｖｅｎｔｒｉｃｕｌａｒ ａｓｓｉｓｔ ｄｅｖｉｃｅ． Ａ ［６］ ＳｃｈｍｉｄｔＴ，Ｂｊａｒｎａｓｏｎ⁃ＷｅｈｒｅｎｓＢ，ＭｏｍｍｅｒｔｚＳ，ｅｔａｌ． Ｄｅｖｅｌｏｐｍｅｎｔ ‐ ｄｏｕｂｌｅ ｂｌｉｎｄｒａｎｄｏｍｉｚｅｄｓｔｕｄｙ［Ｊ］． Ｅｕｒｏｐｅａｎｊｏｕｒｎａｌｏｆｈｅａｒｔｆａｉｌ⁃ ｏｆｅｘｅｒｃｉｓｅ⁃ｒｅｌａｔｅｄｖａｌｕｅｓｉｎｈｅａｒｔｆａｉｌｕｒｅｐａｔｉｅｎｔｓｓｕｐｐｏｒｔｅｄｗｉｔｈａｌｅｆｔ ｕｒｅ，２０１４，１６（４）：４０３⁃４０８． ｖｅｎｔｒｉｃｕｌａｒａｓｓｉｓｔ ｄｅｖｉｃｅ ［Ｊ］． Ｔｈｅ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｊｏｕｒｎａｌ ｏｆ Ａｒｔｉｆｉｃｉａｌ ［２３］ ＤｉｍｏｐｏｕｌｏｓＳＫ，ＤｒａｋｏｓＳＧ，ＴｅｒｒｏｖｉｔｉｓＪＶ，ｅｔａｌ． Ｉｍｐｒｏｖｅｍｅｎｔｉｎｒｅ⁃ Ｏｒｇａｎｓ，２０１９，４２（４）：２０１⁃２０６． ｓｐｉｒａｔｏｒｙｍｕｓｃｌｅｄｙｓｆｕｎｃｔｉｏｎｗｉｔｈｃｏｎｔｉｎｕｏｕｓ⁃ｆｌｏｗｌｅｆｔｖｅｎｔｒｉｃｕｌａｒａｓｓｉｓｔ ［７］ ＳｈｏｅｍａｋｅｒＭＪ，ＤｉａｓＫＪ，ＬｅｆｅｂｖｒｅＫＭ，ｅｔａｌ． Ｐｈｙｓｉｃａｌｔｈｅｒａｐｉｓｔｃｌｉｎ⁃ ｄｅｖｉｃｅｓ［Ｊ］． ＴｈｅＪｏｕｒｎａｌ ｏｆ Ｈｅａｒｔ ａｎｄ Ｌｕｎｇ Ｔｒａｎｓｐｌａｎｔａｔｉｏｎ，２０１０， ｉｃａｌｐｒａｃｔｉｃｅ ｇｕｉｄｅｌｉｎｅ ｆｏｒ ｔｈｅ ｍａｎａｇｅｍｅｎｔ ｏｆ ｉｎｄｉｖｉｄｕａｌｓ ｗｉｔｈ ｈｅａｒｔ ２９（８）：９０６⁃９０８． ｆａｉｌｕｒｅ［Ｊ］． Ｐｈｙｓｉｃａｌｔｈｅｒａｐｙ，２０２０，１００（１）：１４⁃４３． 李晗 冯茹 陈红琢 运动训练在心力衰竭患者心脏康复中的研 ［２４］ ＳａｊｇａｌｉｋＰ， Ｋｉｍ ＣＨ， Ｓｔｕｌａｋ ＪＭ， ｅｔ ａｌ． Ｐｕｌｍｏｎａｒｙ ｆｕｎｃｔｉｏｎ ａｓｓｅｓｓ⁃ ［８］ ， ， ． 究进展 中国康复 ｍｅｎｔｐｏｓｔ⁃ｌｅｆｔｖｅｎｔｒｉｃｕｌａｒａｓｓｉｓｔ ｄｅｖｉｃｅ ｉｍｐｌａｎｔａｔｉｏｎ ［Ｊ］． ＥＳＣ Ｈｅａｒｔ ［Ｊ］． ，２０２０，３５（０４）：２０８⁃２１１． Ｆａｉｌｕｒｅ，２０１９，６（１）：５３⁃６１． ［９］ Ｇｒｏｓｍａｎ⁃ＲｉｍｏｎＬ， Ｌａｌｏｎｄｅ ＳＤ， Ｓｉｅｈ Ｎ， ｅｔ ａｌ． Ｅｘｅｒｃｉｓｅ ｒｅｈａｂｉｌｉｔａ⁃ ［２５］ ＶｏｎＨａｅｈｌｉｎｇＳ，ＧａｒｆｉａｓＭＴ，ＶａｌｅｎｔｏｖａＭ，ｅｔａｌ． Ｍｕｓｃｌｅｗａｓｔｉｎｇａｓ ｔｉｏｎｉｎ ｖｅｎｔｒｉｃｕｌａｒ ａｓｓｉｓｔ ｄｅｖｉｃｅ ｒｅｃｉｐｉｅｎｔｓ： ａ ｍｅｔａ⁃ａｎａｌｙｓｉｓ ｏｆ ｅｆｆｅｃｔｓ ａｎｉｎｄｅｐｅｎｄｅｎｔｐｒｅｄｉｃｔｏｒｏｆｓｕｒｖｉｖａｌｉｎｐａｔｉｅｎｔｓｗｉｔｈｃｈｒｏｎｉｃｈｅａｒｔｆａｉｌ⁃ ｏｎｐｈｙｓｉｏｌｏｇｉｃａｌ ａｎｄ ｃｌｉｎｉｃａｌ ｏｕｔｃｏｍｅｓ ［Ｊ］． Ｈｅａｒｔ ｆａｉｌｕｒｅ ｒｅｖｉｅｗｓ， ｕｒｅ［Ｊ］． Ｊｏｕｒｎａｌｏｆｃａｃｈｅｘｉａ，ｓａｒｃｏｐｅｎｉａａｎｄｍｕｓｃｌｅ，２０２０，１１（５）： ２０１９，２４（１）：５５⁃６７． 翟忠昌 刘玉娥 杨林杰 等 例植入连续血流左心室辅助装 １２４２⁃１２４９． ［１０］ ， ， ， ． ６ 置患者的术后护理 护理学报 ［２６］ ＹｏｓｔＧ，ＢｈａｔＧ． Ｒｅｌａｔｉｏｎｓｈｉｐｂｅｔｗｅｅｎｈａｎｄｇｒｉｐｓｔｒｅｎｇｔｈａｎｄｌｅｎｇｔｈｏｆ ［Ｊ］． ，２０２１，２８（２）：６２⁃６４． ［１１］ 彭洁婧 ， 曾珠 ， 邓永鸿 ， 等 ． ５ 例左心室辅助装置植入患者的术 ｓｔａｙｆｏｒ ｌｅｆｔ ｖｅｎｔｒｉｃｕｌａｒ ａｓｓｉｓｔ ｄｅｖｉｃｅ ｉｍｐｌａｎｔａｔｉｏｎ ［Ｊ］． Ｎｕｔｒｉｔｉｏｎ ｉｎ 后护理 中华护理杂志 ［Ｊ］． ，２０２０，５５（９）：１３４６⁃１３４８． ＣｌｉｎｉｃａｌＰｒａｃｔｉｃｅ，２０１７，３２（１）：９８⁃１０２． 张茜 李永刚 兰俊 等 例植入左心室辅助装置患者的术后 ［１２］ ， ， ， ． １２ ［２７］ Ｌｏｙａｇａ⁃ＲｅｎｄｏｎＲＹ，ＰｌａｉｓａｎｃｅＥＰ，ＡｒｅｎａＲ，ｅｔａｌ． Ｅｘｅｒｃｉｓｅｐｈｙｓｉｏｌ⁃ 护理 中华护理杂志 ［Ｊ］． ，２０２１，５６（６）：９０７⁃９１１． ｏｇｙ，ｔｅｓｔｉｎｇ，ａｎｄ ｔｒａｉｎｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｓｕｐｐｏｒｔｅｄ ｂｙ ａ ｌｅｆｔ ｖｅｎｔｒｉｃｕｌａｒ ［１３］ Ｇａｌ ＴＢ， Ｐｉｅｐｏｌｉ ＭＦ， Ｃｏｒｒａ Ｕ， ｅｔ ａｌ． Ｅｘｅｒｃｉｓｅ ｐｒｏｇｒａｍｓ ｆｏｒ ＬＶＡＤ ａｓｓｉｓｔ ｄｅｖｉｃｅ ［Ｊ］． Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｈｅａｒｔ ａｎｄ Ｌｕｎｇ Ｔｒａｎｓｐｌａｎｔａｔｉｏｎ， ｓｕｐｐｏｒｔｅｄｐａｔｉｅｎｔｓ：ＡｓｎａｐｓｈｏｔｆｒｏｍｔｈｅＥＳＣａｆｆｉｌｉａｔｅｄｃｏｕｎｔｒｉｅｓ［Ｊ］． ２０１５，３４（８）：１００５⁃１０１６． Ｉｎｔｅｒｎａｔｉｏｎａｌｊｏｕｒｎａｌｏｆｃａｒｄｉｏｌｏｇｙ，２０１５，２０１：２１５⁃２１９． ［２８］ ＺａｉｒｉｓＭＮ，Ｐａｔｓｏｕｒａｋｏｓ ＮＧ， Ｇｅｏｒｇｉｌａｓ ＡＴ， ｅｔ ａｌ． Ａｎｅｍｉａ ａｎｄ ｅａｒｌｙ ［１４］ ＢａｃｈｍａｎｎＪＭ， Ｄｕｎｃａｎ ＭＳ， Ｓｈａｈ ＡＳ， ｅｔ ａｌ． Ａｓｓｏｃｉａｔｉｏｎ ｏｆ ｃａｒｄｉａｃ ｍｏｒｔａｌｉｔｙｉｎｐａｔｉｅｎｔｓｗｉｔｈｄｅｃｏｍｐｅｎｓａｔｉｏｎｏｆｃｈｒｏｎｉｃｈｅａｒｔｆａｉｌｕｒｅ［Ｊ］． ｒｅｈａｂｉｌｉｔａｔｉｏｎｗｉｔｈ ｄｅｃｒｅａｓｅｄ ｈｏｓｐｉｔａｌｉｚａｔｉｏｎｓ ａｎｄ ｍｏｒｔａｌｉｔｙ ａｆｔｅｒ ｖｅｎ⁃ Ｃａｒｄｉｏｌｏｇｙ，２０１１，１１９（３）：１２５⁃１３０． ｔｒｉｃｕｌａｒａｓｓｉｓｔｄｅｖｉｃｅｉｍｐｌａｎｔａｔｉｏｎ［Ｊ］． ＪＡＣＣ：ＨｅａｒｔＦａｉｌｕｒｅ，２０１８， ［２９］ ＭｏｒｒｏｎｅＴＭ，ＢｕｃｋＬＡ，ＣａｔａｎｅｓｅＫＡ，ｅｔａｌ． Ｅａｒｌｙｐｒｏｇｒｅｓｓｉｖｅｍｏｂｉ⁃ ６（２）：１３０⁃１３９． ｌｉｚａｔｉｏｎｏｆｐａｔｉｅｎｔｓｗｉｔｈｌｅｆｔｖｅｎｔｒｉｃｕｌａｒａｓｓｉｓｔｄｅｖｉｃｅｓｉｓｓａｆｅａｎｄ ｏｐｔｉ⁃ ［１５］ Ｍｏｎｔａｌｔｏ Ａ， Ｌｏｆｏｒｔｅ Ａ， Ｍｕｓｕｍｅｃｉ Ｆ， ｅｔ ａｌ． Ｍｅｃｈａｎｉｃａｌ ｃｉｒｃｕｌａｔｏｒｙ ｍｉｚｅｓｒｅｃｏｖｅｒｙｂｅｆｏｒｅｈｅａｒｔｔｒａｎｓｐｌａｎｔａｔｉｏｎ［Ｊ］． ＴｈｅＪｏｕｒｎａｌｏｆＨｅａｒｔ ｓｕｐｐｏｒｔｉｎｅｎｄ⁃ｓｔａｇｅｈｅａｒｔ ｆａｉｌｕｒｅ ［Ｍ］． Ｓｗｉｔｚｅｒｌａｎｄ： Ｓｐｒｉｎｇｅｒ Ｉｎｔｅｒ⁃ ａｎｄＬｕｎｇＴｒａｎｓｐｌａｎｔａｔｉｏｎ：ｔｈｅＯｆｆｉｃｉａｌＰｕｂｌｉｃａｔｉｏｎｏｆｔｈｅＩｎｔｅｒｎａｔｉｏｎａｌ ｎａｔｉｏｎａｌＰｕｂｌｉｓｈｉｎｇ，２０１７：１６３⁃１７２． ＳｏｃｉｅｔｙｆｏｒＨｅａｒｔＴｒａｎｓｐｌａｎｔａｔｉｏｎ，１９９６，１５（４）：４２３⁃４２９． ［１６］ ＢｏｕｒｑｕｅＫ，ＣｏｔｔｅｒＣ，ＤａｇｕｅＣ，ｅｔａｌ． Ｄｅｓｉｇｎｒａｔｉｏｎａｌｅａｎｄｐｒｅｃｌｉｎｉ⁃ ［３０］ Ａｌｓａｒａ Ｏ， Ｐｅｒｅｚ⁃Ｔｅｒｚｉｃ Ｃ， Ｓｑｕｉｒｅｓ ＲＷ， ｅｔ ａｌ． Ｉｓ ｅｘｅｒｃｉｓｅ ｔｒａｉｎｉｎｇ ｃａｌｅｖａｌｕａｔｉｏｎｏｆｔｈｅＨｅａｒｔＭａｔｅ３ ｌｅｆｔｖｅｎｔｒｉｃｕｌａｒａｓｓｉｓｔｓｙｓｔｅｍｆｏｒｈｅ⁃ ｓａｆｅａｎｄ ｂｅｎｅｆｉｃｉａｌ ｉｎ ｐａｔｉｅｎｔｓ ｒｅｃｅｉｖｉｎｇ ｌｅｆｔ ｖｅｎｔｒｉｃｕｌａｒ ａｓｓｉｓｔ ｄｅｖｉｃｅ ｍｏｃｏｍｐａｔｉｂｉｌｉｔｙ［Ｊ］． ＡＳＡＩＯｊｏｕｒｎａｌ，２０１６，６２（４）：３７５⁃３８３． ｔｈｅｒａｐｙ［Ｊ］． Ｊｏｕｒｎａｌｏｆｃａｒｄｉｏｐｕｌｍｏｎａｒｙｒｅｈａｂｉｌｉｔａｔｉｏｎａｎｄｐｒｅｖｅｎｔｉｏｎ， ［１７］ ＪｕｎｇＭＨ， Ｇｕｓｔａｆｓｓｏｎ Ｆ． Ｅｘｅｒｃｉｓｅ ｉｎ ｈｅａｒｔ ｆａｉｌｕｒｅ ｐａｔｉｅｎｔｓ ｓｕｐｐｏｒｔｅｄ ２０１４，３４（４）：２３３⁃２４０． ｗｉｔｈ ａ ｌｅｆｔ ｖｅｎｔｒｉｃｕｌａｒ ａｓｓｉｓｔ ｄｅｖｉｃｅ ［Ｊ］． Ｊ Ｈｅａｒｔ Ｌｕｎｇ Ｔｒａｎｓｐｌａｎｔ， ［３１］ ＰｉａＩＬ，ＡｐｓｔｅｉｎＣＳ，ＢａｌａｄｙＧＪ，ｅｔａｌ． Ｅｘｅｒｃｉｓｅａｎｄｈｅａｒｔｆａｉｌｕｒｅ：Ａ ２０１５，３４（４）：４８９⁃４９６． ｓｔａｔｅｍｅｎｔ ｆｒｏｍ ｔｈｅ Ａｍｅｒｉｃａｎ Ｈｅａｒｔ Ａｓｓｏｃｉａｔｉｏｎ Ｃｏｍｍｉｔｔｅｅ ｏｎ ｅｘｅｒ⁃ ［１８］ ＫｅｒｒｉｇａｎＤＪ，Ｃｏｗｇｅｒ ＪＡ， Ｋｅｔｅｙｉａｎ ＳＪ． Ｅｘｅｒｃｉｓｅ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｌｅｆｔ ｃｉｓｅ， ｒｅｈａｂｉｌｉｔａｔｉｏｎ， ａｎｄ ｐｒｅｖｅｎｔｉｏｎ ［Ｊ］． Ｃｉｒｃｕｌａｔｉｏｎ， ２００３， １０７ ｖｅｎｔｒｉｃｕｌａｒ ｄｅｖｉｃｅｓ： Ｔｈｅ ｉｎｔｅｒａｃｔｉｏｎ ｂｅｔｗｅｅｎ ｔｈｅ ｄｅｖｉｃｅ ａｎｄ ｐａｔｉｅｎｔ （８）：１２１０⁃１２２５． 中国康复 年 月 第 卷第 期 ２０２３ ６  ３８ ６ ３７３ ［３２］ ＨａｄｄａｄＴＭ，ＳａｕｒａｖＡ，ＳｍｅｒＡ，ｅｔａｌ． Ｃａｒｄｉａｃｒｅｈａｂｉｌｉｔａｔｉｏｎ ｉｎ ｐａ⁃ ｆｏｒＥａｒｌｙ Ｍｏｂｉｌｉｚａｔｉｏｎ ｉｎ ｔｈｅ ＩＣＵ： Ａ Ｓｙｓｔｅｍａｔｉｃ Ｒｅｖｉｅｗ ［Ｊ］． Ｃｒｉｔ ｔｉｅｎｔｓ ｗｉｔｈｌｅｆｔｖｅｎｔｒｉｃｕｌａｒａｓｓｉｓｔｄｅｖｉｃｅ：ａｓｙｓｔｅｍａｔｉｃｒｅｖｉｅｗａｎｄｍｅｔａ⁃ ＣａｒｅＭｅｄ，２０２０，４８（１１）：１１２１⁃１１２８． ａｎａｌｙｓｉｓ［Ｊ］． Ｊｏｕｒｎａｌ ｏｆ ｃａｒｄｉｏｐｕｌｍｏｎａｒｙ ｒｅｈａｂｉｌｉｔａｔｉｏｎ ａｎｄ ｐｒｅｖｅｎ⁃ ［３７］ ＲｅｉｓｓＮ，ＳｃｈｍｉｄｔＴ，ＬａｎｇｈｅｉｍＥ，ｅｔａｌ． ＩｎｐａｔｉｅｎｔＣａｒｄｉａｃＲｅｈａｂｉｌｉ⁃ ｔｉｏｎ，２０１７，３７（６）：３９０⁃３９６． ｔａｔｉｏｎｏｆＬＶＡＤＰａｔｉｅｎｔｓ⁃ＵｐｄａｔｅｄＲｅｃｏｍｍｅｎｄａｔｉｏｎｓｆｒｏｍｔｈｅＷｏｒｋｉｎｇ ［３３］ ＧａｎｇａＨＶ，ＬｅｕｎｇＡ，ＪａｎｔｚＪ，ｅｔａｌ． Ｓｕｐｅｒｖｉｓｅｄｅｘｅｒｃｉｓｅｔｒａｉｎｉｎｇｖｅｒ⁃ ＧｒｏｕｐｏｆｔｈｅＧｅｒｍａｎＳｏｃｉｅｔｙｆｏｒＰｒｅｖｅｎｔｉｏｎａｎｄＲｅｈａｂｉｌｉｔａｔｉｏｎｏｆＣａｒ⁃ ｓｕｓｕｓｕａｌ ｃａｒｅ ｉｎ ａｍｂｕｌａｔｏｒｙ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｌｅｆｔ ｖｅｎｔｒｉｃｕｌａｒ ａｓｓｉｓｔ ｄｅ⁃ ｄｉｏｖａｓｃｕｌａｒＤｉｓｅａｓｅｓ ［Ｊ］． Ｔｈｅ Ｔｈｏｒａｃｉｃ ａｎｄ ｃａｒｄｉｏｖａｓｃｕｌａｒ ｓｕｒｇｅｏｎ， ｖｉｃｅｓ：ａｓｙｓｔｅｍａｔｉｃｒｅｖｉｅｗ［Ｊ］． ＰｌｏＳｏｎｅ，２０１７，１２（３）：ｅ０１７４３２３． ２０２１，６９（１）：７０⁃８２． 余秋雨 陆晓 高强度间歇训练应用于慢性心力衰竭患者的研究 ［３４］ Ａｄａｍｏｐｏｕｌｏｓ Ｓ， Ｃｏｒｒ Ｕ， Ｌａｏｕｔａｒｉｓ ＩＤ， ｅｔ ａｌ． Ｅｘｅｒｃｉｓｅ ｔｒａｉｎｉｎｇ ｉｎ ［３８］ ， ． 现状 中国康复 ｐａｔｉｅｎｔｓ ｗｉｔｈ ｖｅｎｔｒｉｃｕｌａｒ ａｓｓｉｓｔ ｄｅｖｉｃｅｓ： ａ ｒｅｖｉｅｗ ｏｆ ｔｈｅ ｅｖｉｄｅｎｃｅ ａｎｄ ［Ｊ］． ，２０２２，３７（４）：２４８⁃２５１． ｐｒａｃｔｉｃａｌａｄｖｉｃｅ． Ａ ｐｏｓｉｔｉｏｎ ｐａｐｅｒ ｆｒｏｍ ｔｈｅ Ｃｏｍｍｉｔｔｅｅ ｏｎ Ｅｘｅｒｃｉｓｅ ［３９］ ＨｕｌｚｅｂｏｓＥＨ，ＨｅｌｄｅｒｓＰＪ，ＦａｖｉＮＪ，ｅｔａｌ． Ｐｒｅｏｐｅｒａｔｉｖｅｉｎｔｅｎｓｉｖｅｉｎ⁃ ＰｈｙｓｉｏｌｏｇｙａｎｄＴｒａｉｎｉｎｇａｎｄｔｈｅＣｏｍｍｉｔｔｅｅｏｆＡｄｖａｎｃｅｄＨｅａｒｔＦａｉｌｕｒｅ ｓｐｉｒａｔｏｒｙｍｕｓｃｌｅｔｒａｉｎｉｎｇｔｏｐｒｅｖｅｎｔｐｏｓｔｏｐｅｒａｔｉｖｅｐｕｌｍｏｎａｒｙｃｏｍｐｌｉｃａ⁃ ｏｆｔｈｅＨｅａｒｔＦａｉｌｕｒｅＡｓｓｏｃｉａｔｉｏｎｏｆｔｈｅＥｕｒｏｐｅａｎＳｏｃｉｅｔｙｏｆＣａｒｄｉｏｌｏｇｙ ｔｉｏｎｓｉｎ ｈｉｇｈ⁃ｒｉｓｋ ｐａｔｉｅｎｔｓ ｕｎｄｅｒｇｏｉｎｇ ＣＡＢＧ ｓｕｒｇｅｒｙ： ａ ｒａｎｄｏｍｉｚｅｄ ［Ｊ］． Ｅｕｒｏｐｅａｎｊｏｕｒｎａｌｏｆｈｅａｒｔｆａｉｌｕｒｅ，２０１９，２１（１）：３⁃１３． ｃｌｉｎｉｃａｌｔｒｉａｌ［Ｊ］． Ｊａｍａ，２００６，２９６（１５）：１８５１⁃１８５７． ［３５］ ＤｉＮｏｒａＣ，ＧｕｉｄｅｔｔｉＦ，ＬｉｖｉＵ，ｅｔａｌ． ＲｏｌｅｏｆＣａｒｄｉａｃＲｅｈａｂｉｌｉｔａｔｉｏｎ ［４０］ ＷｏｎｇｖｉｂｕｌｓｉｎＳ，ＨａｂｅｏｓＥＥ，Ｈｕｙｎｈ ＰＰ，ｅｔａｌ． Ｄｉｇｉｔａｌ ｈｅａｌｔｈ ｉｎｔｅｒ⁃ ＡｆｔｅｒＶｅｎｔｒｉｃｕｌａｒＡｓｓｉｓｔＤｅｖｉｃｅＩｍｐｌａｎｔａｔｉｏｎ［Ｊ］． ＨｅａｒｔＦａｉｌｕｒｅＣｌｉｎ⁃ ｖｅｎｔｉｏｎｓｆｏｒｃａｒｄｉａｃ ｒｅｈａｂｉｌｉｔａｔｉｏｎ： ｓｙｓｔｅｍａｔｉｃ ｌｉｔｅｒａｔｕｒｅ ｒｅｖｉｅｗ ［Ｊ］． ｉｃｓ，２０２１，１７（２）：２７３⁃２７８． ＪｏｕｒｎａｌｏｆｍｅｄｉｃａｌＩｎｔｅｒｎｅｔｒｅｓｅａｒｃｈ，２０２１，２３（２）：ｅ１８７７３． ［３６］ ＬａｎｇＪＫ，ＰａｙｋｅｌＭＳ，ＨａｉｎｅｓＫＪ，ｅｔａｌ． ＣｌｉｎｉｃａｌＰｒａｃｔｉｃｅＧｕｉｄｅｌｉｎｅｓ ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■ 外刊拾粹 经皮或常规迷走神经刺激治疗轻度认知障碍 轻度认知障碍 是痴呆症前期的病理状态 表现为记忆或其他认知功能逐渐下降 这项研究评估了经耳皮迷走神经刺激 （ＭＣＩ） ，。",
      "source": "1_2023+左心室辅助装置植入患者运动训练的理论与实践进展.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 474,
      "text": " ［３６］ ＬａｎｇＪＫ，ＰａｙｋｅｌＭＳ，ＨａｉｎｅｓＫＪ，ｅｔａｌ． ＣｌｉｎｉｃａｌＰｒａｃｔｉｃｅＧｕｉｄｅｌｉｎｅｓ ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■ 外刊拾粹 经皮或常规迷走神经刺激治疗轻度认知障碍 轻度认知障碍 是痴呆症前期的病理状态 表现为记忆或其他认知功能逐渐下降 这项研究评估了经耳皮迷走神经刺激 （ＭＣＩ） ，。 对治疗 的疗效 受试者年龄 岁 临床诊断为 参与者被随机分配接受 或 治疗 组 （ｔａＶＮＳ） ＭＣＩ。５５～７５ ， ＭＣＩ。ｔａＶＮＳ ｓｈａｍＶＮＳ。ｔａＶＮＳ 刺激迷走神经分布的心脏 肾脏 假手术组刺激迷走神经分布外的肘部 舟状窝 和肩部 耳穴 受试者 （ＣＯ１５）、 （ＣＯ１０）； （ ，ＳＦ３） （ＳＦ４、５）。每天进行两次 每次 分钟 每周 天 持续 周 主要结局指标为蒙特利尔认知评估基础量表 本研究共纳入 例 ， ３０ ， ５ ， ２４。（ＭＯＣＡ⁃Ｂ）。６０ 患者 两组基线评分差异无统计学意义 周时 组的 评分显著优于 组 Ｐ 在次要结果中 与基 ，。２４ ，ｔａＶＮＳ ＭｏＣＡＢ ｓｈａｍＶＮＳ （ ＝０．０３３）。， 线相比 组在听觉词语学习测试华山版的短期记忆 Ｐ 和长期记忆 Ｐ 方面有更大的改善 结论 本研究发现 ，ｔａＶＮＳ （ ＜０．０５） （ ＜０．０１）。： 经皮耳穴迷走神经刺激可改善轻度认知功能障碍患者的认知表现 朴政文译。（ ） Ｗａｎｇ Ｌ， ｅｔ ａｌ． Ｔｈｅ Ｅｆｆｉｃａｃｙ ａｎｄＳａｆｅｔｙｏｆＴｒａｎｓｃｕｔａｎｅｏｕｓＡｕｒｉｃｕｌａｒＶａｇｕｓＮｅｒｖｅＳｔｉｍｕｌａｔｉｏｎｉｎＰａｔｉｅｎｔｓｗｉｔｈＭｉｌｄＣｏｇｎｉｔｉｖｅＩｍｐａｉｒｍｅｎｔ：Ａ Ｄｏｕｂｌｅ⁃Ｂｌｉｎｄｅｄ， Ｒａｎｄｏｍｉｚｅｄ， Ｃｌｉｎｉｃａｌ Ｔｒｉａｌ． Ｂｒａｉｎ Ｓｔｉｍ． ２０２２，１５ （６）：１４０５⁃１４１４． 中文翻译 由 康复培训与研究合作中心 武汉 组织 ＷＨＯ （ ） 本期由华中科技大学同济医学院附属同济医院 黄晓琳教授主译编。",
      "source": "1_2023+左心室辅助装置植入患者运动训练的理论与实践进展.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 475,
      "text": "4 中国循环杂志 2020年1月 第35卷 第1期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 指南与共识 冠状动脉旁路移植术后心脏康复专家共识 国家心血管病中心，《冠状动脉旁路移植术后心脏康复专家共识》编写委员会 摘要 冠状动脉旁路移植术（ CABG）是治疗冠心病常见的血运重建手段。CABG后心脏康复是一项综合的、整体的全 程医疗管理模式，包括运动治疗、二级预防用药、营养支持、心理管理、戒烟等方面，CABG后规范的心脏康复对于 降低再住院率，提高患者运动能力和生活质量以及预防心血管不良事件等方面具有积极意义。因此，为了促进我国 CABG后心脏康复的规范化发展，国家心血管病中心、CABG后心脏康复专家共识编写委员会在2016年《中西医结 合冠状动脉旁路移植术Ⅰ期心脏康复专家共识》的基础上，就CABG后心脏康复相关问题进行深入探讨，制定了我国 CABG后心脏康复专家共识。其中，针对CABG后心脏康复的术前评估、围术期营养、早期营养支持、重症监护病房（ICU） 期间康复、社会心理因素干预、睡眠管理等重要问题提出了明确建议。关键词 冠心病；冠状动脉旁路移植术；心脏康复；专家共识 Expert Consensus on Cardiac Rehabilitation After Coronary Artery Bypass Grafting National Center for Cardiovascular Diseases， Expert Consensus Writing Committee on Cardiac Rehabilitation After Coronary Artery Bypass Grafting。Corresponding Author: FENG Xue, Email：29611290@qq。com Abstract Coronary artery bypass grafting (CABG) is a common procedure of revascularization in the treatment of coronary heart disease。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 476,
      "text": "ss Grafting。Corresponding Author: FENG Xue, Email：29611290@qq。com Abstract Coronary artery bypass grafting (CABG) is a common procedure of revascularization in the treatment of coronary heart disease。 Cardiac rehabilitation after CABG is a comprehensive medical management model, including exercise therapy, secondary prevention, nutrition support, psychological management, smoking cessation, etc。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 477,
      "text": "Cardiac rehabilitation after CABG is a comprehensive medical management model, including exercise therapy, secondary prevention, nutrition support, psychological management, smoking cessation, etc。 Standardized cardiac (cid:85)(cid:72)(cid:75)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:68)(cid:73)(cid:87)(cid:72)(cid:85)(cid:3)(cid:38)(cid:36)(cid:37)(cid:42)(cid:3)(cid:76)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:74)(cid:85)(cid:72)(cid:68)(cid:87)(cid:3)(cid:70)(cid:79)(cid:76)(cid:81)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3)(cid:86)(cid:76)(cid:74)(cid:81)(cid:76)(cid:191)(cid:70)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:76)(cid:81)(cid:3)(cid:85)(cid:72)(cid:71)(cid:88)(cid:70)(cid:76)(cid:81)(cid:74)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:85)(cid:68)(cid:87)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:85)(cid:72)(cid:68)(cid:71)(cid:80)(cid:76)(cid:86)(cid:86)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)(cid:76)(cid:80)(cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:81)(cid:74)(cid:3)(cid:83)(cid:68)(cid:87)(cid:76)(cid:72)(cid:81)(cid:87)(cid:86)(cid:10)(cid:3)(cid:72)(cid:91)(cid:72)(cid:85)(cid:70)(cid:76)(cid:86)(cid:72)(cid:3) capacity and quality of life, as well as preventing adverse cardiovascular events。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 478,
      "text": "cid:72)(cid:81)(cid:87)(cid:86)(cid:10)(cid:3)(cid:72)(cid:91)(cid:72)(cid:85)(cid:70)(cid:76)(cid:86)(cid:72)(cid:3) capacity and quality of life, as well as preventing adverse cardiovascular events。 In order to promote the standardized development of CABG postoperative cardiac rehabilitation in China, the National Center for Cardiovascular Diseases and the CABG Postoperative Cardiac Rehabilitation Expert Consensus Writing Committee conducted in-depth discussions on the related issues and formulated the current expert consensus on cardiac rehabilitation after CABG on the basis of the 2016 “Expert Consensus on the Phase-I Cardiac Rehabilitation of Integrated Medicine for Coronary artery bypass grafting”。In particular, clear recommendations are made on important issues such as preoperative evaluation, perioperative nutrition, early nutritional support, rehabilitation in intensive care unit, intervention of psychosocial factors, and sleep management, etc。Key words coronary heart disease；coronary artery bypass grafting；cardiac rehabilitation；expert consensus (Chinese Circulation Journal, 2020, 35: 4。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 479,
      "text": "n of psychosocial factors, and sleep management, etc。Key words coronary heart disease；coronary artery bypass grafting；cardiac rehabilitation；expert consensus (Chinese Circulation Journal, 2020, 35: 4。 ) 冠状动脉（冠脉）粥样硬化性心脏病（冠心病） 虑或抑郁等问题，不仅给患者的工作与精神带来巨 是全球范围内最常见且致死率最高的疾病之一[1-2]， 大障碍，而且给家庭及社会带来巨大经济负担和劳 冠脉旁路移植术（CABG）是治疗冠心病最常见的血 动力损失[3-4]。因此，CABG后患者进行心脏康复， 运重建手段。然而很多患者在CABG后，可能会出 是CABG手术治疗的重要辅助方法，是十分必要且 现肺不张、感染、呛咳、活动耐力下降、谵妄、焦 重要的。基金项目：中国医学科学院北京协和医学院“以功能恢复为目标导向的多维度康复干预对冠状动脉旁路移植术后患者康复效果的随机对照研究” （ 2019-F02） 通信作者：冯雪 Email：29611290@qq。com 中图分类号：R541 文献标识码：C 文章编号：1000-3614（2020）01-0004-012 DOI:10。3969/j。issn。1000-3614。2020。01。002 ˝(cid:242)•‰˚(cid:253)(cid:190)(cid:221) 中国循环杂志 2020年1月 第35卷 第1期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 5 心脏康复的益处和安全性已有大量循证医学证 桥血管堵塞或延缓其他冠脉血管再狭窄的风险，防 据支持，有研究显示对CABG后的患者进行心脏康 止可能再次出现CABG的情况，帮助患者早日回归 复干预，可提高患者术后规范应用二级预防药物（包 家庭和社会[7]。心脏康复可广泛应用于排除禁忌证 括抗血小板药物和降脂药物等）的依从性。同时， 后的所有CABG后患者，使其从中受益。通过对CABG后患者危险因素的管理，可帮助患者 2 CABG后心脏康复分期及内容 维持身心健康和提高生活质量，减少再次住院和手 CABG后患者的心脏康复分为3期，即急性期 术的风险，降低发病率和全因死亡率[3, 5]。国际大型 的Ⅰ期康复（院内康复期）、Ⅱ期康复（门诊康复期） 的前瞻性和回顾性研究结果均显示，经过系统评估 及居家的Ⅲ期康复。Ⅰ期康复主要以住院期间的康 和规范性操作的心脏康复，对于CABG后患者是比 复为主，涵盖术前预康复、ICU 期间康复及术后病 较安全的[6]。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 480,
      "text": "持身心健康和提高生活质量，减少再次住院和手 CABG后患者的心脏康复分为3期，即急性期 术的风险，降低发病率和全因死亡率[3, 5]。国际大型 的Ⅰ期康复（院内康复期）、Ⅱ期康复（门诊康复期） 的前瞻性和回顾性研究结果均显示，经过系统评估 及居家的Ⅲ期康复。Ⅰ期康复主要以住院期间的康 和规范性操作的心脏康复，对于CABG后患者是比 复为主，涵盖术前预康复、ICU 期间康复及术后病 较安全的[6]。 因此，全世界范围内（包括英国、美 房康复，主要减少患者术后并发症，增加患者的康 国、加拿大、澳大利亚、奥地利等）的心脏康复指南， 复意识；Ⅱ期康复主要以门诊形式开展，从手术6 都将CABG后进行心脏康复作为ⅠA类的推荐，美 周后开始，包含患者术后36次的心脏康复课程，涉 国心脏协会（AHA）更是强烈建议CABG后患者即可 及运动、营养、心理、睡眠、疼痛管理等方面的康 开展全面康复[7-9]。复内容，帮助患者培养健康的生活方式[3, 7, 11]；Ⅲ期 目前我国心血管患病率及死亡率仍处于上升 康复主要开展于患者的家庭或社区，帮助患者巩固 阶段 [10]，随着每年冠心病患者人数的上升，进行 Ⅱ期康复效果，并养成长期健康的生活方式[7]，改 CABG 手术的患者人数也在逐年递增 [2]。2017 年， 善生活质量，提高生活满意度。我国共进行了 45 455 例 CABG 手术 [10]。但临床常 2。1 Ⅰ期康复（院内康复期） 关注冠心病的治疗，而忽视了冠心病的预防及发病 CABG后的Ⅰ期心脏康复，是对CABG后患者 后的康复。中美 CABG 手术对比研究发现，虽然 在住院期间开展的早期康复，尽早进行干预，可改 在术后住院期死亡率方面，我国与美国没有显著 善患者术后的血流动力学，增加左心室射血功能， 性差异，但患者平均住院时间比美国显著延长 [2]， 提高身体功能及运动储备，减少术后并发症和住院 其原因可能在于手术急性期后的康复、长期康复 时间，降低全因死亡率，提高患者的生活质量。的不足。鉴于此，我国 CABG 后患者心脏康复势 2。1。1 术前心脏康复 在必行。2。1。1。1 术前评估[12] 本共识的制定过程：提出关键问题，系统收集 CABG前应对患者基本情况、心血管危险因素、 相关文献，撰写初稿，提交共识编写委员会专家函 运动能力、营养、睡眠、心理、戒烟、心肺功能等 审，提出修改意见，修订后召开专家讨论会，确定 方面进行评估。终稿，再次提交共识编写委员会专家审核定稿。在 2。1。1。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 481,
      "text": "我国 CABG 后患者心脏康复势 2。1。1 术前心脏康复 在必行。2。1。1。1 术前评估[12] 本共识的制定过程：提出关键问题，系统收集 CABG前应对患者基本情况、心血管危险因素、 相关文献，撰写初稿，提交共识编写委员会专家函 运动能力、营养、睡眠、心理、戒烟、心肺功能等 审，提出修改意见，修订后召开专家讨论会，确定 方面进行评估。终稿，再次提交共识编写委员会专家审核定稿。在 2。1。1。 2术前预康复[13-14] 指南的制定过程中，我们回顾国内外数据库相关文 术前预康复包括指导患者有效咳嗽的方法，通 献近400篇，最终纳入高质量参考文献77篇，由国 过腹式呼吸、缩唇呼吸、呼吸训练器等改善术前肺 家心血管病中心牵头，联合国内数十名多学科专家， 容量；对肩颈、胸椎段进行肢体训练，增大胸廓活动 跨学科合作撰稿。基于中国国情，并结合国外最新 度；对下肢大肌群进行活动，增加下肢肌肉力量；给 研究证据，针对CABG后心脏康复的临床实践进行 予患者社会支持，减少可能出现的术前焦虑。科学论证达成共识，对患者的选择、适应证、术前 2。1。1。3 术前营养 评估、围术期营养、早期营养支持、重症监护病房 推荐手术前对营养状况进行营养风险筛查 （ICU）期间康复、社会心理因素干预、睡眠管理等 （NRS2002营养风险筛查）和营养评估，对存在营养 方面的操作做出了临床推荐。风险和（或）营养不良的患者，术前应积极进行适当 1 CABG后心脏康复团队和方案 营养支持。血清白蛋白水平低于3。0 g/dl的心脏手术 CABG后的心脏康复团队，包括心血管科医师、 患者，术前可补充7~10天的强化营养治疗[15]。康复治疗师、护士、药师、心理医师、营养师等， 2。1。1。4 吸烟和饮酒管理 主要从运动、睡眠、营养、心理、戒烟、二级预防 术前对所有心脏手术患者进行吸烟和饮酒的筛 用药、呼吸、疼痛管理和中医药九个方面共同干预 查[16]。询问患者吸烟和饮酒的情况，并指导患者在 患者，改善CABG后患者的心肺及全身功能，预防 择期手术前4周停止吸烟、饮酒。˝(cid:242)•‰˚(cid:253)(cid:190)(cid:221) 6 中国循环杂志 2020年1月 第35卷 第1期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 2。1。2 ICU期间心脏康复 ④对于术后可能出现肺功能障碍的患者，可进 2。1。2。1 ICU康复评估[12, 17-18] 行呼吸训练器的练习，提高气道气流流通功能[25]。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 482,
      "text": "cid:221) 6 中国循环杂志 2020年1月 第35卷 第1期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 2。1。2 ICU期间心脏康复 ④对于术后可能出现肺功能障碍的患者，可进 2。1。2。1 ICU康复评估[12, 17-18] 行呼吸训练器的练习，提高气道气流流通功能[25]。 对于CABG后转回ICU的患者，每日对患者的 ⑤对于CABG后的常规非机械通气的患者，可 心肺功能、血压、中心动脉压、氧分压、呼吸状况、 进行包括腹式呼吸、呼吸训练器、有效咳嗽、胸部 神经系统情况、体温、疼痛、睡眠、心理、营养、 叩击和呼吸操等呼吸锻炼，增加肺部功能，降低可 谵妄进行评估。能出现肺部感染[12]。2。1。2。2 ICU期间心脏康复内容 （2）早期床上活动[12]：CABG后的早期在ICU （ 1）肺康复：CABG后患者可能合并肺功能减低， 内的活动，可促进肺功能康复，防止或延缓肌肉萎 肺康复可缓解该部分患者的呼吸困难，减少机械通气 缩，提高身体机能。患者一旦脱离急性危险期、病 时间和肺部并发症，提高运动能力，改善生活质量。情稳定并排除禁忌证后，即可开始早期床上活动。①对于需要脱机的机械通气患者，需对动脉血 ①早期床上活动可从增加患者的床头角度开始， 气、胸片、症状等情况综合评估[19]，对患者进行腹 使患者逐步开始半坐位，坐位，独立坐位，床旁坐位。式呼吸训练，训练时适当调节呼吸机参数，推荐患 对于肌力<3级的患者，可进行被动关节活动训练， 者在自主呼吸的状态下进行[12]。主动助力活动，静力性肌肉收缩训练。对于肌力≥3 ②对于有气道分泌物的患者，可通过主动呼吸 级的患者，可开始主动关节活动训练，抗阻训练。循环技术及正确咳痰训练，将支气管树内的分泌物 ②肢体活动从5~10 min开始，逐步增加。在床上 向近端移动，促进肺内分泌物的有效排出，优化气 活动过程中，活动强度依据心率、血压、血氧饱和度、 道功能[20]。呼吸频率和Borg评分而定（Borg评分12~13分为佳）。③对于呼吸肌力量不足，肺不张的患者，可通 ③对于超过 3 天未从 ICU 转回普通病房的患 过高强度吸气肌训练、腹式呼吸、腹部抗阻训练、 者，在排除禁忌证后，可在 ICU 阶段开始逐步的 深呼吸训练，增加最大吸气压力，加强膈肌及腹部 肢体活动。CABG 后患者 ICU 阶段的功能活动内 力量，改善术后肺活量，增加潮气量[21-24]。容详见表1[17]。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 483,
      "text": "g评分而定（Borg评分12~13分为佳）。③对于呼吸肌力量不足，肺不张的患者，可通 ③对于超过 3 天未从 ICU 转回普通病房的患 过高强度吸气肌训练、腹式呼吸、腹部抗阻训练、 者，在排除禁忌证后，可在 ICU 阶段开始逐步的 深呼吸训练，增加最大吸气压力，加强膈肌及腹部 肢体活动。CABG 后患者 ICU 阶段的功能活动内 力量，改善术后肺活量，增加潮气量[21-24]。容详见表1[17]。 表1 CABG后患者重症监护病房期间的功能活动表 步骤 配合度/清醒情况 基础评估 身体姿势 康复治疗 0 不配合S5Q=0 不能完成基础评估 每2小时翻身 无法进行康复 1 低配合度S5Q<3 能完成基础评估 每2小时翻身；保持半坐卧位 关节的被动活动；被动的床上踏车训练；神经肌肉电 刺激 2 中等配合度S5Q=3 能完成基础评估 每2小时翻身；在床上直立坐位； 关节的被动/主动活动；上下肢的小剂量抗阻活动；床 可被动从床上转移至椅子上 上或床旁的主动/被动踏车训练；神经肌肉电刺激 3 接近高配合度 能完成基础评估 每2小时翻身；被动从床上转移 关节的被动/主动活动；上下肢的小剂量抗阻活动； S5Q=4~5 至椅子上；床旁坐位；较大辅 床上或床旁的主动踏车训练；神经肌肉电刺激；日 助下床旁站位 常生活能力训练 4 高配合度S5Q=5 能完成基础评估 被动从床上转移至椅子上；床边 关节的被动/主动活动；上下肢的小剂量抗阻活动； 坐位；较小辅助下床旁站位 床上或床旁的主动踏车训练；人员或支具辅助下步 行；神经肌肉电刺激，日常生活能力训练 5 高配合度S5Q=5 能完成基础评估 主动从床上转移至椅子上；床边 关节的被动/主动活动；上下肢的小剂量抗阻活动； 坐位；主动床旁站位 床旁的主动踏车训练；辅助下步行；神经肌肉电刺 激，日常生活能力训练 注： CABG：冠状动脉旁路移植术；S5Q：标准化5问题问卷 2。1。2。3 谵妄 <50次/min，或>130次/min； 呼吸频率<12次/min， 非药物治疗可作为预防和治疗术后谵妄的一线 或>40次/min； 氧饱和度<88%；出现明显的人机对 干预措施[26]。具体的非药物治疗方案包括呼吸训练、 抗； 患者主观感受状态很差； 出现恶性事件，如患者 疼痛管理、睡眠管理、早期活动。尽早的下地离床 出现摔倒、气切管移位、引流管脱垂等情况应及时 可预防和改善患者的早期谵妄[18]。暂停ICU阶段康复内容，并告知主管医师。2。1。2。4 ICU期间心脏康复终止指标[27] 2。1。3 术后病房心脏康复 CABG后患者出现以下情况：平均动脉压<65 2。1。3。1 术后病房康复评估[25, 28] mmHg（1 mmHg=0。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 484,
      "text": "； 出现恶性事件，如患者 疼痛管理、睡眠管理、早期活动。尽早的下地离床 出现摔倒、气切管移位、引流管脱垂等情况应及时 可预防和改善患者的早期谵妄[18]。暂停ICU阶段康复内容，并告知主管医师。2。1。2。4 ICU期间心脏康复终止指标[27] 2。1。3 术后病房心脏康复 CABG后患者出现以下情况：平均动脉压<65 2。1。3。1 术后病房康复评估[25, 28] mmHg（1 mmHg=0。 133 kPa），或>110 mmHg；心率 患者术后返回病房，要对患者进行针对性的康 ˝(cid:242)•‰˚(cid:253)(cid:190)(cid:221) 中国循环杂志 2020年1月 第35卷 第1期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 7 复评估。（ 2） 功能训练： （ 1）详细了解手术过程、术后超声心动图检测、 ①肢体训练：CABG急性期后，在患者循环稳定 X线胸片、实验室检查结果； 及排除禁忌证后，即可开展早期肢体活动。从术后 （ 2） 评估患者术后疼痛、睡眠、营养； 第1天开始，在医护人员的监督下，在床上进行肢 （ 3）评估患者的焦虑，抑郁[采取焦虑自评量 体被动或主动活动。之后每天逐步从床上肢体主动 表（SAS）和抑郁自评量表（SDS）]； 活动，过渡至床旁活动，病房内步行，上下楼训练， （ 4） 评估患者的伤口疼痛情况，以及下肢肌力 控制运动当量在2~4代谢当量（MET）[29-30]。和耐力。②有氧训练：在患者的耐受范围内，按步骤 2。1。3。2 术后病房心脏康复内容 增加至低 - 中强度的有氧运动，可选择床旁踏车 （ 1）肺部训练：从术后第1天开始，鼓励患者 训练，或下地步行。进行间歇或持续的有氧活动。进行呼吸训练，一直坚持至出院[25, 29-30]。逐渐增加运动时间，从 5 min 进阶至 10~20 min。①对于需改善通气功能、提高通气效率和肺功 在运动过程中，密切监测患者的症状、体征和心 能的患者，可进行腹式呼吸训练、缩唇呼吸训练、 电图等。控制患者的疲劳指数（RPE）在11~13分， 深呼吸治疗，也可配合使用呼吸训练器，增强呼吸 控制运动中的最大心率不超过静息心率增加 20 肌力量[12, 29-31]。次 /min[1, 12, 28, 30-32]。②对于有痰液潴留，肺不张的患者，可在保护 ③肩关节训练：CABG后患者，从术后第1天开 伤口的基础上，进行气道廓清技术。若咳嗽未达到 始，每天2次，在未引起不适的情况下，进行适当 目标效果，可结合体位管理和胸廓震颤辅助咳嗽与 的肩关节活动，直至患者出院。患者可进行提肩， 呼吸训练[29-30]。肩绕环，头部环绕动作等[25]。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 485,
      "text": "12, 29-31]。次 /min[1, 12, 28, 30-32]。②对于有痰液潴留，肺不张的患者，可在保护 ③肩关节训练：CABG后患者，从术后第1天开 伤口的基础上，进行气道廓清技术。若咳嗽未达到 始，每天2次，在未引起不适的情况下，进行适当 目标效果，可结合体位管理和胸廓震颤辅助咳嗽与 的肩关节活动，直至患者出院。患者可进行提肩， 呼吸训练[29-30]。肩绕环，头部环绕动作等[25]。 短期内暂停使用手摇 ③对于心肺功能需改善的患者，可以加强体位 机及划船机进行康复训练，保护好伤口[32]。管理，结合术后的早期活动，提高摄氧量与肢体活 （ 3）活动内容：住院期间的心脏康复的活动内 动能力，减少并发症[29]。容详见表2[25]。表2 CABG后患者住院期间的心脏康复的活动内容 步骤 活动内容 1 呼吸训练（3组10次），上肢和下肢主动运动（3组10次），抬高床头至45度下保持坐位。下肢功率踏车训练（共20 min，5 min热身， 10 min低强度运动，5分钟恢复，30转/min） 2 完成第一步。保持上身直立，在地面步行3次（1 min/次），下肢功率踏车训练（共20 min） 3 完成第二步的主动练习。在病房内步行7 min。床旁座椅坐位训练30 min 4 完成第三步的主动练习。在病房内步行10 min。床旁座椅坐位训练60 min 5 完成第四步的主动练习。在病房内步行15 min。床旁座椅坐位训练120 min 6 完成第五步的主动练习。在病房内步行20 min。台阶训练3次（20 cm的台阶） 7 完成第六步的主动练习。台阶训练6次（20 cm的台阶） 注：CABG：冠状动脉旁路移植术 2。1。3。3 CABG不同手术方案的运动康复 桥血管的患者，术后应及时抬高取血管的下肢，并 CABG中使用的桥血管分为静脉桥和动脉桥两 根据患者的情况选择合适的压力治疗方式如弹力绷 种，大隐静脉是使用最多的静脉桥，而动脉桥则包 带加压包扎、穿戴弹力袜以及间歇性气压治疗等以 括乳内动脉(单侧或者双侧)、桡动脉、胃网膜右动 起到促进静脉血液和淋巴液回流，提高血液循环的 脉等[33]。当选取的桥血管不同，康复的重点也有所 目的[36]。当患者下肢取血管过膝者要注意避免膝关 区别。节过度屈伸。（ 1）大隐静脉作为桥血管：大隐静脉的获取会 （ 2）乳内动脉作为桥血管：左乳内动脉桥是 对下肢的活动造成一定影响，并增加下肢并发症的 CABG中最常使用的动脉桥。据统计，大隐静脉桥 发生风险[34]。选择单侧或双侧大隐静脉作为血管桥 的10年通畅率为50%~60%，而乳内动脉桥的10年 的患者平均卧床时间较长，术后存在肢体肿胀，取 通畅率可达85%~95%[37]。选择乳内动脉作为桥血管 血管肢体切口愈合不良以及术后疼痛等问题，是影 时，术后早期应避免上肢的剧烈活动。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 486,
      "text": "左乳内动脉桥是 对下肢的活动造成一定影响，并增加下肢并发症的 CABG中最常使用的动脉桥。据统计，大隐静脉桥 发生风险[34]。选择单侧或双侧大隐静脉作为血管桥 的10年通畅率为50%~60%，而乳内动脉桥的10年 的患者平均卧床时间较长，术后存在肢体肿胀，取 通畅率可达85%~95%[37]。选择乳内动脉作为桥血管 血管肢体切口愈合不良以及术后疼痛等问题，是影 时，术后早期应避免上肢的剧烈活动。 可进行手指 响早期下床活动的主要因素[35]。选择大隐静脉作为 屈伸、腕屈伸、前臂旋前旋后、肘屈伸等动作，避 ˝(cid:242)•‰˚(cid:253)(cid:190)(cid:221) 8 中国循环杂志 2020年1月 第35卷 第1期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 免长期制动带来的不利影响。心肺耐力，如6分钟步行试验[29, 40]。（ 3）桡动脉作为桥血管：与大隐静脉相比，桡 2。1。4。2 出院宣教 动脉作为血管桥不仅可以减少皮肤瘢痕，而且也能 CABG后常规住院时间为1周左右，出院后及 提高患者舒适度[38]。但是桡动脉的获取过程较为复 门诊康复期前通常需要2~6周的过渡期康复[41]。出 杂，且桡动脉本身容易发生痉挛，稍有不慎也容易 院前应指导患者风险因素管理，戒烟管理，营养摄 造成血管及神经的损伤[39]。入，体力活动等，根据患者的肺功能及体能，为其 选择桡动脉作为桥血管时，术后早期应避免上 制定出院后短期的康复方案，并为其推介至Ⅱ期门 肢的剧烈活动，尤其是前臂的大强度抗阻运动。可 诊心脏康复。通过手指屈伸、腕屈伸、前臂旋前旋后等动作避免 2。2 Ⅱ期康复（门诊康复期） 上肢肿胀及并发症。大量循证医学证明CABG后进行Ⅱ期心脏康复 2。1。3。4 心理干预 可使患者获益，规律的康复干预有助于提高桥血管 从入院开始，应对患者进行持续的心理干预。术 的通畅率，降低再住院率和相关的医疗费用，提高 前向患者解释CABG手术对身体和心理变化的影响， 患者运动能力和生活质量，所有符合条件的CABG 减少患者对CABG手术的过度焦虑和抑郁，帮助患者 后患者都应该进行心脏康复[41]，急性心肌梗死后的 接受并适应现阶段的情绪心理状况。心理干预可以心 CABG及经皮冠脉介入治疗术（PCI）术后患者参加心 理疏导为主，由受过专业训练的人员进行。同时可指 脏康复也可改善预后[42]。导患者进行冥想训练和放松训练，帮助患者减轻压力。2。2。1 CABG后患者门诊康复期评估 鼓励患者听正念音频，保持积极的情绪。对于有严重 门诊康复前需对CABG后患者进行风险因素、 心理问题的患者，可转介至心理咨询师或精神医师处， 临床情况和运动风险评估。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 487,
      "text": "理干预可以心 CABG及经皮冠脉介入治疗术（PCI）术后患者参加心 理疏导为主，由受过专业训练的人员进行。同时可指 脏康复也可改善预后[42]。导患者进行冥想训练和放松训练，帮助患者减轻压力。2。2。1 CABG后患者门诊康复期评估 鼓励患者听正念音频，保持积极的情绪。对于有严重 门诊康复前需对CABG后患者进行风险因素、 心理问题的患者，可转介至心理咨询师或精神医师处， 临床情况和运动风险评估。 进行专业指导[29]。2。2。1。1 风险因素评估 2。1。3。5 戒烟干预 心血管疾病风险是几种风险因素影响的产物。在患者住院的全期，由专业人士对患者进行戒烟 个体风险因素能够以显著的模式聚集在一起，并且 指导。针对每个患者术前的尼古丁依赖评估结果制定 往往会对个体的总心血管风险产生乘法效应。测量 个性化的干预方案。手术后可为患者提供戒烟手册， 任何单一风险因素通常不能充分估计总心血管风 增加患者的戒烟知识及途径。积极与患者的主治医师 险。建议在心肌血运重建后（例如在3个月及之后， 沟通，使患者得到来自主治医师的戒烟支持[10]。至少每年1次）对患者进行重新评估，以便掌握患 2。1。4 出院前的心脏康复 者症状并促进其坚持二级预防措施，并在适当时加 2。1。4。1 出院评估 强药物治疗和改变生活方式[43]。对CABG后患者的 出院前需评估患者焦虑、抑郁状况、睡眠状况、 风险因素评估的主要内容及风险因素管理目标详见 疼痛、与健康相关的生活质量、腿部力量和耐力及 表3。表3 CABG后患者的门诊康复期间风险因素评估的主要内容管理目标 风险因素 目标值 终生吸烟习惯（以及每天吸烟的数量） 不接触任何形式的烟草 活动水平 每周至少150 min的中度有氧活动（30 min，5天/周）或每周75 min的剧烈有氧活动（15 min，5天/周） 或其组合 血压 <130/80 mmHg 体重指数及腰围 体重指数（BMI）：18。5~23。9 kg / m2；腰围：男性＜90 cm或女性＜85 cm 血脂 低密度脂蛋白胆固醇（LDL-C）＜1。8 mmol/L 血糖 糖化血红蛋白（HbA1c ）<7% 注： CABG：冠状动脉旁路移植术。1 mmHg=0。133 kPa 2。2。1。2 CABG后患者临床情况评估 者制定个体化运动处方。在开始运动训练计划前，应对患者的临床情况 2。2。1。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 488,
      "text": "及腰围 体重指数（BMI）：18。5~23。9 kg / m2；腰围：男性＜90 cm或女性＜85 cm 血脂 低密度脂蛋白胆固醇（LDL-C）＜1。8 mmol/L 血糖 糖化血红蛋白（HbA1c ）<7% 注： CABG：冠状动脉旁路移植术。1 mmHg=0。133 kPa 2。2。1。2 CABG后患者临床情况评估 者制定个体化运动处方。在开始运动训练计划前，应对患者的临床情况 2。2。1。 3 CABG后患者运动风险评估 进行综合评估（表4），并实施运动心肺试验，以确 由于对运动训练的反应可能因人而异，根据运 定患者运动训练的安全范围并进行危险分层，为患 动危险分层进行风险评估，以提供适合每位患者的 ˝(cid:242)•‰˚(cid:253)(cid:190)(cid:221) 中国循环杂志 2020年1月 第35卷 第1期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 9 个体化训练计划，为制定运动处方提供安全保障。如患者不能坚持参加门诊康复，根据危险分层 参照美国心肺康复学会（根据患者症状和心脏功能） 的结果，建议低危患者至少参加6~18次心电监护 制定的运动危险分层将参与运动训练的患者分为 下运动，中危患者至少参加12~24次心电监护下运 低、中、高危（表5）。动，高危患者至少参加18~36次心电监护下运动。表4 CABG后患者门诊康复期间的临床情况评估内容 项目 内容 症状 胸痛、心慌、气短、头晕、晕厥史、间歇性跛行、骨关节病症状 病史 （1） 筛查心血管病危险因素 （2） 心电图、超声心动图、生化检测、X线胸片、NYHA心功能分级、加拿大心血管病学会心绞痛分级 （3） 运动系统、神经系统等影响运动的因素 （4） 身体其他重要脏器的功能 （5） 患者日常生活活动水平和运动习惯 运动能力评估 有氧运动能力 （1） 心肺运动实验 （2） 六分钟步行试验 肌肉力量评估 （1） 最大肌力（1RM）的评估 （2） 握力 柔韧性评估 坐位体前屈 平衡能力评估 （1） 单腿站立实验 （2） 功能性前伸 胸骨稳定性 胸骨不稳定量表 肺功能评估 第1秒用力呼气容积、肺活量、第1秒用力呼气容积/肺活量、最大通气量 心理评估 焦虑自评量表和抑郁自评量表 注：CABG：冠状动脉旁路移植术 表5 CABG后患者门诊康复运动危险分层 低危 中危 高危 每一项都符合时为低危 不符合典型高危或低危者为中危 存在任何一项即为高危 运动或恢复期无症状，包括无心绞痛症状或心肌 >中等强度运动（心肺功能储备5~6。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 489,
      "text": "前伸 胸骨稳定性 胸骨不稳定量表 肺功能评估 第1秒用力呼气容积、肺活量、第1秒用力呼气容积/肺活量、最大通气量 心理评估 焦虑自评量表和抑郁自评量表 注：CABG：冠状动脉旁路移植术 表5 CABG后患者门诊康复运动危险分层 低危 中危 高危 每一项都符合时为低危 不符合典型高危或低危者为中危 存在任何一项即为高危 运动或恢复期无症状，包括无心绞痛症状或心肌 >中等强度运动（心肺功能储备5~6。 9 METs） 低强度运动（心肺功能储备＜5METs）或 缺血证据（动态ST-T改变） 或恢复期出现包括心绞痛的症状/征象 恢复期出现包括心绞痛症状/征象；心肌 无休息或运动导致的复杂性心律失常 LVEF 40%~49% 缺血证据（动态ST-T改变） MI、CABG、PCI术后无合并症 休息或运动时出现复杂性心律失常 运动或恢复期血流动力学正常 MI或心脏手术等合并心原性休克或心力 无心理障碍（抑郁、焦虑等） 衰竭 LVEF＞50% 猝死或心脏骤停的幸存者 心肺功能储备≥7 METs 运动时血流动力学异常（特别是运动负荷 血肌钙蛋白正常 增加时收缩压不升或下降，或出现心率 不升） 严重心理障碍 LVEF＜40% 血肌钙蛋白浓度升高 注：MI：心肌梗死；CABG：冠状动脉旁路移植术；PCI：经皮冠状动脉介入治疗；LVEF：左心室射血分数；MET：代谢当量 2。2。1。4 CABG后康复禁忌证[44~45] 房阻滞；严重高血压。（ 1）绝对禁忌证包括：急性心肌梗死2天内；药 2。2。2 CABG后常规运动康复 物未控制的不稳定性心绞痛；引起症状和血流动力 有氧运动是基础，抗阻训练、柔韧性训练和平 学障碍的未控制心律失常；新发严重主动脉狭窄；未 衡训练是有效补充。如无禁忌证，大多数患者可在 控制的症状明显的心力衰竭；急性肺动脉栓塞；急性 出院后1~3周内开始门诊运动康复，即有医师参与、 心肌炎或心包炎；急性主动脉狭窄。心电监护下的运动康复方案，一般每周3次，持续 （ 2）相对禁忌证包括： 明显的心动过速或过缓； 36次或更长时间。中度瓣膜狭窄性心脏病；肥厚型心肌病或其他原因 2。2。2。1 有氧运动训练 所致的流出道梗阻性病变；高度房室阻滞及高度窦 CABG患者有氧运动强度取决于患者的运动相关 ˝(cid:242)•‰˚(cid:253)(cid:190)(cid:221) 10 中国循环杂志 2020年1月 第35卷 第1期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 风险分层和临床情况[46-49]。应根据心肺运动实验结果， 颤患者进行轻中强度的运动，目标运动强度分别在 制定有氧运动处方。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 490,
      "text": "242)•‰˚(cid:253)(cid:190)(cid:221) 10 中国循环杂志 2020年1月 第35卷 第1期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 风险分层和临床情况[46-49]。应根据心肺运动实验结果， 颤患者进行轻中强度的运动，目标运动强度分别在 制定有氧运动处方。 通常规定患者采用中等强度运 VO peak的20%~40%和40%~60%[45]。2 动，如40%~60%的峰值摄氧量（VO peak），随着时 2。2。3。2 心力衰竭 2 间的推移，患者表现出耐受性，可以适当增加运动 通常建议进行大肌群有节奏的有氧运动[57]，在 持续时间，当心率反应随着训练强度的增加而降低 确定运动强度时，医生不仅应考虑当前的症状和运 时，运动强度可以增加，逐渐达到80%的峰值摄氧量。动能力指标，还应考虑心衰严重程度和患者可变参 2。2。2。2 抗阻训练方案 数，如左心室功能，B型利钠肽（BNP）水平和药物 CABG后患者进行呼吸肌训练+有氧运动+抗 治疗。BNP水平>500 pg/ml的患者应该以较低的强 阻训练，包括30 min跑步机和功率踏车的有氧训练， 度开始运动训练，并仔细观察心衰的变化[58]。20 min抗阻训练（哑铃、脚踝负重训练），10 min伸 2。2。4 CABG后常见合并症的运动康复 展和放松训练，连续12周，每周2次，可改善患者 CABG后患者往往存在肥胖、肾脏疾病等合并症， 最大吸气量、最大呼气压、峰值耗氧量及生活质量 针对不同的合并症应实施不同的运动处方和建议。评分[50]。按照运动处方的要求，每次训练8~10组 2。2。4。1 肥胖 肌群，上肢、下肢及躯干肌群可交替训练，应注意 超重或肥胖患者如需减重，其能量消耗必须超 训练前必须有5~10 min的热身或拉伸运动，切忌运 过能量摄入。目标是在3~6个月内至少减轻体重的 动过程中出现Valsalva动作。5%~10%。CABG后合并肥胖的患者，每周应运动 2。2。2。3 柔韧性训练 3~7天，为保证长期控制体重，每天至少30 min中 以上肢、下肢、躯干大肌群为主，以缓慢的方 等强度运动[59-60]，或可以通过累计若干时段，每段 式进行拉伸。逐渐加大活动范围，每个部位拉伸时 至少10 min的体力活动达到总运动量，这种方法可 间6~15 s，逐渐增至30~90 s，期间正常呼吸，强度 增强运动的适应性和持续性[61]。为有牵拉感但不感觉疼痛，每个动作重复3~5次， 2。2。4。2 肾脏疾病 总时间为10 min左右，3~7次/周[51]。由于心血管疾病是慢性肾病患者的主要死亡原 2。2。2。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 491,
      "text": "，或可以通过累计若干时段，每段 式进行拉伸。逐渐加大活动范围，每个部位拉伸时 至少10 min的体力活动达到总运动量，这种方法可 间6~15 s，逐渐增至30~90 s，期间正常呼吸，强度 增强运动的适应性和持续性[61]。为有牵拉感但不感觉疼痛，每个动作重复3~5次， 2。2。4。2 肾脏疾病 总时间为10 min左右，3~7次/周[51]。由于心血管疾病是慢性肾病患者的主要死亡原 2。2。2。 4 其他运动康复训练方法 因，所以进行运动干预是有必要的，CABG后患者 （ 1）高强间歇训练：持续时间短重复多次的高 合并肾功能下降与许多因素有关，包括静坐少动的 强度的运动训练，每两次高强度训练之间穿插较 生活方式、心脏功能障碍、贫血和骨骼肌功能障碍。低强度或无负荷运动进行主动恢复，可显著提高 CABG合并肾病患者每周3~5天有氧运动，2~3天 CABG后患者VO peak、延长运动时间并且在长期 抗阻运动。每天持续20~60 min的有氧运动，如果 2 疗效维持及改善方面优于恒定功率运动[46, 52]。不能耐受这个时间，可以进行每次3~5 min的间歇 （ 2）以神经系统运动为主的训练方案：如可采 运动，每天累计20~60 min，有氧运动强度可采取中 取太极[53]、瑜伽[54-55]等神经系统运动康复形式。等强度有氧运动（[ 40%~60%摄氧量储备（ VO R）]， 2 CABG后每天30 min瑜伽训练可显著提高患者的心 抗阻运动可于30% 最大肌力（1RM） 起始[51]。脏射血分数、降低体重指数（BMI）、血糖、低密度 2。2。5 CABG后药物治疗 脂蛋白胆固醇（LDL-C）、增加高密度脂蛋白胆固醇 CABG后患者对于药物使用的认知和态度，决定 （HDL-C），缓解压力与焦虑[54]。了其二级预防药物依从性。患者对于药物作用机制、 （ 3） 生理性缺血训练（PIT）：可采用等长收缩 副作用的了解，结合自身的经济情况、人口社会学 训练和血压计袖带加压训练[56]。因素、社会关系等，都会影响患者按照指南规范化 2。2。3 CABG后常见并发症的运动康复 使用药物[62]。CABG后患者规范使用药物的依从性与 CABG后可能会出现心房颤动（房颤）、心力衰 坚持随访有关[63]，鼓励患者参加心脏康复项目和接 竭（心衰）等并发症，针对不同的并发症应实施不同 受长期随访可以改善患者药物依从性和危险因素控 的康复策略。制[5]。目前有充分循证证据的二级预防用药包括[5]： 2。2。3。1 心房颤动 2。2。5。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 492,
      "text": " 2。2。3 CABG后常见并发症的运动康复 使用药物[62]。CABG后患者规范使用药物的依从性与 CABG后可能会出现心房颤动（房颤）、心力衰 坚持随访有关[63]，鼓励患者参加心脏康复项目和接 竭（心衰）等并发症，针对不同的并发症应实施不同 受长期随访可以改善患者药物依从性和危险因素控 的康复策略。制[5]。目前有充分循证证据的二级预防用药包括[5]： 2。2。3。1 心房颤动 2。2。5。 1 抗血小板药物 根据心肺运动实验的结果，运动强度应在无 CABG后，阿司匹林（100 mg/d）和氯吡格雷（75 氧阈（anaerobic threshold，AT）水平的强度，或根 mg/d）双联抗血小板治疗应持续12个月；对于长期 据心肺功能储备水平计算步行速度来确定，建议房 抗血小板治疗二级预防，推荐阿司匹林100 mg/d。˝(cid:242)•‰˚(cid:253)(cid:190)(cid:221) 中国循环杂志 2020年1月 第35卷 第1期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 11 对于阿司匹林不耐受或过敏的患者，单用氯吡格雷 脏康复计划的常规筛查的一部分。对于CABG后患 75 mg/d，长期维持治疗是可行的。者，建议采用两阶段筛查方法，首先使用简短的问 2。2。5。2 他汀类药物 卷（STOP-Bang评测表，表7）[68]。评估患者发生 如无禁忌证，应长期使用他汀类药物，使 OSA的可能性，然后在必要时进行客观评估（采用 LDL-C降至<1。8 mmol/L（70 mg/dl）。便携式家庭监护仪或多导睡眠监测）[69]。2。2。5。3 β受体阻滞剂 除非禁忌，既往心肌梗死和左心室收缩功能障 表7 STOP-Bang评测表 碍的CABG患者应进行β受体阻滞剂治疗。身高(cm) 体重(kg) 年龄(岁) 2。2。5。4 血管紧张素转换酶抑制剂（ACEI）类药物 性别 BMI(kg / m2) 脖围(cm) 问题 是 (1分) 否(0分) 近期心肌梗死、左心室收缩功能障碍、糖尿病 1 打鼾 你是否大声打鼾(大过说话声音，或者隔着 和慢性肾脏病的患者，CABG后应给予ACEI类药 关闭的门也能听到)。物进行治疗，术后确定启动治疗时机和选择剂量时 2 疲劳 你是否白天感觉累，疲惫或者想睡觉。应仔细评价肾功能。3 观察 是否有人观察到你睡觉时有呼吸停止现象。4 血压 你是否曾经或者目前是高血压患者。2。2。6 营养支持 5 BMI BMI是否＞35 kg / m2。健康饮食是心血管疾病预防的基石。因此，促 6 年龄 年龄是否超过50岁。进患者出院后的健康平衡饮食对心血管风险管理至 7 脖围 脖围是否大于40 cm。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 493,
      "text": "定启动治疗时机和选择剂量时 2 疲劳 你是否白天感觉累，疲惫或者想睡觉。应仔细评价肾功能。3 观察 是否有人观察到你睡觉时有呼吸停止现象。4 血压 你是否曾经或者目前是高血压患者。2。2。6 营养支持 5 BMI BMI是否＞35 kg / m2。健康饮食是心血管疾病预防的基石。因此，促 6 年龄 年龄是否超过50岁。进患者出院后的健康平衡饮食对心血管风险管理至 7 脖围 脖围是否大于40 cm。 关重要，对患者推荐的饮食模式应该具备以下特征 8 性别 是否男性。（表6）[64]。注：评分标准：<3分为低危，3~5分为中危，>5分为高危；BMI：体重指数 表6 CABG后患者健康饮食模式特征 2。2。8 CABG后社会心理管理 项目 建议摄入量 CABG后患者的心理问题发病率普遍较高，研 饱和脂肪酸 通过多不饱和脂肪酸替代饱和脂肪酸，饱和脂肪酸摄 究显示30%~40%的患者在CABG后存在抑郁、焦 入小于总能量摄入的10％ 虑等情绪障碍问题[70]。CABG前抑郁症状的存在和 反式不饱和脂肪酸 尽可能少摄取，尽量不从加工食品中摄取，并且从天 然食物中摄入小于总能量的1％ 术后恶化都与CABG后患者较差的身体和心理社会 盐 每天<5 g 功能以及较差的生活质量相关，抑郁症是CABG后 纤维 每天25~35 g，优选全麦产品 心脏事件的独立危险因素[71]。低社会经济地位、缺 水果 每天≥200 g（2~3份） 乏社会支持、较高的工作压力和家庭生活压力、他 蔬菜 每天≥200 g（2~3份） 鱼类 每周1~2次，其中一次是富含油脂的鱼类 人敌意、抑郁、焦虑和其他精神障碍导致更高的心 无盐坚果 每天30 g 血管疾病风险并影响患者的预后。饮料 不鼓励使用含糖软饮料和含酒精饮料 2。2。8。1 社会心理因素的评估 酒精饮料的摄入量：男性：限制在2杯/d（20 g/d 的酒精） 和女性：1杯/d（10 g/d的酒精） 建议CABG后使用临床访谈或标准化问卷进行 注：CABG：冠状动脉旁路移植术 心理社会风险因素评估，以确定患者改变生活方式 或坚持服药的潜在障碍。标准化方法可用于评估心 2。2。7 CABG后睡眠管理 理社会因素，或者可以在医生的临床访谈中对心理 在CABG后，阻塞性睡眠呼吸暂停（OSA）与长 社会因素进行初步评估。临床医护人员应根据患者 期心血管事件发生率的增加独立相关[65]。研究表明， 的情况，参照表8进行评估[45]。诸如持续气道正压通气或下颌前移装置等治疗可以 2。2。8。2 社会心理因素的干预 成功治疗OSA，OSA的改善或消除，可改善心脏康 患者社会心理危险因素的治疗可以抵消社会 复效果及生活质量[66-67]。通过对心脏康复人员进行 心理压力、抑郁和焦虑，从而促进行为改变，改善 睡眠障碍筛查的培训，可以部分缓解转诊和治疗的 生活质量和预后。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 494,
      "text": "独立相关[65]。研究表明， 的情况，参照表8进行评估[45]。诸如持续气道正压通气或下颌前移装置等治疗可以 2。2。8。2 社会心理因素的干预 成功治疗OSA，OSA的改善或消除，可改善心脏康 患者社会心理危险因素的治疗可以抵消社会 复效果及生活质量[66-67]。通过对心脏康复人员进行 心理压力、抑郁和焦虑，从而促进行为改变，改善 睡眠障碍筛查的培训，可以部分缓解转诊和治疗的 生活质量和预后。 为了改善社会心理健康，建议在 潜在障碍。患有心血管疾病和存在心理社会症状的患者中进行 筛选OSA的最佳时机是在开始门诊康复计划 多模式行为干预，将健康教育、运动训练和心理治 时，通常在术后4~6周。鉴于OSA治疗的潜在益 疗结合起来，用于社会心理风险因素管理和应对疾 处，应使用可靠和有效的筛查工具作为患者进入心 病[72-73]；对于有抑郁、焦虑或敌意的临床显著症状， ˝(cid:242)•‰˚(cid:253)(cid:190)(cid:221) 12 中国循环杂志 2020年1月 第35卷 第1期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 应考虑转诊心理治疗，药物治疗或协作护理[74-75]； 效的康复策略的运用等，将是CABG后患者康复发 当风险因素本身是可诊断的疾病（例如抑郁症）或 展的内在推动力。其恶化为其他风险因素时，应考虑以预防心血管疾 病为目的的社会心理危险因素的治疗[76]。学术顾问（按姓氏拼音为序）:胡盛寿（中国医学科学院 阜外医院），郑哲（中国医学科学院阜外医院） 编写委员会成员（按姓氏拼音为序）： 表8 评估社会心理危险因素的核心问题 畅怡（中国医学科学院阜外医院），陈碧云（中国医学科 项目 评估内容 学院阜外医院），车琳（上海同济医院），陈伟（中国医学科学 低社会经济地位 您的最高学历是什么。院北京协和医院），陈亚丽（河北医科大学第二医院），丁荣 您是体力劳动者吗。晶（北京大学人民医院），杜鹃（中国医学科学院阜外医院）， 工作与家庭压力 您觉得自己的能力足以达到工作要求吗。您获得的奖励是否符合您的努力。冯雪（中国医学科学院阜外医院），凤玮（中国医学科学院阜 您和配偶有严重问题吗。外医院），付长庚（中国医学科学院西苑医院），郭琪（上海 社会孤立 您一个人住。健康医学院康复学院），黑飞龙（中国医学科学院阜外医院）， 您缺少亲密的知己吗。李响（中国医学科学院阜外医院），刘博淼（中国医学科学院 您去年失去了一位重要的亲戚或朋友吗。抑郁 您是否感到沮丧和绝望。阜外医院），刘慧（河南省濮阳市安阳地区医院），刘盛（中 您对生活失去了兴趣和乐趣吗。国医学科学院阜外医院），刘遂心（中南大学湘雅医院），刘 焦虑 您突然感到恐惧或恐慌吗。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 495,
      "text": "琪（上海 社会孤立 您一个人住。健康医学院康复学院），黑飞龙（中国医学科学院阜外医院）， 您缺少亲密的知己吗。李响（中国医学科学院阜外医院），刘博淼（中国医学科学院 您去年失去了一位重要的亲戚或朋友吗。抑郁 您是否感到沮丧和绝望。阜外医院），刘慧（河南省濮阳市安阳地区医院），刘盛（中 您对生活失去了兴趣和乐趣吗。国医学科学院阜外医院），刘遂心（中南大学湘雅医院），刘 焦虑 您突然感到恐惧或恐慌吗。 文娴（首都医科大学附属北京安贞医院），马晶（中国人民解 您是否经常无法停止或控制担忧。放军总医院），孟舒（上海新华医院），石丽（中国医学科学 敌意 您经常对小事感到生气吗。院阜外医院），宋云虎（中国医学科学院阜外医院），孙寒松 您是否经常对其他人的习惯感到恼火。（中国医学科学院阜外医院），孙洪强（北京大学第六医院）， D型人格 一般来说，您是否经常感到焦虑，烦躁或沮丧。您是否避免与其他人分享您的想法和感受。石熠瑶（中国医学科学院阜外医院），唐熠达（中国医学科学 创伤后应激综合征 您是否曾接触过创伤事件。院阜外医院），万春晓（天津医科大学总医院），王磊（江苏 您是否患有噩梦或侵扰性思想。省中医院），王立清（中国医学科学院阜外医院），徐顺霖（北 其他心理疾病 您是否患有任何其他精神疾病。京大学第三医院），吴岳（中国医学科学院阜外医院），叶红 华（宁波第二医院），喻鹏铭（四川大学华西医院），张国林（广 在标准的康复治疗中进行心理干预可改善患 东省人民医院），张剑（中国人民解放军北部战区医院），张 者的痛苦、抑郁和焦虑 [77]。这些干预措施包括针 书敏（中国医学科学院阜外医院），张宇辉（中国医学科学院 阜外医院） 对心理社会风险因素和应对疾病的个人或团体辅 利益冲突：所有作者均声明不存在利益冲突 导、压力管理课程、认知行为的治疗、冥想、自 主性训练、生物反馈、呼吸、 瑜伽和（或）肌肉放 参考文献 松等。[1] Achttien RJ, Staal JB, van der Voort S, et al。Practice 3 结语 Recommendations Development Group。Exercise-based cardiac 以运动为基础的心脏康复治疗可以降低CABG rehabilitation in patients with coronary heart disease: a practice 后患者总死亡率和再住院率，提高生活质量。医院 guideline[J]。Neth Heart J, 2013, 21(10): 429-438。DOI: 10。1007/ s12471-013-0467-y。监护下的运动与基于家庭的运动方式相结合的心脏 [2] Zheng Z, Zhang H, Yuan X, et al。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 496,
      "text": "h coronary heart disease: a practice 后患者总死亡率和再住院率，提高生活质量。医院 guideline[J]。Neth Heart J, 2013, 21(10): 429-438。DOI: 10。1007/ s12471-013-0467-y。监护下的运动与基于家庭的运动方式相结合的心脏 [2] Zheng Z, Zhang H, Yuan X, et al。 Comparing outcomes of coronary 康复，可使CABG后患者长期获益。在患者住院期 artery bypass grafting among large teaching and urban hospitals in 间、出院早期和基于家庭的维持期，根据患者的情况， China and the United States[J]。Circ Cardiovasc Qual Outcomes, 2017, 10(6)。DOI: 10。1161/CIRCOUTCOMES。116。003327。制定个体化的康复计划，有利于患者的心脏康复。[3] Simon M, Korn K, Cho L, et al。Cardiac rehabilitation: a class 1 在基于家庭的CABG后患者康复训练过程中， recommendation[J]。Cleve Clin J Med, 2018, 85(7): 551-558。DOI: 如何提高患者的依从性仍是一个亟待解决的问题， 10。3949/ccjm。85a。17037。只有患者依从性提高，才能达到预期的康复目的。[4] Huang Y, Zhang R, Culler SD, et al。Costs and effectiveness of cardiac rehabilitation for dialysis patients following coronary 首先，依赖于国家卫生政策的支持，包括加大投入、 bypass[J]。Kidney Int, 2008, 74(8): 1079-1084。DOI: 10。1038/ki。政策引导、基本医保支付比例提升及三级医院转诊 2008。381。制度的完善等; 其次，规范化建设，包括人员培训 [5] Kulik A, Ruel M, Jneid H, et al。American heart association council 认证规范化、建立分级准入制度、建立运动康复临 on cardiovascular surgery and anesthesia。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 497,
      "text": "。1038/ki。政策引导、基本医保支付比例提升及三级医院转诊 2008。381。制度的完善等; 其次，规范化建设，包括人员培训 [5] Kulik A, Ruel M, Jneid H, et al。American heart association council 认证规范化、建立分级准入制度、建立运动康复临 on cardiovascular surgery and anesthesia。 secondary prevention after (cid:70)(cid:82)(cid:85)(cid:82)(cid:81)(cid:68)(cid:85)(cid:92)(cid:3)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:92)(cid:3)(cid:69)(cid:92)(cid:83)(cid:68)(cid:86)(cid:86)(cid:3)(cid:74)(cid:85)(cid:68)(cid:73)(cid:87)(cid:3)(cid:86)(cid:88)(cid:85)(cid:74)(cid:72)(cid:85)(cid:92)(cid:29)(cid:3)(cid:68)(cid:3)(cid:86)(cid:70)(cid:76)(cid:72)(cid:81)(cid:87)(cid:76)(cid:191)(cid:70)(cid:3)(cid:86)(cid:87)(cid:68)(cid:87)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3) 床路径等； 最后，新技术创新和理论体系更新，如 American Heart Association[J]。Circulation, 2015, 131(10): 927- 物联网、可穿戴智能设备的普及、更加精准安全有 964。DOI: 10。1161/CIR。0000000000000182。˝(cid:242)•‰˚(cid:253)(cid:190)(cid:221) 中国循环杂志 2020年1月 第35卷 第1期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 13 [6] 贾丽晔, 郭琪, 王鹏程, 等。运动疗法对心血管疾病患者的影响和 [21] Stiller K。Physiotherapy in intensive care: an updated systematic 作用机理研究进展[J]。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 498,
      "text": "期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 13 [6] 贾丽晔, 郭琪, 王鹏程, 等。运动疗法对心血管疾病患者的影响和 [21] Stiller K。Physiotherapy in intensive care: an updated systematic 作用机理研究进展[J]。 中国康复理论与实践, 2016, 22(9): 1041- review[J]。Chest, 2013, 144(3): 825-847。DOI: 10。1378/chest。12- 1044。DOI: 10。3969/j。issn。1006-9771。2016。09。012。2930。[7] Kim C, Sung J, Lee JH, et al。Clinical practice guideline for cardiac [22] 吴淼, 倪朝民, 吴鸣, 等。机械通气患者早期肺康复治疗的临床观 rehabilitation in Korea[J]。Ann Rehabil Med, 2019, 43(3): 355- 察[J]。中国康复医学杂志, 2018, 33(7): 806-811。DOI: 10。3969/j。443。DOI: 10。5535/arm。2019。43。3。355。issn。1001-1242。2018。07。010。[8] Niebauer J。Cardiac rehabilitation in Austria[J]。Wien Med [23] Pieczkoski SM, Margarites AGF, Sbruzzi G。Noninvasive ventilation Wochenschr, 2018, 168(1-2): 46-49。DOI: 10。1007/s10354-017- during immediate postoperative period in cardiac surgery patients: 0607-x。systematic review and meta-analysis[J]。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 499,
      "text": "i G。Noninvasive ventilation Wochenschr, 2018, 168(1-2): 46-49。DOI: 10。1007/s10354-017- during immediate postoperative period in cardiac surgery patients: 0607-x。systematic review and meta-analysis[J]。 Braz J Cardiovasc Surg, (cid:62)(cid:28)(cid:64)(cid:3) (cid:58)(cid:82)(cid:82)(cid:71)(cid:85)(cid:88)(cid:3445)(cid:72)(cid:3)(cid:54)(cid:15)(cid:3)(cid:49)(cid:72)(cid:88)(cid:69)(cid:72)(cid:70)(cid:78)(cid:3)(cid:47)(cid:15)(cid:3)(cid:38)(cid:79)(cid:68)(cid:85)(cid:78)(cid:3)(cid:53)(cid:36)(cid:15)(cid:3)(cid:72)(cid:87)(cid:3)(cid:68)(cid:79)(cid:17)(cid:3)(cid:36)(cid:88)(cid:86)(cid:87)(cid:85)(cid:68)(cid:79)(cid:76)(cid:68)(cid:81)(cid:3)(cid:38)(cid:68)(cid:85)(cid:71)(cid:76)(cid:82)(cid:89)(cid:68)(cid:86)(cid:70)(cid:88)(cid:79)(cid:68)(cid:85)(cid:3) 2017, 32(4): 301-311。DOI: 10。21470/1678-9741-2017-0032。Health and Rehabilitation Association (ACRA) core components [24] Wang TH, Wu CP, Wang LY。Chest physiotherapy with early of cardiovascular disease secondary prevention and cardiac mobilization may improve extubation outcome in critically ill rehabilitation 2014[J]。Heart Lung Circ, 2015, 24(5): 430-441。DOI: patients in the intensive care units[J]。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 500,
      "text": "econdary prevention and cardiac mobilization may improve extubation outcome in critically ill rehabilitation 2014[J]。Heart Lung Circ, 2015, 24(5): 430-441。DOI: patients in the intensive care units[J]。 Clin Respir J, 2018, 12(11): 10。1016/j。hlc。2014。12。008。2613-2621。DOI: 10。1111/crj。12965。[10] 胡盛寿, 高润霖, 刘力生, 等。《 中国心血管病报告2018》概要[J]。[25] Hjskov IE, Moons P, Hansen NV, et al。Shepp Heart CABG trial- 中国循环杂志, 2019, 34(3): 209-220。DOI: 10。3969/j。issn。1000- comprehensive early rehabilitation after coronary artery bypass 3614。2019。03。001。grafting: a protocol for a randomised clinical trial[J]。BMJ Open, [11] Hillis LD, Smith PK, Anderson JL, et al。2011 ACCF/AHA Guideline 2017, 7(1): e013038。DOI: 10。1136/bmjopen-2016-013038。for Coronary Artery Bypass Graft Surgery: executive summary: a [26] American Geriatrics Society Expert Panel on Postoperative Delirium report of the American College of Cardiology Foundation/American in Older Adults。American geriatrics society abstracted clinical Heart Association Task Force on Practice Guidelines[J]。Circulation, practice guideline for postoperative delirium in older adults[J]。J Am 2011, 124(23): 2610-2642。DOI: 10。1161/CIR。0b013e31823b5fee。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 501,
      "text": "al Heart Association Task Force on Practice Guidelines[J]。Circulation, practice guideline for postoperative delirium in older adults[J]。J Am 2011, 124(23): 2610-2642。DOI: 10。1161/CIR。0b013e31823b5fee。 Geriatr Soc, 2015, 63(1): 142-150。DOI: 10。1111/jgs。13281。[12] 国家心血管病中心, 中西医结合(cid:4318)期心脏康复专家共识委员会。[27] Dong Z, Yu B, Zhang Q, et al。Early rehabilitation therapy is 中西医结合冠状动脉旁路移植术(cid:4318)期心脏康复专家共识[J]。中国 beneficial for patients with prolonged mechanical ventilation after 循环杂志, 2017, 32(4): 314-317。DOI: 10。3969/j。issn。1000-3614。coronary artery bypass surgery[J]。Int Heart J, 2016, 57(2): 241- 2017。04。002。246。DOI: 10。1536/ihj。15-316。[13] Shakouri SK, Salekzamani Y, Taghizadieh A, et al。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 502,
      "text": "): 314-317。DOI: 10。3969/j。issn。1000-3614。coronary artery bypass surgery[J]。Int Heart J, 2016, 57(2): 241- 2017。04。002。246。DOI: 10。1536/ihj。15-316。[13] Shakouri SK, Salekzamani Y, Taghizadieh A, et al。 Effect of (cid:62)(cid:21)(cid:27)(cid:64)(cid:3) (cid:54)(cid:83)(cid:76)(cid:85)(cid:82)(cid:86)(cid:78)(cid:76)(cid:3)(cid:39)(cid:15)(cid:3)(cid:36)(cid:81)(cid:71)(cid:77)(cid:76)(cid:252)(cid:3)(cid:48)(cid:15)(cid:3)(cid:54)(cid:87)(cid:82)(cid:77)(cid:68)(cid:81)(cid:82)(cid:89)(cid:76)(cid:252)(cid:3)(cid:50)(cid:44)(cid:15)(cid:3)(cid:72)(cid:87)(cid:3)(cid:68)(cid:79)(cid:17)(cid:3)(cid:57)(cid:72)(cid:85)(cid:92)(cid:3)(cid:86)(cid:75)(cid:82)(cid:85)(cid:87)(cid:18)(cid:86)(cid:75)(cid:82)(cid:85)(cid:87)(cid:16)(cid:87)(cid:72)(cid:85)(cid:80)(cid:3) respiratory rehabilitation before open cardiac surgery on respiratory (cid:69)(cid:72)(cid:81)(cid:72)(cid:191)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:76)(cid:81)(cid:83)(cid:68)(cid:87)(cid:76)(cid:72)(cid:81)(cid:87)(cid:18)(cid:82)(cid:88)(cid:87)(cid:83)(cid:68)(cid:87)(cid:76)(cid:72)(cid:81)(cid:87)(cid:3)(cid:70)(cid:68)(cid:85)(cid:71)(cid:76)(cid:68)(cid:70)(cid:3)(cid:85)(cid:72)(cid:75)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:83)(cid:85)(cid:82)(cid:74)(cid:85)(cid:68)(cid:80)(cid:86)(cid:3)(cid:68)(cid:73)(cid:87)(cid:72)(cid:85)(cid:3) function: a randomized clinical trial[J]。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 503,
      "text": ")(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:83)(cid:85)(cid:82)(cid:74)(cid:85)(cid:68)(cid:80)(cid:86)(cid:3)(cid:68)(cid:73)(cid:87)(cid:72)(cid:85)(cid:3) function: a randomized clinical trial[J]。 J Cardiovasc Thorac Res, coronary artery bypass grafting surgery[J]。Clin Cardiol, 2017, 40(5): 2015, 7(1): 13-17。DOI: 10。15171/jcvtr。2015。03。281-286。DOI: 10。1002/clc。22656。(cid:62)(cid:20)(cid:23)(cid:64)(cid:3) (cid:48)(cid:82)(cid:71)(cid:76)(cid:70)(cid:68)(cid:3)(cid:48)(cid:15)(cid:3)(cid:38)(cid:68)(cid:86)(cid:87)(cid:76)(cid:74)(cid:79)(cid:76)(cid:82)(cid:81)(cid:76)(cid:3)(cid:51)(cid:15)(cid:3)(cid:48)(cid:76)(cid:81)(cid:82)(cid:87)(cid:87)(cid:76)(cid:3)(cid:36)(cid:15)(cid:3)(cid:72)(cid:87)(cid:3)(cid:68)(cid:79)(cid:17)(cid:3)(cid:51)(cid:86)(cid:92)(cid:70)(cid:75)(cid:82)(cid:79)(cid:82)(cid:74)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3)(cid:83)(cid:85)(cid:82)(cid:191)(cid:79)(cid:72)(cid:3)(cid:76)(cid:81)(cid:3) [29] Pantoni CB, Di Thommazo-Luporini L, Mendes RG, et al。A。coronary artery by-pass graft patients vs。valve replacement patients Continuous positive airway pressure during exercise improves entering cardiac rehabilitation after surgery[J]。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 504,
      "text": ", Mendes RG, et al。A。coronary artery by-pass graft patients vs。valve replacement patients Continuous positive airway pressure during exercise improves entering cardiac rehabilitation after surgery[J]。 Sci Rep, 2018, 8(1): walking time in patients undergoing inpatient cardiac rehabilitation 14381。DOI: 10。1038/s41598-018-32696-5。after coronary artery bypass graft surgery: A RANDOMIZED [15] Engelman DT, Ben Ali W, Williams JB, et al。Guidelines for CONTROLLED TRIAL[J]。J Cardiopulm Rehabil Prev, 2016, 36(1): perioperative care in cardiac surgery: enhanced recovery after 20-27。DOI: 10。1097/HCR。0000000000000144。surgery society recommendations[J]。JAMA Surg, 2019。DOI: 10。[30] Mendes RG, Simes RP, De Souza Melo Costa F, et al。Short-term 1001/jamasurg。2019。1153。supervised inpatient physiotherapy exercise protocol improves [16] Reid MC, Fiellin DA, O'Connor PG。Hazardous and harmful alcohol cardiac autonomic function after coronary artery bypass graft consumption in primary care[J]。Arch Intern Med, 1999, 159(15): surgery-a randomised controlled trial[J]。Disabil Rehabil, 2010, 1681-1689。DOI: 10。1001/archinte。159。15。1681。32(16): 1320-1327。DOI: 10。3109/09638280903483893。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 505,
      "text": "ry care[J]。Arch Intern Med, 1999, 159(15): surgery-a randomised controlled trial[J]。Disabil Rehabil, 2010, 1681-1689。DOI: 10。1001/archinte。159。15。1681。32(16): 1320-1327。DOI: 10。3109/09638280903483893。 [17] Morris PE, Goad A, Thompson C, et al。Early intensive care unit (cid:62)(cid:22)(cid:20)(cid:64)(cid:3) (cid:54)(cid:93)(cid:92)(cid:79)(cid:76)(cid:276)(cid:86)(cid:78)(cid:68)(cid:3)(cid:36)(cid:15)(cid:3)(cid:47)(cid:76)(cid:86)(cid:87)(cid:72)(cid:90)(cid:81)(cid:76)(cid:78)(cid:3)(cid:48)(cid:15)(cid:3)(cid:53)(cid:82)(cid:87)(cid:87)(cid:72)(cid:85)(cid:3)(cid:44)(cid:15)(cid:3)(cid:72)(cid:87)(cid:3)(cid:68)(cid:79)(cid:17)(cid:3)(cid:55)(cid:75)(cid:72)(cid:3)(cid:72)(cid:3446)(cid:70)(cid:68)(cid:70)(cid:92)(cid:3)(cid:82)(cid:73)(cid:3)(cid:76)(cid:81)(cid:83)(cid:68)(cid:87)(cid:76)(cid:72)(cid:81)(cid:87)(cid:3) mobility therapy in the treatment of acute respiratory failure[J]。vs。home-based physiotherapy following coronary artery bypass Crit Care Med, 2008, 36(8): 2238-2243。DOI: 10。1097/CCM。grafting[J]。Int J Environ Res Public Health, 2018, 15(11)。DOI: 10。0b013e318180b90e。3390/ijerph15112572。[18] Evans AS, Weiner MM, Arora RC, et al。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 506,
      "text": "Crit Care Med, 2008, 36(8): 2238-2243。DOI: 10。1097/CCM。grafting[J]。Int J Environ Res Public Health, 2018, 15(11)。DOI: 10。0b013e318180b90e。3390/ijerph15112572。[18] Evans AS, Weiner MM, Arora RC, et al。 Current approach to [32] Ennis S, Lobley G, Worrall S, et al。Early initiation of post- diagnosis and treatment of delirium after cardiac surgery[J]。Ann sternotomy cardiac rehabilitation exercise training (SCAR): Card Anaesth, 2016, 19(2): 328-337。DOI: 10。4103/0971-9784。study protocol for a randomised controlled trial and economic 179634。evaluation[J]。BMJ Open, 2018, 8(3): e019748。DOI: 10。1136/ [19] 胡贇皓, 张炜。中医呼吸导引康复技术对改善慢性阻塞性肺疾病 bmjopen-2017-019748。稳定期患者肺功能的研究[J]。中华中医药学刊, 2016, 34(2): 414- [33] 瞿建宇, 饶辰飞。双侧乳内动脉桥在冠状动脉旁路移植术中的应 417。DOI: 10。13193/j。issn。1673-7717。2016。02。047。用[J]。中国循环杂志, 2019, 34(5): 513-516。DOI: 10。3969/j。issn。[20] Strickland SL, Rubin BK, Drescher GS, et al。AARC clinical practice 1000-3614。2019。05。017。guideline: effectiveness of nonpharmacologic airway clearance [34] Labropoulos N, Bishawi M, Gasparis A, et al。Great saphenous vein therapies in hospitalized patients[J]。Respir Care, 2013, 58(12): stump thrombosis after harvesting for coronary artery bypass graft 2187-2193。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 507,
      "text": "ulos N, Bishawi M, Gasparis A, et al。Great saphenous vein therapies in hospitalized patients[J]。Respir Care, 2013, 58(12): stump thrombosis after harvesting for coronary artery bypass graft 2187-2193。 DOI: 10。4187/respcare。02925。surgery[J]。Phlebology, 2014, 29(4): 215-219。DOI: 10。1258/phleb。˝(cid:242)•‰˚(cid:253)(cid:190)(cid:221) 14 中国循环杂志 2020年1月 第35卷 第1期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 2012。012094。jcj。65。419。[35] 罗珠嘉, 陈玉红。冠脉搭桥术后患者下床活动时间的影响因素分 (cid:62)(cid:23)(cid:28)(cid:64)(cid:3) (cid:51)(cid:79)(cid:129)(cid:86)(cid:86)(cid:3)(cid:38)(cid:40)(cid:15)(cid:3)(cid:37)(cid:76)(cid:79)(cid:79)(cid:76)(cid:81)(cid:74)(cid:3)(cid:40)(cid:15)(cid:3)(cid:43)(cid:72)(cid:79)(cid:71)(cid:3)(cid:38)(cid:15)(cid:3)(cid:72)(cid:87)(cid:3)(cid:68)(cid:79)(cid:17)(cid:3)(cid:47)(cid:82)(cid:81)(cid:74)(cid:16)(cid:87)(cid:72)(cid:85)(cid:80)(cid:3)(cid:72)(cid:3445)(cid:72)(cid:70)(cid:87)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:68)(cid:81)(cid:3)(cid:72)(cid:91)(cid:83)(cid:68)(cid:81)(cid:71)(cid:72)(cid:71)(cid:3) 析[J]。护理学杂志, 2017, 32(14): 6-9。DOI: 10。3870/j。issn。1001- cardiac rehabilitation programme after myocardial infarction 4152。2017。14。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 508,
      "text": "id:72)(cid:91)(cid:83)(cid:68)(cid:81)(cid:71)(cid:72)(cid:71)(cid:3) 析[J]。护理学杂志, 2017, 32(14): 6-9。DOI: 10。3870/j。issn。1001- cardiac rehabilitation programme after myocardial infarction 4152。2017。14。 006。or coronary artery bypass surgery: a five-year follow-up of a [36] Alizadeh-Ghavidel A, Ramezannejad P, Mirmesdagh Y, et al。randomized controlled study[J]。Clin Rehabil, 2011, 25(1): 79-87。Prevention of edema after coronary artery bypass graft surgery by DOI: 10。1177/0269215510376006。compression stockings[J]。Res Cardiovasc Med, 2014, 3(2): e17463。[50] Hermes BM, Cardoso DM, Gomes TJ, et al。Short-term inspiratory DOI: 10。5812/cardiovascmed。17463。muscle training potentiates the benefits of aerobic and resistance [37] Gaudino M, Antoniades C, Benedetto U, et al。Mechanisms, training in patients undergoing CABG in phase II cardiac consequences, and prevention of coronary graft failure[J]。rehabilitation program[J]。Rev Bras Cir Cardiovasc, 2015, 30(4): Circulation, 2017, 136(18): 1749-1764。DOI: 10。1161/ 474-481。DOI: 10。5935/1678-9741。20150043。CIRCULATIONAHA。117。027597。[51] 王正珍主译审。ACSM运动测试与运动处方指南[M]。第九版。北 [38] Zhu YY, Hayward PA, Hadinata IE, et al。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 509,
      "text": " Circulation, 2017, 136(18): 1749-1764。DOI: 10。1161/ 474-481。DOI: 10。5935/1678-9741。20150043。CIRCULATIONAHA。117。027597。[51] 王正珍主译审。ACSM运动测试与运动处方指南[M]。第九版。北 [38] Zhu YY, Hayward PA, Hadinata IE, et al。 Long-term impact of radial 京: 北京体育大学出版社， 2018。artery harvest on forearm function and symptoms: a comparison with [52] Meyer K, Lehmann M, Snder G, et al。Interval versus continuous leg vein[J]。J Thorac Cardiovasc Surg, 2013, 145(2): 412-419。DOI: exercise training after coronary bypass surgery: a comparison of 10。1016/j。jtcvs。2012。01。052。(cid:87)(cid:85)(cid:68)(cid:76)(cid:81)(cid:76)(cid:81)(cid:74)(cid:16)(cid:76)(cid:81)(cid:71)(cid:88)(cid:70)(cid:72)(cid:71)(cid:3)(cid:68)(cid:70)(cid:88)(cid:87)(cid:72)(cid:3)(cid:85)(cid:72)(cid:68)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:72)(cid:3445)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3) [39] 齐弘炜。中国常用动脉化冠状动脉旁路移植术的通畅率及疗效 the exercise methods[J]。Clin Cardiol, 1990, 13(12): 851-861。DOI: [J]。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 510,
      "text": "70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3) [39] 齐弘炜。中国常用动脉化冠状动脉旁路移植术的通畅率及疗效 the exercise methods[J]。Clin Cardiol, 1990, 13(12): 851-861。DOI: [J]。 心血管病学进展, 2015, 36(5): 559-563。DOI: 10。3969/j。issn。10。1002/clc。4960131208。1004-3934。2015。05。009。[53] Lan C, Chen SY, Wong MK, et al。Tai chi chuan exercise for patients [40] Chen YC, Chen KC, Lu LH, et al。Validating the 6-minute walk test with cardiovascular disease[J]。Evid Based Complement Alternat as an indicator of recovery in patients undergoing cardiac surgery: Med, 2013, 2013: 983208。DOI: 10。1155/2013/983208。a prospective cohort study[J]。Medicine (Baltimore), 2018, 97(42): [54] Raghuram N, Parachuri VR, Swarnagowri MV, et al。Yoga based e12925。DOI: 10。1097/MD。0000000000012925。cardiac rehabilitation after coronary artery bypass surgery: one-year [41] Mendes M。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 511,
      "text": "18, 97(42): [54] Raghuram N, Parachuri VR, Swarnagowri MV, et al。Yoga based e12925。DOI: 10。1097/MD。0000000000012925。cardiac rehabilitation after coronary artery bypass surgery: one-year [41] Mendes M。 Is There a role for cardiac rehabilitation after coronary (cid:85)(cid:72)(cid:86)(cid:88)(cid:79)(cid:87)(cid:86)(cid:3)(cid:82)(cid:81)(cid:3)(cid:47)(cid:57)(cid:40)(cid:41)(cid:15)(cid:3)(cid:79)(cid:76)(cid:83)(cid:76)(cid:71)(cid:3)(cid:83)(cid:85)(cid:82)(cid:191)(cid:79)(cid:72)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:83)(cid:86)(cid:92)(cid:70)(cid:75)(cid:82)(cid:79)(cid:82)(cid:74)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3)(cid:86)(cid:87)(cid:68)(cid:87)(cid:72)(cid:86)(cid:16)(cid:16)(cid:68)(cid:3)(cid:85)(cid:68)(cid:81)(cid:71)(cid:82)(cid:80)(cid:76)(cid:93)(cid:72)(cid:71)(cid:3) artery bypass grafting。there is no role for cardiac rehabilitation after controlled study[J]。Indian Heart J, 2014, 66(5): 490-502。DOI: 10。coronary artery bypass grafting[J]。Circulation, 2016, 133(24): 2538- 1016/j。ihj。2014。08。007。2543。DOI: 10。1161/CIRCULATIONAHA。115。017800。[55] Amaravathi E, Ramarao NH, Raghuram N, et al。Yoga-based [42] Neumann FJ, Sousa-Uva M, Ahlsson A, et al。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 512,
      "text": "ion, 2016, 133(24): 2538- 1016/j。ihj。2014。08。007。2543。DOI: 10。1161/CIRCULATIONAHA。115。017800。[55] Amaravathi E, Ramarao NH, Raghuram N, et al。Yoga-based [42] Neumann FJ, Sousa-Uva M, Ahlsson A, et al。 [2018 ESC/EACTS postoperative cardiac rehabilitation program for improving quality Guidelines on myocardial revascularization。The Task Force on (cid:82)(cid:73)(cid:3)(cid:79)(cid:76)(cid:73)(cid:72)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:86)(cid:87)(cid:85)(cid:72)(cid:86)(cid:86)(cid:3)(cid:79)(cid:72)(cid:89)(cid:72)(cid:79)(cid:86)(cid:29)(cid:3)(cid:191)(cid:73)(cid:87)(cid:75)(cid:16)(cid:92)(cid:72)(cid:68)(cid:85)(cid:3)(cid:73)(cid:82)(cid:79)(cid:79)(cid:82)(cid:90)(cid:16)(cid:88)(cid:83)(cid:3)(cid:87)(cid:75)(cid:85)(cid:82)(cid:88)(cid:74)(cid:75)(cid:3)(cid:68)(cid:3)(cid:85)(cid:68)(cid:81)(cid:71)(cid:82)(cid:80)(cid:76)(cid:93)(cid:72)(cid:71)(cid:3) myocardial revascularization of the European Society of Cardiology controlled trial[J]。Int J Yoga, 2018, 11(1): 44-52。DOI: 10。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 513,
      "text": "8)(cid:81)(cid:71)(cid:82)(cid:80)(cid:76)(cid:93)(cid:72)(cid:71)(cid:3) myocardial revascularization of the European Society of Cardiology controlled trial[J]。Int J Yoga, 2018, 11(1): 44-52。DOI: 10。 4103/ (ESC) and European Association for Cardio-Thoracic Surgery (cid:76)(cid:77)(cid:82)(cid:92)(cid:17)(cid:3)(cid:44)(cid:45)(cid:50)(cid:60)(cid:66)(cid:24)(cid:26)(cid:66)(cid:20)(cid:25)(cid:17)(cid:3) (EACTS)] [J]。G Ital Cardiol (Rome), 2019, 20(7): 1-61。DOI: 10。[56] 梅程瑶, 倪隽。生理性缺血训练与缺血预适应的研究进展[J]。中 1714/3203。31801, PMID: 31379378。国康复医学杂志, 2018, 33(11): 1366-1369。DOI: 10。3969/j。issn。[43] Neumann FJ, Sousa-Uva M, Ahlsson A, et al。2018 ESC/EACTS 1001-1242。2018。11。025。guidelines on myocardial revascularization[J]。Eur Heart J, 2019, [57] O'Connor CM, Whellan DJ, Lee KL, et al。Efficacy and safety of 40(2): 87-165。DOI: 10。1093/eurheartj/ehy394。exercise training in patients with chronic heart failure: HF-ACTION [44] 中华医学会心血管病学分会预防学组, 中国康复医学会心血管 randomized controlled trial[J]。JAMA, 2009, 301(14): 1439- 病专业委员会。冠心病患者运动治疗中国专家共识[J]。中华心血 1450。DOI: 10。1001/jama。2009。454。管病杂志, 2015, 43(7): 575-588。DOI: 10。3760/cma。j。issn。0253- [58] Shuichi T, Satoru S, Takeshi B, et al。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 514,
      "text": " trial[J]。JAMA, 2009, 301(14): 1439- 病专业委员会。冠心病患者运动治疗中国专家共识[J]。中华心血 1450。DOI: 10。1001/jama。2009。454。管病杂志, 2015, 43(7): 575-588。DOI: 10。3760/cma。j。issn。0253- [58] Shuichi T, Satoru S, Takeshi B, et al。 Predictors of left ventricular 3758。2015。07。004。remodeling in patients with acute myocardial infarction participating [45] JCS Joint Working Group。Guidelines for rehabilitation in patients in cardiac rehabilitation[J]。Circ J, 2004, 68(3): 214-219。DOI: 10。with cardiovascular disease (JCS 2012) [J]。Circ J, 2014, 78(8): 1253/circj。68。214。2022-2093。DOI: 10。1253/circj。cj-66-0094。[59] Donnelly JE, Blair SN, Jakicic JM, et al。Appropriate physical [46] Moholdt TT, Amundsen BH, Rustad LA, et al。Aerobic interval activity intervention strategies for weight loss and prevention of training versus continuous moderate exercise after coronary artery weight regain for adults[J]。Med Sci Sports Exerc, 2009, 41(2): 459- bypass surgery: a randomized study of cardiovascular effects and 471。DOI: 10。1249/MSS。0b013e3181949333。quality of life[J]。Am Heart J, 2009, 158(6): 1031-1037。DOI: 10。[60] Haskell WL, Lee IM, Pate RR, et al。Physical activity and 1016/j。ahj。2009。10。003。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 515,
      "text": "r effects and 471。DOI: 10。1249/MSS。0b013e3181949333。quality of life[J]。Am Heart J, 2009, 158(6): 1031-1037。DOI: 10。[60] Haskell WL, Lee IM, Pate RR, et al。Physical activity and 1016/j。ahj。2009。10。003。 public health: updated recommendation for adults from the [47] Hsu CJ, Chen SY, Su S, et al。The effect of early cardiac American College of Sports Medicine and the American Heart rehabilitation on health-related quality of life among heart transplant Association[J]。Circulation, 2007, 116(9): 1081-1093。DOI: 10。1161/ recipients and patients with coronary artery bypass graft surgery[J]。CIRCULATIONAHA。107。185649。Transplant Proc, 2011, 43(7): 2714-2717。DOI: 10。1016/j。[61] Macfarlane DJ, Taylor LH, Cuddihy TF。Very short intermittent vs transproceed。2011。04。025。continuous bouts of activity in sedentary adults[J]。Prev Med, 2006, [48] Adachi H, Itoh H, Sakurai S, et al。Short-term physical training 43(4): 332-336。DOI: 10。1016/j。ypmed。2006。06。002。improves ventilatory response to exercise after coronary arterial [62] Khanderia U, Townsend KA, Erickson SR, et al。Medication bypass surgery[J]。Jpn Circ J, 2001, 65(5): 419-423。DOI: 10。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 516,
      "text": "d。2006。06。002。improves ventilatory response to exercise after coronary arterial [62] Khanderia U, Townsend KA, Erickson SR, et al。Medication bypass surgery[J]。Jpn Circ J, 2001, 65(5): 419-423。DOI: 10。 1253/ adherence following coronary artery bypass graft surgery: assessment ˝(cid:242)•‰˚(cid:253)(cid:190)(cid:221) 中国循环杂志 2020年1月 第35卷 第1期（总第259期）Chinese Circulation Journal， January，2020，Vol。35 No。1（Serial No。259） 15 of beliefs and attitudes[J]。Ann Pharmacother, 2008, 42(2): 192- outcome: a prospective study[J]。Lancet, 2001, 358(9295): 1766- 199。DOI: 10。1345/aph。1K497。1771。DOI: 10。1016/S0140-6736(01)06803-9。[63] Salari A, Hasandokht T, Mahdavi-Roshan M, et al。Risk factor [72] Balady GJ, Williams MA, Ades PA, et al。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 517,
      "text": " 2001, 358(9295): 1766- 199。DOI: 10。1345/aph。1K497。1771。DOI: 10。1016/S0140-6736(01)06803-9。[63] Salari A, Hasandokht T, Mahdavi-Roshan M, et al。Risk factor [72] Balady GJ, Williams MA, Ades PA, et al。 Core components of (cid:70)(cid:82)(cid:81)(cid:87)(cid:85)(cid:82)(cid:79)(cid:15)(cid:3)(cid:68)(cid:71)(cid:75)(cid:72)(cid:85)(cid:72)(cid:81)(cid:70)(cid:72)(cid:3)(cid:87)(cid:82)(cid:3)(cid:80)(cid:72)(cid:71)(cid:76)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:79)(cid:79)(cid:82)(cid:90)(cid:3)(cid:88)(cid:83)(cid:3)(cid:89)(cid:76)(cid:86)(cid:76)(cid:87)(cid:15)(cid:3)(cid:191)(cid:89)(cid:72)(cid:3)(cid:92)(cid:72)(cid:68)(cid:85)(cid:86)(cid:3)(cid:68)(cid:73)(cid:87)(cid:72)(cid:85)(cid:3) cardiac rehabilitation/secondary prevention programs: 2007 update: coronary artery bypass graft surgery[J]。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 518,
      "text": "id:92)(cid:72)(cid:68)(cid:85)(cid:86)(cid:3)(cid:68)(cid:73)(cid:87)(cid:72)(cid:85)(cid:3) cardiac rehabilitation/secondary prevention programs: 2007 update: coronary artery bypass graft surgery[J]。 J Cardiovasc Thorac Res, (cid:68)(cid:3)(cid:86)(cid:70)(cid:76)(cid:72)(cid:81)(cid:87)(cid:76)(cid:191)(cid:70)(cid:3)(cid:86)(cid:87)(cid:68)(cid:87)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:36)(cid:80)(cid:72)(cid:85)(cid:76)(cid:70)(cid:68)(cid:81)(cid:3)(cid:43)(cid:72)(cid:68)(cid:85)(cid:87)(cid:3)(cid:36)(cid:86)(cid:86)(cid:82)(cid:70)(cid:76)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:40)(cid:91)(cid:72)(cid:85)(cid:70)(cid:76)(cid:86)(cid:72)(cid:15)(cid:3) 2016, 8(4): 152-157。DOI: 10。15171/jcvtr。2016。31。Cardiac Rehabilitation, and Prevention Committee, the Council [64] Piepoli MF, Hoes AW, Agewall S, et al。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 519,
      "text": "cid:70)(cid:76)(cid:86)(cid:72)(cid:15)(cid:3) 2016, 8(4): 152-157。DOI: 10。15171/jcvtr。2016。31。Cardiac Rehabilitation, and Prevention Committee, the Council [64] Piepoli MF, Hoes AW, Agewall S, et al。 2016 European guidelines on Clinical Cardiology; the Councils on Cardiovascular Nursing, on cardiovascular disease prevention in clinical practice: The Sixth Epidemiology and Prevention, and Nutrition, Physical Activity, and Joint Task Force of the European Society of Cardiology and other Metabolism; and the American Association of Cardiovascular and societies on cardiovascular disease prevention in clinical practice Pulmonary Rehabilitation[J]。Circulation, 2007, 115(20): 2675-2682。(constituted by representatives of 10 societies and by invited experts) DOI: 10。1161/CIRCULATIONAHA。106。180945。Developed with the special contribution of the European Association [73] Piepoli MF, Corr U, Benzer W, et al。Secondary prevention through for Cardiovascular Prevention & Rehabilitation (EACPR) [J]。Eur cardiac rehabilitation: from knowledge to implementation。A position Heart J, 2016, 37(29): 2315-2381。DOI: 10。1093/eurheartj/ehw106。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 520,
      "text": "rough for Cardiovascular Prevention & Rehabilitation (EACPR) [J]。Eur cardiac rehabilitation: from knowledge to implementation。A position Heart J, 2016, 37(29): 2315-2381。DOI: 10。1093/eurheartj/ehw106。 paper from the Cardiac Rehabilitation Section of the European [65] Ucha CHG, Danzi-Soares NJ, Nunes FS, et al。Impact of OSA on Association of Cardiovascular Prevention and Rehabilitation[J]。Eur cardiovascular events after coronary artery bypass surgery[J]。Chest, J Cardiovasc Prev Rehabil, 2010, 17(1): 1-17。DOI: 10。1097/HJR。2015, 147(5): 1352-1360。DOI: 10。1378/chest。14-2152。0b013e3283313592。[66] Lthje L, Andreas S。Obstructive sleep apnea and coronary artery [74] Rutledge T, Redwine LS, Linke SE, et al。A meta-analysis of mental disease[J]。Sleep Med Rev, 2008, 12(1): 19-31。DOI: 10。1016/j。health treatments and cardiac rehabilitation for improving clinical smrv。2007。08。002。outcomes and depression among patients with coronary heart [67] Chai-Coetzer CL, Antic NA, Rowland LS, et al。Primary care vs disease[J]。Psychosom Med, 2013, 75(4): 335-349。DOI: 10。1097/ specialist sleep center management of obstructive sleep apnea and PSY。0b013e318291d798。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 521,
      "text": "zer CL, Antic NA, Rowland LS, et al。Primary care vs disease[J]。Psychosom Med, 2013, 75(4): 335-349。DOI: 10。1097/ specialist sleep center management of obstructive sleep apnea and PSY。0b013e318291d798。 daytime sleepiness and quality of life: a randomized trial[J]。JAMA, (cid:62)(cid:26)(cid:24)(cid:64)(cid:3) (cid:43)(cid:88)(cid:3445)(cid:80)(cid:68)(cid:81)(cid:3)(cid:45)(cid:38)(cid:15)(cid:3)(cid:48)(cid:68)(cid:86)(cid:87)(cid:85)(cid:82)(cid:80)(cid:68)(cid:88)(cid:85)(cid:82)(cid:3)(cid:38)(cid:36)(cid:15)(cid:3)(cid:37)(cid:72)(cid:68)(cid:70)(cid:75)(cid:3)(cid:54)(cid:53)(cid:15)(cid:3)(cid:72)(cid:87)(cid:3)(cid:68)(cid:79)(cid:17)(cid:3)(cid:38)(cid:82)(cid:79)(cid:79)(cid:68)(cid:69)(cid:82)(cid:85)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:70)(cid:68)(cid:85)(cid:72)(cid:3) 2013, 309(10): 997-1004。DOI: 10。1001/jama。2013。1823。for depression and anxiety disorders in patients with recent cardiac [68] Chung F, Abdullah HR, Liao P。STOP-Bang Questionnaire: a events: the Management of Sadness and Anxiety in Cardiology practical approach to screen for obstructive sleep apnea[J]。Chest, (MOSAIC) randomized clinical trial[J]。JAMA Intern Med, 2014, 2016, 149(3): 631-638。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 522,
      "text": "e Management of Sadness and Anxiety in Cardiology practical approach to screen for obstructive sleep apnea[J]。Chest, (MOSAIC) randomized clinical trial[J]。JAMA Intern Med, 2014, 2016, 149(3): 631-638。 DOI: 10。1378/chest。15-0903。174(6): 927-935。DOI: 10。1001/jamainternmed。2014。739。(cid:62)(cid:25)(cid:28)(cid:64)(cid:3) (cid:38)(cid:75)(cid:68)(cid:76)(cid:16)(cid:38)(cid:82)(cid:72)(cid:87)(cid:93)(cid:72)(cid:85)(cid:3)(cid:38)(cid:47)(cid:15)(cid:3)(cid:36)(cid:81)(cid:87)(cid:76)(cid:70)(cid:3)(cid:49)(cid:36)(cid:15)(cid:3)(cid:53)(cid:82)(cid:90)(cid:79)(cid:68)(cid:81)(cid:71)(cid:3)(cid:47)(cid:54)(cid:15)(cid:3)(cid:72)(cid:87)(cid:3)(cid:68)(cid:79)(cid:17)(cid:3)(cid:36)(cid:3)(cid:86)(cid:76)(cid:80)(cid:83)(cid:79)(cid:76)(cid:191)(cid:72)(cid:71)(cid:3)(cid:80)(cid:82)(cid:71)(cid:72)(cid:79)(cid:3) [76] Whalley B, Thompson DR, Taylor RS。Psychological interventions of screening questionnaire and home monitoring for obstructive for coronary heart disease: cochrane systematic review and meta- sleep apnoea in primary care[J]。Thorax, 2011, 66(3): 213-219。DOI: analysis[J]。Int J Behav Med, 2014, 21(1): 109-121。DOI: 10。1007/ 10。1136/thx。2010。152801。s12529-012-9282-x。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 523,
      "text": "systematic review and meta- sleep apnoea in primary care[J]。Thorax, 2011, 66(3): 213-219。DOI: analysis[J]。Int J Behav Med, 2014, 21(1): 109-121。DOI: 10。1007/ 10。1136/thx。2010。152801。s12529-012-9282-x。 [70] Tully PJ, Baker RA。Depression, anxiety, and cardiac morbidity (cid:62)(cid:26)(cid:26)(cid:64)(cid:3) (cid:54)(cid:87)(cid:72)(cid:90)(cid:68)(cid:85)(cid:87)(cid:3)(cid:45)(cid:38)(cid:15)(cid:3)(cid:51)(cid:72)(cid:85)(cid:78)(cid:76)(cid:81)(cid:86)(cid:3)(cid:36)(cid:45)(cid:15)(cid:3)(cid:38)(cid:68)(cid:79)(cid:79)(cid:68)(cid:75)(cid:68)(cid:81)(cid:3)(cid:38)(cid:48)(cid:17)(cid:3)(cid:40)(cid:3445)(cid:72)(cid:70)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:70)(cid:82)(cid:79)(cid:79)(cid:68)(cid:69)(cid:82)(cid:85)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:70)(cid:68)(cid:85)(cid:72)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3) outcomes after coronary artery bypass surgery: a contemporary and depression on risk of cardiovascular events: data from the IMPACT practical review[J]。J Geriatr Cardiol, 2012, 9(2): 197-208。DOI: 10。randomized controlled trial[J]。Psychosom Med, 2014, 76(1): 29-37。3724/SP。J。1263。2011。12221。DOI: 10。1097/PSY。0000000000000022。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 524,
      "text": " IMPACT practical review[J]。J Geriatr Cardiol, 2012, 9(2): 197-208。DOI: 10。randomized controlled trial[J]。Psychosom Med, 2014, 76(1): 29-37。3724/SP。J。1263。2011。12221。DOI: 10。1097/PSY。0000000000000022。 [71] Connerney I, Shapiro PA, McLaughlin JS, et al。Relation between （收稿日期: 2019-11-12） depression after coronary artery bypass surgery and 12-month （ 编辑: 曹洪红） ˝(cid:242)•‰˚(cid:253)(cid:190)(cid:221)。",
      "source": "1_2_冠状动脉旁路移植术后心脏康复专家共识.pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 525,
      "text": "中国介入心脏病学杂志2023年 11 月第31卷第 11期 Chin J Intervent Cardiol, November 2023, Vol 31, No。11  801   专家共识  单纯主动脉瓣反流经股动脉主动脉瓣置换 中国专家共识 2023 中国医师协会心血管内科医师分会结构性心脏病学组 【摘要】 经导管主动脉瓣置换术（TAVR）最初被应用于治疗主动脉瓣狭窄（AS），随后逐 渐拓展到主动脉瓣反流（AR）治疗领域。国内外学者探索使用已上市的经股动脉TAVR（TF-TAVR） 瓣膜以“超适应证”方式治疗AR患者，结果显示可作为外科手术高危患者的另一选择。但AR患 者相较于AS解剖结构、瓣膜选择、操作方式以及并发症有其不同的特点，总体上使用已上市的 TF-TAVR瓣膜治疗AR手术难度大，成功率较AS低。为了促进我国TF-TAVR治疗AR的安全、 规范、健康发展，为该技术的临床使用提供合规性支持和技术指导，中国医师协会心血管内科医师 分会结构性心脏病学组编写了该共识。执笔专家团队针对AR患者TF-TAVR临床实践中的重点 及难点，结合所检索到文献（截至2023年9月1日）的证据力度，梳理出9个核心问题并做出深入 分析，形成9个核心观点，涵盖适应证、瓣膜选择、术前评估、术中操作要点、并发症防治、术后管 理等方面。【关键词】 经导管主动脉瓣置换术； 主动脉瓣反流； 经股动脉 【中图分类号】 R54 Chinese expert consensus on trans-femoral transcatheter aortic valve replacement for pure aortic regurgitation 2023 Structural Heart Disease Group of Chinese College of Cardiovascular Physician Corresponding authors：ZHOU Da-xin，Email：zhou。daxin@zs-hospital。sh。cn；WU Yong-jian，Email： yongjianwu_nccd@163。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 526,
      "text": "itation 2023 Structural Heart Disease Group of Chinese College of Cardiovascular Physician Corresponding authors：ZHOU Da-xin，Email：zhou。daxin@zs-hospital。sh。cn；WU Yong-jian，Email： yongjianwu_nccd@163。 com 【Abstract】 Transcatheter aortic valve replacement （TAVR） was initially used to treat aortic stenosis （AS）， and gradually expanded to the field of aortic regurgitation （AR） treatment。Scholars world wide have explored the use of marketed transfemoral TAVR （TF-TAVR） valves in the treatment of AR patients in a “off-label” manner， and the results have shown that it can be another option for high-risk surgical patients。However， AR patients have different characteristics from AS in terms of anatomical structure， valve selection， operation methods， and complications。Overall， the procedure using TF-TAVR valves that have been marketed for treating AR is more difficult and has a lower success rate than AS。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 527,
      "text": "cture， valve selection， operation methods， and complications。Overall， the procedure using TF-TAVR valves that have been marketed for treating AR is more difficult and has a lower success rate than AS。 In order to promote the safe， standardized， and healthy development of TF-TAVR for AR in China， and to provide compliance support and technical guidance for the clinical use of this technology， the Structural Heart Disease Group of Chinese College of Cardiovascular Physician wrote this consensus。The writing expert team focused on the key and difficult points in the clinical practice of TF-TAVR in AR patients， combined with the evidence strength of the searched literature （as of September 1， 2023）， sorted out nine core issues and conducted in-depth analysis and formed nine core viewpoints， covering indications， valve selection， preoperative evaluation， intraoperative operation points， complication prevention and treatment， postoperative management， and other aspects。【Key words】 Transcatheter aortic valve replacement； Aortic regurgitation； Transfemoral DOI： 10。3969/j。issn。1004-8812。2023。11。001 通信作者：周达新，Email：zhou。daxin@zs-hospital。sh。cn；吴永健，Email：yongjianwu_nccd@163。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 528,
      "text": "y words】 Transcatheter aortic valve replacement； Aortic regurgitation； Transfemoral DOI： 10。3969/j。issn。1004-8812。2023。11。001 通信作者：周达新，Email：zhou。daxin@zs-hospital。sh。cn；吴永健，Email：yongjianwu_nccd@163。 com  802  中国介入心脏病学杂志2023年 11 月第31卷第 11 期 Chin J Intervent Cardiol, November 2023, Vol 31, No。11 经导管主动脉瓣置换术（transcatheter aortic 心动图数据库资料显示，AR的检出率比AS高［24］。valve replacement，TAVR）作为一种安全、有效的 China-DVD的研究（NCT02865798）也显示，在中国 微创介入治疗方式，在治疗主动脉瓣狭窄（aortic 就医人群中，AR的检出率比AS高［25］。浙江大学医学 stenosis，AS）方面已经成为高龄患者的一线治疗手 院附属第二医院的一项基于该医院就诊患者的超声 段［1-4］。TAVR最初被应用于治疗AS，随后逐渐拓展 心动图数据库研究显示，AR与AS检出率相近［26］。到主动脉瓣反流（aortic regurgitation，AR）治疗领 AR可由原发性瓣叶疾病导致，亦可由主动脉根部及 域。研究显示使用经心尖途径TAVR（TA-TAVR）治 升主动脉结构异常引起。欧洲心脏瓣膜病观察性注 疗外科手术高危的AR患者是安全、有效的［5-6］，已 册研究Ⅱ结果显示，退行性变占AR病因的2/3，其他 有器械在我国上市和临床应用，并且得到我国专家 原因还包括感染性和风湿性［27］。AR患者可合并AS， 共识的推荐［7］。经股动脉TAVR（TF-TAVR）较TA- 多见于风湿性及退行性疾病。对于合并AS的AR患 TAVR创伤更小，安全性更高，死亡及并发症发生率 者，其狭窄的瓣口可为TAVR瓣膜提供锚定，这些患 更低［8-11］，我国尚无具有AR适应证的上市TF-TAVR 者行TAVR的技术可行性及安全性高。本共识讨论 器械。国内外学者探索使用已上市的TF-TAVR瓣膜 的是单纯主动脉瓣反流（pure aortic regurgitation， 以“超适应证”方式治疗AR患者，结果显示可作为 PAR）的患者，将PAR定义为：中重度或者重度AR， 外科手术高危患者的另一选择［12-19］。但AR患者相较 主动脉瓣口面积≥2。5 cm2［12］。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 529,
      "text": "证的上市TF-TAVR 者行TAVR的技术可行性及安全性高。本共识讨论 器械。国内外学者探索使用已上市的TF-TAVR瓣膜 的是单纯主动脉瓣反流（pure aortic regurgitation， 以“超适应证”方式治疗AR患者，结果显示可作为 PAR）的患者，将PAR定义为：中重度或者重度AR， 外科手术高危患者的另一选择［12-19］。但AR患者相较 主动脉瓣口面积≥2。5 cm2［12］。 于AS解剖结构、瓣膜选择、操作方式以及并发症有 其不同的特点，总体上使用已上市的TF-TAVR瓣膜 核心观点1：我国目前尚无确切AR患病率的流行 治疗AR手术难度大，成功率较AS低［20-22］。为了促 病学数据，但现有证据显示其流行病学规律不同于西 进我国TF-TAVR治疗AR的安全、规范、健康发展， 方，国内PAR可能更常见（一般推荐，支持文献23-26）。为该技术的临床使用提供合规性支持和技术指导， 22 PAR的干预指征及治疗现状 中国医师协会心血管内科医师分会结构性心脏病学 组编写了该共识。2021年欧洲心脏病学会瓣膜病管理指南［3］对于 执笔专家团队针对AR患者TF-TAVR临床实 症状性重度AR，无论左心室功能如何，推荐外科手 践中的重点及难点，结合所检索到文献（截至2023 术治疗（Ⅰ类推荐，B级证据）；对于无症状重度AR， 年9月1日）的证据力度，梳理出9个核心问题并做 若左心室收缩末期内径＞50 mm或左心室收缩末期内 出深入分析，形成9个核心观点。推荐等级参照 径指数＞25 mm/m2（小体格患者） 或左心室射血分 GRADE（Grading of Recommendations，Assess， 数≤50%，推荐手术治疗（Ⅰ类推荐，B级证据）；无症 Development and Evaluation）证据质量分级与定 状重度AR伴左心室收缩末期内径指数＞20 mm/m2（小 义：强推荐，有证据证明和已达成共识该治疗或操作 体格患者）或左心室射血分数≤55%且外科手术低风 有益、有用、有效，推荐或建议应用；一般推荐，对 险的无症状患者可考虑手术（Ⅱb类推荐，C级证据）。于该治疗或操作的有用/有效性存在矛盾的证据或 该指南对AR的外科手术推荐更早期、更积极， 意见分歧，但更支持有用/有效性的证据/意见；不推 同时提出对于重度AR，且外科手术禁忌或高危的患 荐，有证据证明和已达成共识该治疗或操作无用/无 者，可在经验丰富的中心行TAVR治疗，但没有给出 效，并且在某些情况下是有害的，不推荐应用。所有 具体推荐级别及证据。《经导管主动脉瓣置换术中 核心观点均列出推荐等级及支持文献， 并由核心专 国专家共识（2020更新版）》［1］中提及，使用国产的 家团队进行投票，≥90%专家同意者列为有效推荐。J-Valve瓣膜对PAR行TA-TAVR是安全有效的。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 530,
      "text": "荐，有证据证明和已达成共识该治疗或操作无用/无 者，可在经验丰富的中心行TAVR治疗，但没有给出 效，并且在某些情况下是有害的，不推荐应用。所有 具体推荐级别及证据。《经导管主动脉瓣置换术中 核心观点均列出推荐等级及支持文献， 并由核心专 国专家共识（2020更新版）》［1］中提及，使用国产的 家团队进行投票，≥90%专家同意者列为有效推荐。J-Valve瓣膜对PAR行TA-TAVR是安全有效的。 目前 国内、外有部分中心尝试使用自膨胀式瓣膜对PAR 11 AR的流行病学 进行TAVR治疗，积累了一定的临床证据。《中国经 美国一项以社区人群为基础、调查中度或重度 导管主动脉瓣置入术（TAVI）多学科专家共识》［7］ 瓣膜疾病的研究显示，AR的患病率远低于AS的患病 建议PAR的TAVR适应证：（1）需要行手术治疗的症 率：65~74岁分别为0。6%与1。4%，≥75岁分别为1。7% 状性重度AR；（2）患者传统外科手术风险为禁忌、 与4。6%［23］。在我国，目前尚无确切AR患病率的流 高危或中危；（3）AR解除后预期生存期＞１年。该 行病学数据。复旦大学附属中山医院一项基于超声 建议是基于使用已上市的瓣膜行TA-TAVR。中国介入心脏病学杂志2023年 11 月第31卷第 11期 Chin J Intervent Cardiol, November 2023, Vol 31, No。11  803  部分PAR患者存在瓣环大、左心室流出道（left 式瓣膜行TF-TAVR的适应证建议（需同时满足以 ventricular outflow tract，LVOT）扩张、无钙化狭窄 下条件）：（1）中重度或者重度PAR，具有手术干 的瓣上锚定区域、缺乏LVOT和窦管交界的锚定解剖 预指征（有AR相关症状或者无症状但伴有左心室 结构，瓣膜无法承受舒张期强大的血流压力，使得 收缩末期内径指数＞25 mm/m2或左心室射血分 TAVR瓣膜锚定困难，容易移位。其手术成功率低于 数≤50%）；（2）外科手术禁忌或高危，具体由心脏 AS患者，瓣中瓣置入率、瓣周漏、起搏器植入率、30 d 团队判定；（3）主动脉根部及入路解剖合适；（4） 死亡率均高于AS患者［12-22］。虽然研究显示使用目前 在经验丰富的中心实施或由成熟术者带教完成（中 瓣膜以“超适应证”方式行TF-TAVR治疗AR是可行 心或术者年TAVR完成数＞50台，有心外科备台）； 的，但仅能在解剖合适的患者中应用，具有可回收功 （5）患者纠正AR后预期生存期超过1年。能的二代瓣膜较一代瓣膜的成功率有明显增加［22，28］。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 531,
      "text": "判定；（3）主动脉根部及入路解剖合适；（4） 死亡率均高于AS患者［12-22］。虽然研究显示使用目前 在经验丰富的中心实施或由成熟术者带教完成（中 瓣膜以“超适应证”方式行TF-TAVR治疗AR是可行 心或术者年TAVR完成数＞50台，有心外科备台）； 的，但仅能在解剖合适的患者中应用，具有可回收功 （5）患者纠正AR后预期生存期超过1年。能的二代瓣膜较一代瓣膜的成功率有明显增加［22，28］。 建议由心脏团队结合患者手术指征、外科手术 自膨胀式瓣膜置入后若发生移位，可以选择瓣中瓣的 风险、TF-TAVR的解剖分层、临床医疗条件、患者 方式进行补救，而球囊扩张式瓣膜一旦瓣膜移位，常 目前病况和意愿等多方面因素去综合决策。鉴于目 需要外科手术，风险更大。虽然有个别研究探讨了球 前器械并非专用于AR治疗器械，仍不够完善，应该 囊扩张式瓣膜对外科手术高危AR的可行性，但其瓣 准确地评估AR量，选择合适的手术时机。对于反流 膜移位发生率（3。5%~10。8%）高［29-30］。德国TAVR注 量在中重度及以上且有症状或左心室形态和功能明 册研究显示，TAVR治疗AR，自膨胀式瓣膜相对于球 显改变者（见适应证要求1）才具有手术指征［2］。对 囊扩张式瓣膜有更低的住院死亡率（2。41%比5。17%， 于生物瓣毁损导致的AR，TAVR安全性及有效性良 P=0。039）［31］。数项研究显示，在外科手术高危的AR 好［36-38］，之前《经导管主动脉瓣置换术中国专家共 患者中，TF-TAVR（自膨胀式瓣膜）的疗效不劣于外科 识（2020更新版）》已将外科术后人工生物瓣膜衰 手术（德国注册研究显示要优于外科手术）［31-33］，可 败作为绝对适应证［1］，不在本共识的讨论之内。作为外科手术高危AR患者的一种治疗选择。因此，本 共识更倾向于选择自膨胀式瓣膜。本共识对于PAR患 核心观点4：PAR患者应用我国上市的自膨胀 者的TF-TAVR仅限于使用自膨胀式瓣膜。式瓣膜行TF-TAVR的适应证如下。（1）中重度或 随着器械的改进，在新一代的瓣膜TF-TAVR 者重度AR，具有手术干预指征；（2）外科手术禁 中研制出以PAR为主要适应证的瓣膜，此类瓣膜利 忌或高危； （3）解剖合适；（4）在经验丰富的中心 用“定位件”来锚定瓣膜 ，防止人工瓣膜移位，手 由成熟团队实施；（5）患者纠正AR后预期生存期 术成功率达95%以上［34-35］。目前处于上市前的确证 超过1年（一般推荐，支持文献12-22，31-33）。临床试验阶段。44 术前影像学评估及解剖适应证 核心观点2：对PAR患者行TF-TAVR，“超适 44。11 超声心动图 应证”应用时推荐使用自膨胀式瓣膜，选择可回收 超声心动图在描述瓣膜解剖、量化AR、评估 的瓣膜（强推荐，支持文献12-22，28-33）。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 532,
      "text": "）患者纠正AR后预期生存期 术成功率达95%以上［34-35］。目前处于上市前的确证 超过1年（一般推荐，支持文献12-22，31-33）。临床试验阶段。44 术前影像学评估及解剖适应证 核心观点2：对PAR患者行TF-TAVR，“超适 44。11 超声心动图 应证”应用时推荐使用自膨胀式瓣膜，选择可回收 超声心动图在描述瓣膜解剖、量化AR、评估 的瓣膜（强推荐，支持文献12-22，28-33）。 发病机制、评估心脏大小及功能等方面有不可替代 核心观点3：外科手术高危、解剖合适的PAR， 的作用，AR的量化需结合定性、定量及半定量等参 应用自膨胀式瓣膜行TF-TAVR，其疗效不劣于外 数进行综合考虑［3］。术前应该准确客观地评估反 科手术，是可行的（一般推荐，支持文献31-33）。流量及反流程度，注意反流量随着血压改变的动态 变化。当超声心动图检查存在疑问时可行心脏磁共 33 适应证建议 振检查，有助于对反流进行量化。超声心动图可以 目前指南推荐需要手术干预但外科手术禁忌 对主动脉根部解剖及主动脉瓣形态进行测量，作为 或高危的重度PAR患者，可在经验丰富的中心行 瓣膜选择的参考。TAVR治疗。我国目前还没有以AR为适应证的TF- 44。22 CT血管造影（computed tomography TAVR上市瓣膜。对于无法进行外科手术的PAR angiography，CTA）评估 患者，应用自膨胀式瓣膜进行TF-TAVR是一个可 CTA是评估TF-TAVR解剖结构，预判术中风 行的选择。因此，PAR患者应用我国上市的自膨胀 险，指导TF-TAVR手术策略制定的金标准［39］。需  804  中国介入心脏病学杂志2023年 11 月第31卷第 11 期 Chin J Intervent Cardiol, November 2023, Vol 31, No。11 要多切面、精细地评估可能提供瓣膜锚定力的区 都医科大学附属北京安贞医院团队提出的解剖分型 域，需要对整体路径血管和冠状动脉阻塞风险进行 来预测不同类型的手术成功率［14-15］，复旦大学附属 评估。建议术者及其手术团队、影像科医师对患者 中山医院结构团队提出以瓣环为中心的解剖适应证 术前CTA进行分析。推荐［40］并得到南京市第一医院团队研究的支持［41］， CTA应用回顾性心电门控扫描，扫描范围从 这些理论的可靠性有待于进一步验证。理想的主动 颈内外动脉分叉以上2 cm到股深浅动脉分叉以下 脉根部解剖包括：瓣环较小（周长＜80 mm），升主 2 cm。为更准确地评估LVOT和瓣环情况，测量主 动脉（直径＜40 mm）及窦管交界不宽，主动脉瓣叶 动脉根部各平面时建议选用收缩末期时相（多时 增厚、钙化或粘连，LVOT较小或者室间隔有突出结 相对比后寻找瓣环最大的收缩期时相）。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 533,
      "text": "控扫描，扫描范围从 这些理论的可靠性有待于进一步验证。理想的主动 颈内外动脉分叉以上2 cm到股深浅动脉分叉以下 脉根部解剖包括：瓣环较小（周长＜80 mm），升主 2 cm。为更准确地评估LVOT和瓣环情况，测量主 动脉（直径＜40 mm）及窦管交界不宽，主动脉瓣叶 动脉根部各平面时建议选用收缩末期时相（多时 增厚、钙化或粘连，LVOT较小或者室间隔有突出结 相对比后寻找瓣环最大的收缩期时相）。 重点分析 构等；含有上述2个以上条件的为理想解剖。不利解 可能为人工瓣膜提供锚定力的对象，包括瓣环和 剖包括：瓣环过大（周长＞88 mm），LVOT过宽，升 LVOT区域，窦管交界和升主动脉区域，瓣叶是否 主动脉过宽（直径＞45 mm），横位心（主动脉瓣环 增厚、粘连、钙化，以及瓣环平面的角度；同时评 成角＞60），冠状动脉阻塞风险高等；含有以上1个 估风险，制定完整的手术策略（表1）。需要注意的 及以上的为挑战性解剖。同时，还需要对患者入路情 是，由于主动脉根部角度不同，自膨胀式瓣膜瓣架 况进行评估。与主动脉根部结构的接触面则不同，建议以瓣环平 面为参照，平行于瓣环平面定义其他结构平面，而 核心观点5：建议术前采用CTA评估患者的解 非以垂直主动脉根部中轴线来确定结构平面。具 剖，根据CTA分析结果判断患者是否适合手术，并 体术前评估参数及注意事项见表1。选择合适的瓣膜型号。主动脉根部解剖评估要素 44。33 依据CTA的TF-TAVR解剖适应证 包括主动脉瓣环、LVOT、窦管交界、升主动脉、主 术前依据CTA对主动脉根部、血管路径解剖学 动脉瓣环成角及瓣叶、冠状动脉开口等。同时，还 结构进行准确、充分评估。究竟哪些患者解剖更适 需要对患者入路进行评估（强推荐，支持文献12， 合，目前研究证据有限，多是基于经验性的总结。首 14-15，41）。表表11 PAR患者应用自膨胀式瓣膜行TF-TAVR 的术前CTA评估 TTaabbllee 11 Preoperative CTA evaluation of TF-TAVR using self expanding valves in PAR patients AA和LVOT区域 AA 主动脉窦最低点所在平面：测量周长、面积、最长直径、最短直径、平均直径a 平行于AA平面向左心室方向下移4~8 mm，每间隔2 mm测量该平面的周长、面积、最长直径、最短直径、平均直径a； LVOT 在长轴切面观察室间隔有无突出点及台阶。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 534,
      "text": "TA evaluation of TF-TAVR using self expanding valves in PAR patients AA和LVOT区域 AA 主动脉窦最低点所在平面：测量周长、面积、最长直径、最短直径、平均直径a 平行于AA平面向左心室方向下移4~8 mm，每间隔2 mm测量该平面的周长、面积、最长直径、最短直径、平均直径a； LVOT 在长轴切面观察室间隔有无突出点及台阶。 （1）平行于AA平面向升主动脉方向上移4 mm，每间隔2 mm测量该平面的周长、面积、最长直径、最短直径、平均直径a； 瓣上结构 （2）若为二叶式主动脉瓣，平行于AA平面向升主动脉方向上移至瓣上开口最小平面，每间隔2 mm测量该平面的周长、 面积、最长直径、最短直径、平均直径a STJ和AAO区域 STJ 平行于AA平面向升主动脉方向上移至所有的主动脉窦消失的平面，测量周长、面积、最长直径、最短直径、平均直径a AAO 平行于AA平面向升主动脉方向上移40 mm，测量该平面周长、面积、最长直径、最短直径、平均直径a 瓣叶情况 类型 二叶瓣（窦融合情况）或三叶瓣 形态 有无增厚或钙化或交界粘连 赘生物 有无血栓、菌栓或其他 主动脉窦和冠状动脉 主动脉窦 观察有无窦扩张或窦瘤形成，测量各个窦部直径 冠状动脉高度 测量冠状动脉开口到AA平面的垂直距离 主动脉根部角度 角度 测量AA平面与水平面的夹角 注：a，平均直径=周长/3。14；PAR，单纯主动脉瓣反流；TF-TAVR， 经股动脉导管主动脉瓣置换术；CTA，CT血管造影；AA，主动脉瓣环；LVOT， 左心室流出道；STJ，窦管交界； AAO，升主动脉。中国介入心脏病学杂志2023年 11 月第31卷第 11期 Chin J Intervent Cardiol, November 2023, Vol 31, No。11  805  55 操作规范 投照角度［46］，使三维解剖最低窦的最低点显示在X 线二维图像时，也同样是最低点，并且不被其他根部 55。11 场地设施及人员配备 结构（包括LVOT）影像所遮挡。也可以采用窦重叠 建议在心脏杂交手术室或导管室进行，应具备 法（cusp overlapping）。将辅路进入的猪尾导管放置 心导管介入手术和心外科手术条件［42］。要求建立 于解剖最低窦（通常为无冠窦）的最低点作为位置参 多学科心脏团队，具体要求见《经导管主动脉瓣置 照。将DSA调整到术前CT确定的瓣膜释放角度。术 换术团队建设及运行规范中国专家建议》［43］，并强 者通过先推送输送系统进行瓣膜定位调整，并保持 调有资质的心外科医师和体外循环团队备台，体外 超硬导丝与左心室室壁有一定的相互作用力，以此 循环或体外膜肺氧合（extracorporeal membrane 来增加整个系统的稳定性及调整瓣膜位置。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 535,
      "text": "位置参 多学科心脏团队，具体要求见《经导管主动脉瓣置 照。将DSA调整到术前CT确定的瓣膜释放角度。术 换术团队建设及运行规范中国专家建议》［43］，并强 者通过先推送输送系统进行瓣膜定位调整，并保持 调有资质的心外科医师和体外循环团队备台，体外 超硬导丝与左心室室壁有一定的相互作用力，以此 循环或体外膜肺氧合（extracorporeal membrane 来增加整个系统的稳定性及调整瓣膜位置。 oxygenation，ECMO）等循环支持设备要求能快速 释放瓣膜过程中建议快速心室起搏（频率一 获得，必要时循环辅助装置在运行状态下准备。般在160~200次/分），收缩压稳定在≤60 mmHg 55。22 麻醉方式 （1 mmHg=0。133 kPa）。起始稍慢释放，根据主动脉 对于大部分PAR的患者，由于患者病情较危 根部造影微调输送系统位置，一旦确认位置合适并 重，手术风险较大，有中转外科手术的可能，并且 释放过程需要呼吸控制，因此建议在全身麻醉下， 且瓣膜即将锚定，快速释放瓣膜到可回收位置，过 由经食管超声心动图和数字减影血管造影（digital 程中若瓣膜发生移位、位置不满意，应在可回收位 subtraction angiography，DSA）进行术中监测并 置临界点前停止释放瓣膜，进行回收再释放。若患 引导完成自膨胀式瓣膜的TF-TAVR。某些解剖条 者血压偏低，应及时停止快速起搏，恢复患者呼吸， 件较理想，预估手术难度低，在经验丰富的中心可 待血压、心率、氧饱和度等生命体征稳定后再重新 以尝试局部麻醉或局部麻醉联合静脉镇静麻醉， 开始准备第二次定位与释放。注意瓣膜回收后可能 在经胸超声心动图和DSA引导下进行。会出现形态变化，控制瓣膜回收次数，不要超过推 55。33 瓣膜的选择 荐回收次数。在选择自膨胀式瓣膜的尺寸方面，相较于AS， 55。66 瓣膜释放后的评估 PAR患者往往需要扩大型号的瓣膜来获得更大的径 有创血流动力学：测量升主动脉和左心室的压 向支撑力，从而增加锚定力。建议人工瓣膜的直径 力，计算跨瓣压差和ARI。超声心动图评估瓣膜深 （周长）超大比率在15%~30%。优先选择具有可回 度、瓣周漏和瓣中反流、瓣膜形态、跨瓣压差、左心 收功能瓣膜。室功能、冠状动脉、二尖瓣、心包以及主动脉根部、 55。44 跨瓣和有创血流动力学评估 主动脉弓和降主动脉情况。对于置入较深的瓣膜， 大部分患者跨瓣容易，可直接使用猪尾导管配 超声心动图除了准确评估瓣周漏的程度以外，需要 合普通J形导丝进行跨瓣，也可使用Amplatzer L 仔细评估二尖瓣前叶是否受到人工瓣膜瓣架的影 等指引导管配合直头导丝或亲水涂层直头导丝来 响，观察二尖瓣与瓣架的毗邻关系，二尖瓣瓣叶和 完成。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 536,
      "text": "、二尖瓣、心包以及主动脉根部、 55。44 跨瓣和有创血流动力学评估 主动脉弓和降主动脉情况。对于置入较深的瓣膜， 大部分患者跨瓣容易，可直接使用猪尾导管配 超声心动图除了准确评估瓣周漏的程度以外，需要 合普通J形导丝进行跨瓣，也可使用Amplatzer L 仔细评估二尖瓣前叶是否受到人工瓣膜瓣架的影 等指引导管配合直头导丝或亲水涂层直头导丝来 响，观察二尖瓣与瓣架的毗邻关系，二尖瓣瓣叶和 完成。 跨瓣成功后记录主动脉血压、左心室压力， 瓣下结构（如腱索）是否受损，以及二尖瓣启闭情况 计算平均跨瓣压差和AR指数（aortic regurgitation 和跨瓣压差。主动脉根部造影评估主动脉瓣残余反 index，ARI），ARI=（主动脉舒张压–左心室舒张末 流、冠状动脉情况和排除主动脉夹层。对于走形迂 期压力）/主动脉收缩压100%。同时应行主动脉根 曲、过弓或跨瓣困难、主动脉根部明显扩张和横位 部造影，评估反流程度。评估结束后，在超硬导丝的 心的患者，术后造影除了验证超声心动图评估的残 支撑和引导下送入输送系统。横位心的患者输送系 余反流结果外，还需注意血管路径的情况，尤其是 统跨瓣存在困难，尤其是使用可回收功能的二代瓣 夹层。对比手术前后心电图，结合术中心电图变化和 膜，且AR患者常合并升主动脉扩张，容易出现夹层 瓣膜置入情况来判断是否留置临时起搏器。或破裂［44-45］，建议使用抓捕器改善输送系统与主动 脉根部的同轴性，协助完成跨瓣。在整个瓣膜输送过 核心观点6：PAR患者应用自膨胀式瓣膜行 程中，切勿使用暴力。TAVR，术中应以高速心室起搏辅助，快速释放瓣膜 55。55 瓣膜的释放 到可回收位置，然后根据情况选择回收或完全释放 建议采用“无冠窦最低法”作为释放时的DSA （一般推荐，支持文献14-15，40）。806  中国介入心脏病学杂志2023年 11 月第31卷第 11 期 Chin J Intervent Cardiol, November 2023, Vol 31, No。11 66 并发症的防治 久性起搏器（permanent pacemaker implantation， PPM）植入。PPM的主要危险因素有已经存在的右 本共识AR患者TAVR并发症相关定义参 束支传导阻滞、植入较深（＞6 mm）、选择的瓣膜直 照2021年瓣膜学术研究联盟（Valve Academic 径过大、LVOT钙化等［50］。PAR患者，由于瓣膜选择 Research Consortium，VARC）发布的TAVR临床终 过大、瓣膜经常置入过深、瓣上没有限制作用，因此 点标准定义更新（VARC-3）［47］。PAR患者应用自膨 心脏传导阻滞发生率比AS更高，起搏器植入率也更 胀式瓣膜行TF-TAVR，并发症谱和发生因素与AS 高［12， 22］。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 537,
      "text": "术研究联盟（Valve Academic 径过大、LVOT钙化等［50］。PAR患者，由于瓣膜选择 Research Consortium，VARC）发布的TAVR临床终 过大、瓣膜经常置入过深、瓣上没有限制作用，因此 点标准定义更新（VARC-3）［47］。PAR患者应用自膨 心脏传导阻滞发生率比AS更高，起搏器植入率也更 胀式瓣膜行TF-TAVR，并发症谱和发生因素与AS 高［12， 22］。 因此，术后更需要心电评估和监测，适当 患者有所不同，其中相对常见的并发症防治如下： 延长临时起搏器留置时间及心电监测时间。66。11 瓣膜位置不良或移位 66。44 血管并发症 瓣膜位置不良或移位是AR患者行TAVR最重 血管并发症包括从穿刺点到主动脉根部所有路径 要的并发症之一。AR患者因锚定力弱，进行自膨胀 血管发生的医源性损伤。PAR患者，因其常合并升主动 式瓣膜TF-TAVR治疗时容易出现瓣膜位置不良或 脉扩张，此类血管管壁常薄弱，更易发生升主动脉夹 移位，包括：（1）瓣膜下滑导致置入过深，一般在 层［44-45］，操作应更谨慎，以改善输送系统与血管同轴性 释放后不久即可发生；（2）瓣膜置入位置过高，部 为主要手段寻求平顺通过，切忌暴力。加强术中监测， 分或完全位于瓣环平面以上，移位到主动脉窦上； 超声心动图和主动脉造影时均可随时查探升主动脉、 （3）迟发的瓣膜移位，患者回到病房之后发生瓣 主动脉弓和降主动脉近段情况。一旦发生升主动脉夹 膜移位，多为瓣膜向下移位。这也是AR患者TAVR 手术成功率较低、瓣中瓣概率较高的最主要原 层，往往需要外科干预。其他路径血管（股动脉、髂动 因［12，22］。可回收自膨胀式瓣膜在完全释放之前，可有 脉、腹主动脉）一旦发生夹层，首先评估严重程度，采 限次地回收瓣膜进行重新定位释放，一定程度上避 取保守治疗还是手术干预，心脏团队中的心外科或血 免了术者单次操作失误导致的瓣膜位置不良，有助于 管外科医师可协助评估，若需要手术干预，可选择外周 提高手术成功率［22，28］。对于术中发生的瓣膜置入过 血管球囊封堵、覆膜支架置入或开放手术处理。深，首先是评估TAVR的效果，主要参考瓣周漏和二 66。55 其他并发症 尖瓣的情况。瓣周漏中度及以上，二尖瓣功能不受影 其他的并发症，包括冠状动脉阻塞、脑卒中、 响，采用瓣中瓣处理。若影响了二尖瓣，可谨慎尝试 循环崩溃、出血、血栓形成、栓塞、急性肾损伤等。球囊、第二瓣膜或者圈套器拖拽等将瓣膜上拉［40］， 参照AS的TAVR处理［1-2］。应注意动作轻柔，避免主动脉夹层等并发症发生。若 上述措施失败或者不适合，则需要紧急外科干预。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 538,
      "text": "考瓣周漏和二 66。55 其他并发症 尖瓣的情况。瓣周漏中度及以上，二尖瓣功能不受影 其他的并发症，包括冠状动脉阻塞、脑卒中、 响，采用瓣中瓣处理。若影响了二尖瓣，可谨慎尝试 循环崩溃、出血、血栓形成、栓塞、急性肾损伤等。球囊、第二瓣膜或者圈套器拖拽等将瓣膜上拉［40］， 参照AS的TAVR处理［1-2］。应注意动作轻柔，避免主动脉夹层等并发症发生。若 上述措施失败或者不适合，则需要紧急外科干预。 术 核心观点7：PAR患者应用自膨胀式瓣膜行 中发生的瓣膜置入位置过高，需要瓣中瓣置入，可将 TAVR，术后应该重点监测瓣膜移位、传导阻滞的 瓣膜推送到窦底再置入第二个瓣膜，但需注意冠状 发生（强推荐，支持文献12，21，22，41）。动脉阻塞风险［48］。由于术后有迟发的瓣膜移位可能， 77 术后管理 建议复查超声来追踪瓣膜位置和功能情况。发现术 后移位，结合患者生命体征、瓣膜目前位置和对周围 近年来，在TAVR术后抗栓方面有很多的高质 结构的影响选择再次TAVR或外科干预。量临床研究涌现，其结果也推动了指南的更新。但 66。22 瓣周漏 是，这些证据均是来自于治疗AS患者的经验，对于 AR患者的瓣周漏病因绝大部分来源于瓣膜位 PAR患者是否有别于AS患者尚未可知。参考最新心 置不良，包括置入过深或过高。在瓣膜完全释放以 脏瓣膜病管理指南［3-4］和TAVR术后抗栓共识［51］，对 后，从血流动力学和影像学两方面综合评估瓣膜位 TAVR术后的抗栓策略推荐为：（1）存在其他抗凝指 置和瓣周漏程度［49］，对需要处理的中度以上瓣周 征的患者，单纯口服抗凝药物（oral anticoagulant， 漏，在不影响周围结构（二尖瓣、冠状动脉和升主 OAC）治疗终身，若3个月内有经皮冠状动脉介入治 动脉）的前提下，建议行瓣中瓣置入。疗（percutaneous coronary intervention，PCI）史，予 66。33 传导阻滞 以OAC联合一种抗血小板药物（single antiplatelet 心脏传导阻滞是TAVR最常见的并发症，其中 therapy， SAPT）治疗至PCI术后6个月，之后单纯 高度房室传导阻滞和完全性心脏传导阻滞需要永 OAC终身；（2）不存在其他抗凝指征的患者，SAPT 中国介入心脏病学杂志2023年 11 月第31卷第 11期 Chin J Intervent Cardiol, November 2023, Vol 31, No。11  807  终身，若3个月内有PCI史，予以双联抗血小板药物至 属第二医院），葛均波（复旦大学附属中山医院） PCI术后6个月，之后SAPT终身。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 539,
      "text": "滞和完全性心脏传导阻滞需要永 OAC终身；（2）不存在其他抗凝指征的患者，SAPT 中国介入心脏病学杂志2023年 11 月第31卷第 11期 Chin J Intervent Cardiol, November 2023, Vol 31, No。11  807  终身，若3个月内有PCI史，予以双联抗血小板药物至 属第二医院），葛均波（复旦大学附属中山医院） PCI术后6个月，之后SAPT终身。 通常情况下，患者对慢性AR的耐受性较好，出 参与专家（按姓氏汉语拼音排序）：安健（山西省心 现症状时往往心脏储备功能很差，常有左心室扩大 血管病医院），白明（兰州大学第一医院），陈莎莎（复 心功能下降，患者左心收缩功能的恢复往往较慢， 旦大学附属中山医院），陈韵岱（中国人民解放军总 部分患者术后左心室重构无法逆转，建议术前加强 医院第一医学中心），方军（福建医科大学附属协和医 评估及与患者及家属充分告知［52-54］。建议术后加 院），方臻飞（中南大学湘雅二医院），冯沅（四川大学 强指南推荐的标准药物特别是可改善预后的药物。华西医院），傅国胜（浙江大学医学院附属邵逸夫医 存在心脏房室传导阻滞需要植入起搏器者，推荐希 院），郭延松（福建省立医院），韩克（西安交通大学 氏束起搏或左束支起搏等生理性起搏方式［55-56］。第一附属医院），何奔（上海市胸科医院），江磊（青 对于有左束支传导阻滞者，若心功能持续不能恢 岛大学附属医院），姜正明（首都医科大学附属北京安 复，可以考虑行心脏再同步化治疗［57］。建议术后1 贞医院），晋军（中国人民解放军陆军军医大学第二附 个月（必要时3个月）、6个月、12个月之后每年对患 属医院），孔祥清（江苏省人民医院），李飞（中国人民 者进行随访，随访内容包括患者症状、不良事件、 解放军空军军医大学第一附属医院），李捷（广东省人 生活质量评分及用药情况等，随访的检查包括超声 民医院），李妍（中国人民解放军空军军医大学第一附 心动图、心电图及相关的生化检查。属医院），刘长福（中国人民解放军总医院第一医学中 心），刘巍（北京积水潭医院），陆方林（上海市第一 核心观点8：目前推荐PAR患者使用自膨胀式 人民医院），马根山（东南大学附属中大医院），马为 瓣膜行TAVR，术后抗栓方案参照AS患者的TAVR （北京大学第一医院），潘湘斌（中国医学科学院阜外 （一般推荐，专家观点，无文献支持）。医院），彭小平（南昌大学第一附属医院），宋治远（陆 核心观点9：PAR患者TAVR术后，应该加强指南 军军医大学第一附属医院），王斌（厦门大学附属心血 建议的抗心力衰竭治疗，特别是逆转心肌重构的药 管病医院），王圣（阜外华中心血管病医院），王震（河 物治疗及生理性起搏（一般推荐，支持文献52-57）。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 540,
      "text": "的TAVR （北京大学第一医院），潘湘斌（中国医学科学院阜外 （一般推荐，专家观点，无文献支持）。医院），彭小平（南昌大学第一附属医院），宋治远（陆 核心观点9：PAR患者TAVR术后，应该加强指南 军军医大学第一附属医院），王斌（厦门大学附属心血 建议的抗心力衰竭治疗，特别是逆转心肌重构的药 管病医院），王圣（阜外华中心血管病医院），王震（河 物治疗及生理性起搏（一般推荐，支持文献52-57）。 北医科大学第一医院），吴延庆（南昌大学第二附属 医院），伍伟锋（广西医科大学第一附属医院），徐健 88 展望 （安徽省立医院），徐凯（中国人民解放军北部战区总 现有的经验及研究显示，应用我国已上市的自膨 医院），杨剑（中国人民解放军空军军医大学第一附属 胀式瓣膜对解剖合适的PAR患者行TF-TAVR安全、有 医院），杨毅宁（新疆维吾尔自治区人民医院），于波 效。然而，由于缺乏随机对照研究，必然存在一些不 （哈尔滨医科大学附属第二医院），袁义强（河南省胸 足之处。呼吁相关学者进一步探索，从而惠及更多患 科医院），张戈军（中国医学科学院阜外医院），张海 者。同时，期待经股带瓣膜锚定装置的TAVR瓣膜早日 波（首都医科大学附属北京安贞医院），张龙岩（武汉 获批上市，进一步提高TF-TAVR的安全性和有效性。亚洲心脏病医院），张瑞岩（上海交通大学医学院附属 瑞金医院），张玉顺（西安交通大学第一附属医院）， 核心专家：潘文志（复旦大学附属中山医院），宋光 张志辉（陆军军医大学第一附属医院），赵仙先（中国 远（首都医科大学附属北京安贞医院），周达新（复 人民解放军海军军医大学第一附属医院），周玉杰（首 旦大学附属中山医院），吴永健（中国医学科学院阜 都医科大学附属北京安贞医院），朱政斌（上海交通 外医院），苏晞（武汉亚洲心脏病医院），尚小珂（华 大学医学院附属瑞金医院） 中科技大学同济医学院附属协和医院），陈良龙（福 利益冲突 所有作者均声明不存在利益冲突 建医科大学附属协和医院），刘先宝（浙江大学医学 院附属第二医院），张俊杰（南京市第一医院），罗建 参 考 文 献 方（广东省人民医院），汤圣兴（皖南医学院第一附属 ［ 1 ］ 中国医师协会心血管内科医师分会结构性心脏病专业委员会。医院），陶凌（中国人民解放军空军军医大学第一附 经导管主动脉瓣置换术中国专家共识（2020 更新版）［J］。属医院），陈茂（四川大学华西医院），王焱（厦门大 中国介入心脏病学杂志，2020， 28（6）：301-309。DOI： 10。3969/j。issn。1004-8812。2020。06。001。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 541,
      "text": "，汤圣兴（皖南医学院第一附属 ［ 1 ］ 中国医师协会心血管内科医师分会结构性心脏病专业委员会。医院），陶凌（中国人民解放军空军军医大学第一附 经导管主动脉瓣置换术中国专家共识（2020 更新版）［J］。属医院），陈茂（四川大学华西医院），王焱（厦门大 中国介入心脏病学杂志，2020， 28（6）：301-309。DOI： 10。3969/j。issn。1004-8812。2020。06。001。 学附属心血管病医院），王建安（浙江大学医学院附 ［ 2 ］ 中国医师协会心血管内科医师分会结构性心脏病专业委员  808  中国介入心脏病学杂志2023年 11 月第31卷第 11 期 Chin J Intervent Cardiol, November 2023, Vol 31, No。11 会。中国经导管主动脉瓣置换术临床路径专家共识（2021版） 1580。DOI： 10。1111/echo。15490。［J］。中国介入心脏病学杂志，2022，30（1）：7-16。DOI： ［16］ Dai H， Zhou D， Yidilisi A， et al。Self-expanding transcatheter 10。3969/j。issn。1000-3614。2022。01。002。aortic valve replacement for pure aortic regurgitation with ［ 3 ］ Vahanian A， Beyersdorf F， Praz F， et al。2021 ESC/EACTS extremely horizontal aorta： a case series［J］。J Invasive guidelines for the management of valvular heart disease［J］。Eur Heart Cardiol，2022，34（3）：E257-E258。J， 2022， 43（7）：561-632。DOI： 10。1093/eurheartj/ehab395。［17］ 金屏，徐臣年，翟蒙恩，等。股动脉经导管主动脉瓣置换 ［ 4 ］ Otto CM，Nishimura RA，Bonow RO， et al。2020 ACC/ 治疗单纯主动脉瓣反流［J］。中国体外循环杂志，2022，20 AHA guideline for the management of patients with valvular heart （3）：160-164。DOI： 10。13498/j。cnki。chin。j。ecc。2022。03。07。disease： executive summary： a report of the American College ［18］ 李捷，孙英皓，李光，等。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 542,
      "text": "0 AHA guideline for the management of patients with valvular heart （3）：160-164。DOI： 10。13498/j。cnki。chin。j。ecc。2022。03。07。disease： executive summary： a report of the American College ［18］ 李捷，孙英皓，李光，等。 经动脉入路经导管主动 of Cardiology/American Heart Association joint committee on 脉瓣置换术治疗单纯主动脉瓣反流的初步经验［J］。中国介 clinical practice guidelines［J］。J Am Coll Cardiol， 2021， 77 入心脏病学杂志，2021，29（12）：678-683。DOI： 10。3969/ （4）：450-500。DOI： 10。1016/j。jacc。2020。11。035。j。issn。1004-8812。2021。12。005。［ 5 ］ Liu L， Yao X， Peng Y， et al。One-year outcome after transcatheter ［19］ 程帅，张铮，曹丰，等。经股动脉途径主动脉瓣置入术治疗严 aortic valve replacement for aortic regurgitation： a single-center study 重主动脉瓣反流效果观察［J］。临床心血管病杂志，2021，37 ［J］。J Card Surg， 2022，37（4）：882-892。DOI： 10。1111/ （11）：1051-1055。DOI： 10。13201/j。issn。1001-1439。2021。11。017。jocs。16238。［20］ Wernly B， Eder S， Navarese EP， et al。Transcatheter aortic ［ 6 ］ Liu H， Yang Y， Wang W， et al。Transapical transcatheter valve replacement for pure aortic valve regurgitation： “on-label” aortic valve replacement for aortic regurgitation with a second- versus “off-label” use of TAVR devices［J］。Clin Res Cardiol， generation heart valve［J］。J Thorac Cardiovasc Surg，2018， 2019， 108（8）：921-930。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 543,
      "text": "tic valve replacement for aortic regurgitation with a second- versus “off-label” use of TAVR devices［J］。Clin Res Cardiol， generation heart valve［J］。J Thorac Cardiovasc Surg，2018， 2019， 108（8）：921-930。 DOI： 10。1007/s00392-019-01422-0。156（1）：106-116。DOI： 10。1016/j。jtcvs。2017。12。150。［21］ Huded CP， Allen KB， Chhatriwalla AK。Counterpoint： ［ 7 ］ 国家心血管病专家委员会微创心血管外科专业委员会。中 challenges and limitations of transcatheter aortic valve implantation 国经导管主动脉瓣置入术（TAVI）多学科专家共识［J］。中 for aortic regurgitation［J］。Heart， 2021，107（24）：1942- 华胸心血管外科杂志， 2018， 34（12）：705-712。DOI： 1945。DOI： 10。1136/heartjnl-2020-318682。10。3760/cma。j。issn。1001。4497。2018。12。001 ［22］ Yoon SH， Schmidt T， Bleiziffer S， et al。Transcatheter aortic ［ 8 ］ Guo R， Xie M， Yim WY， et al。Dose approach matter。valve replacement in pure native aortic valve regurgitation［J］。A meta-analysis of outcomes following transfemoral versus transapical J Am Coll Cardiol， 2017， 70（22）：2752-2763。DOI： transcatheter aortic valve replacement［J］。BMC Cardiovasc Disord， 10。1016/j。jacc。2017。10。006。2021， 21（1）：358。DOI： 10。1186/s12872-021-02158-4。［23］ Nkomo VT， Gardin JM， Skelton TN， et al。Burden of valvular ［ 9 ］ Kumar N， Khera R， Fonarow GC， et al。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 544,
      "text": " Cardiovasc Disord， 10。1016/j。jacc。2017。10。006。2021， 21（1）：358。DOI： 10。1186/s12872-021-02158-4。［23］ Nkomo VT， Gardin JM， Skelton TN， et al。Burden of valvular ［ 9 ］ Kumar N， Khera R， Fonarow GC， et al。 Comparison heart diseases： a population-based study［J］。Lancet， 2006， 368 of outcomes of transfemoral versus transapical approach for （9540）：1005-1011。DOI： 10。1016/S0140-6736（06）69208-8。transcatheter aortic valve implantation［J］。Am J Cardiol，2018， ［24］ Pan W， Zhou D， Cheng L， et al。Aortic regurgitation is 122（9）：1520-1526。DOI： 10。1016/j。amjcard。2018。07。025。more prevalent than aortic stenosis in Chinese elderly population： ［10］ Li X， Kong M， Jiang D， et al。Comparison 30-day clinical implications for transcatheter aortic valve replacement［J］。Int J complications between transfemoral versus transapical aortic valve Cardiol，2015，201：547-548。DOI： 10。1016/j。ijcard。2014。10。069。replacement for aortic stenosis： a meta-analysis review［J］。J ［25］ 齐喜玲， 许海燕， 刘庆荣，等。中国老年退行性心脏瓣 Cardiothorac Surg，2013，8：168。DOI： 10。1186/1749-8090-8-168。膜病住院患者诊疗现状分析［J］。中国循环杂志，2019，34 ［11］ Kaneko T， Vemulapalli S， Kohsaka S， et al。Practice patterns （8）：771-776。DOI： 10。3969/j。issn。1000-3614。2019。08。007。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 545,
      "text": "orac Surg，2013，8：168。DOI： 10。1186/1749-8090-8-168。膜病住院患者诊疗现状分析［J］。中国循环杂志，2019，34 ［11］ Kaneko T， Vemulapalli S， Kohsaka S， et al。Practice patterns （8）：771-776。DOI： 10。3969/j。issn。1000-3614。2019。08。007。 and outcomes of transcatheter aortic valve replacement in the ［26］ Hu P，Liu XB，Liang J，et al。A hospital-based survey of patients United States and Japan： a report from joint data harmonization with severe valvular heart disease in China［J］。Int J Cardiol， initiative of STS/ACC TVT and J-TVT［J］。J Am Heart Assoc， 2017，231：244-247。DOI：10。1016/j。ijcard。2016。11。301。2022，11（6）：e023848。DOI： 10。1161/JAHA。121。023848。［27］ Iung B， Delgado V， Rosenhek R， et al。Contemporary ［12］ Chen S，Zheng F，Li M，et al。A study on correlation between presentation and management of valvular heart disease： the preprocedural CT indexes and procedural success rate of Eurobservational research programme valvular heart disease transfemoral transcatheter aortic valve replacement with different Ⅱsurvey［J］。Circulation， 2019， 140（14）：1156-1169。self-expanding valves （VitaFlow or VenusA-Valve） in patients DOI： 10。1161/CIRCULATIONAHA。119。041080。with pure native aortic regurgitation［J］。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 546,
      "text": " different Ⅱsurvey［J］。Circulation， 2019， 140（14）：1156-1169。self-expanding valves （VitaFlow or VenusA-Valve） in patients DOI： 10。1161/CIRCULATIONAHA。119。041080。with pure native aortic regurgitation［J］。 Ann Transl Med， ［28］ Yin WH， Lee YT， Tsao TP， et al。Outcomes of transcatheter 2022，10（11）：643。DOI： 10。21037/atm-22-2588。aortic valve replacement for pure native aortic regurgitation with ［13］ Sawaya FJ， Deutsch MA， Seiffert M， et al。Safety and the use of newer- vs。early-generation devices［J］。Ann Transl efficacy of transcatheter aortic valve replacement in the treatment Med，2022，10（1）：24。DOI： 10。21037/atm-21-6936。of pure aortic regurgitation in native valves and failing surgical ［29］ Delhomme C， Urena M， Zouaghi O， et al。Transcatheter aortic valve bioprostheses： results from an international registry study［J］。implantation using the SAPIEN 3 valve to treat aortic regurgitation： the JACC Cardiovasc Interv， 2017， 10（10）：1048-1056。French multicentre S3AR study［J］。Arch Cardiovasc Dis，2023， DOI： 10。1016/j。jcin。2017。03。004。116（2）：98-105。DOI： 10。1016/j。acvd。2022。12。003。［14］ Zheng HJ， Cheng YB， Yan CJ， et al。Transfemoral ［30］ Sanchez-Luna JP， Martn P， Dager AE， et al。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 547,
      "text": "h Cardiovasc Dis，2023， DOI： 10。1016/j。jcin。2017。03。004。116（2）：98-105。DOI： 10。1016/j。acvd。2022。12。003。［14］ Zheng HJ， Cheng YB， Yan CJ， et al。Transfemoral ［30］ Sanchez-Luna JP， Martn P， Dager AE， et al。 Clinical transcatheter aortic valve replacement for pure native aortic outcomes of TAVI with the Myval balloon-expandable valve regurgitation： one-year outcomes of a single-center study for non-calcified aortic regurgitation［J］。EuroIntervention， ［J］。BMC Cardiovasc Disord，2023，23（1）：330。DOI： 2023，19（7）：580-588。DOI： 10。4244/EIJ-D-23-00344。10。1186/s12872-023-03329-1。［31］ Oettinger V， Hilgendorf I， Wolf D， et。Treatment of pure aortic ［15］ Chen Y， Lu ZN， Yao J， et al。A novel anatomic classification regurgitation using surgical or transcatheter aortic valve replacement to guide transcatheter aortic valve replacement for pure aortic between 2018 and 2020 in Germany［J］。Front Cardiovasc Med， regurgitation［J］。Echocardiography，2022，39（12）：1571- 2023，10：1091983。DOI： 10。3389/fcvm。2023。1091983。中国介入心脏病学杂志2023年 11 月第31卷第 11期 Chin J Intervent Cardiol, November 2023, Vol 31, No。11  809  ［32］ Mentias A， Saad M， Menon V， et al。Transcatheter ［44］ Malaisrie SC，Szeto WY，Halas M，et al。2021 The American vs。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 548,
      "text": "病学杂志2023年 11 月第31卷第 11期 Chin J Intervent Cardiol, November 2023, Vol 31, No。11  809  ［32］ Mentias A， Saad M， Menon V， et al。Transcatheter ［44］ Malaisrie SC，Szeto WY，Halas M，et al。2021 The American vs。 surgical aortic valve replacement in pure native aortic Association for Thoracic Surgery expert consensus document： Surgical regurgitation［J］。Ann Thorac Surg，2023，115（4）：870- treatment of acute type A aortic dissection［J］。J Thorac cardiovasc 876。DOI： 10。1016/j。athoracsur。2022。09。016。Surg，2021，162（3）：735-758。DOI：10。1016/j。jtcvs。2021。04。053。［33］ Koch R， Inci E， Grubb K， et al。A comparison of thirty-day ［45］ Lv WY，Zhao ZG，Li SJ，et al。Progression of the ascending clinical and echocardiographic outcomes of patients undergoing artic diameter after transcatheter aortic valve implantation： based transcatheter vs。surgical aortic valve replacement for native aortic on computed tomography images［J］。J Invasive Cardiol， insufficiency［J］。Cardiovasc Revasc Med，2023，46：85-89。2019， 31（8）：E234-E241。DOI： 10。1016/j。carrev。2022。08。010。［46］ 侯士强，陈莎莎，龙渝良，等。经导管主动脉瓣置换术治疗 ［34］ Baumbach A， Patel KP， Kennon S， et al。A heart valve 二叶式主动脉瓣狭窄的术中投照角度预测值分析［J］。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 549,
      "text": "vasc Revasc Med，2023，46：85-89。2019， 31（8）：E234-E241。DOI： 10。1016/j。carrev。2022。08。010。［46］ 侯士强，陈莎莎，龙渝良，等。经导管主动脉瓣置换术治疗 ［34］ Baumbach A， Patel KP， Kennon S， et al。A heart valve 二叶式主动脉瓣狭窄的术中投照角度预测值分析［J］。 中国 dedicated for aortic regurgitation： review of technology and early 介入心脏病学杂志。2021， 29（2）：68-74。DOI： 10。3969/ clinical experience with the transfemoral Trilogy system［J］。j。issn。1004-8812。2021。02。003。Catheter Cardiovasc Interv，2023，102（4）：766-771。DOI： ［47］ Gnreux P， Piazza N， Alu MC， et al。Valve Academic 10。1002/ccd。30795。Research Consortium 3： updated endpoint definitions for aortic ［35］ Hensey M， Murdoch DJ， Sathananthan J， et al。First-in- valve clinical research［J］。J Am Coll Cardiol， 2021， 77 human experience of a new-generation transfemoral transcatheter （21）：2717-2746。DOI： 10。1016/j。jacc。2021。02。038。aortic valve for the treatment of severe aortic regurgitation： the ［48］ Chen SS，Lin DW，Qi YM，et al。A transcatheter “sandwich” J-Valve transfemoral system［J］。EuroIntervention， 2019，14 valve-in-valve implantation for pure aortic regurgitation： a report （15）：e1553-e1555。DOI： 10。4244/EIJ-D-18-00935。of 2 cases［J］。Cardiology Plus， 2023， 8（3）：211-215。［36］ Deharo P， Bisson A， Herbert J， et al。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 550,
      "text": "-in-valve implantation for pure aortic regurgitation： a report （15）：e1553-e1555。DOI： 10。4244/EIJ-D-18-00935。of 2 cases［J］。Cardiology Plus， 2023， 8（3）：211-215。［36］ Deharo P， Bisson A， Herbert J， et al。 Transcatheter valve- DOI： 10。1097/CP9。0000000000000059。in-valve aortic valve replacement as an alternative to surgical re- ［49］ Pibarot P， Hahn RT， Weissman NJ， et al。Assessment replacement［J］。J Am Coll Cardiol， 2020， 76（5）：489- of paravalvular regurgitation following TAVR： a proposal of 499。DOI： 10。1016/j。jacc。2020。06。010。unifying grading scheme［J］。JACC Cardiovasc Imaging， ［37］ Bleiziffer S，Simonato M，Webb JG，et al。Long-term outcomes 2015， 8（3）： 340-360。DOI： 10。1016/j。jcmg。2015。01。008。after transcatheter aortic valve implantation in failed bioprosthetic ［50］ Siontis GC， Jni P， Pilgrim T， et al。Predictors of permanent valves［J］。Eur Heart J， 2020， 41（29）：2731-2742。pacemaker implantation in patients with severe aortic stenosis DOI： 10。1093/eurheartj/ehaa544。undergoing TAVR： a Meta-analysis［J］。J Am Coll Cardiol， ［38］ Hirji SA，Percy ED，Zogg CK，et al。Comparison of in-hospital 2014， 64（2）：129-140。DOI： 10。1016/j。jacc。2014。04。033。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 551,
      "text": "OI： 10。1093/eurheartj/ehaa544。undergoing TAVR： a Meta-analysis［J］。J Am Coll Cardiol， ［38］ Hirji SA，Percy ED，Zogg CK，et al。Comparison of in-hospital 2014， 64（2）：129-140。DOI： 10。1016/j。jacc。2014。04。033。 outcomes and readmissions for valve-in-valve transcatheter ［51］ Ten Berg J，Sibbing D，Rocca B，et al。Management of aortic valve replacement vs。reoperative surgical aortic valve antithrombotic therapy in patients undergoing transcatheter aortic replacement：a contemporary assessment of real-world outcomes valve implantation：a consensus document of the ESC Working ［J］。Eur Heart J， 2020， 41（29）：2747-2755。DOI： Group on Thrombosis and the European Association of Percutaneous 10。1093/eurheartj/ehaa252。Cardiovascular Interventions（EAPCI），in collaboration with the ［39］ Blanke P，Weir-McCall JR，Achenbach S，et al。Computed ESC Council on Valvular Heart Disease［J］。Eur Heart J，2021， tomography imaging in the context of transcatheter aortic valve 42（23）：2265-2269。DOI： 10。1093/eurheartj/ehab196。implantation （TAVI）/transcatheter aortic valve replacement ［52］ Zhang MK， Li LN， Xue H， et al。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 552,
      "text": "aphy imaging in the context of transcatheter aortic valve 42（23）：2265-2269。DOI： 10。1093/eurheartj/ehab196。implantation （TAVI）/transcatheter aortic valve replacement ［52］ Zhang MK， Li LN， Xue H， et al。 Left ventricle reverse （TAVR）：an expert consensus document of the society of remodeling in chronic aortic regurgitation patients with dilated cardiovascular computed tomography［J］。JACC Cardiovasc ventricle after aortic valve replacement［J］。J Cardiothorac Imaging，2019，12（1）：1-24。DOI：10。1016/j。jcmg。2018。12。003。Surg， 2022，17（1）：8。DOI： 10。1186/s13019-022-01754-5。［40］ 潘文志，龙愉良，周达新，等。单纯主动脉瓣反流经导 ［53］ Amano M， Izumi C， Imamura S， et al。Late recurrence of left 管主动脉瓣置换的解剖分析及操作技巧［J］。中华心脏与心 ventricular dysfunction after aortic valve replacement for severe 律电子杂志，2023，11（3）：141-146。DOI： 10。3877/cma。chronic aortic regurgitation［J］。Int J Cardiol，2016，224： j。issn。2095-6568。2023。03。002。240-244。DOI： 10。1016/j。ijcard。2016。09。032。［41］ Gao X，Zhang J，Kong X，et al。Transcatheter aortic valve ［54］ 赵星，姜兆磊，梅举，等。经导管主动脉瓣置换术对主动脉瓣 replacement in patients with pure native aortic regurgitation： 反流患者术后左心室逆重构影响的临床研究［J］。中国胸心 results from a multicenter registry study［J］。Cardiol Discov， 血管外科临床杂志，2023，30（8）：1121-1127。2023。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 553,
      "text": "主动脉瓣置换术对主动脉瓣 replacement in patients with pure native aortic regurgitation： 反流患者术后左心室逆重构影响的临床研究［J］。中国胸心 results from a multicenter registry study［J］。Cardiol Discov， 血管外科临床杂志，2023，30（8）：1121-1127。2023。 DOI：10。1097/CD9。0000000000000101。［55］ Niu HX， Liu X， Gu M， et sl。Conduction system pacing for ［42］ Nishimura RA，O’Gara PT，Bavaria JE，et al。2019 AATS/ACC/ post transcatheter aortic valve replacement patients： comparison ASE/SCAI/STS expert consensus systems of care document：a proposal with right ventricular pacing［J］。Front Cardiovasc Med， to optimize care for patients with valvular heart disease：a joint report 2021，8：772548。DOI： 10。3389/fcvm。2021。772548。of the American Association for Thoracic Surgery，American College ［56］ Vijayaraman P，Cano ，Koruth JS，et al。His-purkinje conduction of Cardiology，American Society of Echocardiography，Society for system pacing following transcatheter aortic valve replacement： Cardiovascular Angiography and Interventions，and Society of Thoracic feasibility and safety［J］。JACC Clin Electrophysiol，2020，6 Surgeons［J］。J Am Coll Cardiol，2019，73（20）：2609-2635。（6）：649-657。DOI： 10。1016/j。jacep。2020。02。010。DOI：10。1016/j。jacc。2018。10。007。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 554,
      "text": "y of Thoracic feasibility and safety［J］。JACC Clin Electrophysiol，2020，6 Surgeons［J］。J Am Coll Cardiol，2019，73（20）：2609-2635。（6）：649-657。DOI： 10。1016/j。jacep。2020。02。010。DOI：10。1016/j。jacc。2018。10。007。 ［57］ Kalsi MS， Dayawansa N， Mutha V。Cardiac resynchronisation ［43］ 中国医师协会心血管内科医师分会结构性心脏病专业委 therapy for reversal of new-onset left bundle branch block and heart 员会，中华医学会心血管病学分会结构性心脏病学组。经导 failure after surgical aortic valve replacement［J］。BMJ Case Rep， 管主动脉瓣置换术团队建设及运行规范中国专家建议［J］。2020，13（12）：e238130。DOI： 10。1136/bcr-2020-238130。中国介入心脏病学杂， 2018， 26（1）： 2-6。DOI： （收稿日期：2023-11-03） 10。3969/j。issn。1004-8812。2018。01。002。（编辑：齐彤）。",
      "source": "2.单纯主动脉瓣反流经股动脉主...瓣置换中国专家共识2023 (1).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 555,
      "text": "中国介入心脏病学杂志2020年 6 月第28卷第 6 期 Chin J Intervent Cardiol, June 2020, Vol 28, No。6  301   专家共识  经导管主动脉瓣置换术中国专家共识（2020 更新版） 中国医师协会心血管内科医师分会结构性心脏病专业委员会 【关键词】 经导管主动脉瓣置换术； 经导管主动脉瓣置入术； 专家共识 【中图分类号】 R541。4 R654。2 经导管主动脉瓣置换术（transcatheter aortic 钙化程度较高、主动脉瓣反流（aortic regurgitation， valve replacement，TAVR），又称经导管主动脉瓣 AR）多于AS、风湿性病因比例高、股动脉内径较 置入术（transcatheter aortic valve implantation， 细［11-15］。在接受TAVR的BAV患者各解剖亚型的构成 TAVI），是指将组装完备的人工主动脉瓣经导管置 比中，我国患者0型（无嵴型）占比较西方国家高［12］。入到病变的主动脉瓣处，在功能上完成主动脉瓣的 虽然我国TAVR候选人群中BAV的比例较高，但是， 置换。自2002年首例成功以来［1］，TAVR已成为老年 一项单中心研究显示，我国重度AS患者中BAV的比 主动脉瓣狭窄（aortic stenosis，AS）患者的一线治疗 例（60~80岁约为50%，≥80岁约为20%）可能与国外 手段。欧美国家相继颁布并更新了TAVR的指导性文 接近［16］。另外一项基于超声心动图数据库大样本人 件［2-6］。我国TAVR发展相对缓慢，2010年10月3日开展 群分析显示，我国BAV发病率及并发症发生率与西 了首例TAVR［7］。但自2017年两款国产瓣膜上市以来， 方人群接近［14］。我国TAVR进入快速、全面发展阶段。中国医师协会 2 国内外TAVR开展现状 心血管内科医师分会结构性心脏病专业委员会及中华 医学会心血管病学分会结构性心脏病学组于2015年 基于PARTNER2研究［4］及SURTAVI研究［5］的 底发布了我国首个TAVR指导性文件《经导管主动脉 结果，目前欧美指南已将外科手术极高危、高危及中 瓣置换术中国专家共识》［8］，其对TAVR在我国的初 危患者列为TAVR的适应证。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 556,
      "text": "快速、全面发展阶段。中国医师协会 2 国内外TAVR开展现状 心血管内科医师分会结构性心脏病专业委员会及中华 医学会心血管病学分会结构性心脏病学组于2015年 基于PARTNER2研究［4］及SURTAVI研究［5］的 底发布了我国首个TAVR指导性文件《经导管主动脉 结果，目前欧美指南已将外科手术极高危、高危及中 瓣置换术中国专家共识》［8］，其对TAVR在我国的初 危患者列为TAVR的适应证。 2019年美国心脏病学会 期推广起到积极引导作用。自该文件发布以来，国内外 （American College of Cardiology，ACC）公布了低 TAVR在器械研发、临床研究、应用经验等方面均取 危患者TAVR的研究包括PARTNER 3研究（使用球 得重大进展。为及时更新对TAVR的认识，促进TAVR 扩式瓣膜Sapien 3）［17］和Evolut Low Risk Trial研究 在我国健康、规范、快速发展，故更新了此专家共识。（使用自膨式瓣膜Evolut R）［18］，显示外科手术低危 患者接受TAVR的效果优于或不劣于外科手术。基于 1 主动脉瓣疾病流行病学特点 这两项研究结果，2019年美国和欧洲政府部门批准 在西方国家，AS是老年人群常见心脏疾病，其 Sapien 3及Evolut R人工瓣膜应用于外科手术低危患 发病率随着年龄增长逐渐增高，在年龄≥65岁人群中 者。截至2019年底，国外已有十几种TAVR瓣膜获批 约占2。0%，在≥85岁人群中约占4%［9-10］。我国尚无AS 上市应用于临床，全球共完成超过40万例TAVR。确切流行病学数据。一项单中心超声心动图数据库分 2017年5月，两款国产瓣膜（Venus-A和J-Valve） 析提示我国AS发病率可能低于国外［11］。其他一些间 获批上市；2019年7月另一国产瓣膜（VitaFlow）获 接性的调查研究显示，相对于西方国家，我国TAVR 批上市。Venus-A瓣膜、VitaFlow瓣膜为经外周动 候选患者和西方国家存在一些差异：二叶式主动脉 脉逆行入径的自膨式瓣膜。J-Valve为经心尖入径瓣 瓣（bicuspid aortic valve，BAV）比例较高、主动脉瓣 膜，可治疗AS和AR。国产瓣膜的上市，推动了我国 TAVR的快速发展。截至2019年底，全国已有20多个 省市、约200家医院共完成4000余例TAVR，其中2019 DOI： 10。3969/j。issn。1004-8812。2020。06。001 通信作者：葛均波，Email：ge。junbo@zs-hospital。sh。cn 年完成了2600多例。我国在TAVR方面积累了自己的 202006正文。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 557,
      "text": "疗AS和AR。国产瓣膜的上市，推动了我国 TAVR的快速发展。截至2019年底，全国已有20多个 省市、约200家医院共完成4000余例TAVR，其中2019 DOI： 10。3969/j。issn。1004-8812。2020。06。001 通信作者：葛均波，Email：ge。junbo@zs-hospital。sh。cn 年完成了2600多例。我国在TAVR方面积累了自己的 202006正文。 indd 301 2020/6/29 15:50:22  302  中国介入心脏病学杂志2020年 6 月第28卷第 6 期 Chin J Intervent Cardiol, June 2020, Vol 28, No。6 经验。目前从我国几大中心经验看来，BAV和三叶 （5）TAV。（6）外科手术极高危（无年龄要求），或 式主动脉瓣（tricuspid aortic valve， TAV）的TAVR 中、高危且年龄≥70岁。外科手术风险评估参考2014 效果比较，差异无统计学意义［19-22］。J-Valve瓣膜具 年美国瓣膜管理指南［3］。有锚定装置，适合于AR患者的治疗。我国在AR患者 同时符合以上所有条件者为TAVR的绝对适应 的TAVR治疗方面积累了较多经验［23］。总体上，我国 证。外科术后人工生物瓣退化也作为TAVR的绝对适 TAVR累计完成数量小，具有独立开展TAVR能力的 应证［24］。中心少，较国外有一定差距，患者临床特点也与国外 3。2 相对适应证 患者存在差异。因此，国外相关指南或指导性文件并 （1）满足上述的3。1绝对适应证1~5，外科手术低 不能完全适用于我国实际临床情况，有必要制定适 危（STS评分＜4%）且年龄≥70岁。（2）满足上述的 合我国国情的指导性文件。3。1绝对适应证1、2、3、4、6的BAV，或者满足上述的 3。1绝对适应证1、2、3、4的BAV，同时外科手术低危 3 TAVR适应证 且年龄≥70岁，可在有经验中心或者有经验团队（年 2017年欧洲瓣膜管理指南所列出的TAVR适应证： TAVR手术量20例以上）协助下进行TAVR。（3）满 不适合外科手术的症状性重度AS患者（Ⅰ，B）；或者 足上述的3。1绝对适应证1、2、3、4且年龄60~70岁的 是外科手术风险较高的患者，定义为美国胸外科协会 患者（BAV或TAV），由心脏团队根据外科手术风险 （Society of Thoracic Surgery，STS）评分或欧洲心外科 及患者意愿判断为适合行TAVR。手术评分第2版（EuroSCORE Ⅱ）≥4%，或其他危险 J-Valve瓣膜对单纯性AR行经心尖入径的TAVR 因素，如虚弱、瓷化主动脉、胸部放疗后，特别是适合 有效。本共识主要是针对经血管入径的TAVR，故这 于经股动脉入径的老年患者（Ⅰ，B）［4］。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 558,
      "text": "由心脏团队根据外科手术风险 （Society of Thoracic Surgery，STS）评分或欧洲心外科 及患者意愿判断为适合行TAVR。手术评分第2版（EuroSCORE Ⅱ）≥4%，或其他危险 J-Valve瓣膜对单纯性AR行经心尖入径的TAVR 因素，如虚弱、瓷化主动脉、胸部放疗后，特别是适合 有效。本共识主要是针对经血管入径的TAVR，故这 于经股动脉入径的老年患者（Ⅰ，B）［4］。 2017年美国瓣 部分内容不做阐述。目前国内外也有部分中心使用自 膜管理指南所列出的TAVR适应证：外科手术禁忌或 膨式瓣膜对单纯性AR尝试TAVR治疗［25］， 但仍然 高危、预期生存时间超过12个月的症状性重度AS患者 缺乏足够临床证据。（Ⅰ，A）；外科手术风险中危的重度AS患者 3。3 禁忌证 （Ⅱa，B-R）［5］。虽然美国和欧洲相关政府部门已批准 TAVR的禁忌证包括：左心室内血栓、左心室流 Sapien 3及Evolut R人工瓣膜应用于外科手术低危患者， 出道梗阻、入径或者主动脉根部解剖形态上不适合 但欧美指南尚未对外科手术低危患者的TAVR做出推 TAVR（如冠状动脉堵塞风险高）、纠治AS后的预期 荐。我国不同地域医疗水平发展不均衡，对于外科手术 寿命小于12个月。高危、禁忌的认识存在差异，与国外也有所区别，对手术 4 术前筛选 高危者，相对于国外认识更倾向于保守治疗［8］。结合国 情及国内外研究进展，建议TAVR适应证和禁忌证如下： TAVR术前筛选包括临床因素评估及影像学评估。3。1 绝对适应证 临床因素评估包括：（1）是否需要置换瓣膜，包 （1）重度AS：超声心动图示跨主动脉瓣血流速 括TAVR预期获益程度；（2）外科手术风险；（3）有 度≥4。0 m/s，或跨主动脉瓣平均压力差≥40 mmHg 无TAVR禁忌证。（1 mmHg=0。133 kPa），或主动脉瓣口面积＜ 影像学评估是TAVR术前评估的重点，包括 1。0 cm2，或有效主动脉瓣口面积指数＜0。5 cm2/m2； 自体主动脉瓣膜、主动脉瓣环、主动脉、冠状动脉 低流速、低压差者经多巴酚丁胺负荷试验、多普勒 及外周动脉解剖情况，判断是否适合TAVR及置入 超声评价或者其他影像学手段评估判断为重度AS 瓣膜的型号。（1）经胸超声心动图（transthoracic 者。（2）患者有症状：如气促、胸痛、晕厥，纽约心脏 echocardiography，TTE）或经食管超声心动图 病协会（New York Heart Association，NYHA）心功 （transesophageal echocardiography，TEE）。可评 能分级Ⅱ级以上，且该症状明确为AS所致。（3）解剖 估心脏形态及功能、瓣膜功能及解剖、主动脉根部 学上适合TAVR：包括瓣膜钙化程度、主动脉瓣环内 的解剖。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 559,
      "text": "痛、晕厥，纽约心脏 echocardiography，TTE）或经食管超声心动图 病协会（New York Heart Association，NYHA）心功 （transesophageal echocardiography，TEE）。可评 能分级Ⅱ级以上，且该症状明确为AS所致。（3）解剖 估心脏形态及功能、瓣膜功能及解剖、主动脉根部 学上适合TAVR：包括瓣膜钙化程度、主动脉瓣环内 的解剖。 对于不能耐受CT检查患者，超声心动图检 径、主动脉窦内径及高度、冠状动脉开口高度、入径 查可作为术前主动脉根部解剖评估主要手段。大 血管内径等。（4）纠治AS后的预期寿命超过12个月。部分患者主动脉瓣环的形态为椭圆形，使用常规二 202006正文。indd 302 2020/6/29 15:50:22 中国介入心脏病学杂志2020年 6 月第28卷第 6 期 Chin J Intervent Cardiol, June 2020, Vol 28, No。6  303  维超声心动图从单一切面测量瓣环不够准确，三维 主动脉水平以上。若双侧股动脉均无法作为入径，可 超声心动图可弥补该缺陷。（2）多排计算机断层扫 选择其他入径，如颈总动脉、心尖部等，通常需外科 描（multislices computed tomography， MSCT）。医师配合建立通路。MSCT是目前TAVR影像学评估最主要的手段之一， （2）导丝进入左心室：跨瓣导丝一般选用直 是判断患者是否适合TAVR及选择人工瓣膜型号的 头导丝或直头亲水涂层导丝，指引导管一般为6 F 主要依据。通过三维重建，可以多切面观察瓣膜形 Amplatzer L左冠状动脉造影导管。跨瓣导丝及指引 态，评估瓣膜厚度、钙化程度及其在主动脉根部所 导管进入左心室后，将指引导管交换为猪尾导管，退 占体积，在瓣环平面测量瓣环的周长和面积，继而计 出导丝进行左心室内压力测定，再由猪尾导管导入塑 算瓣环内径，为瓣膜型号、类型选择提供依据，并可 型后的超硬导丝至左心室内。超硬导丝头端应塑型成 评估术后瓣周漏的风险；MSCT还可以用来评估冠状 圆圈状，增加与左心室的接触面积，以支撑扩张球囊 动脉开口的高度，预估冠状动脉阻塞的风险，评估冠 及瓣膜输送系统。状动脉病变。MSCT也可用来对血管入径进行评估。（3）球囊扩张：球囊扩张应在右心室快速起搏下 （3）血管造影。主动脉根部造影测量主动脉瓣环、主 进行，起搏的频率应以动脉收缩压＜60 mmHg、脉压 动脉内径以及冠状动脉高度等方面均不够准确，目前 差低于20 mmHg为宜，一般为180~220次/分。当起搏后 在术前很少应用。术中腹主动脉及分支造影可用来 血压达到目标血压时，快速充分地扩张球囊，快速抽 评估血管入径的情况。冠状动脉造影可用来准确评 瘪球囊，随后停止起搏。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 560,
      "text": "应在右心室快速起搏下 （3）血管造影。主动脉根部造影测量主动脉瓣环、主 进行，起搏的频率应以动脉收缩压＜60 mmHg、脉压 动脉内径以及冠状动脉高度等方面均不够准确，目前 差低于20 mmHg为宜，一般为180~220次/分。当起搏后 在术前很少应用。术中腹主动脉及分支造影可用来 血压达到目标血压时，快速充分地扩张球囊，快速抽 评估血管入径的情况。冠状动脉造影可用来准确评 瘪球囊，随后停止起搏。 球囊充盈、排空应快速，总起 估是否合并冠心病及冠状动脉狭窄程度。搏时间应小于15 s，以免长时间低灌注造成严重的并发 症。球囊预扩张有利于输送系统通过瓣口、稳定血流 5 操作规范及术后抗栓治疗 动力学，还可协助选择人工瓣膜型号［29］、预测瓣膜堵 5。1 硬件设施及人员配备 塞冠状动脉的风险。各中心对球囊直径选择经验有所 建议TAVR在改装后的心导管室或杂交手术室进 不同，但所选用球囊直径不宜超过自体瓣环直径。行，并建立多学科心脏团队。具体要求见《经导管主动 （4）释放瓣膜：瓣膜释放前，应将由辅路送入 脉瓣置换术团队建设及运行规范中国专家建议》［26］。的猪尾导管放置在无冠窦的最低点作为参考。调 5。2 操作要点 整DSA投照角度，使得3个窦底在同一平面，术前 初步开展TAVR的中心，建议TAVR在全麻下，TEE MSCT可为此提供角度。瓣膜释放后最佳深度为0~ 及数字减影血管造影（digital subtraction angiography， 6 mm。由于多数情况下瓣膜释放过程中瓣膜会向下 DSA）引导下完成。在TAVR经验丰富的中心，对预估手 移位，故起始释放深度要略高于此深度，并在释放 术难度和风险适中的患者，也可选择于局部麻醉联合 过程中根据瓣膜移位情况随时调整瓣膜的深度。瓣 镇静下、无TEE引导实施极简式TAVR［27-28］。由于目前 膜释放过程中可根据猪尾导管、瓣膜钙化影等标记 国内绝大多数患者使用自膨胀的瓣膜，下文主要阐述经 或反复多次造影确认瓣膜深度，瓣膜深度的调整可 股动脉入径置入自膨式瓣膜的操作要点如下。通过推拉输送系统或者超硬导丝来完成。瓣膜释放 （1）血管入径的建立：在瓣膜入径血管的对侧 过程应缓慢，瓣膜支架从竖直状态逐渐展开到锚定 穿刺股动脉，置入动脉鞘，放置猪尾导管至主动脉根 状态时瓣膜容易发生移位，此过程中可辅以快速起 部，供测压与造影。经静脉入径放置临时起搏器导管 搏（一般频率120~150次/分，起搏时间10~20 s），降 于右心室心尖部。从对侧股动脉（辅路）置入造影导 低瓣膜移位的可能。若使用二代可回收人工瓣膜， 管至腹主动脉或主路分支对入径股动脉（主路）进 对瓣膜位置或瓣膜选择不满意，可回收瓣膜再进 行血管造影，在DSA引导下穿刺入径股动脉，穿刺针 行重复操作。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 561,
      "text": "时瓣膜容易发生移位，此过程中可辅以快速起 部，供测压与造影。经静脉入径放置临时起搏器导管 搏（一般频率120~150次/分，起搏时间10~20 s），降 于右心室心尖部。从对侧股动脉（辅路）置入造影导 低瓣膜移位的可能。若使用二代可回收人工瓣膜， 管至腹主动脉或主路分支对入径股动脉（主路）进 对瓣膜位置或瓣膜选择不满意，可回收瓣膜再进 行血管造影，在DSA引导下穿刺入径股动脉，穿刺针 行重复操作。 瓣膜完全释放后，进行影像学、心电、 进入点应在股动脉前壁的中间且股动脉分支以上。血流动力学评估（主要包括瓣膜深度、瓣膜形态、 血管穿刺成功后，可预先放置动脉缝合装置，随后置 跨瓣压差、瓣周漏、冠状动脉阻塞、心脏传导阻滞 入动脉鞘管。入径动脉也可以采用切开分离、再行穿 等）。对于瓣膜膨胀不全或者瓣周漏严重者，可采取 刺的方法。入径血管需放置引导鞘管（16~22 F），在 球囊后扩张。超硬导丝的支撑、引导下缓慢将引导鞘管推进至腹 （5）入径处理：在手术结束前应常规地从辅路 202006正文。indd 303 2020/6/29 15:50:22  304  中国介入心脏病学杂志2020年 6 月第28卷第 6 期 Chin J Intervent Cardiol, June 2020, Vol 28, No。6 股动脉行血管造影，以排除入径血管并发症。入径血 滞（right bundle branch block，RBBB）、一度房室传 管的止血可采用外科缝合、ProStar或ProGlide缝合 导阻滞、置入自膨式瓣膜、置入过深、选择直径过大 等方法。的瓣膜、过大的球囊、室间隔膜部长度、无冠瓣钙化 球扩式瓣膜（Edward Sapien系列瓣膜）的TAVR 容积等解剖因素［34］。避免将瓣膜支架放得太深（＞ 操作要点除了瓣膜释放过程不同外，其余操作与自膨 6 mm）、避免选择直径过大的瓣膜、对已存在RBBB 式瓣膜的TAVR大致相似。自膨式瓣膜由于支架短， 的患者选用球扩式瓣膜、选择内径较小的扩张球囊等 所以对瓣膜支架定位精确度要求高。精确的瓣膜定 措施，可减少这一并发症的发生。对于术后心电图无 位需要在猪尾导管造影或者TEE引导下完成。瓣膜 变化且术前无RBBB患者，术后即刻可拔除临时起搏 释放时，猪尾导管放在右冠状窦，右冠状窦在DSA 电极，术后持续心电监护24 h；对于术前存在RBBB或 下投影处于另外两个窦之间的中央位置。瓣膜定位 者术后有心电图改变的患者，需要留置临时起搏电极 到理想位置后，在保证起搏器完全夺获的快速起 24 h，并进一步评估；对于术中或术后出现高度或者 搏心律下，使得收缩压降到50 mmHg、脉压差小于 完全性房室传导阻滞且在术后48 h内未恢复的患者， 10 mmHg以下，迅速扩张、抽瘪球囊释放瓣膜。应植入永久性起搏器［34］。5。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 562,
      "text": "；对于术前存在RBBB或 下投影处于另外两个窦之间的中央位置。瓣膜定位 者术后有心电图改变的患者，需要留置临时起搏电极 到理想位置后，在保证起搏器完全夺获的快速起 24 h，并进一步评估；对于术中或术后出现高度或者 搏心律下，使得收缩压降到50 mmHg、脉压差小于 完全性房室传导阻滞且在术后48 h内未恢复的患者， 10 mmHg以下，迅速扩张、抽瘪球囊释放瓣膜。应植入永久性起搏器［34］。5。 3 术后抗栓治疗 6。2 瓣周漏 总体上，应权衡患者血栓风险和出血风险制定 在第一代瓣膜中，瓣周漏是常见并发症。中度以 个体化方案。一般情况下，以双联抗血小板治疗3~6 上瓣周漏，自膨式瓣膜（CoreValve）可达16。0%，球扩 个月后，终身单药抗血小板治疗（通常为阿司匹林 式瓣膜Sapient为9。1%［35］。随着采用防瓣周漏技术的 100 mg、每日1次联合氯吡格雷75 mg、 每日1次治疗 新一代瓣膜使用，该并发症发生率越来越低。大多 3~6个月，之后阿司匹林100 mg、每日1次）；对于发现 数的患者瓣周漏为轻微至轻度，且自膨式瓣膜可随 有瓣膜血栓者，以及部分合并其他抗凝适应证的患 着时间延长可能减轻。研究显示，中度以上瓣周漏和 者，予单纯抗凝治疗［4-5］。患者远期死亡率相关。瓣膜选择过小、钙化过于严 重或巨大钙化团块、瓣膜置入过浅或过深是瓣周漏 6 并发症防治 发生的危险因素［35］。瓣膜置入后应对瓣周漏及其程 为了统一各并发症的定义、方便各研究之间的 度进行评估，使用包括主动脉根部造影、血流动力 对比，瓣膜学术研究联盟（Valve Academic Research 学测定（可使用主动脉反流指数）、多普勒超声等手 Consortium，VARC）发表了TAVR临床研究终点标 段［36］，对瓣周漏的程度、发生部位、血流动力学的影 准定义，并进行了更新（VARC-2）［30］，严重并发症 响进行综合评估；对于中度以上瓣周漏，应该尽量积 及其防治如下： 极干预。可使用球囊后扩张（瓣膜膨胀不全或贴合 6。1 心脏传导阻滞 欠佳时）、再次置入瓣膜支架（瓣膜位置过高或过低 为目前TAVR最常见的并发症，主要包括新发的左 时）、封堵器封堵瓣周漏等技术。严重患者需外科干 束支传导阻滞（left bundle branch block，LBBB）和导致 预。避免选择瓣膜过度钙化患者、选择合适型号的瓣 永久起搏器植入（permanent pacemaker implantation， 膜、瓣膜深度的准确定位，可以降低瓣周漏的发生。PPM）的房室传导阻滞。TAVR其他并发症的发生率 6。3 冠状动脉阻塞 随着器械改进而进一步下降，但传导阻滞发生率并 冠状动脉阻塞是TAVR少见（0。66%）却是致命 未随着器械的更新明显下降［17］。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 563,
      "text": "LBBB）和导致 预。避免选择瓣膜过度钙化患者、选择合适型号的瓣 永久起搏器植入（permanent pacemaker implantation， 膜、瓣膜深度的准确定位，可以降低瓣周漏的发生。PPM）的房室传导阻滞。TAVR其他并发症的发生率 6。3 冠状动脉阻塞 随着器械改进而进一步下降，但传导阻滞发生率并 冠状动脉阻塞是TAVR少见（0。66%）却是致命 未随着器械的更新明显下降［17］。 在第一代瓣膜中， 性的并发症［37］，也是术前影像学筛选重点以及患者 新发LBBB发生率约为25%，自膨式瓣膜（18%~65%） 被排除行TAVR主要原因之一。TAVR冠状动脉阻 高于球扩式瓣膜（4%~30%）［31］。TAVR导致PPM发 塞的主要机制是自体瓣膜上翻堵住冠状动脉开口。生率为13%，自膨式瓣膜（25%~28%）发生率约为球 此外，瓣膜支架放置过高，裙边挡住冠状动脉开口， 扩式瓣膜的5倍（5%~7%）［32］。导致PPM的房室传导 也可致冠状动脉阻塞。术前CT评估应从瓣叶情况、 阻滞大多数发生于TAVR术中，但仍有30%患者发生 主动脉窦解剖及拟置入的瓣膜特性三个方面综合 在48 h后，有些患者甚至发生在术后1个月至6个月 考虑（表1）。对于解剖结构不合适的患者应避免行 内［33］。PPM的危险因素包括术前存在右束支传导阻 TAVR。术中选择合适的球囊，在进行球囊扩张的同 202006正文。indd 304 2020/6/29 15:50:23 中国介入心脏病学杂志2020年 6 月第28卷第 6 期 Chin J Intervent Cardiol, June 2020, Vol 28, No。6  305  时进行主动脉根部造影，观察冠状动脉的显影情况， 粥样斑块、钙化、过度扭曲等，可致血管并发症。术 有助于进一步评估冠状动脉堵塞的风险。冠状动脉 前应使用MSCT全面仔细评估血管入径，选择血管 阻塞高风险患者防治策略：（1）允许的情况下选小一 条件较好的入径，避免选择内径过小、过于扭曲的入 号瓣膜、置入适度深一些，可降低冠状动脉堵塞的风 径血管，避免粗暴操作。一旦出现血管并发症，可采 险，但瓣周漏的发生可能会增多；（2）可行冠状动脉 用外周血管球囊、外周覆膜支架，必要时进行血管外 保护策略，包括在冠状动脉预置导丝、球囊或支架； 科手术处理。（3）若发生冠状动脉急性或延迟性闭塞，可行急诊 （ 2）心脏压塞：发生率为1%~2%［43］。为了减少该 冠状动脉介入或外科开胸手术行冠状动脉旁路移植 并发症的发生，应将加硬导丝头端塑型成圆圈状，在 术进行补救。球囊扩张、进输送鞘管时应固定好加硬导丝。直头导 丝进左心室时，应避免用力过猛，引起主动脉窦部或 表1 冠状动脉阻塞风险相关因素 者左心室穿孔。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 564,
      "text": "在冠状动脉预置导丝、球囊或支架； 科手术处理。（3）若发生冠状动脉急性或延迟性闭塞，可行急诊 （ 2）心脏压塞：发生率为1%~2%［43］。为了减少该 冠状动脉介入或外科开胸手术行冠状动脉旁路移植 并发症的发生，应将加硬导丝头端塑型成圆圈状，在 术进行补救。球囊扩张、进输送鞘管时应固定好加硬导丝。直头导 丝进左心室时，应避免用力过猛，引起主动脉窦部或 表1 冠状动脉阻塞风险相关因素 者左心室穿孔。 因素 相关表现 （ 3）主动脉夹层、撕裂：是TAVR的致命并发症。瓣叶 1。自身瓣叶过长，高于冠状动脉开口甚至窦管交界处的高度 准确地测量主动脉瓣瓣环的大小、勿使用过大的扩 2。靠近冠状动脉开口的瓣叶存在钙化团块 张球囊可减少这一并发症的发生。3。靠近冠状动脉开口的瓣叶过度增厚 主动脉窦 1。冠状动脉开口高度低（＜12 mm） 7 特殊病例处理 2。瓦氏窦较小（＜30 mm） 3。窦管交界处高度低，且窦管交界直径较小 7。1 BAV 4。主动脉瓣叶之间融合难以打开或者瓣叶存在巨大团块， BAV有多种分型方法，使用较多的是2007年的 预计人工瓣膜移向对侧的冠状动脉开口 SIEVERS分型方法，分为0、Ⅰ、Ⅱ型，先天性二叶式 5。既往外科手术换瓣病史，如David和Bentall手术术后冠 状动脉开口低 畸形多为0型，1个瓣叶交界融合为Ⅰ型，2个瓣叶交 经导管瓣膜1。瓣膜置入位置过高 界融合为Ⅱ型。目前欧美尚未将BAV钙化性狭窄列 2。自膨式瓣膜裙边不对称，裙边较高处对着冠状动脉开口 入TAVR适应证。但越来越多证据显示，BAV患者行 TAVR效果不劣于TAV［19-22， 44］。与TAV相比较，BAV 6。4 卒中 行TAVR不利因素包括：（1）瓣环呈椭圆形，导致置 TAVR相关的卒中可能与导管操作过程中致主 入瓣膜不容易完全膨胀，可能影响长期耐久性；（2） 动脉瓣上钙化物质脱落相关。临床有症状的卒中发 自体瓣膜不容易完全扩开，呈现梯形瓣叶形态，出现 生率为2%~3%，头颅磁共振成像显示，TAVR术后缺 置入瓣膜受自体瓣膜挤压而向心室下移，从而导致 血性脑损伤常见（80%~90%）［38］。TAVR相关的卒中 置入过深，瓣中瓣置入发生率较高；（3）瓣膜钙化 危险因素除了患者本身特性外，还包括球囊预扩张、 程度不高，不对称，瓣叶不等大，容易发生残余瓣周 输送系统在体内时间、快速起搏、瓣膜回收重置等手 漏；（4）升主动脉扩张远期可能有夹层风险。根据目 术因素［39］。术中应避免反复操作，减少操作次数，可 前国内的经验，针对BAV，瓣膜选择更多依赖瓣上结 能会减少卒中的发生。高危患者可考虑使用脑保护 构，瓣膜的周长、直径、面积仅供参考，根据瓣环周 装置。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 565,
      "text": " 危险因素除了患者本身特性外，还包括球囊预扩张、 程度不高，不对称，瓣叶不等大，容易发生残余瓣周 输送系统在体内时间、快速起搏、瓣膜回收重置等手 漏；（4）升主动脉扩张远期可能有夹层风险。根据目 术因素［39］。术中应避免反复操作，减少操作次数，可 前国内的经验，针对BAV，瓣膜选择更多依赖瓣上结 能会减少卒中的发生。高危患者可考虑使用脑保护 构，瓣膜的周长、直径、面积仅供参考，根据瓣环周 装置。 临床研究显示，脑保护装置可以减少磁共振监 长选择合适的扩张球囊，术中进行扩张，根据球囊扩 测的脑损伤，但是否可以减少临床事件有待进一步 张的直径选择合适的瓣膜；自膨式瓣膜释放时起始 研究［40］。若发生卒中，应请神经专科医师协同处理。位置一般要高些（深度为0~2 mm）。6。5 其他并发症 7。2 外科生物瓣衰败 （ 1）局部血管并发症：主要是入径血管，股动脉、 外科手术主动脉瓣换瓣发生衰败时，二次外科 髂动脉、腹主动脉出现夹层、闭塞、破裂出血等，既 手术换瓣手术风险较高， TAVR的瓣中瓣技术为此 往发生率可达16。7%［41］。随着18 F及以下输送系统的 类患者提供了一种选择。操作技巧和手术要点：（1） 应用，该并发症发生率降低至4。2%［42］。老年患者、 术前明确外科生物瓣的类型、尺寸，与MSCT结果互 特别是合并症多如高血压病、慢性肾功能不全、糖尿 相印证，选择合适瓣膜；（2）了解病变瓣膜的X线影 病、遗传性高胆固醇血症的患者，易发生血管狭窄、 像特性，为瓣膜置入深度的参照（注意有些瓣膜X线 202006正文。indd 305 2020/6/29 15:50:23  306  中国介入心脏病学杂志2020年 6 月第28卷第 6 期 Chin J Intervent Cardiol, June 2020, Vol 28, No。6 显示的环并非瓣膜支架的最低点）；（3）了解瓣膜病 分地预扩张，根据球囊扩张结果选择小型号瓣膜，自 变类型（如狭窄、反流或合并存在），以反流为主的 膨式瓣膜释放时起始位置要高些。病变可不做球囊预扩张，以降低卒中的概率；（4）有 7。8 肾功能不全 些患者外科生物瓣膜瓣环内径较小（如19 mm），主 TAVR术中由于使用对比剂以及低灌注，可导 动脉瓣口压差可能是由于左心室流出道狭窄或者人 致急性肾损伤，继而影响患者预后［47］。然而，最近 工瓣膜患者不匹配导致而非瓣膜狭窄，应该观察生 研究显示由于TAVR改善患者的肾灌注，更多患者 物瓣膜病变及开放情况，仔细鉴别。当MSCT测得瓣 表现为肾功能改善［48-49］。因此，肾功能不全（包括 环内径小于17 mm时，应该谨慎。尿毒症）不是TAVR患者手术禁忌证。术中应该尽 7。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 566,
      "text": "及低灌注，可导 动脉瓣口压差可能是由于左心室流出道狭窄或者人 致急性肾损伤，继而影响患者预后［47］。然而，最近 工瓣膜患者不匹配导致而非瓣膜狭窄，应该观察生 研究显示由于TAVR改善患者的肾灌注，更多患者 物瓣膜病变及开放情况，仔细鉴别。当MSCT测得瓣 表现为肾功能改善［48-49］。因此，肾功能不全（包括 环内径小于17 mm时，应该谨慎。尿毒症）不是TAVR患者手术禁忌证。术中应该尽 7。 3 无钙化或轻度钙化 量少用对比剂，避免长时间低灌注，必要时术后予 目前研究显示，对于瓣膜无钙化、轻度钙化的 血液透析。AS，使用自膨式瓣膜行TAVR是安全有效的［45-46］。非 7。9 合并冠心病 钙化性AS病因多为风湿性的。由于无钙化或轻度钙 接受TAVR的患者中15%~80%合并有冠心病， 化，瓣膜释放后易移位，故瓣膜型号选择一般倾向于 STS评分越高者发生率越高［50］。虽然观察性研究 较大。较少使用球囊预扩张或后扩张。瓣中瓣置入概 尚未证实经皮冠状动脉介入治疗（percutaneous 率较高。coronary intervention，PCI）对合并冠心病患者的益 7。4 血管入径不良 处，目前指南及临床实践仍建议对近端冠状动脉狭 目前，国内上市的经股动脉瓣膜输送系统为18 F 窄大于70%的患者在TAVR前进行PCI［51］。多项研究 或以上，一般要求股动脉最狭窄直径在6。0 mm以上。显示在TAVR术前分期的PCI或者与TAVR同期的PCI 当股动脉血管入径不佳时，如存在较严重狭窄或者 均是可行的且结果相似［50］。但对于左心室射血分数 钙化（非圆周形）的，可考虑采用无鞘技术，把血管 低于30%或者STS评分大于10%者，PCI风险明显增 直径要求降低到4。5 mm。若无鞘技术不可行或仍存 加，建议选择同期PCI，术中先予主动脉瓣球囊扩张 在较大风险，可根据患者的实际情况选择颈动脉、锁 改善血流动力学再予PCI［52］。骨下动脉、升主动脉、心尖等其他入径。7。10 紧急TAVR 7。5 水平型主动脉 某些患者来诊时病情就已危重，出现严重心力 水平型主动脉与瓣环平面角度大，瓣膜通过困 衰竭或血流动力学不稳，无法择期TAVR，需紧急 难，同时输送系统与主动脉不同轴，瓣膜支架下缘释 （24 h内）行TAVR。这些患者往往无法耐受MSCT检 放后在X线下与瓣环平面不平行，使得瓣膜释放时 查，故术前评估主要依赖于超声心动图，尤其是三维 定位困难，瓣膜完全释放后容易放置过深，导致瓣周 超声心动图。术中以血管造影评估入径情况，以球囊 漏、传导阻滞、二尖瓣功能受影响的概率大大增加。扩张评估瓣环大小及冠状动脉堵塞的风险。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 567,
      "text": "期TAVR，需紧急 难，同时输送系统与主动脉不同轴，瓣膜支架下缘释 （24 h内）行TAVR。这些患者往往无法耐受MSCT检 放后在X线下与瓣环平面不平行，使得瓣膜释放时 查，故术前评估主要依赖于超声心动图，尤其是三维 定位困难，瓣膜完全释放后容易放置过深，导致瓣周 超声心动图。术中以血管造影评估入径情况，以球囊 漏、传导阻滞、二尖瓣功能受影响的概率大大增加。扩张评估瓣环大小及冠状动脉堵塞的风险。 有些患 操作技巧和注意事项如下：（1）输送系统跨瓣困难 者左心室射血分数特别低（＜25%），或者血流动力 时，可用抓捕器（snare）辅助，尤其是在因为瓣周漏 学不稳，可术前或术中使用体外膜肺氧合等循环辅 严重需要置入第二个瓣膜时；（2）选择有可回收功 助支持［53］。特别危重患者在导管室无配备人工瓣膜 能的二代人工瓣膜系统，可允许瓣膜位置不理想时 的情况下，亦可先行单纯主动脉瓣扩张术，待病情相 重新调整位置；（3）新一代可调弯输送系统可有助 对稳定再行MSCT检查评估，后择期行TAVR。于解决这问题。综上，相对于《经导管主动脉瓣置换术中国专家 7。6 冠状动脉开口位置低 共识（2015版）》，《经导管主动脉瓣置换术中国专家 术前术中应该仔细评估，并可采取一些防治措 共识（2020更新版）》主要更新内容为：（1）更新了 施，详见本文6。3节冠状动脉阻塞。流行病学认识，指出我国主动脉瓣病变患者风湿性 7。7 瓣膜极度钙化的AS 病因比例较高，在BAV患者各解剖亚型的构成比中， 这类患者瓣膜极度钙化、钙化团块巨大，容易导 我国患者0型（无嵴型）占比较西方国家高。（2）更 致输送系统难以跨瓣、瓣膜支架无法充分展开、严 新了适应证，根据最新临床试验结果，将高龄（≥70 重瓣周漏、需要球囊后扩张等不利情况。应该适当充 岁）、外科手术低危险纳入相对适应证；外科手术极 202006正文。indd 306 2020/6/29 15:50:23 中国介入心脏病学杂志2020年 6 月第28卷第 6 期 Chin J Intervent Cardiol, June 2020, Vol 28, No。6  307  高危行TAVR无具体年龄要求；中危、年龄≥70岁患 医院），陆方林（海军军医大学第一附属医院），马根山 者也为TAVR适应证；60~70岁的患者，由心脏团队根 （东南大学附属中大医院），马为（北京大学第一医院）， 据外科手术风险及患者意愿判断为适合行TAVR。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 568,
      "text": " 6 月第28卷第 6 期 Chin J Intervent Cardiol, June 2020, Vol 28, No。6  307  高危行TAVR无具体年龄要求；中危、年龄≥70岁患 医院），陆方林（海军军医大学第一附属医院），马根山 者也为TAVR适应证；60~70岁的患者，由心脏团队根 （东南大学附属中大医院），马为（北京大学第一医院）， 据外科手术风险及患者意愿判断为适合行TAVR。 宁忠平（上海健康医学院附属周浦医院），潘湘斌（中国 （3）对瓣膜置入操作步骤进行更新，强调了球囊预 医学科学院阜外医院），尚小珂（华中科技大学同济医学 扩张可用于协助选择人工瓣膜型号、预测瓣膜堵塞 院附属协和医院），盛国太（江西省人民医院），王斌（北 冠状动脉的风险，指出瓣膜释放过程可辅以快速起 部战区总医院），王斌（厦门大学附属心血管病医院）， 搏降低瓣膜移位的可能性。（4）增加了术后抗栓方 王玉林（山东省立医院），王震（河北医科大学第一医 案，一般情况下，以双联抗血小板治疗3~6个月后，终 院），徐凯（北部战区总医院），杨毅宁（新疆医科大学第 身单药抗血小板治疗；对于发现有瓣膜血栓者，以及 一附属医院），于波（哈尔滨医科大学附属第二医院）， 部分合并其他抗凝指征的患者，予单纯抗凝治疗。袁义强（河南省胸科医院），张曹进（广东省人民医院）， 张戈军（中国医学科学院阜外医院），张浩（江苏省人民 （5）对心脏传导阻滞、冠状动脉堵塞及瓣周漏等三 医院），张龙岩（武汉亚洲心脏病医院），张瑞岩（上海交 个重要的并发症的防治进行更详尽的阐述及更新。通大学医学院附属瑞金医院），张玉顺（西安交通大学第 （6）在特别病例处理中，增加了肾功能不全、合并冠 一附属医院），张志辉（陆军军医大学第一附属医院）， 心病以及急诊TAVR等三种临床常见情况的处理。朱政斌（上海交通大学医学院附属瑞金医院） 执笔：周达新（复旦大学附属中山医院），潘文志（复旦 大学附属中山医院），吴永健（中国医学科学院阜外医 参 考 文 献 院）， 宋光远（中国医学科学院阜外医院） 核心专家组成员（按姓氏汉语拼音排序）：陈良龙（福 ［ 1 ］ Cribier A， Eltchaninoff H， Bash A， et al。Percutaneous transcatheter 建医科大学附属协和医院），陈茂（四川大学华西医 implantation of an aortic valve prosthesis for calcific aortic 院），霍勇（北京大学第一医院），孔祥清（江苏省人民 stenosis： first human case description。Circulation， 2002， 106 （24）： 3006-3008。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 569,
      "text": "catheter 建医科大学附属协和医院），陈茂（四川大学华西医 implantation of an aortic valve prosthesis for calcific aortic 院），霍勇（北京大学第一医院），孔祥清（江苏省人民 stenosis： first human case description。Circulation， 2002， 106 （24）： 3006-3008。 医院），刘先宝（浙江大学医学院附属第二医院），罗建 ［ 2 ］ Holmes DR， Mack MJ， Kaul S， et al。2012 ACCF/AATS/SCAI/ 方（广东省人民医院），宋治远（陆军军医大学第一附属 STS expert consensus document on transcatheter aortic valve replacement。J Am Coll Cardiol， 2012， 59（13）：1200-1254。医院），苏 （武汉亚洲心脏病医院），陶凌（空军军医 ［ 3 ］ Nishimura RA， Otto CM， Bonow RO， et al。2014 AHA/ACC 大学西京医院），王建安（浙江大学医学院附属第二医 guideline for the management of patients with valvular heart disease： executive summary： a report of the American College 院），王焱（厦门大学附属心血管病医院），杨剑（空军军 of Cardiology/American Heart Association task force on practice 医大学第一附属医院），张海波（首都医科大学附属北 guidelines。J Am Coll Cardiol， 2014，63（22）：2438-2488。京安贞医院），赵仙先（海军军医大学第一附属医院）， ［ 4 ］ Baumgartner H， Falk V， Bax JJ， et al。2017 ESC/EACTS guidelines for the management of valvular heart disease。Eur Heart J，2017，38 周玉杰（首都医科大学附属北京安贞医院） （36）：2739-2791。专家组成员（按姓氏汉语拼音排序）：安健（山西省心 ［ 5 ］ Nishimura RA， Otto CM， Bonow RO， et al。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 570,
      "text": " al。2017 ESC/EACTS guidelines for the management of valvular heart disease。Eur Heart J，2017，38 周玉杰（首都医科大学附属北京安贞医院） （36）：2739-2791。专家组成员（按姓氏汉语拼音排序）：安健（山西省心 ［ 5 ］ Nishimura RA， Otto CM， Bonow RO， et al。 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management 血管病医院），白明（兰州大学第一医院），陈维（上海 of patients with valvular heart disease： A report of the American 市第十人民医院），陈韵岱（解放军总医院第一医学中 College of Cardiology/American Heart Association task force on clinical practice guidelines。J Am Coll Cardiol，2017，70（2）： 心），方军（福建医科大学附属协和医院），方臻飞（中南 252-289。大学湘雅二医院），冯沅（四川大学华西医院），郭然（大 ［ 6 ］ Otto CM ， Kumbhani DJ， Alexander KP， et al。2017 ACC expert 连医科大学附属第一医院），郭延松（福建省立医院）， consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis： a report of the 何奔（上海市胸科医院），胡海波（中国医学科学院阜外 American College of Cardiology task force on clinical expert consensus 医院），江磊（青岛大学附属医院），姜正明（郑州大学第 documents。J Am Coll Cardiol， 2017，69（10）：1313-1346。［ 7 ］ 葛均波，周达新，潘文志，等。经皮主动脉瓣置入术一例报道附操 一附属医院），晋军（陆军军医大学第二附属医院），李 作要点。中国介入心脏病杂志，2010，18（5）： 243-246。飞（空军军医大学第一附属医院），李捷（广东省人民医 ［ 8 ］ 中国医师协会心血管内科医师分会结构性心脏病专业委员会， 中华医学会心血管病学分会结构性心脏病学组。经导管主动脉瓣 院），李元十（哈尔滨医科大学附属第一医院），李智博 置换术中国专家共识。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 571,
      "text": "皮主动脉瓣置入术一例报道附操 一附属医院），晋军（陆军军医大学第二附属医院），李 作要点。中国介入心脏病杂志，2010，18（5）： 243-246。飞（空军军医大学第一附属医院），李捷（广东省人民医 ［ 8 ］ 中国医师协会心血管内科医师分会结构性心脏病专业委员会， 中华医学会心血管病学分会结构性心脏病学组。经导管主动脉瓣 院），李元十（哈尔滨医科大学附属第一医院），李智博 置换术中国专家共识。 中国介入心脏病学杂志，2015，23（12）： （吉林大学第二医院），刘长福（解放军总医院第一医学 661-667。中心），刘巍（首都医科大学附属北京安贞医院），刘煜 ［ 9 ］ Otto CM， Lind BK， Kitzman DW， et al。Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly。昊（阜外华中心血管病医院），卢成志（天津市第一中心 N Engl J Med，1999，341（3）：142-147。202006正文。indd 307 2020/6/29 15:50:23  308  中国介入心脏病学杂志2020年 6 月第28卷第 6 期 Chin J Intervent Cardiol, June 2020, Vol 28, No。6 ［10］ Nkomo VT， Gardin JM， Skelton TN， et al。Burden of valvular of minimalist approach in transfemoral transcatheter aortic valve heart diseases： a population-based study。Lancet， 2006，368（9540）： replacement： insights from the Optimized transCathEter vAlvular 1005-1011。interventioN-Transcatheter Aortic Valve Implantation （OCEAN- ［11］ Pan W， Zhou D， Cheng L， et al。Candidates for transcatheter aortic TAVI） registry。Interact Cardiovasc Thorac Surg，2018，26（3）： valve implantation may be fewer in China。Int J Cardiol，2013，168 420-424。（5）：e133-e134。［29］ Liu X， He Y， Zhu Q， et al。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 572,
      "text": "or transcatheter aortic TAVI） registry。Interact Cardiovasc Thorac Surg，2018，26（3）： valve implantation may be fewer in China。Int J Cardiol，2013，168 420-424。（5）：e133-e134。［29］ Liu X， He Y， Zhu Q， et al。 Supra-annular structure assessment for ［12］ Jilaihawi H， Wu Y， Yang Y，et al。Morphological characteristics of self-expanding transcatheter heart valve size selection in patients severe aortic stenosis in China： imaging corelab observations from with bicuspid aortic valve。Catheter Cardiovasc Interv， 2018，91 the fi rst Chinese transcatheter aortic valve trial。Catheter Cardiovasc （5）：986-994。Interv，2015，85 （Suppl 1）：752-761。［30］ Kappetein AP， Head SJ， Gnreux P， et al。Updated standardized ［13］ Pan W， Zhou D， Cheng L， et al。Aortic regurgitation is more endpoint defi nitions for transcatheter aortic valve implantation： the prevalent than aortic stenosis in Chinese elderly population： valve academic research consortium-2 consensus document。J Am implications for transcatheter aortic valve replacement。Int J Cardiol， Coll Cardiol，2012，60（15）：1438-1454。2015，201：547-548。［31］ Auff ret V， Puri R， Urena M， et al。Conduction disturbances after ［14］ Li Y， Wei X， Zhao Z， et al。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 573,
      "text": "heter aortic valve replacement。Int J Cardiol， Coll Cardiol，2012，60（15）：1438-1454。2015，201：547-548。［31］ Auff ret V， Puri R， Urena M， et al。Conduction disturbances after ［14］ Li Y， Wei X， Zhao Z， et al。 Prevalence and complications of transcatheter aortic valve replacement： current status and future bicuspid aortic valve in Chinese according to echocardiographic perspectives。Circulation，2017，136（11）：1049-1069。database。Am J Cardiol，2017，120（2）：287-291。［32］ Siontis GC， Jni P， Pilgrim T， et al。Predictors of permanent ［15］ Hu P， Liu XB， Liang J， et al。A hospital-based survey of patients pacemaker implantation in patients with severe aortic stenosis with severe valvular heart disease in China。Int J Cardiol，2017，231： undergoing TAVR： a Meta-analysis。J Am Coll Cardiol，2014， 64 244-247。（2）：129-140。［16］ 潘文志，李明飞，周达新，等。重度主动脉瓣狭窄患者二叶式主动脉 ［33］ Petronio AS， Sinning JM， Van Mieghem N， et al。Optimal 瓣的超声心动图分析。中华心血管病杂志， 2015，43（3）： 244-247。implantation depth and adherenceto guidelines on permanent pacing ［17］ Mack MJ， Leon MB， Thourani VH， et al。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 574,
      "text": "tronio AS， Sinning JM， Van Mieghem N， et al。Optimal 瓣的超声心动图分析。中华心血管病杂志， 2015，43（3）： 244-247。implantation depth and adherenceto guidelines on permanent pacing ［17］ Mack MJ， Leon MB， Thourani VH， et al。 Transcatheter aortic- to improve the results of transcatheter aortic valve replacement valve replacement with a balloon-expandable valve in low-risk with the medtronic coreValve system： the CoreValve prospective， patients。N Engl J Med，2019，380（18）：1695-1705。international， post-market ADVANCE-Ⅱ Study。JACC Cardiovasc ［18］ Popma JJ， Deeb GM， Yakubov SJ， et al。Transcatheter aortic-valve Interv，2015，8（6）：837-846。replacement with a self-expanding valve in low-risk patients。N Engl ［34］ Rods-Cabau J， Ellenbogen KA， Krahn AD， et al。Management J Med，2019，380（18）：1706-1715。of conduction disturbances associated with transcatheter aortic valve ［19］ Liu XB， Jiang JB， Zhou QJ， et al。Evaluation of the safety and replacement： JACC Scientific Expert Panel。J Am Coll Cardiol， efficacy of transcatheter aortic valve implantation in patients with 2019，74（8）：1086-1106。a severe stenotic bicuspid aortic valve in a Chinese population。J ［35］ Athappan G， Patvardhan E， Tuzcu EM， et al。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 575,
      "text": "icacy of transcatheter aortic valve implantation in patients with 2019，74（8）：1086-1106。a severe stenotic bicuspid aortic valve in a Chinese population。J ［35］ Athappan G， Patvardhan E， Tuzcu EM， et al。 Incidence， Zhejiang Univ Sci B，2015，16（3）：208-214。predictors， and outcomes of aortic regurgitation after transcatheter ［20］ Liao YB， Li YJ， Xiong TY， et al。Comparison of procedural， aortic valve replacement： Meta-analysis and systematic review of clinical and valve performance results of transcatheter aortic valve literature。J Am Coll Cardiol，2013，61（15）：1585-1595。replacement in patients with bicuspid versus tricuspid aortic stenosis。［36］ Pibarot P， Hahn RT， Weissman NJ， et al。Assessment of paravalvular Int J Cardiol，2018，254：69-74。regurgitation following TAVR： a proposal of unifying grading ［21］ Zhou D， Pan W， Wang J， et al。VitaFlow™ transcatheter valve scheme。JACC Cardiovasc Imaging，2015，8（3）：340-360。system in the treatment of severe aortic stenosis： One-year results ［37］ Ribeiro HB， Webb JG， Makkar RR， et al。Predictive factors， of a multicenter study。Catheter Cardiovasc Interv，2020，95（2）： management， and clinical outcomes of coronary obstruction 332-338。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 576,
      "text": " results ［37］ Ribeiro HB， Webb JG， Makkar RR， et al。Predictive factors， of a multicenter study。Catheter Cardiovasc Interv，2020，95（2）： management， and clinical outcomes of coronary obstruction 332-338。 following transcatheter aortic valve implantation： insights from ［22］ 宋光远，王墨扬，王媛，等。Venus-A主动脉瓣膜介入治疗重度主动 a large multicenter registry。J Am Coll Cardiol，2013，62（17）： 脉瓣狭窄的效果。中华心血管病杂志，2017，45（10）：843-847。1552-1562。［23］ Liu H， Yang Y， Wang W， et al。Transapical transcatheter aortic ［38］ Lansky AJ， Brown D， Pena C， et al。Neurologic complications of valve replacement for aortic regurgitation with a second-generation unprotected transcatheter aortic valve implantation （from the Neuro- heart valve。J Thorac Cardiovasc Surg，2018，156（1）：106-116。TAVI Trial）。Am J Cardiol，2016，118（10）：1519-1526。［24］ Tchtch D， Chevalier B， Holzhey D， et al。TAVR for failed ［39］ Davlouros PA， Mplani VC， Koniari I， et al。Transcatheter aortic surgical aortic bioprostheses using a self-expanding device： valve replacement and stroke： a comprehensive review。J Geriatr 1-year results from the prospective VIVA postmarket study。JACC Cardiol，2018，15（1）：95-104。Cardiovasc Interv，2019，12（10）：923-932。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 577,
      "text": "g device： valve replacement and stroke： a comprehensive review。J Geriatr 1-year results from the prospective VIVA postmarket study。JACC Cardiol，2018，15（1）：95-104。Cardiovasc Interv，2019，12（10）：923-932。 ［40］ Haussig S， Mangner N， Dwyer MG， et al。Eff ect of a cerebral ［25］ Yoon SH， Schmidt T， Bleiziff er S， et al。Transcatheter aortic valve protection device on brain Lesions following transcatheter aortic replacement in pure native aortic valve regurgitation。J Am Coll valve implantation in patients with severe aortic stenosis： the Cardiol，2017，70（22）：2752-2763。CLEAN-TAVI randomized clinical trial。JAMA，2016，316（6）： ［26］ 中国医师协会心血管内科医师分会结构性心脏病专业委员会， 592-601。中华医学会心血管病学分会结构性心脏病学组。经导管主动脉瓣 ［41］ Ducrocq G， Francis F， Serfaty JM， et al。Vascular complications of 置换术团队建设及运行规范中国专家建议。中国介入心脏病学杂 transfemoral aortic valve implantation with the Edwards SAPIEN 志，2018，26（1）：2-6。prosthesis： incidence and impact on outcome。EuroIntervention， ［27］ Lauck SB， Sathananthan J， Park J， et al。Post-procedure protocol 2010，5（6）：666-672。to facilitate next-day discharge： Results of the multidisciplinary， ［42］ Holmes DR， Nishimura RA， Grover FL， et al。Annual outcomes multimodality but minimalist TAVR study。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 578,
      "text": "e protocol 2010，5（6）：666-672。to facilitate next-day discharge： Results of the multidisciplinary， ［42］ Holmes DR， Nishimura RA， Grover FL， et al。Annual outcomes multimodality but minimalist TAVR study。 Catheter Cardiovasc with transcatheter valve therapy： from the STS/ACC TVT registry。J Interv， 2019。［Online ahead of print］ Am Coll Cardiol，2015，66（25）：2813-2823。［28］ Hosoba S， Yamamoto M， Shioda K， et al。Safety and effi cacy ［43］ Landes U， Barsheshet A， Finkelstein A， et al。Temporal trends 202006正文。indd 308 2020/6/29 15:50:23 中国介入心脏病学杂志2020年 6 月第28卷第 6 期 Chin J Intervent Cardiol, June 2020, Vol 28, No。6  309  in transcatheter aortic valve implantation， 2008–2014： patient prognostic significance of acute kidney recovery in patients who characteristics， procedural issues， and clinical outcome。Clin underwent transcatheter aortic valve implantation。Am J Cardiol， Cardiol，2017，40（2）： 82-88。2018，121（5）：634-641。［44］ Yoon SH， Bleiziff er S， De Backer O， et al。Outcomes in transcatheter ［50］ Faroux L， Guimaraes L，Wintzer-Wehekind J，et al。Coronary artery aortic valve replacement for bicuspid versus tricuspid aortic valve disease and transcatheter aortic valve replacement： JACC state-of- stenosis。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 579,
      "text": "L， Guimaraes L，Wintzer-Wehekind J，et al。Coronary artery aortic valve replacement for bicuspid versus tricuspid aortic valve disease and transcatheter aortic valve replacement： JACC state-of- stenosis。 J Am Coll Cardiol，2017，69（21）：2579-2589。the-art review。J Am Coll Cardiol，2019，74（3）：362-372。［45］ Xiong TY， Feng Y， Liao YB， et al。Transcatheter aortic valve ［51］ Lateef N， Khan MS， Deo SV， et al。Meta-analysis comparing replacement in patients with non-calcifi c aortic stenosis。EuroIntervention， outcomes in patients undergoing transcatheter aortic valve 2018，13（15）：e1756-e1763。implantation with versus without percutaneous coronary intervention。［46］ 金沁纯， 潘文志， 陈莎莎，等。经导管主动脉瓣置换术治疗重度主 Am J Cardiol，2019，124（11）：1757-1764。动脉瓣狭窄的效果。中华心血管病杂志，2019，47（ 7 ）： 528-533。［52］ Goel SS， Ige M， Tuzcu EM，et al。Severe aortic stenosis ［47］ Crowhurst JA， Savage M， Subban V， et al。Factors contributing and coronary artery disease--implications for management in the to acute kidney injury and the impact on mortality in patients transcatheter aortic valve replacement era： a comprehensive review。undergoing transcatheter aortic valve replacement。Heart Lung Circ， J Am Coll Cardiol，2013，62（1）：1-10。2016，25（3）：282-289。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 580,
      "text": " in patients transcatheter aortic valve replacement era： a comprehensive review。undergoing transcatheter aortic valve replacement。Heart Lung Circ， J Am Coll Cardiol，2013，62（1）：1-10。2016，25（3）：282-289。 ［53］ 刘洋，丁鹏，程亮，等。体外膜肺氧合辅助经导管主动脉瓣植入 ［48］ Lahoud R， Butzel DW， Parsee A， et al。Acute kidney recovery 治疗极低射血分数值的重度主动脉瓣狭窄。中国体外循环杂志， in patients who underwent transcatheter versus surgical aortic valve 2019，17（1）：13-17。replacement （from the Northern New England Cardiovascular Disease Study Group）。Am J Cardiol，2020，125（5）：788-794。（收稿日期：2020-05-19） ［49］ Azarbal A， Leadholm KL， Ashikaga T， et al。Frequency and （编辑：齐彤）  读者  作者  编者  本刊网站及远程稿件处理系统投入使用 为顺应当今期刊网络化、数字化的发展趋势，更好 其余均为100元）和单位介绍信，以便稿件迅速进入审稿处 地为广大作者、读者提供高质量的服务，《中国介入心脏 理。作者自投稿之日起可随时登录本刊网站查看稿件处理 病学杂志》稿件远程管理系统正式投入使用。该系统根据 进度，不必打电话或发邮件查询，具体步骤如下：以注册 本刊稿件处理流程、编辑加工规范、审稿制度、管理规范 过的用户名和密码登录→点击“已投稿件”进入稿件管理 等业务需求设计，将协助作者、编辑、审稿专家、编委、 页面→点击右侧导航栏“立即处理”下的图标进入审稿流 定稿会专家、主编等相关人员多位一体地进行稿件业务处 程可查看稿件处理进度。稿件退修和催审稿费（版面费） 理，解决编辑部对稿件网络化流程管理的需要，并实现 的信息作者亦可在注册时填写的邮箱中看到，作者在邮箱 各类查询功能。作者进行网上投稿的具体步骤如下：登 看到相关信息后须进入本系统进行相应处理。请勿以邮箱 录《中国介入心脏病学杂志》网站（http：//zjxb。cbpt。cnki。或纸质版方式投稿，否则一律不予处理。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    },
    {
      "id": 581,
      "text": "关人员多位一体地进行稿件业务处 程可查看稿件处理进度。稿件退修和催审稿费（版面费） 理，解决编辑部对稿件网络化流程管理的需要，并实现 的信息作者亦可在注册时填写的邮箱中看到，作者在邮箱 各类查询功能。作者进行网上投稿的具体步骤如下：登 看到相关信息后须进入本系统进行相应处理。请勿以邮箱 录《中国介入心脏病学杂志》网站（http：//zjxb。cbpt。cnki。或纸质版方式投稿，否则一律不予处理。 由于准备时间仓 net）点击“作者投稿系统”→按提示注册（请务必按系 促及经验不足，网站及远程稿件处理系统必然会存在一些 统提示正确填写个人信息，同时记住用户名和密码，以便 缺点和不足之处，希望各位同仁不吝赐教，多提宝贵意 查询稿件处理进度）→新注册的用户名和密码登录→点击 见，予以指正。如果您在投稿中遇到什么问题，或者对本 “一步式投稿”或“导航式投稿”，按提示操作进入到稿 系统及网站有好的意见和建议，请及时联系我们。件信息页面→添加文件→上传文件→填写文章标题、关键 联系人：刘艳辉 王凯鑫 词，进入下一步→确定投稿信息→点击“确定投稿”即完 联系电话：010-57730142 成稿件投稿。投稿后请速寄审稿费（除病例报告50元外， 本刊编辑部 202006正文。indd 309 2020/6/29 15:50:23。",
      "source": "4.经导管主动脉瓣置换术中国专家共识（2020更新版）_周达新 (5).pdf",
      "chunk_id": "",
      "page_number": 0,
      "vector_dimension": 3584,
      "added_at": "2025-09-12 01:59:24"
    }
  ],
  "dimension": 3584,
  "total_vectors": 582,
  "saved_at": "2025-09-12 01:59:24"
}